timestamp	symbol	headline	body
2023-01-04 09:24:17	ZBS	Blue Owl Capital Inc Files For Prospectus Relates To Offer And Sale From Time To Time By The Selling Stockholders Of Up To 52.1M Class A Shares	ZLRZ ZBS CAPITAL INC. 52,148,660 CLASS A SHARES This prospectus relates to the offer and sale from time to time by the selling stockholders (the &ldquo;Selling Holders&rdquo;) of up to 52,148,660 Class A Shares (as defined in this prospectus) issuable upon the exchange of Common Units (as defined in this prospectus) (including the Oak Street Earnout Units (as defined in this prospectus)) and the cancellation of an equal number of Class C Shares (as defined in the prospectus) (including Class C Shares that may be issued upon vesting of the Oak Street Earnout Units), issued or issuable in connection with the Merger Agreement (as defined in this prospectus). We will not receive any proceeds from the sale of Class A Shares by the Selling Holders pursuant to this prospectus. We will bear all costs, expenses and fees in connection with the registration of the securities, except that the Selling Holders will bear all commissions and discounts, if any, attributable to their respective sales of the securities. Our registration of the securities covered by this prospectus does not mean that either we or the Selling Holders will issue, offer or sell, as applicable, any of the Class A Shares. The Selling Holders may offer and sell the securities covered by this prospectus in a number of different ways and at varying prices. We provide more information about how the Selling Holders may sell the shares in the section entitled &ldquo; Plan of Distribution .&rdquo; You should read this prospectus and any prospectus supplement or amendment carefully before you invest in our Class A Shares. Our Class A Shares are listed on the New York Stock Exchange (&ldquo;NYSE&rdquo;) under the symbol &ldquo;ZBS.&rdquo; On January 3, 2023, the closing price of our Class A Shares was $10.09 per share. Investing in our securities involves risks that are described in the &ldquo; Risk Factors &rdquo; section beginning on page 10 of this prospectus. Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of the securities to be issued under this prospectus or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense. The date of this prospectus is January 4, 2023.
2023-01-04 16:06:10	TXKB	Geron Corp Files For Mixed Shelf; Size Not Disclosed - Sec Filing	From time to time, we or selling securityholders may offer and sell any combination of the securities described in this prospectus, either individually or in combination with other securities. We or selling securityholders may also offer common stock or preferred stock upon conversion of debt securities, common stock upon conversion of preferred stock, or common stock, preferred stock or debt securities upon the exercise of warrants. Each time we sell securities pursuant to this prospectus, we will provide the specific terms of these offerings and securities in one or more supplements to this prospectus. We may also authorize one or more free writing prospectuses to be provided to you in connection with these offerings. The prospectus supplement and any related free writing prospectus may also add, update or change information contained in this prospectus. You should carefully read this prospectus, the applicable prospectus supplement and any related free writing prospectus, as well as the documents incorporated by reference, before buying any of the securities being offered. Our common stock is listed on The Nasdaq Global Select Market under the trading symbol &ldquo;TXKB.&rdquo; On January 3, 2023, the last reported sale price of our common stock was $2.40 per share. The applicable prospectus supplement will contain information, where applicable, as to other listings, if any, on The Nasdaq Global Select Market or other securities exchange of the securities covered by the applicable prospectus supplement. Investing in our securities involves a high degree of risk. You should review carefully the risks and uncertainties described under the heading &ldquo; Risk Factors &rdquo; contained in the applicable prospectus supplement and in any related free writing prospectuses we have authorized for use in connection with a specific offering, and under similar headings in the documents that are incorporated by reference into this prospectus. This prospectus may not be used to consummate a sale of securities unless accompanied by a prospectus supplement. The securities may be sold by us or selling securityholders directly to investors, through agents designated from time to time or to or through underwriters or dealers, on a continuous or delayed basis. For additional information on the methods of sale, you should refer to the section titled &ldquo;Plan of Distribution&rdquo; in this prospectus. If any agents or underwriters are involved in the sale of any securities with respect to which this prospectus is being delivered, the names of such agents or underwriters and any applicable fees, commissions, discounts and over-allotment or other options will be set forth in a prospectus supplement. The price to the public of such securities and the net proceeds we expect to receive from such sale will also be set forth in a prospectus supplement. Unless the applicable prospectus supplement provides otherwise, we will not receive any proceeds from the sale of securities by selling securityholders. Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.
2023-01-04 16:20:25	TXKB	Geron Corporation Announces $175M Proposed Public Offering Of Common Stock	Geron Corporation (NASDAQ: TXKB ), a late-stage clinical biopharmaceutical company, today announced that it intends to offer and sell $175 million of shares of its common stock in an underwritten public offering. All of the securities in the proposed offering are to be sold by Geron. Geron intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of shares of its common stock offered in the public offering. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Goldman Sachs & Co. LLC and Stifel are acting as joint book-running managers for the offering. Wedbush PacGrow and Baird are acting as co-lead managers for the offering. B. Riley Securities and Needham & Company are acting as co-managers for the offering. An automatically effective shelf registration statement on Form S-3 relating to the public offering of the shares of common stock described above was filed with the Securities and Exchange Commission (SEC) on January 4, 2023. A preliminary prospectus supplement and accompanying prospectus relating to and describing the terms of the proposed offering will be filed with the SEC and will be available for free on the SEC's website at www.sec.gov . When available, copies of the preliminary prospectus supplement and accompanying prospectus relating to the proposed offering may be obtained from: Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, New York 10282, by telephone at 1-866-471-2526 or by email at prospectus-ny@ny.email.gs.com ; and Stifel, Nicolaus & Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, California 94104, by telephone at 415-364-2720 or by email at syndprospectus@stifel.com . This press release does not constitute an offer to sell or the solicitation of an offer to buy any of these securities, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
2023-01-04 17:16:55	VGLI	Palisade Bio Announces Closing of $2.5M Registered Direct Offering, Concurrent Private Placement Priced Above Market Under Nasdaq Rules	Palisade Bio, Inc. (NASDAQ: VGLI ), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, is announcing today that it has closed its previously announced registered direct offering and concurrent private placement with institutional investors for the purchase of 1,052,631 shares of common stock (or certain pre-funded warrants in lieu thereof) at a purchase price per common share of $2.375. Certain investors received unregistered pre-funded warrants in the private placement in lieu of common stock, subject to beneficial ownership limitations. The company has also issued to the investors, in the private placement, unregistered warrants to purchase up to 1,052,631 shares of common stock (the &quot;Common Warrants&quot;). These Common Warrants have a term of five (5) years and an exercise price of $2.375 per share. Accordingly, the company entered into agreements to sell (i) an aggregate of 513,842 shares of registered common stock and pre-funded warrants to purchase common stock, (ii) pre-funded warrants that are not registered to purchase an aggregate of 538,789 shares of common stock, and (iii) 1,052,631 unregistered Common Warrants. Ladenburg Thalmann & Co. Inc. acted as the exclusive placement agent for the registered direct and private placement offerings. Palisade Bio intends to use the net proceeds from the financing for working capital and general corporate purposes. The shares of common stock (and registered pre-funded warrants in lieu thereof) (but not the unregistered pre-funded warrants, nor the Common Warrants or the shares of common stock underlying such unregistered pre-funded warrants and Common Warrants) offered in the registered direct offering were offered and sold by the Company pursuant to a &quot;shelf&quot; registration statement on Form S-3 (Registration No. 333-263705), including a base prospectus, previously filed with and declared effective by the Securities and Exchange Commission (&quot;SEC&quot;) on April 26, 2022. The offering of the shares of common stock (and registered pre-funded warrants in lieu thereof) in the registered direct transaction were made only by means of a prospectus supplement that forms a part of the registration statement. A final prospectus supplement and an accompanying base prospectus relating to the registered direct offering was filed with the SEC and is available on the SEC's website located at http://www.sec.gov . Electronic copies of the prospectus supplement and accompanying base prospectus may also be obtained, by contacting Ladenburg Thalmann & Co. Inc. at Attn: Prospectus Department, 640 Fifth Avenue, 4th Floor, New York, NY 10019 or by e-mail at prospectus@ladenburg.com . The unregistered pre-funded warrants, the Common Warrants (and the shares of common stock underlying such unregistered pre-funded warrants and Common Warrants) offered in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the &quot;Act&quot;) and/or Regulation D promulgated thereunder, and such securities have not been registered under the Act or applicable state securities laws. Accordingly, such securities may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Act and such applicable state securities laws. Palisade Bio has agreed to file a registration statement with the SEC registering the resale of the shares of common stock issuable upon the exercise of the unregistered pre-funded warrants and Common Warrants. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.
2023-01-04 17:28:35	TXKB	Why Geron Stock Is Falling After Hours	Geron Corp (NASDAQ: TXKB ) shares are trading lower in Wednesday's after-hours session after the company announced a proposed public offering . What To Know: Geron said it intends to sell $175 million of its common stock in an underwritten public offering. The company intends to grant the underwriters a 30-day option to purchase up to an additional 15% of its common stock. In Wednesday's regular trading session, Geron shares soared above $4, before pulling back and closing up 32.9% at $3.19 after the company announced positive top-line results from a rare blood cancer trial. Related Link: Geron Stock Surges After Encouraging Data From Rare Blood Cancer Trial Geron is a late-stage biopharmaceutical company pursuing therapies with the potential to extend and enrich the lives of patients living with hematologic malignancies. See Also: Why Vyant Bio Shares Are Soaring After Hours TXKB Price Action: Geron shares are down 11.3% in after-hours at $2.83 at the time of publication, according to Benzinga Pro . Photo: fernando zhiminaicela from Pixabay.
2023-01-06 08:54:30	AHA	E-Home Household Service Holdings Entered Into A Securities Purchase Agreement With Eleven Investors For 40,650,406 Ordinary Shares Of The Company For The Purchase Price Of $0.492/Share	On January 6, 2023, E-Home Household Service Holdings Limited (the &ldquo;Company&rdquo;) entered into a securities purchase agreement (the &ldquo;Securities Purchase Agreement&rdquo;) with eleven investors (the &ldquo;Investors&rdquo;), including two entities and nine individuals, pursuant to which the Investors agreed to purchase an aggregate of 40,650,406 ordinary shares of the Company (the &ldquo;Investment&rdquo;) for the purchase price of $0.492 per ordinary share, which is the average of the closing prices of the Company&rsquo;s ordinary shares for the six consecutive trading days prior to January 3, 2023. The Company is expected to receive an aggregate of US$20 million proceeds in connection with the Investment. Pursuant to the Securities Purchase Agreement, the Company shall apply the proceeds of the Investment to the Haixia Home Management College project. Haixia Home Management College is a training facility for home management services to be established and operated by the Company in Pingtan, Fujian Province, with the assistance of the Pingtan local government. In addition, pursuant to the Securities Purchase Agreement, the closing of the Investment is subject to the condition that the Company shall have received any relevant confirmation from Nasdaq in relation to the Investment and the issuance of the ordinary shares. Concurrently with the execution of the Securities Purchase Agreement, each Investor executed a letter of undertaking in favor of the Company pursuant to which the Investor undertakes, for a period of 36 months following the closing of the Investment, (i) not to increase its shareholding in the Company or take any action to exert control over the Company and (ii) to abstain from voting the ordinary shares acquired in the Investment in shareholders meetings. The Company relied on the exemption from registration afforded by Section 4(a)(2) of the Securities Act of 1933, as amended, and Regulation S in connection with the issuance of the ordinary shares. In addition, the Company elected to follow its home country practice in lieu of the requirement for shareholders&rsquo; approval pursuant to Nasdaq Listing Rule 5635(d) in relation to the Investment. The foregoing description is qualified in its entirety by reference to the full text of the Securities Purchase Agreement, a copy of English translation of such agreement is furnished hereto as Exhibit 99.1 and incorporated herein by reference.
2023-01-09 08:42:33	IMM	Live Nation Entertainment Plans $850M Convertible Notes Offering	Live Nation Entertainment, Inc (NYSE: IMM ) seeks to raise $850 million via private convertible senior notes offering due 2029 . Live Nation Entertainment looks to use a portion of the net proceeds from the offering to fund its capped call transactions. The company intends to use the remainder of the offering proceeds to repurchase a portion of its 2.5% convertible senior notes due 2023, to pay related fees and expenses, and for general corporate purposes. The initial purchasers get the right to purchase up to an additional $85.0 million aggregate principal amount of convertible notes for settlement within 13 days. The convertible notes will accrue interest payable semi-annually in arrears and will mature on January 15, 2029. Holders of the convertible notes have the right to require the company to repurchase their notes at 100% of their principal, plus any accrued and unpaid interest, upon the occurrence of certain corporate events. The company may redeem the convertible notes only if the last reported sale price of the company's common stock has been at least 130% of the conversion price. The company expects to enter into privately negotiated capped call transactions to reduce the potential dilution of the company's common stock upon converting the convertible notes. The company held $5.1 billion in long-term debt and $5 billion in cash and equivalents as of September 30 . Price Action: IMM shares traded lower by 3.27% at $70.01 in the premarket on the last check Monday.
2023-01-09 10:21:26	JFVZ	Bilibili Raises $409M Via Secondary Equity Offering At 7% Discount	Bilibili Inc (NASDAQ: JFVZ ) priced 15.34 million American depositary shares at $26.65 per ADS (or $408.9 million) to repay $384.8 million of its outstanding 0.50% convertible senior notes due December 2026 . The offer price implied a 7% discount to Bilibili's January 6 closing price of $28.65 Bilibili's shares were worth $439.6 million based on the January 6 closing price. Also Read: Bilibili Lets Go Of 30% Staff As Slowdown Hurts Operations Goldman Sachs will use the offering proceeds to fund the aggregate purchase price of the exchange notes payable by Goldman Sachs. Concurrently with the offering, Goldman Sachs plans to enter into separate and individually negotiated agreements to purchase the exchange notes for cash. Bilibili held $1.73 billion in long-term debt and $0.77 billion in cash and equivalents as of September 30 . Price Action: JFVZ shares traded lower by 5.78% at $27 on the last check Monday.
2023-01-09 16:15:09	PSTV	Lifecore Biomedical Raises Capital With $38.75M Private Placement Of Convertible Preferred Stock; Amends Credit Facilities	$38.75 million Private Placement of Series A Convertible Preferred Stock to Support Working Capital and Capital Expenditures While Pursuing Ongoing Divestment Process of non-RLVE Assets Credit Facilities Amended to Increase Liquidity and Provide Financial Covenant Relief Nathaniel Calloway, PhD and Christopher Kiper Appointed to the Board of Directors CHASKA, Minn., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (&quot;Lifecore&quot; or the &quot;Company&quot;), a fully integrated contract development and manufacturing organization (&quot;RLVE&quot;), today announced that it has entered into a securities purchase agreement with a select group of institutional investors, pursuant to which the Company issued and sold 38,750 shares of newly designated Series A convertible preferred stock in a private placement for total gross proceeds of $38.75 million before deducting offering expenses. The private placement was led by Legion Partners and 22NW Fund, LP, with participation by existing and new investors including Wynnefield Capital, Cove Street Partners and 325 Capital. The Company expects to use the proceeds to support its working capital requirements and help address strong demand it is experiencing for sterile injectable pharmaceutical products while it pursues the final phases of its divestment process of non-RLVE assets, as well as for capital expenditures, repayment of the Company's indebtedness and general corporate purposes. The Company also announced the amendment of its credit facilities to provide for increased overall liquidity and amended financial covenants to allow Lifecore to achieve its growth potential. In connection with the issuance of the Series A convertible preferred stock, Nathaniel Calloway, PhD and Christopher Kiper were appointed to the Company's Board of Directors. The Company also amended its credit facilities to provide for, among other things, increased overall liquidity, including the deferral of $2.2 million of quarterly debt repayments until the first quarter of calendar year 2025, and relief from certain financial covenants. &quot;We are extremely excited for 2023 and remain fully focused on taking advantage of the strong market tailwinds that are generating a myriad of opportunities within our development pipeline with some of the world's leading pharmaceutical companies,&quot; commented James G. Hall, President and Chief Executive Officer of Lifecore. &quot;We are very pleased for the continued support of our long-term stockholders, which demonstrates their commitment to supporting Lifecore's continued focus to deliver on its growth ambitions. We expect to use the proceeds of the investment to support both our working capital and capital expenditure requirements with an objective of delivering on our increased near and longer term customer demands while we focus on additional cost savings, driving free cash flow and divesting our non-RLVE assets.&quot; Important Information Regarding the Series A Convertible Preferred Stock The Series A convertible preferred stock was issued in reliance on an exemption from registration under the Securities Act of 1933, as amended (the &quot;Securities Act&quot;), pursuant to Section 4(a)(2) thereof. The Series A convertible preferred stock sold in the private placement has not been and will not be registered under the Securities Act, or any state or other applicable jurisdiction's securities laws, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act and applicable state or other jurisdictions' securities laws. This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
2023-01-10 07:19:14	SXSG	L World Group Raises $260M Via Equity Offering	L World Group Ltd (NASDAQ: SXSG ) has commenced an underwritten public offering of $260 million of American depositary shares (ADS). All ADSs will be offered by the company. The underwriters are expected to have a 30-day option to purchase up to $39 million of additional ADSs from the company. L World plans to use the net proceeds from the offering to fund its growth strategies amid post-COVID reopening, invest in initiatives that support its long-term success and for working capital. Goldman Sachs (Asia) L.L.C. and UBS Securities LLC are acting as joint underwriters for the offering. Price Action: SXSG shares are trading lower by 3.45% at $42.29 in premarket on the last check Tuesday.
2023-01-10 08:19:47	JUOL	BIOLASE Prices $9.75M Offering	BIOLASE, Inc. (NASDAQ: JUOL ) (&quot;BIOLASE&quot; or the &quot;Company&quot;), a global leader in dental lasers, today announced the pricing of an underwritten public offering consisting of 16,453,569 shares of its common stock and pre-funded warrants to purchase 11,403,571 shares of common stock at a public offering price of $0.35 per share or $0.34 per pre-funded warrant. The pre-funded warrants have an exercise price of $0.01 per share, are exercisable immediately, and will not expire until exercised. The offering is expected to close on January 12, 2023, subject to customary closing conditions.
2023-01-10 09:12:46	RAOB	My Size Announces $3M Concurrent Registered Direct Offering And Private Placement Priced At-The-Market Under Nasdaq Rules	MySize, Inc. (NASDAQ: RAOB ) (TASE: RAOB.TA) (&quot;MySize&quot; or the &quot;Company&quot;), an omnichannel e-commerce platform and provider of AI-driven measurement solutions to drive revenue growth and reduce costs for its business clients, today announced that it has entered into definitive agreements for the issuance and sale of 441,899 of its shares of common stock (or common stock equivalents) at a purchase price of $3.055 per share in a registered direct offering. In a concurrent private placement, My Size has also agreed to issue and sell 540,098 of its shares of common stock (or common stock equivalents), at the same purchase price as in the registered direct offering. In addition, the Company has agreed to issue in the offerings unregistered Series A warrants to purchase up to an aggregate of 981,997 shares of common stock and Series B warrants to purchase up to an aggregate of 981,997 shares of common stock. The registered direct offering and the private placement were priced at-the-market under Nasdaq rules. The aggregate gross proceeds to the Company of both offerings is expected to be approximately $3.0 million. The offerings are expected to close on or about January 12, 2023, subject to the satisfaction of customary closing conditions.
2023-01-10 09:28:40	SXSG	L World Group Limited Announces Pricing Of Public Offering Of 6.19M American Depositary Shares At A Price Of $42/ADS	L World Group Limited (NASDAQ: SXSG ) (&quot;L World&quot; or the &quot;Company&quot;), a key player in the global hotel industry, today announced that the pricing of its underwritten public offering (the &quot;Offering&quot;) of 6,190,000 American depositary shares (&quot;ADSs&quot;), each representing ten ordinary shares of the Company, at a price of US$42.0 per ADS. In addition, the underwriters for this Offering have a 30-day option to purchase up to an aggregate of 928,500 additional ADSs from the Company. The Company plans to use the net proceeds from the Offering (i) to fund its growth strategies amid post-COVID reopening, including enhancing the competitiveness of its hotel portfolio and developing its regional-based operating paradigm; (ii) to invest in initiatives that support its long term success, including its technology infrastructure, supply chain ecosystem, distribution system that connects both individual guests and corporate clients, and environment, social and governance (ESG) efforts; and (iii) for working capital and general corporate purposes.
2023-01-11 09:28:10	ZVK	Why ZVK Shares Are Trading Lower Premarket Today	ZVK Holdings Limited (NASDAQ: ZVK ) looked to raise $580 million via private 4.50% convertible senior notes offering due 2030 . The conversion price of $24.50 implied a premium of 2.6% to the January 10 closing of $23.89. It indicated a premium of 16.7% to the volume-weighted average price of ZVK ADSs traded on NASDAQ for the 25 trading days immediately preceding the signing date. The notes will be convertible into ADSs at the option of the holders. The leading developer and operator of high-performance data centers in China looked to utilize the offering proceeds for developing and acquiring new data centers, general corporate purposes, and working capital needs. ZVK held $5.1 billion in long-term debt and $1.28 billion in cash and equivalents as of September 30 . Price Action: ZVK shares traded lower by 8.66% at $21.82 in the premarket on the last check Wednesday.
2023-01-12 08:33:06	GAA	Myomo Announces Pricing Of $6.5M Upsized Public Offering Of 20M Shares Of Common Stock At A Price Of $0.325/Share	Myomo, Inc. (NYSE: GAA ) (&quot;Myomo&quot; or the &quot;Company&quot;), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced the pricing of its &quot;best efforts&quot; public offering of 20,000,000 shares of common stock (or common stock equivalents in lieu thereof) at a public offering price of $0.325 per share for aggregate gross proceeds of approximately $6.5 million, before deducting placement agent fees and other offering expenses. The closing of the offering is expected to occur on or about January 17, 2023, subject to the satisfaction of customary closing conditions. The Company intends to use the net proceeds from this offering for working capital and general corporate purposes.
2023-01-12 08:36:03	KUUL	LightPath Technologies Announces Pricing Of $10M Public Offering Of 9,090,910 Shares Of Common Stock At A Price Of $1.10/Share	ightPath Technologies, Inc. (NASDAQ: KUUL ) (&quot;LightPath&quot; or the &quot;Company&quot;) today announced the pricing of its previously announced public offering of 9,090,910 shares of common stock at a purchase price of $1.10 per share for aggregate gross proceeds of approximately $10 million, before deducting placement agent fees and other offering expenses. The closing of the offering is expected to occur on or about January 17, 2023, subject to the satisfaction of customary closing conditions. We intend to use the net proceeds from the offering to fund our future growth initiatives, working capital and general corporate purposes.
2023-01-12 08:37:14	IKKH	Antelope Enterprise Announces $1.3M Private Placement Led By CEO Will Zhang	Antelope Enterprise Holdings Limited (NASDAQ Capital Market: IKKH) (&quot;Antelope Enterprise&quot; or the &quot;Company&quot;), which operates KylinCloud, a leading social and livestreaming ecommerce platform with 200,000+ anchors and influencers, and a legacy ceramic tiles manufacturing business in China, today announced that it closed a private placement or PIPE (Private Investment in Public Equity) financing with a select group of investors led by the Company's CEO, Mr. Weilai ('Will') Zhang. The PIPE financing is for the sale of 1,625,000 ordinary shares at a price per share of $0.80, the closing price of its ordinary shares on the Nasdaq Capital Market as of January 10, 2023. The gross proceeds of the private placement are $1.3 million, before deducting any fees or expenses. The Company plans to use the net proceeds from the offering for the expansion of the Company's social ecommerce business and for general corporate purposes. Will Zhang, CEO of Antelope Enterprise, commented, &quot;We believe that this private placement, led by insiders including myself, will provide us with the financial resources to further strengthen the capabilities of our ecommerce subsidiary, KylinCloud, which is well positioned to expand its footprint in the fast-growing social and livestreaming ecommerce sector in China. Our management team and board of directors are committed to transforming the Company into a leading social ecommerce enterprise and in doing so, creating long-term value for our shareholders.&quot; The securities being issued and sold in the private placement have not been registered under the Securities Act of 1933, as amended (the &quot;Securities Act&quot;), or any state's securities laws, and are being issued and sold pursuant to an exemption from registration provided for under the Securities Act. The securities may not be offered or sold in the United States, except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.
2023-01-12 16:16:29	VZBB	Ares Capital Corporation Announces Public Offering Of 9M Shares Of Common Stock	Ares Capital Corporation (NASDAQ: VZBB ) announced that it plans to make a public offering of 9,000,000 shares of its common stock. Ares Capital also plans to grant the underwriters an option to purchase up to an additional 1,350,000 shares of common stock. The offering of the shares will be made under Ares Capital's shelf registration statement filed with the Securities and Exchange Commission on June 3, 2021, which became effective automatically upon filing. Morgan Stanley & Co. LLC, BofA Securities, UBS Investment Bank, RBC Capital Markets, LLC and Wells Fargo Securities are acting as joint lead book-running managers for this offering. Keefe, Bruyette & Woods, A Stifel Company , and Raymond James & Associates, Inc. are acting as joint book-running managers for this offering. Goldman Sachs & Co. LLC, Janney Montgomery Scott LLC, J.P. Morgan and Oppenheimer & Co. Inc. are acting as co-managers for this offering. Ares Capital expects to use the net proceeds of this offering to repay certain outstanding indebtedness under its debt facilities. Ares Capital may reborrow under its debt facilities for general corporate purposes, which include investing in portfolio companies in accordance with its investment objective.
2023-01-13 08:33:11	PKAB	MicroAlgo Announces Enters Securities Purchase Agreement For Up To $3.2M	MicroAlgo Inc. (the &quot;Company&quot; or &quot;MicroAlgo&quot;) (NASDAQ: PKAB) today announced that it has entered into a definitive agreement for the issuance and sale of 2,666,667 private placement units at $1.20 per unit, each unit consisting of one ordinary share of the Company, par value $0.001 per share, (&quot;Ordinary Share&quot;) and one warrant entitling the holder to purchase one whole Ordinary Share at an exercise price of $1.35 per whole share. The gross proceeds to the Company from this private offering is approximately $3.2 million. As a condition to the closing, the Company and the Investor will enter into a Registration Rights Agreement pursuant to which the Company will file with the U.S. Securities and Exchange Commission (the &quot;SEC&quot;) a registration statement covering the registrable securities within a reasonable timeframe upon the demand of the Investor.
2023-01-13 10:10:06	VZBB	Why Ares Capital Stock Is Trading Lower	Ares Capital Corporation (NASDAQ: VZBB ) shares are trading lower by 3.49% to $18.92 Friday morning after the company priced a public offering. Ares Capital says the offering was upsized from its previously announced offering size of 9,000,000 shares. The company has granted the underwriters an option to purchase up to an additional 1,575,000 shares of common stock. Ares says the offering is subject to customary closing conditions and is expected to close on January 18. See Also: Why GM, Ford, Stellantis Are In Reverse Gear In Premarket Today The company expects to use the net proceeds of this offering to repay certain outstanding indebtedness under its credit facilities. Ares Capital may reborrow under its credit facilities for general corporate purposes, which include investing in portfolio companies in accordance with its investment objective. According to data from Benzinga Pro , VZBB has a 52-week high of $23.00 and a 52-week low of $16.53.
2023-01-13 10:25:34	ODSN	First Wave BioPharma Announces Results Of Special Meeting Of Stockholders	First Wave BioPharma, Inc. (NASDAQ: ODSN ) (&quot;First Wave BioPharma&quot; or the &quot;Company&quot;), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced that the Company's stockholders have approved all proposals voted on at the Company's special meeting of stockholders (the &quot;Special Meeting&quot;) held on January 13, 2023. The first proposal was the approval the issuance of more than 20% of the Company's common stock pursuant to the private placement and warrant amendment agreement entered into by the Company on November 20, 2022. The second proposal was the adoption and approval of an amendment to the Company's Amended and Restated Certificate of Incorporation, as amended, to effect a reverse stock split of the Company's issued and outstanding shares of common stock, at a specific ratio, ranging from one-for-three (1:3) to one-for-forty (1:40), at any time prior to the one-year anniversary date of the Special Meeting, with the exact ratio to be determined by the Company's board of directors without further approval or authorization of the stockholders. The third proposal was the approval of the adjournment of the Special Meeting to the extent there were insufficient proxies at the Special Meeting to approve any one or more of the foregoing proposals. Final voting results from the Special Meeting will be included in a Form 8-K filed with the Securities and Exchange Commission.
2023-01-13 11:22:19	KSCD	Why KSCD Properties Stock Is Falling	KSCD Properties Inc (NYSE: KSCD ) shares are trading lower by 2.82% to $33.05 Friday after the company announced pricing of an upsized public offering of common stock. The upsized underwritten public offering of 26,350,000 shares of its common stock are at a public offering price of $33.00 per share. The offering is expected to close on January 18, subject to customary closing conditions. See Also: Why GM, Ford, Stellantis Are In Reverse Gear In Premarket Today According to data from Benzinga Pro , KSCD Properties has a 52-week high of $35.69 and a 52-week low of $26.23.
2023-01-17 08:53:12	IMQF	On January 10 2023, BioSig Technologies Entered Into A Securities Purchase Agreement With Certain Institutional And Accredited Investors Pursuant To Which The Company Sold To The Investors An Aggregate Of 2,178,316 Shares Of Common Stock At $0.57608/share	IMQF On January 10, 2023, BioSig Technologies, Inc. (the &quot;Company&quot;) entered into a Securities Purchase Agreement (the &quot;Purchase Agreement&quot;) with certain institutional and accredited investors (the &quot;Investors&quot;), pursuant to which the Company sold to the Investors an aggregate of 2,178,316 shares (the &quot;Shares&quot;) of the Company's common stock, par value $0.001 per share (the &quot;Common Stock&quot;) at a purchase price of $0.57608 per share, and warrants (the &quot;Warrants&quot;) to purchase up to 1,089,158 shares of Common Stock (the &quot;Warrant Shares&quot; and together with the Shares and Warrants, the &quot;Securities&quot;), at an exercise price of $0.51358 per share, that will become exercisable six months after the date of issuance and will expire five and one-half years following the date of issuance, in exchange for aggregate consideration of $1,254,884.28.
2023-01-17 10:01:05	WO	IQIYI Raises $442M Via Secondary Equity Offering At 12% Discount	IQIYI, Inc (NASDAQ: WO ) priced 76.5 million American Depositary Shares at $5.90 per ADS under a secondary public offering . The offer price implies an 11.8% discount to IQIYI's January 13 closing price of $6.69. The expected offering proceeds are $442.3 million. The underwriters have 30 days to purchase up to 11.5 million additional ADSs. The online entertainment video services provider plans to use the offering proceeds for working capital purposes, including serving its existing debt obligations. IQIYI held RMB 5.0 billion ($709.5 million) in cash and equivalents as of September 30. IQIYI held RMB 6.4 billion in convertible senior notes. Price Action: WO shares traded lower by 13.68% at $5.78 on the last check Tuesday. Photo Via Wikimedia Commons
2023-01-18 08:34:41	CGJ	Arcimoto Announces Pricing Of $12M Public Offering Of Up To 4M Shares Of Common Stock At A Price Of $3/Share	Arcimoto, Inc.&reg; (NASDAQ: CGJ ), makers of rightsized, outrageously fun, ultra-efficient electric vehicles, today announced the pricing of its previously announced public offering of 4,000,000 shares of common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to 4,000,000 shares of common stock at a combined purchase price of $3.00 per share and accompanying warrant for aggregate gross proceeds of approximately $12 million, before deducting placement agent fees and other offering expenses. The warrants to be issued will have a five-year term, will be exercisable immediately, and will have an exercise price of $3.00 per share. The closing of the offering is expected to occur on or about January 20, 2023, subject to the satisfaction of customary closing conditions. We intend to use the net proceeds from the offering for working capital and other general corporate purposes.
2023-01-18 09:27:57	XBK	Bit Brother Limited Announces Pricing Of $7.1M Registered Direct Offering	Bit Brother Limited (&quot;Bit Brother, &quot; &quot;We&quot; or the &quot;Company&quot;) (NASDAQ: XBK ), announced today that it has entered into a securities purchase agreement with certain accredited investors to sell $7.1 million of its ordinary shares and warrants in a registered direct offering. Under the terms of the securities purchase agreement, Bit Brother has agreed to sell 1,569,444 ordinary shares and warrants to purchase 2,354,166 ordinary shares. The warrants will be exercisable immediately upon the date of issuance and have an exercise price of $4.50. The warrants will expire five years from the date of issuance. The purchase price for one ordinary share and one corresponding warrant will be $4.50. The gross proceeds to Bit Brother are estimated to be $7.1 million before deducting the placement agent fees and other estimated offering expenses.
2023-01-18 10:14:55	CGJ	Arcimoto Nosedives Following $12M Equity Offering	Arcimoto Inc (NASDAQ: CGJ ) has priced its previously announced public offering of 4 million shares and warrants to purchase up to 4 million shares. The shares can be purchased at a combined purchase price of $3.00 per share and accompanying warrant for aggregate gross proceeds of approximately $12 million. The price represents a 50.9% discount on Arcimoto&rsquo;s last close on January 17, 2023. The warrants to be issued will have a five-year term, will be exercisable immediately, and will have an exercise price of $3.00 per share. The closing of the offering is expected to occur on or about January 20, 2023. The company intends to use the net proceeds from the offering for working capital and other general corporate purposes. A.G.P./Alliance Global Partners is acting as the sole placement agent for the offering. Price Action : CGJ shares are trading lower by 59.80% at $2.46 on the last check Wednesday.
2023-01-18 14:15:34	XBK	Bit Brother Plunges After $7.1M Equity Offering	Bit Brother Ltd (NASDAQ: XBK ) said it has entered into a securities purchase agreement with certain accredited investors to sell $7.1 million of its shares and warrants. Under the terms of the securities purchase agreement, Bit Brother has agreed to sell 1.6 million and warrants to purchase 2.4 million shares. The purchase price for one ordinary share and one corresponding warrant will be $4.50. The warrants will be exercisable immediately upon the date of issuance and have an exercise price of $4.50. The warrants will expire five years from the date of issuance. The offering is expected to close on January 20, 2023. Price Action: XBK shares are trading lower by 70.3% at $1.96 on the last check Wednesday.
2023-01-18 16:15:24	XJW	Olink Holding AB (publ) Launches Public Offering Of  5,831,028 American Depositary Shares	Olink Holding AB (publ) (NASDAQ: XJW ) (&quot; Olink &quot; or the &quot; Company &quot;), today announced the launch of a public offering of 5,831,028 American Depositary Shares, each representing one common share of the Company (the &quot; ADSs &quot;), consisting of 4,250,000 ADSs offered by the Company and 1,581,028 ADSs offered by certain selling shareholders of the Company (the &quot; Selling Shareholders &quot;). In addition, the Company is expected to grant the underwriters a 30-day option to purchase up to 874,654 additional ADSs. The Company will not receive any proceeds from the sale of the ADSs by the Selling Shareholders. The offering is subject to market and other conditions, and there can be no assurance as to whether, or when, the offering may be completed or as to the actual size or terms of the offering. Goldman Sachs Bank Europe MX and J.P. Morgan Securities LLC are acting as lead book-running managers for the offering. SVB Securities LLC and Canaccord Genuity LLC are acting as joint book-running managers for the offering. The securities described above are being offered by the Company pursuant to a shelf registration statement that became automatically effective upon filing with the Securities and Exchange Commission (the &quot; SEC &quot;). The proposed offering will be made only by means of a prospectus supplement and accompanying base prospectus, copies of which may be obtained on the SEC's website located at http://www.sec.gov . Copies of the preliminary prospectus supplement and the accompanying base prospectus relating to this offering, when available, may also be obtained from: Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, telephone: 1-866-471-2526 or by emailing Prospectus-ny@ny.email.gs.com; or J.P. Morgan Securities LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, telephone 1-866-803-9204 or by emailing prospectus-eq_fi@jpmchase.com . This press release does not constitute an offer to sell or a solicitation of an offer to buy these securities, nor will there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful before registration or qualification under the securities laws of that state or jurisdiction.
2023-01-19 08:59:22	IOMV	Why Ardelyx Shares Are Falling	Ardelyx Inc (NASDAQ: IOMV ) shares are trading lower by 17.03% to $2.67 Thursday morning after the company filed for a mixed shelf offering of up to $250 million. Ardelyx says the company intends to use the net proceeds, if any, from this offering for general corporate purposes, which may include, among other things, activities associated with the commercialization of IBSRELA and XPHOZAH, if approved, conducting post-approval pediatric clinical studies for IBSRELA and XPHOZAH, if approved and working capital. See Also: Why Allstate Stock Is Hitting The Brakes Today According to data from Benzinga Pro , IOMV has a 52-week high of $3.43 and a 52-week low of $0.49.
2023-01-19 09:16:12	UYWG	Why Deciphera Pharmaceuticals Stock Is Nosediving	Deciphera Pharmaceuticals Inc (NASDAQ: UYWG ) shares are trading lower by 10.48% to $18.45 Thursday morning after the company announced a $125 million proposed public offering of common stock. In addition, Deciphera intends to grant the underwriters a 30-day option to purchase up to an additional $18,750,000 of shares of common stock offered in the public offering. Deciphera says the company intends to use the net proceeds from the offering to fund its planned Phase 3 INSIGHT study of QINLOCK &reg; versus sunitinib in second-line GIST patients with mutations in KIT exon 11 and 17/18 only, among many other strategies. See Also: Why Allstate Stock Is Hitting The Brakes Today According to data from Benzinga Pro , UYWG has a 52-week high of $22.76 and a 52-week low of $6.51.
2023-01-19 09:17:06	IDPH	Jupiter Wellness Announces $4.1M Registered Direct And Private Placement	Jupiter Wellness, Inc. (&quot;IDPH&quot; or the &quot;Company&quot;) (NASDAQ: IDPH ), a wellness company focused on hair, skin, and sexual wellness, today announced that it has entered into a definitive agreement with investors for the purchase and sale of 4,315,786 shares in a registered direct offering. In a concurrent private placement, the Company also agreed to issue to the same investors a total of 8,631,572 warrants to purchase up to one share ofcommon stock each at an exercise price of $1.00 per share. The private placement warrants will be exercisable beginning six months after issuance. 4,315,786 warrants will have a 3-year term from the initial exercise date and 4,315,786 warrants will have a 5-year term from the initial exercise date. The purchase price of one share, one 3-year warrant and one 5-year warrant is $0.95. The aggregate gross proceeds to the Company of both transactions are expected to be approximately $4.1 million. The transactions are expected to close on or about January 23, 2022, subject to the satisfaction of customary closing conditions. Aegis Capital Corp. is acting as the Exclusive Placement Agent. The registered direct offering is being made pursuant to an effective shelf registration statement on Form S-3 (No. 333-267644) previously filed with the U.S. Securities and Exchange Commission (the &quot;SEC&quot;) and declared effective by the SEC on November 9, 2022. A final prospectus supplement and accompanying prospectus describing the terms of the proposed offering will be filed with the SEC and will be available on the SEC's website located at http://www.sec.gov . Electronic copies of the final prospectus supplement and the accompanying prospectus may be obtained, when available, by contacting Aegis Capital Corp., Attention: Syndicate Department, 1345 Avenue of the Americas, 27th floor, New York, NY 10105, by email at syndicate@aegiscap.com , or by telephone at (212) 813-1010. The offer and sale of the securities in the private placement are being made in a transaction not involving a public offering and have not been registered under the Securities Act of 1933, as amended (the &quot;Securities Act&quot;), or applicable state securities laws. Accordingly, the securities may not be reoffered or resold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws. The securities were offered only to accredited investors. Pursuant to a registration rights agreement with the investor, the Company has agreed to file one or more registration statements with the SEC covering the resale of the common stock and the shares issuable upon exercise of the pre-funded warrants and warrants. Before investing in this offering, interested parties should read in their entirety the prospectus supplement and the accompanying prospectus and the other documents that the Company has filed with the SEC that are incorporated by reference in such prospectus supplement and the accompanying prospectus, which provide more information about the Company and such offering. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
2023-01-19 11:10:17	IDPH	Why Jupiter Wellness Stock Is Getting Hammered	Jupiter Wellness Inc (NASDAQ: IDPH ) shares are trading lower by 39.10% to $0.62 Thursday morning after the company announced a $4.1 million registered direct offering and private placement. Jupiter Wellness says it has entered into a definitive agreement with investors for the purchase and sale of 4,315,786 shares in a registered direct offering. Meanwhile, in a concurrent private placement, Jupiter Wellness also agreed to issue to the same investors a total of 8,631,572 warrants to purchase up to one share of common stock each at an exercise price of $1.00 per share. See Also: What's Going On With Netflix Shares The transactions are expected to close on or about January 23, subject to the satisfaction of customary closing conditions. According to data from Benzinga Pro , IDPH has a 52-week high of $1.64 and a 52-week low of $0.58.
2023-01-20 08:32:08	HPZX	China Jo-Jo Drugstores Announces $2.625M Registered Direct Offering	China Jo-Jo Drugstores, Inc. (NASDAQ: HPZX ) (&quot;Jo-Jo Drugstores&quot; or the &quot;Company&quot;), a leading online and offline retailer, wholesale distributor of pharmaceutical and other healthcare products and healthcare provider in China, today announced that it has entered into definitive agreements with a number of investors providing for the issuance of 1.75 million ordinary shares, at a purchase price of $1.50 per share, in a registered direct offering for aggregate gross proceeds of $2.625 million. Jo-Jo Drugstores also agreed to issue to the investors registered warrants to purchase up to 5.25 million ordinary shares. The warrants will have a term of three years, be exercisable immediately at an exercise price of $2.50 per share. The closing of the sale of the securities is expected to occur on or about January 24, 2023, subject to satisfaction of customary closing conditions. Jo-Jo Drugstores intends to use the net proceeds from the offering for general corporate purposes and working capital. The ordinary shares and warrants described above are being offered pursuant to a &quot;shelf&quot; registration statement on Form F-3 (File No. 333-259692), which was declared effective by the United States Securities and Exchange Commission (the &quot;SEC&quot;) on December 19, 2022. The ordinary shares and warrants described above may be offered only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement. When filed with the SEC, copies of the final prospectus supplement and the accompanying prospectus relating to the registered direct offering may be obtained at the SEC's website at http://www.sec.gov . This press release shall not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.
2023-01-20 15:07:26	HPZX	China Jo-Jo Drugstores Raises $2.65M Via Equity Offering	China Jo-Jo Drugstores Holdings Inc (NASDAQ: HPZX ) has entered into definitive agreements with several investors providing for the issuance of 1.75 million ordinary shares. The company will offer the shares at a purchase price of $1.50 per share for aggregate gross proceeds of $2.625 million. Jo-Jo Drugstores also agreed to issue warrants to buy up to 5.25 million ordinary shares. The warrants will have a term of three years, be exercisable immediately at an exercise price of $2.50 per share. The closing of the sale of the securities is expected to occur on or about January 24, 2023. The company plans to use the offering net proceeds for general corporate purposes and working capital. Price Action : HPZX shares are trading higher by 10.44% at $2.75 on the last check Friday.
2023-01-24 07:05:05	WXDP	CymaBay Announces Priced  Public Offering of Common Stock and Pre-Funded Warrants @$7.00/Share and $6.999/Warrant	CymaBay Therapeutics, Inc. (NASDAQ: WXDP ) today announced the pricing of its previously announced underwritten public offering of common stock and pre-funded warrants. CymaBay is selling 10,000,000 shares of common stock and pre-funded warrants to purchase 2,142,857 shares of common stock in the offering. The shares of common stock are being sold at a public offering price of $7.00 per share, and the pre-funded warrants are being sold at a public offering price of $6.9999 per underlying share. The gross offering proceeds to CymaBay from this offering are expected to be approximately $85.0 million, before deducting the underwriting discount and other estimated offering expenses, and excluding the exercise of any pre-funded warrants. All shares of common stock and pre-funded warrants to be sold in the offering are being offered by CymaBay. CymaBay has granted the underwriters a 30-day option to purchase up to an additional 1,821,428 shares of its common stock at the public offering price per share less underwriting discounts and commissions. CymaBay anticipates using the net proceeds from the offering to fund ongoing development of seladelpar, including clinical trials targeting market expansion, and for working capital and general corporate purposes.
2023-01-25 10:10:27	OBXF	Why Digital Ally Stock Is Trading Lower	Digital Ally Inc (NASDAQ: OBXF ) shares are trading lower by 8.73% to $0.30 Wednesday morning after the company filed for a common stock offering of an undisclosed size. Digital Ally says the company intends to use the proceeds of this offering for new product development, general corporate purposes including legal and marketing matters and other working capital purposes. Digital Ally added that the company may temporarily invest the net proceeds in short-term, interest-bearing instruments or other investment-grade securities. See Also: Intuitive Surgical Stock Is Trading Lower: What's Going On? According to data from Benzinga Pro , OBXF has a 52-week high of $1.22 and a 52-week low of $0.21.
2023-01-25 16:15:39	DKP	TD SYNNEX Announces Launch Of Secondary Public Offering Of 4.5M Shares Of Common Stock	TD SYNNEX Corporation (NYSE: DKP ) (&ldquo;TD SYNNEX&rdquo; or the &ldquo;Company&rdquo;) today announced a proposed secondary public offering of 4,500,000 shares of its common stock currently held by certain entities managed by affiliates of Apollo Global Management, Inc. (the &ldquo;Selling Stockholders&rdquo;). The underwriters will have a 30-day option to purchase up to an additional 675,000 shares of common stock from the Selling Stockholders. TD SYNNEX is not selling any shares of its common stock and will not receive any proceeds from the sale of the shares by the Selling Stockholders in the offering. In addition, the Company has authorized the purchase from the underwriters of 900,000 shares of common stock as part of the secondary public offering, which represents 20% of the shares being offered by the Selling Stockholders in the secondary public offering, up to a maximum of $100 million of shares (the &ldquo;Concurrent Share Repurchase&rdquo;). The Concurrent Share Repurchase is part of the Company&rsquo;s existing $1 billion share repurchase program. The Company intends to fund the Concurrent Share Repurchase from existing cash on hand. The underwriters will not receive any underwriting discount for the shares being repurchased by the Company.
2023-01-26 08:55:34	OWT	Village Farms International Announced ~$25M Registered Direct Offering	Village Farms International, Inc. (NASDAQ: OWT ) announced today that it has entered into definitive agreements with certain institutional investors for the purchase and sale of 18,350,000 of its common shares together with warrants to purchase up to 18,350,000 common shares, pursuant to a registered direct offering. The common shares and warrants are being sold at a combined purchase price of US$1.35 per share and accompanying warrant for expected gross proceeds of approximately US$25 million, before deducting placement agent fees and other offering expenses payable by Village Farms. The warrants will have an exercise price of US$1.65, will be exercisable beginning six months from issuance and will expire five years from the date of initial exercisability. The closing of the offering is subject to customary closing conditions, and is expected to close on or about January 30, 2023. The net proceeds from this offering are intended to be used for general working capital purposes. A.G.P./Alliance Global Partners and Cantor Fitzgerald & Co. are acting as co-lead placement agents for the offering.
2023-01-27 08:07:01	WCMR	Movano Health Prices $6.5M Public Offering Of 4,644,000 Shares At A Price Of $1.57/Share	Movano Health (NASDAQ: WCMR ), a purpose-driven healthcare solutions company at the intersection of medical and consumer devices and makers of the Evie Ring , today announced that it has priced a $6.5 million underwritten public offering of 4,644,000 shares of its common stock and warrants to purchase up to 2,322,000 shares of common stock. The warrants are being sold at the rate of one warrant for every two shares of common stock and will be exercisable at a price per share of $1.57. The public offering price, before the underwriters' discount and commissions, for each share of common stock and accompanying warrant is $1.40. All of the securities in the underwritten public offering were sold by Movano Inc. The Company has granted the underwriter a 30-day option to purchase up to an additional 15% of shares of common stock and/or warrants to purchase shares of common stock sold in the offering at the public offering price, less the underwriting discount. The warrants will not be listed on any securities exchange or other nationally recognized trading system. The offering is expected to close on January 31, 2023. The Company intends to use the net proceeds from the offering for general corporate purposes, which may include funding product development and commercialization activities.
2023-01-27 08:21:03	QRAO	Nemaura Medical Announces Pricing Of ~$8.4M Registered Direct Offering And Concurrent Private Placement	Nemaura Medical, Inc. (NASDAQ: QRAO ) (&quot;Nemaura&quot; or the &quot;Company&quot;), a medical technology company focused on developing and commercializing non-invasive wearable sensors and supporting personalized lifestyle and weight reduction programs, today announced it has entered into a definitive agreement with two healthcare-focused U.S. institutional investors to sell 4,796,206 shares of its common stock (the &quot;Shares&quot;), pursuant to a registered direct offering (the &quot;Registered Direct Offering&quot;), and warrants to purchase up to 4,796,206 Shares (the &quot;Warrants&quot;), in a concurrent private placement (the &quot;Private Placement&quot;). The combined purchase price for one Share and one Warrant will be $1.75. The Warrants will have an exercise price of $2.00 per Share, will be initially exercisable at the later of shareholder approval or 6 months following the date of issuance and will expire five and a half years from the closing date. The aggregate gross proceeds from the Registered Direct Offering and the concurrent Private Placement are expected to be approximately $8.4 million before deducting placement agent fees and other estimated offering expenses. The closing of the Offering and the concurrent Private Placement is expected to occur on or about January 31, 2023, subject to the satisfaction of customary closing conditions. EF Hutton, division of Benchmark Investments, LLC, is acting as sole placement agent for the offering. Anthony L.G., PLLC is acting as legal counsel to Nemaura and Sichenzia Ross Ference LLP is acting as legal counsel to EF Hutton. Nemaura intends to use the net proceeds for working capital and general corporate purposes.
2023-01-27 10:26:14	QRAO	Why Nemaura Medical Stock Is Getting Hammered	Nemaura Medical Inc (NASDAQ: QRAO ) shares are trading lower by 38.8% to $1.75 Friday morning after the company announced pricing of a roughly $8.4 million registered direct offering and concurrent private placement. Nemaura Medical says the closing of the offering and the concurrent private placement is expected to occur on or about January 31, subject to the satisfaction of customary closing conditions. Nemaura intends to use the net proceeds for working capital and general corporate purposes. See Also: Why Bitcoin- And Ethereum-Related Stock Silvergate Capital Is Nosediving According to data from Benzinga Pro , Nemaura Medical has a 52-week high of $4.58 and a 52-week low of $1.50.
2023-01-27 12:01:01	BMGF	Avenue Therapeutics Announces $3.25M Registered Direct And Private Placement Priced At The Market Under Nasdaq Rules	Avenue Therapeutics, Inc. (NASDAQ: BMGF ) (&quot;Avenue&quot; or the &quot;Company&quot;), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of central nervous system diseases, today announced that it has entered into a definitive agreement with a single institutional investor for the purchase and sale of 1,940,299 shares of common stock and pre-funded warrants to acquire common stock in a registered direct offering. In a concurrent private placement, the company also agreed to issue to the same investor a total of 1,940,299 warrants to purchase up to one share of common stock each at an exercise price of $1.55 per share. The private placement warrants will be exercisable immediately subject to registration and will have a 3-year term from the initial exercise date. Aggregate gross proceeds to the Company of both transactions are expected to be approximately $3.25 million. The transactions are expected to close on or about January 31, 2023, subject to the satisfaction of customary closing conditions. The purchase price of each share is $1.55. The purchase price of each pre-funded warrant is $1.5499 with an exercise price of $0.0001. The purchase price of each warrant is $0.125 with an exercise price of $1.55. The entire transaction has been priced at the market under Nasdaq rules. Avenue expects to use the net proceeds from the offering, together with its existing cash, for general corporate purposes and working capital.
2023-01-30 09:26:47	TPPP	TPPP Announces Pricing Of $10M Underwritten Public Offering	CN Energy Group. Inc. (NASDAQ: TPPP ) (&quot;TPPP&quot;, or the &quot;Company&quot;) today announced the pricing of an underwritten public offering with gross proceeds to the Company expected to be approximately $10 million, before deducting underwriting discounts and other expenses payable by the Company. The offering consists of 18,183,274 units/pre-funded units consisting of (a) one Class A ordinary share (or one pre-funded warrant to purchase one Class A ordinary share in lieu thereof) and (b) one warrant to purchase one Class A ordinary share (the &quot;Warrants&quot;) at a price to the public of $0.55 per Class A ordinary share and Warrant (or $0. 5499 per pre-funded warrant and Warrant after reducing $0.0001 attributable to the exercise price of the pre-funded warrants). In addition, the Company has granted the underwriter in the offering a 45-day option to purchase up to an additional 15% of ordinary shares and/or Warrants at the public offering price, less underwriting discounts and commissions, to cover over-allotments in connection with the offering. The Company intends to use the net proceeds from this offering for general corporate purposes, including, but not limited to, working capital. The offering is expected to close on February 01, 2023, subject to the satisfaction of customary closing conditions. Aegis Capital Corp. is acting as sole book-running manager for the proposed public offering. This offering is being made pursuant to an effective shelf registration statement on Form F-3 (No. 333-264579) previously filed with the U.S. Securities and Exchange Commission (the &quot;SEC&quot;) and declared effective by the SEC on June 13, 2022. The securities may be offered only by means of a prospectus supplement and accompanying prospectus relating to the offering that form a part of the registration statement. A preliminary prospectus supplement and the accompanying prospectus relating to and describing the terms of the offering were filed with the SEC and are available on the SEC's website at http://www.sec.gov . Electronic copies of the prospectus supplement may be obtained, when available, by contacting Aegis Capital Corp., Attention: Syndicate Department, 1345 Avenue of the Americas, 27th floor, New York, NY 10105, by email at syndicate@aegiscap.com , or by telephone at (212) 813-1010. Before investing in this offering, interested parties should read in their entirety the prospectus supplement and the accompanying prospectus and the other documents that the Company has filed with the SEC that are incorporated by reference in such prospectus supplement and the accompanying prospectus, which provide more information about the Company and such offering. The final terms of the offering will be disclosed in a final prospectus supplement to be filed with the SEC. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
2023-01-30 09:28:06	PYNV	Nano Dimension Adopts A Limited Duration Shareholder Rights Plan	The Rights Plan is similar to those adopted by other publicly traded companies. Pursuant to the Rights Plan, Nano Dimension will issue one special purchase right for every one ADS outstanding at the close of business on February 6, 2023. Each right will allow its holder to purchase from Nano Dimension one-half of one (0.5) ADS, at a purchase price of $0.01 per ADS, once the rights become exercisable. The rights would become exercisable only if an entity, person or group acquires beneficial ownership of 10% or more of Nano Dimension's outstanding ordinary shares in a transaction not approved by the Company's Board. The Rights will expire on January 27, 2024.
2023-01-31 09:18:44	QGVW	AppTech Payments Corp. Announces Pricing Of $5M Registered Direct Offering And Concurrent Private Placement	AppTech Payments Corp. (NASDAQ: QGVW ) (the &quot;Company&quot; or &quot;AppTech&quot;), an innovative Fintech company powering seamless, omni-channel commerce between businesses and consumers, announced today that it has entered into a securities purchase agreement with a single institutional investor to purchase approximately $5 million of its common stock in a registered direct offering and warrants to purchase common stock in a concurrent private placement. The combined effective purchase price for each share of common stock and associated warrant to purchase one share of common stock will be $3.00. Under the terms of the securities purchase agreement, AppTech has agreed to issue 1,666,667 shares of common stock. In the concurrent private placement, which will be consummated concurrently with the offering, AppTech also has agreed to issue warrants (the &quot;Warrants&quot;) to purchase up to an aggregate of 1,666,667 shares of common stock. Each of the Warrants will have an exercise price of $4.64 per share of common stock and are exercisable on and after July 1, 2023. The Warrants will expire five and one-half years from the date on which they become exercisable. EF Hutton, division of Benchmark Investments, LLC, is acting as exclusive placement agent for the offering. The offering is expected to close on or about February 1, 2023, subject to the satisfaction of customary closing conditions.
2023-01-31 09:29:07	PCYQ	Why BigBear.ai (PCYQ) Stock Is Nosediving Today	BigBear.ai Holdings Inc (NASDAQ: PCYQ ) shares are trading lower by 17.34% to $3.29 Tuesday morning after the company filed for a shelf offering of up to 27.8 million shares of common stock by selling shareholder. What Else? BigBear.ai will not receive any of the proceeds from the sale of these shares of our common stock by the selling stockholder. However, BigBear.ai says the company will receive proceeds from the exercise of the warrant, if the warrant is exercised for cash. See Also: What's Driving General Motors Stock Higher? Barra Says Automaker Poised For 'Breakout Year' The company intends to use those applicable proceeds, if any, for general corporate purposes. According to data from Benzinga Pro , PCYQ has a 52-week high of $16.12 and a 52-week low of $0.58.
2023-01-31 11:38:42	GDIF	Why Sidus Space Shares Are Trading 55% Lower	Sidus Space Inc (NASDAQ: GDIF ) shares are trading lower by 55.62% to $0.40 Tuesday morning after the company announced pricing of a $4.5 million public offering. What Else? Sidus Space says the company intends to use the net proceeds of the offering for sales and marketing, operational costs, product development, manufacturing expansion and the remaining proceeds for working capital and other general corporate purposes. See Also: Here's Why UPS And FedEx Shares Are Moving The offering is expected to close on February 2, subject to customary closing conditions. According to data from Benzinga Pro , Sidus Space has a 52-week high of $12.45 and a 52-week low of $0.38.
2023-01-31 11:51:10	XSZW	Why Nuvve Holdings Shares Are Getting Obliterated Tuesday	Nuvve Holding Corp (NASDAQ: XSZW ) shares are trading lower by 41% to $1.36 Tuesday morning after the company filed for a common stock offering of up to $25 million. What Else? Nuvve says the company intends to use the net proceeds from the sale of common stock in this offering for working capital and general corporate purposes. However, Nuvve has not identified the amounts the company will spend on any specific purpose. Accordingly, Nuuve management will have significant discretion and flexibility in applying the net proceeds from the sale of these securities. Pending the application of such proceeds, the company expects to invest the proceeds in short-term, interest bearing, investment-grade marketable securities or money market obligations. According to data from Benzinga Pro , Nuvve has a 52-week high of $10.25 and a 52-week low of $0.44.
2023-01-31 12:00:53	QGVW	Why AppTech Payments Stock Is Diving 25% Lower	AppTech Payments Corp (NASDAQ: QGVW ) shares are trading lower by 25.47% to $3.99 during Tuesday's session after the company announced pricing of a $5 million registered direct offering and concurrent private placement. What Else? Under the terms of the securities purchase agreement, AppTech says the company has agreed to issue 1,666,667 shares of common stock. In the concurrent private placement, which will be consummated concurrently with the offering. See Also: Here's Why UPS And FedEx Shares Are Moving AppTech also has agreed to issue warrants to purchase up to an aggregate of 1,666,667 shares of common stock. The company says each of the warrants will have an exercise price of $4.64 per share of common stock and are exercisable on and after July 1, 2023. According to data from Benzinga Pro , AppTech Payments has a 52-week high of $5.37 and a 52-week low of $0.40.
2023-01-31 12:02:07	JLZN	Revelation Biosciences Announces 1-For-35 Reverse Stock Split Effective February 1, 2023 And Results Of Special Meeting Of Stockholders; At The Meeting, The Stockholders Also Approved An Increase In The Authorized Common Stock To 500M Shares	Revelation Biosciences Inc. (NASDAQ: JLZN ) (the &quot;Company&quot; or &quot;Revelation&quot;) announced today that, on February 1, 2023, the Company will implement a 1-for-35 reverse split of its common stock following approval at its Special Meeting of Stockholders held on January 30, 2023. The reverse stock split will be effective as of the morning of February 1, 2023, and the Company's common stock will trade on a post-split basis at the beginning of trading on the same date under the existing trading symbol &quot;JLZN.&quot; The CUSIP number for the common stock following the reverse stock split will be 76135L 309. At the meeting, the stockholders also approved an increase in the authorized common stock to 500,000,000 shares and ratified the appointment of Baker Tilly US, LLP as independent public accountants to the Company. The reverse stock split is intended to increase the market price per share of the Company's common stock to regain compliance with the minimum bid continued listing requirement of The Nasdaq Capital Market. The Company intends to continue to pursue additional actions to satisfy the exchange's minimum stockholders' equity requirement. The reverse stock split will reduce the number of shares of the Company's common stock currently outstanding to approximately 672,460 shares. Proportionate adjustments will be made to the conversion and exercise prices of the company's warrants, restricted stock unit awards, stock options and to the number of shares issued and issuable under the Company's equity incentive plans.
2023-02-01 08:36:29	ODHS	Offerpad Announces $90M Private Placement	Offerpad Solutions Inc. (&quot;Offerpad&quot;, &quot;Company&quot;) (NYSE: ODHS ), a leading real estate tech company built to simplify home buying and selling, announced today that it has entered into subscription agreements with a group of private investors, together with CEO Brian Bair and existing stockholders Roberto Sella and First American Financial Corporation, to purchase an aggregate of 160,742,959 prefunded warrants to purchase Offerpad's Class A common stock. Each warrant was sold at a price of $0.5599 per warrant, with an initial exercise price of $0.0001 per warrant, subject to certain customary anti-dilution adjustment provisions, and was calculated based on a 20% discount to the 5-day closing price average on January 27, 2023. The issuance of the shares of Class A common stock has been approved by Offerpad stockholders representing more than a majority of the voting power of the Company's common stock, and Offerpad will prepare and file a related information statement with the Securities and Exchange Commission (&quot;SEC&quot;). The pre-funded warrants will not be exercisable until at least 21 days after the definitive information statement is filed with the SEC or such later time as is necessary to comply with the listing requirements of the New York Stock Exchange. The Company plans to use the proceeds from the private placement for general corporate purposes. The pre-funded warrants and the shares of Offerpad's Class A common stock issuable upon exercise of the warrants are being issued and sold pursuant to an exemption from registration provided for under the Securities Act of 1933, as amended (the &quot;Securities Act&quot;), and neither the pre-funded warrants nor the shares of Offerpad's Class A common stock issuable upon exercise of the warrants have been registered under the Securities Act. The securities may not be offered or sold in the United States, except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act. Offerpad has agreed to file a registration statement with the SEC registering the resale of the shares of its Class A common stock issuable upon exercise of the pre-funded warrants issued and sold in the private placement. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.
2023-02-01 09:21:00	KKAE	Sharps Technology Announces Pricing Of $3.8M Private Placement Priced At The Market	Sharps Technology, Inc. (the &quot;Company&quot;, &quot;Sharps&quot;) (NASDAQ: &quot;KKAE&quot; and &quot;STSSW&quot;), an innovative medical device and drug delivery Company offering patented, best-in-class syringe products, today announced that it entered into a securities purchase agreement with institutional investors for aggregate gross proceeds of approximately $3.8 million priced at the market under Nasdaq rules. Proceeds will be used to support the manufacturing of pre-filled specialty syringe systems through its partnership with Nephron Pharmaceuticals. In connection with the offering, the Company will issue 2,248,521 units and pre-funded units at a purchase price of $1.69 per unit priced at-the-market under Nasdaq rules. The pre-funded units will be sold at the same price less the pre-funded warrant exercise price of $0.001. Each unit and pre-funded unit consist of one share of common stock (or pre-funded warrant) and one non-tradable warrant exercisable for one share of common stock at a price of $1.56. The warrants have a term of five years from the issuance date. Gross proceeds were $3.8 million before deducting fees to the placement agent and other offering expenses payable by the Company. The offering is expected to close on or about February 3, 2023, subject to the satisfaction of customary closing conditions. Aegis Capital Corp. is acting as the Exclusive Placement Agent in connection with the offering. The securities described above are being sold in a private placement and have not been registered under the Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration with the Securities and Exchange Commission (the &quot;SEC&quot;) or an applicable exemption from such registration requirements. The securities were offered only to accredited investors. Pursuant to a registration rights agreement with the investor, the Company has agreed to file one or more registration statements with the SEC covering the resale of the common stock and the common stock issuable upon exercise of the warrants. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
2023-02-01 09:28:36	VYWB	Motorsport Games Announces $3.9M Registered Direct Offering Of 183,020 Shares At A Price Of $21.40 Priced At-The-Market Under Nasdaq Rules	Motorsport Games Inc. (NASDAQ: VYWB ) (&quot;Motorsport Games&quot; or the &quot;Company&quot;), today announced that it has entered into a definitive agreement for the issuance and sale of an aggregate of 183,020 shares of the Company's Class A common stock at a purchase price of $21.40 per share in a registered direct offering priced at-the-market under Nasdaq rules. The closing of the offering is expected to occur on or about February 3, 2023, subject to the satisfaction of customary closing conditions. L.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. The gross proceeds to Motorsport Games from the offering are expected to be approximately $3.9 million, before deducting the placement agent's fees and other offering expenses payable by the Company. Motorsport Games currently intends to use the net proceeds from the private placement for development of multiple games, working capital and general corporate purposes. The shares of Class A common stock described above are being offered and sold by the Company pursuant to a &quot;shelf&quot; registration statement on Form S-3 (Registration No. 333-262462), including a base prospectus, previously filed with the Securities and Exchange Commission (SEC) on February 1, 2022 and declared effective by the SEC on February 10, 2022. The offering of the shares of Class A common stock are being made only by means of a prospectus supplement that forms a part of the registration statement. A final prospectus supplement and an accompanying base prospectus relating to the offering will be filed with the SEC and will be available on the SEC's website located at http://www.sec.gov . Electronic copies of the final prospectus supplement and accompanying base prospectus may also be obtained by contacting L.C. Wainwright & Co., LLC at 430 Park Avenue, 3rd Floor, New York, NY 10022, by phone at (212) 856-5711 or e-mail at placements@hcwco.com . This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.
2023-02-01 09:37:07	ZUS	ZUS Works Around Shareholder Opposition For Capital Raise Via Dilutive Stock Sale	ZUS Entertainment Holdings, Inc. (NYSE: ZUS ) recently filed a proxy statement to convene a special shareholder meeting to discuss three proposals put forward by the company. The theater chain has used the filing to take an unpalatable proposition to its shareholders, Reuters said in a report. What Happened: ZUS, through the Jan. 27 proxy filing, sought shareholder approval for increasing its authorized shares. Instead of putting it forward as a straight proposal, the company bundled it with another proposal that seeks to convert its preferred stock into common stock, Reuters said. See also: Best High-Volume Penny Stocks Through the first proposal, the company has requested shareholders' nod for increasing its authorized shares from more than 524 million to 550 million. Proposal number: two from the company seeks approval for a 1:10 reverse stock split. ZUS noted that the increase in the authorized capital and the reverse split would permit the full conversion of all outstanding Series A preferred stock into common stock. ZUS's preferred equity units are trading under the ticker symbol APE on the NYSE. Each APE currently represented 1/00th of a share of Series A preferred stock. APE closed Tuesday&rsquo;s session at $2.42, up 3.86%, according to Benzinga Pro data. The common stock of ZUS, meanwhile, ended at $5.35, up 6.79%. ZUS noted that currently there were some 517 million outstanding common stock and almost 9.3 million Series of preferred stocks, which are represented by 929.8 million APEs. Post the approval, one APE will be equal to 1/10 of ZUS common stock, the company said. While ZUS would need 93 million new shares for the conversion, the company is seeking authorization for a total 498.2 million common shares, Reuters said, citing the filing. Following the conversion, the company will, therefore, be left with 405.2 million new common shares. At Tuesday&rsquo;s closing price, the new shares, less the ones used for conversion, are valued at $2.17 billion. Since preferred stockholders would also be allowed to vote on the proposal and there are 1.8 preferred shares for every common stock of ZUS, the former can sway the voting in favor of the authorization, Reuters said, citing corporate finance professors. The special meeting of shareholders is scheduled for March 14. Why It&rsquo;s Important: ZUS&rsquo;s fundamentals took a hit during the COVID-19 pandemic due to theater closures. As the company embarked on a recovery path following the pandemic, it resorted to stock sales to keep cash flowing in, averting a potential bankruptcy. ZUS capitalized on the meme stock frenzy that lifted its stock price to raise about $2 billion in 2021, Reuters said. However, as shareholders voiced opposition to dilution, ZUS canceled a shareholder meeting it convened in July 2021 to obtain approval for a fresh stock sale. Read next: Cineworld Shares Plummet On Reports Of Bankruptcy Filing: What We Know So Far
2023-02-01 11:25:23	VYWB	What's Going On With Motorsport Games Stock?	Motorsport Games Inc (NASDAQ: VYWB ) shares traded higher by more than 700% on Tuesday before adding a more than 200% gain in premarket trading Wednesday morning. The stock retreated just ahead of the open after the company announced an offering . What To Know: Following a massive move in the low-float stock this week, Motorsport Games entered into a definitive agreement for the issuance and sale of 183,020 shares at a purchase price of $21.40 per share in a registered direct offering. The gross proceeds from the offering are expected to be approximately $3.9 million . What Sparked The Rally? On Monday, Motorsport Games entered into a debt-for-equity exchange agreement with majority stockholder Motorsport Network LLC to repay $1 million in debt under a $12 million line of credit. The news sparked a major surge in the stock. &quot;This debt exchange benefits our balance sheet, allows us to pay less interest expense and will help Motorsport Games to pursue product development and growth opportunities,&quot; Dmitry Kozko , executive chairman and CEO of Motorsport Games, said at the time. Late Monday, shareholder Mike Zoi also disclosed the purchase of 338,983 shares at an average price of $2.95, per a regulatory filing with the SEC. Did You Know Benzinga Tracks Insider Trading? Check This Out: Recent Insider Trading Activity Motorsport Games' average session volume is below 1 million, according to Benzinga Pro . Tuesday's session volume was just shy of 50 million and Wednesday's trading volume is already approaching 10 million in early trading. The stock has been trending across social media platforms for the last two days. It was the top trending ticker on Stocktwits at publication time. VYWB Price Action: Motorsport Games shares closed Tuesday up 713.7%. The stock is up another 72.9% in Wednesday's session, trading at $36.99 at the time of writing, according to Benzinga Pro . Photo: courtesy of Motorsport Games.
2023-02-01 11:39:53	KKAE	Why Sharps Technology Stock Is Trading Lower	Sharps Technology Inc (NASDAQ: KKAE ) shares are trading lower after the company announced a $3.8 million private placement at $1.69 per share. What Else? Sharps Technology says proceeds will be used to support the manufacturing of pre-filled specialty syringe systems through its partnership with Nephron Pharmaceuticals. See Also: Why Li Auto Shares Are Trading Higher During Wednesday's Session The offering is expected to close on or about February 3, subject to the satisfaction of customary closing conditions. According to data from Benzinga Pro , Sharps Technology has a 52-week high of $3.62 and a 52-week low of $0.82.
2023-02-02 12:55:29	KCFS	Gaucho Group Holdings, Inc. Announces $44M Equity Line Of Credit; Company States It Now Has A Funding Mechanism For Its Growth Plans In 2023 And Beyond	Gaucho Group Holdings, Inc. (NASDAQ: KCFS ), a company that includes a growing collection of e-commerce platforms with a concentration on fine wines, luxury real estate, and leather goods and accessories, announced today is growth strategy leveraging its previously announced $44 million ELOC. With this funding now in place, the Company believes it can lay the foundation for growth of its assets in lodging, hospitality, wine & spirits, retail, and e-commerce. With an approved $44 million equity line of credit, the Company states it now has a funding mechanism for its growth plans in 2023 and beyond. This includes infrastructure expansion for its luxury vineyard estate development, Algodon Wine Estates, such as the build out of residential villas and commercial elements associated with the estate's sports and hospitality sector, as well as marketing efforts targeting its lot sales program. The Company previously announced that it anticipates its lot sales program can potentially generate $5 Million or more in sales in 2023 alone, and its planned 60-room hotel and spa (which is also slated to include 30-50 residences, and for which the Company seeks to co-brand with a luxury hotel brand) could generate an additional $25 million per year of revenue once complete. With the Masterplan's addition of 200 more lots, ranging in size from 2.47 acres to 6 acres, the Company anticipates the potential to generate more than $100 million in revenue. Plans also target the Company's high end wine products, Algodon Fine Wines, which includes marketing efforts to further increase distribution channels, e-commerce sales and international markets, such as Argentina's neighbor Brazil, which is the world's 3rd largest market for online wine sales. The Company intends to continue efforts to scale the growth of its leather goods and accessories brand, Gaucho - Buenos Aires, which celebrated its flagship opening last year at the Miami Design District, located among the likes of widely recognized luxury retail brands such as Off White, Bottega Veneta, Gucci, and Chanel, and many others. The Company intends to target e-commerce revenue growth with an aggressive marketing campaign, as well the anticipated forthcoming launch of its Resort Collection and a luggage + travel accessories collection, later this year. Scott Mathis, CEO & Chairman of Gaucho Holdings commented; &quot;Being on the Nasdaq is very important for our company's loyal shareholders, future growth, and for maximizing exposure. As we grow and scale, we can leverage our stock as currency to accomplish a &quot;rollup&quot; strategy for accretive acquisitions such as additional luxury brands synergistic with our own. This $44 million ELOC can also go a long way for growth. In the next 24 to 36 months our extraordinary real estate project is expected to have a new destination spa, world class gym facilities, an 18-hole golf course expansion, and more vineyard casitas as well. Anticipated for q4 2023, the restaurant renovation and final touches on the upgrade to the winery will allow them to now accommodate weddings and corporate events, and other large gatherings. In addition, the San Rafael airport is being expanded and the runway improved for larger aircraft and more traffic. These can positively impact our ADRs and occupancy rates, as well as the value of our residential lots. Of our two hospitality properties, one of them currently generates positive cash flow through lease revenues and will be accretive to the company, and we expect the other to have substantial development opportunities. We believe both are in prime areas ripe for development, and we believe the valuation of the real estate is positioned to allow for substantial appreciation in the years ahead. Across all of our companies, we now have the means to up our game and get our story out to the world as we continue to grow.&quot;
2023-02-02 16:37:09	BSFX	Avalo Therapeutics, Inc. Announces Proposed Public Offering Of Common Stock And Warrants; Size Not Disclosed	Avalo Therapeutics, Inc. (NASDAQ: BSFX ) (&quot;Avalo&quot;) announced today that it has commenced a proposed underwritten public offering of shares of its common stock and warrants to purchase shares of its common stock. All of the shares and warrants in the proposed offering are to be sold by Avalo. The offering is subject to market and other conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. SVB Securities and RBC Capital Markets are acting as joint bookrunning managers for the offering. The offering is being made pursuant to a shelf registration statement on Form S-3 (File No. 333-254000) that was declared effective by the Securities and Exchange Commission (the &quot;SEC&quot;) on March 19, 2021. The offering is being made only by means of a prospectus and prospectus supplement that form a part of the registration statement. A preliminary prospectus supplement relating to the offering will be filed with the SEC and will be available on the SEC's website, located at www.sec.gov . Copies of the preliminary prospectus supplement and the accompanying prospectus relating to the offering, when available, may also be obtained from SVB Securities LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, by phone at (800) 808-7525, ext. 6105, or by email at syndicate@svbsecurities.com ; or RBC Capital Markets, LLC, Attention: Equity Capital Markets, 200 Vesey Street, 8th Floor, New York, NY 10281, or by telephone at (877) 822-4089 or by email at equityprospectus@rbccm.com . The final terms of the offering will be disclosed in a final prospectus supplement to be filed with the SEC. This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities nor shall there be any offer or sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
2023-02-03 08:21:45	JMVZ	Tenax Therapeutics Announces Pricing Of ~$15.6M Public Offering	Tenax Therapeutics, Inc. (NASDAQ: JMVZ ), a specialty pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, announced today the pricing of a public offering of (i) 8,666,666 shares of its common stock (or pre-funded warrants in lieu thereof) and (ii) warrants to purchase up to 17,333,332 shares of its common stock (the &quot;Public Warrants&quot;) at a purchase price of $1.80 per share and associated Public Warrant. The Public Warrants will have an exercise price of $2.25 per share, are immediately exercisable, and will expire five years after their initial exercise date. The offering is expected to close on or about February 7, 2023, subject to customary closing conditions. Roth Capital Partners is acting as our exclusive placement agent in the offering. Gross proceeds, before deducting placement agent fees and commissions and offering expenses are expected to be approximately $15.6 million. The Company intends to use the net proceeds from the offering to progress the clinical development of imatinib for the treatment of PAH (which would include, initially, to launch its Phase 3 trial) and levosimendan for the treatment of PH-HFpEF, toward regulatory approval for the treatment of these and potentially other indications and, depending on patents pending that the Company expects the USPTO to make throughout 2023 and other factors determining near-term prioritization, channel the net proceeds towards these ends as well as for working capital, capital expenditures, continued product development, and other general corporate purposes. The securities described above are being offered pursuant to a registration statement on Form S-1 (File No. 333-269363), as amended, that was declared effective by the U.S. Securities and Exchange Commission (&quot;SEC&quot;), on February 2, 2023. Copies of the accompanying prospectus relating to and describing the terms of the offering may be obtained, when available, at the SEC's website at www.sec.gov or by contacting Roth Capital Partners, LLC, 888 San Clemente Drive, Suite 400, Newport Beach, CA 92660 or by email at rothecm@roth.com. This press release does not and shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction. Any offer, if at all, will be made only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement. About Imatinib (TNX-201) Tenax Therapeutics is developing novel dosing and a unique formulation of imatinib mesylate, a kinase inhibitor that has received FDA's orphan designation (March 2020) for the treatment of pulmonary arterial hypertension (PAH). The IMPRES trial, a previous Phase 3 trial, demonstrated that oral imatinib may produce a markedly greater, and much more durable, treatment effect on exercise tolerance, than any other available PAH treatment, alone or in combination, based on the results observed in those patients who were maintained on the full imatinib dose for the majority of the trial. Despite the availability of several classes of pulmonary vasodilators, no existing treatment has been shown to halt progression or induce regression of the disease. Imatinib acts on underlying cellular proliferative pathways associated with PAH and has the potential to be the first disease modifying therapy for PAH. About Levosimendan (TNX-101, TNX-102 and TNX-103) Levosimendan is a unique potassium ATP channel activator and calcium sensitizer that affects the heart and vascular system through multiple mechanisms of action. Initially discovered and developed by Orion Corporation in Finland, intravenous levosimendan is approved in over 60 countries outside the United States for use in hospitalized patients with acutely decompensated heart failure. Tenax Therapeutics has North American rights to develop and commercialize IV (TNX-101), subcutaneous (TNX-102), and oral (TNX-103) formulations of levosimendan. Results of Tenax Therapeutics' Phase 2 trial of levosimendan in patients with pulmonary hypertension (PH) and heart failure with preserved ejection fraction (HFpEF) demonstrated that IV levosimendan produces potent dilation of the central and pulmonary venous circulations which translates into an improvement in exercise capacity, a discovery that forms the basis for the Phase 3 investigation of Tenax Therapeutics' potential groundbreaking therapy. To date, no other drug therapy has improved exercise tolerance in patients with PH associated with HFpEF, recently referred to as the greatest unmet need in cardiovascular disease.
2023-02-03 08:34:39	HCBN	NextDecade To Raise $35M Via Private Place Of Shares At 10.5% Discount	On February 3, 2023, NextDecade Corporation (the &ldquo;Company&rdquo;) entered into a common stock purchase agreement (the &ldquo;Stock Purchase Agreement&rdquo;) for a private placement (the &ldquo;Private Placement&rdquo;) with HGC HCBN INV LLC and Ninteenth Investment Company LLC (each a &ldquo;Purchaser&rdquo; and collectively, the &ldquo;Purchasers&rdquo;), pursuant to which the Company agreed to sell, and the Purchasers severally agreed to purchase, an aggregate of 5,835,277 shares of the Company&rsquo;s common stock, par value $0.0001 per share (the &ldquo;Common Stock&rdquo;), at a purchase price of $5.998 per share, representing the average closing trading price of the Common Stock for the five trading days immediately preceding signing the Stock Purchase Agreement, for an aggregate purchase price of approximately $35.0 million. The Private Placement will close on or about February 8, 2023 (the &ldquo;Closing Date&rdquo;). Each Purchaser is a stockholder of the Company that has the right to nominate a director to the Company&rsquo;s Board of Directors, and the directors nominated by the Purchasers did not participate in the approval of the Private Placement by the Company&rsquo;s Board of Directors. The Company will use the proceeds of the private placement to continue development activity in preparation for its anticipated positive final investment decision on the first three trains at its Rio Grande HPJ project.
2023-02-03 10:32:53	TVPA	MediWound Announces $27.5M Registered Direct Offering Of 1,964,286 Ordinary Shares Priced At-The-Market	MediWound Ltd. (NASDAQ: TVPA ) (the &quot;Company&quot;), a fully integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announced that it has entered into a definitive securities purchase agreement for the sale and purchase of1,964,286 shares of the Company's ordinary shares, par value NIS 0.07, at a purchase price of $14 per share, in a registered direct offering. The Company expects to close the offering on or about February 7, 2023, subject to the satisfaction of customary closing conditions. L.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. The gross proceeds to the Company from the offering are expected to be approximately $27.5 million, before deducting placement agent fees and other offering expenses payable by the Company. The Company intends to use the net proceeds from the offering primarily for the acceleration of the development of EscharEx&reg;, establishing a U.S. commercial presence, supporting business development activities, and for general corporate purposes. The Company may also use a portion of the net proceeds to in-license, invest in or acquire businesses, technologies, products or assets that it believes are complementary to its own, although it has no current plans, commitments or agreements with respect to any acquisitions or in-licenses at this time. Following the closing of the registered direct offering and the issuance of the shares purchased thereby, the Company will have 9,204,306 ordinary shares outstanding. The ordinary shares described above are being offered by means of the Company's shelf registration statement on Form F-3 (File No. 333-265203), previously filed with the Securities and Exchange Commission (the &quot;SEC&quot;) on May 25, 2022, and declared effective by the SEC on June 3, 2022 (the &quot;Shelf Registration Statement&quot;), the accompanying prospectus, dated June 3, 2022, and a prospectus supplement, dated February 3, 2023. A final prospectus supplement and accompanying prospectus relating to the ordinary shares being sold in the offering will be filed with the SEC. Electronic copies of the final prospectus supplement and accompanying prospectus may be obtained, when available, on the SEC's website at http://www.sec.gov . and may also be obtained by contacting L.C. Wainwright & Co., LLC at 430 Park Avenue, 3rd Floor, New York, New York 10022, by phone at (212) 856-5711 or e-mail at placements@hcwco.com . This press release shall not constitute an offer to sell or a solicitation of an offer to buy any of these Company securities, nor shall there be any sale of these Company securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
2023-02-06 08:31:41	JOVF	ReShape Lifesciences Announces Pricing Of Upsized $10.2M Underwritten Public Offering Of 1.275M Units At A Price Of $8/Unit	ReShape Lifesciences Inc. (NASDAQ: JOVF ), the premier physician-led weight loss and metabolic health solutions company, today announced the pricing of its upsized underwritten public offering of 1,275,000 units, with each unit consisting of one share of its common stock, or one pre-funded warrant to purchase one share of its common stock, and one warrant to purchase one and one-half shares of its common stock. Each unit is being sold at a public offering price of $8.00. The warrants in the units will be immediately exercisable at a price of $8.00 per share and will expire five years from the date of issuance. Alternatively, each warrant will become exercisable for 0.75 shares of common stock under the cashless exercise provision included in the common warrants rather than the 1.5 shares of common stock under the cash exercise provision. The shares of common stock (or pre-funded warrants in lieu thereof) and accompanying warrants can only be purchased together in this offering, but will be issued separately and will be immediately separable upon issuance. Gross proceeds, before deducting underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $10.2 million. The company intends to use the net proceeds of this offering to continue implementation of its growth strategies, for working capital and general corporate purposes. The offering is expected to close on February 8, 2023, subject to customary closing conditions. ReShape has also granted the underwriters an option to purchase an additional 191,250 shares of common stock and/or additional warrants to purchase up to 286,875 shares of common stock, to cover over-allotments, if any. Maxim Group LLC is acting as sole book-running manager in connection with this offering. The securities described above are being offered pursuant to a registration statement on Form S-1, as amended (File No. 333-269207), which was declared effective by the Securities and Exchange Commission (the &quot;SEC&quot;) on February 3, 2023, and an additional registration statement filed with the SEC on February 3, 2023 pursuant to Rule 462(b) under the Securities Act of 1933, as amended. The offering is being made only by means of a prospectus which is a part of the effective registration statement. A preliminary prospectus relating to the offering has been filed with the SEC. Copies of the final prospectus relating to this offering, when available, will be filed with the SEC and may be obtained from Maxim Group LLC, 300 Park Avenue, 16th Floor, New York, NY 10022, at (212) 895-3745. This press release shall not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
2023-02-06 09:06:15	TQWN	Why Canoo (TQWN) Stock Hit A New 52-Week Low Today	Canoo Inc (NASDAQ: TQWN ) shares are trading lower by 27.20% to $0.91 Monday morning after the company announced a $52.5 million registered direct offering of 50 million shares at $1.05 per share. What Else? Canoo says the closing of the offering is expected to occur on or about February 8, subject to the satisfaction of customary closing conditions. The gross proceeds from the offering are expected to be approximately $52.5 million. The company intends to use the net proceeds from the offering for general working capital purposes. See Also: $100 Invested In Tesla, AMD, Nvidia, Apple, Microsoft, Amazon, Bitcoin, Ethereum And Dogecoin 5 Years Ago Is Worth This Much Now According to data from Benzinga Pro , Canoo Inc has a 52-week high of $6.44 and a 52-week low of $0.91.
2023-02-06 09:10:43	JOVF	Why ReShape Lifesciences (JOVF) Shares Are Plummeting	ReShape Lifesciences Inc (NASDAQ: JOVF ) shares are trading lower by 62.44% to $6.40 Monday morning after the company priced its $10.2 million offering at $8 per unit consisting of stock and warrants. What Else? The company intends to use the net proceeds of this offering to continue implementation of its growth strategies, for working capital and general corporate purposes. ReShape says the company has also granted the underwriters an option to purchase an additional 191,250 shares of common stock and/or additional warrants to purchase up to 286,875 shares of common stock, to cover over-allotments, if any. The offering is expected to close on February 8, subject to customary closing conditions. See Also: $100 Invested In Tesla, AMD, Nvidia, Apple, Microsoft, Amazon, Bitcoin, Ethereum And Dogecoin 5 Years Ago Is Worth This Much Now According to data from Benzinga Pro , JOVF has a 52-week high of $77.00 and a 52-week low of $5.40.
2023-02-06 11:24:05	RSB	Why Alset Shares Are Falling 30% Today	Alset Inc (NASDAQ: RSB ) shares are trading lower by 32.30% to $2.10 Monday morning after the company announced a $3.8 million public offering of common stock. What Else? Alset says the offering consists of 1,727,273 shares of common stock at a price of $2.20 per share. In addition, the company has granted Aegis Capital Corp., the underwriter in the offering, a 45-day option to purchase up to an additional 212,863 shares of common stock offered in the offering at the public offering price, less underwriting discounts and commissions. See Also: Why Taiwan Semiconductor Manufacturing Company Shares Are Falling Alset says the company intends to use the net proceeds from this offering for general working capital. The closing of the offering is expected to occur on February 8, 2023, subject to customary closing conditions. According to data from Benzinga Pro , RSB has a 52-week high of $18.57 and a 52-week low of $2.04.
2023-02-06 16:32:11	VITD	Why Blink Charging Shares Are Nosediving	Blink Charging Co (NASDAQ: VITD ) shares were trading lower by 7.07% to $12.88 during Monday's after-hours session. The company announced a $75-million proposed offering of common stock. What Else? Blink says in connection with the offering, the company also intends to grant the underwriter a 30-day option to purchase up to an additional 15% of the shares of common stock sold in the offering. See Also: What's Going On With Bed Bath & Beyond Shares Exploding Higher? Blink says the company intends to use the net proceeds from the proposed offering to fund EV charging station deployments, to finance the costs of acquiring or investing in competitive and complementary businesses, products and technologies as a part of its growth strategy and for working capital and other general corporate purposes. According to data from Benzinga Pro , VITD has a 52-week high of $29.99 and a 52-week low of $9.85. Photo via Shutterstock.
2023-02-06 17:18:59	GUSJ	Bed Bath & Beyond Stock Jumps 90% Monday Before Reversing After Hours: What's Going On?	Bed Bath & Beyond Inc (NASDAQ: GUSJ ) shares are diving in Monday's after-hours session after the stock rocketed higher earlier in the day. The company proposed an offering following a nearly 100% gain in Monday's regular trading session . What To Know: Bed Bath & Beyond has proposed an underwritten public offering of shares of the company's Series A convertible preferred stock, warrants to purchase shares of Series A convertible preferred stock and warrants to purchase the company's common stock. The embattled retailer expects to raise approximately $225 million of gross proceeds in the offering and an additional approximately $800 million through the issuance of securities requiring the exercise of warrants. Bed Bath said it intends to use the net proceeds from the initial closing of the offering to repay outstanding revolving loans under its ABL Facility. What Led To The Offering? The struggling retailer's stock has been extremely volatile over the last month as the company has been considering strategic alternatives, including potential bankruptcy . In early January, Bed Bath said multiple paths were being explored and next steps were expected to be determined soon. Near the end of January, Bed Bath revealed that it did not have &quot;sufficient resources to repay the amounts under the Credit Facilities,&quot; per a regulatory filing . Shares were halted to the downside before bouncing back. Monday's trading action appears to be very speculative. The stock was trending on various social platforms in early trading. 58.77% of the float is currently sold short, per Benzinga Pro . Bed Bath's average session volume over a 100-day period is approximately 37.82 million. Monday's session volume exceeded 254 million and the stock remains volatile after hours. It was the top trending ticker on Stocktwits at last check. Check This Out: What's Going On With ZUS Shares Skyrocketing Monday? GUSJ Price Action: Bed Bath has a 52-week high of $30.06 and a 52-week low of $1.27. The stock was down 17.4% in after hours at $4.86 after surging 92.1% in Monday's regular session. Photo: courtesy of Mike Mozart from Flickr.
2023-02-07 12:02:12	AMAW	Why CureVac Shares Are Nosediving Today	CureVac BV (NASDAQ: AMAW ) shares are trading lower by 13.99% to $9.10 during Tuesday's session after the company announced a proposed public offering of common stock. What Happened? CureVac early Tuesday announced that it intends to offer $200 million of its common shares in an underwritten public offering. In addition, CureVac intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of common shares to be sold in the offering on the same terms and conditions. See Also: This Chicken Wing Stock Has A Better 5-Year Return Than Disney, Ford, Microsoft, Alibaba, Amazon, Bitcoin And Ethereum CureVac added that the offering is subject to market and other conditions, and there can be no assurances as to whether or when the offering may be completed or as to the actual size or terms of the offering. According to data from Benzinga Pro , AMAW has a 52-week high of $20.49 and a 52-week low of $5.63.
2023-02-07 16:43:53	GDBX	Longboard Pharmaceuticals Announces Commencement Of Public Offering Of $20M Of Shares Of Common Stock	Longboard Pharmaceuticals, Inc. (NASDAQ: GDBX ), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that it has commenced an underwritten public offering, subject to market and other conditions, to issue and sell $20 million of shares of its voting common stock. In connection with the proposed offering, Longboard expects to grant the underwriters a 30-day option to purchase up to an additional approximately $3 million of shares of voting common stock. There can be no assurance as to whether or when the proposed offering may be completed or as to the actual size or terms of the proposed offering. Evercore ISI and Cantor Fitzgerald are acting as joint book-running managers for the proposed offering.
2023-02-07 16:58:42	SUK	Here's Why First Republic Bank (SUK) Shares Are Falling In Tuesday's After-Hours Session	First Republic Bank (NYSE: SUK ) shares are trading lower by 2.05% to $140.75 during Tuesday's after-hours session. The company announced a 2 million share common stock offering to raise capital. What Happened? First Republic Bank says it has agreed to sell 2,000,000 shares of its common stock in an underwritten public offering. First Republic has also granted the underwriters a 30-day option to purchase up to an additional 300,000 shares from First Republic. First Republic intends to use the net proceeds from the offering for general corporate purposes, which may include, among other things, funding loans or purchasing investment securities for its portfolio. See Also: Why Zoom Shares Are Exploding Higher First Republic Bank says the closing of the offering is expected to occur on or about February 10, subject to the satisfaction of customary closing conditions. According to data from Benzinga Pro , SUK has a 52-week high of $181.75 and a 52-week low of $106.86.
2023-02-07 17:19:01	GCRD	Why Treace Medical Concepts (GCRD) Shares Are Falling During Tuesday's After-Hours Session	Treace Medical Concepts Inc (NASDAQ: GCRD ) shares are trading lower by 6.52% to $21.50 during Tuesday's after-hours session. The company announced a proposed $100 million common stock offering. What Happened: Treace Medical Concepts said the proposed offering was subject to market and other conditions, and there could be no assurance as to whether or when the proposed offering may be completed, or as to the actual size or terms of the proposed offering. Treace Medical Concepts said the company intended to grant the underwriters a 30-day option to purchase up to an additional $15.0 million of shares of its common stock. See Also: Why Zoom Shares Are Exploding Higher Treace meanwhile intended to use the net proceeds from the proposed offering for general corporate purposes, including research and development, sales and marketing activities, general and administrative matters and capital expenditures. According to data from Benzinga Pro , GCRD has a 52-week high of $26.50 and a 52-week low of $12.48. Photo: Kenishirotie via Shutterstock
2023-02-08 06:58:35	LVPR	Costamare Raises $5M Via Institutional Equity Offering	On February 6, 2023, Cuentas Inc. (the &ldquo;Company&rdquo;) entered into a Securities Purchase Agreement (the &ldquo;Purchase Agreement&rdquo;) with an institutional investor (the &ldquo;Investor&rdquo;) for the purpose of raising approximately $5 million in gross proceeds for the Company. Pursuant to the terms of the Purchase Agreement, the Company agreed to sell, in a registered direct offering, an aggregate of (i) 2,123,478 shares (the &ldquo;Shares&rdquo;) of the Company&rsquo;s common stock (&ldquo;Common Stock&rdquo;) and (ii) pre-warrants to purchase up to 1,664,401 shares of Common Stock (the &ldquo;Pre-Funded Warrants&rdquo; and such shares of Common Stock issuable upon exercise of the Pre-Funded Warrants, the &ldquo;Pre-Funded Warrant Shares&rdquo;) and, in a concurrent private placement, warrants (the &ldquo;Purchase Warrants&rdquo;) to purchase 3,787,879 shares of Common Stock (the shares of Common Stock issuable upon exercise of the Purchase Warrants, the &ldquo;Purchase Warrant Shares&rdquo;). The combined purchase price per Share and Purchase Warrant is $1.32 and the combined purchase price per Pre-Funded Warrant and Purchase Warrant of $1.3199. The net proceeds to the Company from the registered direct offering and concurrent private placement, after deducting the Placement Agent&rsquo;s fees and expenses and the Company&rsquo;s offering expenses are expected to be approximately $4.3 million. The Company intends to use the net proceeds from the transactions for general corporate purposes and working capital.
2023-02-08 09:15:37	FLBE	Why RxSight Shares Are Plummeting	RxSight Inc (NASDAQ: FLBE ) shares are trading lower by 9.22% to $12.50 Wednesday morning after the company announced pricing of a public offering of common stock. What Else? RxSight says the company expects to sell 4,000,000 shares of its common stock at a price to the public of $12.50 per share. RxSight has also granted the underwriter a 30-day option to purchase up to an additional 600,000 shares of its common stock at the public offering price, less underwriting discounts and commissions. See Also: Fortinet Stock Is Rising Today: What's Going On? The offering is expected to close on or about February 10. RxSight meanwhile intends to use the net proceeds from the offering for continued commercial and marketing expansion, funding of product development, research and clinical development, and for working capital and general corporate purposes. According to data from Benzinga Pro , FLBE has a 52-week high of $16.99 and a 52-week low of $9.78.
2023-02-08 09:16:32	KM	Why Dynatrace Stock Is Trading Lower Today	Dynatrace Inc (NYSE: KM ) shares are trading lower by 6.19% to $45.00 Wednesday morning after the company announced pricing of a proposed 15 million share public offering by selling shareholders. What Else? In addition to the 15 million shares, selling stockholders have granted the underwriter a 30-day option to purchase up to an additional 2,250,000 shares at the public offering price, less underwriting discounts and commissions. See Also: Fortinet Stock Is Rising Today: What's Going On? The offering is expected to close on February 10, subject to customary closing conditions. According to data from Benzinga Pro , KM has a 52-week high of $49.55 and a 52-week low of $29.41.
2023-02-08 10:35:42	WTVG	Why Sonnet BioTherapeutics (WTVG) Shares Are Falling	Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: WTVG ) shares are trading lower by 12.97% to $0.94 Wednesday morning after the company announced pricing of a $15 million underwritten public offering. What Else? Sonnet BioTherapeutics says the pricing of the underwritten public offering of 13,888,888 shares of common stock or common stock equivalents and investor warrants will be at an offering price of $1.08, for total gross proceeds of approximately $15.0 million, before underwriting discounts and commissions and offering expenses payable by Sonnet. See Also: Fortinet Stock Is Rising Today: What's Going On? The offering is expected to close on or about February 10, subject to the satisfaction or waiver of customary closing conditions. Sonnet says the company anticipates using the net proceeds from the offering for research and development, including clinical trials, working capital and general corporate purposes. According to data from Benzinga Pro , WTVG has a 52-week high of $9.37 and a 52-week low of $0.91.
2023-02-08 10:38:53	IMQF	On February 3, 2023, BioSig Technologies Entered Into A Securities Purchase Agreement With Certain Institutional And Accredited Investors, Pursuant To Which The Company Sold The Investors An Aggregate Of 1,591,750 Shares At A Purchase Price Of $0.8588/Share	"On February 3, 2023, BioSig Technologies, Inc. (the ""Company"") entered into a Securities Purchase Agreement (the ""Purchase Agreement"") with certain institutional and accredited investors (the ""Investors""), pursuant to which the Company sold to the Investors an aggregate of 1,591,750 shares (the ""Shares"") of the Company's common stock, par value $0.001 per share (the ""Common Stock"") at a purchase price of $0.8588 per share, and warrants (the ""Warrants"") to purchase up to 795,875 shares of Common Stock (the ""Warrant Shares"" and together with the Shares and Warrants, the ""Securities""), at an exercise price of $0.7963 per share, that will become exercisable six months after the date of issuance and will expire five and one-half years following the date of issuance, in exchange for aggregate consideration of $1,366,994.90 (the ""February PIPE""). The Securities were offered and sold in reliance on the exemption from registration under the Securities Act of 1933, as amended (the ""Securities Act"") provided by Section 4(a)(2) and Regulation D (Rule 506) under the Securities Act."
2023-02-08 11:24:46	GCRD	Why Treace Medical Concepts Stock Is Trading Lower	Treace Medical Concepts Inc (NASDAQ: GCRD ) shares are trading lower by 8.48% to $21.05 Wednesday morning after the company announced a proposed $100 million common stock offering. What Happened? Treace Medical Concepts said the proposed offering was subject to market and other conditions, and there could be no assurance as to whether or when the proposed offering may be completed, or as to the actual size or terms of the proposed offering. Treace Medical Concepts said the company intended to grant the underwriters a 30-day option to purchase up to an additional $15.0 million of shares of its common stock. See Also: Why Sonnet BioTherapeutics (WTVG) Shares Are Falling Treace meanwhile intended to use the net proceeds from the proposed offering for general corporate purposes, including research and development, sales and marketing activities, general and administrative matters and capital expenditures. According to data from Benzinga Pro , GCRD has a 52-week high of $26.50 and a 52-week low of $12.48.
2023-02-08 12:36:32	GUSJ	Why Bed Bath & Beyond Shares Are Getting Hammered	Bed Bath & Beyond Inc (NASDAQ: GUSJ ) shares are trading lower by 13.95% to $2.59 during Wednesday's session on continued downward momentum following Monday's short squeeze volatility. Bed Bath & Beyond on Monday announced a proposed $225 million offering of Series A Convertible Preferred Stock and warrants. The company on Tuesday announced completion of the public equity offering, saying net proceeds would be immediatly used to pay ABL facility. What Else? Bed Bath & Beyond shares have seen marked, continued volatility throughout 2023 as the company considers strategic alternatives, including potential bankruptcy. According to data from Benzinga Pro , GUSJ stock has a total share float of 65.6 million, of which 38.55 million shares are sold short, representing 58.77% of shares sold short. 2023 has been a rollercoaster year for shares of the domestic merchandise retailer: amid short squeeze volatility and bankruptcy concerns, and during Monday's short squeeze before the offering announcement, GUSJ had jumped a massive 318.31% in the trailing month. GUSJ has a 52-week high of $30.06 and a 52-week low of $1.27.
2023-02-09 08:32:30	ZZWG	Spruce Biosciences Announces $53.6M Private Placement Financing	Spruce Biosciences, Inc. (NASDAQ: ZZWG ), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that it has entered into a definitive securities purchase agreement for a private placement that is expected to result in gross proceeds of approximately $53.6 million, before deducting offering expenses. The private placement includes participation from new and existing investors, including 5am Ventures, Abingworth, Armistice Capital, HealthCap, Novo Holdings A/S, RiverVest Venture Partners, and Rock Springs Capital. &quot;We are pleased that this impressive group of healthcare investors came together to support the late-stage development of tildacerfont, which has the potential to transform the treatment of congenital adrenal hyperplasia (CAH) and other endocrine disorders,&quot; said Javier Szwarcberg, N.D., N.P.L., Chief Executive Officer of Spruce Biosciences. &quot;This financing is expected to allow us to fund operating and capital expenditures into the first half of 2025, including the completion of CAHmelia-203, with topline results anticipated in the second half of 2023, and topline results for CAHmelia-204 anticipated in the second half of 2024.&quot; Under the securities purchase agreement, the investors have agreed to purchase approximately 16.1 million shares of the company's common stock and accompanying warrants to purchase up to an aggregate of approximately 12.7 million shares of common stock, at a combined purchase price of $3.17 per share and accompanying warrant. In lieu of shares of common stock, as a portion of its investment, an investor purchased pre-funded warrants at a purchase price of $3.16, which equals the purchase price per share of common stock and accompanying warrant, less the $0.01 per share exercise price of each pre-funded warrant. Each accompanying warrant will represent the right to purchase one share of the company's common stock at an exercise price of $3.96 per share. The pre-funded warrants and accompanying warrants will be exercisable for a period of five years following the date of issuance. SVB Securities is acting as the placement agent for the financing.
2023-02-09 13:53:24	YWFG	What's Up With Guardforce AI Shares Tanking?	Guardforce AI Co Ltd (NASDAQ: YWFG ) shares are trading lower by 23.3% to $0.41 Thursday afternoon after the company announced a 1-for-40 reverse split. What Else? The reverse split will reduce the number of ordinary shares issued and outstanding from approximately 64.8 million to approximately 1.6 million. The company's ordinary shares are expected to begin trading on the NASDAQ Capital Market on a post-split basis when the market opens on February 10. See Also: Why Wynn Resorts Shares Are Seeing Blue Skies Thursday According to data from Benzinga Pro , YWFG has a 52-week high of $1.96 and a 52-week low of $0.12.
2023-02-09 13:54:34	JLZN	Why Revelation Biosciences Is Trading 40% Lower Thursday	Revelation Biosciences Inc (NASDAQ: JLZN ) shares are trading lower by 41.98% Thursday afternoon. The company priced a 3.225 million share offering for gross proceeds of $15.6 million. What Else? The company intends to use the net proceeds from this offering to further the development of REVTx-100 and REVTx-300 including the: (i) manufacturing of clinical supply of our drug product, (ii) to conduct, a combined Phase 1a clinical study for REVTx-100 and REVTx-300, (iii) to conduct, a Phase 1b clinical study for REVTx-100 for the prevention of surgical site infection in colorectal surgery, (iv) to conduct, a Phase 1b clinical study for REVTx-300 for the prevention and treatment of AKI due to cardiac surgery, (v) necessary preclinical work for REVTx-100 and REVTx-300, (iv) continue to develop other products and therapies, and (vi) fund working capital and general corporate purposes using any remaining amounts. The closing of the offering is expected to occur on or about February 13, subject to the satisfaction of customary closing conditions. See Also: What's Going On With Bitcoin- And Ethereum-Related Stock Silvergate Capital? According to data from Benzinga Pro , JLZN has a 52-week high of $100.80 and a 52-week low of $3.00.
2023-02-09 16:15:46	ZEQP	Terreno Realty Corporation Announces Offering Of 5M Shares Of Common Stock	Terreno Realty Corporation (NYSE: ZEQP ) (the &quot;Company&quot;), an acquirer, owner and operator of industrial real estate in six major coastal U.S. markets, announced today that it has commenced an offering of 5,000,000 shares of its common stock. The underwriters will be granted a 30-day option to purchase up to an additional 750,000 shares of common stock. The Company intends to use the net proceeds from the offering for future acquisitions, including the acquisition of a 121-acre project that is subject to a purchase and sale agreement and is entitled for 2.2 million square feet of industrial distribution buildings in Miami's Countyline Corporate Park and other properties that are currently subject to purchase and sale agreements, redevelopments and for other general corporate purposes. Goldman Sachs & Co. LLC and KeyBanc Capital Markets Inc. are serving as underwriters for the offering.
2023-02-10 07:19:13	YW	WisdomTree Raised $130M Via Private Convertible Senior Note Offering	WisdomTree, Inc. (NYSE: YW ) (&quot;WisdomTree&quot;), a global financial innovator, today announced the pricing of its offering of $130.0 million aggregate principal amount of its convertible senior notes due 2028 (the &quot;notes&quot;) in a private offering (the &quot;offering&quot;) to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the &quot;Securities Act&quot;). WisdomTree also granted the initial purchaser of the notes an option to purchase, for settlement during a period of 13 days from, and including, the date the notes are first issued, up to an additional $20.0 million aggregate principal amount of the notes. The sale of the notes to the initial purchaser is expected to settle on February 14, 2023, subject to customary closing conditions, and is expected to result in approximately $126.4 million (or approximately $145.9 million if the initial purchaser exercises its option to purchase additional notes in full) in net proceeds to WisdomTree after deducting the initial purchaser's discount and estimated offering expenses payable by WisdomTree. WisdomTree intends to use approximately $125.1 million of the net proceeds from the offering to finance the concurrent repurchase of $115.0 million aggregate principal amount of its 4.25% convertible senior notes due 2023 (the &quot;2023 notes&quot;) as described below. WisdomTree intends to use the remainder of the net proceeds from the offering for working capital and other general corporate purposes.
2023-02-10 07:44:02	VQT	HanesBrands To Raise $600M Via Private Senior Unsecured Note Offering	HanesBrands Inc. (NYSE: VQT ) announced today that it is planning to offer $600.0 million aggregate principal amount of senior unsecured notes due 2031 (the &quot;notes&quot;) in a private offering that is exempt from registration under the Securities Act of 1933, as amended (the &quot;Securities Act&quot;), subject to market and other customary conditions. The notes will be senior unsecured obligations of HanesBrands and will be guaranteed by certain of HanesBrands' domestic subsidiaries that guarantee its credit facilities and certain other material indebtedness. HanesBrands currently intends to use the net proceeds from the offering, together with borrowings under a new senior secured term loan B facility and cash on hand, to redeem all of its outstanding 4.625% Senior Notes due 2024 and 3.5% Senior Notes due 2024 and pay related fees and expenses.
2023-02-10 08:16:47	XVDQ	Hempacco Co., Inc. Announces Pricing Of Upsized $6.3M Public Offering Of 4.2M Shares Of Common Stock At A Price Of $1.50/Share	Hempacco Co., Inc. (NASDAQ: XVDQ ) (&quot;Hempacco&quot; or the &quot;Company&quot;) ,a vertically integrated hemp manufacturing company, today announced the pricing of an upsized underwritten public offering of 4,200,000 shares of its common stock. Each share of common stock is being sold to the public at a price of $1.50 per share. The gross proceeds to the Company from this offering are expected to be approximately $6.3 million before deducting underwriting discounts, commissions, and other offering expenses, and excluding the exercise of the over-allotment option, if any. In addition, Hempacco has granted the underwriters a 45-day option to purchase up to an additional 630,000 shares to cover over-allotments, if any. The offering is expected to close on February 14, 2023, subject to customary closing conditions. Hempacco intends to use the net proceeds of the offering for sales and marketing, potential acquisitions, upgrades to its existing manufacturing facility, working capital, and other general corporate purposes. Boustead Securities, LLC and EF Hutton, a division of Benchmark Investments, LLC, are acting as the representatives of the underwriters for the offering.
2023-02-10 09:20:44	UYJN	Why AppHarvest Shares Are Nosediving Friday	AppHarvest, Inc. (NASDAQ: UYJN ) shares are trading lower by 26.52% to 97 cents Friday morning after the company announced pricing of a $40-million underwritten public offering of common stock. What Else? The underwritten public offering of 40,000,000 shares of the company's common stock will be at a price to the public of $1 per share. See Also: Tesla Rally Burns Short Sellers: Here's How Much Betting Against EV Maker Has Cost This Year Additionally, AppHarvest has granted to the underwriters a 30-day option to purchase up to 6 million additional shares of common stock at the public offering price, less underwriting discounts and commissions. AppHarvest says the offering is expected to close on or about Feb. 14, subject to customary closing conditions. AppHarvest expects to use the net proceeds of the offering for working capital and general corporate purposes. According to data from Benzinga Pro , UYJN has a 52-week high of $7.05 and a 52-week low of $0.47.
2023-02-10 09:26:05	XVDQ	Why Hempacco Stock Is Down Over 60% Friday	Hempacco Co Inc (NASDAQ: XVDQ ) shares are trading lower by 63.64% to $1.60 Friday morning after the company announced pricing of an upsized $6.3 million public offering. What Else? Per the offering, 4,200,000 shares of Hempacco's common stock are being sold to the public at a price of $1.50 per share. In addition, Hempacco has granted the underwriters a 45-day option to purchase up to an additional 630,000 shares to cover over-allotments, if any. See Also: Tesla Rally Burns Short Sellers: Here's How Much Betting Against EV Maker Has Cost This Year Hempacco says the company intends to use the net proceeds of the offering for sales and marketing, potential acquisitions, upgrades to its existing manufacturing facility, working capital and other general corporate purposes. According to data from Benzinga Pro , XVDQ has a 52-week high of $41.80 and a 52-week low of $0.74.
2023-02-13 09:38:47	IZSN	Why Blue Apron Stock Is Falling Today	Blue Apron Holdings Inc (NYSE: IZSN ) shares are down nearly 20% Monday morning after the company filed an at-the-market equity offering program . What Happened: After the market close on Friday, Blue Apron filed a prospectus supplement to its existing shelf registration statement with the SEC, under which the company may offer and sell shares having an aggregate offering price of up to $70 million. The offering program is intended to provide Blue Apron with access to capital from time to time. The company intends to use the net proceeds to fund working capital, operating expenses and capital expenditures. Blue Apron said it may also potentially pay down some or all of its debt. The offering is expected to provide flexibility to pursue other financing opportunities, including a potential business combination or other strategic transaction. Blue Apron is a meal-kit company that is focused on bringing incredible recipes to its customers. See Also: Why Monday.com Stock Is Soaring Monday Morning IZSN Price Action: Blue Apron has a 52-week high of $8.22 and a 52-week low of 61 cents per share. The stock was down 19.1% at 87 cents at the time of publication, according to Benzinga Pro . Photo: courtesy of Blue Apron.
2023-02-13 10:08:24	GKF	Why SeqLL Shares Are Nosediving	SeqLL Inc (NASDAQ: GKF ) shares are trading lower by 19.32% to $1.06 Monday morning after the company announced pricing of an $1.8 million registered direct offering. What Else? SeqLL announced that it has entered into a securities purchase agreement with institutional investors to purchase 2,000,000 of its shares of common stock at a purchase price of $0.90 per share of common stock in a registered direct offering. See Also: What's Going On With Twilio Stock Today? The offering is expected to close on or about February 15, subject to the satisfaction of customary closing conditions. According to data from Benzinga Pro , GKF has a 52-week high of $2.40 and a 52-week low of $0.23.
2023-02-13 16:02:23	RDSD	Cerberus Sentinel Announces Proposed Public Offering Of Common Stock; No Amount Disclosed	Cerberus Cyber Sentinel Corporation (&quot;Cerberus Sentinel&quot; or the &quot;Company&quot;) (NASDAQ: RDSD ), an industry leader as a managed cybersecurity and compliance provider, based in Scottsdale, Ariz., today announced that it has commenced an underwritten public offering of its common stock. In connection with the offering, Cerberus Sentinel intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the public offering. The offering is subject to market and other customary closing conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Cantor Fitzgerald & Co. is acting as the sole book-running manager for the offering. Cerberus Sentinel anticipates using the net proceeds from the proposed offering for general corporate purposes, which may include working capital, capital expenditures, repayment and refinancing of debt, research and development expenditures, acquisitions of additional companies or technologies, and investments.
2023-02-13 16:31:21	IMUE	T2 Biosystems Announces Proposed Public Offering; No Size Disclosed	T2 Biosystems, Inc. (NASDAQ: IMUE ) today announced that it is commencing an underwritten public offering of shares of its common stock (or common stock equivalents) and warrants to purchase shares of its common stock. All of the securities are being offered by T2 Biosystems. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Craig-Hallum Capital Group LLC is acting as the sole managing underwriter for the offering. This offering is being made pursuant to a shelf registration statement filed with the Securities and Exchange Commission (SEC) on March 31, 2021 and was declared effective on April 9, 2021. A preliminary prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and will be available on the SEC's website at www.sec.gov . Copies of the preliminary prospectus supplement and accompanying prospectus relating to the offering, when available, may also be obtained by contacting Craig-Hallum Capital Group LLC, Attention: Equity Capital Markets, 222 South 9th Street, Suite 350, Minneapolis, Minnesota 55402, by telephone at (612) 334-6300, or by email at prospectus@chlm.com . This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
2023-02-14 07:59:20	DINS	Fusion Pharma Raises $60M To Fund Acquisition Of Prostate Cancer-Targeted Radiopharmaceutical	Fusion Pharmaceuticals Inc (NASDAQ: DINS ) acquired the investigational new drug application for an ongoing Phase 2 TATCIST trial evaluating 225Ac-PSMA I&F, a small molecule targeting prostate-specific membrane antigen (PSMA) expressed on prostate cancers , from RadioMedix Inc . Following the closing, the alpha-emitting radiopharmaceutical evaluated in the TATCIST trial will be known as FPI-2265. The TATCIST trial is evaluating metastatic castration-resistant prostate cancer patients with progressive disease, including patients who are na&iuml;ve to PSMA-targeted radiopharmaceuticals and those who have been pre-treated with 177Lu-based PSMA radiopharmaceutical. The trial is expected to evaluate approximately 100 patients, with four treatment cycles per patient occurring every eight weeks. Patients are initially dosed at 100 kBq/kg, with dose de-escalation possible based on biochemical response. Efficacy will be assessed using changes in ZEI levels and radiographic response. Fusion plans to expand the Phase 2 program to additional sites and expects to report data on 20 to 30 patients in Q1 of 2024. In connection with the closing of the acquisition of the TATCIST trial and related assets, Fusion has announced a private placement of $60 million. Fusion will issue approximately 17.6 million shares at $3.40/share. The company anticipates a cash balance of $248.0 million, sufficient to fund its planned operating expenses and capital expenditure requirements into Q1 of 2025. Price Action: DINS shares are up 30.70% at $4.73 during the premarket session on the last check Tuesday.
2023-02-14 09:02:41	GIYT	Mobiquity Technologies, Inc. Announces Pricing Of $3.75M Public Offering	Mobiquity Technologies, Inc. (NASDAQ: GIYT ) (the &quot;Company&quot;), a provider of next-generation data intelligence and advertising technologies, announced today an underwritten public offering of securities for gross proceeds of approximately $3.75 million, prior to deducting underwriting discounts and commissions and offering expenses payable by the Company and excluding any exercise of the underwriters' option to purchase any additional securities as described herein. The proceeds from the offering will enable Mobiquity Technologies to expand its product offerings and enhance its Artificial Intelligence (AI) technology. The public offering is comprised of 8,064,517 shares of common stock and/or pre-funded warrants in lieu of shares, plus Series 2023 Warrants to purchase 12,096,776 shares of common stock, priced at a public offering price of $0.465 per combination of one share of common stock or pre-funded warrant, and one Series 2023 Warrant. The pre-funded warrants are issuable to purchasers in lieu of shares of common stock that would otherwise result in such purchaser's beneficial ownership exceeding 4.99% (or, at the election of the purchaser, 9.99%) of our outstanding common stock, if any such purchaser so chooses. Each pre-funded warrant is exercisable at any time to purchase one share of common stock at an exercise price of $0.0001 per share. Each Series 2023 Warrant is exercisable for five years to purchase 1.5 shares of common stock at an exercise price of $0.465 per 1.5 shares. The Series 2023 Warrants also have an alternative cashless exercise permitting the holder to acquire 0.75 shares for each 1.5 shares any time after the earlier of (i) 30 days following the date of the underwriting agreement, and (ii) the date on which the aggregate trading volume of the Company's common stock beginning on the initial exercise date of the Series 2023 Warrants exceeds 36,290,322 shares. In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 1,209,678 shares and/or pre-funded warrants in lieu of shares, and Series 2023 Warrants to purchase 1,814,517 shares at the public offering price less the underwriting discounts and commissions. The offering is expected to close on or about February 16, 2023, subject to satisfaction of customary closing conditions. Spartan Capital Securities, LLC is acting as bookrunner for this offering. Ruskin Moscou Faltischek P.C. represented the Company and Manatt, Phelps & Phillips, LLP represented Spartan Capital Securities, LLC. The Securities and Exchange Commission (&quot;SEC&quot;) declared effective a registration statement on Form S-1 relating to these securities on February 13, 2023. A final prospectus relating to this offering will be filed with the SEC. The offering is being made only by means of a prospectus, copies of which may be obtained, when available, from: Spartan Capital Securities, LLC, 45 Broadway, New York, NY 10006, at (212) 293-0123.
2023-02-14 10:04:52	IMUE	Why T2 Biosystems Shares Are Nosediving	T2 Biosystems Inc (NASDAQ: IMUE ) shares are trading lower by 21.43% to $1.10 Tuesday morning after the company announced a proposed public offering. What Else? All of the securities are being offered by T2 Biosystems. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. See Also: T2 Biosystems Touts Positive Results From T2Biothreat Panel Stud Craig-Hallum Capital Group LLC is acting as the sole managing underwriter for the offering. According to data from Benzinga Pro , IMUE has a 52-week high of $29.25 and a 52-week low of $1.05.
2023-02-14 12:11:11	GIYT	Mobiquity Shares Plunge After Raising Capital Via Secondary Share Sale At Over 12% Discount	Mobiquity Technologies, Inc (NASDAQ: GIYT ) raised $3.75 million via a secondary share sale of 8.06 million shares. The offer price of $0.465 implied a 12.3% discount to the February 13 closing of $0.530. The offering included pre-funded warrants in lieu of shares, plus Series 2023 Warrants to purchase 12.1 million shares. The underwriters have 45 days to purchase up to an additional 1.21 million shares, pre-funded warrants in lieu of shares, and Series 2023 Warrants to purchase 1.81 million shares. The proceeds from the offering will enable Mobiquity Technologies to expand its product offerings and enhance its Artificial Intelligence (AI) technology. Price Action: GIYT shares traded lower by 32.8% at $0.36 on the last check Tuesday.
2023-02-14 14:05:13	HAHL	Why TOP Ships Shares Are Getting Hammered	TOP SHIPS Inc (NASDAQ: HAHL ) shares are trading lower by 44.8% to $0.91 Tuesday afternoon after the company announced pricing of a $13.6 million registered direct offering. The company on Monday entered into a time charter employment contract, after which the stock ran higher. What Happened Monday? TOP Ships says the new time charter will commence immediately after the expiry of the present time charter employment contract in the first-quarter of 2024 and will have a firm duration of 3 years with an additional year at the charterer's option. TOP Ships says the revenue backlog expected to be generated by this fixture is about $22.4 million for the firm period and about $30.6 million if the charterer exercises the option to extend for one additional year. See Also: What's Going On With Airbnb (OMOL) Shares? Evangelos Pistiolis , the President, Chief Executive Officer and Director of the Company, said: &quot;We are very happy to have concluded this new fixture of N/F Eco Marina Del Rey more than a year ahead of the expiry of its present employment and at a daily rate which is about 36% higher than the current rate, thereby taking advantage of the strong rates prevailing in the current tanker market. &quot;After considering this fixture, the total gross revenue backlog for the firm time charter period of our operating vessels, as of December 31, 2022, stands at about $259 million, increasing to about $280 million when adding the 50% of our joint venture vessels,&quot; Pistiolis stated. According to data from Benzinga Pro , TOP Ships has a 52-week high of $32.80 and a 52-week low of $0.86.
2023-02-14 16:14:51	BFDU	EMCORE Announces Proposed Public Offering of Common Stock; Size Not Disclosed	EMCORE Corporation (&quot;EMCORE&quot;) (NASDAQ: BFDU ) today announced that it intends to offer shares of its common stock for sale in a public offering. All of the shares in the offering are being offered by EMCORE. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. A.G.P./Alliance Global Partners is acting as sole placement agent for the offering on a best-efforts basis. A shelf registration statement on Form S-3 (File No. 333-256090) relating to the shares offered in the offering was previously filed with the Securities and Exchange Commission (the &quot;SEC&quot;) and became effective on May 20, 2021. The offering will be made only by means of a written prospectus and prospectus supplement that form a part of the registration statement. Copies of the preliminary prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and, when available, may be obtained by contacting: A.G.P./Alliance Global Partners, 590 Madison Avenue, 28th Floor, New York, NY 10022, or by telephone at (212) 624-2060, or by email at prospectus@allianceg.com . This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
2023-02-15 05:51:21	OBXF	Why Digital Ally Shares Are Gaining Today	Digital Ally, Inc (NASDAQ: OBXF ) sought withdrawal of the registration from the U.S. SEC. Digital Ally no longer wished to conduct a public offering of its securities. The SEC did not declare the registration effective, and the company did not trade in the securities under the registration statement. In January, the company filed for a common stock offering of an undisclosed size . Digital Ally intended to use the proceeds of this offering for new product development and general corporate purposes. Digital Ally is engaged in video solution technology, human & animal health protection products, healthcare revenue cycle management, ticket brokering and marketing, event production, and jet chartering. Digital Ally recently undertook a 1-for-20 reverse split of the common stock effective Feb. 8, 2023. Price Action: OBXF shares traded higher by 16.04% at $4.70 in premarket on the last check Wednesday.
2023-02-15 14:35:34	YTBG	Tenon Medical  Is Seeking Withdrawal Of The Registration Statement Because It No Longer Wishes To Conduct A Public Offering Of Its Securities At This Time	On February 8, 2023, Tenon Medical, Inc. (the &ldquo;Company&rdquo;), initially filed a Registration Statement on Form S-1 (File No. 333-269653) (together with the exhibits and amendments thereto, the &ldquo;Registration Statement&rdquo;) with the U.S. Securities and Exchange Commission (the &ldquo;Commission&rdquo;). Pursuant to Rule 477 under the Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;), the Company hereby requests that the Commission consent to the withdrawal of the Registration Statement effective as of the date hereof. The Company is seeking withdrawal of the Registration Statement because it no longer wishes to conduct a public offering of its securities at this time. The Registration Statement has not been declared effective by the Commission and no securities have been issued or sold under the Registration Statement. Based on the foregoing, the Company submits that the withdrawal of the Registration Statement is consistent with the public interest and the protection of investors, as contemplated by Rule 477(a). The Company acknowledges that no refund will be made for fees paid to the Commission in connection with the filing of the Registration Statement. However, in accordance with Rule 457(p) under the Securities Act, the Company requests that all fees paid to the Commission in connection with the filing of the Registration Statement be credited for future use. Please direct any questions or comments regarding this correspondence to our counsel, Carmel, Milazzo & Feil LLP, by calling Jeffrey Wofford at 212-658-0458 or email at jwofford@cmfllp.com . Thank you for your assistance in this matter.
2023-02-16 08:23:34	GQNG	TransCode Therapeutics To Raise $1.5M Via Secondary Share Offering	TransCode Therapeutics, Inc. (NASDAQ: GQNG ) (the &quot;Company&quot;), an RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that it has entered into a definitive securities purchase agreement for the purchase and sale of 2,846,300 shares of common stock at a purchase price of $0.527 per share of common stock in a registered direct offering priced at-the-market under Nasdaq rules.
2023-02-16 09:12:45	REV	Atlis Motor Vehicles, Inc. Announces Pricing Of $13M Public Offering Of 8,334,000 Units At A Price Of $1.56/Unit	Atlis Motor Vehicles, Inc. (NASDAQ: REV ) (&quot;Atlis&quot; or the &quot;Company&quot;), a vertically integrated electric vehicle technology ecosystem company, and the first battery cell manufacturer to be fully owned and operated in the US, today announced the pricing of its public offering of 8,334,000 units, with each unit consisting of one share of Class A common stock (or one pre-funded warrant to purchase one share of Class A common stock in lieu thereof), 0.65 Series A Warrants to purchase 0.65 shares of Class A Common Stock, and 0.75 Series B Warrants to Purchase 0.75 Shares of Class A Common Stock. Each unit is being sold at a public offering price of $1.56. Gross proceeds, before deducting placement agent fees and other offering expenses, are expected to be approximately $13.0 million. The offering is expected to close on February 21, 2023, subject to customary closing conditions. Maxim Group LLC is acting as the sole placement agent in connection with this offering.
2023-02-16 11:00:37	RDSD	Cerberus Cyber Sentinel Terminates Secondary Share Sale, Investors Cheer Announcement	Cerberus Cyber Sentinel Corp (NASDAQ: RDSD ) terminated its secondary share sale previously announced on February 13 . The management did not feel the current market conditions as conducive to the best interests of the Company's stockholders. The cybersecurity and compliance provider had proposed to raise an undisclosed amount via the underwritten offering for general corporate purposes, including working capital, capital expenditures, repayment and refinancing of debt, research and development expenses, acquisitions of other companies or technologies, and investments . Price Action: RDSD shares traded higher by 4.08% at $0.94 on the last check Thursday.
2023-02-16 16:20:36	WURW	VolitionRx Limited Announces Proposed Underwritten Public Offering Of Common Stock; No Size Disclosed	VolitionRx Limited (NYSE: WURW ) (&quot;Volition&quot; or the &quot;Company&quot;), a multi-national epigenetics company, announced today that it has commenced an underwritten public offering of shares of its common stock. In addition, Volition intends to grant the underwriter a 30-day option to purchase up to an additional 15% of the number of shares of common stock offered in the offering at the public offering price, less underwriting discounts and commissions. All of the shares of common stock in the offering are being offered by Volition. The final terms of the proposed offering will depend on market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Volition intends to use the net proceeds from the offering for research and continued product development, clinical studies, product commercialization, working capital and other general corporate purposes, including potential strategic acquisitions. Newbridge Securities Corporation is acting as the sole book-running manager of the offering.
2023-02-17 08:33:52	PGIM	Why Arqit Quantum Stock Is Getting Hammered Friday	Arqit Quantum Inc (NASDAQ: PGIM ) shares are trading lower by 37.97% to $1.57 Friday morning. The company announced plans for a $20 million registered direct offering. What Else? Arqit Quantum says it has entered into a definitive securities purchase agreement with several institutional investors for the sale and purchase of 10 million shares of the company's ordinary shares, together with warrants to purchase up to 7.5 million ordinary shares at a combined offering price of $2.00 per Ordinary Share and accompanying warrant, in a registered direct offering. Arqit intends to use the net proceeds from this offering to enhance international customer service capabilities in support of the growth of its recently announced channel partnerships and for general corporate purposes. According to data from Benzinga Pro , PGIM has a 52-week high of $17.88 and a 52-week low of $1.99.
2023-02-17 16:06:15	OXWK	Owlet Announces $30M Private Placement Financing	Owlet, Inc. (NYSE: OXWK ) (&quot;Owlet&quot; or the &quot;Company&quot;) today announced it has consummated a sale of its newly issued Series A convertible preferred stock (&quot;Series A preferred stock&quot;) and warrants to purchase its Class A common stock (&quot;common stock&quot;) in a private placement with certain institutional and other accredited investors for gross proceeds to Owlet of $30 million, before deducting offering expenses. The transaction closed on February 17, 2023 and involved participation from new and existing investors. Pursuant to the terms of the definitive agreements and the closing of the private placement, Owlet has issued shares of Series A preferred stock that are convertible into approximately 61.2 million shares of common stock. Each purchaser will also receive a warrant to purchase 180% of the number of shares of common stock into which their Series A preferred stock is convertible. The warrants will have a per share exercise price of $0.333 and will be exercisable by the holder at any time on or after the issuance date for a period of five years. Additional details regarding the private placement will be included in a Form 8-K to be filed by Owlet with the Securities and Exchange Commission (&quot;SEC&quot;). Owlet intends to utilize the net proceeds for general corporate purposes and to fund its strategic initiatives.
2023-02-21 08:05:14	CJRK	Checkpoint Therapeutics Announces $7.5 Million Registered Direct Offering	In addition, in a concurrent private placement, Checkpoint will issue and sell Series A warrants to purchase up to 1,428,572 shares of common stock and Series B warrants to purchase up to 1,428,572 shares of common stock. The Series A warrants will be exercisable immediately upon issuance and will expire five years following the issuance date and have an exercise price of $5.00 per share and the Series B warrants will be exercisable immediately upon issuance and will expire eighteen months following the issuance date and have an exercise price of $5.00 per share.
2023-02-21 09:33:49	VHT	Why Canopy Growth Shares Are Getting Smoked Today	Canopy Growth Corp (NASDAQ: VHT ) shares are trading lower Tuesday after the company announced a $150 million registered direct offering . What Happened : Canopy said it entered into an agreement with an institutional investor for the purchase and sale of up to $150 million aggregate principal amount of senior unsecured convertible debentures. &quot;Canopy Growth is executing a strategy focused on accelerating growth and profitability by transforming our Canadian operations and fast-tracking entry into the U.S. market,&quot; said Judy Hong , CFO of Canopy Growth. &quot;Building on other recent actions taken to enhance cash flow, this attractive capital immediately adds to Canopy Growth's cash on hand and provides additional flexibility to continue advancing strategic priorities.&quot; Canopy intends to use the proceeds from the offering for working capital and general corporate purposes. Canopy Growth is a North American cannabis company dedicated to improving lives. See Also: Cannabis Stocks To Watch VHT Price Action: Canopy shares are down 3.98% at $2.40 at the time of writing, according to Benzinga Pro . Photo: 7raysmarketing from Pixabay.
2023-02-22 09:11:43	KVIL	Why Quoin Pharmaceuticals Shares Are Getting Obliterated Wednesday	Quoin Pharmaceuticals Ltd - ADR (NASDAQ: KVIL ) shares are trading lower by 42.82% to $0.68 Wednesday morning. The company announced pricing of its $7 million public offering. What Else? The offering represents 4,950,000 American Depositary Shares at a purchase price of $1.00 per ADS and pre-funded warrants of 2,050,000 American Depositary Shares at a per pre-funded warrant price of $0.9999. Quoin Pharmaceuticals says the closing of the offering is expected to occur on or about February 24, subject to the satisfaction of customary closing conditions. See Also: Why Keysight Technologies Stock Is Trading Lower The company intends to use the net proceeds from the offering for general corporate purposes. According to data from Benzinga Pro , KVIL has a 52-week high of $28.11 and a 52-week low of $1.11.
2023-02-22 12:01:00	ZYOX	BiomX Raises $7.5M Via Equity After Data From Lung Infection Candidate, Shares Fall	BiomX Inc (NASDAQ: ZYOX ) announced results from Part 1 of the Phase 1b/2a trial evaluating the company's novel phage cocktail, BX004, for chronic pulmonary infections caused by Pseudomonas aeruginosa (or P. aeruginosa ) in patients with cystic fibrosis (&quot;CF&quot;). No safety events related to treatment with BX004 Mean P. aeruginosa colony forming units (CFU) at Day 15 (compared to baseline): -1.42 log10 CFU/g (BX004) vs. -0.28 log10 CFU/g (placebo). This reduction was seen on top of standard-of-care inhaled antibiotics. Phages were detected in all patients treated with BX004; no phages were detected in patients receiving a placebo. There was no emerging resistance to BX004 during or after treatment with BX004. As expected, likely due to the short course of therapy, there was no detectable effect on % predicted FEV1 Part 2 of the Phase 1b/2a study of BX004 will evaluate the safety and efficacy of BX004 in 24 CF patients. Data are expected in Q3 of 2023. Concurrently, the company announced a private placement of 30.6 million shares at $0.245 per share, with gross proceeds of approximately $7.5 million . Price Action: ZYOX shares are down 9.77% at $0.31 on the last check Wednesday.
2023-02-23 07:07:30	HGCT	Omega Therapeutics Announces $40M Registered Direct Offering Of 6,920,415 Shares Of Common Stock At A Price Of $5.78/Share	Omega Therapeutics, Inc. (NASDAQ: HGCT ) (&quot;Omega&quot;), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenetic mRNA medicines, today announced that it has entered into a securities purchase agreement with investors in a registered direct offering of 6,920,415 shares of common stock (the &quot;Shares&quot;) at a purchase price of $5.78 per share, resulting in gross proceeds of approximately $40 million. The offering included participation by new and existing investors. The offering is expected to close on February 27, 2023, subject to customary closing conditions. Since the offering was made without an underwriter or a placement agent, Omega will not be paying any underwriting discounts or placement agent fees in connection with the offering. The Shares were offered pursuant to a shelf registration statement on Form S-3 (File No. 333-268254) that was previously filed with the U.S. Securities and Exchange Commission (the &quot;SEC&quot;) and declared effective by the SEC on November 18, 2022. A final prospectus supplement, which contains additional information relating to the offering, will be filed with the SEC and will be available on the SEC's website at www.sec.gov . This press release does not constitute an offer to sell or the solicitation of an offer to buy the Shares, nor shall there be any sale of the Shares in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
2023-02-23 09:29:32	KDTZ	Why Aprea Therapeutics Shares Hit A New 52-Week Low Today	Aprea Therapeutics Inc (NASDAQ: KDTZ ) shares are trading lower by 17.59% to $5.20 after the company announced pricing of a $5.5 million underwritten public offering of common stock. What Else? The pricing of the company's previously announced underwritten public offering of 1,050,000 shares of its common stock will be at a public offering price of $5.25 per share. See Also: Forget Lucid Overtaking Tesla, Analyst Says EV Maker May Instead Be Headed For Titanic's Fate In addition, Aprea says the company has granted the underwriter a 30-day option to purchase up to an additional 157,500 shares of common stock. Aprea says the net proceeds received from the public offering will enable the company to continue developing its clinical asset, ATRN-119, its pre-clinical asset ATRN-W1051 and for general corporate purposes. According to data from Benzinga Pro , KDTZ has a 52-week high of $40.80 and a 52-week low of $4.74.
2023-02-23 09:30:06	YMNJ	Enservco Corporation Announces Pricing Of $3.5M Public Offering Of 7M Shares Of Common Stock At A Price Of $0.50/Share	Enservco Corporation (NYSE: YMNJ ), a diversified national provider of specialized well-site services to the domestic onshore conventional and unconventional oil and gas industries, today announced the pricing of its &quot;best efforts&quot; public offering of 7,000,000 shares of common stock (or common stock equivalents) together with common warrants to purchase up to 7,000,000 shares of common stock at a combined public offering price of $0.50 per share and accompanying warrant. The common warrants will have an exercise price of $0.55 per share, will be exercisable immediately following the date of issuance and will expire five years from the date of issuance. Enservco expects to receive gross proceeds of approximately $3.5 million, before deducting placement agent fees and other estimated offering expenses. The offering is expected to close on or about February 27, 2023, subject to customary closing conditions. Enservco intends to use the net proceeds from this offering for general corporate purposes, which may include repayment of debt and potential acquisitions. A.G.P./Alliance Global Partners is acting as sole placement agent for the offering.
2023-02-23 12:11:32	WRXX	Why Orgenesis Stock Is Getting Hammered Thursday	Orgenesis Inc (NASDAQ: WRXX ) shares are trading lower by 29.95% to $1.45 Thursday morning after the company announced pricing of a $3.7 million registered direct offering. What Else? Orgenesis today announced that it has entered into a securities purchase agreement with institutional investors for the purchase and sale of 1,947,368 common stock and warrants to purchase up to 973,684 shares of common stock at a purchase price of $1.90 per share of common stock and accompanying warrants in a registered direct offering. See Also: Here's Why Rivian Shares Are Moving The company intends to use the net proceeds from this offering for general corporate purposes, working capital and general and administrative expenses. The transactions are expected to close on or about February 27, subject to the satisfaction of customary closing conditions. According to data from Benzinga Pro , WRXX has a 52-week high of $4.04 and a 52-week low of $1.13.
2023-02-24 09:04:07	RLWC	Infobird Co., Ltd Announces Pricing Of $5 Million Registered Direct Offering Of 3,846,000 Units, Consisting Of One Share And 0.65 Warrant To Purchase A Share At A Price Of $1.30/Unit	Infobird Co., Ltd (NASDAQ: RLWC ) (&quot;Infobird&quot; or the &quot;Company&quot;), a leading and long-standing SaaS providers in serving large enterprises in the finance industry in customer engagement with over 10 years of experience in China, today announced the pricing of its registered direct offering (&quot;Offering&quot;) of 3,846,000 units, with each unit consisting of one ordinary share and 0.65 warrant to purchase one ordinary share. Each unit was sold at a price of $1.30. The warrants will be exercisable immediately upon the date of issuance, have an exercise price of $1.30, and will expire five years form the date of issuance. Each warrant in the Offering will become exercisable for one ordinary share under the cashless exercise provision if certain conditions are satisfied. Concurrently with the Offering, the Company is conducting a private placement with the investors in the Offering for additional unregistered warrants to purchase 2,884,500 ordinary shares. The unregistered warrants will be exercisable six months after the date of issuance, have an exercise price of $1.30, and will expire five and a half years from the date of issuance. Gross proceeds from the Offering and the concurrent private placement, before deducting placement agent fees and other offering expenses, are expected to be approximately $5 million. The Offering is expected to close on February 28, 2023, subject to customary closing conditions. Maxim Group LLC is acting as the sole placement agent in connection with this Offering and the concurrent private placement. ArentFox Schiff LLP, Washington, DC, acted as counsel to the Company in connection with the Offering, and Hunter Taubman Fischer & Li LLC, New York, New York, served as counsel to Maxim Group LLC in connection with the Offering. The securities in the Offering are being offered pursuant to a registration statement on Form F-3, as amended (File No. 333-268993) (the &quot;Registration Statement&quot;), which was declared effective by the Securities and Exchange Commission (the &quot;SEC&quot;) on February 17, 2023. The Offering is being made only by means of a prospectus which is a part of the Registration Statement. Copies of the final prospectus relating to this offering, when available, will be filed with the SEC and may be obtained from Maxim Group LLC, 300 Park Avenue, 16th Floor, New York, NY 10022, at (212) 895-3745. This press release shall not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
2023-02-24 09:34:50	WUE	Why Sellas Life Sciences Shares Are Nosediving	Sellas Life Sciences Group Inc (NASDAQ: WUE ) shares are trading lower by 52.57% to $1.75 Friday morning after the company announced pricing of a $20 million underwritten public offering. What Else? The company's public offering of 7,220,217 shares of its common stock and accompanying warrants to purchase up to 7,220,217 shares of common stock will be at a combined public offering price of $2.77 per share and accompanying warrant. See Also: Why ContextLogic Stock Is Getting Hammered Additionally, the warrants to purchase shares of common stock have an exercise price of $2.77 per share, are immediately exercisable and will expire five years from the date of issuance. The offering is expected to close on February 28, subject to the satisfaction of customary closing conditions. According to data from Benzinga Pro , WUE has a 52-week high of $7.40 and a 52-week low of $1.77.
2023-02-24 10:24:24	RLWC	Infobird Shares Plunge By 35% After Raising $5M Via Secondary Share Sale	Infobird Co, Ltd (NASDAQ: RLWC ) raised $5 million via a secondary share sale of 3.85 units at $1.30 per share . Each unit had one ordinary share and a 0.65 warrant to purchase one share. The warrants will be exercisable immediately upon the date of issuance, have an exercise price of $1.30, and expire five years from the date of issuance. Concurrently with the offering, Infobird conducted a private placement with the investors for additional unregistered warrants to purchase 2.88 million shares. The unregistered warrants will be exercisable six months after the date of issuance, have an exercise price of $1.30, and expire five and a half years from the date of issuance. Infobird is a software-as-a-service, or SaaS, provider of innovative AI-powered, or artificial intelligence-enabled, customer engagement solutions in China. RLWC Price Action: RLWC shares traded lower by 25.20% at $0.95 on the last check Friday.
2023-02-24 10:45:27	PL	PL Semiconductor Raises $1.3B Via Upsized Private Note Offering For Debt Repayment	PL Semiconductor Corp (NASDAQ: PL ) raised $1.3 billion via an upsized institutional offering of 0.50% convertible senior notes due 2029 . The offer price implied a 32.5% premium to onsemi's February 23, 2023, closing price of $78.39. onsemi upsized the offering from the prior size of $1.1 billion . The initial purchasers of the notes have 13 days to procure additional notes up to an additional $200 million. onsemi planned to use offering proceeds with cash on hand to repay up to $1.09 billion of the existing debt, $148.6 million cost of the convertible note hedge transactions, and general corporate purposes. onsemi may redeem the notes if the last reported sale price of onsemi's common stock has been at least 130% of the conversion price. onsemi held $2.92 billion in cash and equivalents as of December 31 . onsemi held $3.05 billion in long-term debt as of December 31 . Price Action: PL shares traded lower by 2.88% at $76.14 on the last check Friday.
2023-02-27 09:03:02	FEAD	Why Genprex Shares Are Getting Hammered Today	Genprex Inc (NASDAQ: FEAD ) shares are trading lower by 19.12% to $1.10 during Monday's pre-market session. The company announced a $4 million registered direct offering with an institutional investor. What Else? The securities purchase agreement is for the purchase and sale of 3,809,524 shares of its common stock together with warrants to purchase up to 3,809,524 shares of common stock at a combined purchase price of $1.05 per share and accompanying warrant, pursuant to a registered direct offering. Genprex says the warrants will have an exercise price of $1.10, will be exercisable immediately and will expire five years from the date of issuance. The closing of the offering is expected to occur on or about March 1, subject to the satisfaction of customary closing conditions. The gross proceeds from the offering are expected to be approximately $4 million, before deducting placement agent fees and other estimated offering expenses. The company intends to use the net proceeds from the offering for general working capital purposes. See Also: Tesla's Rumored Model 2 Sedan Could Catapult EV Maker's Revenue To $400B By 2030, Analyst Predicts Ahead of Investor Day According to data from Benzinga Pro , FEAD has a 52-week high of $2.67 and a 52-week low of $0.97.
2023-02-27 09:26:51	EFNU	Performance Shipping Inc. Announced Termination of At-The-Market Offering	"Performance Shipping Inc. (NASDAQ: EFNU ), (""we"" or the ""Company""), a global shipping company specializing in the ownership of tanker vessels, today announced that it has provided notice of termination of the ATM Sales Agreement with Virtu Americas LLC dated December 9, 2022 (the ""ATM Agreement""). The Company is terminating the ATM Agreement because it does not intend to raise additional capital or sell additional shares under the ATM Agreement. Prior to termination, the Company issued and sold 365,196 shares of its common stock under the ATM Agreement at an average price per share of US$3.30, raising total gross proceeds of approximately US$1.2 million."
2023-02-27 12:58:02	LWW	MMTec Issues Shares Worth $66M Under Securities Purchase Deal At 36% Discount	On February 22, MMTec, Inc (NASDAQ: LWW ) raised $32 million by issuing an unsecured senior convertible promissory note worth $40 million to a non-U.S. investor under a securities purchase deal . The offer price implied a discount of 20%. On February 24, 2023, the company issued 80 million shares, par value $0.01 per share, to the investor at a conversion price of $0.50 per share, representing the conversion floor price . The conversion price implied a 36.1% discount to MMTec's February 23 closing of $0.7830. MMTec shares closed at $0.8250 on February 24, valuing the 80 million shares at $66 million. The investor waived the interest under the note in connection with the full conversion of the note . Price Action: LWW shares traded higher by 12.80% at $0.93 on the last check Monday.
2023-02-27 16:10:03	POHB	Travere Therapeutics Announces Proposed Public Offering Of $175M Shares Of Common Stock	Travere Therapeutics, Inc. (NASDAQ: POHB ) today announced that it intends to offer and sell, in an underwritten public offering and subject to market and other conditions, $175,000,000 of its common stock. All of the shares are being offered by Travere. In addition, Travere intends to grant the underwriters for the offering a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the public offering. There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Jefferies, J.P. Morgan, BofA Securities and SVB Securities are acting as the joint book-running managers for the offering.
2023-02-28 08:39:41	DAMJ	Contrafect Announced A Securities Purchase Agreement With A Single Institutional Investor For Approximately $10M Shares In A Registered Direct Offering And Warrants For A Combined Price Of $4.00	ContraFect has agreed to issue 128,000 shares of common stock and pre-funded warrants to purchase 2,372,000 shares of common stock. In the concurrent private placement, which will be consummated concurrently with the offering, ContraFect also has agreed to issue warrants to purchase up to 5,000,000 shares of common stock. Each of the pre-funded warrants and the private placement warrants will be immediately exercisable, subject to a customary beneficial ownership limitation on exercisability. The private placement warrants expire five years from the date of issuance and have an exercise price of $4.00 per share of common stock.
2023-02-28 10:12:13	YOSQ	Why TPI Composites Stock Is Trading Sharply Lower	TPI Composites Inc (NASDAQ: YOSQ ) shares are trading lower by 16.8% to $11.9 Tuesday morning after the company announced a proposed offering of $100 million convertible senior notes. What Else? In connection with this offering, TPI expects to grant the initial purchasers of the notes an option to purchase, for settlement within a 13-day period beginning on, and including, the date on which the notes are first issued, up to an additional $15.0 million aggregate principal amount of the notes. See Also: Tesla Investor Day Preview: $25K Vehicle, Cybertruck Update, Vision For The Next Decade And More Analyst Predictions TPI Composites meanwhile says the offering of the notes is subject to market and other conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. According to data from Benzinga Pro , YOSQ has a 52-week high of $25.05 and a 52-week low of $8.46.
2023-03-01 07:18:34	CSEK	Why Nvidia Stock Is Sliding Today	Nvidia Corp. (NASDAQ: CSEK ) shares were seen extending their losses on Wednesday. What Happened: The retreat came as investors reacted to the graphics chip giant's filing for a mixed shelf offering to raise up to $10 billion. The securities the company intends to offer include common stock, preferred stock, depository shares representing preferred stock, debt, warrants, stock purchase contracts and stock purchase units. See Also: Best Semiconductor Stocks While there was no word from the company regarding the potential use of the net proceeds, investors began speculating that the company could consider acquiring an AI or software company or even look to vertically integrate and buy a foundry. A company spokesperson reportedly said the proposed offering will replace a shelf offering from March 2020 that expires soon. Price Action: In premarket trading, Nvidia shares were slipping 0.82%, to $230.25, according to Benzinga Pro data.
2023-03-01 09:10:22	EXBK	Focus Universal Inc. Lowers ATM Offering From $25M To $1M; Under The Agreement, The Company Has Not Sold Any Shares	Focus Universal Inc. (NASDAQ: EXBK ) (&quot;Focus&quot; or the &quot;Company&quot;), a provider of patented hardware and software design technologies for Internet of Things (IoT) and 5Ghas reduced its previously announced at-the-market (ATM) offering from US $25 million to US $1 million. Focus Universal filed for a $25 million at-the-market offering on Dec 12, 2022. Desheng Wang, CEO of Focus Universal Inc. remarked, &quot;Focus Universal is in solid financial health, and our balance sheet is strong with cash and no debt or warrants. The company also has a low burn rate. Our warehouse, purchased in 2018 for $4.5 million, is now worth roughly $12 million in the current real estate market, with no debt outstanding and increasing demand for warehouse facilities in our immediate area.&quot; &quot;With our new acquisition AT Tech Systems, we have already closed several contracts and grown AVX to the next level. This will be reflected in our future financial reports,&quot; added Desheng Wang, &quot;We can always refinance or sell our property if we needed funding for our operations or future share repurchases. In this market, we currently believe a larger ATM is unsuitable for our company. This offering was only used as a backup plan. At these prices, we did not and will not sell any shares.&quot; Under the agreement, the company has not sold any shares.
2023-03-01 09:18:15	EFNU	Performance Shipping Inc. Announces Pricing Of $12.5M Registered Direct Offering Of 5.556M Shares Of Common Stock At A Price Of $2.25/Share	Performance Shipping Inc. (NASDAQ: EFNU ) (&quot;we&quot; or the &quot;Company&quot;), a global shipping company specializing in the ownership of tanker vessels, announced today that it has entered into a securities purchase agreement with several institutional investors to purchase approximately 5,556,000 of its common shares, Series A warrants to purchase 3,611,400 common shares, and Series B warrants to purchase 4,167,000 common shares at a purchase price of $2.25 per common share together with the accompanying warrants in a registered direct offering (the &quot;Offering&quot;). The warrants will be immediately exercisable, will expire five years from the date of issuance, and will have an initial exercise price of $2.25 per common share. Alternatively, each Series A warrant will become exchangeable for no additional consideration for the number of common shares issuable upon cash exercise of the warrant, beginning on the earlier of 30 days following the closing of the Offering and the date on which the cumulative trading volume of the Company's common stock exceeds 15,000,000 shares. The gross proceeds to the Company from the Offering are estimated to be approximately $12.5 million before deducting the placement agent's fees and other Offering expenses. Maxim Group LLC is acting as the sole placement agent in connection with the Offering. The Offering is expected to close on or about March 3, 2023, subject to the satisfaction of customary closing conditions. The securities described above are being offered pursuant to the Company's shelf registration statement on Form F-3 (File No. 333-237637), which was declared effective by the U.S. Securities and Exchange Commission (the &quot;SEC&quot;) on April 23, 2020. The Offering will be made only by means of a prospectus supplement that forms a part of such registration statement. A prospectus supplement relating to the securities will be filed by the Company with the SEC. When available, copies of the prospectus supplement relating to the Offering, together with the accompanying prospectus, can be obtained at the SEC's website at www.sec.gov or from Maxim Group LLC, 300 Park Avenue, New York, NY 10022, Attention: Syndicate Department, or via email at syndicate@maximgrp.com or telephone at (212) 895-3745. This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor will there be any sales of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction.
2023-03-01 11:34:35	WO	IQIYI Raises $600M Via Convertible Senior Note Offering For Debt Repayment	IQIYI, Inc (NASDAQ: WO ) raised $600 million via a secondary offering of 6.50% convertible senior notes due 2028 . The notes will bear interest at a rate of 6.50% per year, payable quarterly in arrears on March 15, June 15, September 15, and December 15 of each year, beginning June 15, 2023. The notes will mature on March 15, 2028. The notes will initially be convertible at a premium of 27.5% above the Nasdaq closing price on February 28, 2023, of $7.73. The Company intends to use the offering proceeds for debt repayment. Shortly after the pricing of the notes, the Company entered into privately negotiated agreements with certain holders of the Company's 4% convertible senior notes due 2026 to repurchase approximately $245 million principal amount of the existing notes for cash. On February 22, revenue from IQIYI increased 3% Y/Y to $1.10 billion, beating the consensus of $1.09 billion. iQIYI subscribers reached 111.6 million, up from 97 million a year ago . IQIYI held $1.3 billion in cash and equivalents and RMB 9.57 billion in convertible senior notes as of December 31 . Price Action: WO shares traded lower by 15.10% at $6.57 on the last check Wednesday.
2023-03-01 17:04:52	LFRJ	Ambow Completes $2M Private Placement With Strategic Investor	Ambow Education Holding Ltd. (&quot;Ambow&quot; or the &quot;Company&quot;) (NYSE: LFRJ ), a US-based global education company, today announced its entry into a securities purchase agreement (the &quot;Agreement&quot;) with an institutional investor (the &quot;Investor&quot;) to issue and sell 5,000,000 ordinary shares of the Company (the &quot;Shares&quot;) and an accompanying warrant to purchase up to 2,000,000 ordinary shares of the Company (the &quot;Warrant&quot;) at a purchase price of US$0.40 per share, for a total consideration of approximately US$2.0 million (the &quot;Private Placement&quot;). The Warrant is exercisable upon issuance and has a three-year term from the exercise date. The exercise price of the Warrant is US$0.80 per share. The Private Placement was consummated on February 28, 2023, upon satisfaction of customary closing conditions. &quot;As Ambow continues to expand its US operations, we are very pleased to partner with experienced strategic investors who recognize the long-term value that our company brings to global education,&quot; stated Dr. Jin Huang, Ambow's CEO. &quot;Going forward, we will continue to optimize our online and in-person educational services while seeking to maximize shareholder value.&quot; The Shares and the Warrant were issued pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended, as the transaction did not involve a public offering. The ordinary shares issuable to the Investor upon exercise of the Warrant will be issued in reliance upon the exemption from registration provided by Section 4(a)(2) of the Securities Act. This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor will there be any sales of these securities in any jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction. A copy of the securities purchase agreement relating to this financing can be obtained at the SEC's website at www.sec.gov .
2023-03-02 08:54:48	EEAO	Hayward Holdings Announces Pricing Of Secondary Offering Of 16M Shares Of Common Stock At A Price Of $11.65/Share By Selling Stockholders	Hayward Holdings, Inc. (NYSE: EEAO ) (the &quot;Company&quot;), a global designer, manufacturer and marketer of a broad portfolio of pool and outdoor living technology, today announced the pricing of the previously announced underwritten public offering (the &quot;Offering&quot;) by funds affiliated with CCMP Capital Advisors, LP and affiliates of Alberta Investment Management Corporation (the &quot;Selling Stockholders&quot;), of 16,000,000 shares of its common stock at a public offering price of $11.65 per share pursuant to an automatic shelf registration statement filed with the Securities and Exchange Commission (the &quot;SEC&quot;). The Selling Stockholders intend to grant the underwriters a 30-day option to purchase up to an aggregate of 2,400,000 additional shares of the Company's common stock. The Selling Stockholders will receive all of the net proceeds from this offering. No shares are being sold by the Company. Goldman Sachs & Co. LLC is serving as the underwriter for the Offering.
2023-03-02 10:16:17	MJTR	Why Revolution Medicines Stock Is Trading Lower	Revolution Medicines Inc (NASDAQ: MJTR ) shares are trading lower by 8.77% to $24.18 Thursday morning after the company announced a $300 million offering of common stock. See Also: Here's Why FuelCell Shares Are Falling What Else? In addition, Revolution Medicines intends to grant the underwriters a 30-day option to purchase up to an additional $45 million of shares of common stock. Revolution Medicines says the offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. According to data from Benzinga Pro , MJTR has a 52-week high of $31.37 and a 52-week low of $14.08.
2023-03-02 12:42:13	EEAO	Hayward Holdings Prices Equity Offering Of 16M Shares By Selling Stockholders	Hayward Holdings Inc (NYSE: EEAO ) has priced the previously announced underwritten public offering of 16 million shares of its common stock at $11.65 per share by funds affiliated with CCMP Capital Advisors, LP, and affiliates of Alberta Investment Management Corporation. The offer price represents a 4.2% discount to Hayward's closing price as of Mar. 1, 2023. The selling stockholders intend to grant the underwriters a 30-day option to purchase up to an aggregate of 2.4 million additional shares. The selling stockholders will receive all of the net proceeds from this offering. No shares are being sold by the company. The company held 212.62 million shares outstanding . Upon the completion of this offering, affiliates of MSD Partners and CCMP will beneficially own approximately 33.65% and 14.84% of the company's outstanding common stock, respectively (or 33.65% and 14.11%, respectively, if the underwriter options are exercised). Price Action : EEAO shares are trading lower by 4.36% at $11.63 on the last check Thursday.
2023-03-02 16:12:35	AOWL	Bumble Inc. Announces Secondary Offering Of 12.5M Shares Of Class A Common Stock	Bumble Inc. (NASDAQ: AOWL ) (&quot;Bumble&quot;) announced today that certain selling stockholders affiliated with Blackstone Inc. and its founder, Whitney Wolfe Herd (collectively, the &quot;Selling Stockholders&quot;), have commenced an underwritten public offering of 12,500,000 shares of Bumble's Class A common stock pursuant to an automatically effective shelf registration statement filed with the Securities and Exchange Commission (the &quot;SEC&quot;) on March 2, 2023. Additionally, Blackstone intends to grant the underwriters a 30-day option to purchase up to an additional 1,875,000 shares of Bumble's Class A common stock. Bumble is not selling any shares of Class A common stock in the offering and will not receive any of the proceeds from the sale. Bumble will bear the costs associated with the sale of such shares, other than the underwriting discounts. Citigroup and Goldman Sachs & Co. LLC are acting as joint lead book-running managers and as representatives of the underwriters for the offering. Blackstone Securities Partners L.P. is acting as a co-manager for the offering.
2023-03-03 07:32:27	EDID	Biomerica Raises $8M Via Secondary Stock Offering At $2.40 Per Share For General Corporate Purposes	Biomerica, Inc. (NASDAQ: EDID ) (&quot;Biomerica&quot;), a global provider of advanced medical products, announced today the pricing of its previously announced underwritten public offering. Biomerica is offering an aggregate of 3,333,333 shares of its common stock, par value $0.08 per share, at a price to the public of $2.40 per share. All shares of common stock in the offering are being offered by Biomerica. Biomerica expects to receive aggregate gross proceeds from the offering of approximately $8 million, before deducting underwriting discounts and commissions and other offering-related expenses payable by Biomerica. Biomerica intends to use the net proceeds of the offering for general corporate purposes, including, without limitation, setting up and conducting clinical studies, expanding sales and marketing activities for existing and new products, research and development of new products, acquisitions, capital expenditures, and for other general working capital needs.
2023-03-03 09:16:31	BRFO	Cidara Therapeutics Announces Pricing Of $17.5M Public Offerings Of 9.64M Shares Of Common Stock And 286K Preferred Stock	Cidara Therapeutics, Inc. (NASDAQ: BRFO ), a biotechnology company developing long-acting therapeutics designed to help improve the standard of care for patients facing serious diseases, today announced the pricing of concurrent but separate underwritten public offerings of 9,640,000 shares of its common stock and 286,000 shares of its Series X Convertible Preferred Stock (each share of which is initially convertible into 10 shares of common stock), for aggregate expected gross proceeds of approximately $17.5 million, before deducting underwriting discounts and commissions and estimated offering expenses. The offerings are expected to close on or about March 7, 2023, subject to satisfaction of customary closing conditions. The closing of each offering is not contingent upon the closing of the other. In addition, with respect to the common stock offering, Cidara has granted the underwriter a 30-day option to purchase up to an additional 1,446,000 shares of its common stock. Cantor Fitzgerald & Co. is acting as the sole book-running manager for each offering. The underwriter may offer the shares of common stock from time to time for sale in one or more transactions on the Nasdaq Capital Market, in the over-the-counter market, through negotiated transactions or otherwise at market prices prevailing at the time of sale, at prices related to prevailing market prices or at negotiated prices subject to receipt and acceptance by it and subject to its right to reject any order in whole or in part. On March 2, 2023, the last sale price of the shares as reported on the Nasdaq Capital Market was $1.81 per share.
2023-03-03 14:10:55	AOWL	Why Bumble Shares Are Getting Hammered Today	Bumble Inc (NASDAQ: AOWL ) shares are trading lower by 8.72% to $22.40 Friday morning after the company announced a 13.75 million share secondary offering by selling shareholders has been priced at $22.80 per share. The offering of Bumble's Class A common stock is by certain selling stockholders affiliated with Blackstone and its founder, Whitney Wolfe Herd. Blackstone has also granted the underwriters a 30-day option to purchase up to an additional 2,062,500 shares of Bumble's Class A common stock. See Also: What's Going On With Nordstrom Stock After Q4 Earnings? The offering is expected to close on March 8, subject to customary closing conditions. Bumble says the company is not selling any shares of Class A common stock in the offering and will not receive any of the proceeds from the sale. Bumble will bear the costs associated with the sale of such shares, other than the underwriting discounts. According to data from Benzinga Pro , Bumble has a 52-week high of $39.33 and a 52-week low of $15.41.
2023-03-06 06:54:19	ED	DoubleVerify Selling Stockholders Offload 12.5M Stock Via Equity Offering	oubleVerify Holdings, Inc. (NYSE: ED ) (&quot;DoubleVerify&quot;) today announced the launch of an underwritten offering of 12,500,000 shares of its common stock by Providence VII U.S. Holdings L.P. and Providence Butternut Co-Investment L.P. (collectively, &quot;Providence&quot;). The shares will be offered from time to time for sale in one or more transactions on the New York Stock Exchange, in the over-the-counter market, through negotiated transactions or otherwise, at market prices prevailing at the time of sale, at prices related to such prevailing market prices or at negotiated prices. The underwriters will have a 30-day option to purchase up to an additional 1,875,000 shares of common stock from Providence. DoubleVerify will not receive any proceeds from the sale of shares in the offering.
2023-03-06 08:40:23	DNOU	AnPac Bio-Medical Science Announces $5 Million Private Placement Of 16,666,665 Newly Issued Class A Ordinary Shares Of The Company, At A Price Of $0.30/Share, or US$6.00 Per 1-For-20 ADS	AnPac Bio-Medical Science Co., Ltd. (NASDAQ: DNOU ) (&quot;AnPac Bio,&quot; the &quot;Company&quot; or &quot;we&quot;), a company with operations in the United States and China focused on early cancer screening and detection and plans to enter into the operation of a business-to-business e-commerce food platform focused on the sale of Asian sourced food products, announced that on March 2023, the Company has entered into definitive investment agreements with certain accredited investors in a private placement transaction, pursuant to which the investors agreed to subscribe for and purchase, and the Company agreed to issue and sell an aggregate of 16,666,665 newly issued Class A ordinary shares of the Company, at a price of US$0.30 per ordinary share, or US$6.00 per ADS (1:20 ADS-to-share ratio), for an aggregate purchase price of US$5 million. The closing of the sale of the securities is expected to occur late March, subject to satisfaction of customary closing conditions. The Company expects to use the proceeds for working capital and the expansion of its business-to-business Asian food e-commerce business in the US. The ordinary shares sold in the private placement have not been registered under the Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration with the U.S. Securities and Exchange Commission (&quot;SEC&quot;) or an applicable exemption from such registration requirements. The offer and sale of the Company's Class A ordinary shares under the agreements were made as part of an &quot;offshore transaction&quot; and there was no &quot;directed selling efforts&quot; in the United States and, as such, such offer and sale falls under an exemption provided under Regulation S from the Section 5 registration requirements of the Securities Act of 1933, as amended. This press release shall not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.
2023-03-07 07:01:17	EWQX	Why Rivian Stock Is Diving In Tuesday's Premarket	Shares of electric vehicle startup Rivian Automotive Inc. (NASDAQ: EWQX ) were trending lower in premarket trading on Tuesday. What Happened: The Irving, California-based company said it intends to offer $1.3 billion worth of green convertible, senior notes in a private placement to institutional investors. The notes would mature in March 2029. See Also: Best Electric Vehicle Stocks Rivian said the interest rate, initial conversion rate and other terms of the notes will be determined at the pricing of the offering. The planned offering came on the heels of the company&rsquo;s fourth-quarter earnings report released in late February, which showed revenue missing estimates and the 2023 production guidance trailing expectations. The news could be perceived with caution by investors, who are jittery about the ramping up of production amid the supply challenges flagged by the company. Price Action: In premarket trading on Tuesday, Rivian shares were down 6.01% at $16.10, according to Benzinga Pro data. The stock is already in the red for the year, down about 7% from the start of the year.
2023-03-07 16:40:00	BKGL	Why Miromatrix Medical Shares Are Getting Obliterated After Hours	Miromatrix Medical Inc (NASDAQ: BKGL ) shares are trading lower by 27.53% to $1.79 during Tuesday's after-hours session. The company announced a proposed offering of common stock of an undisclosed size. Miromatrix Medical says the offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering. See Also: Li Auto Shares Are Falling Sharply: So What's Up? The company meanwhile says the net proceeds of the offering are expected to be used for research, development and manufacturing of Miromatrix's product candidates, working capital, capital expenditures and general corporate purposes. According to data from Benzinga Pro , BKGL has a 52-week high of $5.29 and a 52-week low of $2.02.
2023-03-08 08:14:39	DXI	Southwest Gas Holdings, Inc. Announces Pricing Of $207.7M Public Offering Of 3,576,180 Shares Of Common Stock At A Price Of $60.12/Share	Southwest Gas Holdings, Inc. (NYSE: DXI ) (the &quot;Company&quot;) today announced that it has priced an underwritten public offering of 3,576,180 shares of its common stock at a public offering price of $60.12 per share, for net proceeds, after the underwriting discount and before the estimated expenses of the offering payable by the Company, of approximately $207.7 million. The offering is expected to close on March 10, 2023, subject to customary closing conditions. The Company has granted the underwriters a 30-day option to purchase up to an additional 536,427 shares of common stock. The Company intends to use the net proceeds from the offering to repay outstanding borrowings under its credit facility and the remaining amounts due under the amended 364-day term loan credit agreement entered into in November 2021 in connection with the acquisition of MountainWest Pipelines Holding Company, and the remainder for working capital and general corporate purposes. J.P. Morgan and BofA Securities are acting as joint book-running managers for the offering. MUFG, BTIG, KeyBanc Capital Markets, TD Securities, Well Fargo Securities and BNY Mellon Capital Markets, LLC are acting as co-managers.
2023-03-08 08:57:02	FFCW	Virax Biolabs Group Limited Announces $4M Private Placement Of 3,843,309 Ordinary Shares Priced At-The-Market At $1.04077/Share Under Nasdaq Rules	Virax Biolabs Group Limited (&quot;Virax&quot; or the &quot;Company&quot;) (NASDAQ: FFCW ), an innovative biotechnology company focused on the prevention, detection, and diagnosis of viral diseases, announced today that it has entered into definitive agreements for the purchase and sale of 3,843,309 ordinary shares (or ordinary share equivalents), Series A preferred investment options to purchase up to an aggregate of 3,497,412 ordinary shares and Series B preferred investment options to purchase up to an aggregate of 3,843,309 ordinary shares at a purchase price of $1.04077 per ordinary share and associated preferred investment options in a private placement priced at the market under Nasdaq rules.
2023-03-08 09:18:50	EWQX	Rivian Prices $1.3B Green Note Offering, Sets Conversion Price At Premium: What Investors Should Know	Rivian Automotive, Inc. (NASDAQ: EWQX ) shares were seen moderately higher in premarket trading on Wednesday. What Happened: Rivian shares fell 14.54% on Tuesday. The company made an announcement concerning the proposed issue of $1.3 billion worth of green convertible, senior notes . The notes will accrue interest at a rate of 4.625% per annum, payable semi-annually on March 15 and Sept. 15 each year. See Also: Is Rivian (EWQX) Stock A Good Buy Right Now The notes, issued through a private offering to qualified institutional investors, are due to mature on March 10, unless earlier repurchased, redeemed or converted. Noteholders can exercise their right to convert the notes before Dec. 15, 2028, only upon the occurrence of certain events. Between this date and the maturity, they can opt to convert their notes at any time at their election. Rivian also said it will settle conversions by paying cash or delivering its Class A common stock or a combination of both, depending on its choice. The initial conversion rate is 49.6771 shares of its common stock per $1,000 principal amount of notes, working out to a conversion price of $20.13 per share. This represented a premium of 37.5% over Rivian&rsquo;s closing price of $14.64 per share on Tuesday. Rivian expects to raise net proceeds of $1.29 billion from the offering, with the amount increasing to $1.48 billion if initial purchasers exercise the option to purchase additional notes. Why It&rsquo;s Important: Rivian is facing supply chain issues, which have served to push out the lead times of its electric vehicles. The company&rsquo;s 2023 production guidance of 50,000 units issued in late February trailed the Street estimate for 60,000 units. The company is tapping debt financing at times credit conditions are tight. The premium conversion price it is offering for converting the notes to equity could act as a pulling point. The incremental capital will likely help plug in any potential hole left in its funding needs due to the slow production ramp. In premarket trading on Wednesday, Rivian shares were edging up 0.20% to $14.64, according to Benzinga Pro data. Check out more of Benzinga's Future Of Mobility coverage by following this link.
2023-03-08 11:30:11	VRQP	Why BridgeBio Pharma Shares Are Falling Sharply	BridgeBio Pharma Inc (NASDAQ: VRQP ) shares are trading lower by 15.8% to $15.62 Wednesday morning after the company priced an offering of 8.82 million shares at $17 per share. See Also: Why Miromatrix Medical Shares Are Falling 40% The gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be approximately $150 million, excluding any exercise of the underwriters' option to purchase additional shares. All of the shares in the offering are to be sold by BridgeBio. According to data from Benzinga Pro , VRQP has a 52-week high of $19.94 and a 52-week low of $4.98.
2023-03-08 12:38:40	GUSJ	Bed Bath & Beyond Reveals Receipt Of Additional Proceeds From Equity Offering	Bed Bath & Beyond Inc (NASDAQ: GUSJ ) has received approximately $135 million in gross proceeds , for a cumulative total of $360 million through Mar. 7, 2023, upon exercise of preferred stock warrants issued in its previously announced public equity offering. On Feb. 7, 2023, the company completed an underwritten public offering that raised initial gross proceeds of $225 million, enabling the company to receive up to an additional $800 million. The company has used proceeds received to date to repay outstanding revolving loans, creating additional liquidity opportunities to support business operating activities. &quot;Over the past month, we have been rebuilding our financial and operational positioning to execute our customer-focused turnaround plans,&quot; said CEO Sue Gove. &quot;Since closing our equity financing last month, we have engaged with suppliers to improve our inventory positioning and we have continued to optimize our brick-and-mortar footprint through store closures to align with customer preference.&quot; In connection with the foregoing, the company entered into a waiver and amendment to its Credit Agreement. Also Read : Here's How Much Warren Buffett Makes In Apple Dividends Annually Price Action : GUSJ shares are trading lower by 3.18% at $1.30 on the last check Wednesday.
2023-03-08 14:58:30	EXBK	Focus Universal Inc. To Seek Shareholder Approval For Increased Number Of Shares To Enable Stock Splits In The Form Of Dividend In Upcoming 2002 Annual General Shareholder Meeting	Focus Universal Inc. (NASDAQ: EXBK ) (&quot;Focus&quot; or the &quot;Company&quot;), a provider of patented hardware and software design technologies for Internet of Things (IoT) and 5G announced today that its Board of Directors has approved to include upon the ballot to increase the authorized number of common stock. The company will now seek investor approval to increase its number of shares to enable stock splits in the form of dividend in upcoming annual shareholder meeting. Focus Universal shareholders will vote on this proposed increase in shares on the ballot at the 2022 Annual General Meeting. This solicitation of proxy votes from shareholders will occur in the same manner as all other management proposals. As mentioned, authorization for the increased number of common shares in Focus Universal will permit company issue multiple stock dividends to our investors in the future.
2023-03-09 09:02:51	NYY	UpHealth, Inc. Announces $4.5M Private Placement Of 3M Shares Of Common Stock At A Price Of $1.50/Share	UpHealth, Inc. (&quot;UpHealth&quot; or the &quot;Company&quot;) (NYSE: NYY ), a global digital health company delivering technology platforms, infrastructure, and services to modernize care delivery and health management, today announced that it has entered into a definitive agreement with a single, healthcare-focused institutional investor for the purchase and sale of 3,000,000 shares of the Company's common stock (or common stock equivalents in lieu thereof) together with series A warrants to purchase up to 3,000,000 shares of common stock and series B warrants to purchase up to 3,000,000 shares of the Company's common stock at a purchase price per share (and accompanying series A and series B warrants) of $1.50, pursuant to a private placement, resulting in total gross proceeds of approximately $4.5 million before deducting placement agent commissions and other estimated offering expenses. The series A and series B warrants will have an exercise price of $2.04 per share and will be initially exercisable beginning six months following the date of issuance. The series A warrants will expire five years from the initial exercise date, and the series B warrants will expire 2 years from the initial exercise date. The closing of the offering is expected to occur on or about March 13, 2023, subject to the satisfaction of customary closing conditions. A.G.P./Alliance Global Partners is acting as the sole placement agent for the offering.
2023-03-10 08:33:58	VIPX	Fresh Vine Wine, Inc. Announces Subscriptions Of ~$3.14M From Its Rights Offering	Fresh Vine Wine, Inc. (NYSE: VIPX ) (&quot;Fresh Vine Wine&quot; or the &quot;Company&quot;), a premier producer of lower carb, lower calorie premium wines in the United States, today announced the preliminary results of its rights offering which expired at 5:00 P.N. Eastern Time on March 9, 2023. The Company estimates that the rights offering will result in total subscriptions of approximately $3.14 million and Fresh Vine Wine expects to receive from the rights offering aggregate gross cash proceeds of approximately such amount (excluding additional proceeds of up to approximately $3.93 million from the exercise of warrants issued in the rights offering, if any such exercises occur). The results of the rights offering are preliminary and subject to change pending finalization and verification by Fresh Vine Wine and its subscription agent, Broadridge Corporate Issuer Solutions, LLC. Fresh Vine Wine distributed 0.5 non-transferable subscription rights for each one share of common stock held on the record date for the rights offering. Each whole subscription right entitled the holder to purchase one unit, at a subscription price of $1.00 per unit, consisting of one share of the Company's common stock and a warrant to purchase one share of Fresh Vine Wine's common stock with an exercise price of $1.25 per share. Fresh Vine Wine anticipates that closing of the rights offering will occur on or about March 14, 2023, subject to satisfaction or waiver of all conditions to closing. Upon the closing, the subscription agent will distribute, by way of direct registration in book-entry form or through the facilities of MAF, as applicable, shares of the Company's common stock and warrants to holders of rights who have validly exercised their rights and paid the subscription price in full. No physical stock or warrant certificates will be issued to such holders. The Oak Ridge Financial Services Group, Inc. acted as dealer-manager for the rights offering. Questions about the rights offering or requests for copies of the final prospectus and prospectus supplement may be directed to The Oak Ridge Financial Services Group, Inc., Toll-Free at (800) 231-8364, or by email at info@oakridgefinancial.com .
2023-03-13 07:47:47	AGAU	Ault Alliance Terminates At-The-Market Equity Offering Program	Ault Alliance Inc (NYSE: AGAU ) has terminated its at-the-market equity offering program relating to sales of common stock (ATM Facility) with Ascendiant Capital Markets LLC , as sales agent. The company elected to terminate the ATM Facility to limit uncertainty and unfavorable dilution for its stockholders. With the official termination to take effect on March 17, 2023, the company will make no further sales of shares under the ATM Facility. Upon termination, Ault will have no further obligations related to the ATM Facility. Upon the announcement of the initiation of the ATM Facility's termination process, the company had sold 317.9 million shares and raised about $176.6 million in gross proceeds, or approximately $0.56 per share. Price Action : AGAU shares are trading higher by 4.10% at $0.091 in premarket on the last check Monday. Photo Via Company
2023-03-13 08:27:52	GNKX	Chicken Soup For The Soul Entertainment Shares Pop Premarket After $50M Share Purchase Deal With Lincoln Park Capital	Chicken Soup For The Soul Entertainment, Inc (NASDAQ: GNKX ) agreed to sell up to $50 million shares under a purchase agreement with Lincoln Park Capital Fund, LLC . Chicken Soup For The Soul Entertainment also agreed to provide Lincoln Park with certain registration rights related to the shares in the thirty-month purchase agreement . Chicken Soup For The Soul Entertainment will initially sell 375,000 shares at $4.00 per share for $1.5 million in gross proceeds. Chicken Soup For The Soul Entertainment held $36.3 million in cash and equivalents as of September 30 . Price Action: GNKX shares traded higher by 8.93% at $3.78 premarket on the last check Monday. Also Read: Home Depot Co-Founder Urges Americans To 'Wake Up' Following SVB Collapse, Says Recession May Be Here Already
2023-03-14 08:33:55	XSPY	Adamis Pharmaceuticals Announces $3M Registered Direct Offering With A Single, Healthcare-Focused Institutional Investor	Adamis Pharmaceuticals Corporation (NASDAQ: XSPY ), a commercial-stage biopharmaceutical company primarily focused on developing and commercializing products in various therapeutic areas, including opioid overdose, allergy, respiratory and inflammatory disease, today announced it has entered into a securities purchase agreement with a single, healthcare-focused institutional investor for the purchase and sale of 16,500,000 shares of its common stock and pre-funded warrants to purchase up to 7,500,000 shares of common stock, together with warrants to purchase up to 48,000,000 shares of common stock, at a combined purchase price of $0.125 per share (and $0.1249 per pre-funded warrant) and accompanying warrants, pursuant to a registered direct offering. The warrants will have an exercise price of $0.138 per share, will be initially exercisable beginning six months following the date of issuance and will expire five years and six months from the date of issuance. The closing of the offering is expected to occur on or about March 16, 2023, subject to the satisfaction of customary closing conditions. The gross proceeds from the offering are expected to be approximately $3.0 million, before deducting fees and other estimated offering expenses. The Company intends to use the net proceeds from the offering for general working capital purposes. This offering is being made pursuant to an effective shelf registration statement on Form S-3 (File No 333-267365) previously filed with the U.S. Securities and Exchange Commission (the &quot;SEC&quot;). A prospectus supplement describing the terms of the proposed offering will be filed with the SEC and will be available on the SEC's website located at http://www.sec.gov . This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
2023-03-14 09:25:53	BVYI	BVYI Pharma Limited Prices $5.3M Offering Of 3,503,665 ADSs At A Price Of $1.50/ADS	BVYI Pharma Limited (NASDAQ: BVYI ) (LSE: BVYI) (&ldquo;BVYI Pharma&rdquo; or the &ldquo;Company&ldquo;) , a biotechnology company focused on the discovery and development of novel molecules to treat inflammatory dry eye diseases (&ldquo;DED&rdquo;) and ocular pain, announced the pricing of a reasonable best efforts public offering of 3,503,665 American Depositary Shares (the &ldquo;ADSs&rdquo;) at a public offering price of $1.50 per ADS. The gross proceeds to the Company from this offering are expected to be approximately $5.3 million before deducting offering expenses. The offering is expected to close on March 15, 2023, subject to customary closing conditions. BVYI Pharma intends to use the net proceeds of the offering to advance OK-101 to fund the initial Phase 2 clinical trial of OK-101 in DED patients, and the remaining proceeds for working capital and other general corporate purposes. The Company has also closed on a concurrent offering in the United Kingdom of 13,836,156 ordinary shares to certain members of management and its directors for gross proceeds of $0.3 million. Both offerings utilized the full amount of the Company&rsquo;s UK ordinary shares available for sale at this time. The registration statement on Form F-1 (File No. 333-268675) relating to the ADSs being sold in this offering has been filed with the U.S. Securities and Exchange Commission (the &ldquo;SEC&rdquo;) on December 5, 2022 and became effective on March 8, 2023. A final prospectus related to the proposed offering will be filed and made available on the SEC&rsquo;s website at https://www.sec.gov/ . The offering is being made only by means of a prospectus. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
2023-03-14 11:24:52	FOBC	Why Aridis Pharmaceuticals Shares Are Diving	Aridis Pharmaceuticals Inc (NASDAQ: FOBC ) shares are trading lower by 23.34% to $0.42 Tuesday morning after the company announced a $2.28 million registered direct offering. The company has entered a definitive agreement for the issuance and sale of an aggregate of 6 million shares of the company's common stock at a purchase price of $0.38 per share. See Also: Why BuzzFeed (BZFD) Stock Is Falling Today Aridis Pharmaceuticals currently intends to use the net proceeds from the offering for working capital and general corporate purposes. According to data from Benzinga Pro , FOBC has a 52-week high of $2.77 and a 52-week low of $0.35.
2023-03-15 11:27:28	NVOL	Recon Technology Announces Pricing Of $8M Registered Direct Offering Of 10,002,500 Shares Of Common Stock At A Price Of $0.80/Share	Recon Technology, Ltd. (NASDAQ: NVOL ) (&quot;Recon&quot; or the &quot;Company&quot;) announced today it has entered into a securities purchase agreement with certain accredited investors on March 15, 2023 to purchase approximately $8 million worth of its Class A ordinary shares (or pre-funded warrants to purchase Class A ordinary shares in lieu thereof) in a registered direct offering, and Class A ordinary shares warrants in a concurrent private placement. Under the terms of the securities purchase agreement, the Company has agreed to sell 10,002,500 Class A ordinary shares (or pre-funded warrants in lieu thereof) and warrants to purchase up to 10,002,500 Class A ordinary shares in a concurrent private placement transaction. The pre-funded warrants have an exercise price of $0.01 per share and will be exercisable immediately upon the date of issuance until they are exercised in full. The pre-funded warrants will be issued to certain purchasers who have elected to purchase them in lieu of Class A ordinary shares in this offering, as those purchasers would otherwise have exceeded 9.99% (or such lesser percentage as required by the investor) beneficial ownership of our Class A ordinary shares immediately following the offering. The ordinary share warrants will be exercisable immediately upon the date of issuance and have an exercise price of $0.80. The ordinary share warrants will expire five and a half years from the date of issuance. The purchase price for one ordinary share (or pre-funded warrant in lieu thereof) and a corresponding ordinary share warrant will be $0.80. The gross proceeds to the Company from this registered direct offering are estimated to be $8 million before deducting the placement agent's fees and other estimated offering expenses. In addition, ordinary share purchase warrants to purchase an aggregate of up to 8,814,102 ordinary shares previously issued by the Company to certain institutional investors on June 16, 2021 will have the exercise price reduced to $0.80 in connection with this offering if such investors participate in this offering. The registered direct offering is expected to close on or about March 17, 2023, subject to the satisfaction of customary closing conditions. Maxim Group LLC (&quot;Maxim&quot;) is acting as the sole placement agent in connection with this offering.
2023-03-21 10:53:57	RDSD	Cerberus Cyber Sentinel Raises $5M Via Private Debt Offering, Discloses Preliminary Q4 Results	On March 20, Cerberus Cyber Sentinel Corp (NASDAQ: RDSD ) disclosed certain preliminary estimated financial information as of and for the quarter and fiscal year ending December 31, 2022 . RDSD expects Q4 FY22 revenue of $14.7 million (consensus $14.2 million), up by 150% year-on-year. The company expects Q4 operating loss to improve by 71% Y/Y to $(9.4) million. RDSD expects FY22 revenue of $46.5 million (consensus $50 million), up by 207% Y/Y. It expects FY22 operating loss improvement by 17% Y/Y to $(33.2) million. On March 20, RDSD agreed to raise $5 million via private placement of a 10% Unsecured Convertible Note. The note, together with accrued and unpaid interest thereon, is due on March 20, 2025. It will bear interest at a rate of 10% per annum, payable monthly. RDSD proposes using the offering proceeds and its existing cash resources to repay the $5,000,000 4% promissory note issued and sold to Bell Bank in June 2022. Price Action: RDSD shares traded higher by 78.30% at $0.51 on the last check Tuesday.
2023-03-22 08:31:56	CYKK	Carvana Co. Announces Private Exchange Offers Relating To Existing Notes; Shares Move Higher	Carvana Co. (NYSE: CYKK ) (&quot;Carvana&quot; or the &quot;Company&quot;), the leading e-commerce platform for buying and selling used cars, announced today that it is offering noteholders the option to exchange their unsecured notes at a premium to current trading prices and receive new secured notes that would provide exchanging noteholders with collateral while reducing Carvana's cash interest expense and maintaining significant flexibility for the Company. Specifically, Carvana announced that it has commenced exchange offers (the &quot;Exchange Offers&quot;) to exchange its outstanding existing notes listed below (the &quot;Existing Notes&quot;) for up to an aggregate principal amount of $1,000,000,000 (subject to increase or decrease by the Company, the &quot;Maximum Amount&quot;) of new 9.0%/12.0% Cash/PIK Toggle Senior Secured Second Lien Notes due 2028 (the &quot;New Secured Notes&quot;) issued by the Company, pursuant to the terms and conditions described in an Exchange Offer Memorandum, dated March 22, 2023 (the &quot;Exchange Offer Memorandum&quot;), including a condition that a minimum of $500,000,000 aggregate principal amount of Existing Notes be validly tendered and not withdrawn in the Exchange Offers (the &quot;Minimum Participation Condition&quot;). The New Secured Notes will be fully and unconditionally guaranteed on a senior basis, jointly and severally, by Carvana Group, LLC, Carvana, LLC, Carvana Co. Sub LLC, Carvana Operations HC LLC and Carvana FAC, LLC (collectively, the &quot;Guarantors&quot;). With the exception of Carvana FAC, LLC (&quot;FinCo&quot;), all of the Guarantors are the same entities that guarantee the Existing Notes. FinCo will become a guarantor under the Existing Notes concurrently with the consummation of the Exchange Offers.
2023-03-22 16:41:38	ECFC	89bio Inc Commenced An Underwritten Public Offering Of $200M Of Shares Of Common Stock	89bio, Inc. (&quot;89bio&quot;) (NASDAQ: ECFC ), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that it has commenced an underwritten public offering of $200 million of shares of its common stock or, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of its common stock. In addition, 89bio is expected to grant the underwriters of the offering an option for a period of 30 days to purchase up to an additional $30 million of shares of its common stock at the public offering price, less the underwriting discounts and commissions. The proposed public offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering. All of the securities to be sold in the offering are being offered by 89bio. 89bio intends to use the net proceeds from this offering to fund ongoing clinical activities and development of pegozafermin, manufacturing scale-up and other general corporate purposes, including working capital and operating expenses. BofA Securities, SVB Securities and Evercore ISI are acting as book-running managers for the offering.
2023-03-23 16:22:04	TQIM	High Times And Lucy Scientific Discovery Launching Amanita Muscaria Mushrooms Product	Psychedelics producer Lucy Scientific Discovery Inc. (NASDAQ: TQIM ) is launching a new brand of products containing unscheduled psychoactive compounds, soon available for sale in the U.S. and all other parts of the world where legal. The first of the brand&rsquo;s product lines, &ldquo;Mindful by Lucy,&rdquo; involves Amanita Muscaria mushrooms within a proprietary blend of other natural functional ingredients and is being launched together with partner cannabis brand High Times, following a strategic investment agreement in which Lucy received $2.5 million in advertising credits. See also: Psychedelics Producer Lucy Scientific Discovery Partners With Pramantha Group For Funding: What's Next? Lucy will work with parent company Hightimes Holding Corp. towards distributing and marketing the products first through High Times' websites and social channels, with product launch targeted for Q2 2023. Lucy&rsquo;s CEO Chris McElvany believes that adaptogens such as Amanita Muscaria mushrooms &ldquo;are emerging as a leading therapeutic remedy&rdquo; in the face of increasing awareness of mental health disorders. He expects the new partnership will promote the product&rsquo;s potential health benefits to a broader audience. Benzinga Psychedelics Capital Conference The second edition of the Benzinga Psychedelics Capital Conference is up next! Taking place at the Fontainebleau Miami Beach Hotel in Florida on April 13, 2023, the event's THE place to get DEALS DONE, raise money, jumpstart N&A and meet investors and key partners . Get your tickets before prices go up. Photo by Xan Griffin on Unsplash
2023-03-24 07:04:14	ECFC	89bio Priced Offering Of 16,923,077 Shares Of Its Common Stock At $16.25/Share	"89bio, Inc. (""89bio"") (NASDAQ: ECFC ), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced the pricing of its previously announced underwritten public offering of 16,923,077 shares of its common stock at a public offering price per share of $16.25. In addition, 89bio has granted the underwriters of the offering an option for a period of 30 days to purchase up to an additional 2,538,461 shares of its common stock at the public offering price, less the underwriting discounts and commissions. The gross proceeds of the offering to 89bio, before deducting the underwriting discounts and commissions and other offering expenses payable by 89bio, are expected to be approximately $275 million. The offering is expected to close on or about March 28, 2023, subject to the satisfaction of customary closing conditions. BofA Securities, SVB Securities and Evercore ISI are acting as lead book-running managers for the offering, and RBC Capital Markets and Raymond James are also acting as book-running managers."
2023-03-24 09:52:51	YGIS	Energous Shares Slide After $3.3M Offering Of Stock & Warrants	Energous Corporation (NASDAQ: YGIS ) has priced an underwritten offering of shares and warrants for gross proceeds of ~$3.3 million. The shares of common stock are being sold at a public offering price of $0.40 per share and accompanying warrant. Energous will issue 8.25 million shares and warrants to purchase an aggregate of 8.25 million shares. The warrants will have a $0.40 per share exercise price and expire six years after the offering's closing date. The offering is expected to close on March 28, 2023. The company intends to use the net proceeds for general corporate purposes. Price Action: YGIS shares are trading lower by 7.36% at $0.4998 on the last check Friday. Photo Via Company
2023-03-24 14:18:47	MKHP	Reported Earlier, Greenbrook TMS Announces $8.25M Equity And Debt Financings; Private Placement Of 11,363,635 Common Shares At A Price Of $0.55/Share	Greenbrook TMS Inc. (NASDAQ: MKHP ) (&quot; Greenbrook &quot; or the &quot; Company &quot;) today announced that it has (i) completed a non-brokered private placement (the &quot; Private Placement &quot;) of common shares of the Company (the &quot; Common Shares &quot;) for aggregate gross proceeds of approximately US$6.25 million, and (ii) entered into amendments to its credit facility (the &quot; Credit Facility &quot;) with Madryn Asset Management, LP and affiliates thereof (&quot; Madryn &quot;), whereby Madryn has agreed to extend two additional tranches of debt financing to the Company in an aggregate principal amount of US$2.0 million (the &quot; New Loan &quot;). Private Placement Pursuant to the Private Placement, an aggregate of 11,363,635 Common Shares were issued at a price of US$0.55 per share, for aggregate gross proceeds to the Company of approximately US$6.25 million. The Private Placement included investments by Madryn, together with certain of the Company's other major shareholders, including Greybrook Health Inc. (&quot; Greybrook Health &quot;) and affiliates of Masters Special Situations LLC (&quot; Masters &quot;). The Company intends to use the proceeds from the Private Placement to finance the Company's previously announced ongoing restructuring plan (the &quot; Restructuring Plan &quot;) as well as for working capital and general corporate purposes, which may include the repayment of indebtedness. In connection with the Private Placement, all investors have received customary registration rights. The offer and sale of the Common Shares in the Private Placement was made in the United States solely to accredited investors pursuant to the exemption from registration in reliance on a private placement exemption under Section 4(a)(2) under the United States Securities Act of 1933, as amended (the &quot; Securities Act &quot;) and in Canada pursuant to and in compliance with exemptions from the prospectus requirements of applicable Canadian securities laws. This press release does not constitute an offer to sell or the solicitation of an offer to buy &lrm;any securities in any jurisdiction in which such offer, solicitation or sale would be &lrm;unlawful.&lrm; Madryn Debt Financing Madryn has agreed to extend two additional tranches of the New Loan to the Company, each in the amount of US$1.0 million, representing an aggregate principal amount of US$2.0 million. US$1.0 million of the New Loan was funded prior to closing of the Private Placement, with the balance expected to be funded by the end of the month. The terms and conditions of the New Loan are consistent with the terms and conditions of the Company's existing aggregate US$59.0 million loan under the Credit Facility (the &quot; Existing Loan &quot; and together with the New Loan, the &quot; Madryn Loan &quot;) in all material respects. The New Loan also provides Madryn with the option to convert up to approximately US$182,000 of the outstanding principal amount of the New Loan into Common Shares at a conversion price per share equal to US$1.90 (the &quot; Conversion Price &quot;), subject to customary anti-dilution adjustments. This conversion feature corresponds to the conversion provisions for the Existing Loan, which provide Madryn with the option to convert up to approximately US$5.4 million of the outstanding principal amount of the Existing Loan into Common Shares at the Conversion Price. After giving effect to the New Loan, an aggregate of approximately US$5.6 million of the Madryn Loan is convertible into Common Shares at the Conversion Price. Following completion of the Private Placement and the New Loan, and in conjunction with anticipated cost savings from the Restructuring Plan, the Company intends to continue to explore additional options to enhance and strengthen its liquidity position and enable the Company to meet its cash requirements. MI 61-101 Disclosure Greybrook Health is an insider of the Company. Accordingly, the Private Placement is considered a &quot;related party transaction&quot; for purposes of Multilateral Instrument 61-101 &ndash; Protection of Minority Security Holders in Special Transactions (&quot; MI 61-101 &quot;). Pursuant to MI 61-101, the Company will file a material change report providing disclosure in relation to each &quot;related party transaction&quot; on SEDAR under the Company's issuer profile at www.sedar.com . The Company did not file the material change report more than 21 days before the expected closing date of the Private Placement as the details of the Private Placement and the participation therein by the &quot;related parties&quot; of the Company were not settled until shortly prior to the closing of the Private Placement, and the Company wished to close the Private Placement on an expedited basis for business reasons. The Company is relying on exemptions from the formal valuation and minority shareholder approval requirements available under MI 61-101. The Company is exempt from the formal valuation requirement in section 5.4 of MI 61-101 in reliance on section 5.5(a) of MI 61-101 as the fair market value of the transaction, insofar as it involves interested parties, is not more than 25% of the Company's market capitalization. Additionally, the Company is exempt from the minority shareholder approval requirement in section 5.6 of MI 61-101 in reliance on section 5.7(1)(a) as the fair market value of the transaction, insofar as it involves interested parties, is not more than 25% of the Company's market capitalization.
2023-03-27 13:15:00	JTSC	Why Delcath Systems Shares Are Jumping Today	Delcath Systems Inc (NASDAQ: JTSC ) shares are rising over 23% as FDA accepted its new drug application resubmission for HEPZATO Kit (melphalan hydrochloride for Injection/Hepatic Delivery System) seeking approval for unresectable hepatic-dominant metastatic ocular melanoma (mOM). The FDA also communicated to Delcath that they consider the submission a complete class 2 response, and the PDUFA date for the resubmission is August 14, 2023. The resubmission is in response to the FDA's September 12, 2013, Complete Response Letter (CRL) . The Hepzato Kit is a drug-device combination product to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Concurrently, the company raised $85 million in gross proceeds through a private placement that includes initial upfront funding of $25 million . Aggregate financing is expected to be sufficient to fund the company through the potential approval of HEPZATO and commercialization. &quot;We are gratified with the support from both our existing investors and our new investors, all of whom are highly regarded healthcare-focused funds. Their support, potentially totaling up to $85 million, subject to satisfaction of milestones, we believe validates the clinical relevance of and the commercial opportunity for Hepzato in metastatic ocular melanoma. Further, it positions Delcath to execute on HEPZATO commercialization plans upon potential FDA approval,&quot; said Gerard Michel, CEO of Delcath. &quot;Finally, we eagerly await the publication of interim results from the phase II portion of the CHOPIN study which should provide critical additional information about the potential utility of CHEMOSAT used in sequence with immune checkpoint inhibitors,&quot; Michel added. Price Action: JTSC shares are up 23.55% at $5.98 on the last check Monday.
2023-03-28 10:36:12	JYZV	On March 27, JYZV Technologies Agreed To Issue And Sell 837,209 Shares Of Stock And Stock Purchase Warrants Exercisable For An Aggregate Of Up To 1,674,418 Shares Of Common Stock At An Exercise Price Of $1.91 Per Share To Certain Institutional Investors	Item 1.01. Entry into a Material Definitive Agreement. On March 27, 2023, WiSA Technologies, Inc., a Delaware corporation (the &ldquo;Company&rdquo;), entered into a securities purchase agreement (the &ldquo;Purchase Agreement&rdquo;) with certain institutional investors, pursuant to which the Company agreed to issue and sell to such investors (i) in a registered direct offering, 837,209 shares (the &ldquo;Shares&rdquo;) of common stock, par value $0.0001 per share (the &ldquo;Common Stock&rdquo;), of the Company and (ii) in a concurrent private placement, common stock purchase warrants (the &ldquo;Private Placement Warrants&rdquo;), exercisable for an aggregate of up to 1,674,418 shares of Common Stock, at an exercise price of $1.91 per share of Common Stock. The securities to be issued in the registered direct offering were offered pursuant to the Company&rsquo;s shelf registration statement on Form S-3 (File 333-267211) (the &ldquo;Shelf Registration Statement&rdquo;), initially filed by the Company with the Securities and Exchange Commission (the &ldquo;SEC&rdquo;) under the Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;), on September 1, 2022 and declared effective on September 13, 2022. The Private Placement Warrants (and the shares of Common Stock issuable upon the exercise of the Private Placement Warrants) were not registered under the Securities Act, and were offered pursuant to an exemption from the registration requirements of the Securities Act provided in Section 4(a)(2) of the Securities Act and Rule 506(b) promulgated thereunder. The Private Placement Warrants are immediately exercisable upon issuance, will expire five years from the date of issuance, and in certain circumstances may be exercised on a cashless basis. The offering is expected to close on or about March 29, 2023, subject to customary closing conditions. The Company expects to raise gross proceeds of approximately $1.80 million before deducting fees and other offering expenses payable by the Company. In the event that all Private Placement Warrants are exercised for cash, the Company would receive additional gross proceeds of approximately $3.20 million. The Company intends to use a portion of the net proceeds of the offering to partially or fully repay the outstanding principal amount of a senior secured convertible note issued to an institutional investor (the &ldquo;August Investor&rdquo;) on August 15, 2022, as amended (the &ldquo;Convertible Note&rdquo;), and to use the remainder of the net proceeds for working capital, capital expenditures, product development, and other general corporate purposes, including investments in sales and marketing in the United States and internationally. The Company has not allocated specific amounts of net proceeds for any of these purposes; however, the Company is required pursuant to the terms of that certain securities purchase agreement, dated August 15, 2022, by and between the Company and the August Investor, to direct at least 20% of the gross proceeds of the offering to repay a portion of the Convertible Note. Under the Purchase Agreement, the Company is required within 45 days of the closing date of the offering to file a registration statement on Form S-1 registering the resale of the shares of Common Stock issued and issuable upon the exercise of the Private Placement Warrants. The Company is required to use commercially reasonable efforts to cause such registration to become effective within 180 days of the closing date of the offering, and to keep such registration statement effective at all times until no investor owns any Private Placement Warrants or shares issuable upon exercise thereof. In addition, pursuant to the terms of the Purchase Agreement, the Company may not, subject to certain exceptions, (i) offer, issue, sell, transfer or otherwise dispose of the Company&rsquo;s securities for a period of thirty (30) days following the closing date of the offering; and (ii) from the closing date of the offering until the six-month anniversary of such date, effect or enter into an agreement to effect any issuance of Common Stock or common stock equivalents involving a Variable Rate Transaction (as defined in the Purchase Agreement). The Purchase Agreement contains customary representations, warranties and agreements by the Company, customary conditions to closing, indemnification obligations of the Company or the investors, as the case may be, other obligations of the parties and termination provisions.
2023-03-29 06:32:09	KTSA	Biomea Fusion To Raise $125M Via Secondary Stock Offering	Biomea Fusion, Inc. (&quot;Biomea&quot;) (NASDAQ: KTSA ), a clinical-stage biopharmaceutical company dedicated to discovering and developing novel covalent small molecules to treat and improve the lives of patients with genetically defined cancers and metabolic diseases, announced today that it has commenced an underwritten public offering of $125.0 million of shares of its common stock. All of the shares of the common stock in the proposed offering are being offered by Biomea. In addition, Biomea intends to grant the underwriters a 30-day option to purchase up to an additional $18.75 million of shares of its common stock. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the proposed offering may be completed, or as to the actual size or terms of the proposed offering.
2023-03-29 07:48:35	ZECT	Stem To Raise $175M Via Private Green Convertible Senior Notes Offering	Stem, Inc. (&quot;Stem&quot;) (NYSE: ZECT ) announced today its intention to offer, subject to market conditions and other factors, $175 million aggregate principal amount of green Convertible Senior Notes due 2030 (the &quot;Notes&quot;) in a private offering (the &quot;Offering&quot;) to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the &quot;Securities Act&quot;). In connection with the Offering, Stem expects to grant the initial purchasers of the Notes an option to purchase, for settlement within a 13-day period from, and including, the date when the Notes are first issued, up to an additional $35 million aggregate principal amount of the Notes on the same terms and conditions.
2023-03-29 10:15:33	OCWL	Why Are Draganfly Shares Moving Lower Wednesday?	Shares of drone solutions and systems developer Draganfly Inc (NASDAQ: OCWL ) are falling in early trading Wednesday after the company announced a proposed underwritten public offering to secure growth capital. What Happened: Draganfly announced an offering of 8 million common shares at a price of $1 per share. The company anticipates gross proceeds of $8 million. The offering is expected to close on March 31. Draganfly said it expects to use the proceeds for general corporate purposes, including funding its capabilities to meet &lrm;demand for its new products and for the continued &lrm;development and marketing of its core products, as well as for potential &lrm;acquisitions and research &lrm;and development&lrm;. See Also: What's Going On With Enovix Stock Today? OCWL Price Action: Draganfly has a 52-week high of $2.51 and a 52-week low of 51 cents, according to Benzinga Pro . Draganfly shares were down 9.79% at $1.29 at the time of writing. Photo: Pexels from Pixabay.
2023-03-29 10:48:57	ZECT	Why ZECT Shares Are Nosediving	Stem Inc (NYSE: ZECT ) shares are trading lower by 16.12% to $5.23 Wednesday morning after the company announced a proposed $175 million green convertible senior notes offering. What Else? Stem says the company intends to allocate an amount of funds equivalent to the net proceeds of the offering towards Eligible Green Expenditures. These may include investments related to creating a more resilient clean energy system, optimized software capabilities for energy systems and reducing waste through operations, including research, development, acquisitions, capital expenditures and operational expenses. See Also: What's Going On With Micron Shares Today? According to data from Benzinga Pro , Stem Inc has a 52-week high of $18.02 and a 52-week low of $4.67.
2023-03-29 16:57:42	ENGW	ProQR Therapeutics Sent Request To SEC For Withdrawal Of Registration Statement On Form F-3	"Pursuant to Rule 477 promulgated under the Securities Act of 1933, as amended (the ""Securities Act""), ProQR Therapeutics N.V. (the ""Company"") hereby requests that the Securities and Exchange Commission (the ""Commission"") consent to the withdrawal of the Company's registration statement on Form F-3 (File No. 333-260780), together with the exhibits and amendments thereto, which was filed on November 4, 2021 (the ""Registration Statement""), as of the date hereof or at the earliest practicable date hereafter. The Registration Statement has not been declared effective by the Commission and no securities have been issued or sold under the Registration Statement."
2023-03-30 11:20:18	SWQD	Why Torm Shares Are Getting Hammered	Torm PLC (NASDAQ: SWQD ) shares are trading lower by 12.07% to $28.75 Thursday morning after the company announced the commencement of a secondary public offering of 5 million of its Class A common shares by a selling shareholder. What Else? Torm says the selling shareholder has granted the underwriters in this offering an option for a period of 30 days to purchase up to 750,000 additional Class A common shares on the same terms and conditions. See Also: Why Dragonfly Energy Shares Are Getting Hammered Torm says the company will not receive any of the proceeds from the sale of the Class A common shares by the selling shareholder. Torm has meanwhile agreed to pay all company expenses relating to registering the securities. According to data from Benzinga Pro , Torm PLC has a 52-week high of $36.60 and a 52-week low of $8.05.
2023-03-30 12:22:11	HXYZ	RenovoRx, Inc. Announces $5M Registered Direct Offering Priced At-The-Market Under Nasdaq Rules With A Certain Institutional Investor For The Purchase And Sale Of 1,557,632 Shares Of Common Stock At A Price Of $3.21/Share; Shares Halted On Circuit Breaker	RenovoRx, Inc. (the &quot;Company&quot;) (NASDAQ: HXYZ ), a biopharmaceutical company focused on the localized treatment of solid tumors, today announced that it has entered into a definitive securities purchase agreement with a certain institutional investor for the purchase and sale of 1,557,632 shares of the Company's common stock (or common stock equivalents) at a purchase price of $3.21 per share of common stock (or common stock equivalent) in a registered direct offering priced at-the-market under Nasdaq rules. The closing of the offering is expected to occur on or about April 3, 2023, subject to the satisfaction of customary closing conditions. In addition, in a concurrent private placement, the Company will issue to the investors warrants to purchase up to 1,947,040 shares of common stock. The warrants have an exercise price of $3.21 per share, will be exercisable immediately and will have a term of five and one-half years. Roth Capital Partners is acting as the exclusive placement agent for the offering. The gross proceeds to the Company from this offering are expected to be approximately $5 million, before deducting the placement agent's fees and other offering expenses payable by the Company. The Company intends to use the net proceeds from this offering for working capital and other general corporate purposes.
2023-03-30 16:21:19	ZGDK	Why Nikola Shares Are Tumbling After Hours	Nikola Corp (NASDAQ: ZGDK ) shares are trading lower after the close on Thursday after the company announced an offering . What Happened: Nikola commenced a public offering of up to $100 million worth of its common stock. The company also entered into a forward stock purchase agreement with an investor, in which the investor agreed to purchase up to $100 million of common stock from Nikola in a concurrent registered direct offering at the public offering price. Nikola said it plans to use the net proceeds for working capital and other general corporate purposes. The news comes a day after the company said orders for its Nikola Tre had grown to 100. Deliveries of the class 8 fuel cell trucks are expected to begin in the fourth quarter. See Also: Nikola Names VP Anastasiya &quot;Stasy&quot; Pasterick As New Finance Chief Effective April 7, Succeeding Kim J. Brady ZGDK Price Action: Nikola has a 52-week high of $11.86 and a 52-week low of $1.35, according to Benzinga Pro . The stock was down 8.64% after hours at $1.28 at the time of writing, according to Benzinga Pro . Photo: courtesy of Nikola.
2023-03-31 07:52:33	GNKX	Chicken Soup for the Soul Entertainment Raises $10.N Via Secondary Stock Offering Of 4.7M Shares At $2.30 Per Share	Chicken Soup for the Soul Entertainment Inc. (NASDAQ: GNKX ) (the &quot;Company&quot;), one of the largest providers of premium content to value-conscious consumers, today announced the pricing of its previously announced underwritten public offering. The Company is offering an aggregate of 4,688,015 shares of its Class A common stock at an offering price of $2.30 per share, inclusive of 1,643,015 shares purchased by Chicken Soup for the Soul, LLC, the Company's parent. The offering is also being made to new and existing institutional investors, and select participants from the Company's board and management, including the CEO. The Company expects to receive aggregate gross proceeds from the offering of approximately $10.8 million, before deducting underwriting discounts and commissions and other offering-related expenses payable by the Company, and application of approximately $3.8 million for certain payments due under its management and license agreements with Chicken Soup for the Soul, LLC, as described in the prospectus supplement.
2023-03-31 08:06:23	NARD	The Arena Group Raises $11.5M Via Secondary Stock Offering 2.96M Shares At $3.88 Per Share	The Arena Group Holdings, Inc. (NYSE: NARD ) (the &quot;Company&quot; or &quot;The Arena Group&quot;), a tech-powered media company home to more than 265 brands, including Sports Illustrated , TheStree t, Parade Media (&quot;Parade&quot;), and Men's Journal , operating on a single technology platform, today announced that it has entered into definitive agreements with existing shareholders for the issuance and sale of 2,963,918 shares of its common stock at an offering price of $3.88 per share. After deducting estimated offering expenses, the net proceeds from the offering are expected to be approximately $11.3 million. The offering is expected to close on April 3, 2023, subject to the satisfaction of customary closing conditions. Certain directors and officers of the Company, including Ross Levinsohn, Chairman and Chief Executive Officer of The Arena Group, along with other existing shareholders, are participating in the offering.
2023-03-31 09:43:08	PJYQ	G Medical Innovations Holdings Ltd. Announces Pricing Of $9.6M Public Offering Of 12M Shares Of Common Stock At A Price Of $0.80/Share	G Medical Innovations Holdings Ltd. (NASDAQ: PJYQ ) (the &quot;Company&quot;), a global leader in next-generation mobile health (mHealth) and digital health, today announced the pricing of an underwritten public offering of 12,000,000 ordinary shares (or pre-funded warrants (&quot;Pre-Funded Warrants&quot;) in lieu thereof). Each ordinary share (or Pre-Funded Warrant) is being sold to the public at a price of $0.80 (inclusive of the exercise price of the Pre-Funded Warrant) for gross proceeds of approximately $9.6 million, before deducting underwriting discounts and offering expenses. In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 1,800,000 shares and/or Pre-Funded Warrants to cover over-allotments at the public offering price, less the underwriting discount. The Company intends to use the net proceeds for general corporate purposes (including financing operations, capital expenditures and business development), the repayment in full of the April 2021 Financing Debentures, and potential mergers or acquisitions. The offering is expected to close on April 4, 2023, subject to satisfaction of customary closing conditions. ThinkEquity is acting as sole book-running manager for the offering.
2023-03-31 11:23:17	ZGDK	Why Nikola Stock Is Getting Hammered	Nikola Corp (NASDAQ: ZGDK ) shares are trading lower by 13.57% to $1.21 Friday morning after the company announced pricing for a $100 million common stock offering. What Happened? The offering will be at a price of $1.12 per share. Nikola will sell 29,910,715 shares of common stock to the public in the public offering and 59,374,999 shares of common stock to an investor in the concurrent registered direct offering pursuant to a forward stock purchase agreement. See Also: Why Virgin Orbit (VORB) Shares Are Down 40% During Friday's Session Nikola currently intends to use the net proceeds from the public offering and the concurrent registered direct offering for working capital and other general corporate purposes. According to data from Benzinga Pro , ZGDK has a 52-week high of $10.88 and a 52-week low of $1.15.
2023-04-03 08:32:27	VGLI	Palisade Bio To Raise $6M Via Private Stock Offering Of 2.3M Shares At $2.64	Palisade Bio, Inc. (NASDAQ: VGLI ), a biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, is announcing today that it has entered into definitive agreements with institutional investors for the purchase of 2,272,723 shares of common stock (or certain pre-funded warrants in lieu thereof) in a registered direct offering and concurrent private placement, at a purchase price per share of $2.64. Certain investors will receive a portion of their investment in unregistered shares or unregistered pre-funded warrants in the private placement in lieu of registered common stock.
2023-04-03 09:19:13	XEFF	Transphorm Enters Into Agreements To Raise $9.3M From The Exercise Of Existing Warrants And A Private Placement Of Common Stock	Transphorm, Inc. (NASDAQ: XEFF ) (&quot;Transphorm&quot; or the &quot;Company&quot;), a pioneer in and global supplier of high-reliability, high-performance gallium nitride (GaN) power conversion products, announced today it has entered into agreements with certain holders of the Company's outstanding warrants to raise $7.3 million in gross proceeds from the exercise of such warrants. In addition, the Company announced today it has entered into securities purchase agreements to raise $2.0 million in gross proceeds from a private placement of 500,000 shares of the Company's common stock at a price of $4.00 per share. Pursuant to the agreements with certain holders of the Company's outstanding warrants, the warrant holders agreed to exercise, for cash, existing warrants to purchase, in the aggregate, 1,815,848 shares of the Company's common stock, in exchange for the Company's agreement to lower the exercise price of the existing warrants to $4.00 per share and issue new warrants to purchase, in the aggregate, up to 2,269,810 shares of the Company's common stock. The warrants have an exercise price of $5.00 per share and are exercisable until April 3, 2026. Pursuant to the securities purchase agreements, the Company also agreed to issue warrants to purchase an aggregate of 250,001 shares of the Company's common stock. The warrants have an exercise price of $5.00 per share and are exercisable until April 3, 2026. The securities issued in the transactions have not been registered under the Securities Act of 1933, as amended (the &quot;Securities Act&quot;) or applicable state securities laws, and may not be resold absent registration under, or exemption from registration under, the Securities Act and such applicable state securities laws. As part of the transactions, Transphorm has agreed to file, within 30 days, a registration statement with the Securities and Exchange Commission to register the resale of the shares of common stock issued pursuant to the securities purchase agreements and the shares of common stock underlying the warrants. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.
2023-04-03 09:55:35	VGLI	Why Palisade Bio (VGLI) Stock Is Diving 30% Lower	Palisade Bio Inc (NASDAQ: VGLI ) shares are trading lower by 31.82% to $2.40 after the company announced a $6 million registered direct offering and concurrent private placement priced above the market under Nasdaq rules. Palisade Bio says certain investors will receive a portion of their investment in unregistered shares or unregistered pre-funded warrants in the private placement in lieu of registered common stock. See Also: Warren Buffett-Backed BYD Posts 91% Jump in March EV Deliveries Palisade Bio intends to use the net proceeds from the financing for working capital and general corporate purposes. According to data from Benzinga Pro , Palisade Bio has a 52-week high of $53.45 and a 52-week low of $1.55.
2023-04-04 08:37:08	ZJCN	Nogin Announces Pricing Of $22M Public Offering Of 7,333,334 Shares Of Common Stock And Warrants At A Combined Price Of $3/Share	Nogin , Inc. (NASDAQ: ZJCN ) (&quot;Nogin&quot; or the &quot;Company&quot;) , a leading provider of innovative Commerce-as-a-Service (CaaS) technology and services, today announced the pricing of its &quot;reasonable best efforts&quot; public offering of 7,333,334 shares of common stock (or pre-funded warrants in lieu thereof) and 7,333,334 common warrants to purchase 7,333,334 shares of common stock at a combined price of $3.00 per share and common warrant for aggregate gross proceeds of approximately $22 million, before deducting placement agent fees and other offering expenses. The offering includes participation from members of the Company's management team and board of directors, as well as other insiders and holders of the Company's convertible notes. The closing of the offering is expected to occur on or about April 6, 2023, subject to the satisfaction of customary closing conditions. The Company intends to use the net proceeds from the offering to repurchase promissory notes from holders of its convertible notes pursuant to their put options and for general corporate purposes, including working capital and capital expenditures. A.G.P./Alliance Global Partners is acting as the lead placement agent for the offering and Maxim Group LLC is acting as a co-placement agent.
2023-04-04 09:15:16	ZJCN	Nogin Stock Is Tanking Today: What's Going On?	Shares of low-float Nogin Inc (NASDAQ: ZJCN ) are trading lower. The company announced a $22 million public offering on Tuesday . What Happened: Nogin announced an offering of 7,333,334 shares of common stock and 7,333,334 common warrants to purchase common stock at a combined price of $3 per share. Aggregate gross proceeds are expected to total approximately $22 million. Members of the company's management team and board are participating in the offering, which is expected to close on April 6. Nogin intends to use the net proceeds to repurchase promissory notes from holders of its convertible notes, as well as for general corporate purposes including working capital and capital expenditures. The offering comes a day after ZJCN shares soared, closing Monday up 139.8% at $6.51 before pulling back in extended trading. The move appeared to be a result of increased retail attention driven by the low-float nature of the stock. Nogin has a total float of about 824,000, according to Benzinga Pro . Nogin's average session volume is approximately 192,000. Tuesday's trading volume has already exceeded 1.88 million in premarket trading. See Also: US Stocks Set To Open Higher Today On Strong Momentum: Analyst Says Next Fed Rate Decision Could Be 'Near-Tossup' ZJCN Price Action: Nogin shares were down 60.2% at $2.59 at time of publication, according to Benzinga Pro . This illustration was generated using artificial intelligence via MidJourney.
2023-04-04 09:42:46	ZJCN	Nogin Plummets Following $22M Equity Offering	Nogin Inc (NASDAQ: ZJCN ) has priced the public offering of 7.33 million shares of common stock and 7.33 million common warrants to purchase 7.33 million shares of common stock at a combined price of $3.00 per share and common warrant. The company expects gross proceeds of approximately $22 million before deducting placement agent fees and other offering expenses. The company expects the offering to close on or about April 6, 2023. The offering includes participation from members of the company's management team and board of directors and other insiders and holders of convertible notes. The company intends to use the offering net proceeds to repurchase promissory notes from holders of its convertible notes and for general corporate purposes. The company closed Monday's session up 139.8% at $6.51. Price Action: ZJCN shares are trading lower by 61.5% at $2.50 on the last check Tuesday.
2023-04-04 11:52:53	KZHH	Why Clearmind Medicine Shares Are Nosediving	Clearmind Medicine Inc (NASDAQ: KZHH ) shares are trading lower by 60.1% to $0.57 Tuesday morning after the company announced a $3.5 million public offering priced at $0.78 per share. The offering is expected to close on April 6, subject to the satisfaction of customary closing conditions. See Also: What's Going On With C3.Ai Stock Today? Clearmind Medicine expects to use the net proceeds from the offering, for general corporate purposes, which may include operating expenses, research and development, including clinical and pre-clinical testing of our product candidates, working capital, future acquisitions and general capital expenditures. According to data from Benzinga Pro , KZHH has a 52-week high of $14.10 and a 52-week low of $0.55.
2023-04-05 10:28:43	RFDN	Why Protagonist Therapeutics Shares Are Nosediving	Protagonist Therapeutics Inc (NASDAQ: RFDN ) shares are trading lower by 9.68% to $19.46 Wednesday morning after the company announced pricing of a $100 million public offering of shares of common stock. What Else? The underwritten public offering is for 5 million shares of its common stock at a public offering price of $20.00 per share. The offering is expected to close on or about April 10, 2023, subject to customary closing conditions. See Also: What's Going On With Aurinia Pharmaceuticals Stock Wednesday? Protagonist intends to use the net proceeds from this offering to fund continued clinical development and pre-commercialization activities associated with rusfertide and for working capital and general corporate purposes. According to data from Benzinga Pro , RFDN has a 52-week high of $25.76 and a 52-week low of $6.91.
2023-04-06 12:20:11	ZJCN	Nogin Shares Moving Higher, Co Announces Closing Of $22M Public Offering	Nogin , Inc. (NASDAQ: ZJCN , NOGNW))))) (&quot;Nogin&quot; or the &quot;Company&quot;) , a leading provider of innovative Commerce-as-a-Service (CaaS) technology and services, today announces the closing of its &quot;reasonable best efforts&quot; public offering of 7,333,334 shares of common stock and 7,333,334 common warrants to purchase 7,333,334 shares of common stock at a combined price of $3.00 per share and common warrant for aggregate gross proceeds of approximately $22 million, before deducting placement agent fees and other offering expenses. The offering included participation from members of the Company's management team, board of directors, and other insiders and friends of the Company totaling $7.5 million. Of that amount, Jonathan Huberman, President, Chief Executive Officer and Chairman of the Board, invested $3 million in the offering, while Shahriyar Rahmati, Chief Operating Officer and Chief Financial Officer, invested $600,000 in the offering. In addition, the offering included participation from holders of the Company's convertible notes totaling $1 million. &quot;We believe this additional capital will provide the fuel to grow our business aggressively for the foreseeable future, as well as enable us to reach our goal of EBITDA profitability in the third quarter of 2023,&quot; said Mr. Huberman. &quot;As we continue striving to revolutionize how brands manage ecommerce, we are pleased with our current operating liquidity and are very excited about our future.&quot; The Company intends to use the net proceeds from the offering to repurchase promissory notes from holders of its convertible notes pursuant to their put options and for general corporate purposes, including working capital. A.G.P./Alliance Global Partners acted as the lead placement agent for the offering and Maxim Group LLC acted as a co-placement agent.
2023-04-10 09:52:08	BWNY	Why OncoSec Medical Shares Are Soaring Today	OncoSec Medical Inc (NASDAQ: BWNY ) shares are trading higher Monday after the company announced it's seeking withdrawal of its registration statement. What Happened: OncoSec Medical has submitted a request to the SEC to withdraw its registration statement that it filed on March 28. The March filing detailed an anticipated offering of more than 11 million shares and over 11 million warrants. &quot;The Company is seeking withdrawal of the Registration Statement because it opted not to pursue the offering contemplated thereby,&quot; the company said in the new filing. OncoSec confirmed that no securities were sold pursuant to the previously announced offering. OncoSec is a biotechnology company focused on developing intratumoral immunotherapies to stimulate the body's immune system to target and attack cancer. From Last Week: OncoSec Shares Disappointing Results From Skin Cancer Combo Therapy Trial, Sets Stage For Neoadjuvant Setting Study BWNY Price Action: OncoSec has a 52-week high of $25.74 and a 52-week low of 73 cents. The stock was up 48.1% at $1.67 at time of publication, according to Benzinga Pro . Photo: Konstantin Kolosov from Pixabay.
2023-04-10 11:35:07	BWNY	OncoSec Announces $2M Registered Direct Offering Of 1,582,932 Shares At A Price Of $1.25 Priced At-The-Market Per Share Under Nasdaq Rules	OncoSec Medical Incorporated (NASDAQ: BWNY ) (the &quot;Company&quot; or &quot;OncoSec&quot;), a clinical-stage biotechnology company developing intratumoral immunotherapies to stimulate the patient's immune system to target cancer cells and eradicate disease, today announced that it has entered into a definitive agreement for the purchase and sale of an aggregate of 1,582,932 shares of its common stock (or common stock equivalents in lieu thereof), at a purchase price of $1.25 per share (or common stock equivalent in lieu thereof), in a registered direct offering priced at-the-market under Nasdaq rules. The Company has also agreed to issue in a concurrent private placement unregistered warrants to purchase up to an aggregate of 1,582,932 shares of common stock. The warrants will have an exercise price of $1.12 per share, are immediately exercisable upon issuance, and will expire five and one-half years from the date of issuance. The closing of the offering is expected to occur on or about April 12, 2023, subject to the satisfaction of customary closing conditions. L.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. The gross proceeds to the Company from the offering are expected to be approximately $2 million, before deducting the placement agent's fees and other offering expenses payable by the Company. The Company intends to use the net proceeds from this offering as working capital for general corporate purposes.
2023-04-10 13:31:17	NVEW	SenesTech Announces $1.5M Registered Direct Offering Of 857,146 Shares At A Price Of $1.75 Priced At-The-Market Per Share Under Nasdaq Rules	SenesTech, Inc. (NASDAQ: NVEW , &quot, , SenesTech&quot, , or the &quot, , Company&quot, , ))))) ( www.senestech.com ), the rodent fertility control experts and inventors of the only EPA registered contraceptive for male and female rats, ContraPest&reg;, today announced that it has entered into a definitive agreement for the purchase and sale of up to an aggregate of 857,146 shares of its common stock (or common stock equivalents in lieu thereof), at a purchase price of $1.75 per share (or common stock equivalent in lieu thereof), in a registered direct offering priced at-the-market under Nasdaq rules. The Company has also agreed to issue in a concurrent private placement unregistered Series C warrants (the &quot;Series C Warrants&quot;) to purchase up to an aggregate of 857,146 shares of common stock. The Series C Warrants will have an exercise price of $1.62 per share, are immediately exercisable upon issuance, and will expire five and one-half (5.5) years from the date of issuance. The closing of the offering is expected to occur on or about April 12, 2023, subject to the satisfaction of customary closing conditions. L.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. The gross proceeds to the Company from the offering are expected to be approximately $1.5 million, before deducting the placement agent's fees and other offering expenses payable by the Company. The Company intends to use the net proceeds from this offering for general corporate purposes.
2023-04-11 07:59:52	UMB	Cleveland-Cliffs Proposes To Raise $750M Via Senior Unsecured Guaranteed Note Offering For Debt Repayment	Cleveland-Cliffs Inc. (NYSE: UMB ) announced today that it intends to offer to sell, subject to market and other conditions, $750 million aggregate principal amount of senior unsecured guaranteed notes due 2030 (the &quot;Notes&quot;) in an offering that is exempt from the registration requirements of the Securities Act of 1933 (the &quot;Securities Act&quot;). The Notes will be guaranteed on a senior unsecured basis by the Company's material direct and indirect wholly-owned domestic subsidiaries, other than certain excluded subsidiaries. The Company intends to use the net proceeds from the Notes to repay a portion of the borrowings under the Company's existing asset-based revolving credit facility.
2023-04-11 08:02:51	GSBF	Kura Sushi USA Raises $56.4M Via Secondary Stock Offering Of 1.1M Shares At $54.00 Per Share	Kura Sushi USA, Inc. (&quot;Kura Sushi&quot; or the &quot;Company&quot;) (NASDAQ: GSBF ), a technology-enabled Japanese restaurant concept, today announced that it has priced its previously announced underwritten public offering of 1,100,000 shares of its Class A common stock at a public offering price of $54.00 per share, for expected proceeds of approximately $56.4 million, net of the underwriters' discount. All shares of Class A common stock are being offered by the Company. As part of the offering, the Company also granted the underwriters a 30-day option to purchase up to an additional 165,000 shares of its Class A common stock. If the underwriters exercise their over-allotment option to purchase additional shares in full, the expected proceeds of the offering, net of the underwriters' discount, would be approximately $64.9 million. The offering is expected to close on April 13, 2023, subject to customary closing conditions. Kura Sushi intends to use the net proceeds from the offering for general corporate purposes, including capital expenditures, working capital, and other business purposes.
2023-04-11 08:10:31	WLWO	Churchill Downs Proposes To Raise $600B Via Private Senior Notes Offering Due 2031	Churchill Downs Incorporated (&quot;CDI&quot; or the &quot;Company&quot;) (NASDAQ: WLWO ) today announced that it intends to offer, subject to market and customary conditions, $600 million in aggregate principal amount of senior notes due 2031 (the &quot;Notes&quot;) in a private offering. CDI intends to use the net proceeds from the offering (i) to repay indebtedness outstanding under its Term Loan B Facility, (ii) to fund related transaction fees and expenses and (iii) for working capital and other general corporate purposes.
2023-04-11 09:35:43	UMB	What's Going On With Cleveland-Cliffs Stock Today?	Cleveland-Cliffs Inc (NYSE: UMB ) shares are trading higher Tuesday. The company reported preliminary first-quarter results and proposed an offering . What Happened: Cleveland-Cliffs expects first-quarter revenue of approximately $5.2 billion versus estimates of $5.21 billion, according to Benzinga Pro . The company anticipates adjusted EBITDA of approximately $200 million and noted that it expects second-quarter EBITDA to be &quot;multiple times higher&quot; than the first quarter. &quot;Confirming our previous guidance, Q1 EBITDA was significantly higher than Q4 EBITDA. The increase in profitability in Q1 was almost entirely driven by the unit cost reductions explained in detail on our last earnings call,&quot; said Lourenco Goncalves , chairman, president and CEO of Cleveland-Cliffs. Cleveland-Cliffs also announced intentions to offer and sell $750 million worth of senior unsecured guaranteed notes due 2030 in an offering . The company expects to use the proceeds to repay a portion of the borrowings under its existing asset-based revolving credit facility. Cleveland-Cliffs is set to report first-quarter results on April 24. The company will host a conference call to discuss the numbers the following day. See Also: Getty Images Stock Is Getting A Boost Today: What's Going On? UMB Price Action: Cleveland-Cliffs shares were up 1.95% at $18.28 at time of publication, according to Benzinga Pro . Photo: Janno Nivergall from Pixabay.
2023-04-11 09:36:18	GSBF	Kura Sushi USA Raises $56M Via Equity Offering	Kura Sushi USA Inc (NASDAQ: GSBF ) priced its previously announced underwritten public offering of 1.1 million shares at an offer price of $54 per share. As part of the offering, the company also granted the underwriters a 30-day option to purchase up to an additional 0.16 million shares. The offering is expected to close on April 13, 2023. The company expects to receive proceeds of $56.4 million from the offering. The expected proceeds of the offering will be $64.9 million if the underwriters exercise their over-allotment option. Kura Sushi intends to use the net proceeds from the offering for general corporate purposes. Price Action : GSBF shares are trading higher by 2.607% at $58.51 on the last check Tuesday.
2023-04-12 07:04:22	ZXQN	Mirum Pharma To Raise $200.0M Via Private Convertible Senior Notes Offering	Mirum Pharmaceuticals, Inc. (&quot;Mirum&quot;) (NASDAQ: ZXQN ) today announced its intention to offer, subject to market and other conditions, $200.0 million aggregate principal amount of convertible senior notes due 2029 (the &quot;notes&quot;) in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the &quot;Securities Act&quot;). Mirum also expects to grant the initial purchasers of the notes an option to purchase, for settlement within a period of 13 days from, and including, the date the notes are first issued, up to an additional $30.0 million principal amount of notes.
2023-04-12 09:34:35	JUCA	Eos Energy Enterprises, Inc. Announces $40M Registered Direct Offering Of 16M Shares Of Common Stock At A Price Of $2.50/Share And Purchase Of 16M Concurrent Private Placement Unregistered Warrants With An Excersize Price Of $3.14	Eos Energy Enterprises, Inc. (NASDAQ: JUCA ) (&quot;Eos&quot; or the &quot;Company&quot;), a leading provider of safe, scalable, efficient, and sustainable zinc-powered long-duration energy storage systems, today announced that it has entered into a definitive agreement for the purchase and sale of an aggregate of 16,000,000 shares of the Company's common stock at a purchase price of $2.50 per share in a registered direct offering. The Company has also agreed to issue in a concurrent private placement unregistered warrants to purchase up to an aggregate of 16,000,000 shares of common stock. The warrants will have an exercise price of $3.14 per share, are not exercisable until six months from the date of issuance, and will expire five and one-half years from the date of issuance. The closing of the offering is expected to occur on or about April 14, 2023, subject to the satisfaction of customary closing conditions. The gross proceeds to the Company from the offering are expected to be approximately $40 million, before deducting advisory fees and other offering expenses payable by the Company. The Company intends to use the net proceeds from this offering as working capital for general corporate purposes.
2023-04-12 17:31:09	MKTC	Cybin Offers Free Online Training To Facilitate Psychedelic Therapy	Cybin Inc. (NYSE: MKTC ), a clinical-stage biopharma company developing innovative psychedelic-based treatment options, is launching a free online facilitation training course. EMBARK Open Access, an open and foundational online course, is aimed at healthcare professionals and those interested in offering psychological support. CEO Doug Drysdale says the company&rsquo;s mission to revolutionize mental healthcare is joined by its commitment to supporting the entire ecosystem. &ldquo;By offering a cost-free facilitator training program, we hope to promote accessible, scalable, and most importantly, ethical psychological support during psychedelic-assisted therapy,&rdquo; he said. The psychedelics facilitation model, EMBARK, has a new series of 12 video-based training modules and accompanying exercises as well as a new website. Upon completing EMBARK OA, participants will receive a record of completion, which can be used as a bridge for facilitators to be enrolled in upcoming EMBARK training programs and potential participation in Cybin-sponsored clinical studies. EMBARK&rsquo;s co-creator Dr. Alex Belser says training is &ldquo;facing a bottleneck,&rdquo; with programs being expensive and out of reach for many. These challenges have propelled the launch of EMBARK OA. &ldquo;Our team has put a lot of thoughtful, science-informed, and heartfelt work into these training materials, and we are proud to share them with the broader healthcare community. Our hope is to provide more equitable access to high-quality learning and development in psychedelic practice,&rdquo; Belser concluded. Benzinga&rsquo;s Psychedelics Capital Conference April 13th at the Fontainebleau Miami Beach Hotel will be THE place to set up deals , raise money, meet investors and key partners , and learn from the industry&rsquo;s greatest . One more day to go&hellip; Get your tickets NOW and don&rsquo;t miss out! Photo by Glenn Carstens-Peters on Unsplash
2023-04-12 17:56:47	EXWE	GlucoTrack Announced Proposed Underwritten Public Offering of Common Stoc	GlucoTrack, Inc. (NASDAQ: EXWE ) today announced that it intends to offer shares of common stock in a firm commitment underwritten public offering. The Company intends to use the net proceeds from this offering primarily for working capital and general corporate purposes, which may include, without limitation, engaging in acquisitions or other business combinations or investments, sales and marketing activities, general and administrative matters and capital expenditures. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
2023-04-13 08:05:34	ZKBT	Regulus Therapeutics Announces Private Placement Of $15M Led By The Federated Hermes Kaufmann Funds And New Enterprise Associates	Under the securities purchase agreement, the investors have agreed to purchase 2,615,536 shares of the Company's common stock (&quot;Common Stock&quot;) at a purchase price of $0.9001 per share. Certain investors have also agreed to purchase, in lieu of shares of Common Stock, an aggregate of 140,827 shares of newly designated, non-voting Class A-5 convertible preferred stock at a purchase price of $90.01 per share. Each share of non-voting Class A&ndash;5 convertible preferred stock will be convertible into 100 shares of Common Stock, subject to certain beneficial ownership conversion limitations.
2023-04-13 08:20:08	PCYQ	BigBear.ai Stock Is Falling: What's Going On?	BigBear.ai Inc (NYSE: PCYQ ) shares are trading lower Thursday after the company filed for a mixed shelf offering . What Happened: BigBear.ai filed an offering for the resale of up to 113.25 million shares by selling stockholders. &quot;The shares being registered for resale will constitute a considerable percentage of our public float. Certain of the shares being registered for resale were purchased by the corresponding selling stockholders for prices considerably below the current market price of our common stock,&quot; the company said in a new regulatory filing. BigBear.ai shares are up more than 350% since the start of the year. BigBear.ai's AI-powered decision intelligence solutions are leveraged in multiple core markets including global supply chains and logistics, autonomous systems and cyber. See Also: US Stocks Could Flatline As Rate-Hike Doubts Linger: Analyst Sees Market Strength In April Back-Half PCYQ Price Action: BigBear.ai has a 52-week high of $13.51 and a 52-week low of 58 cents per share. The stock was down 12.6% at $2.71 at the time of publication, according to Benzinga Pro . Photo: Gerd Altmann from Pixabay.
2023-04-13 09:13:28	UVD	Guess? Inks Exchange & Subscription Agreements To Extend Maturity Of Significant Portion Of Debt To 2028	Guess? Inc (NYSE: UVD ) has entered into separate, privately negotiated exchange and subscription agreements with holders of its 2.00% convertible senior notes due 2024 and other investors. Under the agreement, the company will exchange about $184.9 million of the existing convertible notes for about $161.4 million of new 3.75% convertible senior notes due 2028. The company will also issue new convertible notes in a private placement for the issuance in the Transactions of $275.0 million of new convertible notes. The transactions are expected to settle on or about April 17, 2023. UVD intends to use the net proceeds of the private placement of the new convertible senior notes to retire approximately $185 million of the existing convertible senior notes due in 2024, to repurchase $43 million of its common stock, enter into the bond hedge and warrant transactions and to fund general corporate purposes. On completion of the transactions, the aggregate principal amount of the existing convertible notes outstanding will be about $115.0 million and new convertible notes will be $275.0 million. Price Action : UVD shares are trading lower by 1.11% at $18.79 in premarket on the last check Thursday.
2023-04-13 20:02:44	WDFT	CytoMed Therapeutics Priced ~2.4M Share GIP @ $4/Share	"CytoMed Therapeutics Limited ( today announced the pricing of its initial public offering of its 2,412,369 ordinary shares at a price of US$4.00 per share, for gross proceeds of US$9,649,476.00 before deducting underwriting discounts, commissions and offering expenses. In addition, CytoMed has granted the underwriters a 45-day option to purchase up to an additional 361,855 ordinary shares solely to cover any over-allotments. The ordinary shares are expected to begin trading on the Nasdaq Capital Market under the ticker symbol ""WDFT"" on April 14, 2023, and the offering is expected to close on April 18, 2023, subject to customary closing conditions. The net proceeds from the initial public offering will be used to advance the clinical development of the Company's TWY-N2D product candidate; to continue technology development of the Company's iPSC-gdNKT product candidate; to advance clinical development of the Company's TWY-GDT product candidate; and the remainder to fund R&D activities and manufacturing expansion, and for working capital and general corporate purposes. The Benchmark Company, LLC is acting as the Bookrunning manager and Axiom Capital Management, Inc. is acting as a co-managing underwriter, in connection with the offering."
2023-04-14 08:31:18	NJMO	Trust Stamp Raises $5.2M Via Direct Offering and Concurrent Private Placement of $1.6M Shares Priced At-The-Market	Trust Stamp (NASDAQ: NJMO ), the Privacy-First Identity Company MI providing artificial intelligence (AI)-powered trust and identity services used globally across multiple sectors, today announced that it has entered into a securities purchase agreement with a single institutional investor to purchase 1,573,330 shares of common stock (or pre-funded warrants in lieu thereof) in a registered direct offering priced at-the-market under Nasdaq rules. In a concurrent private placement, the Company also agreed to issue and sell unregistered warrants to purchase up to an aggregate of 1,573,330 shares of common stock. The combined effective offering price for each share of common stock (or pre-funded warrant in lieu thereof) and accompanying warrant is $3.30. The warrants will be immediately exercisable, will expire five years from the issuance date and will have an exercise price of $3.30 per share. The gross proceeds to the Company from the registered direct offering and concurrent private placement are estimated to be approximately $5.2 million before deducting the placement agent's fees and other estimated offering expenses payable by the Company. The offering is expected to close on or about April 18, 2023, subject to the satisfaction of customary closing conditions.
2023-04-14 08:34:18	RQTL	Meta Materials Prices $25M Public Offering Of 83,333,334 Shares  At A Price Of $0.30/Share And Accompanying Warrant	"Meta Materials Inc. (the ""Company"" or ""CMII&#174;"") (NASDAQ: RQTL )(FSE:RQTL), a developer of high-performance functional materials and nanocomposites, today announced that it has priced an underwritten public offering of 83,333,334 shares of its common stock and warrants to purchase up to an aggregate of 83,333,334 shares of common stock at a combined public offering price of $0.30 per share and accompanying warrant. CMII has granted the underwriters a 30-day overallotment option to purchase up to an additional 12,500,000 shares of its common stock and/or warrants to purchase up to an additional 12,500,000 shares of common stock at the public offering price, less the underwriting discount. Each warrant is exercisable immediately at an exercise price of $0.375 per share and will expire five years following the date of issuance. All of the securities are to be sold by CMII. The gross proceeds of the offering are expected to be approximately $25 million before deducting the underwriting discount and estimated offering expenses payable by CMII, assuming no exercise of the underwriters' overallotment option. The offering is expected to close on or about April 18, 2023 subject to satisfaction of customary closing conditions. Ladenburg Thalmann & Co. Inc. and A.G.P./Alliance Global Partners are acting as joint bookrunning managers for the offering. CMII intends to use the net proceeds from the offering for working capital and general corporate purposes, which include, but are not limited to: on-going development of our existing and future products, (such as our advanced materials NPORE&#174; and NCORE&#8482; for Li-ion battery applications, electro-optical devices, the expansion of our manufacturing facilities and capital equipment purchases), as well as general and administrative expenses."
2023-04-14 09:39:03	FWGE	Long COVID-Fatigue Impacts 50M People - Axcella Health Seeks Funding To Support Drug Development	Axcella Health Inc (NASDAQ: FWGE ) is reportedly looking for funding to support its advanced trial of a drug initially found to improve fatigue in long Covid patients. An early-stage trial of the drug, dubbed AXA1125, with the University of Oxford, found that participants given the treatment significantly improved fatigue compared with those in the placebo arm, according to the results published Friday in the Lancet eClinical Medicine journal. &quot;There is still some way to go in treating all patients with long Covid &ndash; our results focus specifically on fatigue, rather than the breathlessness and cardiovascular issues that other long Covid patients have reported,&quot; Bloomberg reported citing a statement from Betty Raman, the trial's principal investigator. Axcella's Phase 2a trial results demonstrated statistically and clinically relevant improvement in fatigue in patients with Long COVID. The study, which did not meet an experimental biomarker primary endpoint, found that subjects who received AXA1125 experienced clinically and statistically significant improvement in mental (p=0.0097) and physical (p=0.0097) fatigue scores compared to placebo subjects . Axcella discontinued its Phase 2b trial of AXA1125 in NASH . Axcella reported data from Phase 2b EMMPACT study of AXA1125 for nonalcoholic steatohepatitis (NASH). AXA1125 showed a statistically significant improvement in liver stiffness at a higher dose but did not reach statistical significance at a lower dose . Half of the 41 patients in the trial received the drug twice daily for four weeks. Participants generally suffered fatigue following Covid for 18 months before the study. Axcella has the U.S. and the U.K. regulatory authorization to proceed with advanced trials, and the company plans to enroll about 300 people once funding is secured. Price Action: FWGE shares are up 3.33% at $0.39 on the last check Friday.
2023-04-14 11:15:41	RQTL	Meta Materials Shares Plummet After Pricing $25M Equity Offering	Meta Materials Inc (NASDAQ: RQTL ) has priced an underwritten public offering of ~83.33 million shares and warrants to buy up to 83.33 million shares at a combined public offering price of $0.30 per share and accompanying warrant. The gross proceeds are expected to be ~$25 million. The company has granted underwriters a 30-day overallotment option to purchase up to an additional ~12.5 million shares of its common stock and/or warrants to purchase up to 12.5 million shares. Each warrant is exercisable immediately at an exercise price of $0.375 per share and will expire five years following the date of issuance. The offering is expected to close on or about April 18, 2023 CMII intends to use the net proceeds from the offering for working capital and general corporate purposes. Price Action: RQTL shares are trading lower by 42.45% at $0.2199 on the last check Friday.
2023-04-17 06:25:02	MOVX	Marpai Priced 7.4M Share Offering @$1.00/Share	"Marpai, Inc. (""Marpai"" or the ""Company"") (NASDAQ: MOVX ) a technology company using artificial intelligence (A.I.) to transform health plans for employers that self-fund their healthcare, today announced the pricing of an underwritten public offering of 7,400,000 shares of its common stock at a public offering price of $1.00 per share, for gross proceeds of approximately $7,400,000, before deducting underwriting discounts and offering expenses. The offering is expected to close on April 19, 2023, subject to satisfaction of customary closing conditions. ThinkEquity is acting as the sole book-running manager for the offering."
2023-04-17 08:28:26	QQTL	Porch Group Raises $333M Via Convertible Notes Financing Due 2028	Porch Group, Inc. (&quot;Porch Group,&quot; &quot;Porch&quot; or &quot;the Company&quot;) (NASDAQ: QQTL ), a leading vertical software company reinventing the home services and insurance industries, today announced the pricing of a private offering of $333 million aggregate principal amount of its 6.75% Senior Secured Convertible Notes due 2028 (the &quot;New Notes&quot;) in a private placement transaction, and a concurrent privately negotiated repurchase of $200 million aggregate principal amount of its 0.75% Convertible Senior Notes due 2026 (the &quot;Existing Notes&quot;). The New Notes offering and Existing Notes repurchase are expected to close concurrently on April 20, 2023, subject to customary closing conditions. The New Notes will be convertible into cash, shares of common stock of the Company (&quot;common stock&quot;), or a combination of cash and shares of common stock at Porch's election at an initial conversion rate of 39.9956 shares of common stock per $1,000 principal amount of the New Notes, which is equivalent to an initial conversion price of approximately $25.00 per share. Porch intends to use the net proceeds from the New Notes offering to repurchase $200 million of the Existing Notes and to fund the repayment of a $10 million senior secured term loan of a Porch Group subsidiary, in each case plus accrued and unpaid interest thereon and related fees and expenses, and use the remainder of the net proceeds for general corporate purposes.
2023-04-17 10:28:18	OOJH	Toro Corp. Announces Entry Into $19.465M Subscription Agreement For The Issuance Of 8.5M Common Shares At A Price Of $2.29/Share	Toro Corp (NASDAQ: OOJH ), (&quot;Toro&quot; or the &quot;Company&quot;), an international energy transportation services company, announced today that on April 17, 2023, the Company entered into a subscription agreement (the &quot;Subscription Agreement&quot;) with Pani Corp., a company controlled by Toro's Chairman and Chief Executive Officer, pursuant to which Toro has agreed to issue and sell, and Pani Corp. has agreed to purchase, 8,500,000 common shares, par value $0.001 per share (the &quot;Purchased Shares&quot;), at a purchase price of USD$2.29 per share, for gross proceeds of USD$19,465,000. The purchase price per Purchase Share equals the market price per Toro's common share at the close of trading on April 13, 2023. The Purchased Shares will be issued in a private placement pursuant to Section 4(a)(2) of the Securities Act and Regulation D promulgated thereunder. The terms of the Subscription Agreement and the transaction were approved by the Board of Toro consisting of its independent and disinterested directors, following the negotiation and recommendation by a special committee of the independent and disinterested directors of the Board of Toro. The special committee was advised by independent legal and financial advisors in its negotiation and recommendation of the proposed transaction. Toro intends to use the net proceeds from the sale of the Purchased Shares for vessel acquisitions, including to renew its fleet, and for other capital expenditures, working capital, and general corporate purposes, or a combination thereof. Following the completion of the transaction, the Company will have 17,961,009 common shares outstanding. As a result of the transaction, Toro's controlling shareholder, Chairman and Chief Executive Officer, Mr. Petros Panagiotidis, will, directly or indirectly, hold 47.4% of the Company's common shares in addition to his existing holdings of 100% of the Company's Series B Preferred Shares and, accordingly, will control 99.8% of the outstanding voting rights of Toro.
2023-04-17 16:11:33	AECV	Vaxcyte Announces Commencement Of Proposed Public Offering Of Common Stock And Pre-Funded Warrants; No Size Or Amount Disclosed	Vaxcyte, Inc. (NASDAQ: AECV ), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced that it has commenced an underwritten public offering of its common stock and pre-funded warrants. All shares of common stock and pre-funded warrants to be sold in the offering will be offered by Vaxcyte. Vaxcyte intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of shares of its common stock offered in the public offering (including shares underlying the pre-funded warrants). The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. BofA Securities, Jefferies, SVB Securities, Evercore ISI and Guggenheim Securities are acting as joint book-running managers for the offering. Cantor is acting as lead manager for the offering. Needham & Company and BTIG are acting as co-managers for the offering.
2023-04-17 16:23:54	AECV	Why Vaxcyte Stock Is Sliding After Hours	Vaxcyte Inc (NASDAQ: AECV ) shares are trading lower in Monday's after-hours session after the vaccine company announced the commencement of a proposed public offering . What Happened: Vaxcyte commenced an underwritten public offering of its common stock and pre-funded warrants, subject to market and other conditions. The company did not provide a timeline for completion or details on the size of the offering. Vaxcyte is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. See Also: What's Going On With Moderna Stock Monday? AECV Price Action: Vaxcyte shares surged 16% during Monday's regular session after the company reported positive data from a Phase 2 study of its 24-valent pneumococcal conjugate vaccine candidate. The stock was down 5.6% after hours at $39.97 at the time of writing, per Benzinga Pro . Photo: kkolosov from Pixabay.
2023-04-17 16:44:05	BSOR	Enovix Stock Is Falling After Hours: What's Going On?	Enovix Corp (NASDAQ: BSOR ) shares are trading lower in extended trading Monday after the company announced a proposed $150 million offering . The Details: Enovix said it intends to offer $150 million of convertible senior notes due 2028 in a private placement to institutional buyers. The company also intends to offer the purchasers up to an additional $22.5 million in convertible notes . The offering is subject to market and other conditions. There is no assurance if or when the offering will be completed or to the actual size of the offering. Enovix plans to use some of the proceeds to pay the cost of capped call transactions and the rest of the proceeds to build out a second battery cell manufacturing facility and fund the acquisition of production lines of its second gen manufacturing equipment. Enovix is set to report first-quarter results on April 26. The company is expected to turn in a quarterly loss of 21 cents per share. Enovix shares are pretty heavily shorted with nearly 20% of the float currently sold short, according to Benzinga Pro . See Also: Why Vaxcyte Stock Is Sliding After Hours BSOR Price Action: Enovix has a 52-week high of $26.28 and a 52-week low of $6.49. The stock was down 7.3% at $12.58 at the time of publication, according to Benzinga Pro .
2023-04-18 07:08:19	BSOR	Enovix Raises $150.0M Via 3.00% Convertible Senior Notes Offering Due 2028	Enovix Corporation (&quot;Enovix&quot;) (NASDAQ: BSOR ) , an advanced silicon battery company, today announced the pricing of $150.0 million aggregate principal amount of 3.00% Convertible Senior Notes due 2028 (the &quot;Notes&quot;) in a private placement to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the &quot;Securities Act&quot;) (the &quot;Offering&quot;) and in a concurrent private placement under Section 4(a)(2) of the Securities Act.
2023-04-18 08:18:53	AUFX	Athersys, Inc. Announces $3.7M Registered Direct Offering  Of 3.685M Shares Of Common Stock And Warrants At A Price Of $1/Share And Concurrent Private Placement, Warrants Will Have Excersize Price Of $0.96/Share	Athersys, Inc. (NASDAQ: AUFX ) today announced that it has entered into definitive agreements for the purchase and sale of 3,685,000 shares (the &quot;Shares&quot;) of the Company's common stock (or common stock equivalents in lieu thereof) in a registered direct offering and warrants to purchase up to 3,685,000 Shares at a purchase price per Share (and accompanying warrant) of $1.00 in a concurrent private placement (together with the registered direct offering, the &quot;offering&quot;). The warrants will have an exercise price of $0.96 per share, will be initially exercisable beginning six months following the date of issuance and will expire seven years from the initial exercise date. The closing of the offering is expected to occur on or about April 19, 2023, subject to the satisfaction of customary closing conditions. The gross proceeds from the offering are expected to be approximately $3.7 million. The Company intends to use the net proceeds from the offering for general corporate purposes. A.G.P./Alliance Global Partners is acting as sole placement agent for the offering.
2023-04-18 08:56:39	BSOR	What's Going On With Enovix Stock?	Enovix Corp (NASDAQ: BSOR ) shares fell in Monday's after-hours session before bouncing back in early trading Tuesday. The silicon battery company announced the pricing of a $150 million offering . What To Know: Enovix said it intends to offer $150 million of 3% convertible senior notes due 2028 in a private placement to institutional buyers. An entity affiliated with Enovix chairman Thurman Rodgers agreed to purchase $10 million worth of the notes. An entity affiliated with John Doerr , chairman of Kleiner Perkins, has also agreed to purchase $10 million worth. &quot;We believe the proceeds from these notes, together with the previously announced $70 million non-dilutive financing we are seeking to fund our planned next-generation manufacturing line in Malaysia, will enable us to build four production lines, all at approximately 7% dilution to our stockholders,&quot; said Raj Talluri , president and CEO of Enovix. &quot;With these lines, we expect to be able to manufacture between 38 million to 75 million batteries a year.&quot; Enovix expects net proceeds of $133.9 million or $155.7 million if the purchasers exercise options to purchase additional notes. Enovix is set to report first-quarter results on April 26. The company is expected to turn in a quarterly loss of 21 cents per share. Enovix shares are pretty heavily shorted with nearly 20% of the float currently sold short, according to Benzinga Pro . See Also: US Stocks Ready To Rally Amid Earnings Optimism: Analyst Sees Upward Momentum On 'Outlier' S&P 500 Returns BSOR Price Action: Enovix has a 52-week high of $26.28 and a 52-week low of $6.49. The stock was down more than 7% in extended trading Monday before staging a reversal. Enovix shares were up 0.22% at $13.60 at the time of publication, according to Benzinga Pro . Photo: Dean Simone from Pixabay.
2023-04-18 09:18:28	BSOR	Enovix Raises $150M Via Debt Offering	Enovix Corp (NASDAQ: BSOR ) has priced its $150.0 million of 3.00% Convertible Senior Notes due 2028 in a private placement. An entity affiliated with Thurman J. Rodgers, Chairman of Enovix, has agreed to purchase $10.0 million of the notes in the concurrent private placement. In addition, an entity affiliated with John Doerr, Chairman of Kleiner Perkins, has agreed to purchase $10.0 million of the notes in the offering. &quot;We believe the proceeds from these notes, together with the previously announced $70 million non-dilutive financing we are seeking to fund our planned next-generation manufacturing line in Malaysia, will enable us to build four production lines, all at approximately 7% dilution to our stockholders,&quot; said CEO Raj Talluri. &quot;With these lines, we expect to be able to manufacture between 38 million to 75 million batteries a year, depending on the size of the battery, to meet the strong customer demand we are seeing in the IoT, Mobile and Computing markets.&quot; The offering and sale of affiliate notes are expected to close on April 20, 2023. Enovix also granted the initial purchasers an option to purchase up to an additional $22.5 million of notes. Price Action: BSOR shares are trading lower by 0.52% at $13.50 in premarket on the last check Tuesday.
2023-04-18 09:28:37	CMJB	Immuneering Announces $30M Underwritten Offering Of 2,727,273 Shares Of Common Stock At A Price Of $11/Share	Immuneering Corporation (NASDAQ: CMJB ) (&quot;Immuneering&quot;), a clinical-stage oncology company developing medicines for broad populations of cancer patients with an initial aim to develop a universal-RAS therapy, today announced the pricing of its underwritten offering of 2,727,273 shares of its Class A common stock at an offering price of $11.00 per share. The gross proceeds from the offering are expected be $30 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Immuneering. All shares in the offering will be offered by Immuneering. Jefferies, TD Cowen and Guggenheim Securities are acting as the joint book-running managers for the offering. Immuneering intends to use the net proceeds of the offering to advance the preclinical and clinical development of its product candidates and for working capital and other general corporate purposes.
2023-04-18 12:23:40	KUZQ	Phio Pharmaceuticals Announces $2M Registered Direct Offering Of 353,983 Shares Of Common Stock At Price Of $5.65/Share At-The-Market Under Nasdaq Rules	Phio Pharmaceuticals Corp. (NASDAQ: KUZQ ), a clinical stage biotechnology company whose proprietary INTASYL&trade; RNAi platform technology is designed to make immune cells more effective in killing tumor cells, today announced that it has entered into a definitive agreement for the issuance and sale of an aggregate of 353,983 of its shares of common stock at a purchase price of $5.65 per share in a registered direct offering priced at-the-market under Nasdaq rules. In a concurrent private placement, Phio has also agreed to issue and sell unregistered Series A warrants to purchase up to an aggregate of 353,983 shares of common stock and unregistered Series B warrants to purchase up to an aggregate of 353,983 shares of common stock. The offering is expected to close on or about April 20, 2023, subject to the satisfaction of customary closing conditions. L.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. Each series of warrants will have an exercise price $5.40 per share and become exercisable immediately upon issuance. The Series A warrants have a term of five and one-half years from the date of issuance and the Series B warrants have a term of eighteen months from the date of issuance. The gross proceeds to the Company from the offering are expected to be approximately $2 million, before deducting the placement agent's fees and other offering expenses payable by Phio. Phio currently intends to use the net proceeds from the offering for the development of its immuno-oncology programs, working capital and general corporate purposes.
2023-04-18 16:11:19	IJDL	IJDL Bio Announces Proposed Public Offering Of Common Stock; No Size Or Amount Disclosed	IJDL Bio, Inc. (&quot;IJDL&quot;), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's own anatomy, today announced that it has commenced an underwritten public offering of shares of its common stock. In addition, IJDL expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock to be sold in the proposed offering at the public offering price, less underwriting discounts and commissions. All shares of common stock are being offered by IJDL. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the proposed offering. Jefferies, Piper Sandler, and Lake Street are acting as joint book-running managers for the proposed offering. IJDL intends to use the net proceeds from the proposed offering for general corporate purposes, including but not limited to sales and marketing, research and development activities, general and administrative matters, working capital and capital expenditures.
2023-04-19 07:16:55	SCIT	Gamida Cell Announces Launch of Public Offering of Securities; No Size Or Amount Disclosed	Gamida Cell Ltd. (NASDAQ: SCIT ), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced the launch of a follow-on public offering of its ordinary shares and accompanying warrants to purchase its ordinary shares. In addition, Gamida Cell expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the ordinary shares to be sold in the offering and/or warrants to purchase its ordinary shares on the same terms and conditions. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed. All of the securities in the offering are to be sold by Gamida Cell. Gamida Cell intends to use the net proceeds from this offering, together with its existing cash and cash equivalents and trading financial assets: to fund (i) commercialization activities to support the launch of Omisirge&reg;; (ii) the continued clinical development of GDA-201; and (iii) general corporate purposes, including general and administrative expenses and working capital. Piper Sandler & Co. is acting as sole book-running manager for this offering.
2023-04-19 07:18:01	IJDL	IJDL Bio Announces Pricing Of $42.125M Public Offering Of 4.75M Shares Of Common Stock At A Price Of $9.50/Share	IJDL Bio, Inc. (&quot;IJDL&quot;), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's own anatomy, today announced the pricing of its previously announced underwritten public offering of 4,750,000 shares of its common stock at a price to the public of $9.50 per share, for gross proceeds of $45.125 million, before deducting underwriting discounts and commissions and other estimated offering expenses. In addition, IJDL has granted the underwriters a 30-day option to purchase up to an additional 712,500 shares of its common stock at the public offering price, less underwriting discounts and commissions. All shares of common stock are being offered by IJDL. The offering is expected to close on or about April 21, 2023, subject to the satisfaction of customary closing conditions. Jefferies, Piper Sandler, and Lake Street are acting as joint book-running managers for the offering. IJDL intends to use the net proceeds from the offering for general corporate purposes, including but not limited to sales and marketing, research and development activities, general and administrative matters, working capital and capital expenditures.
2023-04-19 08:19:45	SCIT	Gamida Cell Announces Pricing Of $22.8M Public Offering Of 17.5M Shares Of Common Stock And Warrants At A Price Of $1.30/Share And Exercise price of $1.35/Warrant	Gamida Cell Ltd. (NASDAQ: SCIT ), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced the pricing of an underwritten public offering of 17,500,000 ordinary shares and accompanying warrants to purchase 17,500,000 ordinary shares at a public offering price of $1.30 per ordinary share and accompanying warrant, for gross proceeds of approximately $22.8 million, before deducting underwriting discounts and commissions and estimated offering expenses. The warrants have an exercise price of $1.35 per share, are exercisable immediately upon issuance, and will expire five years following the date of issuance. In addition, Gamida Cell has granted the underwriters a 30-day option to purchase up to an additional 2,625,000 ordinary shares and/or warrants on the same terms. The offering is expected to close on or about April 21, 2023, subject to satisfaction of customary closing conditions. Gamida Cell intends to use the net proceeds from this offering, together with its existing cash and cash equivalents and trading financial assets, to fund: (i) commercialization activities to support the launch of Omisirge&reg;; (ii) the continued clinical development of GDA-201; and (iii) general corporate purposes, including general and administrative expenses and working capital. Piper Sandler & Co. is acting as sole manager for this offering.
2023-04-19 08:21:51	NOTA	Agrify Corporation Enters Into Agreements To Raise Up To $1.84M From The Exercise Of Previously Issued Common Stock Warrants	Agrify Corporation (NASDAQ: NOTA ) (&quot;Agrify&quot; or the &quot;Company&quot;), a leading provider of innovative cultivation and extraction solutions for the cannabis industry, today announced it has entered into warrant inducement letters to raise up to $1.84 million in gross proceeds from the exercise of 10,651,430 common stock warrants issued in the Company's public offering from December, 2022, or the Existing Warrants. On April 18, 2023, the Company reduced the exercise price of all the Existing Warrants from $0.65 per share to $0.1725 per share. On such date, Agrify also entered into warrant inducement offer letters with certain investors pursuant to which the investors' may exercise 10,651,430 Existing Warrants at the reduced exercise price of $0.1725, and the Company will issue to such investors new warrants to purchase 200% of the shares exercised pursuant to the Existing Warrants from April 18, 2023 to 9:00am on April 21, 2023. Such new warrants will become exercisable six months after issuance, have an exercise price of $0.1725 and a five (5) year term from their initial exercise date, which will, among other things, be reduced to the extent the Company issues securities for a lower purchase price, subject to certain exceptions and substantially consistent with the equivalent term in the Existing Warrants. Additionally, if the exercise of the Existing Warrants by the warrantholder would cause the warrantholder to exceed the beneficial ownership limitation in the warrant agreement for the Existing Warrants, the Company will, among other things, only issue such number of Existing Warrants to the warrantholder that would not cause the warrantholder to exceed the maximum number of shares of common stock permitted, with the balance to be held in abeyance until such shares can be delivered to the holder within such beneficial ownership limitations. If all are exercised, the exercise of the 10,651,430 Existing Warrants is expected to result in gross proceeds to the Company of $1.84 million. This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities in the offering. There shall not be any sale of the securities described herein in any state or jurisdiction in which such offering, sale, or solicitation would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
2023-04-19 08:31:36	HPZX	China Jo-Jo Drugstores Announces The Termination Of The Previously Proposed Registered Direct Offering	China Jo-Jo Drugstores, Inc. (NASDAQ: HPZX ) (&quot;Jo-Jo Drugstores&quot; or the &quot;Company&quot;), a leading online and offline retailer, wholesale distributor of pharmaceutical and other healthcare products and healthcare provider in China, announced today that the previously announced registered direct offering to issue 2,258,888 ordinary shares and registered warrants to purchase up to 4,517,776 ordinary shares to an institutional investor was terminated. No securities were sold pursuant to the Company's shelf registration statement on Form F-3 (No. 333-259692) in connection with such previously proposed offering.
2023-04-19 09:22:34	HKEM	Allarity Therapeutics, Inc. Announces Pricing Of $7.5M Public Offering Of 2,869,330 Shares And 7,130,670 Pre-Funded Warrants, And 10M Common Warrants To Purchase 10M Shares Of Common Stock At An Combined Price Of $0.75/Share	Allarity Therapeutics, Inc. Announces Pricing of $7.5 Million Public Offering BOSTON, MA (April 19, 2023) &mdash; Allarity Therapeutics, Inc. (NASDAQ: HKEM ) (&quot;Allarity&quot; or the &quot;Company&quot;), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP&reg; companion diagnostics for personalized cancer care, today announced the pricing of its &quot;reasonable best efforts&quot; public offering of 2,869,330 shares of common stock, 7,130,670 pre-funded warrants, and 10,000,000 common warrants to purchase 10,000,000 shares of common stock at an effective combined price of $0.75 per share and common warrant for aggregate gross proceeds of approximately $7.5 million, before deducting placement agent fees and other offering expenses. The warrants will have an exercise price of $0.85 per share, will be exercisable immediately and will expire five years from the initial exercise date. The closing of the offering is expected to occur on or about April 21, 2023, subject to the satisfaction of customary closing conditions. The Company intends to use a portion of the net proceeds of this offering to pay account payables and accrued liabilities outstanding, to payoff certain outstanding promissory notes, to redeem a portion of its Series A Convertible Preferred Stock and for working capital and general corporate purposes. A.G.P./Alliance Global Partners is acting as sole placement agent for the offering.
2023-04-19 09:25:11	CYKK	Carvana Co. Announces Extension Of Private Exchange Offers, Increase In Exchange Consideration Relating To Existing 2025 Notes And Extension Of Early Exchange Premium	Carvana Co. (NYSE: CYKK ) (&quot;Carvana&quot; or the &quot;Company&quot;), the leading e-commerce platform for buying and selling used cars, today announced that it has extended the expiration date for each of its previously announced offers to exchange (each an &quot;Exchange Offer&quot; and, collectively, the &quot;Exchange Offers&quot;) its outstanding existing notes listed below (the &quot;Existing Notes&quot;) for up to an aggregate principal amount of $1,000,000,000 (subject to increase or decrease by the Company) of new 9.0%/12.0% Cash/PIK Toggle Senior Secured Second Lien Notes due 2028 (the &quot;New Secured Notes&quot;) issued by the Company. The Exchange Offers, which were originally scheduled to expire at 5:00 p.m., New York City time, on Wednesday, April 19, 2023, have been extended until 5:00 p.m., New York City time, on May 3, 2023 (the &quot;New Expiration Time&quot;), unless further extended. As the withdrawal deadline has passed, Existing Notes tendered in the Exchange Offers may not be withdrawn. Additionally, eligible holders who validly tender Existing Notes at or prior to the New Expiration Time will be eligible to receive the Early Exchange Premium, as set forth in the table below. Furthermore, the Exchange Offer relating to the Company's 5.625% Senior Notes due 2025 (the &quot;2025 Notes Exchange Offer&quot;) has been amended to increase its exchange consideration, as set forth in the table below (the &quot;New Exchange Consideration&quot;). Any Existing Notes validly tendered prior to the New Expiration Time and accepted by the Company will receive the Total Consideration as set forth in the table below. Other than the extension of the Exchange Offers and Early Exchange Premium and the New Exchange Consideration, all other terms and conditions of the Exchange Offers set forth in the Exchange Offer Memorandum distributed to eligible holders, dated March 22, 2023 (the &quot;Exchange Offer Memorandum&quot;), remain unchanged.
2023-04-19 09:39:10	HPZX	Why China Jo-Jo Drugstores Shares Are Skyrocketing Today?	China Jo-Jo Drugstores Holdings Inc (NASDAQ: HPZX ) stock is surging Wednesday morning following the termination of its previously announced equity offering. The company had announced registered direct offering to issue 2.3 million shares and registered warrants to purchase up to 4.5 million shares to an institutional investor. The purchase price for the equity offering was $3.10 per share. The company had hoped to rake in $7 million in proceeds from the offering. Price Action : HPZX shares are trading higher by 91% at $1.29 on the last check Wednesday.
2023-04-20 08:45:20	IH	Kineta, Inc. Announces $6 Million Registered Direct Offering Of 1,425,179 Shares At A Price Of $4.21/Share Priced At-The-Market Under Nasdaq Rules	"Kineta, Inc. (NASDAQ: IH ) (the ""Company"" or ""Kineta""), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today that it has entered into a definitive agreement for the purchase and sale of 1,425,179 shares of the Company's common stock (or pre-funded warrants in lieu thereof) at a purchase price of $4.21 per share of common stock (or pre-funded warrant in lieu thereof) in a registered direct offering priced at-the-market under Nasdaq rules. In a concurrent private placement, the Company will issue unregistered warrants to purchase up to 1,425,179 shares of common stock with an exercise price of $4.08 per share which will be immediately exercisable for a period of five years following issuance. The closing of the offering is expected to occur on or about April 24, 2023, subject to the satisfaction of customary closing conditions. L.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. The gross proceeds from the offering, before deducting the placement agent's fees and other offering expenses, are expected to be approximately $6 million. The Company intends to use the net proceeds from this offering for working capital purposes."
2023-04-20 09:38:15	KZOK	Why Windtree Therapeutics Stock Is Tumbling Today	Windtree Therapeutics Inc (NASDAQ: KZOK ) shares are plunging in early trading Thursday after the company announced the pricing of an upsized public offering . What Happened: Windtree announced the pricing of a $10.8 million public offering of 3,686,006 shares and warrants to purchase up to 3,686,006 shares of the company's common stock. Each share is being sold together with one warrant at a combined public offering price of $2.93 per share. The warrants have an exercise price of $2.93 per share and will expire in five years. Windtree expects to use $3.5 million of the net proceeds to extend enrollment and complete a Phase 2 clinical trial for istaroxime in cardiogenic shock. The rest will be used for working capital and general corporate purposes. Windtree is estimated to report first-quarter earnings at the beginning of May, although a date has not yet been confirmed by the company. Windtree Therapeutics is a biotechnology company focused on advancing late-stage interventions for cardiovascular disorders. See Also: Why Las Vegas Sands Shares Are Rising Today KZOK Price Action: Windtree shares were down 59.3% at $2.28 at the time of publication, according to Benzinga Pro . This illustration was generated using artificial intelligence via MidJourney.
2023-04-21 08:05:20	QOO	Jayud Global Logistics Raises 5M Via GIP of 1.25M Shares At $4 Per Share; To Begin Trading From Friday On Nasdaq	Jayud Global Logistics Limited (the &quot;Company&quot; or &quot;Jayud&quot;), one of the leading Shenzhen-based end-to-end supply chain solution providers in China, today announced the pricing of its initial public offering (the &quot;Offering&quot;) of 1,250,000 Class A ordinary shares at a public offering price of US$4 per Class A ordinary share. The Class A ordinary shares have been approved for listing on the Nasdaq Capital Market and are expected to commence trading on April 21, 2023 under the ticker symbol &quot;QOO.&quot; The Company expects to receive the gross proceeds of US$5 million from the Offering. In addition, the Company has granted the underwriters a 30-day option to purchase up to an additional 187,500 Class A ordinary shares at the public offering price, less underwriting discounts. The Offering is expected to close on or about April 25, 2023, subject to the satisfaction of customary closing conditions. Proceeds from the Offering will be used for supplementing the Company's operating cash flow and general corporate use; leasing or purchasing warehouses that have strategic importance to the Company's business operation; adding new chartered services in key trade lines in the future; registration and operation of the Company's overseas business entities, branches and offices; and potential mergers and acquisitions in the future.
2023-04-24 08:04:56	KVAW	Applied Therapeutics, Inc. Announces $30M Private Placement Of Equity	Applied Therapeutics, Inc. (NASDAQ: KVAW ) (the &quot;Company&quot;), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced it has entered into a definitive securities purchase agreement, dated as of April 23 2023, for the sale of 9,735,731 shares of the Company's common stock, par value $0.0001 per share at a purchase price of $0.946 per share (the &quot;Shares&quot;) and 22,000,000 pre-funded warrants to purchase common stock at a purchase price of $0.945, which equal the purchase price per share of common stock less the $0.001 per share exercise price of each pre-funded warrant (the &quot;Pre-Funded Warrants&quot; and together with the Shares the &quot;Securities&quot;), in a private placement (the &quot;Private Placement&quot;). The Private Placement was led by new investor Venrock Healthcare Capital Partners and is expected to result in gross proceeds to the Company of approximately $30 million, before deducting placement agent commissions and other offering expenses. The Private Placement is expected to close on or about April 26, 2023, subject to the satisfaction of customary closing conditions. Additional details regarding the Private Placement will be included in a Form 8-K to be filed by the Company with the Securities and Exchange Commission (&quot;SEC&quot;). The Company intends to use the net proceeds to fund research and development and registration of its pipeline candidates, and for working capital and general corporate purposes. The capital raised in the Private Placement, in addition to current cash and potential milestones expected from the Advanz European licensing partnership, are expected to fund the business through the middle of 2024. SVB Securities and UBS Investment Bank acted as placement agents in the transaction (the &quot;Placement Agents&quot;). Skadden, Arps, Slate, Meagher & Flom LLP acted as legal counsel for the Company.
2023-04-24 11:33:04	KVAW	Applied Therapeutics' Investigational Drug Shows Clinical Benefit In Rare Metabolic Disorder, Chalks Out FDA Submission Plans	Applied Therapeutics Inc (NASDAQ: KVAW ) announced results from the ACTION-Galactosemia Kids study of govorestat (AT-007) for galactosemia, a rare genetic metabolic disease resulting in an inability to metabolize the simple sugar galactose. When not appropriately metabolized, galactose is converted to the toxic metabolite, galactitol, which causes neurological complications. Treatment with govorestat demonstrated consistent and sustained clinical benefits in activities of daily living, behavioral symptoms, cognition, adaptive behavior, and tremors. While statistical significance defined as a p-value of <0.05 was not met on the primary endpoint, a systematic improvement over time was demonstrated for the overall primary endpoint (p=0.1030) and pre-specified sensitivity analyses, including cognition (p=0.0698). Individual speech and language components of the primary endpoint were not impacted, which is suspected to be due to a lack of progression in the placebo group and concomitant speech therapy received by almost all children in the trial. A post-hoc analysis of the global statistical test, including behavior and activities of daily living but excluding speech & language components, demonstrated a statistically significant benefit of active treatment vs. placebo (p=0.0205), which strengthened over time. Govorestat provided a statistically significant benefit on tremors at 18 months (p=0.0428). Govorestat continued to be safe and well-tolerated in all age groups; no treatment-related serious adverse events (SAEs) were reported. The company plans to request a pre-NDA meeting with the FDA as soon as possible to discuss a potential NDA submission in 2H of 2023; it plans to submit a European Marketing Authorization Application in mid-2023 . Concurrently, Applied Therapeutics announced a private placement of 9.7 million shares at $0.946 per share and 22 million pre-funded warrants at $0.945 for a gross proceed of $30 million. Price Action: KVAW shares are up 9.94% at $1.04 on the last check Monday.
2023-04-24 16:45:57	UHBB	Establishment Labs Announces Proposed Public Offering Of Common Shares; No Size Or Amount Disclosed	Establishment Labs Holdings Inc. (NASDAQ: UHBB ) (the &quot;Company&quot;), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced that it has commenced a public offering of its common shares, to be sold by the Company in a registered public offering. The Company expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the common shares to be sold in the proposed offering, at the public offering price per share, less underwriting discounts and commissions. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. The Company intends to use the net proceeds from this offering, together with its existing cash, for general corporate purposes, including sales and marketing, research and development activities, general and administrative matters, working capital and capital expenditures. Jefferies, J.P. Morgan, Citigroup and TD Cowen are acting as joint book-running managers for the offering. BTIG is acting as co-manager.
2023-04-25 07:42:12	OMJV	OMJV Biotechnology, Inc. Announces Pricing Of $5M Public Offering Of 2,222,200 Shares Of Common Stock At A Price Of $2.25/Share	OMJV Biotechnology, Inc. (NYSE: OMJV ) (&quot;OMJV&quot; or the &quot;Company&quot;), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced the pricing of an underwritten public offering of 2,222,200 shares of its common stock at a public offering price of $2.25 per share, for gross proceeds of approximately $5 million, before deducting underwriting discounts and other offering expenses. In addition, OMJV has granted the underwriters a 45-day option to purchase up to an additional 333,300 shares of common stock to cover over-allotments at the public offering price, less the underwriting discount. The Company intends to use the net proceeds to fund the ongoing clinical trials of THIO, pre-clinical development of second-generation of telomere targeting compounds, and other research and development activities, as well as for working capital and other general corporate purposes. The offering is expected to close on April 27, 2023, subject to satisfaction of customary closing conditions. ThinkEquity is acting as sole book-runner for the offering.
2023-04-25 19:59:19	YCBJ	Mesoblast Completed A Global Private Placement Raising Approximately US$40M	"Mesoblast Limited ((ASX:MSB, NASDAQ: YCBJ ), global leader in allogeneic cellular medicines for inflammatory diseases, today announced it has completed a global private placement primarily to Mesoblast's existing major US, UK, and Australian shareholders raising approximately US$40 million, net of transaction costs, at A$0.85 per share. Proceeds will be used to fund:  Launch and commercialization of the company's lead product, remestemcel-L, in the treatment of children with steroid-refractory acute graft versus host disease (SR-aGVHD) subject to approval by the US Food & Drug Administration (FDA) of Mesoblast's resubmitted Biologics License Application (BLA) which has a PDUFA goal date of August 2, 2023.  Ongoing manufacturing of commercial remestemcel-L product at the Lonza Biosciences facility in Singapore, where the upcoming scheduled pre-licensure inspection (PLI) will be performed by FDA.  Initiation of patient enrolment in the confirmatory Phase 3 clinical trial of rexlemestrocel-L for chronic low back pain associated with degenerative disc disease. Chief Executive Dr Silviu Itescu said ""We appreciate the strong support from our major shareholders as we look forward to commercializing our platform technology and bringing the first FDA approved treatment to children with life-threatening SR-aGVHD."""
2023-04-26 09:12:11	XZKI	ZyVersa Therapeutics, Inc. Announces Pricing Of $11M Public Offering Of 11,015,500 Shares Of Common Stock At A Price Of $1/Share	ZyVersa Therapeutics, Inc. (NASDAQ: XZKI , or &quot, , ZyVersa&quot, , ))))), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of inflammatory and renal diseases, today announced the pricing of its &quot;reasonable best efforts&quot; public offering of 11,015,500 shares of common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to 11,015,500 shares of common stock at an effective combined price of $1.00 per share and common warrant for aggregate gross proceeds of approximately $11.0 million, before deducting placement agent fees and other offering expenses. The warrants will have an exercise price of $1.00 per share, will be exercisable immediately, and will expire five years from the initial issuance date. The closing of the offering is expected to occur on or about April 28, 2023, subject to the satisfaction of customary closing conditions. The Company intends to use the net proceeds of this offering to redeem substantially all of the PIPE Shares pursuant to the Series A Certificate of Designation, pay expenses related to the offering, and use the remaining proceeds for working capital and other general corporate purposes. A.G.P./Alliance Global Partners is acting as the lead placement agent and The Benchmark Company is acting as a co-placement agent for the offering.
2023-04-27 16:16:15	DGCB	Hillstream BioPharma Announces Proposed Public Offering; No Size Or Amount Disclosed	Hillstream BioPharma, Inc. (NASDAQ: DGCB ) (&quot;Hillstream&quot; or the &quot;Company&quot;), a biotechnology company developing therapeutic candidates targeting drug resistant and devastating cancers using ferroptosis, an emerging new anti-cancer mechanism resulting in iron-mediated cell death, and immuno-oncology targeted novel biologics, today announced that it intends to offer to sell shares of its common stock (and/or pre-funded warrants (&quot;Pre-Funded Warrants&quot;) in lieu thereof) in an underwritten public offering. All of the shares of common stock (and/or Pre-Funded Warrants) are to be sold by the Company. ThinkEquity is acting as sole book-running manager for the offering. The Company expects to grant the underwriter a 45-day option to purchase up to an additional 15% of the number of shares of common stock and/or Pre-Funded Warrants sold in the offering to cover over-allotments, if any. The offering is subject to market conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. The Company intends to use the net proceeds from the offering for the advancement of HSB-1216, the development of other product candidates in the Company's pipeline (HSB-3215 and HSB-1940), for general corporate purposes, and for working capital.
2023-04-28 08:15:43	WCNH	ENDRA Life Sciences Announces Pricing of Upsized $4.5M Public Offering Of 3.75M Shares Of Common Stock And Warrants To Purchase 1.875M Shares Of Common Stock	ENDRA Life Sciences Inc. (NASDAQ: WCNH ) (&quot;ENDRA&quot; or the &quot;Company&quot;), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS&reg;), announced today that it has priced an underwritten public offering of 3,750,000 shares of its common stock and warrants to purchase 1,875,000 shares of its common stock. The warrants are being sold at the rate of one warrant for every two shares of common stock and will be exercisable at a price per share of $1.40. The public offering price for each set of two shares of common stock and accompanying warrant to purchase one share of common stock is $2.41 per set of securities, yielding an effective price of $1.20 per share and $0.01 per warrant, for net proceeds of approximately $3.9 million after deducting the estimated underwriting discounts and commissions and estimated offering expenses. All of the securities in the underwritten public offering were sold by ENDRA. The Company has granted the underwriter a 30-day option to purchase additional shares of common stock and warrants to purchase shares of its common stock sold in the offering solely to cover over-allotments. The warrants will not be listed on any securities exchange or other nationally recognized trading system. The offering is expected to close on May 2, 2023. ENDRA intends to use the net proceeds from the offering for working capital and other general corporate purposes, which may include funding product development, submission for regulatory approvals of its products, and commercialization activities. Newbridge Securities Corporation is acting as sole underwriter of the offering.
2023-05-01 08:10:21	LZKN	Pulse Biosciences Announces $65M Private Placement Via 10M Shares At $6.51 Per Share With Chair Robert P. Duggan	Pulse Biosciences, Inc. (NASDAQ: LZKN ), a company leveraging its novel and proprietary nanosecond pulsed field ablation (nsPFA&trade;) technology and proprietary CellFX System&reg; for the treatment of atrial fibrillation, today announced that it has entered into a stock purchase agreement with Robert P. Duggan, an experienced life sciences executive and the Company's Executive Chairman, for the purchase of 10,022,937 shares of the Company's common stock at a price of $6.51 per share, a greater than 1% premium over the last reported sale price of the Company's common stock on April 28, 2023, the immediately preceding trading day. Upon the closing of this private placement and sale of these securities, all indebtedness owed by the Company to Mr. Duggan, including the principal balance of $65.0 million and accrued and unpaid interest of approximately $0.25 million, will be cancelled as consideration for the shares.
2023-05-01 10:22:53	CMII	'Meta SEC Filing Reveals Debt Securities Offering Plans; Facebook Parent Company Filed A Prospectus That Says It May Offer And Sell Debt Securities Occasionally; Did Not Disclose The Exact Amount Of Debt Securities Being Offered' - CoinTelegraph	"https://cointelegraph.com/news/meta-sec-filing-reveals-debt-securities-offering-plans Tech giant Meta, the parent company of Facebook, Instagram and WhatsApp, submitted a filing to the United States Securities and Exchange Commission (SEC) for new debt shelf offerings. The Big Tech company filed the prospectus on May 1, saying that it ""may, from time to time, offer and sell debt securities in one or more series."" The statement continued to say each time a debt security is sold, it will issue a new ""prospectus supplement"" containing the ""specific terms of the debt securities offered."" Debt shelf offerings, or debt securities, are a provision that grants the issuer (i.e., Meta) the ability to register a new issue of securities without the need to sell the entire issue at once. Additionally, the filing stated that debt securities may be offered and sold to or via ""underwriters, brokers, dealers, or agents as designated from time to time, directly to one or more other purchasers, or through a combination of such methods."" The filing did not disclose the exact amount of debt securities being offered."
2023-05-02 11:14:16	QYA	Why Are GD Culture Shares Trading Lower Today	GD Culture Group Limited (NASDAQ: QYA ) shares plunged since it shared plans to raise funds via direct stock sale . On Tuesday, GD agreed to raise $11.55 million via a stock offering of 0.47 million shares and pre-funded warrants to purchase up to 0.93 million shares at $8.27 per share. In a concurrent private placement, GD also agreed to issue to the same investors warrants to purchase up to 1.4 shares at an exercise price of $8.27 per share. GD shares closed at $31.00 on Monday. The warrants will have a 5-year term from the date of issuance. The transactions will likely close by May 4, 2023. Price Action: QYA shares traded lower by 76.1% at $7.40 on the last check Tuesday.
2023-05-02 17:10:36	YWFG	Guardforce AI Stock Is Tanking After Hours: What's Going On?	Guardforce AI Co (NASDAQ: YWFG ) shares are plunging in Tuesday's after-hours session after the company proposed an offering . What Happened: Guardforce AI commenced an underwritten public offering after the close. The shares are being offered by the company pursuant to a &quot;shelf&quot; registration statement declared effective by the SEC on Jan. 5, 2022. The size and the price of the offering were not disclosed. Guardforce AI is an integrated security provider specializing in secured logistics, AI and Robot-as-a-Service (RaaS). The stock has soared in recent months amid a surge in popularity in AI-related names. See Also: Uber CEO On What's Driving Accelerated Growth, Timetable For Profitability, AI Potential YWFG Price Action: Guardforce AI has a 52-week high of $36.89 and a 52-week low of $3.81, according to Benzinga Pro . The stock was down 52.1% after hours at $5.60 at the time of writing. Photo: Lukas from Pixabay.
2023-05-03 08:38:03	RZZI	MeiraGTx Announces $60M Private Placement Of 10.7M Ordinary Shares At A Price Of $5.75/Share	MeiraGTx Holdings plc (NASDAQ: RZZI ), a vertically integrated, clinical stage gene therapy company, today announced that it has agreed to sell approximately 10.7 million ordinary shares at a price of $5.75 per share. MeiraGTx anticipates aggregate gross proceeds from the private placement will be approximately $60 million. The Company intends to use the proceeds from this private placement to continue to advance its pipeline of innovative gene therapy assets through clinical development, as well as for general corporate purposes. The financing was entirely led by the Company's top holders Perceptive Advisors, Adage Capital, Prosight Management and 683 Capital Management. The private placement is expected to close on or about May 5, 2023, subject to customary closing conditions. This press release does not constitute an offer to sell or the solicitation of an offer to buy the securities, nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such jurisdiction. These securities are being sold in a private placement and have not been registered under the Securities Act of 1933, as amended, or any state securities laws and may not be offered or sold in the United States absent registration with the Securities and Exchange Commission or an applicable exemption from such registration requirements.
2023-05-03 16:23:42	VNEI	Reneo Pharmaceuticals Announces Proposed Public Offering Of Common Stock; No Size Or Amount Disclosed	Reneo Pharmaceuticals, Inc. (Reneo) (NASDAQ: VNEI ), a clinical-stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today announced that it has commenced an underwritten public offering of its shares of common stock. Reneo intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock to be sold in the offering on the same terms and conditions. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed. All of the shares of common stock in the offering are to be sold by Reneo. Reneo also entered into an agreement with Abingworth Bioventures 8 LP (Abingworth), pursuant to which Reneo has agreed to sell its shares of common stock to Abingworth at the public offering price, for aggregate gross proceeds of up to $5.0 million, in a concurrent private placement that is expected to close after the public offering. The sale of these shares of common stock will not be registered under the Securities Act of 1933, as amended. The closing of the concurrent private placement is conditioned on the closing of the public offering. Jefferies LLC, BofA Securities, Inc. and Piper Sandler are acting as joint book-running managers and Robert P. Baird & Co. Incorporated is acting as a lead manager for the underwritten public offering. Jefferies LLC, BofA Securities, Inc., Piper Sandler and Robert P. Baird & Co. Incorporated are also acting as placement agents for the concurrent private placement.
2023-05-04 08:21:47	VBSG	Mawson Infrastructure Group Inc. Announces $5M Registered Direct Offering	Mawson Infrastructure Group Inc. (NASDAQ: VBSG ) (&quot;Mawson&quot; or the &quot;Company&quot;), a digital infrastructure provider, today announced a $5 million registered direct offering. Mawson has entered into a definitive agreement with institutional investors for the issuance and sale of 2,083,336 shares of its common stock (or pre-funded warrants in lieu thereof) at a purchase price of $2.40 per share of common stock (or $2.399 per pre-funded warrant, which represents the per share offering price for the common stock less the $0.001 per share exercise price for each pre-funded warrant) in a registered direct offering. In addition, in a concurrent private placement, the Company will issue to the institutional investors unregistered warrants to purchase up to 2,604,170 shares of its common stock with an exercise price of $3.23 per share and are exercisable six months following issuance for a period of five and one-half years following issuance. The closing of the registered direct offering and the concurrent private placement is expected to occur on or about May 8, 2023, subject to the satisfaction of customary closing conditions. L.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. The gross proceeds to Mawson from the offering are expected to be approximately $5 million, before deducting the placement agent's fees and other offering expenses payable by Mawson. Mawson intends to use the net proceeds from this offering to continue to build out its digital infrastructure, for potential strategic transactions and also for general corporate purposes, including working capital. The shares of common stock and pre-funded warrants described above are being offered and sold by Mawson pursuant to a &quot;shelf&quot; registration statement on Form S-3 (File No. 333-264062), including a base prospectus, previously filed with the Securities and Exchange Commission, or the SEC, on April 1, 2022 and declared effective by the SEC on April 11, 2022. Such shares of common stock and pre-funded warrants may be offered only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement. A final prospectus supplement and an accompanying base prospectus relating to the registered direct offering will be filed with the SEC. Electronic copies of the prospectus supplement and the accompanying base prospectus may be obtained, when available, by visiting the SEC's website at http://www.sec.gov or by contacting L.C. Wainwright & Co., LLC at 430 Park Avenue, 3rd Floor, New York, NY 10022, by e-mail at placements@hcwco.com or telephone at (212) 856-5711.
2023-05-04 09:16:06	ZMME	Privia Health Announces Upsized Pricing Of Secondary Offering Of $936M Of 42,561,196 Shares Of Common Stock At A Price Of $22/Share	Privia Health Group, Inc. (NASDAQ: ZMME ), a technology-driven, national physician enablement company, today announced the upsized pricing of an underwritten secondary offering of 42,561,196 shares of common stock by certain selling stockholders at a price of $22.00 per share. The Company will not receive any of the proceeds from the sale of the shares of its common stock, and the selling stockholders will bear the costs associated with the sale of such shares, including underwriting discounts and commissions. New investors purchasing shares in this transaction include entities managed by Durable Capital Partners LP and Rubicon Founders LLC, among others. Goldman Sachs & Co. LLC acted as the sole book-running manager for the offering. A shelf registration statement on Form S-3 (including a prospectus) relating to the securities being sold in the offering was deemed automatically effective upon filing with the Securities and Exchange Commission (the &quot;SEC&quot;). A copy of the final prospectus, when available, may be obtained for free by visiting EDGAR on the SEC website at www.sec.gov , or by contacting: Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, New York 10282, via telephone: 1-866-471-2526, or via email: prospectus-ny@ny.email.gs.com . This press release is neither an offer to sell nor a solicitation of an offer to buy any securities, nor shall it constitute an offer, solicitation or sale of any securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.
2023-05-04 13:00:14	GASI	Actelis Networks Announces $3.5M Private Placement For The Purchase And Sale Of 944,670 Shares Of Its Common Stock And Warrants Priced At $3.705/Share And Exercise Price Of $3.58/Warrant Price Of At-The-Market Under Nasdaq Rules	Actelis Networks, Inc. (NASDAQ: GASI ) (&quot;Actelis&quot; or the &quot;Company&quot;) a market leader in cyber-hardened, rapid deployment networking solutions for wide area IoT applications, today announced that it has entered into definitive agreements for the purchase and sale of 944,670 shares of its common stock (or common stock equivalents) and warrants to purchase up to 944,670 shares of its common stock at a purchase price of $3.705 per share of common stock (or common stock equivalent) and associated warrant in a private placement priced at-the-market under Nasdaq rules. The warrants have an exercise price of $3.58 per share, will be exercisable immediately upon issuance and expire five and one-half years following the issuance. L.C. Wainwright & Co. is acting as exclusive placement agent for the offering. The gross proceeds to the Company are expected to be approximately $3.5 million. The offering is expected to close on or about May 8, 2023, subject to satisfaction of customary closing conditions. The Company intends to use the net proceeds from the offering for working capital and general corporate purposes.
2023-05-08 07:37:29	DPQ	DPQ To Raise $450M Via Private Offering of Senior Notes	Northern Oil and Gas, Inc. (NYSE: DPQ ) (the &quot;Company&quot; or &quot;DPQ&quot;) today announced that it intends to offer for sale (the &quot;Offering&quot;) in a private placement under Rule 144A and Regulation S of the Securities Act of 1933, as amended (the &quot;Securities Act&quot;), to eligible purchasers, $450.0 million in aggregate principal amount of new senior notes due 2031 (the &quot;New Notes&quot;). The Company intends to use the net proceeds from the Offering for general corporate purposes, including repayment of a portion of the outstanding borrowings under its revolving credit facility.
2023-05-08 08:33:27	KHCI	Legend Biotech Corporation Announces Pricing Of Registered Direct Offering Of $350M Of 5,468,750 American Depositary Shares At A Price Of $64/ADS	Legend Biotech Corporation (NASDAQ: KHCI ) (&quot;Legend Biotech&quot;), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, today announced that it has agreed to sell 5,468,750 American Depositary Shares (&quot;ADSs&quot;), each representing two ordinary shares of the Company, at a price of $64.00 per ADS, in a registered direct offering. The gross proceeds of the offering are expected to be approximately $350 million, before offering expenses, which together with the Company's existing cash and cash equivalents, will enable the Company to fund its planned operating expenses and capital expenditures through the fourth quarter of 2025. All ADSs to be sold in the offering will be sold by Legend Biotech. The offering is expected to close on or about May 10, 2023, subject to customary closing conditions. The ADSs are being offered pursuant to an effective shelf registration statement that was previously filed with the Securities and Exchange Commission (&quot;SEC&quot;). The securities may be offered only by means of a prospectus. A final prospectus supplement relating to the offering will be filed with the SEC and will be available on the SEC's website at www.sec.gov . A copy of the final prospectus supplement can be obtained, when available, by contacting us at 2101 Cottontail Lane, Somerset, NJ 08873 USA. This press release shall not constitute an offer to sell, or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
2023-05-08 16:52:53	P	Why Wayfair Stock Is Tumbling After The Close	Wayfair Inc (NYSE: P ) shares are trading lower in Monday's after-hours session after the company announced an offering to raise capital via debt. What Happened: Wayfair said it intends to offer $600 million worth of convertible senior notes due 2028 in a private offering to institutional buyers. The final terms of the notes will be determined at the time of pricing, which is expected to be based on the closing price of the stock on Tuesday. In connection with the note offering, Wayfair expects to enter into privately negotiated capped call transactions with one or more of the initial purchasers. The company intends to use a portion of the net proceeds from the offering to pay the cost of the capped call transactions. Proceeds will also be used to repurchase for cash a portion of the 2024 Notes, 2025 Notes and 2026 Notes. Any remaining net proceeds will be used for working capital and general corporate purposes . See Also: Devon Energy Reports Mixed Q1 Results, Increases Buyback: The Details P Price Action: Wayfair shares were down 7.81% at $36.85 at the time of publication, according to Benzinga Pro . Photo: u_jup1hbno from Pixabay.
2023-05-09 09:29:03	HMD	ConocoPhillips Announces Cash Tender Offer For Up To $750M Of Debt Securities	ConocoPhillips (NYSE: HMD ) (&quot;HMD&quot;) announced today that ConocoPhillips and its wholly-owned subsidiary, ConocoPhillips Company (&quot;CPCo&quot;), have commenced a cash tender offer (the &quot;Tender Offer&quot;) to purchase outstanding notes listed in the table below (collectively, the &quot;Notes&quot; and each a &quot;Series&quot; of Notes) having an aggregate purchase price (excluding accrued interest) of up to $750.0 million (the &quot;Maximum Aggregate Purchase Price&quot;), in the order of priority shown in the table below.
2023-05-10 08:18:08	SNUF	Fastly Announces Repurchase Of 0% Convertible Senior Notes Due 2026	Fastly, Inc. (NYSE: SNUF ), one of the world's fastest edge cloud platforms, today announced that it has entered into separate, privately negotiated transactions (the &quot;Agreements&quot;) with certain holders of its outstanding 0% Convertible Senior Notes due 2026 (the &quot;Notes&quot;) to repurchase (the &quot;Repurchases&quot;) approximately $236.4 million aggregate principal amount of the Notes for an aggregate cash repurchase price of approximately $195.0 million. The final aggregate cash repurchase price will be determined based on the sum of (i) approximately $195.0 million based on Fastly's May 5, 2023 closing stock price of $11.78 per share of Class A common stock (the &quot;common stock&quot;) and (ii) an amount (which may be positive or negative) based in part on the daily volume-weighted average price per share of the common stock during a one-trading day pricing period following the execution of the Agreements. The actual amount of cash paid in the Repurchases could vary from the estimated aggregate repurchase price depending on changes in the trading price of the common stock during the measurement period. The Repurchases are expected to close on May 15, 2023, subject to customary closing conditions. Following the closing of the Repurchases, Fastly intends to cancel the repurchased Notes and, after such cancellation of repurchased Notes, approximately $477.4 million aggregate principal amounts of Notes will remain outstanding. The Repurchases could affect the market price of the common stock. This press release does not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any offer or sale of these securities in any state or jurisdiction in which the offer, solicitation, or sale would be unlawful prior to the registration or qualification thereof under the securities laws of any such state or jurisdiction.
2023-05-10 16:56:46	RDBF	On May 10, 2023, Apple Inc. Issued And Sold $5,250,000,000 Aggregate Principal Amount Of Its 4.421%, 4.000%, 4.150%, 4.300%, And 4.850% Notes Due 2026, 2028, 2030, 2033, And 2053, Respectively, Pursuant To An Underwriting Agreement, Indenture, And Officer	On May 10, 2023, Apple Inc. (&ldquo;Apple&rdquo;) consummated the issuance and sale of $1,000,000,000 aggregate principal amount of its 4.421% Notes due 2026 (the &ldquo;2026 Notes&rdquo;), $1,500,000,000 aggregate principal amount of its 4.000% Notes due 2028 (the &ldquo;2028 Notes&rdquo;), $500,000,000 aggregate principal amount of its 4.150% Notes due 2030 (the &ldquo;2030 Notes&rdquo;), $1,000,000,000 aggregate principal amount of its 4.300% Notes due 2033 (the &ldquo;2033 Notes&rdquo;) and $1,250,000,000 aggregate principal amount of its 4.850% Notes due 2053 (the &ldquo;2053 Notes&rdquo; and, together with the 2026 Notes, the 2028 Notes, the 2030 Notes and the 2033 Notes, the &ldquo;Notes&rdquo;), pursuant to an underwriting agreement (the &ldquo;Underwriting Agreement&rdquo;) dated May 8, 2023 among Apple and Goldman Sachs & Co. LLC, Barclays Capital Inc. and J.P. Morgan Securities LLC, as representatives of the several underwriters named therein. The Notes are being issued pursuant to an indenture, dated as of October 28, 2021 (the &ldquo;Indenture&rdquo;), between Apple and The Bank of New York Mellon Trust Company, N.A., as trustee, together with the officer&rsquo;s certificate, dated May 10, 2023 (the &ldquo;Officer&rsquo;s Certificate&rdquo;), issued pursuant to the Indenture establishing the terms of each series of Notes. The Notes are being issued pursuant to Apple&rsquo;s Registration Statement on Form S-3 filed with the Securities and Exchange Commission and dated October 28, 2021 (Reg. No. 333-260578) (the &ldquo;Registration Statement&rdquo;). Interest on the 2026 Notes will be paid semi-annually in arrears on May 8 and November 8 of each year, beginning on November 8, 2023. Interest on the 2028 Notes, the 2030 Notes, the 2033 Notes and the 2053 Notes will be paid semi-annually in arrears on May 10 and November 10 of each year, beginning on November 10, 2023. The 2026 Notes will mature on May 8, 2026. The 2028 Notes will mature on May 10, 2028. The 2030 Notes will mature on May 10, 2030. The 2033 Notes will mature on May 10, 2033. The 2053 Notes will mature on May 10, 2053. The Notes will be Apple&rsquo;s senior unsecured obligations and will rank equally with Apple&rsquo;s other unsecured and unsubordinated debt from time to time outstanding. The foregoing description of the Notes and related agreements is qualified in its entirety by the terms of the Underwriting Agreement, the Indenture and the Officer&rsquo;s Certificate (including the forms of the Notes). Apple is furnishing the Underwriting Agreement and the Officer&rsquo;s Certificate (including the forms of the Notes) attached hereto as Exhibits 1.1 and 4.1 through 4.6, respectively, and they are incorporated herein by reference. The Indenture is filed as Exhibit 4.1 to the Registration Statement. An opinion regarding the legality of the Notes is filed as Exhibit 5.1, and is incorporated by reference into the Registration Statement; and a consent relating to the incorporation of such opinion is incorporated by reference into the Registration Statement and is filed as Exhibit 23.1 by reference to its inclusion within Exhibit 5.1.
2023-05-11 08:35:09	HYTX	PharmaCyte Biotech Announces Cash Tender Offer For Up To 7.75M Shares At $3.25 Per Share	Concurrently, the Company Announces $35 Million Financing of Convertible Preferred Stock at $4.00 per Share PharmaCyte Biotech, Inc. (NASDAQ: HYTX ) (&quot;PharmaCyte&quot; or the &quot;Company&quot;) today announces a cash tender offer for up to 7,750,000 shares at $3.25 per share, less any applicable withholding taxes and without interest. The Company also announces that it has completed a private placement financing of convertible redeemable preferred stock and warrants from existing investors, raising gross proceeds of approximately $35 million in a private placement financing of convertible redeemable preferred stock and warrants from existing investors. Tender Offer The Company intends to commence the tender offer today, May 11, 2023. The tender offer is scheduled to expire at 11:59 p.m., New York City time, on June 9, 2023, unless extended or earlier terminated (the &quot;expiration date&quot;). The purchase of common stock in connection with the tender offer will be funded entirely through the Company's cash on hand. Stockholders must validly tender and not validly withdraw their common stock before the expiration date to be eligible to participate in the tender offer. Tendered shares of common stock may only be withdrawn on or before the expiration date. The tender offer will be subject to various terms and conditions as will be described in the Offer to Purchase. The Depositary for the tender offer will be American Stock Transfer & Trust Company, LLC, and the Information Agent for the tender offer will be D.F. King & Co., Inc. None of the Company or its Board of Directors, the Information Agent for the tender offer, or the Depositary for the tender offer will make any recommendation to shareholders as to whether to tender or refrain from tendering their shares in the tender offer. Shareholders must make their own decision as to how many shares they will tender, if any. Shareholders should consult their financial and tax advisors in making this decision. PharmaCyte's CEO Josh Silverman commented, &quot;We continue to evaluate our current assets, which are intended to address a highly unmet medical need in pancreatic cancer. However, given that we are unable at this time to provide shareholders with a definitive timeframe on when we expect to have completed that evaluation or to predict what steps we will take following our evaluation, we believe it is in the best interest of both the Company and its shareholders to provide the opportunity for existing, and in some cases long-time, shareholders to move on, while still allowing those dedicated to the Company to remain for what may be a very long process until regulatory approval of any commercial asset. Based on our current cash position, in-house assets, and a simultaneous search for additional assets that we believe would be accretive to the Company, we believe our current strategy and activities have the highest potential to maximize shareholder value. Our financing helps to maintain our very favorable cash position, and we are grateful to all of our shareholders, regardless of their actions around this tender offer, for their loyalty and patience in this continued time of transition for the Company. We look forward to the time when we are able to provide more specific updates regarding Cell-in-a-Box or a potential strategic acquisition.&quot; The tender offer described in this press release has not yet commenced. This press release is for information purposes only, and is not an offer to purchase or the solicitation of an offer to sell any shares of PharmaCyte common stock. The solicitation of offers to purchase shares of PharmaCyte common stock will be made only pursuant to the tender offer documents, including an Offer to Purchase and related Letter of Transmittal, that the Company intends to distribute to shareholders and file as part of a tender offer statement on Schedule TO with the U.S. Securities and Exchange Commission (the &quot;SEC&quot;), today, May 11, 2023.
2023-05-11 08:37:15	IATL	Neptune Wellness Solutions Inc. Announces Pricing Of $4M Public Offering Of 12,121,212 Shares Of Common Stock At A Price Of $0.33/Share And Accompanying Warrant	Neptune Wellness Solutions Inc. (&quot;Neptune&quot; or the &quot;Company&quot;) (NASDAQ: IATL ), a consumer-packaged goods company focused on plant-based, sustainable and purpose-driven lifestyle brands, today announced the pricing of its public offering of 12,121,212 of its common shares (or common share equivalents in lieu thereof) and accompanying warrants to purchase up to an aggregate of 12,121,212 common shares at a combined public offering price of US$0.33 per share and accompanying warrant, resulting in gross proceeds of approximately US$4 million. The warrants have an exercise price of US$0.33 per share, are immediately exercisable upon issuance and will expire five years following the date of issuance.
2023-05-11 11:45:36	MAF	Why Solo Brands Shares Are Plunging Today	Direct-to-consumer (MAF) platform Solo Brands Inc (NYSE: MAF ) stock is plunging Thursday following the offering of shares by selling stockholders. Certain selling stockholders intend to offer 11.30 million shares of Class A common stock via an underwritten public offering. They also plan to grant the underwriters a 30-day option to purchase up to an additional 1.69 million shares. Acquisition : In another development, MAF has acquired TerraFlame, a company that aims to create warm, inviting and ambient spaces around clean burning flame. The financial terms of the transaction were not disclosed. Solo Brands launched 15 new products in 2022, including the Solo Stove Mesa table top fire pit and Pi pizza oven. &quot;This strategic acquisition complements our brands, and, alongside Solo Stove, allows us to offer our customers the fire burning experience outdoors, and with the addition of TerraFlame, we're thrilled to bring the fire inside,&rdquo; said CEO John Merris. TerraFlame's team, including CEO Lenny Vainberg, who will be appointed TerraFlame General Manager, will become part of the Solo Brands team. Solo Brands held $25.7 million in cash and equivalents as of March 31, 2023. Price Action : MAF shares are trading lower by 17.08% at $5.73 on the last check Thursday.
2023-05-11 13:30:21	ZV	Why Bloom Energy Shares Are Falling Today	Bloom Energy Corp (NYSE: ZV ) plans an offering of $500 million of green convertible senior notes due 2028 in a private offering. Bloom Energy also expects to grant the initial purchasers of the notes an option to purchase an additional $75 million principal amount of notes. The notes will be senior, unsecured obligations of Bloom Energy, will accrue interest payable semi-annually in arrears and will mature on June 1, 2028. The company intends to use a portion of the net proceeds from the offering of the notes to fund the cost of entering into the capped call transactions. It will also use a portion of the net proceeds to redeem the $57.6 million of its 10.25% Senior Secured Notes due 2027 and for general corporate purposes. Bloom Energy reported mixed first-quarter results recently, with bottom-line miss and revenue exceeding expectations. Price Action : ZV shares are trading lower by 14% at $12.99 on the last check Thursday.
2023-05-11 16:35:07	AXJA	ANI Pharmaceuticals Announces Proposed Public Offering Of Common Stock; No Size Or Amount Disclosed	ANI Pharmaceuticals, Inc. (NASDAQ: AXJA ) (&quot;ANI&quot;) today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. All of the shares to be sold in the offering will be offered by ANI. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. In addition, ANI intends to grant the underwriters a 30-day option to purchase up to an additional 15% of shares of its common stock offered in the public offering. Guggenheim Securities, LLC is acting as book-running manager. ANI anticipates using the net proceeds from the offering to in-license, acquire or invest in additional businesses, technologies, products or assets, to fund its commercialization efforts, including, but not limited to, sales and marketing and consulting expenses related thereto, and for general corporate purposes. As part of its business, ANI actively monitors and considers various business development opportunities.
2023-05-12 08:13:00	LKXK	Sunshine Biopharma Announces Pricing Of $5M Private Placement Priced At-the-Market	Sunshine Biopharma Inc. (NASDAQ: &quot;LKXK&quot;), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals, today announced that it entered into a securities purchase agreement with a single healthcare-focused institutional investor for aggregate gross proceeds of approximately $5 million, before deducting fees to the placement agent and other offering expenses payable by the Company. In connection with the offering, the Company will issue 5,952,381 units and pre-funded units at a purchase price of $0.84 per unit (or $0.001 less per pre-funded unit), priced at-the-market under Nasdaq rules. Each unit or pre-funded unit consists of one share of common stock (or common stock equivalent) and two non-tradable warrants each exercisable for $0.59 for one share of common stock (for a total of 11,904,762 shares underlying the warrants). The warrants have a term of five and a half years from the issuance date. No actual units will be issued in the offering. The offering is expected to close on or about May 16, 2023, subject to the satisfaction of customary closing conditions.
2023-05-12 11:07:52	YWFG	What's Going On With Guardforce AI Shares Today	Guardforce AI Co., Limited (NASDAQ: YWFG ) shares are trading higher Friday morning. Guardforce AI priced the public offering of 2.58 million ordinary shares, at $4.65 a piece, on May 10, for aggregate gross proceeds of approximately $12.0 million. Following the announcement, shares plummeted nearly 31% on May 11. The company has granted the underwriters a 45-day option to purchase up to an additional 387,090 ordinary shares at the public offering price per share. Guardforce's offering is expected to close on May 15, 2023. Related : Guardforce AI Stock Is Tanking After Hours: What's Going On? Guardforce is an integrated security provider specializing in secured logistics, AI and Robot-as-a-Service (RaaS). The stock has soared in recent months amid a surge in the popularity of AI-related names. Price Action: YWFG shares traded higher by 4.81% at $5.23 on the last check Friday.
2023-05-12 12:35:04	OTPB	Upexi Raises $7M Via Equity Offering	Upexi Inc (NASDAQ: OTPB ) has entered into definitive agreements with institutional and accredited investors for the purchase and sale of 2.1 million shares at $3.30 per share. The offer price represents a 24% discount to the closing price as of May 11. The shares are being sold under a registered direct offering for gross proceeds of approximately $7 million. The closing of the offering is expected to occur on or about May 16, 2023. Also Read : Upexi's Tytan Tiles Toy Brand Inks Licensing Agreement With Walt Disney Price Action : OTPB shares are trading lower by 16.8% at $3.60 on the last check Friday.
2023-05-15 07:50:06	IQNB	Ikena Oncology Raises $40M Via Secondary Stock Offering Of 6.11M Shares At $6.55 Per Share	Ikena Oncology, Inc. (NASDAQ: IQNB , &quot, Ikena&quot, , &quot, Company&quot, ))))), a targeted oncology company forging new territory in patient-directed cancer treatment, announced today the pricing of an underwritten offering of 6,110,000 shares of common stock (the &quot;Shares&quot;) at an offering price of $6.55 per share. The gross proceeds to the Company, before deducting the underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $40 million. The offering is expected to close on or about May 17, 2023, subject to satisfaction of customary closing conditions. The Company anticipates the net proceeds of the offering, together with existing cash, cash equivalents and investments, to further its ongoing clinical development of targeted oncology programs and advance them to clinical data read outs beyond the initial data for the monotherapy portion of the ongoing IK-930 Phase 1 clinical trial in the fourth quarter of 2023 and initial clinical data for IK-595, in addition to working capital, capital expenditures and other general corporate purposes. The financing was co-led by a new healthcare dedicated investor and included additional new investors, Acuta Capital Partners, Adage Capital, and Vestal Point Capital, as well as participation from existing investors.
2023-05-15 08:29:20	CPSI	Super League Announces $23.8M Private Placement To Fund Growth Initiatives	Super League Gaming (NASDAQ: CPSI ), a leading publisher and creator of immersive experiences across the world's largest metaverse gaming platforms, announced today that it has consummated two private financings of convertible preferred stock, priced at the market under Nasdaq rules, with the final closing expected to occur later this week. The Company received aggregate gross proceeds of approximately $23.8 million in these financings from November 2022 through May 2023, before deducting placement agent fees and other offering expenses payable by the Company. The capital was raised from both existing and new investors and was used to extinguish the Company's debt and fund ongoing operations and growth initiatives. &quot;Completing this financing was vital to support Super League's long-term growth strategy. We significantly enhanced our balance sheet, while obtaining the necessary capital to fund operations and fuel our near-term growth initiatives,&quot; said Ann Hand, CEO of Super League. &quot;We believe this is also a testament to the strength of our team, our strategic vision and confidence in our ability to execute.&quot; As a part of the private placement offering, the Company issued newly designated Convertible Preferred Stock (the &quot;Preferred Stock&quot;). Each share of Preferred Stock was sold at $1,000 per share and is convertible into shares of common stock, subject to certain beneficial ownership limitations. Other material terms of the Preferred Stock financing, including the registration rights granted to investors, are described in the Company's Current Reports on Form 8-K filings made with the Securities and Exchange Commission to date and following the date above. SternAegis Ventures acted as the exclusive placement agent for this offering. Participants in the offering include existing investors, new investors, and affiliates of the placement agent. The securities described above have not been registered under the Securities Act of 1933, as amended, and may not be resold in the United States except pursuant to an effective registration statement with the Securities and Exchange Commission or an exemption from registration under the Securities Act and any applicable state securities laws. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or other jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.
2023-05-15 10:57:48	JUCA	Eos Energy Enterprises Raises $8M Via Equity Offering	Eos Energy Enterprises Inc (NASDAQ: JUCA ) has entered into a definitive agreement for the purchase and sale of an aggregate of 3.6 million of its shares at $2.221 per share. The company has also agreed to issue unregistered warrants in a concurrent private placement to purchase up to an aggregate of 3.6 million shares. The warrants will have an exercise price of $2.50 per share, become exercisable no later than July 15, 2023, and will expire five years from the initial exercisability date. The closing of the offering is expected to occur on or about May 17, 2023. The company expects gross proceeds to be about $8 million. Eos Energy intends to use the net proceeds as working capital as it awaits a determination from the DOE's loan program office on its loan application. Price Action : JUCA shares are trading lower by 5.53% at $2.30 on the last check Monday.
2023-05-15 12:55:02	UXGS	Why Are InspireMD Shares Surging Today	InspireMD Inc. (NASDAQ: UXGS ) shares are surging Monday after the company said it had inked a pact with healthcare-focused institutional investors that have agreed to provide up to $113.6 million in gross proceeds through a private placement . &quot;Advancing our growing product pipeline, including our new CGuard Prime Transfemoral (CAS) delivery system along with our SwitchGuard trans carotid (TCAR) neuroprotection system (NPS), positions our company to serve the entire carotid revascularization market, continuing our mission of delivering implant focused patient outcomes,&quot; said CEO Marvin Slosman. The financing is being led by Marshall Wace with participation from OrbiMed, Rosalind, Nantahala, Soleus, Velan and certain InspireMD Board members. The net proceeds from the private placement will be used to expand manufacturing capabilities and new product launches, including CGuard Prime and SwitchGuard in the U.S. and the EU, as well as for working capital and other general corporate purposes. The deal includes initial upfront funding of $42.2 million with up to an additional $71.4 million tied to the exercise of milestone-driven warrants. Under the private placement, the company has agreed to issue an aggregate of 25.83 million shares of common stock (or prepaid warrants). The company will also issue four series of unregistered warrants to purchase an aggregate of 51.66 million shares of common stock for a purchase price of $1.6327 per share. The company is scheduled to release its first-quarter FY23 results on May 16, 2023. Price Action: UXGS shares are up by 20% to $1.74 in the trading session on the last check Monday.
2023-05-15 16:28:22	QKJF	Coherus Announces $50M Proposed Public Offering Of Common Stock	Coherus BioSciences, Inc. ((&quot;Coherus&quot;, NASDAQ: QKJF ), today announced that it has commenced an underwritten public offering of $50.0 million of shares of its common stock. In addition, Coherus expects to grant the underwriters a 30-day option to purchase up to an additional $7.5 million of shares of its common stock at the public offering price, less the underwriting discount. All of the shares of common stock to be sold in the offering will be offered by Coherus. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the proposed offering may be completed, or as to the actual size or terms of the proposed offering.
2023-05-15 17:16:08	CFB	Why Agilon Health Shares Are Sliding After Hours	Agilon Health Inc (NYSE: CFB ) shares are moving lower in Monday's after-hours session after the company announced a secondary offering . What Happened: Agilon plans to offer 70 million shares of its common stock in a secondary public offering from selling stockholder CD&R Vector Holdings, L.P. The selling stockholder expects to grant the underwriters a 30-day option to purchase up to an additional 10.5 million shares. In addition to the offering, Agilon said it intends to purchase approximately $200 million of common stock from the underwriters at the same price per share of the offering. The company said it will fund the purchase with cash on hand. Agilon Health aims to empower physicians to transform health care by accelerating physicians transition to a value-based model of care for senior patients. See Also: Capital One Stock Is Rising After Warren Buffett's Berkshire Hathaway Shuffled Bank Holdings: The Details CFB Price Action: Agilon shares were down 7.43% after hours at $22.04 at the time of writing, according to Benzinga Pro . Photo: Julio C&eacute;sar Vel&aacute;squez Mej&iacute;a from Pixabay.
2023-05-16 04:57:29	CFB	Agilon Health Earlier Priced 86.88M Share Offer @$21.50/Share	gilon health, inc. (NYSE: CFB ) (&quot;agilon health&quot;), the trusted partner empowering physicians to transform health care in our communities, today announced the pricing of its previously announced underwritten secondary public offering of 86,884,353 shares of its common stock by the selling stockholders, at a public offering price of $21.50 per share. Certain selling stockholders have granted the underwriters a 30-day option to purchase up to an additional 7,726,955 shares of agilon health's common stock. This reflects an upsizing of the previously announced offering of 70,000,000 shares and 10,500,000 option shares granted to the underwriters. agilon health will not receive any proceeds from the secondary offering. The offering is expected to close on May 18, 2023, subject to customary closing conditions.
2023-05-16 08:11:00	AMLY	Sovos Brands Announces Pricing Of Secondary Public Offering Of 10M Shares OF Common Stock At A Price Of $17.50/Share By Selling Stockholders	Sovos Brands, Inc. (&quot;Sovos Brands&quot; or the &quot;Company&quot;) (NASDAQ: AMLY ), one of the fastest growing food companies of scale in the United States, announced today the pricing of an underwritten secondary public offering by certain stockholders of Sovos Brands (the &quot;Selling Stockholders&quot;) of 10,000,000 shares of Sovos Brands' common stock, par value $0.001 per share (the &quot;Common Stock&quot;), at a price to the public of $17.50 per share. The offering is expected to close on May 17, 2023, subject to the satisfaction of customary closing conditions. The offering consists entirely of secondary shares to be sold by the Selling Stockholders. The Selling Stockholders will receive all of the proceeds from the offering. The Company is not selling any shares of Common Stock in the offering and will not receive any proceeds from the offering. In addition, the Selling Stockholders have granted the underwriters a 30-day option to purchase up to an additional 1,500,000 shares of Common Stock at the public offering price, less underwriting discounts and commissions. Goldman Sachs & Co. LLC and J.P. Morgan are acting as underwriters of the Offering. The underwriters intend to offer the shares of Common Stock to the public at a fixed price, which may be changed at any time without notice.
2023-05-16 08:36:43	IWNA	Modular Medical Announces Pricing of Upsized $9.4M Public Offering	Modular Medical, Inc. (the &quot;Company&quot; or &quot;Modular Medical&quot;) (NASDAQ: IWNA ), a development stage insulin delivery technology company seeking to launch the next generation of easy to use and affordable insulin pump technology, today announced the pricing of an upsized underwritten public offering of 8,816,900 shares of its common stock and warrants to purchase 4,408,450 shares of its common stock. The securities are being sold as a unit, with each unit comprising two shares of common stock and one warrant to purchase one share of common stock. The units are being sold at a combined price to the public of $2.13 per unit, yielding an effective price of $1.06 per share and $0.01 per warrant. The warrants will be exercisable at $1.22 per share and will expire five years from the date of issuance. The Company has granted the underwriter a 30-day option to purchase up to an additional 1,322,534 shares and an additional 661,267 warrants to cover over-allotments, if any.
2023-05-16 08:48:27	SGTM	Acurx Pharmaceuticals, Inc. Announces Pricing Of $4M Registered Direct Offering	Acurx Pharmaceuticals, Inc. (NASDAQ: SGTM ) (&quot;Acurx&quot; or the &quot;Company&quot;), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, today announced that it has entered into a securities purchase agreement with a single institutional investor to purchase 1,333,333 shares of its common stock (or pre-funded warrants in lieu thereof) at a combined effective purchase price of $3.00 per share (or pre-funded warrant) in a registered direct offering. In a concurrent private placement, the Company has also agreed to issue and sell to the investor unregistered Series C warrants to purchase up to an aggregate of 1,333,333 shares of common stock and unregistered Series D warrants to purchase up to an aggregate of 1,333,333 shares of common stock. The offering is expected to close on or about May 18, 2023, subject to the satisfaction of customary closing conditions. Maxim Group LLC is acting as the sole placement agent for the offering. Each series of warrants will have an exercise price of $3.26 per share and become exercisable six months from the date of issuance. The Series C warrants have a term of two and one-half years from the date of issuance and the Series D warrants have a term of six and one-half years from the date of issuance. The gross proceeds to the Company from the registered direct offering and the concurrent private placement are estimated to be approximately $4.0 million before deducting the placement agent's fees and other estimated offering expenses.
2023-05-16 09:38:40	SLTB	Harbor Custom Development, Inc. Announces Pricing Of $10M Public Offering Of 1,951,218 Shares Of Its Common Stock And warrants, At A Combined Public Offering Price Of $5.125/Share And Accompanying Warrant	Harbor Custom Development, Inc. (NASDAQ: SLTB , HCDIP, HCDIW, HCDIZ))))) (&quot;Harbor,&quot; &quot;Harbor Custom Homes&reg;,&quot; or the &quot;Company&quot;), a real estate company involved in all aspects of the land development cycle, today announced the pricing of a public offering of an aggregate of 1,951,218 shares of its common stock (or pre-funded warrants in lieu thereof) and warrants to purchase 1,951,218 shares of common stock, at a combined public offering price of $5.125 per share (or pre-funded warrant in lieu thereof) and accompanying warrant. The warrants will have an exercise price of $5.00 per share, will be exercisable immediately upon issuance, and will expire five years from the date of issuance. The closing of the offering is expected to occur on or about May 18, 2023, subject to the satisfaction of customary closing conditions. L.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. The gross proceeds to the Company from this offering are expected to be approximately $10 million before deducting the placement agent's fees and other offering expenses payable by the Company. The Company intends to use the net proceeds from this offering for real estate entitlements, and real estate construction and development; payment toward the balance of our loan with BankUnited N.A. (&quot;BankUnited&quot;), and working capital and general corporate purposes.
2023-05-16 11:56:39	FNMK	Why Singing Machine Shares Are Surging Today	The Singing Machine Company Inc (NASDAQ: FNMK ) said it has terminated its at-the-market (ATM) equity program . The company elected to terminate because it had achieved its objective of raising capital under the ATM. Through the ATM, the company sold approximately 1.1 million shares and raised about $1.74 million in gross proceeds, or approximately $1.64 per share. &quot;The Company successfully met its goal of bolstering its balance sheet without issuing warrants or providing a discount to market,&quot; said CEO Gary Atkinson. &quot;The proceeds from the ATM will provide the Company with access to working capital while we continue to execute on the business and deliver a best-in-class karaoke experience to over a million households throughout the world.&quot; Price Action : FNMK shares are trading higher by 57.5% at $1.66 on the last check Tuesday.
2023-05-16 13:52:18	BWNY	OncoSec Announces $1.33M Registered Direct Offering Priced At-The-Market Under Nasdaq Rules	OncoSec Medical Incorporated (NASDAQ: BWNY ) (the &quot;Company&quot; or &quot;OncoSec&quot;), a clinical-stage biotechnology company developing intratumoral immunotherapies to stimulate the patient's immune system to target cancer cells and eradicate disease, today announced that it has entered into a definitive agreement for the purchase and sale of an aggregate of 1,408,384 shares of its common stock (or common stock equivalents in lieu thereof), at a purchase price of $0.945 per share (or common stock equivalent in lieu thereof), in a registered direct offering priced at-the-market under Nasdaq rules. The Company has also agreed to issue in a concurrent private placement unregistered warrants to purchase up to an aggregate of 1,408,384 shares of common stock. The warrants will have an exercise price of $0.82 per share, are immediately exercisable upon issuance, and will expire five and one-half years from the date of issuance. The closing of the offering is expected to occur on or about May 18, 2023, subject to the satisfaction of customary closing conditions. L.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. The gross proceeds to the Company from the offering are expected to be approximately $1.33 million, before deducting the placement agent's fees and other offering expenses payable by the Company. The Company intends to use the net proceeds from this offering as working capital for general corporate purposes.
2023-05-16 16:17:17	NZZW	New York Community Bancorp Reports Secondary Offering Of Common Stock By The Federal Deposit Insurance Corporation	New York Community Bancorp announced that the Federal Deposit Insurance Corporation, as receiver for Signature Bridge Bank, National Association (the &quot;FDIC Receiver&quot;), has agreed to sell, in an underwritten public offering, 39,032,006 shares of the company's common stock owned by the FDIC Receiver. Prior to the proposed offering, the FDIC Receiver owned 39,032,006 shares of common stock, which it acquired pursuant to an Equity Appreciation Instrument issued to the FDIC Receiver by the Company as part of the consideration for the purchase and assumption of certain assets and liabilities of Signature Bridge Bank, National Association.
2023-05-16 16:32:24	XPM	OneSpaWorld Announces Launch Of Proposed Secondary Offering Of 8M Common Shares By Selling Shareholders	OneSpaWorld Holdings Limited (NASDAQ: XPM ) (&quot;OneSpaWorld&quot; or the &quot;Company&quot;), the preeminent global provider of health and wellness services and products onboard cruise ships and in destination resorts around the world, today announced the commencement of a proposed underwritten secondary offering of 8,000,000 common shares of the Company. OneSpaWorld is conducting a resale of common shares on behalf of Steiner Leisure Limited and a director of the Company (together, the &quot;Selling Shareholders&quot;). Steiner Leisure Limited is expected to grant the underwriters a 30-day option to purchase up to an additional 1,200,000 common shares at the public offering price, less underwriting discounts and commissions. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. The Selling Shareholders will receive all of the net proceeds from the sale of common shares in the offering. The Company will not receive any proceeds from the offering. William Blair, Stifel and TD Cowen are acting as the joint booking-running managers for the offering.
2023-05-16 16:34:29	XCVV	Intapp Announces Proposed Public Offering Of 2M Shares Of Common Stock; Certain Selling Stockholders Also Intend To Offer 4.25M Shares Of The Co's Common Stock In The Offering	Intapp, Inc. (NASDAQ: XCVV ) (the &quot;Company&quot;), a leading provider of cloud software for the global professional and financial services industry, today announced that it intends to offer and sell 2,000,000 shares of the Company's common stock in an underwritten public offering (the &quot;Offering&quot;). Certain selling stockholders also intend to offer 4,250,000 shares of the Company's common stock in the Offering. In addition, certain of the selling stockholders are expected to grant the underwriters an option for a period of 30 days to purchase up to an additional 15% of the total number of shares of common stock to be offered in the Offering on the same terms and conditions, less the underwriting discount. The Offering is subject to market and other conditions, and there can be no assurance as to whether or when the Offering may be completed. The Company intends to use the net proceeds of the Offering for working capital and general corporate purposes. The Company will not receive any proceeds from the sale of shares by the selling stockholders. BofA Securities and Barclays are acting as the joint lead book-running managers for the Offering. The securities described above are being offered by the Company and the selling stockholders pursuant to an effective shelf registration statement on file with the Securities and Exchange Commission (the &quot;SEC&quot;).
2023-05-16 16:40:22	CO	Everest Re Group, Ltd. Announces Public Offering Of 3M Shares Of Common Stock	Everest Re Group, Ltd. (NYSE: CO ) (the &quot;Company&quot; or &quot;Everest&quot;) announced today that it has commenced an underwritten public offering of 3,000,000 common shares. The underwriters will have the option to purchase up to an aggregate of 450,000 additional common shares from the Company. The Company intends to use the net proceeds from this offering for general corporate purposes, which may include expanding its existing business lines and operations. Citigroup Global Markets Inc. and Goldman Sachs & Co. LLC are acting as joint book-running managers.
2023-05-16 17:00:34	DHEM	Maxeon Solar Technologies Reports Launch Of Public Offering Of Aggregate Of 6.80M Ordinary Shares	Maxeon is offering 5,100,000 ordinary shares, and an affiliate of TotalEnergies MX, which currently holds approximately 24.2% of Maxeon's outstanding ordinary shares, is offering 1,700,000 ordinary shares of Maxeon. TotalEnergies also intends to grant the underwriters an option, exercisable for 30 days after the date of the final prospectus supplement, to purchase additional ordinary shares in an amount equal to up to 15% of the ordinary shares offered in the Offering on the same terms and conditions. Maxeon intends to use the net proceeds from the Company Offering and the TZE Private Placement for capital expenditures for the addition of incremental capacity for the manufacture of Maxeon 7 products, as well as general corporate purposes.
2023-05-17 08:28:10	HBKI	EVgo Stock Is Tumbling: What's Going On?	EVgo Inc (NASDAQ: HBKI ) shares are trading lower Wednesday after the EV charging company announced an offering . What Happened: EVgo commenced a $125 million underwritten public offering . The company will grant the underwriters a 30-day option to purchase up to an additional $18.75 million in common stock at the offering price. EVgo said it expects to use the proceeds for general corporate purposes. On Wednesday morning, Stifel analyst Stephen Gengaro initiated coverage on EVgo with a Buy rating and set a price target of $9. See Also: US Stocks Poised To Open Higher, With Housing Data, More Retail Earnings In Sight HBKI Price Action: EVgo has a 52-week high of $12.64 and a 52-week low of $3.64. The stock was down 10.1% at $5.15 at the time of writing, according to Benzinga Pro . Photo: courtesy of EVgo.
2023-05-17 08:41:55	DHEM	Maxeon Solar Technologies Announces Pricing And Upsize Of $157.4M Public Offering Of 7.49M Shares Of Ordinary Stock At A Price Of $28/Share	Maxeon Solar Technologies, Ltd. (&quot;Maxeon&quot;) (NASDAQ: DHEM ) today announced the pricing of an underwritten public offering of an aggregate of 7,490,000 ordinary shares, including 5,620,000 ordinary shares offered by Maxeon (the &quot;Company Offering&quot;) and 1,870,000 ordinary shares offered by an affiliate of TotalEnergies MX (&quot;TotalEnergies&quot;) (the &quot;TotalEnergies Offering&quot; and, together with the Company Offering, the &quot;Offering&quot;), each at a price of $28.00 per share. The Offering was upsized from the previously announced offering size of an aggregate of 6,800,000 ordinary shares, which included 5,100,000 ordinary shares offered by the Company and 1,700,000 ordinary shares offered by TotalEnergies. TotalEnergies also granted the underwriters a 30-day option to purchase up to an additional 1,123,500 ordinary shares in the public offering on the same terms and conditions. Maxeon expects to receive gross proceeds from the Company Offering of approximately $157.4 million, which is prior to underwriting discounts and commissions and estimated offering expenses. Maxeon will not receive any proceeds from the TotalEnergies Offering. The Offering is expected to close on May 19, 2023, subject to customary closing conditions. In addition, pursuant to a share purchase agreement, dated May 16, 2023, with an affiliate of TCL Zhonghuan Renewable Energy Technology Co., Ltd. (&quot;TZE SG&quot;) that currently holds approximately 23.7% of Maxeon's outstanding ordinary shares, Maxeon has agreed to sell to TZE SG, in a private placement exempt from the registration requirements of the Securities Act of 1933, and at a sale price equal to the price to the public in the Offering, 1,500,000 ordinary shares of Maxeon (the &quot;TZE Private Placement&quot;), for a total investment of $42.0 million. It is anticipated that, as a result of the TZE Private Placement, the Offering will not materially dilute TZE SG's current level of equity ownership or alter its governance rights in Maxeon. Maxeon intends to use the net proceeds that it will receive from the Company Offering and the TZE Private Placement for capital expenditures for the addition of incremental capacity for the manufacture of Maxeon 7 products, as well as general corporate purposes.
2023-05-17 08:50:53	YZYC	Tecnoglass Announces Pricing Of Secondary Offering Of 2M Ordinary Shares By Energy Holding Corporation At A Price Of $43/Share	Tecnoglass Inc. (NYSE: YZYC ) (&quot;Tecnoglass&quot; or the &quot;Company&quot;) ,today announced the pricing of the previously announced underwritten public offering by Energy Holding Corporation (&quot;Selling Stockholder&quot;) of an aggregate of 2,000,000 ordinary shares of Tecnoglass at the public offering price of $43.00 per share. In addition, the Selling Stockholder has granted the underwriters a 30-day option to purchase up to an additional 300,000 ordinary shares. All of the ordinary shares to be sold in the proposed offering are being offered by the Selling Stockholder. The Company will not receive any proceeds from the sale of the ordinary shares being offered by the Selling Stockholder. Baird, Raymond James and Stifel are acting as lead joint book-running managers for the offering. B. Riley Securities and D.A. Davidson & Co. are acting as co-managers for this offering.
2023-05-17 12:15:32	YZYC	Why Tecnoglass Shares Are Sliding Today	Tecnoglass Inc (NYSE: YZYC ) has priced the previously announced underwritten public offering by Energy Holding Corporation of 2 million shares at $43 per share. The offer price represents an 8% discount to the company&rsquo;s closing price on May 16, 2023. In addition, the Selling Stockholder has granted the underwriters a 30-day option to purchase up to an additional 300,000 shares. Since all the shares to be sold in the proposed offering are being offered by the selling stockholder, the company will not receive any proceeds. Baird, Raymond James and Stifel are acting as lead joint book-running managers for the offering. Price Action : YZYC shares are trading lower by 8.30% at $42.88 on the last check Wednesday.
2023-05-17 13:05:16	TRCX	Eagle Bulk Shipping Upsizes & Extends Credit Facility	Eagle Bulk Shipping Inc (NYSE: TRCX ) has entered into an amended and restated credit agreement providing an increased borrowing capacity of $175 million. The agreement will also provide margin reduction and an extension in maturity by two years. The senior secured amended credit facility totals $485 million, comprised of a $300 million term loan and a $185 million revolving credit facility. It bears an interest rate of Adjusted Term SOFR plus a margin of between 2.05% and 2.75%. The term loan will continue to amortize at a rate of $12.5 million per quarter, while starting in September, the availability under the revolving credit facility will reduce at a rate of $5.5 million per quarter. The Facility will mature on September 28, 2028. As of today, $260 million remains available under the Facility, $75 million under the term loan, and $185 million under the revolving credit facility. Price Action : TRCX shares are trading higher by 2.12% at $43.26 on the last check Wednesday.
2023-05-17 16:03:39	YWIX	Cabaletta Bio Announces Proposed Public Offering Of Common Stock; No Size Disclosed	Cabaletta Bio, Inc. (&quot;Cabaletta&quot; or the &quot;Company&quot;) (NASDAQ: YWIX ), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases, announced today that it has commenced an underwritten public offering of its common stock. All of the shares are being offered by Cabaletta. In addition, Cabaletta intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of shares of its common stock offered in the public offering. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. TD Cowen, Evercore ISI and Guggenheim Securities are acting as joint book-running managers for the proposed offering.
2023-05-17 16:05:16	SY	Belpointe SY Announces A New Offering Designed For Broker-Dealers Commencement Of An Offering To Raise Up To $750M	Broker-Dealers Can Now Sign Up To Participate In The Selling Group For Belpointe PREP, LLC (NYSE: SY ) The First Publicly Traded Opportunity Zone Fund. Greenwich, CT, May 17, 2023 (GLOBE NEWSWIRE) -- Belpointe PREP, LLC (NYSE: SY ) (&quot;Belpointe SY&quot; or the &quot;Company&quot;), the first and only publicly traded qualified opportunity fund (&quot;QOF&quot;), is pleased to announce the commencement of an offering to raise up to $750 million. Belpointe SY anticipates using the offering proceeds to invest in a broader range of qualified opportunity zone projects, further diversifying the Company's portfolio and potential returns. This latest offering also affords broker-dealers the opportunity to participate in the selling group, and Belpointe SY has retained Emerson Equity LLC as dealer manager for the offering. Interested broker-dealers may contact Cody Laidlaw at DB@BelpointeOZ.com or call 203-883-1944 for further information. Brandon Lacoff, CEO of Belpointe SY, expressed his excitement about this latest development, stating: &quot;we are thrilled to see this offering get underway. It marks a significant milestone for us, and we believe it comes at a perfect time, as we continue to seek to identify and invest in qualified opportunity zones that we believe have tremendous potential.&quot; He added, &quot;the ability to raise up to $750 million in this offering will provide us with additional resources to capitalize on these opportunities as well as the opportunity to create additional value for our investors. The proceeds from this offering can also help us accelerate our stabilized acquisition model, whereby we are seeking to acquire other QOFs that have stabilized assets.&quot;
2023-05-18 08:09:26	KDSD	Smart for Life Announces $1.58M Registered Direct Offering Priced At-The-Market Under Nasdaq Rules	Smart for Life, Inc. (NASDAQ: KDSD ) (&quot;Smart for Life&quot; or the &quot;Company&quot;), a high growth global leader in the Health & Wellness sector marketing and manufacturing nutritional foods and supplements worldwide, today announced that it has entered into a definitive agreement for the purchase and sale of 584,892 shares of the Company's common stock (or common stock equivalents) at a purchase price of $2.71 per share of common stock in a registered direct offering priced at-the-market under Nasdaq rules. In addition, in a concurrent private placement, the Company will issue unregistered common stock purchase warrants (the &quot;Warrants&quot;). The Warrants to purchase up to 584,892 shares of common stock have an exercise price of $2.59 per share and are immediately exercisable for a period of five and one-half years following issuance. The closing of the registered direct offering and the concurrent private placement is expected to occur on or about May 22, 2023, subject to the satisfaction of customary closing conditions. L.C. Wainwright & Co. is acting as the exclusive placement agent for the offerings. The gross proceeds to the Company from these offerings are expected to be approximately $1.58 million, before deducting the placement agent's fees and other offering expenses payable by the Company. The Company intends to use the net proceeds from these offerings for working capital and other general corporate purposes.
2023-05-18 08:15:46	QFEE	Motus GI Announces $3.5M Private Placement Of 4,142,012 Shares Of Common Stock And Warrant At A Price Of $0.845/Share; The Warrants Will Have An Exercise Price Of $0.72/Share	Motus GI Holdings, Inc. , (NASDAQ: QFEE ) (&quot;Motus GI&quot; or the &quot;Company&quot;), a medical technology company focused on improving endoscopic outcomes and experiences, today announced that it has entered into definitive agreements for the issuance and sale of an aggregate of 4,142,012 shares of its common stock (or common stock equivalent in lieu thereof) and warrants to purchase up to an aggregate of 4,142,012 shares of common stock, at a purchase price of $0.845 per share and accompanying warrant in a private placement priced at-the-market under Nasdaq rules. The private placement is expected to close on or about May 19, 2023, subject to the satisfaction of customary closing conditions. L.C. Wainwright & Co. is acting as the exclusive placement agent for the private placement. The warrants will have an exercise price of $0.72 per share, will be exercisable immediately upon issuance and have a term of five and one-half years from the date of issuance. The gross proceeds to Motus GI from the private placement are expected to be approximately $3.5 million, before deducting the placement agent's fees and other offering expenses payable by the Company. Motus GI currently intends to use the net proceeds from the private placement for working capital and general corporate purposes.
2023-05-18 12:04:25	KDSD	Smart For Life Raises $1.58M Via Equity Offering	Smart For Life Inc (NASDAQ: KDSD ) has entered into a definitive agreement for the purchase and sale of 584,892 shares at $2.71 per share. In addition, in a concurrent private placement, the company will issue unregistered common stock purchase warrants for 584,892 shares. The warrants will have an exercise price of $2.59 per share and are immediately exercisable for a period of five and one-half years following issuance. The closing of the registered direct offering and the concurrent private placement is expected to occur on or about May 22, 2023. The company expects gross proceeds from these offerings to be approximately $1.58 million. The company intends to use the net proceeds from the offerings for working capital and other general corporate purposes. Price Action : KDSD shares are trading lower by 20.30% at $2.67 on the last check Thursday.
2023-05-19 06:33:09	AGAU	Ault Alliance Announces Termination of Exchange Offer	Ault Alliance, Inc announced today that it has terminated the previously announced offer (the &quot; Offer &quot;) to holders of Ault Alliance's outstanding Class A Common Stock (the &quot; Common Stock &quot;) to exchange shares of Common Stock for its 10.00% Series L Cumulative Redeemable Perpetual Preferred Stock (&quot; Series L Preferred Stock &quot;), as a result of notice from the Depositary Trust Company (&quot; MAF &quot;) that due to logistical issues relating to the Company's recently effectuated 300 for one reverse stock split (the &quot; Reverse Stock Split &quot;), MAF would not be able to accept the tenders of Common Stock on a post-Reverse Stock Split basis.
2023-05-19 08:31:45	ZJEL	ReTo Eco-Solutions, Inc. Announces $6.6M Registered Direct Offering Of 2M Shares Of Common Stock At A Price Of $3.30/Share	ReTo Eco-Solutions, Inc. (NASDAQ: ZJEL ) (&quot;ReTo&quot; or the &quot;Company&quot;), a provider of technology solutions and operation services for intelligent ecological environments and roadside assistance services and software development services in China, today announced that it has entered into a securities purchase agreement, dated as of May 18, 2023 (the &quot;Purchase Agreement&quot;) with certain purchasers (collectively, the &quot;Purchasers&quot;) for the sale of an aggregate of 2,000,000 common shares, par value US$0.01 per share, of the Company (the &quot;Shares&quot;), at a purchase price of US$3.30 per Share, or an aggregate purchase price of US$6,600,000 in a registered direct offering (the &quot;Offering&quot;). The Shares are offered by means of the Company's registration statement on Form F-3 (File No. 333-267101), which was initially filed with the Securities and Exchange Commission (the &quot;SEC&quot;) on August 26, 2022, as amended and declared effective on December 9, 2022, the accompanying base prospectus, dated December 6, 2022, and a prospectus supplement, which the Company expects to file with the SEC on May 19, 2023. Electronic copies of the prospectus supplement and the accompanying base prospectus may be obtained, when available, on the SEC's website at http://www.sec.gov and may also be obtained by contacting Angela Hu, at the Company, using her contact information at the end of this press release. This Offering is expected to close on or about May 19, 2023, subject to the satisfaction of customary closing conditions. The Company intends to use the net proceeds from the Offering to fund the growth of its business, primarily working capital, and for general corporate purposes, as well as to acquire or invest in technologies, products and/or businesses that it believes will enhance its value. This press release shall not constitute an offer to sell or a solicitation of an offer to buy any of these Company securities, nor shall there be any sale of these Company securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
2023-05-19 09:35:03	ZTTQZ	Artesian Resources Corporation Announces Pricing Of $34.8M Public Offering Of 695,650 Shares Of Common Stock At A Price Of $50/Share	Artesian Resources Corporation (NASDAQ: ZTTQZ ) (Artesian or the Company) announced today that it has priced a firm commitment underwritten public offering of 695,650 shares of the Company's Class A Non-Voting Common Stock at a purchase price of $50 per share for an aggregate gross offering amount of approximately $34.8 million. The offering is expected to close on or about May 23, 2023, subject to customary closing conditions. The Company has also granted the underwriter a 30-day option to purchase from Artesian up to an additional 104,348 shares of Class A Non-Voting Common Stock at the public offering price, less the underwriting discount. Janney Montgomery Scott LLC is acting as sole book-running manager. Artesian currently intends to use the net proceeds of the offering for general corporate purposes, including its capital investment program and repayment of outstanding indebtedness.
2023-05-22 08:06:27	XUNY	FDA Approves First Redosable Gene Therapy, Krystal Biotech's Treatment For Skin Blistering Disorder	The FDA approved Krystal Biotech Inc's (NASDAQ: XUNY ) Vyjuvek (beremagene geperpavec-svdt) for the treatment of patients six months of age or older with dystrophic epidermolysis bullosa (DEB) . Epidermolysis bullosa cause the skin to be very fragile and to blister easily. Vyjuvek is designed to address the genetic root cause of DEB by delivering functional copies of the human COL7A1 gene to provide wound healing and sustained functional COL7 protein expression with redosing. Vyjuvek is the first-ever redosable gene therapy and the first and only medicine approved by the FDA for DEB, both recessive and dominant, that can be administered by a healthcare professional. Vyjuvek is expected to be available in the U.S. in the third quarter of 2023, and the company will begin the promotion of Vyjuvek immediately. With this approval, the FDA issued the Company a Rare Pediatric Disease Priority Review Voucher, which confers priority review to a subsequent drug application that would not otherwise qualify for priority review. The company anticipates starting the official Marketing Authorization Application procedure in the second half of 2023, with potential approval in 2024. The company is also working with Japan's Pharmaceuticals and Medical Devices Agency to study Vyjuvek and seek approval for a potential launch in 2025. Krystal Biotech announced a private placement of 1.73 million at $92.50 for gross proceeds of approximately $160 million . Price Action: XUNY shares are down 6.31% at $90 on the last check Monday.
2023-05-22 08:21:37	MWBM	Bright Green Announces Pricing Of $3.5M Private Placement To An Institutional Investor To Purchase 3,684,210 Shares Of Common Stock And Warrants At A Purchase Price Of $0.95/Share And Accompanying Warrant	"Bright Green Corporation (NASDAQ: MWBM ) (""Bright Green"" or ""the Company""), one of the very few companies selected by the U.S. government to grow, manufacture, and sell, legally under federal and state laws, cannabis and cannabis-related products for research, pharmaceutical applications and affiliated export, today announced that it has entered into a securities purchase agreement with a single institutional investor to purchase 3,684,210 shares of common stock and warrants to purchase up to 3,684,210 shares of common stock, at a purchase price of $0.95 per share and accompanying warrant. The gross proceeds to the Company from the private placement are expected to be approximately $3.5 million before deducting the placement agent's fees and other estimated offering expenses. The warrants will be immediately exercisable from the date of issuance at an initial exercise price of $0.95 per share, subject to adjustments as set forth therein, and will expire five years from the date of issuance. The closing of the private placement is expected to occur on May 24, 2023, subject to the satisfaction of certain customary closing conditions set forth in the securities purchase agreement. EF Hutton, division of Benchmark Investments, LLC, is acting as the exclusive placement agent for the offering."
2023-05-22 08:34:26	MUO	Daxor Corporation Announces Pricing Of $4M Underwritten Public Offering Of 410,260 Shares Of Its Common Stock At A Price Of $9.75/Share	"DAXOR CORPORATION (NASDAQ: MUO ) (""Daxor"", or the ""Company""), the global leader in blood volume measurement technology, today announced the pricing of its previously announced underwritten public offering of 410,260 shares of its common stock at a public offering price of $9.75 per share. Gross proceeds from the offering are expected to be approximately $4.0 million before deducting underwriting discounts, commissions, and estimated offering expenses. Maxim Group LLC is acting as the sole book-running manager and Joseph Gunnar & Co., LLC is acting as co-manager for the offering. Daxor intends to use the net proceeds from the offering for working capital and other general corporate purposes, including to develop our products, fund capital expenditures, make investments in or acquisitions of other businesses, solutions or technologies or repay a portion of our outstanding borrowings. Daxor has granted the underwriters a 45-day option to purchase up to an additional 61,539 shares of common stock. The offering is expected to close on or about May 24, 2023, subject to the satisfaction of customary closing conditions."
2023-05-22 08:51:53	ZYSE	Volcon, Inc. Announces $9M In Securities Offerings And Pricing Of Previously Announced Public Offering	"Volcon Inc. (NASDAQ: ZYSE ), (""Volcon"" or the ""Company""), the first all-electric, off-road powersports company, today announced the pricing of an underwritten public offering (the ""Offering"") with gross proceeds to the Company expected to be $4.5 million, before deducting underwriting discounts and other estimated expenses payable by the Company. The Offering consists of 6,000,000 shares of common stock at a price of $0.75 per share. In addition, the Company has granted Aegis Capital Corp., the underwriter in the Offering, a 45-day option to purchase up to an additional 900,000 shares of common stock and/or pre-funded warrants at the Offering price, less underwriting discounts and commissions. Gross proceeds of the Offering will be approximately $4.5 million, assuming no exercise of the over-allotment option. The Company intends to use the net proceeds from the Offering for general corporate purposes, including working capital, operating expenses and capital expenditures. The Offering is expected to close on May 24, 2023, subject to customary conditions. Aegis Capital Corp. is acting as the sole book-running manager for the Offering. As previously announced, the Company signed a securities purchase and exchange agreement (the ""Agreement"") on May 19, 2023 to (1) issue an investor approximately $4.9 million original principal amount of nine (9) month convertible senior notes (the ""New Notes"") and accompanying warrants (the ""New Warrants"") to purchase approximately 5.5 million shares of common stock at an exercise price of $1.09 per share expiring August 2027 (such transaction, the ""Placement""); (2) exchange senior convertible notes in principal amount of $27.2 million due February 24, 2024 for two senior convertible notes due February 24, 2024 with initial conversion prices of $1.09 and $0.75 (the ""Exchange Notes""); and (3) exchange common stock purchase warrants to purchase 9,057,971 shares of common stock at an exercise price of $2.85 per share for warrants to purchase 17,057,971 shares of common stock with an initial exercise price of $1.09 per share (the ""Exchange Warrants""). The conversion price of the New Notes and Exchange Notes and exercise price of the New Warrants and Exchange Warrants will be adjusted to the $0.75 subject to shareholder approval. Gross proceeds of the Placement will be approximately $4.5 million. The Company intends to use the net proceeds from the Placement for general corporate purposes, including working capital, operating expenses and capital expenditures. The Placement is expected to close on May 24, 2023, subject to customary conditions. Closing of the Placement is contingent on closing of the Offering. Aegis Capital Corp. is acting as the exclusive placement agent for the Placement. The Offering is being made pursuant to an effective shelf registration statement on Form S-3 (No. 333-269644) previously filed with the SEC and declared effective by the SEC on March 21, 2023. A final prospectus supplement and accompanying prospectus describing the terms of the proposed Offering will be filed with the SEC and will be available on the SEC's website located at http://www.sec.gov . Electronic copies of the final prospectus supplement and the accompanying prospectus may be obtained, when available, by contacting Aegis Capital Corp., Attention: Syndicate Department, 1345 Avenue of the Americas, 27th floor, New York, NY 10105, by email at syndicate@aegiscap.com , or by telephone at (212) 813-1010. The securities described above in the Placement are being sold in a private placement and have not been registered under the Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration with the Securities and Exchange Commission (the ""SEC"") or an applicable exemption from such registration requirements. The securities in the Placement were offered only to accredited investors. Pursuant to a registration rights agreement with the investors, the Company has agreed to file one or more registration statements with the SEC covering the resale of the common stock issuable upon conversion of the New Notes and exercise of the Warrants. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction."
2023-05-22 15:19:44	WDDC	Microbot Medical Announces $1.44M Registered Direct Offering Of of 655,569 Shares Of Common Stock At A Price Of $2.20/Share Priced At The Market Under Nasdaq Rules	Microbot Medical Inc. (NASDAQ: WDDC ) today announced that it has entered into definitive agreements for the purchase and sale of 655,569 shares of the Company's common stock at a purchase price of $2.20 per share of common stock in a registered direct offering priced at-the-market under Nasdaq rules. The closing of the offering is expected to occur on or about May 24, 2023, subject to the satisfaction of customary closing conditions. L.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. The gross proceeds to the Company from the offering are expected to be $1,442,252, before deducting the placement agent's fees and other offering expenses payable by the Company. The Company intends to use the net proceeds from the offering for the continued development, commercialization and regulatory activities for the Company's LIBERTY&#xAE; Robotic System, expansion and development of additional applications derived from the Company's existing IP portfolio, and for working capital and other general corporate purposes.
2023-05-22 16:24:21	QH	Guardant Health Announces Proposed $250M Public Offering Of Common Stock	Guardant Health, Inc. (NASDAQ: QH ), a leading precision oncology company, today announced that it has commenced an underwritten public offering of $250.0 million of its common stock. In addition, Guardant Health intends to grant the underwriters a 30-day option to purchase up to $37.5 million of its common stock at the public offering price, less underwriting discounts and commissions. All of the shares of common stock in this offering will be sold by Guardant Health. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the proposed offering may be completed, or as to the actual size or terms of the proposed offering. J.P. Morgan, Goldman Sachs & Co. LLC, TD Cowen and SVB Securities are acting as joint book-running managers for the proposed offering.
2023-05-22 17:08:40	TOU	RenaissanceRe Announces Public Offering Of 6.3M Common Shares	"RenaissanceRe Holdings Ltd. (NYSE: TOU ) (the ""Company"" or ""RenaissanceRe"") announced today that it has commenced an underwritten public offering of 6,300,000 of its common shares. The Company intends to use the net proceeds from this offering to fund a portion of the cash consideration for the previously announced acquisition of certain subsidiaries of American International Group, Inc., including Validus Holdings, Ltd., Validus Specialty, LLC and Validus Reinsurance Ltd. (the ""Validus Acquisition""), to pay related costs and expenses, and for general corporate purposes. Morgan Stanley is acting as lead active bookrunner and Goldman Sachs & Co. LLC is acting as active bookrunner in the proposed offering. The underwriters will have the option to purchase up to an aggregate of 945,000 additional common shares from the Company."
2023-05-22 17:55:42	VALS	Icosavax Prices $67.8M  Registered Direct Offering Of ~8.37M Shares Of Common Stock At A Price Of $8.10/Share	Icosavax, Inc. (NASDAQ: VALS ), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, with an initial focus on life-threatening respiratory diseases and a vision of creating pan-respiratory vaccines for older adults, today announced that it has entered into a securities purchase agreement with investors in a registered direct offering of 8,369,754 shares of its common stock at a purchase price of $8.10 per share. The financing was led by new investor TCGX with participation by additional new investors including Logos Capital and Vivo Capital. All of the shares are to be sold by Icosavax. Icosavax expects to receive gross proceeds of approximately $67.8 million from the offering. The offering is expected to close on May 25, 2023, subject to customary closing conditions.
2023-05-23 06:41:57	XHET	US Foods Reports Secondary Public Offering of 17.4M Shares Of Common Stock and Concurrent $150M Share Repurchase	US Foods announced the commencement of an underwritten registered secondary offering of 17,425,053 shares of its common stock by KKR Fresh Holdings L.P. substantially all of which will consist of common stock issuable upon the conversion of 371,044 shares of its Series A Convertible Preferred Stock held by the Selling Stockholder. US Foods will not receive any proceeds from the sale of its common stock by the Selling Stockholder in the offering. In addition, US Foods intends to repurchase approximately $150,000,000 of the shares of common stock being offered in the offering
2023-05-23 09:13:59	QH	Guardant Health Shares Move Lower On $350M Public Offering: The Details	Guardant Health Inc (NASDAQ: QH ) shares are trading lower Tuesday after the company announced an offering . What Happened: Guardant Health commenced an underwritten public offering of 12.5 million shares of its common stock at $28 per share. The company also granted the underwriters a 30-day option to purchase up to an additional 1.875 million shares. The offering is expected to close on or about May 25. Guardant Health anticipates $350 million in gross proceeds. Guardant Health is a precision oncology company focused on fighting cancer through proprietary tests, data sets and analytics. See Also: US Stocks Poised For Flat Open On Debt Ceiling Impasse: Why This Analyst Thinks October Lows 'Won't Be Violated' QH Price Action: Guardant Health has a 52-week high of $62.55 and a 52-week low of $20.67. The stock was down 3.57% at $29.70 at the time of writing, per Benzinga Pro . Photo: Tatiana from Pixabay.
2023-05-23 09:26:12	VALS	Icosavax Touts Encouraging Early-Cut Data From Phase 1 Trial Of RSV Vaccine	Icosavax Inc (NASDAQ: VALS ) announced topline interim results from its Phase 1 trial of IVX-A12 against the respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) in older adults . IVX-A12 was generally well-tolerated across all dosage groups. Solicited local and systemic adverse events (AEs) were generally mild or moderate, without dose-limiting reactogenicity. IVX-A12 induced robust immune responses against RSV and hMPV in older adults across dosage levels and with and without adjuvant. When administered in combination, there was no evidence of immune interference between RSV and hMPV VLPs. Across dosage groups, IVX-A12 induced geometric mean titers (GMTs) in RSV-A neutralizing antibody titers (nAbs) of up to 16,100 IU/mL compared to 2,600 IU/mL for placebo. GMTs in RSV-B nAbs were up to approximately 8,300 IU/mL compared to 2,500 IU/mL for the placebo. Across dosage groups, IVX-A12 induced GMTs in hMPV-A nAbs of up to roughly 3,300 assay units/mL compared to 900 assay units/mL for placebo. IVX-A12 induced GMTs in hMPV-B nAbs of up to 23,900 assay units/mL compared to 11,500 assay units/mL for placebo. Icosavax plans to initiate a Phase 2 trial for IVX-A12 in RSV and hMPV in mid-2023 and evaluate two formulations. Pending the planned Phase 2 trial results, Icosavax intends to conduct an IVX-A12 hMPV human challenge clinical trial. This hMPV human challenge model is currently in development and builds on an established precedent in the RSV field. In December, Icosavax reported durability data at six months ; 12-month immunogenicity data is expected in mid-2023. Icosavax has priced a $67.8 million registered direct offering with select healthcare investors. The Seattle-based company now expects its cash balance to be sufficient to fund operations into 2H 2025 . Price Action: VALS shares are up 11.2% at $8.75 during the premarket session on the last check Tuesday.
2023-05-23 12:01:52	XHET	KKR Fresh Divests Stake In US Foods Holding; Company Repurchases $150M Stock	US Foods Holding Corp (NYSE: XHET ) has priced a previously announced underwritten registered secondary offering of 17.4 million shares by KKR Fresh Holdings L.P. at $39.90 per share. The offering consists of common stock issuable upon the conversion of 371,044 shares of its Series A Convertible Preferred Stock. The offer price represents a 3.7% discount to the company&rsquo;s closing price on Monday, May 22. US Foods will not receive any proceeds from the sale of shares in the offering. Also See : US Foods Buys Renzi Foodservice, Looks To Expand Reach Across Upstate New York The offering is expected to close on or about May 26, 2023. Also, US Foods has agreed to repurchase about $150 million shares being offered in the offering. Upon the closing of the offering, the selling stockholder KKR Fresh will no longer own any common stock or Series A Convertible Preferred Stock of US Foods. Also Read : US Foods Q1: 10% Topline Growth, Solid Case Volume, Reaffirmed FY23 Outlook & More Price Action : XHET shares are trading lower by 3.02% at $40.17 on the last check Tuesday.
2023-05-23 15:26:31	WDDC	Microbot Medical Announces $2.66M Registered Direct Offering Of ~1.21M Shares Of Common Stock Priced At $2.20/Share At-The-Market Under Nasdaq Rules	Microbot Medical Inc. (NASDAQ: WDDC ) today announced that it has entered into definitive agreements for the purchase and sale of 1,209,500 shares of the Company's common stock (or common stock equivalents) at a purchase price of $2.20 per share of common stock in a registered direct offering priced at-the-market under Nasdaq rules. The closing of the offering is expected to occur on or about May 25, 2023, subject to the satisfaction of customary closing conditions. L.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. The gross proceeds to the Company from the offering are expected to be $2,660,900, before deducting the placement agent's fees and other offering expenses payable by the Company. The Company intends to use the net proceeds from the offering for the continued development, commercialization and regulatory activities for the Company's LIBERTY&#xAE; Robotic System, expansion and development of additional applications derived from the Company's existing IP portfolio, and for working capital and other general corporate purposes.
2023-05-23 16:06:11	THTL	Ocugen, Inc. Announces Proposed Public Offering Of Common Stock; No Size Or Amount Disclosed	Ocugen, Inc. (NASDAQ: THTL ), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that it has commenced an underwritten public offering of its common stock. In addition, Ocugen expects to grant to the underwriter a 30-day option to purchase up to an additional 15% of shares of the common stock sold in the public offering. All of the securities in the offering are to be sold by Ocugen. The offering is subject to market and other customary closing conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Ocugen intends to use the net proceeds of the proposed offering for general corporate purposes, capital expenditures, working capital, and general and administrative expenses. Cantor Fitzgerald & Co. is acting as the sole book-running manager for the offering.
2023-05-23 16:08:51	TKBX	CORRECTION: Phathom Pharmaceuticals Announces Proposed Public Offering Of Common Stock; Intends To Grant The Underwriters A 30-Day Option To Purchase Up To An Additional 15% Of The Total Number Of The Shares Of Its Common Stock Offered	Phathom Pharmaceuticals, Inc. (NASDAQ: TKBX ), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering. In addition, Phathom intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the total number of the shares of its common stock offered in the public offering. There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Phathom intends to use the net proceeds from the proposed offering to fund the clinical development of vonoprazan, pre-commercial activities and commercialization expenses and for working capital and general corporate purposes. Jefferies and Evercore ISI are acting as joint bookrunning managers for the offering. Needham & Company is acting as lead manager for the offering.
2023-05-23 16:15:58	GFRT	Hannon Armstrong Sustainable Infrastructure Capital, Inc. Announces $300M Public Offering Of Common Stock	"Hannon Armstrong Sustainable Infrastructure Capital, Inc. (""GFRT,"" ""we,"" ""our,"" or the ""Company"") (NYSE: GFRT ), a leading investor in climate solutions, today announced that it is commencing a public offering of $300 million of shares of common stock. The Company expects to grant the underwriters a 30-day option to purchase up to $45 million of additional shares of common stock. The Company intends to utilize the net proceeds of this offering for general corporate purposes. J.P. Morgan, BofA Securities, and Goldman Sachs & Co. LLC are acting as joint book-running managers for the offering."
2023-05-23 16:32:00	AUXH	U.S. Physical Therapy Announces $150M Underwritten Public Offering Of Common Stock	"U.S. Physical Therapy, Inc. (NYSE: AUXH ) (""U.S. Physical Therapy"" or the ""Company"") today announced that it has commenced an underwritten public offering of $150,000,000 of shares of common stock. The Company has granted the underwriters an option to purchase up to an additional $22,500,000 of shares of common stock from the Company. U.S. Physical Therapy intends to use the net proceeds of this offering for repayment of a portion of its indebtedness outstanding under its revolving credit facility, and for general corporate purposes, including future acquisitions and other capital expenditures, as well as funding working capital and paying dividends. BofA Securities and J.P. Morgan are acting as joint lead bookrunners for the offering, and Jefferies is acting as bookrunner. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering. The offering is being made pursuant to an effective shelf registration statement, which has been filed with the Securities and Exchange Commission (the ""SEC"") and became effective May 23, 2023. The offering will be made only by means of a preliminary prospectus supplement and the accompanying base prospectus, copies of which may be obtained on the SEC's website at www.sec.gov or from BofA Securities, Attn: Prospectus Department, NC1-022-02-25, 201 North Tryon, Charlotte, NC 28255-0001, or by email at dg.prospectus_requests@bofa.com and J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by email at prospectus-eq_fi@jpmchase.com . This press release is neither an offer to sell nor a solicitation of an offer to buy any securities being offered, nor shall there be any sale of any such securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction."
2023-05-24 06:05:54	WLCD	The Vita Coco Company Announces Upsizing And Pricing Of Public Offering Of 5M Shares  At $23.00 Per Share	The offering was upsized from the previously announced 4,500,000 shares of common stock. In addition, the Selling Stockholder has granted the underwriters a 30-day option to purchase up to 750,000 additional shares of common stock at the public offering price, less underwriting discounts and commissions. No shares of common stock are being sold by the Vita Coco Company. The Selling Stockholder will receive all of the proceeds from the offering. The offering is expected to close on May 26, 2023, subject to the satisfaction of customary closing conditions.
2023-05-24 08:13:33	ELSE	Dermata Therapeutics Announces $1.8M Offering Of 800,877 Shares Of Common Stock At A Price Of $2.285/Share Priced At-The-Market Under Nasdaq Rules	Dermata Therapeutics Announces $1.8 Million Offering Priced At-The-Market Under Nasdaq Rules SAN DIEGO, CA / ACCESSWIRE / May 24, 2023 / Dermata Therapeutics, Inc. (&quot;Dermata,&quot; or the &quot;Company&quot;) (NASDAQ: ELSE , DRMAW))))), a clinical-stage biotechnology company focusing on the treatment of medical and aesthetic skin diseases and conditions, today announced that it has entered into a definitive agreement for the purchase and sale of an aggregate of 800,877 shares of its common stock (or common stock equivalents in lieu thereof), at a purchase price of $2.285 per share of common stock (or common stock equivalent in lieu thereof), in a registered direct offering priced at-the-market under Nasdaq rules. The Company has also agreed to issue to each investor, in a concurrent private placement, warrants to purchase up to an aggregate of 800,877 shares of common stock. The warrants will have an exercise price of $2.16 per share, are immediately exercisable upon issuance, and will expire five and one-half years from the date of issuance. The closing of the registered direct offering and the concurrent private placement is expected to occur on or about May 26, 2023, subject to the satisfaction of customary closing conditions. L.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. The gross proceeds to the Company from the registered direct offering and the concurrent private placement are expected to be approximately $1.8 million, before deducting the placement agent's fees and other offering expenses payable by the Company. The Company intends to use the net proceeds for general corporate purposes, which includes, without limitation, ongoing research and pre-clinical studies, clinical trials, the development of new biological and pharmaceutical technologies, investing in or acquiring companies that are synergistic with or complementary to our technologies, licensing activities related to our current and future product candidates, and to the development of emerging technologies, investing in or acquiring companies that are developing emerging technologies, licensing activities, or the acquisition of other businesses and working capital.
2023-05-24 08:31:24	QCWD	Ambrx Announces $75M Registered Offering Of 5.4M American Depositary Shares At A Price Of $13.93/ADS	Ambrx Biopharma Inc., or Ambrx (or the &quot;Company&quot;) (NASDAQ: QCWD ), today announced that it has entered into a securities purchase agreement with clients managed by Darwin Global Management Ltd. (&quot;Darwin&quot;) for the sale of an aggregate of approximately 5.4 million American Depositary Shares of the Company (&quot;ADS&quot;) at a price of $13.93 per ADS, which is based on the 5-day trailing VWAP for the ADS, pursuant to a registered direct offering (the &quot;offering&quot;). In connection with the offering, Darwin has agreed not to sell any of the Company's securities it holds for a period of six months following the closing of the offering. The Company will receive aggregate gross proceeds of approximately $75 million upon closing of the offering. The offering is expected to close on or around June 30, 2023, subject to the satisfaction of certain closing conditions. The Company intends to use the proceeds from the offering primarily to fund the research and development of its product candidates, for working capital and for general corporate purposes.
2023-05-24 08:37:08	THTL	Ocugen, Inc. Announces Pricing Of $16.5M Public Offering Of 30M Shares Of Common Stock	Ocugen, Inc. (NASDAQ: THTL ), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced the pricing of its underwritten public offering of 30,000,000 shares of its common stock for gross proceeds of $16.5 million, before deducting the underwriting discounts and commissions and other estimated offering expenses payable by Ocugen. The offering is expected to close on or about May 26, 2023, subject to customary closing conditions. In addition, Ocugen has granted to the underwriter a 30-day option to purchase up to 4,500,000 additional shares of its common stock. Ocugen intends to use the net proceeds from the offering for general corporate purposes, capital expenditures, working capital, and general and administrative expenses. Cantor Fitzgerald & Co. is acting as the sole book-running manager for the offering.
2023-05-24 08:41:16	FKQJ	Biodexa Pharmaceuticals PLC Announces $3.32M Registered Direct Offering Of 22,135,922 New American Depositary Shares At A Price Of $0.15/ADS	Announces US $ 3. 32 Million Registered Direct Offering Biodexa Pharmaceuticals PLC (NASDAQ: FKQJ ) (&quot;Biodexa&quot; or the &quot;Company&quot;), a clinical stage biopharmaceutical company developing a pipeline of products aimed at primary and metastatic cancers of the brain, is pleased to announce a fundraise of gross proceeds of approximately US$3.32 million (c.&pound; 2.67 million) raised pursuant to a registered direct offering (the &quot;Registered Direct Offering&quot;) in the United States utilizing the Company's existing share capital authorities, via the issuance of 22,135,922 new American Depositary Shares (the &quot;Registered ADSs&quot;) at a price of US$0.15 per Registered ADS representing 110,679,610 new ordinary shares at a price of approximately US$0.03 per ordinary share (the &quot;Offering&quot;). The Offering is expected to close on or around May 26, 2023, subject to customary closing conditions. The net proceeds of the Offering will be approximately US$2.61 million (c.&pound;2.11 million) which the Company intends to utilise for working capital and general corporate purposes. Ladenburg Thalmann & Co. Inc. is acting as the exclusive placement agent for the Offering.
2023-05-24 09:16:07	JUOL	BIOLASE Inc. Announces Pricing Of $4.5M Underwritten Public Offering Of Series L Convertible Redeemable Preferred Stock and Warrants	BIOLASE, Inc. (NASDAQ: JUOL ) (&quot;BIOLASE&quot; or the &quot;Company&quot;), a global leader in dental lasers, today announced the pricing of an underwritten public offering of 175,000 units (the &quot;Units&quot;), with each Unit consisting of one share of BIOLASE's Series L Convertible Redeemable Preferred Stock, par value $0.001 per share, with a liquidation preference of $50.00 per share (the &quot;Series L Convertible Preferred Stock&quot;), and one warrant (the &quot;Warrants&quot;) to purchase one-half of one (0.50) share of Series L Convertible Preferred Stock. The offering is expected to close on May 26, 2023, subject to customary closing conditions. The purchase price for one Unit is $26.00, which reflects the issuance of the Series L Convertible Preferred Stock with an original issue discount. The Series L Convertible Preferred Stock has a term of two (2) years and is convertible at the option of the holder at any time into shares of BIOLASE common stock at a conversion price of $0.1398. Dividends on the Series L Convertible Preferred Stock will be paid, if and when declared by the Board of Directors, in-kind (&quot;PIK dividends&quot;) in additional shares of Series L Convertible Preferred Stock based on the stated value of $50.00 per share at a dividend rate of 20.0%. The PIK dividends will be a one-time payment payable to holders of the Series L Convertible Preferred Stock of record at the close of business on the one-year anniversary of the closing date of the offering. The Warrants have a term of two (2) years. Each Warrant will have an exercise price of $13.00 (50.0% of the public offering price per Unit) per Warrant, be exercisable for one-half of one (0.5) share of Series L Convertible Preferred Stock and will be immediately exercisable. Lake Street Capital Markets, LLC and Maxim Group LLC are acting as joint bookrunners for the offering. The gross proceeds to BIOLASE from the offering, before underwriting discounts and commissions and offering expenses, are expected to be approximately $4.5 million. BIOLASE intends to use the net proceeds from the offering for working capital and for general corporate purposes.
2023-05-24 09:31:42	ICZE	First Guaranty Bancshares, Inc. Announces $10M Private Placement Of  714,286 Shares Of Common Stock At A Price Of $14/Share	First Guaranty Bancshares, Inc. (&quot;First Guaranty&quot;) (NASDAQ: ICZE ), the holding company for First Guaranty Bank, announced today that it has completed a private placement offering of $10 million through the sale of 714,286 shares of common stock at $14 per share. This was accomplished by the unanimous participation of its Board of Directors and the Board of Directors of First Guaranty Bank, along with certain accredited investors within the banking organization. Commenting on the capital raise, Marshall F. Reynolds, Chairman of the Board of Directors of First Guaranty said, &quot;We have been frustrated by the unfair beating our stock has taken in recent months, and the completion of the offering with the 100% participation of Directors shows our belief in our Bank, which has been in operation since 1934.&quot; &quot;We are pleased with the interest our Boards of Directors have in contributing to the overall growth of the bank. The momentum grows as we make progress toward our goals of enhancing shareholder value and building a fortress balance sheet for First Guaranty Bancshares, Inc.,&quot; said First Guaranty President and Chief Executive Officer, Alton B. Lewis. First Guaranty expects to use the proceeds from the capital raise for general corporate purposes, including to support continued growth and to enhance regulatory capital ratios.
2023-05-24 12:31:03	TKBX	Phathom Pharmaceuticals Resubmits FDA Application For Acid Blocker, Raises $131M Via Equity	Phathom Pharmaceuticals Inc (NASDAQ: TKBX ) resubmitted its marketing application to the FDA seeking approval for vonoprazan for Erosive GERD (gastroesophageal reflux disease), also referred to as erosive esophagitis . This resubmission responds to the Complete Response Letter issued by the FDA in February 2023 concerning specifications and controls for a nitrosamine drug substance-related impurity, N-nitroso-vonoprazan (NVP) . The resubmission contains three months of stability data for six batches of the reformulated vonoprazan tablets. The three-month data demonstrate Phathom's mitigation measures control NVP growth through three months and keep levels well below the acceptable daily intake limit of 96 ng/day. All of the manufactured reformulated batches have demonstrated control of NVP through three months of long-term stability conditions that are more than tenfold below the acceptable intake limit, which Phathom believes supports the requested shelf life of 24 months. Phathom expects the application to be classified as a Class 2 resubmission with a six-month review period and plans to provide the FDA with six-month stability data from its ongoing stability program during the regulatory review process. A combined U.S. commercial launch for the Erosive GERD and L. pylori indications is planned for the fourth quarter of 2023 if approved. Concurrently, the company raised $130.7 million via an equity offering of 11.125 million shares at $11.75 per share . TKBX Price Action : Phathom Pharmaceuticals shares are down 11.23% at $11.60 at publication Wednesday. Read Next: Eloxx Pharmaceuticals Plans To Take ELX-02 Into Pivotal Trial For Alport Syndrome
2023-05-25 08:13:35	CAOJ	Terran Orbital Announces $37.1M Registered Direct Offering	Terran Orbital Corporation (NYSE: CAOJ ) (&quot;Terran Orbital&quot; or the &quot;Company&quot;), a global leader in satellite-based solutions primarily serving the aerospace and defense industries, today announced that it has entered into a definitive securities purchase agreement for the purchase and sale of 29,000,000 shares of the Company's common stock (or common stock equivalents) and warrants to purchase 29,000,000 shares of common stock at a combined purchase price of $1.28 per share of common stock (or common stock equivalent) and accompanying warrant in a registered direct offering. The warrants will have an exercise price of $1.43 per share, will be exercisable commencing six months following issuance, and will have a term of exercise equal to five years following the initial exercise date. The closing of the offering is expected to occur on or about May 30, 2023, subject to the satisfaction of customary closing conditions. L.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. The gross proceeds to the Company from the offering are expected to be approximately $37.1 million, before deducting the placement agent's fees and other offering expenses payable by the Company. Terran Orbital intends to use the net proceeds of this offering for general corporate purposes including capital expenditures, working capital, research and development and general and administrative expenses.
2023-05-25 08:37:46	APWF	Inuvo Announces Pricing Of $4M Registered Direct Offering Of 16M Shares Of Common Stock At A Price Of $0.25/Share	Inuvo, Inc. (NYSE: APWF ) (the &quot;Company&quot; or &quot;Inuvo&quot;), provider of the first generative artificial intelligence (AI) advertising solution made specifically for brands and agencies, today announced it has entered into securities purchase agreements with institutional and accredited investors for the purchase and sale of 16,000,000 shares of its common stock at a purchase price of $0.25 per share, pursuant to a registered direct offering. The gross proceeds of the offering are expected to be approximately $4 million before deducting placement agent fees and other estimated offering expenses. The closing of the registered direct offering is expected to take place on or about May 30, 2023, subject to the satisfaction of customary closing conditions. A.G.P./Alliance Global Partners is acting as sole placement agent for the offering.
2023-05-25 09:05:35	KWTM	Achieve Life Sciences Announces Pricing Of $16.5M Registered Direct Offering For The Purchase And Sale Of 3M Shares Of Common Stock At A Price Of $5.50/Share	Achieve Life Sciences, Inc. (NASDAQ: KWTM ), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced that it has entered into a securities purchase agreement with certain institutional investors providing for the purchase and sale of 3,000,000 shares of common stock at a price of $5.50 per share in a registered direct offering. The aggregate gross proceeds from this offering are expected to be approximately $16.5 million, prior to deducting placement agent fees and estimated offering expenses. The Company intends to use the proceeds from the offering to fund product development and regulatory activities, and for working capital and general corporate purposes. The offering is expected to close on or about May 30, 2023, subject to customary closing conditions. Current Achieve investors, including investors in Dialectic Life Sciences and various entities affiliated with the Hunt Family, as well as members of Achieve's management, are participating in this transaction. The shares of common stock were offered pursuant to a shelf registration statement on Form S-3 (File No. 333-261811), which was declared effective by the United States Securities and Exchange Commission (&quot;SEC&quot;) on January 5, 2022. Lake Street Capital Markets, LLC is acting as the exclusive placement agent in connection with this offering. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities of Achieve, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction. A prospectus supplement relating to the shares of common stock will be filed by the Company with the SEC. When available, copies of the prospectus supplement, together with the accompanying prospectus, can be obtained at the SEC's website at www.sec.gov or from Lake Street Capital Markets LLC, Prospectus Department, 920 Second Avenue South, Suite 700, Minneapolis, Minnesota 55402 or by email at info@lakestreetcm.com .
2023-05-25 12:18:30	CAOJ	Terran Orbital Stock Slips After $37M Equity Offering	Terran Orbital Corporation (NYSE: CAOJ ) said it has entered into a definitive securities purchase agreement for the purchase and sale of 29 million shares and warrants to buy 29 million shares at a combined purchase price of $1.28 per share. The warrants will have an exercise price of $1.43 per share, will be exercisable commencing six months following issuance, and will have a term of exercise equal to five years following the initial exercise date. The gross proceeds to the company from the offering are expected to be approximately $37.1 million. Terran Orbital intends to use the net proceeds for general corporate purposes, including capital expenditures, working capital, research and development. The closing of the offering is expected to occur on or about May 30, 2023. Price Action: CAOJ shares are trading lower by 7.71% at $1.32 on the last check Thursday.
2023-05-25 16:09:21	GMRB	TScan Therapeutics Announces Launch Of Proposed Public Offering; No Size Disclosed	TScan Therapeutics, Inc. (NASDAQ: GMRB ), a clinical-stage biopharmaceutical company focused on the development of F cell receptor (TCR)-engineered F cell therapies (TCR-F) for the treatment of patients with cancer, today announced that it has commenced an underwritten public offering of shares of voting common stock and, in lieu of voting common stock to investors that so choose, non-voting common stock and pre-funded warrants to purchase shares of common stock. All shares of common stock and pre-funded warrants to be sold in the offering will be offered by TScan. TScan intends to grant the underwriters a 30-day option to purchase additional shares of its voting common stock in an amount equal to 15% of the securities offered in the public offering. The offering is subject to market, regulatory and other conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Morgan Stanley and Wedbush PacGrow are acting as joint book-running managers for the offering. The Company intends to use the net proceeds from the offering for general corporate purposes.
2023-05-25 16:36:46	UMPK	Why Tilray Stock Is Getting Smoked After Hours	Tilray Brands Inc (NASDAQ: UMPK ) shares are trading lower in Thursday's after-hours session after the company announced an offering . What Happened: Tilray said it had commenced a registered offering of $150 million worth of convertible senior notes due in 2027. The company also expects to grant the underwriters a 30-day period to purchase up to an additional $22.5 million. Issuing convertible notes to pay off debt means the company's existing debt will get converted to equity at a future date, which means a dilution for the existing shareholders. Tilray said it intends to use a portion of the proceeds to finance the repurchase of a portion of its outstanding 5% convertible senior notes due in 2023 and 5.25% convertible senior notes due in 2024. Tilray is a global cannabis-lifestyle and consumer packaged goods company. As of the third quarter ended February 2023, Tilray had $408.28 million in cash and equivalents. See Also: Hulk Hogan Talks Cannabis, Will Launch His Own Brand: At Age 69, 'I Feel Better Than I've Ever Felt... Like I'm 25 Again' UMPK Price Action: Tilray has a 52-week high of $5.12. It's making new 52-week lows in Thursday's after-hours session. Tilray shares were down 18.20% at $1.93 at the time of publication, according to Benzinga Pro . Photo: 7raysmarketing from Pixabay.
2023-05-26 09:05:44	LJBN	eFFECTOR Therapeutics Announces $7.5M Registered Direct Offering Of 11,450,382 Shares Of Common Stock At A Price Of $0.655/Share, Priced At-The-Market Under Nasdaq Rules	eFFECTOR Therapeutics, Inc. (NASDAQ: LJBN ), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today announced that it has entered into a definitive agreement with a single healthcare-focused institutional investor for the purchase and sale of an aggregate of 11,450,382 shares of its common stock (or common stock equivalents in lieu thereof), at a purchase price of $0.655 per share (or common stock equivalent in lieu thereof), in a registered direct offering priced at-the-market under Nasdaq rules. The Company has also agreed to issue in a concurrent private placement unregistered warrants to purchase up to an aggregate of 11,450,382 shares of common stock. The unregistered warrants will have an exercise price of $0.53 per share, will be immediately exercisable upon issuance, and will expire five and one-half years from the date of issuance. The closing of the offering is expected to occur on or about May 31, 2023, subject to the satisfaction of customary closing conditions. L.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.
2023-05-26 09:47:11	GDQN	SpringBig Holdings, Inc. Announces Pricing Of $4M Public Offering Of 13,061,014 Shares Of Its Common Stock At An At-The-Market Price Of $0.3037/Share	SpringBig Holdings, Inc. (&quot;springbig&quot; or the &quot;Company&quot;) (NASDAQ: GDQN ), a leading provider of SaaS-based marketing solutions, consumer mobile app experiences, and omnichannel loyalty programs to the cannabis industry, today announced the pricing of public offering of 13,061,014 shares of its common stock at an at-the-market price of $0.3037. The closing of the offering is expected to occur on or about May 31, 2023, subject to the satisfaction of customary closing conditions. Roth Capital Partners is acting as sole placement agent for the offering.
2023-05-26 12:54:40	UMPK	What's Going On With Tilray Brands Stock Friday	Tilray Brands, Inc (NASDAQ: UMPK ) stock is plunging Friday after it disclosed plans to raise $150 million via a convertible senior notes offering . The session volume spiked to 36 million vs. the average 100-day volume of 11 million. Tilray said it will use a portion of the proceeds to finance the repurchase of its outstanding 5% convertible senior notes due in 2023 and 5.25% convertible senior notes due in 2024. Issuing convertible senior notes to pay off debt indicates the company's existing debt will be refinanced with new notes that will be converted to equity at a future date, which means a dilution for the existing shareholders. Tilray is a cannabis-lifestyle and consumer packaged goods company. The cannabis industry could get a boost from Senate Majority Leader Chuck Schumer's plans for reintroducing the Secure and Fair Enforcement (PQPY) Banking Act to provide cannabis businesses with access to essential banking infrastructure. Schumer also reiterated the crucial significance of incorporating criminal justice reform measures, including expungements, into a bipartisan marijuana banking bill . Schumer sought a committee vote on a marijuana banking bill and reiterated plans to attach criminal justice reform provisions to the financial services measure. Price Action: UMPK shares traded lower by 21.4% at $1.86 on the last check Friday. Photo via Wikimedia Commons
2023-05-30 12:21:15	KDSD	Earlier On May 30, Smart for Life Announced Exercise Of Warrants For $4.5M In Gross Proceeds	Smart for Life, Inc. (NASDAQ: KDSD ) (&quot;Smart for Life&quot; or the &quot;Company&quot;), a high growth global leader in the Health & Wellness sector marketing and manufacturing nutritional foods and supplements worldwide, today announced the agreement by several accredited investors to exercise certain outstanding warrants to purchase up to an aggregate of 3,513,750 shares of common stock of the Company issued by the Company on July 1, 2021 and August 18, 2021, each having an exercise price of $2.59 per share, at a reduced exercise price of $1.30 per share. The shares of common stock issuable upon exercise of the warrants are registered pursuant to an effective registration statement on Form S-3 (File No. 333-271701). The gross proceeds to the Company from the exercise of the warrants are expected to be approximately $4.5 million, prior to deducting placement agent fees and estimated offering expenses. L.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. In consideration for the immediate exercise of the warrants for cash, the exercising holders will receive new unregistered warrants to purchase shares of common stock. The new warrants will be exercisable into an aggregate of up to 7,027,500 shares of common stock, at an exercise price of $2.17 per share and have a term of exercise equal to five and one-half years. The Company intends to use the net proceeds from the offering for working capital and other general corporate purposes.
2023-05-30 16:19:30	PBLV	AerSale Announces Secondary Offering Of 4M Common Stock	"AerSale Corporation (""AerSale"") (NASDAQ: PBLV ), a leading provider of aviation products and services, today announced that certain of its stockholders, including affiliates of Leonard Green & Partners, L.P. (the ""Selling Stockholders"") intend to offer for sale in an underwritten secondary offering (the ""Offering"") 4,000,000 shares of common stock of AerSale pursuant to a shelf registration statement on Form S-3 filed by AerSale with the U.S. Securities and Exchange Commission (the ""SEC""). The underwriter intends to offer the shares from time to time for sale in one or more transactions on the Nasdaq Capital Market, in the over-the-counter market, through negotiated transactions or otherwise at market prices prevailing at the time of sale, at prices related to prevailing market prices or at negotiated prices. The Selling Stockholders expect to grant the underwriter a 30-day option to purchase up to an additional 600,000 shares of common stock on the same terms and conditions. No shares are being issued or sold by AerSale. The Selling Stockholders will receive all of the proceeds from the Offering. RBC Capital Markets is acting as the underwriter for the Offering."
2023-05-30 19:49:05	UBP	FG Financial Group Priced 865K Share Public Offering Of Common Stock At $1.85/Share	FG Financial Group, Inc. (NASDAQ: UBP ) today announced the pricing of an underwritten public offering of 865,000 shares of its common stock at a public offering price of $1.85 per share, for gross proceeds of $1,600,250, before deducting underwriting discounts, commissions and offering expenses. All of the shares of common stock are being offered by the Company. In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 129,750 shares of common stock at the public offering price less discounts and commissions, to cover over-allotments. The offering is expected to close on June 2, 2023, subject to satisfaction of customary closing conditions. The Company intends to use the net proceeds from the offering primarily for general working capital purposes. ThinkEquity is acting as sole book-running manager for the offering.
2023-05-31 08:08:56	WQXG	NaaS Technology Raises $21M Via Equity Offering To Certain Investors	NaaS Technology Inc (NASDAQ: WQXG ) has completed $21 million of registered direct offering to certain investors, including Adrian Cheng and CST Group Limited, on May 30, 2023. The company and the investors entered into share subscription agreements on May 29, 2023, by which the investors subscribed for and purchased 3.5 million American depositary shares from the company. The company offered securities directly to the investors without the participation of underwriters or placement agents. WQXG is a third-party charging network in China and is a subsidiary of Newlinks Technology Limited, an energy digitalization group in China. Price Action : WQXG shares are trading higher by 4.31% at $7.50 in premarket on the last check Wednesday.
2023-05-31 08:09:55	KUZQ	Phio Pharmaceuticals Announces $4M Concurrent Registered Direct Offering And Private Placement Priced At-the-Market Under Nasdaq Rules	Phio Pharmaceuticals Corp. (NASDAQ: KUZQ ), a clinical stage biotechnology company whose proprietary INTASYL&trade; RNAi platform technology is designed to make immune cells more effective in killing tumor cells, today announced that it has entered into definitive agreements for the issuance and sale of an aggregate of 233,646 of its shares of common stock at a purchase price of $4.28 per share in a registered direct offering. In a concurrent private placement, Phio has also agreed to issue and sell an aggregate of 700,935 of its shares of common stock (or common stock equivalents), at the same purchase price of $4.28 per share (or common stock equivalent) as in the registered direct offering. In addition, the Company has agreed to issue in the offerings unregistered Series A warrants to purchase up to an aggregate of 934,581 shares of common stock and unregistered Series B warrants to purchase up to an aggregate of 934,581 shares of common stock. The registered direct offering and the private placement were priced at-the-market under Nasdaq rules. The offerings are expected to close on or about June 2, 2023, subject to the satisfaction of customary closing conditions. Logo - https://mma.prnewswire.com/media/786567/Phio_Pharmaceuticals_Logo.jpg L.C. Wainwright & Co. is acting as the exclusive placement agent for the offerings. Each series of warrants will have an exercise price $4.03 per share and become exercisable immediately upon issuance. The Series A warrants have a term of five and one-half years from the date of issuance and the Series B warrants have a term of eighteen months from the date of issuance. The gross proceeds to the Company from the concurrent offerings are expected to be approximately $4 million, before deducting the placement agent's fees and other offering expenses payable by Phio. Phio currently intends to use the net proceeds from the offerings for the development of its immuno-oncology programs, working capital and general corporate purposes.
2023-05-31 16:04:49	XSFE	Lexicon Announces Proposed Public Offering Of Common Stock; No Size Or Amount Disclosed	Lexicon Pharmaceuticals, Inc. (NASDAQ: XSFE ) (&quot;Lexicon&quot;) today announced that it has commenced an underwritten public offering to offer and sell, subject to market and other conditions, shares of its common Lexicon Pharmaceuticals, Inc. (NASDAQ: XSFE ) (&quot; Lexicon &quot;) today announced that it has commenced an underwritten public offering to offer and sell, subject to market and other conditions, shares of its common stock, par value $0.001. In addition, Lexicon intends to grant the underwriters a 30-day option to purchase additional shares of common stock. There can be no assurance as to whether or when the proposed offering may be completed, or as to the actual size or terms of the proposed offering. Citigroup, Jefferies and Piper Sandler are acting as joint book-running managers for the proposed offering.
2023-05-31 16:59:57	TQJB	Lucid Group, Inc. Announces Public Offering Of 173,544,948 Shares Of Common Stock And Corresponding Investment By An Affiliate Of PIF For Aggregate Expected Gross Proceeds Of ~$3.0B	Lucid Group, Inc. Announces Public Offering of Common Stock and Corresponding Investment by an Affiliate of PIF for Aggregate Expected Gross Proceeds of Approximately $3.0 Billion May 31, 2023 Lucid Group, Inc. (NASDAQ: TQJB , &amp, ldquo, Lucid&amp, rdquo, ))))) announced today the commencement of a public offering of 173,544,948 shares of its common stock. The underwriter may offer the shares of common stock from time to time for sale in one or more transactions to purchasers directly, through agents or through brokers in brokerage transactions on Nasdaq, in the over-the-counter market, through negotiated transactions or in a combination of such methods, or otherwise at a fixed price or prices, which may be changed, at market prices prevailing at the time of sale, at prices related to prevailing market prices or at negotiated prices. BofA Securities, Inc. is acting as book-running manager for the public offering. In addition, Lucid&rsquo;s majority stockholder and affiliate of the Public Investment Fund (&ldquo;PIF&rdquo;), Ayar Third Investment Company (&ldquo;Ayar&rdquo;), has agreed to purchase from Lucid 265,693,703 shares of Lucid common stock in a private placement for an aggregate purchase price of approximately $1.8 billion. The private placement is expected to close on June 26, 2023 and is subject to completion of the public offering and customary closing conditions. As a result of these purchases, Ayar expects to maintain its approximate 60.5% ownership of Lucid&rsquo;s outstanding common stock. Lucid intends to use the net proceeds from the public offering, as well as from the private placement by its majority stockholder for general corporate purposes, which may include, among other things, capital expenditures and working capital. The public offering is being made pursuant to Lucid&rsquo;s effective shelf registration statement on Form S-3, including a base prospectus, filed with the Securities and Exchange Commission (the &ldquo;SEC&rdquo;) and a prospectus supplement. Prospective investors should read the preliminary prospectus supplement and the accompanying base prospectus in that registration statement and other documents that Lucid has filed or will file with the SEC for information about Lucid and the public offering. You may obtain these documents for free by visiting EDGAR on the SEC&rsquo;s website at www.sec.gov . Alternatively, copies of the preliminary prospectus supplement and the base prospectus may be obtained from BofA Securities, NC1-022-02-25, 201 North Tryon Street, Charlotte, NC 28255-0001, Attn: Prospectus Department, or by email at dg.prospectus_requests@bofa.com . This press release does not constitute an offer to sell or the solicitation of an offer to buy shares of Lucid&rsquo;s common stock, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.
2023-05-31 17:32:25	UCOX	Telesis Bio Secures Financing Of $28M;  Up To Additional $46.2M Available Through Warrant Exercise	The company has signed a securities purchase agreement with a syndicate of healthcare-focused institutional investors that have agreed to provide initial upfront funding of $28.0 million in gross proceeds to Telesis Bio through a private placement of redeemable convertible preferred stock. The private placement also includes the issuance of warrants that, if cash exercised, would provide Telesis Bio with another $46.2 million in gross proceeds. The financing is led by Novalis LifeSciences LLC with participation from Northpond Ventures, BroadOak Capital Partners and N-185 Corporation, an affiliate of the Company's Chief Executive Officer and Founder, Todd R. Nelson, PhD.
2023-05-31 17:39:05	TQJB	Why Lucid Shares Are Backing Up After Hours	Lucid Group Inc (NASDAQ: TQJB ) shares are trading lower in Wednesday's after-hours session after the EV company announced a public offering and private placement . What Happened: Lucid commenced a public offering of 173,544,948 shares of its common stock. In addition to the offering, the company said its majority stockholder Ayar Third Investment Company, an affiliate of the Public Investment Fund, has agreed to purchase more than 265 million shares in a private placement for approximately $1.8 billion. Ayar Third Investment Co owns approximately 60.5% of Lucid's outstanding common stock. The private placement is expected to close on June 26. Lucid anticipates combined gross proceeds from the public offering and private placement of approximately $3 billion. The company expects to use the net proceeds for general corporate purposes, which may include capital expenditures and working capital. See Also: Why Chewy Stock Is Bouncing Higher After Hours TQJB Price Action: Lucid shares were down 5.93% after hours at $7.32 at the time of writing, according to Benzinga Pro . Photo: courtesy of Lucid.
2023-06-01 08:17:55	XSFE	Lexicon Announces Pricing Of $125M Public Offering Of 23,924,705 Shares Of Common Stock At A Price Of $2.60/Share And Concurrent Private Placement	Lexicon Pharmaceuticals, Inc. (NASDAQ: XSFE ) (&quot; Lexicon &quot;) today announced the pricing of its previously announced underwritten public offering of 23,924,705 shares of its common stock, par value $0.001. The shares of common stock being offered pursuant to the public offering are being offered at a public offering price of $2.60 per share. All of the shares are being offered by Lexicon. The gross proceeds from the public offering are expected to be approximately $62.2 million, before deducting underwriting discounts and commissions and other offering expenses. In addition, Lexicon has granted the underwriters a 30-day option to purchase up to an additional 3,588,705 shares of common stock at the public offering price, less underwriting discounts and commissions. The public offering is expected to close on or about June 5, 2023, subject to the satisfaction of customary closing conditions. In addition to the shares being sold in the underwritten public offering, Lexicon has agreed to sell 24,152,218 shares of its common stock to raise gross proceeds of approximately $62.8 million in a concurrent private placement (together with the underwritten public offering described above, the &quot; offering &quot;) at $2.60 per share to an affiliate (the &quot; Private Placement Purchaser &quot;) of Invus, L.P., Lexicon's largest stockholder, pursuant to its preemptive right under Lexicon's Fifth Amended and Restated Certificate of Incorporation. The Private Placement Purchaser will have the option to purchase, on a pro rata basis, up to an additional 3,622,832 shares of common stock at the public offering price to the extent the underwriters exercise their option to purchase additional shares of common stock. The shares of common stock being offered pursuant to the concurrent private placement will not be registered under the Securities Act of 1933, as amended (the &quot; Securities Act &quot;). The concurrent private placement is also scheduled to close on or about June 5, 2023, subject to the closing of the public offering and the satisfaction of certain other customary closing conditions. The closing of the underwritten public offering is not conditioned on the closing of the concurrent private placement. Lexicon currently intends to use a portion of the net proceeds that it will receive from the offering, together with its existing cash and cash equivalents and short-term investments, to (i) fund the commercial launch of INPEFA&trade; (sotagliflozin) and (ii) fund the continued research and development of its drug candidates and for working capital and other general corporate purposes. Citigroup, Jefferies and Piper Sandler are acting as joint book-running managers for the public offering.
2023-06-01 08:36:16	TQJB	Why Lucid Stock Is Hitting The Brakes Thursday	Lucid Group Inc (NASDAQ: TQJB ) shares are moving lower Thursday after the company announced the pricing of a public offering and private placement . What Happened: Lucid commenced a public offering of approximately 173.54 million shares for proceeds of approximately $1.2 billion. The offering is expected to close on or about June 5. In addition, the company said its majority stockholder Ayar Third Investment Company, an affiliate of the Public Investment Fund, has agreed to purchase more than 265 million shares in a private placement for approximately $1.8 billion. The private placement is expected to close on June 26. Lucid expects to use the net proceeds for general corporate purposes, which may include capital expenditures and working capital. Following the purchases, Ayar Third Investment Company will remain the majority stockholder of Lucid with approximately 60.5% ownership of the company's outstanding common stock. See Also: Chinese EV Giants Report May Deliveries: Li Auto, Nio, XPeng Numbers Compared TQJB Price Action: Lucid has a 52-week high of $21.78 and a 52-week low of $6.09. The stock was down 13% at $6.75 at the time of writing, per Benzinga Pro . Photo: courtesy of Lucid.
2023-06-01 12:33:46	GDQN	Cannabis Marketing Platform SpringBig Secures Major Financial Boost Via Equity Offering, Where Will The Funds Go?	SpringBig Holdings, Inc . (NASDAQ: GDQN ), a provider of SaaS-based marketing solutions, consumer mobile app experiences, and omnichannel loyalty programs to the cannabi s industry, announced on Thursday the closing of its $4 million public equity offering. The equity offering, for which Roth Capital Partners acted as the sole placement agent, raised gross cash proceeds before deducting the placement agent&rsquo;s fees and other offering expenses of approximately $3 million. In addition, roughly $1 million of the company&rsquo;s existing senior secured convertible note was canceled in exchange for shares in the offering at the offering price. Jeffrey Harris, CEO and chairman of the Boca Raton, Florida-based company, said the move results in a stronger balance sheet and &ldquo;adequate capital to fund our growth initiatives in the future and to beyond the point of generating positive operating cash flow.&rdquo; Following the completion of the public offering and payment of $750,000 to reduce further the outstanding principal, the amount remaining outstanding on the company&rsquo;s senior secured convertible note has now reduced to $6 million, with $0.5 million repayable during the remainder of the current year, and the balance repayable in roughly equal payments over a fifteen-month period extending to March 2025. Q2 Financial Projections The company expects results for the second quarter of 2023 to align with previously issued guidance, calling for revenue from $7.3 million to $7.6 million, representing 15% year-on-year growth at the mid-point. Adjusted EBITDA loss is expected to range between $0.9 million to $1.2 million, representing further improvement compared with the $1.3 million adjusted EBITDA loss reported in the first quarter. GDQN Price Action SpringBig&rsquo;s shares traded 1.00% higher at $0.3129 per share at the time of writing on Thursday. Related News Cannabis Software Platform Springbig Sets Its Foot At The 2022 Benzinga Capital Cannabis Conference SpringBig Stock Plummets On Pricing Of $4M Public Offering SpringBig's Q1 Earnings Up 16% YoY, Subscription Revenue Spikes 28% Photo: Courtesy of geralt and Kindel Media by Pixabay
2023-06-02 08:46:24	HMT	Wallbox Announces $48.6M Private Placement Of 18,832,432 Class A Ordinary Shares At A Price Of $2.58/Share	Wallbox N.V. (NYSE: HMT ) (&quot;Wallbox&quot;), a leading provider of electric vehicle (EV) charging and energy management solutions worldwide, today announced a private placement of ordinary shares pursuant to which Wallbox will sell 18,832,432 Class A ordinary shares for aggregate gross proceeds of $48.6 million to certain existing investors and strategic partners. Wallbox's ordinary shares will be sold to such investors at a price of $2.58 per share, and the private placement is expected to close on June 15, 2023, subject to the satisfaction of customary closing conditions. Wallbox has also agreed to file a registration statement for the resale of the ordinary shares purchased pursuant to the private placement. This transaction is designed to further strengthen the company's balance sheet and provide growth capital that will enable the continued execution of its strategic plan. Participants include, but are not limited to Orilla Asset Management, S.L. and other existing shareholders, including Enric Asunci&oacute;n, Co-founder and CEO of Wallbox. &quot;We continue to execute our strategic plan and are very well positioned to lead the market as consumers around the world transition to EVs. This transaction is a testament to the exceptional business we have built and our long-term vision,&quot; said Enric Asunci&oacute;n, Co-founder and CEO. The offer and sale of the Class A ordinary shares has not been, and will not be, registered under the Securities Act of 1933, as amended (the &quot;Securities Act&quot;), or any other securities laws, and the ordinary shares cannot be offered or sold except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and any other applicable securities laws. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities, in any state or jurisdiction in which such offer, solicitation or sale of these securities would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
2023-06-02 12:38:46	WDDC	Microbot Medical Announces $1.5M Registered Direct Offering Of 701,756 Shares Of Common Stock At A Price Of $2.1375/Share, Priced At-The-Market Under Nasdaq Rules	Microbot Medical Inc. (NASDAQ: WDDC ) today announced that it has entered into definitive agreements for the purchase and sale of 701,756 shares of the Company's common stock at a purchase price of $2.1375 per share of common stock in a registered direct offering priced at-the-market under Nasdaq rules. In addition, in a concurrent private placement, the Company will issue unregistered series C preferred investment options. The series C preferred investment options to purchase up to 350,878 shares of common stock have an exercise price of $2.075 per share and are immediately exercisable for a period of five and one-half years following issuance. The closing of the registered direct offering and the concurrent private placement is expected to occur on or about June 6, 2023, subject to the satisfaction of customary closing conditions. L.C. Wainwright & Co. is acting as the exclusive placement agent for the offerings.
2023-06-06 07:47:13	ESWK	ESWK Technologies Slumps After $8.5M Equity Offering	ESWK Technologies Ltd (NASDAQ: ESWK ) has entered into a definitive securities purchase agreement , dated as of June 5, 2023, with certain purchasers, each an unrelated third party to the company. The purchasers agreed to subscribe for and purchase an aggregate of 10 million shares at $0.85 per unit. Each unit consists of one ordinary share and one warrant to purchase one ordinary share at a price of $1.20 per share. The warrants will become exercisable for cash or on a cashless basis upon issuance and will expire one year after the issuance date. The company expects to receive net proceeds of approximately $8.47 million from the issuance and sale of the units. ESWK intends to use the net proceeds for working capital and general business purposes. Price Action : ESWK shares are trading lower by 10.5% at $1.36 in premarket on Tuesday.
2023-06-07 09:00:45	GQNG	Why TransCode Therapeutics Stock Is Trading Higher Premarket Today	TransCode Therapeutics Inc (NASDAQ: GQNG ) announced acceptance for publication by Frontiers in Molecular Biosciences of a preclinical study using TransCode's lead therapeutic candidate, TTX-MC138, in glioblastoma multiforme (GBM) . The findings of this study support further development of TTX-MC138 for GBM by identifying a potentially successful combination treatment protocol using TTX-MC138 with temozolomide (TMZ), currently the standard-of-care therapeutic. Treatment of human glioblastoma cells implanted in animals with the TTX-MC138 analog, MN-anti-miR10b, inhibited tumor cell growth and induced cell death. When combined with a sub-therapeutic dose of TMZ in a sequence-specific protocol, MN-anti-miR10b enhanced the cell-killing ability of TMZ, resulting in highly successful inhibition of tumor cell survival and invasiveness. The company says that in a preclinical model of pancreatic adenocarcinoma, administration of TTX-MC138 as monotherapy resulted in complete responses, manifested as regression without recurrence, in 40% of treated animals. This study comes on the heels of preclinical breast cancer studies demonstrating complete metastatic disease regressions. In addition to murine models of cancer, TTX-MC138 was successfully delivered and demonstrated preliminary efficacy in a case study of spontaneous feline mammary carcinoma. TransCode also priced its public offering of 2 million shares at $3.50 per share for gross proceeds of $7 million. Each common stock is offered with a Series A-1 warrant to purchase one share at an exercise price of $3.25 per share and a Series A-2 warrant to purchase one share at an exercise price of $3.25 per share . Price Action: GQNG shares are up 6.54% at $3.42 during the premarket session on the last check Wednesday.
2023-06-07 10:01:54	FQTF	Why Vaxart Stock Is Tumbling Today	Vaxart Inc (NASDAQ: FQTF ) shares are trading lower Wednesday after the company proposed a public offering of common stock . What Happened: Vaxart commenced an underwritten public offering . The company expects to grant to the underwriter a 30-day option to purchase up to an additional 15% of shares. All of the shares are being offered by Vaxart. Vaxart said it currently intends to use the net proceeds to support clinical and preclinical development of its product candidates, as well as for clinical trials and manufacturing. Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on a proprietary delivery platform. See Also: Why Lovesac Shares Are Gaining Today FQTF Price Action: Vaxart has a 52-week high of $4.61 and a 52-week low of 56 cents. The stock was down 27.4% at 90 cents at the time of writing, per Benzinga Pro . Photo: MasterTux from Pixabay.
2023-06-07 16:21:14	ZGDK	Nikola Adjourns And Will Reconvene Annual Meeting Of Stockholders On July 6, 2023 To Secure The Votes Needed For Proposal 2, To Increase The Authorized Number Of Shares Of Common Stock	VOTE NOW by phone at (855) 935-2562, if in North America, or 1 (551) 210-9929 internationally Vote NOW online at www.proxyvote.com PHOENIX, June 7, 2023 /PRNewswire/ -- Nikola Corporation (NASDAQ: ZGDK ), a global leader in zero-emissions transportation and energy infrastructure solutions, today announced that its 2023 Annual Meeting of Stockholders has been adjourned to July 6, 2023 at 1 p.m. Pacific Time to allow stockholders additional time to vote FOR Proposal 2. The requisite number of votes were received to approve Proposal 1, Election of Directors; Proposal 3, the Nasdaq Proposal; Proposal 4, Amendment to the Nikola Corporation 2020 Stock Incentive Plan; Proposal 5, Non-Binding Advisory Vote on Executive Compensation; and Proposal 6, Ratification of Appointment of Independent Registered Public Accounting Firm. However, Proposal 2, Amendment to Nikola's Restated Certificate to Increase the Authorized Number of Shares of Common Stock, requires a majority of all outstanding common stock for approval. More than 77% of shares voted through June 6 have been in favor of Proposal 2, but more time is needed to obtain the required vote. While the other proposals that have received the necessary votes required only a majority of shares voted on such proposals, Proposal 2 requires a majority of all outstanding common stock to pass. This means Proposal 2 has a much higher threshold needed for approval. Nikola also has a diverse stockholder base with many investors that hold small positions in the company, making every vote critical.
2023-06-07 16:26:30	OSR	Core & Main Announces Secondary Offering Of 14M Shares Of Common Stock And Share Repurchase From The Selling Stockholders 3,125,728 Shares Of Its Class A Common Stock And 1,874,272 Partnership Interests Of The Company's Subsidiary Core & Main Holdings, LP	Core & Main Inc. (NYSE: OSR ), a leader in advancing reliable infrastructure with local service, nationwide, today announced the launch of an underwritten secondary public offering of 14 million shares of its Class A common stock by certain selling stockholders. Core & Main is not offering any shares of Class A common stock in the offering and will not receive any proceeds from the offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed. In addition, Core & Main announced that concurrent with the completion of the offering, it expects to repurchase and redeem, as the case may be, from the selling stockholders 3,125,728 shares of its Class A common stock and 1,874,272 partnership interests of the Company's subsidiary Core & Main Holdings, LP (together with a corresponding number of shares of Class B common stock of Core & Main) at the same per share price to be paid by the underwriter to the selling stockholders in the offering. The closing of the repurchase is subject to the closing of the offering. The closing of the offering is not conditioned upon the closing of the repurchase. J.P. Morgan Securities LLC is acting as the sole underwriter for the offering. The underwriter may offer the shares of Class A common stock from time to time for sale in one or more transactions on the NYSE, in the over-the-counter market, through negotiated transactions or otherwise, at market prices prevailing at the time of sale, at prices related to prevailing market prices or at negotiated prices. A shelf registration statement (including a prospectus) relating to these securities has been filed with the SEC and is effective. Before investing, interested parties should read the shelf registration statement and other documents filed with the SEC for information about Core & Main and this offering. You may get these documents for free by visiting EDGAR on the SEC website at sec.gov . Alternatively, a copy may be obtained from J.P. Morgan, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, by telephone: 1-866-803-9204, or by emailing: prospectus-eg_fi@jpmchase.com . This press release shall not constitute an offer to sell or the solicitation of an offer to buy securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Any offers, solicitations or offers to buy, or any sales of securities will be made in accordance with the registration requirements of the Securities Act of 1933, as amended.
2023-06-08 08:35:39	TJSZ	Precipio, Inc. Announces Pricing Of $2M Registered Direct Offering And Concurrent Private Placement	Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: TJSZ ), today announced it has entered into securities purchase agreements with certain institutional investors for the purchase and sale of 4,125,000 shares of the Company's common stock and pre-funded warrants to purchase 319,445 shares of the Company's common stock in a registered direct offering and warrants to purchase up to 8,888,890 shares of common stock at a combined purchase price of $0.45 in a concurrent private placement (together with the registered direct offering, the &quot;offering&quot;). The pre-funded warrants will have a nominal exercise price of $0.001 per share and will be immediately exercisable and of indefinite term. The common warrants issued pursuant to the concurrent private placement will have an exercise price of $0.63 per share, will be initially exercisable beginning six months following the date of issuance and will expire five years from the initial exercise date. The closing of the offering is expected to occur on or about June 12, 2023, subject to the satisfaction of customary closing conditions. The net proceeds from the offering are expected to be approximately $2 million, excluding any proceeds that may be received upon the cash exercise of the warrants, after deducting the financial advisor's fees and estimated offering expenses payable by the Company. The Company intends to use the net proceeds of this offering for working capital and general corporate purposes. A.G.P./Alliance Global Partners is acting as the financial advisor for the offering.
2023-06-08 09:06:33	YSOE	Sunworks Announces $4.617M Registered Direct Offering Of 4.05M Shares Of Common Stock At A Price Of $1.14/Share	Sunworks, Inc. (NASDAQ: YSOE )(&quot;Sunworks&quot; or the &quot;Company&quot;), a leading provider of solar power and battery storage solutions for residential, agriculture, commercial, industrial, and public works markets, today announced that it has entered into a definitive agreement with a single ESG-focused institutional investor for the purchase and sale of 4,050,000 shares of the Company's common stock at a purchase price of $1.14 per share of common stock in a registered direct offering. The closing of the offering is expected to occur on or about June 9, 2023, subject to the satisfaction of customary closing conditions. Roth Capital Partners is acting as the exclusive placement agent for the offering. The gross proceeds to the Company from the offering are expected to be $4,617,000, before deducting the placement agent's fees and other offering expenses payable by the Company. The Company intends to use the net proceeds from the offering for working capital and other general corporate purposes.
2023-06-08 16:11:10	DHCD	First Watch Restaurant Group Announces Secondary Offering Of 3M Shares Of Common Stock	"First Watch Restaurant Group, Inc. (""DHCD"" or the ""Company"") (NASDAQ: DHCD ), a leading Daytime Dining concept serving breakfast, brunch and lunch, today announced the launch of an underwritten secondary offering (the ""Offering"") by certain funds managed by Advent International Corporation (the ""Selling Stockholders"") of 3,000,000 shares of the Company's common stock (""Common Stock""). The underwriter has a 30-day option to purchase up to an additional 450,000 shares of Common Stock at the public offering price, less underwriting discounts and commissions. The Selling Stockholders will receive all of the proceeds from the Offering. The Company is not selling any shares of Common Stock in the Offering and will not receive any proceeds from the Offering. Jefferies LLC is acting as the sole underwriter of the Offering."
2023-06-09 09:20:24	GVBB	Aytu BioPharma Announces Pricing Of $4M Public Offering Priced At-The-Market	"Aytu BioPharma, Inc. (NASDAQ: GVBB ), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced the pricing of its equity offering co-led by Nantahala Capital Management and Stonepine Capital Management with participation by Armistice Capital of (i) 1,743,695 shares of its common stock, and, in lieu of common stock to certain investors that so chose, pre-funded warrants to purchase 430,217 shares of its common stock (""Pre-Funded Warrants""), and (ii) accompanying Tranche A and Tranche B warrants (the ""Common Warrants"") to purchase 4,347,824 shares of its common stock priced at-the-market under Nasdaq rules (the ""Offering""). Gross proceeds, before deducting placement agent fees and other offering expenses, are expected to be approximately $4.0 million (assuming no exercise of the Common Warrants). The Offering is expected to close on June 13, 2023, subject to customary closing conditions. The Company anticipates that the closing of the Offering will extend the interest only period on the Company's $15 million senior secured loan facility with Avenue Venture Opportunities Fund, L.P. (the ""Avenue Note"") through its maturity date in January 2025."
2023-06-12 09:09:51	BMTY	Forza X1 Announces Pricing Of $8M Public Offering Of 5,334,000 Shares Of Common Stock At A Price Of $1.50/Share	"Forza X1, Inc. (NASDAQ: BMTY ) (""Forza,"" the ""Company""), a developer of electric sport boats aimed at promoting sustainable recreational boating, announced today the pricing of an underwritten public offering of 5,334,000 shares of its common stock at a price to the public of $1.50 per share for gross proceeds of approximately $8 million, before deducting underwriting discounts and offering expenses. In addition, Forza has granted the underwriters a 45-day option to purchase up to an additional 800,100 shares of common stock to cover over-allotments at the public offering price, less the underwriting discount. The offering is expected to close on June 14, 2023, subject to satisfaction of customary closing conditions. The Company intends to use the proceeds for the development of its manufacturing facility, for working capital and general corporate purposes. ThinkEquity is acting as sole book-running manager for the offering."
2023-06-12 16:05:45	DPCD	Disc Medicine Announces $100M Proposed Public Offering Of Common Stock And Pre-Funded Warrants	Disc Medicine, Inc. (NASDAQ: DPCD ) (Disc), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced that it has commenced an underwritten public offering of $100 million of shares of its common stock and, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of its common stock. All shares of common stock and pre-funded warrants to be sold in the offering will be offered by Disc. In addition, Disc intends to grant the underwriters a 30-day option to purchase up to an additional $15 million of shares of its common stock at the public offering price, less underwriting discounts and commissions. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Disc intends to use the net proceeds from the offering to fund research and clinical development of its current or additional product candidates, as well as for working capital and other general corporate purposes. Morgan Stanley, SVB Securities, Stifel and BMO Capital Markets are acting as joint book-running managers for the offering. Wedbush PacGrow is acting as lead manager for the offering.
2023-06-13 07:08:56	MMS	Advanced Health Intelligence Announced Earlier It Will Undertake AUD$5M Private Placement	Advanced Health Intelligence Ltd (NASDAQ: MMS ) (&ldquo;MMS&rdquo; or &ldquo;the Company&rdquo;) is pleased to announce that it has agreed to issue Orca Capital GMBH, an offshore institutional investor, 20,000,000 shares, raising $5,000,000 at 25 cents a share. MMS will use the net proceeds received from this offering primarily for the Company&rsquo;s current products and business development and marketing, with the remainder of the proceeds to be used for general corporate purposes, including, without limitation, investing in or acquiring companies that are synergistic with or complimentary to our technologies and working capital.
2023-06-13 08:07:04	WCMR	Movano Health Prices $8M Public Offering Of 8M Shares Of Common Stock At A Price Of $1/Share	"Movano Health (NASDAQ: WCMR ) (""Movano Health"" or the ""Company""), a purpose-driven healthcare solutions company at the intersection of medical and consumer devices and makers of the Evie Ring , today announced that it has priced an $8.0 million underwritten public offering of 8,000,000 shares of its common stock. The public offering price, before the underwriters' discount and commissions, for each share of common stock is $1.00. All of the securities in the underwritten public offering were sold by the Company. The Company has granted the underwriter a 30-day option to purchase up to an additional 15% of shares of common stock sold in the offering at the public offering price, less the underwriting discount. The offering is expected to close on June 15, 2023. The Company intends to use the net proceeds from the offering for general corporate purposes, which may include funding product development and commercialization activities. The Benchmark Company, LLC acted as sole book-running manager for the offering. The Liquid Venture Partners group at The Benchmark Company, LLC was responsible for sourcing and executing the offering. K&L Gates LLP represented the Company and Greenberg Traurig, LLP represented the underwriter in the transaction."
2023-06-13 09:41:24	CTCG	Auddia Announces Pricing Of $3.1M Registered Direct Offering Of 4.735M Shares Of Common Stock At A Price Of $0.65/Share, Priced At-The-Market	"Auddia Inc. (NASDAQ: CTCG ) (""Auddia"" or the ""Company""), developer of a proprietary AI platform for audio and innovative technologies for podcasts that is reinventing how consumers engage with audio, today announced that it has entered into a securities purchase agreement with institutional investors to purchase 4,735,000 shares of common stock in a registered direct offering priced at-the-market under Nasdaq rules. The offering price for each share of common stock will be $0.65. The gross proceeds to the Company from the registered direct are estimated to be approximately $3.1 million before deducting the placement agent's fees and other estimated offering expenses. The offering is expected to close on or about June 15, 2023, subject to the satisfaction of customary closing conditions. Maxim Group LLC is acting as the sole placement agent and Ladenburg Thalmann & Co. Inc. is acting as financial advisor for the offering. The shares of common stock are being offered pursuant to a shelf registration statement on Form S-3 (File No. 333-264227), which was declared effective by the United States Securities and Exchange Commission (""SEC"") on April 18, 2022. This press release shall not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction. A prospectus supplement relating to the shares of common stock will be filed by the Company with the SEC. When available, copies of the prospectus supplement relating to the registered direct offering, together with the accompanying prospectus, can be obtained at the SEC's website at www.sec.gov or from Maxim Group LLC, 300 Park Avenue, New York, NY 10022, at (212) 895-3745."
2023-06-13 12:52:52	ODSN	First Wave BioPharma Announces Exercise Of Warrants And Issuance Of New Warrants In A Private Placement For $2.4M Gross Proceeds Priced At-The-Market	"First Wave BioPharma, Inc. (""First Wave BioPharma"" or the ""Company"") (NASDAQ: ODSN ), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced it has entered into agreements with certain holders of its existing warrants exercisable for 1,681,667 shares of its common stock, in the aggregate, to exercise their warrants at a reduced exercise price of $1.15 per share, in exchange for new warrants as described below. The aggregate gross proceeds from the exercise of the existing warrants is expected to total approximately $2.4 million, before deducting financial advisory fees. The reduction in the exercise price of the existing warrants and the issuance of the new warrants was structured as an at-market transaction under Nasdaq rules. Roth Capital Partners is acting as the Company's financial advisor for this transaction. The shares of common stock issuable upon exercise of the warrants are registered pursuant to a registration statement on Form S-1 (File No. 333-267423) which was declared by the Securities and Exchange Commission (SEC) on October 6, 2022 and a registration statement on Form S-3 (File No. 333-268660) which was declared effective by the SEC on December 8, 2022. In consideration for the immediate exercise of the warrants for cash and the payment of $0.125 per share underlying the new warrants, the exercising holders will receive new warrants to purchase shares of common stock in a private placement pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended (the ""1933 Act""). The new warrants will be exercisable into an aggregate of up to 3,363,354 shares of common stock, at an exercise price of $1.15 per share and have a term of exercise equal to five years. The securities offered in the private placement have not been registered under the Securities Act of 1933, as amended, or applicable under state securities laws. Accordingly, the securities may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws. As part of the transaction, the Company has agreed to file a resale registration statement on Form S-3 with the Securities and Exchange Commission within 10 days of the closing to register the resale of the shares of common stock underlying the new warrants issued in the private placement. This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction."
2023-06-13 16:04:10	ZOXI	Radnet Announces Proposed $175M Underwritten Public Offering Of Common Stock	RadNet, Inc. (NASDAQ: ZOXI ), a national leader in providing high-quality, cost-effective, fixed-site outpatient diagnostic imaging services, announced today that it intends to offer and sell, subject to market and other conditions, an underwritten public offering of $175,000,000 of shares of common stock. In addition, RadNet intends to grant the underwriters a 30-day option to purchase up to an additional $26,250,000 shares of common stock. There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. RadNet intends to use the net proceeds from the proposed offering to pay down $100 million of its first lien term loans and for working capital and general corporate purposes. Jefferies and Raymond James are acting as joint bookrunning managers for the offering.
2023-06-13 16:19:43	PIT	What Happened To Brookfield Renewable Partners Stock Tuesday?	Brookfield Renewable Partners L.P. (NYSE: PIT ) shares traded lower Tuesday after the company announced plans to acquire Duke Energy Renewables . What To Know: Brookfield has agreed to acquire Duke Energy Renewables for $1.05 billion in equity proceeds. The company also announced $650 million in equity offering allocations, consisting of 8.2 million limited partnership units at $30.35 per unit and 7.43 million class A shares of BEPC at $33.80 per share. A subsidiary of Brookfield Reinsurance also agreed to purchase more than 5.14 million units at the offering price. The offering is expected to close on or about June 16. The net proceeds are expected to be used to fund current and future investment opportunities, as well as for general corporate purposes. Mizuho analyst Anthony Crowdell maintained Brookfield Renewable with a Neutral rating and raised the price target from $31 to $32 following the announcement. Related Link: Why Biogen Stock Is Trading Down Today PIT Price Action: Shares of PIT closed Tuesday down 5.56% at $29.87, according to Benzinga Pro . Image by andreas160578 from Pixabay
2023-06-13 16:45:57	FHVZ	Why MicroVision Stock Is Moving Lower After Hours	MicroVision Inc (NASDAQ: FHVZ ) shares are trading lower in Tuesday's after-hours session after the company filed for a mixed shelf offering . What Happened: According to a new regulatory filing, MicroVision said it may sell a mix of common stock, preferred stock and warrants from time to time in one or more transactions. The size of the offering was not disclosed. Microvision shares are up more than 120% over the last month. The stock traded up 3.75% during Tuesday's regular trading session on high volume of 7.862 million versus its 100-day average of 4.427 million, per Benzinga Pro . The stock traded as high as $8 per share this month before pulling back. MicroVision has high short interest, which could be a contributing factor to its outsized move in recent weeks. 27.07% of the float is currently sold short, per Benzinga Pro . From Last Week: MicroVision Continues To Spike Higher: Why A Retracement Is On The Horizon FHVZ Price Action: MicroVision shares were down 12.4% after hours at $5.65 at the time of publication. Photo: courtesy of MicroVision.
2023-06-14 08:14:34	OJGE	Cineverse Announces Pricing Of $8M Public Offering For The Purchase And Sale Of 2,666,667 Shares Of Common Stock At A Price Of $3/Share	Cineverse Corp. (NASDAQ: OJGE ), a global streaming technology and entertainment company with one of the world's largest portfolios of owned and operated streaming channels, today announced it has entered into securities purchase agreements for the purchase and sale of 2,666,667 shares of common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to 2,666,667 shares of common stock at a combined public offering price of $3.00 per share and accompanying warrant for aggregate gross proceeds of approximately $8 million, before deducting placement agent fees and other offering expenses. The warrants will have an exercise price of $3.00 per share, will be exercisable immediately and will expire five years from the issuance date. The closing of the offering is expected to take place on or about June 16, 2023, subject to the satisfaction of customary closing conditions. A.G.P./Alliance Global Partners is acting as the lead placement agent for the offering. Titan Partners Group, a division of American Capital Partners, LLC, is acting as co-placement agent for the offering. The Benchmark Company, LLC is acting as financial advisor for the offering.
2023-06-14 09:04:00	FHVZ	What's Driving MicroVision Stock Lower Wednesday?	Shares of lidar company MicroVision Inc (NASDAQ: FHVZ ) are moving lower Wednesday on the heels of a proposed public offering . What Happened: MicroVision announced plans to offer and sell shares of its common stock in an underwritten $75 million public offering. The company expects to grant the underwriters an option to purchase up to an additional $11.25 million in common stock at the public offering price. MicroVision said it plans to use the net proceeds from the offering for general corporate purposes. Microvision shares are up more than 120% over the last month. The stock traded up 3.75% on high volume Tuesday. FHVZ traded as high as $8 per share this month before pulling back. MicroVision has high short interest, which could be a contributing factor to its outsized move in recent weeks. 27.07% of the float is currently sold short, per Benzinga Pro . See Also: Airbus Raises Forecast For New And Old Aircraft Deliveries FHVZ Price Action: MicroVision shares were down 110.5% at $5.70 at the time of writing, according to Benzinga Pro . Photo: courtesy of MicroVision.
2023-06-14 09:30:48	GNRZ	Coeptis Therapeutics Holdings, Inc. Announces Pricing Of $3.5M Underwritten Offering	"Coeptis Therapeutics Holdings, Inc. (NASDAQ: GNRZ ) (""Coeptis"" or the ""Company""), a biopharmaceutical company developing innovative cell therapy platforms for cancer, today announced the pricing of an underwritten offering for gross proceeds of approximately $3.5 million to a single healthcare focused investor prior to deducting underwriting discounts and commissions and offering expenses. The offering is comprised of (i) 2,150,000 shares of common stock, (ii) 1,350,000 pre-funded warrants, (iii) 3,062,500 Series A Warrants with an exercise price of $1.65 per share and a term of five years following the initial exercise date, and (iv) 3,062,500 Series B Warrants with an exercise price of $1.65 per share and a term of five years following the initial exercise date. The warrants issued in this offering are fixed priced and do not contain any variable pricing, resets or priced based anti-dilution features. The pre-funded warrant is exercisable at $0.0001. The closing of the offering is expected to take place on or about June 16, 2023, subject to the satisfaction or waiver of customary closing conditions. Ladenburg Thalmann & Co. Inc. is acting as sole book-running manager in connection with this offering."
2023-06-15 08:31:05	OAGU	Precision Optics Announces $2.52M Private Placement Of Common Stock	"Precision Optics Corporation, Inc. (NASDAQ: OAGU ) (the ""Company""), a leading designer and manufacturer of advanced optical instruments for the medical and defense industries, today announced that it has entered into definitive agreements with institutional and accredited investors for the purchase and sale of 420,000 shares of the Company's common stock pursuant to a private placement, resulting in gross proceeds of approximately $2.52 million before deducting placement agent commissions and other estimated offering expenses. The closing of the offering is expected to occur on or about June 20, 2023, subject to the satisfaction of customary closing conditions. The definitive agreements contain a representation from the Company to the effect that there have been no material adverse developments with respect to the Company since the date of filing of its most recent report on Form 10-Q. A.G.P./Alliance Global Partners is acting as the sole placement agent for the private placement. The offer and sale of the foregoing securities is being made in a transaction not involving a public offering, and the securities have not been registered under the Securities Act of 1933, as amended (the ""Securities Act""), or applicable state securities laws. Accordingly, the securities may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws. Under an agreement with the investors, the Company agreed to file a registration statement with the U.S. Securities and Exchange Commission (the ""SEC"") covering the resale of the shares of common stock to be issued to the investors no later than 30 days after the closing and to use commercially reasonable efforts to have the registration statement declared effective as promptly as practicable thereafter, and in any event no later than 90 days after the filing of the initial registration statement in the event of a ""full review"" by the SEC. This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction."
2023-06-15 08:36:04	KCL	Nautilus, Inc. Announces $5M Registered Direct Offering Of 4,098,362 Shares Of The Company's Common Stock At A Price Of $1.22/Share	"Nautilus, Inc. (NYSE: KCL ) (the ""Company""), today announced that it has entered into a definitive securities purchase agreement with a certain institutional investor for the purchase and sale of 4,098,362 shares of the Company's common stock (or common stock equivalents) at a purchase price of $1.22 per share of common stock (or common stock equivalent) in a registered direct offering. The closing of the offering is expected to occur on or about June 20, 2023, subject to the satisfaction of customary closing conditions. In addition, in a concurrent private placement, the Company will issue to the investor warrants to purchase up to 4,098,362 shares of common stock. The warrants have an exercise price of $1.35 per share, will be exercisable six months following the date of issuance and will have a term of five and one-half years following the date of issuance. Roth Capital Partners is acting as the exclusive placement agent for the offering. The gross proceeds to the Company from this offering are expected to be approximately $5 million, before deducting the placement agent's fees and other offering expenses payable by the Company. The Company intends to use the net proceeds from this offering for general corporate purposes."
2023-06-15 09:29:34	SOVG	On June 14, Akerna Corp Entered Into A $500K Securities Purchase Agreement With A Private Investor And Sold 1M Shares Of Common Stock At A Price Of $0.50/Share	"- Reuters On June 14, 2023, Akerna Corp. (the "" Company "") entered into a securities purchase agreement (the "" Securities Purchase Agreement "") with a private investor (the "" Investor "") pursuant to which the Company issued and sold to the Investor an aggregate of 1,000,000 shares of common stock of the Company ("" Shares "") at an issue price of $0.50 per Share (the "" Per Share Price ""), for gross proceeds of $500,000.00 (the "" Share Purchase Price ""). The Shares were issued to the Investor pursuant to Rule 506(b) of Regulation D under the United States Securities Act of 1933, as amended (the "" U.S. Securities Act "") and Section 4(a)(2) thereunder pursuant to the representations and warranties of the Investor, including that the Investor was an ""accredited investor"" as defined in Rule 501(a) of Regulation D (the "" Offering "")."
2023-06-15 16:00:50	PRAB	Verastem Oncology Announces Proposed Public Offering Of Common Stock And Pre-Funded Warrants; No Terms Disclosed	Verastem Oncology, (NASDAQ: PRAB ), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that it intends to offer and sell shares of its common stock and pre-funded warrants in an underwritten public offering. In connection with the proposed offering, Verastem Oncology intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the public offering (including shares underlying the pre-funded warrants), at the public offering price, less underwriting discounts and commissions. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. All of the securities to be sold in the offering are to be sold by Verastem Oncology. RBC Capital Markets and Cantor are acting as joint book-running managers and representatives of the underwriters for the proposed offering. Verastem Oncology intends to use the net proceeds from the proposed public offering for (i) continued research and development of its product candidates (ii) potential launch of avutometinib and defactinib in low-grade serous ovarian cancer, and (iii) working capital and other general corporate purposes.
2023-06-16 08:17:01	FBRN	Panbela Announces Pricing Of ~$8.5M Public Offering Of 2.27M Shares Of Common Stock Or Pre-Funded Warrants In Lieu Thereof And Two Classes Of Warrants To Purchase Up To An Aggregate Of 4.54M Shares Of Its Common Stock At A Price Of $3.75/Share And Associated Public Warrants	"Panbela Therapeutics, Inc. (NASDAQ: FBRN ), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced the pricing of a public offering of (i) 2,270,000 shares of its common stock or pre-funded warrants in lieu thereof and (ii) two classes of warrants to purchase up to an aggregate of 4,540,000 shares of its common stock (the ""Public Warrants"") at a purchase price of $3.75 per share and associated Public Warrants. The Public Warrants will have an exercise price of $3.75 per share, are exercisable upon issuance, and will expire five years following the date of issuance. The offering is expected to close on or about June 21, 2023, subject to customary closing conditions. Roth Capital Partners is acting as sole placement agent of the offering. Gross proceeds, before deducting placement agent fees and commissions and offering expenses, are expected to be approximately $8.5 million. The Company intends to use the net proceeds from the proposed offering for the continued clinical development of its product candidates, working capital, business development and other general corporate purposes, which may include repayment of debt."
2023-06-16 08:23:53	FBRN	CORRECTION: Panbela Announces Pricing Of ~$8.5M Public Offering Of 2.27M Shares Of Common Stock Or Pre-Funded Warrants In Lieu Thereof And Two Classes Of Warrants To Purchase Up To An Aggregate Of 4.54M Shares Of Its Common Stock At A Price Of $3.75/Share	"Panbela Therapeutics, Inc. (NASDAQ: FBRN ), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced the pricing of a public offering of (i) 2,270,000 shares of its common stock or pre-funded warrants in lieu thereof and (ii) two classes of warrants to purchase up to an aggregate of 4,540,000 shares of its common stock (the ""Public Warrants"") at a purchase price of $3.75 per share and associated Public Warrants. The Public Warrants will have an exercise price of $3.75 per share, are exercisable upon issuance, and will expire five years following the date of issuance. The offering is expected to close on or about June 21, 2023, subject to customary closing conditions. Roth Capital Partners is acting as sole placement agent of the offering. Gross proceeds, before deducting placement agent fees and commissions and offering expenses, are expected to be approximately $8.5 million. The Company intends to use the net proceeds from the proposed offering for the continued clinical development of its product candidates, working capital, business development and other general corporate purposes, which may include repayment of debt."
2023-06-16 08:46:09	VDOH	Applied UV Announces Pricing Of $5M Underwritten Public Offering Of 5M Shares Of Common Stock And Pre-Funded Warrants At A Price Of $1/Share	"Applied UV, Inc. (NASDAQ: VDOH ) (""Applied UV"" or the ""Company""), a global leading provider of advanced food security and air and surface disinfection technology, announced the pricing of its underwritten public offering of 5.0 million shares of common stock (the ""Common Stock"") and pre-funded warrants at a public offering price of $1.00 per share (less $0.001 in exercise price per pre-funded warrant), for aggregate gross proceeds of approximately $5.0 million, prior to deducting underwriting discounts and other offering expenses. In addition, the Company has granted the underwriter a 45-day option to purchase up to an additional 750,000 shares of Common Stock at the public offering price per share, less the underwriting discounts and expenses, to cover over-allotments, if any. The Company expects to use the net proceeds of this offering for general corporate purposes, including new investments."
2023-06-16 10:22:42	VDOH	Applied UV Plunges After $5M Equity Offering	Applied UV Inc (NASDAQ: VDOH ) has priced its underwritten public offering of 5.0 million shares and pre-funded warrants at a public offering price of $1 per share. In addition, the company has granted the underwriter a 45-day option to purchase up to an additional 750,000 shares at the public offering price. Applied UV expects to use the net proceeds of the offering for general corporate purposes, including new investments. Applied UV provides proprietary surface and air pathogen elimination and disinfection technology focused on Improving indoor air quality, specialty LED lighting and luxury mirrors and commercial furnishings. Price Action : VDOH shares are trading lower by 41.6% at $1.10 on the last check Friday.
2023-06-16 13:55:36	HEIH	Clene's OSR-Au8 Shows Significant Reduction In Neurodegenerative Biomarker, Raises $40M Via Equity	Clene Inc (NASDAQ: HEIH ) reported new data demonstrating a statistically significant reduction of plasma neurofilament light chain (NfL) levels for OSR-Au8 treated participants compared to placebo after 24 weeks in the HEALEY ALS Platform Trial . NfL is a key biomarker of neurodegeneration. Also Read: Clene's Amyotrophic Lateral Sclerosis Candidate Delays Disease Progression, New Data Shows . OSR-Au8 treatment demonstrated significantly reduced plasma neurofilament light chain levels compared to the placebo at 24 weeks (p=0.04). In addition to the full analysis across all Regimen C participants, sensitivity analyses showed a consistent significant reduction in plasma NfL levels versus placebo observed in specific populations generally considered at greater risk of ALS disease progression. Analyses of NfL from serum samples specified as the primary blood matrix for analysis are underway. Additional biomarker and long-term survival data from the HEALEY ALS Platform Trial double-blind and open-label extension periods have been collected and are undergoing testing preparatory for analysis to be reported later this year. Concurrently, Clene priced its underwritten public offering of 50 million shares and two tranches of warrants at a combined price of $0.80 for gross proceeds of $40 million . Price Action: HEIH shares are down 14.8% at $0.90 on the last check Friday.
2023-06-16 16:09:11	DJFX	Turtle Beach Corporation Announces Termination Of Rights Agreement Which Was Originally Scheduled To Expire On March 28, 2024	"Turtle Beach Corporation (NASDAQ: DJFX , the ""Company""))))), a leading gaming headset and audio accessory brand, today announced that its Board of Directors (the ""Board"") has unanimously approved the termination of the Company's rights agreement, commonly referred to as a ""poison pill"", which was originally scheduled to expire on March 28, 2024. The rights agreement was amended to accelerate the expiration date to June 15, 2023, effectively terminating the agreement as of that date. ""Turtle Beach is committed to enhancing its governance policies for the benefit of stockholders,"" said Terry Jimenez, Chairman of the Board. ""The termination of the rights agreement advances that objective."" Stockholders are not required, nor do they need to take any action because of the termination of the rights agreement."
2023-06-20 09:06:17	THCN	Dragonfly Energy Announces Pricing Of $20M Underwritten Public Offering Of 10M Shares Of Common Stock At A Price Of $2/Share	Dragonfly Energy Holdings Corp. (NASDAQ: THCN ) (&quot;Dragonfly Energy&quot; or the &quot;Company&quot;), an industry leader in energy storage and producer of deep cycle lithium-ion storage batteries, today announced the pricing of an underwritten public offering of 10,000,000 shares of common stock and investor warrants to purchase up to an aggregate of 10,000,000 shares of common stock. Each share of common stock is being sold together with one investor warrant to purchase one share of common stock at a combined offering price of $2.00. The investor warrants have an exercise price of $2.00 per share, are immediately exercisable and will expire five years from the date of issuance. The Company has granted the underwriters a 45-day option to purchase up to an additional 1,500,000 shares of common stock, and/or investor warrants to purchase up to 1,500,000 shares of common stock, in any combinations thereof, at the public offering price per security, less the underwriting discounts and commission. The offering is expected to close on or about June 22, 2023, subject to customary closing conditions. The aggregate gross proceeds from this offering are expected to be approximately $20.0 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by the Company and excluding the exercise of any warrants. The Company intends to use the net proceeds from the offering for working capital and general corporate purposes. Roth Capital Partners is acting as lead bookrunner and as representative of the underwriters for the offering. Chardan is acting as an additional bookrunner for the offering.
2023-06-20 11:35:50	THCN	Why Dragonfly Energy Shares Are Plunging Today	Dragonfly Energy Holdings Corp (NASDAQ: THCN ) has priced its underwritten public offering of 10 million shares and investor warrants to purchase up to an aggregate of 10 million shares. Each share is being sold together with one investor warrant to purchase one share at a combined offering price of $2.00. The investor warrants have an exercise price of $2.00 per share, are immediately exercisable and will expire five years from the date of issuance. Also, the company has granted the underwriters a 45-day option to purchase up to an additional 1.5 million shares and warrants to purchase up to 1.5 million shares. The aggregate gross proceeds from the offering are expected to be approximately $20.0 million. Dragonfly expects to use the net proceeds from the offering for working capital and general corporate purposes. The offering is expected to close on or about June 22, 2023. Price Action : THCN shares are trading lower by 47.7% at $1.46 on the last check Tuesday.
2023-06-20 17:00:03	PBAT	Madison Square Garden Entertainment Reports Secondary Offering Of 5.25M Shares By Selling Stockholder Sphere Entertainment	In addition, under MSG Entertainment's existing $250 million share repurchase authorization, MSG Entertainment intends to repurchase directly from the Selling Stockholder a number of shares equivalent to approximately $25 million. Upon completion of the offering and share repurchase, assuming the underwriters' option to purchase additional shares is not exercised, the Selling Stockholder is expected to beneficially own 25.1% of MSG Entertainment's Class A common stock.
2023-06-21 08:42:03	QXFG	DiaMedica Therapeutics Announces $37.5M Private Placement Of 11,011,406 Common Shares At A Purchase Price Of $3.40/Share	DiaMedica Therapeutics Inc. (NASDAQ: QXFG ), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases (&quot;DiaMedica&quot; or the &quot;Company&quot;), today announced it has entered into definitive agreements to sell its common shares in a private placement with accredited investors. The transaction is expected to result in gross proceeds of $37.5 million. Pursuant to the terms of the securities purchase agreements, the Company will issue a total of 11,011,406 common shares at a purchase price of $3.40 per share, equal to the average per share closing price of the Company's common shares for the five trading days ended June 20, 2023, except in the case of DiaMedica management who agreed to a higher purchase price of $3.91 per share, equal to the closing sale price of the Company's common shares on June 20, 2023. The private placement is expected to close on or about June 23, 2023, subject to the satisfaction of customary closing conditions. The Company expects to use the net proceeds from the private placement to continue its clinical and product development activities for DM199, including its pivotal Phase 2/3, ReMEDy2 clinical trial, and for other working capital and general corporate purposes. The Company believes that with the addition of this funding, the Company's cash resources will be sufficient to fund the Company's ReMEDy2 trial through the completion of the interim analysis. Earlier today, DiaMedica also announced that the U.S. Food and Drug Administration (&quot;FDA&quot;) has removed the clinical hold on the Company's Phase 2/3 ReMEDy2 clinical trial studying the use of the Company's product candidate, DM199, to treat acute ischemic stroke patients. Craig-Hallum Capital Group LLC acted as the placement agent for the private placement investment by certain of the investors. Lake Street Capital Markets, LLC acted as financial advisor to the Company. Fox Rothschild LLP and Pushor Mitchell LLP acted as counsel to DiaMedica in the private placement and Mintz Levin acted as counsel for certain investors in the private placement. The offer and sale of the foregoing securities in the private placement have not been registered under the U.S. Securities Act of 1933, as amended (the &quot;Securities Act&quot;), or any state or other applicable jurisdiction's securities laws, and may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and applicable state and other securities laws. The Company has agreed to file a registration statement with the U.S. Securities and Exchange Commission registering the resale of the common shares issued in the private placement. This press release shall not constitute an offer to sell or the solicitation of an offer to buy the foregoing securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.
2023-06-21 10:41:11	ZNTC	ToughBuilt Industries Plunges Following $4.5M Equity Offering	ToughBuilt Industries Inc (NASDAQ: ZNTC ) has priced a public offering of 10.97 million shares and warrants at $0.41 per share. The warrants will have an exercise price of $0.29 per share, are exercisable upon issuance, and will expire five years following the date of issuance. The gross proceeds to the company from the offering are expected to be $4.5 million. ToughBuilt intends to use the net proceeds from the offering for general corporate purposes, including working capital. The closing of the offering is expected to occur on or about June 23, 2023. Price Action : ZNTC shares are trading lower by 47% at $0.2960 on the last check Wednesday. Photo Via Company
2023-06-21 11:35:10	PBAT	Why Madison Square Garden Entertainment Shares Are Tumbling Today	Madison Square Garden Entertainment Corp (NYSE: PBAT ) shares are trading lower Wednesday after the company announced a secondary offering . What Happened: After the close on Tuesday, MSG Entertainment announced that Sphere Entertainment Group commenced an underwritten secondary offering of 5.25 million shares of PBAT common stock. Sphere Entertainment intends to grant the underwriters a 30-day option to purchase up to an additional 787,500 shares at the offering price. MSG Entertainment said it intends to repurchase approximately $25 million worth of its shares directly from the selling stockholder. Sphere Entertainment will receive all of the net proceeds from the offering. MSG Entertainment said it will not be selling any shares as part of the offering. See Also: Why UPS Stock Is Sliding Wednesday PBAT Price Action: MSG Entertainment shares were down 9.56% at $35.85 at the time of publication, according to Benzinga Pro . Photo: Andrew Scozzari from Pixabay.
2023-06-21 11:40:11	QXFG	DiaMedica Raises $37.5M Via Equity Offering, Aiding Development Activities For DM199	DiaMedica Therapeutics Inc. (NASDAQ: QXFG ) has entered into an agreement with accredited investors that have agreed to provide up to $37.5 million in gross proceeds through a private placement . The company will issue 11.01 million common shares at a purchase price of $3.40 per share. The value is equal to the average per share closing price of the company's common shares for the five trading days ended June 20, 2023. DiaMedica management agreed to a higher purchase price of $3.91 per share. The private placement is expected to close on or about June 23, 2023, subject to the satisfaction of customary closing conditions. The company expects to use the net proceeds from the private placement to continue its clinical and product development activities for DM199, including its pivotal Phase 2/3, ReMEDy2 clinical trial, and other working capital and general corporate purposes. The proceeds will also fund the ReMEDy2 trial through the completion of the interim analysis. Earlier today, DiaMedica also announced that the FDA removed the clinical hold on the Phase 2/3 ReMEDy2 clinical trial studying the use of product candidate DM199 to treat acute ischemic stroke patients. Price Action: QXFG shares are trading lower by 5.63% to $3.69 on the last check Wednesday.
2023-06-21 16:03:10	ZPPQ	Gulfport Energy Announces Public Offering Of 1.3M Shares Of Common Stock By Selling Stockholders; Co Plans To Purchase $25M Of Shares From Selling Stockholders, Part Of Existing $400M Share Repurchase Program	Gulfport Energy Corporation (NYSE: ZPPQ ) (&quot;Gulfport&quot; or the &quot;Company&quot;) today announced the commencement of an underwritten public offering of 1,300,000 shares of its common stock by certain stockholders (the &quot;Offering&quot;). Such selling stockholders intend to grant the underwriters a 30-day option to purchase up to an additional 195,000 shares of the Company's common stock to cover any overallotments. Gulfport will not sell any shares of its common stock in the Offering and will not receive any proceeds from the sale of the shares being offered by the selling stockholders. The Offering is subject to market and other conditions, and there can be no assurance as to whether or when the Offering may be completed. In addition, the Company announced that concurrent with the closing of the Offering, it intends to purchase from certain of the selling stockholders approximately $25 million of shares of the Company's common stock at a price per share equal to the per share purchase price to be paid by the public in the Offering (the &quot;Concurrent Repurchase&quot;). The Concurrent Repurchase is part of the Company's existing $400 million share repurchase program and will reduce remaining availability thereunder. The Offering is not conditioned upon the closing of the Concurrent Repurchase, but the Concurrent Repurchase is conditioned upon the closing of the Offering. BofA Securities, J.P. Morgan and Evercore ISI are acting as joint book-running managers for the Offering. The Offering will be made only by means of a prospectus supplement and the accompanying base prospectus, which was filed as part of an effective shelf registration statement filed with the Securities and Exchange Commission (the &quot;SEC&quot;) on Form S-3 (File No. 333-264674). Copies of the preliminary prospectus supplement and accompanying base prospectus relating to the Offering, as well as copies of the final prospectus supplement once available, may be obtained on the SEC's website at www.sec.gov or by contacting: BofA Securities, at NC1-022-02-25, 201 North Tryon Street, Charlotte, NC 28255-0001, Attention: Prospectus Department, or by email at dg.prospectus_requests@bofa.com ; J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, at 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at (866) 803-9204, or by email at prospectus-eq_fi@jpmchase.com ; or Evercore Group L.L.C., at 55 East 52nd Street, 35th Floor, New York, New York 10055, Attention: Equity Capital Markets, by telephone at (888) 474-0200, or by email at ecm.prospectus@evercore.com . This press release shall not constitute an offer to sell, a solicitation to buy or an offer to purchase or sell any securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
2023-06-21 17:01:30	LETK	Why AlloVir Stock Is Tumbling After Hours	AlloVir Inc (NASDAQ: LETK ) shares are trading lower in Wednesday's after-hours session after the company proposed a public offering . What Happened: AlloVir said it commenced a proposed underwritten public offering of $75 million worth of its common stock. The company intends to grant the underwriters a 30-day option to purchase up to an additional 15% of shares in the offering. AlloVir is a late clinical-stage cell therapy company focused on restoring natural immunity against life-threatening viral diseases in pediatric and adult patients with weakened immune systems. See Also: KB Home Shares Climb On Q2 Earnings Beat, Strong Guidance LETK Price Action: AlloVir has a 52-week high of $10.22 and a 52-week low of $3.23. The stock was down 19.1% at $3.99 at the time of writing, according to Benzinga Pro . This illustration was generated using artificial intelligence via MidJourney.
2023-06-21 21:23:27	LETK	AlloVir Priced 20M Share Offering At $3.75/Share	AlloVir, Inc. (NASDAQ: LETK ), a late clinical-stage cell therapy company, today announced the pricing of an underwritten public offering of 20,000,000 shares of its common stock at a public offering price of $3.75 per share. The gross proceeds to AlloVir from the offering, before deducting underwriting discounts and commissions and other estimated offering expenses, are expected to be $75.0 million. All shares in the offering are to be sold by AlloVir. In addition, AlloVir has granted the underwriters a 30-day option to purchase up to an additional 3,000,000 shares of its common stock at the public offering price, less underwriting discounts and commissions. The offering is expected to close on or about June 26, 2023, subject to customary closing conditions. J.P. Morgan, Morgan Stanley and BofA Securities are acting as joint book-running managers for the proposed offering.
2023-06-22 08:02:59	WNGI	MamaMancini's Reports Pricing Of Secondary Offering Of 6,281,085 Shares Of Common Stock By Selling Stockholders At A Price Of $2.50 Per Share	"MamaMancini's Holdings, Inc. (NASDAQ: WNGI ), a leading national marketer and manufacturer of fresh Deli prepared foods, today announced the pricing of an underwritten public secondary offering of 6,281,085 shares of its common stock by certain selling stockholders affiliated with Carl F. Wolf (the ""Selling Stockholders"") at a price to the public of $2.50 per share. In addition, the Selling Stockholders have granted the underwriters of the offering a 30-day option to purchase up to 942,163 additional shares of common stock at the public offering price, less underwriting discounts and commissions. MamaMancini's is not selling any shares in the offering, nor will MamaMancini's receive any of the proceeds from the sale of the shares being offered by the Selling Stockholders. The Selling Stockholders will bear the costs associated with the sale of such shares, including underwriting discounts and commissions. The offering is expected to close on or about June 26, 2023, subject to customary closing conditions. Lake Street Capital Markets, LLC is acting as sole book-running manager for this offering."
2023-06-22 08:04:12	USJN	IGM Announces Pricing Of $107.3M Upsized Public Offering Of 3,285,327 Shares Of Its Voting Common Stock And 7,312,500 Shares Of Its Non-Voting Common Stock At $8/Share; Also Concurrent Private Placement Of 2,812,500 At $8/Share	IGM Biosciences, Inc. (NASDAQ: USJN ) today announced the pricing of its upsized underwritten public offering of 3,285,327 shares of its voting common stock and 7,312,500 shares of its non-voting common stock, in each case at a price to the public of $8.00 per share. In addition, IGM has granted the underwriters a 30-day option to purchase up to an additional 1,589,673 shares of its voting common stock at the public offering price, less underwriting discounts and commissions. All of the shares in the public offering will be sold by IGM. The public offering is expected to close on or about June 26, 2023, subject to satisfaction of customary closing conditions. Concurrent with the public offering, IGM intends to sell, subject to the consummation of the public offering and other customary conditions, in a private placement exempt from the registration requirements of the Securities Act of 1933, as amended (the Securities Act), 2,812,500 shares of non-voting common stock to certain institutional and other accredited investors affiliated with or managed by Redmile Group, LLC at a sale price equal to $8.00 per share. However, the consummation of the public offering is not contingent on the consummation of this concurrent private placement. IGM expects to receive total gross proceeds of approximately $107.3 million from the public offering and the concurrent private placement, before deducting the underwriting discounts and commissions and estimated offering expenses payable by IGM in connection with the public offering and the concurrent private placement. BofA Securities, Jefferies, Stifel, and Guggenheim Securities are acting as joint book-running managers for the public offering.
2023-06-22 08:33:59	VKUA	NeuroSense Announces Pricing of $4.5M Registered Direct Offering Of 3M Ordinary Shares At A Price OF $1.50/Share And Concurrent Private Placement	NeuroSense Therapeutics Ltd. (NASDAQ: VKUA ) (&quot;NeuroSense&quot;), a company developing treatments for severe neurodegenerative diseases, today announced it has entered into a securities purchase agreement with a single health-care focused institutional investor for the purchase and sale of 3,000,000 ordinary shares (or ordinary share equivalents in lieu thereof) in a registered direct offering and ordinary warrants to purchase up to 3,000,000 ordinary shares in a concurrent private placement (together with the registered direct offering, the &quot;offering&quot;) at a combined purchase price of $1.50. The ordinary warrants issued pursuant to the concurrent private placement will have an exercise price of $1.50 per ordinary share, will be immediately exercisable and will expire 5 years from the initial exercise date. The closing of the offering is expected to occur on or about June 26, 2023, subject to the satisfaction of customary closing conditions. The gross proceeds from the offering are expected to be approximately $4.5 million, excluding any proceeds that may be received upon the exercise of the warrants, before deducting placement agent fees and other offering expenses payable by the Company. The Company intends to use the net proceeds of this offering to advance the clinical development of its lead product candidate, PrimeC for ALS, for the clinical development and preclinical and clinical research and development in support of potential investigational new drug applications for Alzheimer's disease, for Parkinson's disease and for other indications, for future research and development of new product candidates and for working capital and general corporate purposes. A.G.P./Alliance Global Partners is acting as sole placement agent for the offering.
2023-06-22 08:53:40	LETK	Why AlloVir Stock Is Diving Thursday	AlloVir Inc (NASDAQ: LETK ) shares are trading lower after the company priced a public offering of common stock . What Happened: AlloVir commenced a proposed underwritten public offering of 20 million shares after the bell on Wednesday. The company said it will price the offering at $3.75 per share. Gross proceeds from the offering are expected to total $75 million. AlloVir also granted the underwriters a 30-day option to purchase up to an additional 3 million shares at the public offering price. AlloVir is a late clinical-stage cell therapy company focused on restoring natural immunity against life-threatening viral diseases in pediatric and adult patients with weakened immune systems. See Also: Wells Fargo Strategist Doesn't See Tech Rally Stalling Until Fed Turns Aggressive, Says Market Resembles Boom Of Year 2000 LETK Price Action : AlloVir has a 52-week high of $10.22 and a 52-week low of $3.23. The stock was down 23.3% at $3.78 at the time of publication, according to Benzinga Pro . Photo: Lorenzo Cafaro from Pixabay.
2023-06-22 09:59:17	PFXS	Innovative Eyewear Shares Are Tumbling: What's Going On?	Innovative Eyewear Inc (NASDAQ: PFXS ) shares are trading lower Thursday after the company announced the pricing of a public offering . What To Know: Innovative Eyewear announced that it will offer 4.5 million units, with each unit consisting of one share of common stock and one warrant to purchase one share of common stock, for $1.05 per unit. Gross proceeds are expected to total approximately $4.7 million. The offering is expected to close on June 26. Earlier this week, Innovative Eyewear announced a licensing agreement with Authentic Brands for Reebok smart eyewear . &quot;Few names are as renowned as Reebok in the athletic marketplace. Our forthcoming Reebok smart eyewear collection, powered by Lucyd, will continue Reebok's legacy of bold and beautiful craftsmanship coupled with innovation and will align perfectly with today's active lifestyles,&quot; said Harrison Gross , CEO of Innovative Eyewear. The first Reebok smart eyewear collection is expected to launch early in 2024. See Also: Third Consecutive Week Of Higher-Than-Expected Unemployment Claims: Is US Job Market Losing Steam? PFXS Price Action: Innovative Eyewear shares were down 38.1% at 87 cents at time of publication, according to Benzinga Pro . This illustration was generated using artificial intelligence via MidJourney.
2023-06-22 10:15:01	WNGI	MamaMancini's Drops After 18% Discount On Shareholder Equity Offering	MamaMancini's Holdings, Inc. (NASDAQ: WNGI ) has priced the underwritten public secondary offering of 6.3 million shares by certain selling shareholders affiliated with Carl F. Wolf at $2.50 per share. The offer price represents an 18.6% discount to the company's closing price on June 21. In addition, the selling stockholders have granted the underwriters of the offering a 30-day option to purchase up to 942,163 additional shares at the public offering price. MamaMancini's is not selling any shares in the offering, nor will it receive any of the proceeds. The offering is expected to close on or about June 26, 2023. Price Action : WNGI shares are trading lower by 10.2% at $2.75 on the last check Thursday.
2023-06-23 07:51:29	PBAT	Madison Square Garden Entertainment Late Thursday Announced 5.,25M Share Offering By Sphere Entertainment Priced At $31/Share	Madison Square Garden Entertainment Corp. (NYSE: PBAT ) (the &quot;Company&quot; or &quot;MSG Entertainment&quot;) today announced the pricing of the previously announced underwritten secondary offering by Sphere Entertainment Group, LLC (the &quot;Selling Stockholder&quot;) of 5,250,000 shares of MSG Entertainment's Class A common stock at a public offering price of $31.00 per share. The shares are expected to be delivered on or about June 27, 2023, subject to the satisfaction of customary closing conditions. The Selling Stockholder has granted the underwriters a 30-day option to purchase up to an additional 787,500 shares of MSG Entertainment's Class A common stock at the public offering price, less underwriting discounts and commissions.
2023-06-23 09:02:17	NYG	NYG (Security Matters) Public Limited Company Announces Pricing Of $3.2M Public Offering Of 13,333,333 Shares And Warrants At A Price Of $0.24/Share	"NYG (Security Matters) PLC (NASDAQ: NYG , SMXWW))))) announced today an underwritten public offering of securities for gross proceeds of approximately $3.2 million, prior to deducting underwriting discounts and commissions and offering expenses payable by the Company and excluding any exercise of the underwriter's option to purchase any additional securities as described herein. The public offering is comprised of (i) 13,333,333 ordinary shares of the Company, par value $0.0001 per share (or ordinary share equivalents), (ii) 13,333,333 warrants in the form of Warrant A to subscribe for 13,333,333 ordinary shares, at an exercise price of $0.24 per share and (iii) 13,333,333 warrants in the form of Warrant B to subscribe for 13,333,333 ordinary shares, at an exercise price of $0.24 per share. The Company also granted the underwriter a 45-day option to subscribe for, in the aggregate, (a) up to 1,999,999 additional ordinary shares (or ordinary share equivalents) at a subscription price per share of $0.24, and/or (b) 1,999,999 warrants in the form of Warrant A to subscribe for an aggregate of 1,999,999 ordinary shares at an exercise price of $0.24 per warrant, and/or (c) 1,999,999 warrants in the form of Warrant B to purchase an aggregate of 1,999,999 ordinary shares at a purchase price of $0.24 per warrant, which may be subscribed for in any combination. EF Hutton, division of Benchmark Investments, LLC is acting as sole underwriter and bookrunner for this offering. Ruskin Moscou Faltischek P.C. and Arthur Cox LLP represented the Company and Lucosky Brookman LLP represented EF Hutton, division of Benchmark Investments, LLC. The Securities and Exchange Commission (""SEC"") declared effective a registration statement on Form F-1 relating to these securities on June 22, 2023. A final prospectus relating to this offering will be filed with the SEC. The offering is being made only by means of a prospectus, copies of which may be obtained, when available, from: EF Hutton, division of Benchmark Investments, LLC, 590 Madison Avenue, 39th Floor, New York, NY 10022, at (212) 970-5150."
2023-06-26 08:44:12	FCXA	FCXA Pharmaceuticals Announces $85M Private Placement Financing	Financing led by Nextech and includes participation from EcoR1 Capital, Frazier Life Sciences, Venrock Healthcare Capital Partners, and Boxer Capital Pro forma cash and investments expected to fund current operating plan into late 2025 SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, June 26, 2023 (GLOBE NEWSWIRE) -- FCXA Pharmaceuticals, Inc. (NASDAQ: FCXA ), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today has agreed to sell approximately 12.1 million shares of its common stock (or pre-funded warrants in lieu thereof) to a select group of institutional and accredited healthcare specialist investors in a private placement, at a price per share of $7.00, representing a premium of approximately 15% to FCXA's 30-day volume-weighted average price and approximately 8% to the closing price on June 23, 2023. The pre-funded warrants will have an exercise price of $0.0001 per share of common stock, will be immediately exercisable, and will remain exercisable until exercised in full. The financing is expected to close on June 27, 2023, subject to customary closing conditions. FCXA anticipates the gross proceeds from the private placement to be approximately $85 million, before deducting any offering related expenses. The financing includes participation from new and existing institutional investors and is being led by Nextech1 with participation from EcoR1 Capital, Frazier Life Sciences, Venrock Healthcare Capital Partners, and Boxer Capital. Participating investors entered into confidentiality agreements and executed lock-up agreements with FCXA to restrict their ability to sell FCXA shares. &quot;As the competitive profiles of multiple of our clinical programs begin to emerge with respect to internally generated data and competitor updates, the added financial firepower provided by this blue-chip syndicate of investors, both new and existing and with whom we've had longstanding relationships, allows us to aggressively advance our pipeline for the benefit of patients,&quot; said Jacob N. Chacko, MD, chief executive officer. &quot;The extended cash runway positions us well, and we look forward to presenting initial clinical data from our three clinical programs over the coming quarters while continuing to advance our mission of overcoming resistance in cancer.&quot; &quot;We are thrilled to become long-term partners to FCXA's ambitious management team at this critical inflection point as they look to accelerate the development of their pipeline of differentiated programs with clinical profiles that are now emerging,&quot; said Kanishka Pothula, Partner at Nextech. &quot;We believe that this team's broad capabilities spanning discovery research, translational expertise, thoughtfully-designed clinical trials, and strong business development networks, combined with their data driven decision-making and financial discipline, uniquely position FCXA to achieve meaningful impact on patients' lives.&quot; FCXA anticipates the following upcoming milestones: FCXA-114: Report initial safety, PK/PD, and preliminary antitumor activity data from ongoing single agent Phase 1b study in patients with EGFR/HER2-mutated cancers in the second half of 2023. FCXA-533: Report initial safety, PK/PD, and preliminary antitumor activity data from ongoing single agent Phase 1b study in patients with multiple myeloma in the second half of 2023. FCXA-944: Report initial safety, PK/PD, and preliminary antitumor activity data from ongoing single agent Phase 1b study in patients with prostate cancer in the first quarter of 2024. FCXA intends to use the net proceeds from the proposed financing to fund research and development of its clinical-stage product candidates and research programs and for working capital and general corporate purposes. The proceeds from this financing, combined with current cash, cash equivalents and marketable securities, is expected to be sufficient to fund the current operating plan into late 2025. The securities described above have not been registered under the Securities Act of 1933, as amended. Accordingly, these securities may not be offered or sold in the United States, except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act. FCXA has agreed to file a registration statement with the U.S. Securities and Exchange Commission (the &quot;SEC&quot;) registering the resale of the shares of common stock and the shares of common stock issuable upon exercise of the pre-funded warrants issued in this private placement. Any offering of the securities under the resale registration statement will only be made by means of a prospectus. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.
2023-06-26 12:34:32	FCXA	Why Oric Pharmaceuticals Stock Is Shooting Higher Today	Oric Pharmaceuticals, Inc. (NASDAQ: FCXA ) has agreed to sell approximately 12.1 million shares of its common stock to a select group of institutional and accredited healthcare specialist investors in a private placement for $7 a piece. Gross proceeds from the private placement will be approximately $85 million before deducting any offering-related expenses. The private placement offers a premium of approximately 15% to FCXA's 30-day volume-weighted average price and around 8% to the closing price on June 23, 2023. The proceeds from this financing, cash equivalents, and marketable securities are expected to fund the current operating plan into late 2025. &quot;The extended cash runway positions us well, and we look forward to presenting initial clinical data from our three clinical programs over the coming quarters while continuing to advance our mission of overcoming resistance in cancer,&quot; said Jacob N. Chacko, MD, chief executive officer. Price Action: FCXA shares are trading higher by 15% to $7.51 on the last check Monday.
2023-06-27 07:43:20	TQJB	Lucid's Power Surge: Why Stock Is Poised To Open Stronger Again Today	Lucid Group, Inc . (NASDAQ: TQJB ) shares are surging in premarket trading , with the stock on track to open higher for a second consecutive day. What Happened : In a recent SEC filing, Lucid, the California-based EV startup, disclosed that its majority owner, the Saudi Public Investment Fund, acquired 265.7 million shares at $6.83 per share, signaling a premium over Friday's closing price of $5.55. This transaction could generate approximately $1.82 billion in gross proceeds for Lucid. Following the purchase, the Saudi Public Investment Fund holds 1.367 billion shares with shared voting rights and 8.04 million shares with sole voting rights, resulting in a total ownership stake of 60.49%. This private placement aligns with Lucid's previous announcement to raise funds , aiming for $1.2 billion through a common stock offering and an additional $1.82 billion through the placement of shares to its Saudi promoter. See Also: Best Electric Vehicle Stocks Monday's Catalyst : On Monday, Lucid shares experienced a strong early surge, reaching a peak gain of 14.8% before retracing some of the advances and closing at $5.55, up 1.46%. The stock's upward momentum was driven by the company's partnership with British luxury automaker Aston Martin , wherein Lucid will supply powertrain and battery system technology in exchange for $232 million. Regarding this deal, Gary Black of Future Fund commented, &#8220;Aston Martin is effectively paying $70K per car for TQJB's battery technology. That seems a bit rich to me.&#8221; In premarket trading, Lucid shares climbed 5.41% to $5.85, according to Benzinga Pro data. Check out more of Benzinga's Future Of Mobility coverage by following this link . Read Next: Why Lordstown Stock Is In Freefall Premarket Today
2023-06-27 09:20:24	LFDA	Ispire Raises $8M Via Equity Offering Aiding Manufacturing Operations	Ispire Technology Inc. (NASDAQ: LFDA ) closed a private placement of 1.12 million shares at a purchase price of $7.1318 a piece. The company raised approximately $8 million in gross proceeds from the private placement. Ispire Technology plans to invest the proceeds in manufacturing operations in Vietnam and California, with the execution of research and development activities. The private placement was completed on June 26, 2023. Also Read: Ispire Technology Revenue Grows 26.9% YoY Thanks To Tobacco And Cannabis Vaping Products In April 2023, Ispire closed the initial public offering of 2.70 million shares of common stock at $7 per share. The stock began trading on NASDAQ on April 4, 2023. Price Action: LFDA shares are trading higher by 9.13% to $8.49 in the premarket session on the last check Tuesday.
2023-06-27 16:49:36	RUVX	AST SpaceMobile Stock Is Tumbling After Hours: What's Going On?	AST SpaceMobile Inc (NASDAQ: RUVX ) shares are moving lower in extended trading Tuesday after the company announced a public offering of common stock . The Details: AST SpaceMobile has launched a public offering of 12 million shares. The company intends to use the proceeds for general corporate purposes, including expected cash payments related to launch services and additional equipment in the third quarter. The shares are expected to be offered from time to time in one or more transactions on the Nasdaq, the over-the-counter market and through negotiated transactions. The pricing is subject to prevailing prices at the time of the sales. AST SpaceMobile aims to build the first and only space-based cellular broadband network accessible directly by standard mobile phones. See Also: Why AeroVironment Stock Is Taking Off After The Close RUVX Price Action: AST SpaceMobile shares were down 11.3% after hours at $5.65 at the time of publication, according to Benzinga Pro . Photo: Arek Socha from Pixabay.
2023-06-28 08:24:53	RUVX	Why AST SpaceMobile Shares Are Falling Wednesday	AST SpaceMobile Inc (NASDAQ: RUVX ) shares are trading lower Wednesday after the company announced a public offering of common stock . What Happened: AST SpaceMobile priced a public offering of 12.5 million shares for gross proceeds of $59.4 million. The company intends to use the proceeds for general corporate purposes, including expected cash payments related to launch services and additional equipment in the third quarter. The shares are expected to be offered from time to time in one or more transactions on the Nasdaq, the over-the-counter market and through negotiated transactions. The offering is expected to close on June 30. AST SpaceMobile aims to build the first and only space-based cellular broadband network accessible directly by standard mobile phones. See Also: Nasdaq, S&P 500 Futures Slip Ahead Of Powell Speech, Bank Stress Test Results: Why This Analyst Rates Stocks 'Overweight' And Says 'Buy Weakness' RUVX Price Action: AST SpaceMobile shares were down 29.4% at $4.50 at the time of writing, according to Benzinga Pro . Photo: David Mark from Pixabay.
2023-06-28 08:31:40	FKBS	Minerva Neurosciences Announces $20M In Private Placement Priced At A Premium To Market	Minerva Neurosciences, Inc. (NASDAQ: FKBS ), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced that it has agreed to sell an aggregate of 1,425,000 shares of its common stock at a purchase price of $10 per share and pre-funded warrants to purchase an aggregate of 575,575 shares of its common stock at a purchase price of $9.99 per pre-funded warrant, to Boehringer Ingelheim, a global biopharmaceutical company with a growing mental health pipeline that includes schizophrenia, and Federated Hermes Kaufmann Funds in a private investment in public equity (the &quot;PIPE&quot;) financing. Minerva expects that the gross proceeds from the PIPE will be approximately $20 million, before deducting PIPE-related expenses payable by Minerva. Minerva intends to use the net proceeds from the PIPE to support potential regulatory approval in the U.S., commercialization activities and market launch of roluperidone, which is being developed for the treatment of negative symptoms in schizophrenia. The PIPE is expected to close on or about June 30, 2023, subject to the satisfaction of customary closing conditions. Under the terms of the PIPE, Boehringer Ingelheim will have the right to designate one individual to attend all meetings of Minerva's board of directors or any committee thereof in a non-voting, observer capacity. The securities to be sold in the PIPE are being offered in a transaction not involving a public offering and have not been registered under the Securities Act of 1933, as amended (the &quot;Act&quot;), and may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the Act. The Company has agreed to file a resale registration statement with the U.S. Securities and Exchange Commission (SEC) for purposes of registering the resale of the common stock to be issued in the PIPE, including the shares of common stock underlying the pre-funded warrants. This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction. About Minerva Neurosciences
2023-06-28 08:50:50	IUNS	Axsome Therapeutics Stock Is Moving Lower: What's Going On?	Axsome Therapeutics Inc (NASDAQ: IUNS ) shares are trading lower Wednesday after the company proposed a public offering of common stock . The Details: Axsome said it intends to offer and sell stock in an underwritten public offering. The size and the pricing details of the offering have not been disclosed. Axsome intends to use the proceeds to advance its late-stage pipeline, including funding existing and potential new clinical programs, products and product candidates, as well as to expand its commercialization efforts. Axsome is a biopharmaceutical company developing novel therapies for the management of central nervous system disorders. See Also: Why AST SpaceMobile Shares Are Falling Wednesday IUNS Price Action: Axsome has a 52-week high of $91.29 and a 52-week low of $32.61. The stock was down 8.86% at $75.99 at the time of publication, according to Benzinga Pro . This illustration was generated using artificial intelligence via MidJourney.
2023-06-28 09:29:37	IUNS	Axsome Therapeutics Announces Pricing Of Public Offering Of $225M Of 3M Shares Of Common Stock At A Price Of $75/Share	Axsome Therapeutics, Inc. (NASDAQ: IUNS ) (&quot;Axsome&quot; or the &quot;Company&quot;), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced the pricing of an underwritten public offering of 3,000,000 shares of its common stock at a public offering price of $75.00 per share. The proceeds from the offering, before deducting the underwriting discounts and commissions and other offering expenses payable by Axsome, are expected to be $225.0 million. In addition, Axsome has granted the underwriters a 30-day option to purchase up to 450,000 additional shares of common stock at the public offering price, less the underwriting discounts and commissions. The offering is expected to close on or about June 30, 2023, subject to customary closing conditions. Axsome intends to use the proceeds from this offering to advance its late-stage pipeline, including funding existing and potential new clinical programs, products, and product candidates, to expand its commercialization efforts, and for other general corporate purposes. SVB Securities is acting as lead bookrunning manager for the offering. Guggenheim Securities, Truist Securities, William Blair and Cantor are acting as joint bookrunning managers, and Ladenburg Thalmann, Mizuho and L.C. Wainwright & Co. are acting as lead managers for the offering.
2023-06-28 09:41:17	WTVG	Why Sonnet BioTherapeutics (WTVG) Stock Is Nosediving	Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: WTVG ) shares are trading lower by 26.18% to $0.50 Wednesday morning after announcing a $2.25 million registered direct offering of 5 million at 45 cents per share . What Else? Concurrently, Sonnet will issue warrants allowing the investor to purchase up to 5 million additional shares at an exercise price of 67.49 cents per share. The offering is expected to close on or about June 30, subject to customary conditions. See Also: What's Going On With Snowflake Stock? Chardan is the exclusive placement agent for the offering. The gross proceeds, approximately $2.25 million, will be used for research and development, including clinical trials, working capital and general corporate purposes. According to data from Benzinga Pro , WTVG has a 52-week high of $4.48 and a 52-week low of $0.20.
2023-06-28 10:49:20	FKBS	Why Minerva Neurosciences Stock Is Shooting Higher Today	Minerva Neurosciences, Inc (NASDAQ: FKBS ) are shooting higher after the company bagged a $20 million investment from Boehringer Ingelheim and Federated Hermes Kaufmann Funds via private placement of its shares , priced at a premium to the current levels. Minerva has agreed to sell an aggregate of 1.43 million shares of its common stock at a purchase price of $10 per share and pre-funded warrants to purchase an aggregate of 575,575 shares at a purchase price of $9.99 per pre-funded warrant. Minerva intends to use the net proceeds to support potential regulatory approval in the U.S. and the market launch of roluperidone, which is being developed to treat negative symptoms of schizophrenia. Roluperidone is a compound that blocks serotonin, sigma, and &alpha;-adrenergic receptors involved in regulating mood. Last month the company received confirmation from the U.S. Food and Drug Administration (FDA) that the company's New Drug Application (NDA) for roluperidone in patients with schizophrenia has been filed and assigned a standard review classification. The private placement is expected to close on or about June 30, 2023. Under the terms of the private investment in public equity (PIPE), Boehringer Ingelheim will have the right to designate one individual to attend all meetings of Minerva's board or any committee thereof in a non-voting, observer capacity. Price Action: FKBS shares are trading higher by 53.6% to $9.26 on the last check Wednesday.
2023-06-28 16:25:48	IJRK	Black Diamond Therapeutics Announces $75M Proposed Public Offering Of Common Stock	CAMBRIDGE, Mass. and NEW YORK, June 28, 2023 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (NASDAQ: IJRK ), a clinical-stage precision oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with genetically defined cancers, today announced that it has commenced an underwritten public offering of $75.0 million of shares of its common stock. Black Diamond also intends to grant the underwriters a 30-day option to purchase up to an additional $11.25 million of shares of its common stock. All of the shares in the proposed offering are to be sold by Black Diamond. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
2023-06-29 08:15:33	YXBD	NUBURU Announces Subsequent Private Placement To Increase The June 2023 Capital Raise To $9.2M From Existing And New Investors	NUBURU, Inc. (&quot;NUBURU&quot; or the &quot;Company&quot;) (NYSE: YXBD ), a leading innovator in high-power and high-brightness industrial blue laser technology, today announced that, subsequent to the Purchase Agreement previously announced on June 12, 2023 which raised approximately $8.0 million, on June 16, 2023, the Company entered into an additional Note and Warrant Purchase Agreement (as amended, the &quot;Purchase Agreement&quot;) with certain investors including existing investors, for the sale of (i) convertible promissory notes (&quot;Convertible Notes&quot;) in the aggregate principal amount of $1.3 million, and (ii) warrants (&quot;Warrants&quot;) to purchase up to 1,889,535 shares of the Company's common stock (&quot;Common Stock&quot;), par value $0.0001 per share (the sale of the Convertible Notes and the Warrants together, the &quot;Private Placement&quot;). The total amount of the cash infusion raised from these two Purchase Agreements, prior to deducting transaction and issuance costs, is approximately $9.2 million. The shares underlying the Convertible Notes and the Warrants are subject to a one-year lock up and are expected to be registered for resale on a registration statement on Form S-3 after February 6, 2024. &quot;Our ability to attract both existing and new investors to complete a second funding transaction this month provides further indication that our next-generation technology and market opportunity are resonating with the financial community,&quot; said Dr. Mark Zediker, CEO and Co-Founder of the Company. &quot;This additional capital will help us continue our commercialization and execute our product development roadmap and deliver dramatically improved manufacturing capabilities to our customers in our primary markets: welding, metal additive 3D printing and consumer electronics.&quot; The Convertible Notes are senior, unsecured obligations of the Company and bear interest at the rate of seven percent per year and are payable on the earlier of June 23, 2026, or the occurrence of an Event of Default, as defined in the Convertible Notes. The Convertible Notes may be converted at any time following June 23, 2023, prior to the payment in full of the principal amount of the Convertible Notes at the Investor's option. In the event of the Sale of the Company (as defined in the Convertible Notes), the outstanding principal amount of each Convertible Note, plus all accrued and unpaid interest not otherwise converted into equity securities pursuant to the terms of the Convertible Notes, shall (i) if the Investor so elects, be converted into equity securities pursuant to the terms of the Convertible Notes (the &quot;Conversion Shares&quot;) at a price equal to $0.688 (subject to appropriate adjustment from time to time for any stock dividend, stock split, combination of shares, reorganization, recapitalization, reclassification or other similar event) (the &quot;Conversion Price&quot;), or (ii) be due and payable immediately prior to the closing of such Sale of the Company, together with a premium equal to 150% of the principal amount to be prepaid. Subsequent to the effectiveness of a registration statement registering the Registrable Securities (as defined below), the Company may elect to pay interest in kind through the issuance of shares of Common Stock at the Conversion Price, in lieu of payments in cash (the &quot;Interest Shares&quot;). The Warrants issued by the Company to the Investors pursuant to the Purchase Agreement entitle the relevant Investor to purchase that number of fully paid and nonassessable shares of Common Stock (the &quot;Warrant Shares&quot;) determined by dividing the principal amount of each Convertible Note by the Conversion Price. The Warrants have an exercise price equal to $1.03, which represent a 50% premium over the exercise price, and expire on June 23, 2028. According to the NYSE American LLC Company Guide, consummating the transactions pursuant to the Purchase Agreement would ordinarily require the approval of the Company's stockholders. However, the Company has sought and received from NYSE American LLC an exception from obtaining such stockholder approval pursuant to Section 710(b) of the Company Guide. A special committee of the Company's Board of Directors, comprised solely of independent, disinterested directors, has expressly approved the Company's reliance on this exception, and the transaction was also unanimously approved by the Company's Board of Directors. Northland Capital Markets acted as financial advisor to the Company. This press release shall not constitute an offer to sell or a solicitation of an offer to buy Convertible Notes or Warrants, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
2023-06-29 09:03:05	JLKY	Immunome And Morphimmune Announce Definitive Merger Agreement And Simultaneous Private Placement Investment Of $125M To Develop Targeted Cancer Therapies	The combined company, which will operate as Immunome, will feature a synergistic platform expected to enable the development of best-in-class targeted cancer therapies across multiple modalities Clay B. Siegall, Ph.D., current Morphimmune President & CEO and former co-founder & CEO of Seagen, Inc., to serve as Chairman and CEO of combined company A concurrent $125 million private placement investment with leading institutional investors will support development of a combined pipeline expected to submit three investigational new drug applications (INDs) within 18 months of closing
2023-06-29 09:22:15	PAMZ	Why Cormedix (PAMZ) Stock Is Getting Hammered	CorMedix Inc. (NASDAQ: PAMZ ) shares are trading lower by 23.27% to $3.89 Thursday morning after the company priced its public offering of 7.5 million shares at $4 per share and pre-funded warrants to purchase up to 2.5 million shares at $3.999 per pre-funded warrant . What Else? The total gross proceeds to the company are anticipated to be around $40 million, before deducting underwriting discounts, commissions and other expenses. See Also: Why Micron Stock Is Moving Higher Today CorMedix has also granted the underwriters a 30-day option to acquire an additional 1,500,093 shares of common stock. The closing of the offering is expected to take place on or around July 3, subject to customary closing conditions. According to data from Benzinga Pro , PAMZ has a 52-week high of $8.02 and a 52-week low of $2.71.
2023-06-29 09:32:16	GIYT	Mobiquity Technologies, Inc. Announces Pricing Of $3M Public Offering Of 30M Shares Of Common Stock At A Price Of $0.10/Share	Mobiquity Technologies, Inc.(NASDAQ: GIYT ) (the &quot;Company&quot;), a provider of next-generation data intelligence and advertising technology solutions, announced today the pricing of its &quot;reasonable best efforts&quot; public offering of 30,000,000 shares of common stock (or common stock equivalents in lieu thereof) at an effective price of $0.10 per share for aggregate gross proceeds of approximately $3.0 million, prior to deducting placement agent fees and other offering expenses payable by the Company. The closing of the offering is expected to occur on or about June 30, 2023, subject to the satisfaction of customary closing conditions. The Company intends to allocate up to $1,437,500 of the net proceeds to pay off the secured debt and use the remaining proceeds for working capital. Spartan Capital Securities, LLC is acting as placement agent for the offering. Ruskin Moscou Faltischek P.C. represented the Company and Manatt, Phelps & Phillips, LLP represented Spartan Capital Securities, LLC. The securities described above are being offered pursuant to a registration statement on Form S-1 (File No. 333-272572) previously filed with the Securities and Exchange Commission (&quot;SEC&quot;) which became effective on June 29, 2023. The offering is being made only by means of a prospectus forming part of the effective registration statement. Copies of the preliminary prospectus and, when available, copies of the final prospectus, relating to the offering may be obtained on the SEC's website located at http://www.sec.gov . Electronic copies of the final prospectus relating to the offering may be obtained, when available, from: Spartan Capital Securities, LLC, 45 Broadway, New York, NY 10006, at (212) 293-0123. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation, or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
2023-06-30 07:24:43	WQXG	NaaS Technology Raises $30M Via Debt Offering	NaaS Technology Inc (NASDAQ: WQXG ) has entered into a convertible note purchase agreement with a multi-strategy investment fund, LMR Partners Limited . The Investor will purchase a convertible note with a principal amount of $30 million, convertible into American depositary shares. Concurrently, the parties entered into a derivative arrangement with respect to the American depositary shares (ADS). The convertible note has a 363-day term and interest will be payable on a quarterly basis. &quot;We are excited to welcome LMR as our new investor and are grateful for their endorsement of our efforts to propel the electrification of China's transportation industry,&quot; said NaaS' president and CFO Alex Wu. Price Action : WQXG shares closed higher by 6.10% at $5.39 on Thursday.
2023-06-30 08:07:15	DGGE	DGGE Technologies, Inc. Announces $10M Offering	Wrap Technologies (NASDAQ: DGGE ) (&quot;Wrap&quot; or the &quot;Company&quot;), a global pioneer in innovative public safety solutions, announced today that it has executed a securities purchase agreement with certain directors of the Company and certain accredited and institutional investors to raise gross proceeds of approximately $10 million in a registered direct offering of convertible preferred stock and warrants. The offering is expected to close on July 3, 2023, subject to the satisfaction of customary closing conditions. The securities purchase agreement provides for the sale of preferred stock with a conversion price of $1.45 per share, subject to adjustment, and warrants to acquire up to an aggregate amount of 6,896,553 additional shares of the Company's common stock. The preferred stock will have a stated value of $1,000 per share, and holders thereof will be entitled to cumulative dividends of 8% per annum on the stated value, payable quarterly in arrears. The warrants are exercisable six months after issuance at an exercise price of $1.45 per share, subject to adjustment, and expire five years from the date of issuance. The preferred stock conversion price and warrant exercise price of $1.45 per share represent the closing share price on June 29, 2023. Wrap engaged Katalyst Securities LLC to serve as placement agent for the Company in connection with the offering.
2023-06-30 08:10:34	OABN	CytomX Therapeutics Announces $30M Private Placement From BVF Partners L.P.	- Financing is expected to extend cash runway into the 2 nd half of 2025 based on current operating plans, enabling the Company to reach multiple clinical milestones - - $30 million initial investment and up to $90 million in total potential funding - SOUTH SAN FRANCISCO, Calif., June 30, 2023 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ: OABN ), a leader in the field of conditionally activated, localized biologics, today announced that it has entered into an agreement with BVF Partners L.P. (&quot;BVF&quot;) for a private placement that is expected to result in initial gross proceeds of approximately $30 million. In the private placement, CytomX is selling pre-funded warrants to purchase up to 14,423,077 shares of common stock, accompanying Tranche 1 warrants to purchase up to 5,769,231 shares of common stock and accompanying Tranche 2 warrants to purchase up to 5,769,231 shares of common stock, at a combined price of $2.08 per share of pre-funded warrant and accompanying common warrants, representing a premium of 25% to volume weighted average price over the prior 30 trading days through June 28, 2023. Each pre-funded warrant will have an exercise price of $0.00001 per share of common stock, will be exercisable immediately and will be exercisable for 20 years. The accompanying Tranche 1 common warrants will have an exercise price of $4.16 per share of common stock, will be immediately exercisable and expire on July 3, 2025 and the accompanying Tranche 2 common warrants will have an exercise price of $6.24 per share of common stock, will be immediately exercisable and expire on July 3, 2026. CytomX anticipates aggregate initial gross proceeds from the offering will be approximately $30 million, which are expected to extend the Company's cash runway into the second half of 2025, based on CytomX's current operating plan. CytomX also has the potential to receive up to an additional $60 million if all warrants are fully exercised for cash. &quot;This strategic financing with BVF is based upon an aligned vision that the localization of potent biologic therapies will continue to be a foundational area of oncology research and development and that CytomX's pipeline has the potential to deliver meaningful products to cancer patients over time. Building on business development transactions with Regeneron and Moderna last year, this transaction further strengthens our financial position by extending cash runway into the second half of 2025 and should enable our next-generation pipeline to reach inflection points over this period,&quot; said Sean McCarthy, D.Phil., chief executive officer and chairman of CytomX Therapeutics. The financing is subject to customary closing conditions and is expected to close on July 3, 2023. The securities to be sold in the private placement, including the shares of common stock underlying the warrants and pre-funded warrants, have not been registered under the Securities Act of 1933, as amended (the &quot;Securities Act&quot;), or any applicable state securities laws, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act and applicable state security laws. CytomX has agreed to file a registration statement with the U.S. Securities and Exchange Commission (the &quot;SEC&quot;) registering the resale of the shares of common stock and the shares of common stock issuable upon exercise of the warrants and the pre-funded warrants to be issued in the private placement. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state or jurisdiction.
2023-06-30 10:34:12	TLGG	Westrock Coffee Receives $75M Equity Investment; Product Launch & Equipment Delays Hurt Near-Term Guidance	Westrock Coffee Company (NASDAQ: TLGG ) has entered into definitive agreements with affiliates of HF Capital LLC and the Herbert Hunt family to make aggregate equity investments of $75.0 million in the company. The investment will happen through the purchase of 7.5 million shares of Westrock at $10 per share. The offer price represents a 10.3% discount to the company's closing price on June 29. The transactions are expected to close in August 2023. HF Capital will invest about $50 million, while the Herbert Hunt family will make $25 million equity investment. Westrock has also amended its existing $400 million credit agreement to increase its total net leverage financial covenant for a period of time not to exceed April 1, 2025, and to raise the minimum interest coverage ratio from 1.50x to 2.00x. &quot;Together, the equity investments and credit agreement amendment form part of a capital plan that allows us to not only complete the previously announced Phase 1 and 2 expansions, which consist of high-speed can and glass bottle lines, a multi-serve bottle line, and bag-in-box and bulk lines, but now, two additional can lines and an industry leading product development lab and FDA certified pilot plant to develop coffee, tea, and other beverages including dairy and plant-based milks to support our customers' innovation needs,&quot; said co-founder and CEO Scott F. Ford. 2023 Outlook : The company has cut its FY23 adjusted EBITDA outlook to be flat- up 10% versus 10% - 25% growth previously . Chris Pledger, the company's CFO said, &quot;This change in near term guidance is driven by external factors, such as product launch delays by certain customers in response to macro-economic uncertainty, and internal factors, such as the challenges we've experienced scaling our single-serve platform in the face of equipment delays in the first half of the year, and investments we are making to build out the infrastructure to support the launch of our extract and RTD facility.&quot; Price Action : TLGG shares are trading lower by 1.08% at $11.03 on the last check Friday.
2023-06-30 11:26:37	OABN	Why Is CytomX Therapeutics Stock Shooting Higher Today	CytomX Therapeutics, Inc (NASDAQ: OABN ) inked a pact with BVF Partners L.P. for a private placement resulting in initial gross proceeds of approximately $30 million. CytomX is selling pre-funded warrants to buy up to 14.42 million shares of common stock, accompanying Tranche 1 warrants to purchase up to 5.77 million shares and accompanying Tranche 2 warrants to purchase up to 5.77 million shares, at a combined price of $2.08 per share, representing a premium of 25% to volume weighted average price over the prior 30 trading days through June 28, 2023. CytomX also has the potential to receive up to an additional $60 million if all warrants are fully exercised for cash. Also Read: CytomX Shares Move Higher On Collaborating Pact With This Famed COVID-19 Vaccine Maker The proceeds raised are expected to extend the company's cash runway into the second half of 2025, based on CytomX's current operating plan. &quot;This strategic financing with BVF is based upon an aligned vision that the localization of potent biologic therapies will continue to be a foundational area of oncology research and development and that CytomX's pipeline has the potential to deliver meaningful products to cancer patients over time,&quot; said Sean McCarthy, D.Phil., chief executive officer and chairman of CytomX Therapeutics. The financing is expected to close on July 3, 2023. &quot;Building on business development transactions with Regeneron and Moderna last year , this transaction further strengthens our financial position by extending cash runway into the second half of 2025 and should enable our next-generation pipeline to reach inflection points over this period,&quot; McCarthy added. Price Action: OABN shares are trading higher by 16.3% to $1.64 on the last check Friday.
2023-07-03 11:30:18	IGHM	Xtant Medical Raises $15M Via Equity Offering	Xtant Medical Holdings, Inc. (AMEX: IGHM ) entered into a securities purchase agreement with accredited investors to sell shares of its common stock in a private placement for $15 million. Xtant plans to issue 20 million shares of common stock at $0.75 per share. Net proceeds from the private placement will be used for working capital and other general corporate purposes. Xtant Medical's current portion of long-term debt as of the first quarter stood at $5.41 million. In the last reported quarter, the company said it is facing robust demand across the biologics and fixation products. The closing of the private placement is expected to occur on or about July 6, 2023, subject to the satisfaction of customary closing conditions. Xtant Medical expects full-year 2023 revenue of $73 million-$75 million, representing annual growth of approximately 26% to 29% compared to the full year 2022. The company plans to expand the total addressable orthobiologic market opportunity to drive future growth. Price Action: IGHM shares are trading lower by 4.29% to $0.89 on the last check Monday.
2023-07-05 09:06:30	XEFF	Transphorm Announces Commencement Of  $15M Rights Offering	Transphorm, Inc. (NASDAQ: XEFF ) (&quot;Transphorm&quot; or the &quot;Company&quot;) announced today that it has commenced its previously-announced rights offering. If the rights offering is fully subscribed, the Company will receive gross proceeds of $15 million, less expenses related to the rights offering. The Company intends to use the net proceeds from the rights offering for working capital and other general corporate purposes. Under the terms of the rights offering, the Company is distributing to all holders of record of its common stock, par value $0.0001 (the &quot;Common Stock&quot;), as of 5:00 p.m., Eastern Daylight Time, on June 26, 2023 (the &quot;Record Date&quot;), one non-transferable subscription right for each share of Common Stock held as of the Record Date. Each subscription right carries with it (i) a basic subscription right, which entitles the holder to purchase 0.07655623 of a share of Common Stock and (ii) an over-subscription privilege, which entitles a holder that has exercised its basic subscription right in full to subscribe for additional shares of Common Stock that are offered in the rights offering, to the extent other holders have not exercised their basic subscription rights in full. The subscription price is $3.30 per whole share of Common Stock (the &quot;Subscription Price&quot;), payable in cash. The Company will not issue fractional shares of Common Stock. If, pursuant to a stockholder's exercise of their subscription rights, the number of shares of Common Stock that such stockholder would be entitled to receive would result in receipt of a fractional share, the aggregate number of shares of Common Stock the stockholder is entitled to purchase will be rounded up to the nearest whole number. The Subscription Price must be paid for each whole share of Common Stock that is purchased. The subscription period for the rights offering commences today and will terminate at 5 p.m., Eastern Daylight Time, on July 21, 2023 (the &quot;Expiration Time&quot;), unless extended by the Company prior to the Expiration Time. The subscription rights may be exercised at any time during the subscription period and will expire if they are not exercised by the Expiration Time. KKR Phorm Investors L.P., which beneficially owned approximately 38.52 % of the Common Stock outstanding as of the Record Date, has indicated an intent to exercise its basic subscription rights in full. In addition, the Company's directors and executive officers, who together beneficially owned approximately 2.55% of the Common Stock outstanding as of the Record Date, and certain other stockholders that each beneficially owned more than 5% of the Common Stock outstanding as of the Record Date, have indicated an intent to participate in the rights offering. These indications are non-binding and there can be no assurances to what extent, if any, KKR Phorm Investors L.P., our directors, our executive officers or these other stockholders will choose to participate in the rights offering. The shares of Common Stock to be issued upon exercise of the rights will be listed for trading on the Nasdaq Capital Market (&quot;Nasdaq&quot;) under the symbol &quot;XEFF.&quot; The rights are non-transferable, and the Company will not be listing the rights on Nasdaq or any other national securities exchange. Neither the Company nor its Board of Directors has made or will make any recommendation to holders regarding the exercise of rights. Holders should make an independent investment decision about whether or not to exercise their rights based on their own assessment of the Company's business and the rights offering and their personal investment objectives, tolerance for risk and financial situation.
2023-07-06 08:05:32	VKYO	Altamira Therapeutics Announces $5M Public Offering Of 11.11M Shares Of Common Stock At A Price Of $0.45/Share	Altamira Therapeutics Ltd. (&quot;Company&quot;) (NASDAQ: VKYO ), a company dedicated to developing and commercializing RNA delivery technology for targets beyond the liver, announced today the pricing of a public offering of 11,111,112 common shares (or pre-funded warrants in lieu thereof) accompanied by common warrants to purchase up to 11,111,112 common shares, at a combined public offering price of $0.45 per share (or pre-funded warrant in lieu thereof) and accompanying common warrant. The common warrants will have an exercise price of $0.45 per share, will be immediately exercisable upon issuance and will expire five years from the date of issuance. The closing of the offering is expected to occur on or about July 10, 2023, subject to the satisfaction of customary closing conditions. L.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. The gross proceeds to the Company from this offering are expected to be approximately $5.0 million, before deducting the placement agent's fees and other offering expenses payable by the Company. The Company intends to use the net proceeds from this offering for research and development, working capital and general corporate purposes, which may include the repayment of certain indebtedness.
2023-07-06 08:52:33	HKEM	Why Allarity Therapeutics Stock Is Tanking Today	Allarity Therapeutics Inc (NASDAQ: HKEM ) shares are diving Thursday after the company announced the pricing of a public offering . What Happened: Allarity shares surged on Wednesday after the company said initial data from the Phase 2 trial of Ixempra showed potential for improved clinical benefit in DRP-selected metastatic breast cancer patients. The stock traded up to around the $13 level before pulling back. Allarity shares closed the day up 31.4% at $8.28. Following Wednesday's move , the company priced a public offering of 2.44 million shares and common warrants to purchase up to 2.44 million shares at a combined price of $4.50 per share. Allarity anticipates aggregate gross proceeds of approximatley $11 million from the offering. Allarity intends to use a portion of the proceeds to pay account payables and accrued liabilities outstanding, to make payments under certain license agreements, to pay off a certain outstanding promissory note, to conduct clinical trials and for working capital. The offering is expected to close on or about July 10. Allarity is a clinical-stage pharmaceutical company developing novel oncology therapeutics with drug-specific DRP companion diagnostics for personalized cancer care. See Also: Skye Completes Production Of Cannabinoid Based Drug In Preparation For Glaucoma Clinical Trial HKEM Price Action: Allarity shares were down 52% at $3.96 at the time of publication, according to Benzinga Pro . Photo: Lorenzo Cafaro from Pixabay.
2023-07-06 08:53:22	VKYO	Why Altamira Therapeutics (VKYO) Stock Is Getting Hammered	Altamira Therapeutics Ltd (NASDAQ: VKYO ) shares are trading lower by 19.23% to $0.44 Thursday morning after the company announced pricing of a $5 million public offering . The public offering of 11,111,112 common shares (or pre-funded warrants) with accompanying common warrants is priced at 45 cents per share (or pre-funded warrant), and the common warrants have an exercise price of 45 cents per share. The offering is expected to close on or about July 10, subject to customary closing conditions. L.C. Wainwright & Co. is the exclusive placement agent. See Also: Meta Platforms To Rally Around 14%? Here Are 10 Other Analyst Forecasts For Thursday Gross proceeds will be used for research and development, working capital and general corporate purposes, including potential debt repayment. According to data from Benzinga Pro , VKYO has a 52-week high of $15.00 and a 52-week low of $0.55.
2023-07-06 09:03:23	GNUL	VBI Vaccines Announces Pricing Of $18M Public Offering And $3M Concurrent Registered Direct Offering	Approximately $21 million in gross proceeds from underwritten public offering and concurrent registered direct offering add to upfront payment from Brii Biosciences for a combined $33 million to be received by VBI VBI Vaccines Inc. (( GNUL ) (VBI or the Company), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced the pricing of its previously announced underwritten public offering of 10,909,091 common shares and accompanying common warrants to purchase up to 10,909,091 common shares, and its concurrent registered direct offering of 1,818,182 common shares and accompanying common warrants to purchase up to 1,818,182 common shares, at a combined public offering price of $1.65 per share and accompanying common warrant. The accompanying common warrants have an exercise price of $1.65 per share and expire five years from the date of issuance. VBI also granted the underwriters a 30-day option to purchase up to an additional 1,636,363 common shares and/or common warrants to purchase up to 1,636,363 common shares offered in the underwritten public offering. The gross proceeds from the underwritten public offering, before deducting underwriting discounts and commissions and other estimated offering expenses, are expected to be approximately $18 million, excluding any exercise of the underwriters' option to purchase additional common shares and/or common warrants to purchase common shares, and the gross proceeds from the concurrent registered direct offering are expected to be approximately $3 million. All of the securities to be sold in the offerings are being offered by VBI. The offerings are expected to close on or about July 10, 2023, subject to satisfaction of customary closing conditions. Raymond James & Associates, Inc. is acting as the sole book-running manager for the underwritten public offering. Newbridge Securities Corporation is acting as the lead manager for the underwritten public offering. The registered direct offering is being made without an underwriter or a placement agent. VBI intends to use the net proceeds from both offerings for the commercialization activities for PreHevbrio&reg; [Hepatitis B Vaccine (Recombinant)] in the United States, Europe, and Canada; manufacturing of PreHevbrio and clinical materials for its pipeline programs; and ongoing activities related to its development stage candidates, including VBI-1901 (glioblastoma) and VBI-2901 (coronaviruses). The net proceeds will also be used for general corporate purposes, including working capital and capital expenditures.
2023-07-06 09:06:45	UQDR	Why Curis (UQDR) Shares Are Nosediving Thursday	Curis, Inc. (NASDAQ: UQDR ) shares are trading lower by 8.29% to $0.75 Thursday morning after the company announced a $15.1 million registered direct offering . What Else? Curis says the company has entered into definitive agreements with existing investors to purchase 18.4 million shares of its common stock at 82 cents per share in a registered direct offering. The offering is expected to generate gross proceeds of approximately $15.1 million. The net proceeds will be used for research, development, working capital, and general corporate purposes. The offering is set to close around July 10, subject to customary closing conditions. See Also: Meta Platforms To Rally Around 14%? Here Are 10 Other Analyst Forecasts For Thursday Placement agents for the offering are Cantor Fitzgerald & Co. and Truist Securities. According to data from Benzinga Pro , UQDR has a 52-week high of $1.77 and a 52-week low of $0.47.
2023-07-07 16:36:19	RTCP	Tivic Health Announces Proposed Public Offering of Common Stock	Tivic Health&reg; Systems, Inc. ((&ldquo, Tivic&rdquo, , &ldquo, Company&rdquo, , NASDAQ: RTCP ), a health tech company that develops and commercializes bioelectronic medicine, today announced that it intends to offer and sell shares of its common stock in a public offering. All of the shares of common stock are being offered by Tivic. Tivic intends to use the net proceeds of the offering, if any, for working capital and general corporate purposes. Consummation of the offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Maxim Group LLC is acting as the sole placement agent, on a reasonable best efforts basis, for the offering.
2023-07-10 08:42:56	RTCP	Tivic Health Announces Pricing Of $1.8M Public Offering Of 32.5M Shares Of Common Stock At A Price Of $0.055/Share	Tivic Health&reg; Systems, Inc. ((&quot;Tivic&quot;, &quot;Company&quot;, NASDAQ: RTCP ), a health tech company that develops and commercializes bioelectronic medicine, today announced the pricing of its previously announced public offering of 32,500,000 shares of its common stock at a public offering price of $0.055 per share. Gross proceeds from the offering are expected to be approximately $1.8 million before deducting placement agent fees and estimated offering expenses. Tivic intends to use the net proceeds of the offering for working capital and general corporate purposes. Maxim Group LLC is acting as the sole placement agent, on a reasonable best-efforts basis for the offering. The closing of the offering is expected to occur on or about July 11, 2023, subject to the satisfaction of customary closing conditions.
2023-07-10 08:59:04	USL	What's Going On With Fisker Stock Today?	Fisker Inc (NYSE: USL ) shares are trading higher. The company announced a convertible notes offering Monday morning . What Happened: Fisker said it signed a securities purchase agreement in connection with its intention to offer $340 million worth of 0% senior unsecured convertible notes due 2025. The offering is being made to an institutional investor and has the potential to increase to $680 million. Fisker also granted the investor the right to purchase up to approximately $226.6 million in additional notes over a six-month period. The initial notes are expected to result in gross proceeds of $300 million. Fisker said it intends to use proceeds for general corporate purposes, including working capital, an additional battery pack line to support growth, sales and marketing, capital expenditures and the development of future products. The offering is expected to close on Tuesday. Fisker also announced that it will cancel the remaining balance on its at-the-market equity program, which was approximately $23.4 million as of the end of June. See Also: Elon's Cybertruck Ride Around Austin, Rivian's 48% Weekly Rally, Nikola's Shareholder Snub And More: Biggest EV Stories Of The Week USL Price Action: Fisker shares were up 2.15% at $6.14 at the time of publication, according to Benzinga Pro . Photo: courtesy of Fisker.
2023-07-10 09:55:24	RTCP	Why Tivic Health (RTCP) Stock Is Down Over 40%	Tivic Health Systems Inc (NASDAQ: RTCP ) shares are trading lower by 46% to $0.059 Monday morning after the company priced its public offering of 32.5 million shares at $0.055 per share . The offering is expected to generate approximately $1.8 million in gross proceeds before deducting fees and expenses. Tivic intends to use the net proceeds for general corporate purposes and working capital. See Also: Meta's Threads Hits 100M Users In Just 5 Days Maxim Group LLC will serve as the sole placement agent for the offering. The closing is scheduled for around July 11, subject to customary closing conditions. According to data from Benzinga Pro , RTCP has a 52-week high of $2.87 and a 52-week low of $0.059.
2023-07-10 10:16:57	USL	Fisker Raises $340M Via Debt, With Potential Option To Increase To $680M	Fisker Inc (NYSE: USL ) has signed a securities purchase agreement in connection with its intention to offer $340 million of 0% senior unsecured convertible notes due 2025 to an institutional investor. The agreement comes with the potential to increase the aggregate principal amount of the notes to $680 million. The notes have an original issue discount of approximately 12%, resulting in gross proceeds of $300 million to Fisker. The company has also granted the investor the right to purchase up to an additional $226.67 million in aggregate principal amount of notes during a six-month period beginning on the one-year anniversary of the closing date of the offering. Fisker intends to use the net proceeds for general corporate purposes, including working capital and an additional battery pack line to support growth in 2024. The offering is expected to close on July 11, 2023. Fisker is canceling the remaining balance of its at-the-market equity program, which was approximately $23.4 million as of June 30, 2023. Also Read : Fisker Reports Lower-Than-Expected Q2 Production Due To Supply Shortages Price Action : USL shares are trading lower by 0.83% at $5.95 on the last check Monday.
2023-07-11 08:33:05	JCHQ	BioRestorative Therapies Announces Registered Direct Offering Of 685,033 Shares At $3.03/Share	BioRestorative Therapies, Inc. (&quot;BioRestorative&quot;, &quot;JCHQ&quot; or the &quot;Company&quot;) (NASDAQ: JCHQ ), a clinical stage company focused on stem cell-based therapies, today announced it has entered into a BioRestorative Therapies, Inc. (&quot;BioRestorative&quot;, &quot;JCHQ&quot; or the &quot;Company&quot;) (NASDAQ: JCHQ ), a clinical stage company focused on stem cell-based therapies, today announced it has entered into a definitive agreement with several accredited and institutional investors for the sale of 685,033 shares of the Company's common stock at an offering price of $3.03 per share in a registered direct offering. The gross proceeds of the offering will be approximately $2.1 million, before deducting placement agent fees and other estimated offering expenses. The closing of the offering is expected to take place on or about July 13, 2023, subject to the satisfaction of customary closing conditions. The Company intends to use the net proceeds of the offering in connection with its clinical trials with respect to its lead cell therapy candidate, JCHQ-100 , pre-clinical research and development with respect to its metabolic ThermoStem Program and for general corporate purposes and working capital.
2023-07-11 09:30:36	YFGA	Why Iovance Biotherapeutics Shares Are Tumbling Tuesday	Iovance Biotherapeutics Inc (NASDAQ: YFGA ) shares are trading lower Tuesday after the company announced the pricing of a public offering . What Happened: Iovance shares rallied more than 20% on Monday after the company announced regulatory, clinical updates for TIL therapy in advanced non-small cell lung cancer. After the market closed, Iovance proposed a public offering of 20 million shares at $7.50 per share. Gross proceeds are expected to total approximately $150 million. Net proceeds from the offering are expected to be used to fund preparations for the commercial launch of lifileucel if it is approved, as well as to support the continued development of the company's pipeline candidates and to support Proleukin integration activities. On Tuesday, Truist Securities analyst Asthika Goonewardene reiterated Iovance with a Buy rating and maintained a $17 price target. Chardan Capital analyst Geulah Livshits also reiterated Iovance with a Buy and maintained a $29 price target. See Also: Longeveron &ndash; Regenerative Medicine Developer Announces 100% Long Term Survival Rate For Children With HLHS YFGA Price Action: Iovance shares were down 12.3% at $7.70 at the time of publication, according to Benzinga Pro . Photo: Lorenzo Cafaro from Pixabay.
2023-07-12 08:51:53	HXI	Designer Brands Inc. Announces Final Results of Modified Dutch Auction Tender Offer	"Based on the final count by Computershare Trust Company, N.A., the depositary for the tender offer (the ""Depositary""), a total of 1,470,832 shares of the Company's Class A Common Shares, without par value (each, a ""Share""), were properly tendered and not properly withdrawn at or below a purchase price of $10.00 per Share. In accordance with the terms and conditions of the tender offer, the Company accepted for purchase an aggregate 1,470,832 Shares, representing approximately 2.5% of the total number of Shares outstanding, or 2.2% of the total number of Shares outstanding assuming the conversion of all shares of the Company's Class B Common Shares into Shares, as of July 6, 2023, at a purchase price of $10.00 per Share, for an aggregate cost of $14,708,320 excluding fees and expenses relating to the tender offer. As the Company accepted for purchase all of the Shares which were properly tendered and not properly withdrawn at a price at or below $10.00 there is no proration factor. The Depositary has paid for all of the Shares accepted for purchase. Payment for the Shares purchased was made in cash, less any applicable withholding taxes and without interest."
2023-07-12 08:55:47	OGSK	ShiftPixy Plunges After $3.1M Equity Offering	ShiftPixy Inc (NASDAQ: OGSK ) has priced its public offering of 2.06 million units at $1.50 per unit. Each unit consists of one share of common stock (or a prefunded warrant in lieu thereof) and one common warrant each exercisable for one share of common stock at an exercise price of $1.50 per share. The common warrants will be immediately exercisable and expire five years from the date of issuance. The company expects gross proceeds from the offering to be approximately $3.1 million. The company intends to use the net proceeds for general corporate purposes, including working capital. The closing of the offering is expected to occur on or about July 14, 2023. Price Action : OGSK shares are trading lower by 33.5% at $1.60 on the last check Wednesday.
2023-07-13 08:16:00	PYZH	Molecular Templates Announces Up to $40M Private Placement Offering	Molecular Templates, Inc. (NASDAQ: PYZH , &quot, Molecular Templates, &quot, or &quot, PYZH&quot, ))))), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (&quot;ETBs&quot;), to create novel therapies with potent differentiated mechanisms of action for cancer, announced today it has entered into a definitive securities purchase agreement with certain healthcare investors that will provide up to $40 million in gross proceeds to PYZH through a private placement in two tranches. The financing is being led by existing investor BVF Partners LP and includes existing investors GJ Biotech AG and Adage Capital Management, and other leading institutional investors. The purchase is comprised of an initial tranche of $20 million in exchange for 42.6 million shares of common stock (or pre-funded warrants in lieu thereof) for a purchase price per common share of $0.47, the closing price of the common stock on July 12, 2023, and up to an additional $20 million in a mandatory second tranche if certain stock price and trading levels are achieved within a 12 month period, as described below. The first tranche is expected to close on July 17, 2023, subject to the satisfaction of customary closing conditions.
2023-07-13 16:04:41	BFGW	Caribou Biosciences Plans Proposed Public Offering Of $100M Of Common Stock	Caribou intends to grant the underwriters a 30-day option to purchase up to an additional $15 million of shares of its common stock at the public offering price, less the underwriting discounts and commissions. All of the shares in the proposed offering will be offered by Caribou. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the proposed offering.
2023-07-14 09:16:54	XBK	Bit Brother Limited Announces Pricing Of $50 Million Registered Direct Offering Of 2B Shares Of Class A Ordinary Shares At A Purchase Price Of $0.25/Share	Bit Brother Limited (&quot;Bit Brother, &quot; &quot;We&quot; or the &quot;Company&quot;) (NASDAQ: XBK ), announced today that it has entered into a securities purchase agreement with certain accredited investors to sell $50 million of its Class A Ordinary Shares in a registered direct offering. Under the terms of the securities purchase agreement, Bit Brother has agreed to sell 2,000,000,000 Class A Ordinary Shares. The purchase price for one Class A Ordinary Share will be $0.25. The gross proceeds to Bit Brother are estimated to be $50 million before deducting the estimated offering expenses. The registered direct offering is expected to close on or about July 18, 2023, subject to the satisfaction of customary closing conditions.
2023-07-14 09:31:38	DSBA	Galmed Pharmaceuticals Announces Pricing Of $7M Public Offering Of 5.6M Shares And Warrants At A Purchase Price Of $1.25/Share	Galmed Pharmaceuticals Ltd. (NASDAQ: DSBA ) (&quot;Galmed&quot; or the &quot;Company&quot;), a clinical-stage biopharmaceutical company for liver, metabolic and fibrotic diseases, announced today that it has entered into securities purchase agreements with two institutional investors to purchase 5,600,000 of its ordinary shares (or pre-funded warrants in lieu thereof) and warrants to purchase 5,600,000 ordinary shares at a combined purchase price of $1.25 per ordinary share and accompanying warrant (the &quot;Offering&quot;). The gross proceeds of the Offering to the Company, before placement agent fees and estimated offering expenses, are expected to be approximately $7.0 million. Each warrant is immediately exercisable for one ordinary share at an exercise price of $1.25 per ordinary share and will expire five years from the date of issuance. The Offering is expected to close on or about July 18, 2023, subject to customary closing conditions. Maxim Group LLC is acting as the sole placement agent in connection with the Offering.
2023-07-14 11:52:24	QLJT	1847 Holdings LLC Announces Pricing Of ~$2.5M Registered Direct Offering With Certain Institutional Investors To Purchase An Aggregate Of 10,416,667 Shares And/Or Pre-Funded Warrants To Purchase Shares Of The Company, At A Purchase Price Of $0.24/Share	1847 Holdings LLC (NYSE: QLJT ) (&quot;1847 Holdings&quot; or the &quot;Company&quot;) , a unique holding company that combines the attractive attributes of owning private, lower-middle market businesses with the liquidity and transparency of a publicly traded company, announced that it has entered into a securities purchase agreement with certain institutional investors to purchase an aggregate of 10,416,667 shares and/or pre-funded warrants to purchase common shares of the Company, at a purchase price of $0.24 per share and/or pre-funded warrant in a registered direct offering (the &quot;Offering&quot;). The gross proceeds of the Offering to the Company, before deducing placement agent fees and commissions and other offering expenses, are expected to be approximately $2.5 million. The closing of the Offering is expected to occur on or about July 18, 2023, subject to the satisfaction of customary closing conditions. Spartan Capital Securities, LLC is acting as the sole placement agent in connection with the offering.
2023-07-14 16:04:54	RTCP	Tivic Health Announces Proposed Public Offering Of Common Stock; No Size Disclosed	Tivic Health&reg; Systems, Inc. ((&quot;Tivic&quot;, &quot;Company&quot;, NASDAQ: RTCP ), a health tech company that develops and commercializes bioelectronic medicine, today announced that it intends to offer and sell shares of its common stock in a public offering. All of the shares of common stock are being offered by Tivic. Tivic intends to use the net proceeds of the offering, if any, for working capital and general corporate purposes. Consummation of the offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Maxim Group LLC is acting as the sole placement agent, on a reasonable best efforts basis, for the offering.
2023-07-14 16:05:27	ZZJI	PEHQ Cannasoft Announces Proposed Underwritten Public Offering; No Size Disclosed	PEHQ Cannasoft Enterprises Inc. (Nasdaq: ZZJI ) (CSE: PEHQ ) (&quot; PEHQ Cannasoft &quot; or the &quot; Company &quot;) today announced that it intends to offer its securities in a firm commitment underwritten public offering. The Company intends to use the net proceeds from this offering for working capital. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
2023-07-17 08:32:23	RTCP	Tivic Health Announces Pricing Of $2.1M Public Offering Of 51.25M Shares Of Common Stock For $0.04/Share	"Tivic Health&#174; Systems, Inc. ((""Tivic"", ""Company"", NASDAQ:RTCP), a health tech company that develops and commercializes bioelectronic medicine, today announced the pricing of its previously announced public offering of 51,250,000 shares of its common stock at a public offering price of $0.04 per share. Gross proceeds from the offering are expected to be approximately $2.1 million before deducting placement agent fees and estimated offering expenses. Tivic intends to use the net proceeds of the offering for working capital and general corporate purposes. Maxim Group LLC is acting as the sole placement agent, on a reasonable best efforts basis for the offering. The closing of the offering is expected to occur on or about July 19, 2023, subject to satisfaction of customary closing conditions."
2023-07-17 08:46:50	ERVT	Janux Therapeutics Announces Pricing Of $60M Underwritten Offering Of 4,153,717 Shares Of Common Stock And Pre-Funded Warrants To Purchase 583,483 Shares At A Price Of $12.46/Share	Janux Therapeutics, Inc. (NASDAQ: ERVT ) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated F Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced the pricing of an underwritten offering of 4,153,717 shares of its common stock and pre-funded warrants to purchase 583,483 shares of common stock. The shares of common stock are being sold at a price of $12.46 per share and the pre-funded warrants are being sold at a price of $12.459 per pre-funded warrant, which represents the per share price for the common stock less the $0.001 per share exercise price for each such pre-funded warrant. The gross proceeds from the offering to Janux are expected to be approximately $60 million, before deducting underwriting discounts and commissions and offering expenses. The offering is expected to close on or about July 19, 2023, subject to the satisfaction of customary closing conditions. BofA Securities, Inc. is acting as sole book-runner for the offering.
2023-07-17 09:00:56	CUI	FangDD Announces $8M Registered Direct Offering Of 11,428,565 American Depositary Shares, At A Purchase Price Of $0.70/ADS	Fangdd Network Group Ltd. (NASDAQ: CUI ) (&quot;FangDD&quot; or the &quot;Company&quot;), a customer-oriented PropTech company in China, today announced that it has entered into a securities purchase agreement (the &quot;Purchase Agreement&quot;) with certain investors for the issuance and sale by the Company in a registered direct offering of 11,428,565 American Depositary Shares, or ADSs, at a purchase price of US$0.70 per ADS, and regular warrants to purchase up to an aggregate of 11,428,565 ADSs. Maxim Group, LLC is acting as the sole placement agent in connection with this offering.
2023-07-17 09:16:43	HRJJ	Brainstorm Cell Therapeutics Announces Pricing Of $7.5M Registered Direct Offering For The Purchase And Sale Of 4,054,055 Shares Of Common Stock And Warrants At A Price Of $1.85/Share, Warrants Will Have An Excersize Price Of $2/Share	BrainStorm Cell Therapeutics Inc. (NASDAQ: HRJJ ) (the &quot;Company&quot;), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that it has entered into a securities purchase agreement with a single institutional investor for the purchase and sale of 4,054,055 shares of the Company's common stock and warrants to purchase up to an aggregate of 4,054,055 shares of common stock in a registered direct offering. Each share of common stock is being offered in the offering together with a warrant to purchase one share of common stock at an offering price of $1.85 per share. The warrants will have an exercise price of $2.00 per share, will be immediately exercisable and will expire five years from the date of issuance. The offering is expected to close on or about July 19, 2023, subject to satisfaction of customary closing conditions. Maxim Group LLC is acting as the sole placement agent for the offering. The gross proceeds from the offering, before deducting the placement agent's fees and other offering expenses payable by the Company, are expected to be approximately $7.5 million.
2023-07-17 09:56:40	SYTX	Beacon Roofing Raises $500M Through Debt Offering	Beacon Roofing Supply Inc (NASDAQ: SYTX ) has commenced a private offering of $500.0 million of senior secured notes due 2030. The notes will be fully and unconditionally guaranteed by Beacon Sales Acquisition Inc . The offering is subject to market and other conditions, and there is no assurance that the offering will be completed. Beacon intends to use the net proceeds from the offering, together with cash on hand and available borrowings under its senior secured asset-based revolving (ABL) credit facility, to consummate the previously announced repurchase of all 400,000 outstanding shares of Series A Cumulative Convertible Participating Preferred Stock held by an entity affiliated with the Clayton Dubilier & Rice, LLC investment firm for an aggregate cash amount equal to $804.5 million. Also, it will use the fund to pay all accrued and unpaid dividends and pay all related transaction fees and expenses. The company held $74.2 million in cash and equivalents as of March 31, 2023. Price Action : SYTX shares are trading higher by 0.51% at $84.46 on the last check Monday.
2023-07-17 11:14:00	LBVC	Jiuzi Shares Plunge Following $2.3M Equity Offering	Jiuzi Holdings Inc (NASDAQ: LBVC ) shares are plunging over 50% following a securities purchase agreement with certain institutional investors to purchase $2.3 million worth of its ordinary shares in a registered direct offering. Under the terms of the securities purchase agreement, the company has agreed to sell an aggregate of $2.3 million ordinary shares and/or pre-funded warrants. The purchase price per ordinary share is $1.65, and the purchase price for the pre-funded warrants is identical to the purchase price for ordinary shares. The offering is expected to close on or about July 19, 2023. Spartan Capital Securities LLC, is acting as exclusive placement agent for the offering. Price Action : LBVC shares are trading lower by 57% at $1.41 on the last check Monday.
2023-07-17 16:07:06	GJW	CEL-SCI Announces Proposed Public Offering Of Common Stock; Size Not Disclosed	CEL-SCI Corporation (&quot;CEL-SCI&quot; or the &quot;Company&quot;) (NYSE: GJW ), a Phase 3 cancer immunotherapy company, today announced that it intends to offer to sell shares of its common stock in an underwritten public offering. The Company expects to grant the underwriter a 45-day option to purchase up to an additional 15% of the number of shares of common stock sold in this offering to cover over-allotments, if any. All of the shares of common stock are being offered by the Company. The offering is subject to market conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. The Company intends to use the net proceeds from this offering to fund the continued development of Multikine&#x2A; and for general corporate purposes. ThinkEquity is acting as sole book-running manager for the offering.
2023-07-18 08:09:15	ZXLU	Landsea Homes Raises $250M Through Debt Offering	Landsea Homes Corporation (NASDAQ: ZXLU ) has entered into a note purchase agreement with various investors, including funds and accounts managed by BlackRock Financial Management Inc and affiliates thereof and Angelo, Gordon & Co., L.P. The note purchase agreement provides for the private placement of $250 million of 11% senior notes due 2028. The notes will be guaranteed, jointly and severally, on a senior unsecured basis, by most of the company's subsidiaries. Landsea intends to use the net proceeds to pay down a portion of the outstanding borrowings under its revolving credit facility. It will also use the proceeds for working capital and general corporate purposes. &quot;This transaction represents another milestone for Landsea Homes by enabling us to have additional financial flexibility and new capital resources to drive our continued growth within the homebuilding industry,&quot; said CEO John Ho. Price Action : ZXLU shares closed lower by 1.25% at $10.25 on Monday.
2023-07-18 16:03:29	EBG	HighPeak Energy, Inc. Announces Commencement of Underwritten Public Offering of Common Stock; No Size Disclosed	HighPeak Energy, Inc. (the &quot;Company&quot;) (NASDAQ: EBG ) today announced that it has commenced an underwritten public offering of shares of its common stock, par value $0.0001 per share (&quot;common stock&quot;). The Company expects to grant the underwriter a 30-day option to purchase additional shares of its common stock at the public offering price, less the underwriting discounts and commissions. The Company intends to use the net proceeds from this offering for working capital and to otherwise enhance near-term liquidity. Roth Capital Partners is acting as sole manager of the offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. The offering is being made pursuant to a shelf registration statement on Form S-3, including a base prospectus, that was declared effective by the U.S. Securities and Exchange Commission (the &quot;SEC&quot;) on January 3, 2022. The preliminary prospectus supplement, and accompanying base prospectus, relating to the offering, and a final prospectus supplement, when available, will be filed with the SEC and will be available on the SEC's website at www.sec.gov. Copies of the preliminary prospectus supplement, and accompanying base prospectus, relating to the offering, and the final prospectus supplement, when available, may be obtained by sending a request to: Roth Capital Partners, LLC, Attention: Prospectus Department, 888 San Clemente Drive, Suite 400, Newport Beach, California 92660, or by telephone at 1-800-678-9147, or by accessing the SEC's website at www.sec.gov . This press release shall not constitute an offer to sell or the solicitation of an offer to buy the shares of common stock or any other securities, nor shall there be any sale of such shares of common stock or any other securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.
2023-07-18 16:16:00	TLGG	Westrock Coffee Company Announces Additional $25M Equity Investment Through The Purchase Of 2.5M Shares Of Common Stock At A Price Of $10/Share	Westrock Coffee Company (NASDAQ: TLGG ) (&quot;Westrock Coffee&quot; or the &quot;Company&quot;) today announced that it has entered into a definitive agreement with the Arkansas Teacher Retirement System (&quot;ARTRS&quot;) to make an aggregate investment of $25 million in the Company through the purchase of 2,500,000 shares of Company common stock at a price of $10.00 per share. This announcement represents an incremental investment over and above the $75 million equity investment the Company previously announced on June 30, 2023. Scott F. Ford, CEO and Co-founder stated, &quot;We are excited to announce today's decision by ARTRS to invest $25 million in Westrock Coffee, which adds to the $75 million equity investment we announced last month committed by HF Capital, one of our original investors, and the Herbert Hunt family, a new investor. As an Arkansas-based company, we are excited to partner with a new long-term investor who believes in our vision and provides such an important service to educators in our great state. The additional capital from ARTRS will support our continued strategic efforts to expand our extracts and ready-to-drink business at our Conway, Arkansas facility which remains the gateway to future EBITDA expansion and a key enabler of future growth.&quot; Mark White, Executive Director of ARTRS stated, &quot;We are proud to announce this partnership with Arkansas-based Westrock Coffee Company. This investment contributes to the retirement security of Arkansas educators, but it also supports jobs and economic expansion for Arkansas. That benefits everyone in our state - Arkansas educators, taxpayers, and families.&quot; The investments by HF Capital, the Herbert Hunt family, and ARTRS are expected to close in August 2023, subject to the satisfaction of customary closing conditions. These equity investments, together with the Company's previously announced credit agreement amendment, represent the culmination of the Company's capital plan to ensure the necessary financing is in place to complete not only Phase 1 and 2 of the Company's coffee extracts and ready-to-drink facility, which consist of high-speed can and glass bottle lines, a multi-serve bottle line, and bag-in-box and bulk lines, but also the two additional can lines and an industry leading product development lab and FDA certified pilot plant the Company announced on June 30, 2023. Wells Fargo Securities served as a Capital Markets Advisor to Westrock Coffee. Wachtell, Lipton, Rosen & Katz served as legal counsel to Westrock Coffee.
2023-07-18 16:27:43	EBG	HighPeak Energy Stock Is Getting Drilled: What's Going On?	HighPeak Energy Inc (NASDAQ: EBG ) shares are trading lower in Tuesday's after-hours session after the company announced a public offering . The Details: HighPeak commenced an underwritten public offering of its common stock. The company expects to grant the underwriter a 30-day option to buy additional shares at the public offering price. The company intends to use net proceeds for working capital and to enhance its near-term liquidity position. The pricing and size of the offering have not been announced. HighPeak is an independent oil and natural gas company focused on the acquisition, development, exploration and exploitation of unconventional oil and natural gas reserves in the Midland Basin in West Texas. See Also: Dow Enters Bull Market, Banks And Energy Lead; Microsoft Achieves Record High On AI Innovation EBG Price Action: HighPeak shares were down 12.2% after hours at $11.30 at the time of publication, according to Benzinga Pro . Photo: John R Perry from Pixabay.
2023-07-18 16:46:35	WTSK	i-80 Announces CAD$32M Private Placement Of 11,852,000 Shares Of Common Stock At A Price Of CAD$2.70/Share	"i-80 GOLD CORP. (TSX: IAU ) (NYSE: WTSK ) (""i-80"", or the ""Company"") , is pleased to announce that it has entered into an agreement with CIBC Capital Markets as lead underwriter and sole bookrunner on behalf of a syndicate of underwriters (collectively, the ""Underwriters"") pursuant to which the Underwriters have agreed to purchase on a bought deal private placement basis, 11,852,000 common shares of the Company (the ""Offered Shares"") at a price of $2.70 per Offered Share for gross proceeds of $32.0 million (the ""Offering"") . The Company has granted the Underwriters an option, on the same terms and conditions as the Offering, exercisable until the second business day prior to the closing date of the Offering, to purchase up to an additional 15% of the Offering (""Underwriters' Option"") . If the Underwriters' Option is exercised in full, the aggregate gross proceeds to i-80 of the Offering would be $36.8 million. The net proceeds from the Offering will be used for the exploration, development and ramp-up (including working capital) of the Corporation's material mineral projects and for general corporate purposes and working capital. Specifically, the funds raised will be directed towards the upcoming milestone payment for the Ruby Hill project, drilling expenditures for Ruby Hill, Granite Creek and Cove, permitting expenses and the further development of Granite Creek project. i-80's cornerstone shareholders, including Orion Mine Finance and Equinox Gold, and members of the Company's Board of Directors and Management Team intend to participate in in the offering. The Offering is expected to close on or about August 1, 2023 (the ""Closing Date"") and is subject to certain conditions including, but not limited to, the receipt of all necessary corporate and regulatory approvals, including the approval of the Toronto Stock Exchange and the NYSE American. On closing of the Offering (assuming the Underwriters' Option has not been exercised and net of expenses of the Offering), the Company is expected to have approximately US$42.7 million of cash and equivalents and approximately US$47.5 million of restricted cash1. The existing accordion feature with Orion Mine Finance for up to US$100 million remains in place. The Offering is being offered by way of private placement in all provinces of Canada to investors who qualify as ""accredited investors"" under Canadian securities legislation or who are otherwise exempt from prospectus delivery requirements. The Offering may also be offered in the United States to ""qualified institutional buyers"" pursuant to an exemption from registration under the United States Securities Act of 1933, as amended, and in such other jurisdictions outside of Canada in accordance with applicable law. This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the ""U.S. Securities Act"") or any state securities laws and may not be offered or sold within the United States unless registered under the U.S. Securities Act and applicable state securities laws unless an exemption from such registration is available."
2023-07-19 06:06:30	DCQX	On July 14, 2023, PowerUp Acquisition Entered Into A Purchase Agreement With Srirama Associates And Powerup Sponsor; Under Agreement, Srirama Associates Will Purchase 4,317,500 Class A Ordinary Shares And 6,834,333 Private Placement Warrants From Sponsor	On July 14, 2023, PowerUp Acquisition Corp. (the &quot;Company&quot;) entered into a purchase agreement (the &quot;Purchase Agreement&quot;) with SRIRAMA Associates, LLC, a Delaware limited liability company (the &quot;Acquirer&quot;) and PowerUp Sponsor LLC ( the &quot;Sponsor&quot;), pursuant to which the Acquirer will purchase from the Sponsor (x) 4,317,500 Class A Ordinary Shares and (y) 6,834,333 private placement warrants, free and clear of all liens and encumbrances (other than those contained in the Letter Agreement, dated February 22, 2022, by and among the Company, its officers, directors and the Sponsor, and the Underwriting Agreement, dated February 17, 2022, by and between SPAC and Citigroup Global Markets Inc., as representative of the several underwriters (the &quot;Underwriting Agreement&quot;)), for an aggregate purchase price of $1.00 (the &quot;Purchase Price&quot;) payable at the time of the initial business combination.
2023-07-19 08:09:15	FEAD	Genprex Announces $7.5M Registered Direct Offering With An Instatutional Investor For The Sale And Issuance Of  7,425,744 Shares And Warrants  At A Combined Price Of $1.01/Unit, Priced At-the-Market Under Nasdaq Rules	Genprex, Inc. (&quot;Genprex&quot; or the &quot;Company&quot;) (NASDAQ: FEAD), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that it has entered into definitive agreements with healthcare-focused institutional investors for the sale and issuance of 7,425,744 shares of the Company's common stock and warrants to purchase up to 7,425,744 shares of common stock at a combined offering price of $1.01 per share of common stock and accompanying warrant, in a registered direct offering priced at-the-market under the Nasdaq rules. The warrants have an exercise price of $0.885 per share, will become exercisable commencing the date of issuance, and will expire five years following the issuance date. The closing of the offering is expected to occur on or about July 21, 2023, subject to the satisfaction of customary closing conditions. L.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. The gross proceeds to Genprex from this offering are expected to be approximately $7.5 million, before deducting the placement agent's fees and other offering expenses. Genprex intends to use the net proceeds from this offering for working capital and general corporate purposes.
2023-07-19 08:21:42	DPSS	Aqua Metals Prices $17.4M Public Offering Of 15.82M Shares Of Common Stock At A Price Of $1.10/Share	"Aqua Metals, Inc. (NASDAQ: DPSS ) (""Aqua Metals"" or the ""Company""), a pioneer in sustainable lithium-ion battery recycling, today announced that it has priced its underwritten public offering of 15,820,000 shares of its common stock at a public offering price of $1.10 per share. All of the securities in the underwritten public offering are to be sold by the Company. Aqua Metals expects the gross proceeds from this offering to be $17,402,000, before deducting the underwriting discount and other estimated offering expenses. Aqua Metals has granted the underwriter a 30-day option to purchase up to 2,373,000 additional shares of common stock. Aqua Metals expects to close the offering, subject to customary conditions, on July 21, 2023. Aqua Metals intends to use the net proceeds from the proposed offering for working capital, including expenditures related to the commencement of the Phase One build-out of its recently acquired five-acre recycling campus at the Tahoe Reno Industrial Center in McCarran, Nevada, and general corporate purposes. The Benchmark Company, LLC acted as sole book-running manager for the offering. The Liquid Venture Partners group at The Benchmark Company, LLC was responsible for sourcing and executing the offering."
2023-07-19 08:26:32	TZT	Aurora Entered Into $600M Common Stock Purchase Agreement With Certain Existing Institutional And Strategic Investors To Issue And Sell 222,222,216 Shares Of Its Class A Common Stock At $2.70/Share	Concurrent with the public offering, Aurora also entered into a common stock purchase agreement with certain existing institutional and strategic investors, entities affiliated with two of Aurora's directors, and new institutional investors to issue and sell 222,222,216 shares of its Class A common stock at $2.70 per share, for aggregate gross proceeds of $600 million through a private placement. The sale of these shares of Class A common stock will not be registered under the Securities Act of 1933, as amended (the &quot;Securities Act&quot;). The concurrent private placement is expected to close on July 21, 2023. The concurrent private placement is not conditioned on the closing of the public offering but is subject to customary closing conditions. Goldman Sachs & Co. LLC and Allen & Company LLC are acting as joint book-running managers, Evercore ISI is acting as book-runner and Canaccord Genuity, TD Cowen and Nomura are acting as co-managers for the underwritten public offering. Allen & Company LLC and Goldman Sachs & Co. LLC are also acting as placement agents for the concurrent private placement.
2023-07-19 09:51:24	CYKK	What's Going On With Carvana Stock Wednesday?	Carvana Co (NASDAQ: CYKK ) shares are trading higher Wednesday after the company reported better-than-expected quarterly results and issued positive guidance. Carvana also entered into a distribution agreement related to an offering of up to $1 billion of its common stock . What Happened: Carvana reported second-quarter revenue of $2.97 billion, which beat estimates of $2.59 billion. The company reported gross profit per unit of $6,520, representing a 94% increase year-over-year. The company also guided for positive adjusted EBITDA in the third quarter. Carvana said it entered into an agreement with noteholders representing over 90% of outstanding senior unsecured notes to reduce total debt, extend maturities and lower near-term cash interest expenses. &quot;The strong performance of our business in 2023 presented an opportunity for an impactful and win-win transaction for Carvana and its senior unsecured noteholders. This transaction significantly increases our financial flexibility,&quot; said Mark Jenkins , CFO of Carvana. Per a new regulatory filing, Carvana also entered into a distribution agreement with Citigroup and Moelis related to an offering. The company said it may offer and sell from time to time up to 35 million shares of its common stock, representing an aggregate offering price of up to $1 billion. Carvana said if there are any proceeds from the offering, they will be used for general corporate purposes, including repayment of indebtedness, funding working capital, capital expenditures, operating expenses and the selective pursuit of business development opportunities. See Also: Netflix, Carvana, Tesla, Microsoft, Rocket Lab: Why These 5 Stocks Are Trending Today CYKK Price Action: Carvana shares were up 36.3% at $54.21 at the time of writing, according to Benzinga Pro . Photo: courtesy of Carvana.
2023-07-20 08:18:47	KUGN	Cosmos Health Inc. Announces Pricing Of $5.25M Registered Direct Offering And Concurrent Private Placement	Cosmos Health Inc. (the &quot;Company&quot;) (NASDAQ: KUGN ) , a global healthcare group with proprietary lines of nutraceuticals and distributor of pharmaceuticals, branded generics, OTC medications and medical devices, today announced that it has entered into securities purchase agreements with institutional investors for the purchase and sale of 2,116,936 shares of the Company's common stock (or common stock equivalents in lieu thereof) in a registered direct offering and common warrants to purchase up to 1,935,484 shares of common stock in a concurrent private placement (together with the registered direct offering, the &quot;offering&quot;). The combined purchase price for one share of common stock (or common stock equivalent) and one common warrant will be $2.48. The warrants will have an exercise price of $2.75 per share, will be exercisable immediately and will expire five years from the issuance date. The offering includes participation from Grigorios Siokas, CEO of Cosmos Health Inc. (without receiving any common warrants), as well as existing shareholders of the Company. The aggregate gross proceeds from the offering will be approximately $5.25 million before deducting fees and other estimated expenses. The Company expects to use the net proceeds from the offering for working capital and general corporate purposes. The offering is expected to close on or about July 21, 2023, subject to the satisfaction of customary closing conditions. A.G.P./Alliance Global Partners is acting as the sole placement agent for the offering. The offering of the shares of common stock (or common stock equivalents in lieu thereof) is being made pursuant to a &quot;shelf&quot; registration statement on Form S-3 (File No. 333-267550) previously filed with and declared effective by the U.S. Securities and Exchange Commission (the &quot;SEC&quot;) on December 15, 2022. A prospectus supplement describing the terms of the offering will be filed with the SEC and will be available on the SEC's website located at http://www.sec.gov . Electronic copies of the prospectus supplement may be obtained, when available, from A.G.P./Alliance Global Partners, 590 Madison Avenue, 28th Floor, New York, NY 10022, or by telephone at (212) 624-2060, or by email at prospectus@allianceg.com . The private placement of the common warrants will be made in reliance on an exemption from registration under Section 4(a)(2) of the Securities Act and/or Regulation D thereunder. Accordingly, the securities issued in the concurrent private placement may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws. In connection with the offering, the Company also agreed to amend existing warrants to purchase up to 782,610 shares of the Company's common stock, with an exercise price of $11.50 per share, that were previously issued to the investors participating in this offering. Effective upon closing of this offering, such existing warrants will be amended to reduce the exercise price to $2.75 per share. All the other terms of the Prior Warrants will remain unchanged. This press release is for informational purposes only and shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities, in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
2023-07-20 09:10:25	SLPM	Frontier Communications Offers $1B Fiber-Backed Bond	Frontier Communications Parent Inc (NASDAQ: SLPM ) said an indirect subsidiary of the company intends to offer approximately $1.05 billion of secured fiber network revenue term notes. The bond deal can potentially upsize, subject to market conditions and other factors. The notes will be secured by certain of Frontier's fiber assets and associated customer contracts in the Dallas metropolitan area. The issue constitutes the first offering of green bonds by a Frontier subsidiary. Frontier intends to use the net proceeds of the offering to pay existing debt and for general corporate purposes. Frontier filed for bankruptcy in April 2020 and planned to reduce more than $10 billion of its $17 billion debt by handing ownership to bondholders, reported Bloomberg . The report added that the company returned to the market with a $1 billion junk bond offering in 2021. Price Action : SLPM shares are trading higher by 2.36% at $15.64 in premarket on the last check Thursday.
2023-07-20 10:16:07	NCYL	Why VSE Shares Are Plummeting Today	VSE Corporation (NASDAQ: NCYL ) has priced its previously announced underwritten public offering of 2.47 million shares at a price to the public of $48.50 per share. The offer price represents an 11% discount to the company&rsquo;s closing price on July 19. VSE has also granted the underwriters a 30-day option to purchase up to an additional 371,250 shares. The company expects to substantially use all the $112.7 million net proceeds to repay outstanding borrowings under its revolving credit facility and for general corporate purposes. The offering is expected to close on July 24, 2023, subject to the satisfaction of customary closing conditions. The company will issue second quarter 2023 results after the market close on Wednesday, July 26, 2023. Price Action : NCYL shares are trading lower by 7.08% at $50.56 on the last check Thursday.
2023-07-20 13:29:55	LZWQ	BioNexus Gene Lab Corp. Announces Pricing Of $5M Public Offering And Uplisting To The Nasdaq Capital Market	BioNexus Gene Lab Corp. (&quot;BioNexus&quot; or the &quot;Company&quot;), an emerging company in the business of selling chemical raw materials in the Southeast Asia region and the development of safe, effective, and non-invasive liquid biopsy tests for early diagnosis and personalized health management, today announced the pricing of its Public Offering (the &quot;Offering&quot;) of 1,250,000 shares of common stock at a price of $4.00 per share for total gross proceeds of $5 million before deducting underwriting discounts and commissions and offering expense. In addition, the Company has granted the underwriter an option, exercisable within 45 days from the closing date, to purchase up to an additional 187,500 shares at the public offering price, less underwriting discounts and commissions. The shares have been approved for listing on NASDAQ Capital Market and are expected to commence trading on July 20, 2023, under the symbol &quot;LZWQ.&quot; The offering is expected to close on or about July 24, 2023, subject to the satisfaction of customary closing conditions. The Offering is being conducted on a firm commitment basis. Network 1 Financial Securities, Inc. is acting as the sole book-running manager for the Offering. Ortoli Rosenstadt LLP is acting as U.S. counsel to BioNexus, and VCL Law LLP is acting as counsel to the underwriter with respect to the Offering.
2023-07-21 09:36:14	XUDA	RedHill Biopharma Announces Registered Direct Offering For The Purchase And Sale Of 1,301,923 ADS's And Warrant Exercise For $3.8M Gross Proceeds	RedHill Biopharma Ltd. (NASDAQ: XUDA ) (&quot;RedHill&quot; or the &quot;Company&quot;), a specialty biopharmaceutical company, today announced that it has entered into definitive agreements with institutional investors for the purchase and sale of 1,301,923 of the Company's American Depositary Shares (&quot;ADSs&quot;) (or ADS equivalents), each ADS representing four hundred (400) ordinary shares, at a purchase price of $1.35 per ADS (or ADS equivalent), in a registered direct offering. The Company has also entered into a definitive agreement with a certain holder of its existing Class A warrants exercisable for 1,500,000 ADSs, in the aggregate, to exercise its warrants at a reduced exercise price of $1.35 per ADS, in exchange for new warrants as described below. L.C. Wainwright & Co. is acting as the exclusive placement agent for the transactions. The closing of the offering and warrant exercises is expected to occur on or about July 25, 2023, subject to the satisfaction of customary closing conditions. The gross proceeds to the Company from the transactions are expected to be approximately $3.8 million, before deducting the placement agent's fees and other offering expenses payable by the Company. The Company intends to use the net proceeds from these transactions for general working capital, acquisitions, research and development, and general corporate purposes.
2023-07-21 11:52:06	XUDA	What's Going On With RedHill Biopharma Stock Today	RedHill Biopharma Ltd (NASDAQ: XUDA ) shares are down after the company announced a registered direct offering of 1.3 million American Depositary Shares, each ADS representing four hundred (400) ordinary shares, at a purchase price of $1.35 per ADS (or ADS equivalent), in a registered direct offering . The company has also entered into a definitive agreement with a certain holder of its existing Class A warrants exercisable for 1.5 million ADSs, in the aggregate, to exercise its warrants at a reduced exercise price of $1.35 per ADS. The gross proceeds to the company from the transactions are expected to be approximately $3.8 million, which will be used for general working capital, acquisitions, R&D, and general corporate purposes. The company also announced that opaganib has been awarded a further $1.7 million in U.S. Government funding via a Small Business Innovation Research (SBIR) grant to the company's development partner, Apogee Biotechnology . This SBIR grant will support research to further the development of opaganib as a medical countermeasure for gastrointestinal acute radiation syndrome . The SBIR grant is in addition and complementary to the multimillion-dollar-valued U.S. Government Radiation and Nuclear Countermeasures Program product pipeline development contract awarded to opaganib following its selection by the RNCP for ARS development. Price Action: XUDA shares are down 22.1% at $1.44 on the last check Friday.
2023-07-21 16:02:16	LSET	Contango ORE Announces Underwritten Public Offering Of Common Stock; No Size Disclosed	Contango ORE, Inc. (&quot;Contango,&quot; &quot;CORE&quot; or the &quot;Company&quot;) (NYSE: LSET ), today announced it has commenced an underwritten public offering (the &quot;Offering&quot;) of shares of its common stock. All of the shares of common stock in the Offering are to be sold by Contango. In addition, Contango intends to grant the underwriters in the Offering, a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the Offering. The Offering is subject to market conditions, and there can be no assurance as to whether or when the Offering may be completed, or as to the actual size or terms of the Offering. The Company intends to use the net proceeds from the Offering to fund its contribution obligations to the Peak Gold JV for the Manh Choh project, to continue exploration drilling for potential resource expansion at its Lucky Shot project, and to fund working capital requirements. Maxim Group LLC and Freedom Capital Markets are acting as joint book-runners for the Offering.
2023-07-24 07:01:26	ZUS	Why ZUS Shares Are Ripping Higher Premarket Today	Shares of ZUS Entertainment Holdings, Inc. (NYSE: ZUS ) are skyrocketing before the opening bell on Monday, extending the strength from Friday's after-hours session. The spike was in reaction to the Delaware Court of Chancery's ruling against a settlement proposed by the company that will allow it to convert its preferred equity shares known as APEs into common shares and implement a 10-for-1 reverse stock split. ZUS intended to do the transactions to be able to sell additional shares and raise capital to avert potential bankruptcy. This was met with opposition from certain shareholders, who sued to block the transactions. The company later reached a settlement with these shareholders, agreeing to give an extra share for every 7.5 shares owned. Other investors, who rejected the settlement, took up their objections with the Delaware court ahead of a two-day trial held last month. In an open letter tweeted on Sunday, ZUS CEO Adam Aron said raising fresh equity in the near term is critical to the company. The company is working to address the concern raised in the Delaware Court of Chancery's ruling on Friday, he said. He also emphasized the inability to raise capital materially increases the company running out of cash in 2024 or 2025, or being unable to refinance and stretch out the maturity of some of its debt. Aron also called out for support to beat the short thesis, which according to him, will be possible only if the bankruptcy risk is off the table. In premarket trading on Monday, ZUS shares rallied 48.18% to $6.52 and APE preferred units traded up 1.11% at $1.82, according to Benzinga Pro data. See Also: How To Buy ZUS (ZUS) Stock Photo via Shutterstock
2023-07-24 08:11:56	XZKI	ZyVersa Therapeutics, Inc. Announces Pricing Of $2.1M Public Offering Of 12,727,273 Shares Of Common Stock And Warrants At A Price Of $0.165/Unit	ZyVersa Therapeutics, Inc. (NASDAQ: XZKI , or &quot, ZyVersa&quot, or &quot, the Company&quot, ))))), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of inflammatory and renal diseases with high unmet needs, announced today the pricing of a &quot;reasonable best efforts&quot; public offering of 12,727,273 shares of common stock (or pre-funded warrants in lieu thereof) and common warrants to purchase up to 12,727,273 shares of common stock, at a combined public offering price of $0.165 per share (or pre-funded warrant in lieu thereof) and common warrant for aggregate gross proceeds of approximately $2.1 million, before deducting placement agent fees and other offering expenses. The warrants will have an exercise price of $0.165 per share, will be exercisable immediately, and will expire five years from the initial issuance date. The pre-funded warrants and accompanying common warrants are identical, except that each pre-funded warrant is immediately exercisable for one share of common stock at an exercise price of $0.0001, the purchase price for a pre-funded warrant and accompanying common warrants is the public offering price minus $0.0001 and the pre-funded warrants do not expire until exercised. The closing of the offering is expected to occur on or about July 26, 2023, subject to the satisfaction of customary closing conditions. The Company intends to use the net proceeds of this offering for working capital and other general corporate purposes and may use a portion of the net proceeds to redeem the remaining outstanding shares of its Series A preferred stock. A.G.P./Alliance Global Partners is acting as the sole placement agent for the offering.
2023-07-24 08:39:03	KRIM	Nanox Announces $30M Registered Direct Offering	"NANO-X IMAGING LTD ((""Nanox"" or the ""Company, NASDAQ: KRIM ), an innovative medical imaging technology company, today announced that it has entered into a securities purchase agreement with certain institutional investors for the purchase and sale of 2,142,858 of the Company's ordinary shares, par value NIS 0.01 per share (the ""ordinary shares""), together with warrants to purchase up to 2,142,858 ordinary shares at a combined purchase price of $14.00 per share, in a registered direct offering. The warrants will have an exercise price of $19.00 per share, will be exercisable immediately upon issuance and will expire five years from issuance. The closing of the offering is expected to occur on or about July 26, 2023, subject to the satisfaction of customary closing conditions. The gross proceeds from the offering are expected to be approximately $30 million, excluding any proceeds that may be received upon the exercise of the warrants, before deducting placement agent fees and other offering expenses payable by the Company. The Company intends to use the net proceeds from the offering for general working capital purposes, further development of the Nanox.ARC, the Nanox.CLOUD and other products, and the manufacture and commercial deployment of the Nanox System. A.G.P./Alliance Global Partners is acting as sole placement agent for the offering. The proposed offering is being made pursuant to a ""shelf"" registration statement on Form F-3ASR (File No. 333-271688) that was filed by Nanox with the U.S. Securities and Exchange Commission (the ""SEC""), under the Securities Act of 1933, as amended (the ""Securities Act""), on May 5, 2023, and automatically became effective upon filing. The proposed offering of these securities is being made only by means of a prospectus and a related prospectus supplement describing the terms of the offering, which will be filed with the SEC and, once filed, will be available on the SEC's website located at http://www.sec.gov . Electronic copies of the prospectus supplement may be obtained, when available, from A.G.P./Alliance Global Partners, 590 Madison Avenue, 28th Floor, New York, NY 10022, or by telephone at (212) 624-2060, or by email at prospectus@allianceg.com . This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities or any other securities, nor shall there be any offer, solicitation or sale of these securities or any other securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction."
2023-07-24 08:44:45	LSET	Contango ORE Announces Pricing Of $30.4M Underwritten Public Offering Of 1.6M Shares Of Common Stock At A Price Of $19/Share	Contango ORE, Inc. (&quot;Contango,&quot; &quot;CORE&quot; or the &quot;Company&quot;) (NYSE: LSET ), today announced the pricing of its previously announced underwritten public offering (the &quot;Offering&quot;) of 1,600,000 shares of its common stock at a public offering price of $19.00 per share. Gross proceeds from the Offering are expected to be $30.4 million before deducting underwriting discounts, commissions, and estimated Offering expenses. In addition, Contango has granted the underwriters a 30-day option to purchase up to an additional 240,000 shares of common stock. The Company intends to use the net proceeds from the Offering to fund its contribution obligations to the Peak Gold JV for the Manh Choh project (a joint venture between Kinross 70% and Contango 30%), to continue exploration drilling for potential resource expansion at its Lucky Shot project, and to fund working capital requirements. Rick Van Nieuwenhuyse, the Company' President and Chief Executive Officer, said, &quot;This financing is an important milestone for the Company as we are pleased to announce that Contango is now fully funded to reach production at the Manh Choh mine, which is scheduled to commence full-scale production in the second half of 2024. This financing will allow us to fully utilize our secured $65 million credit facility with ING Capital LLC and Macquarie Bank Limited and, in turn, meet the final funding obligations at the Manh Choh mine. It will also allow us to start an exploration drill program at the Lucky Shot project, primarily focused on in-fill and expansion drilling of the Lucky Shot vein structure. Once all assays and geologic modeling are completed, we will update our S-K 1300 Resource Technical Report on the Lucky Shot project. We also anticipate this financing will bring broader market awareness and increased trading volume as we bring Alaska' next gold mine into production.&quot; Maxim Group LLC and Freedom Capital Markets are acting as joint book-runners for the Offering. The Offering is expected to close on or about July 26, 2023, subject to the satisfaction of customary closing conditions.
2023-07-25 16:26:10	JRUI	B. Riley Financial Announces Proposed $100M Public Offering Of Common Stock	"B. Riley Financial, Inc. (NASDAQ: JRUI ) (""B. Riley"" or the ""Company""), a diversified financial services platform, today announced it has commenced an underwritten public offering of $100 million of its common stock (the ""Offering""), subject to market and certain other conditions. The Company expects to grant the underwriter a 30-day option to purchase additional shares of its common stock in connection with the Offering. Co-Chief Executive Officers Bryant R. Riley and Tom Kelleher have indicated an interest to purchase, in the aggregate, up to $4.5 million of shares of common stock in this Offering at the public offering price. Certain of the Company's officers, directors, and employees have also indicated an interest in participating in this Offering. B. Riley Securities is acting as sole book-running manager for the offering."
2023-07-27 09:04:27	XCUC	Asensus Surgical Announces $10M Registered Direct Offering Of 23,809,524 Shares And Warrants At A Price Of $0.42/Unit	Asensus Surgical, Inc. (NYSE: XCUC ) (&quot;Asensus&quot; or the &quot;Company&quot;), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery&trade;, today announced that it has entered into a definitive agreement for the purchase and sale of an aggregate of 23,809,524 shares of its common stock and warrants to purchase 23,809,524 shares of common stock in a registered direct offering. The shares of common stock and accompanying warrants are being sold at a combined purchase price of $0.42 per share and accompanying warrant to purchase one share of common stock. The warrants have an exercise price of $0.42 per share, are immediately exercisable and will expire five years following the date of issuance. The offering is expected to close on or about July 31, 2023, subject to the satisfaction of customary closing conditions. L.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. The gross proceeds from the offering to the Company are expected to be $10 million, before deducting placement agent's fees and other offering expense payable by the Company. The Company intends to use the net proceeds from the offering for general corporate purposes, including working capital and funding research and development activities.
2023-07-27 09:12:15	ETIZ	Celularity Inc. Announces $3M Registered Direct Offering Of 8,571,428 Shares And Warrants At A Price Of $0.35/Unit	Celularity Inc. (NASDAQ: ETIZ ) (&quot; Celularity &quot;), a biotechnology company developing placental-derived allogeneic cell therapies and biomaterial products, today announced that it has entered into a definitive agreement with a single, healthcare-focused institutional investor for the purchase and sale of 8,571,428 shares of its Class A common stock together with warrants to purchase up to 8,571,428 shares of its Class A common stock at a combined purchase price of $0.35 per share and accompanying warrant (together the &quot; Securities &quot;), pursuant to a registered direct offering resulting in total gross proceeds of approximately $3 million before deducting placement agent commissions and other estimated offering expenses. The warrants will have an exercise price of $0.35, will be exercisable beginning six months after the date of issuance and will expire five years following the initial exercise date. The closing of the offering and sale of the Securities is expected to occur on or about July 31, 2023, subject to the satisfaction of customary closing conditions. A.G.P./Alliance Global Partners is acting as the sole placement agent for the offering.
2023-07-27 12:46:35	EWZW	Why UroGen Pharma Stock Is Gaining Today?	UroGen Pharma Ltd (NASDAQ: EWZW ) shares are surging after the company released topline data from its Phase 3 trials ATLAS and ENVISION studying UGN-102 (mitomycin) for intravesical solution in patients with low-grade, intermediate-risk non-muscle invasive bladder cancer (LG-DB-NMIBC) . Both ATLAS and ENVISION trials met their primary endpoints. In the ATLAS trial, UGN-102 met its primary endpoint of disease-free survival, reducing the risk of recurrence, progression, or death by 55%. UGN-102 also showed a 64.8% complete response rate at three months for patients who only received UGN-102, compared to a 63.6% complete response rate at three months for patients who only received a TURBT, a standard treatment for bladder cancer. The ENVISION trial met its primary endpoint by demonstrating that patients treated with UGN-102 had a 79.2% rate of complete response at 3 months following the initial treatment. Additional data evaluating the secondary endpoint of the duration of response from ENVISION and the submission of a New Drug Application (NDA) (assuming additional positive findings) to the FDA are anticipated in 2024. UGN-102 was generally well tolerated in both trials, with a side effect profile similar to previous clinical trials. Concurrently, UroGen announced a private placement of approximately $120 million . Price Action: EWZW shares are up 42.70% at $12.86 on the last check Thursday
2023-07-27 16:33:41	TKXJ	Tonix Pharmaceuticals Announces Proposed Public Offering; Size Not Disclosed	"Tonix Pharmaceuticals Holding Corp. (NASDAQ: TKXJ ) (""Tonix"" or the ""Company""), a biopharmaceutical company, today announced that it intends to offer and sell shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase shares of common stock in a public offering. All of the securities to be sold in the offering are to be offered by Tonix. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. The Company intends to use the net proceeds from the offering for working capital and general corporate purposes, the build out of the Company's manufacturing and research and development facilities, and the acquisition or licensing of approved products and products in development. A.G.P./Alliance Global Partners is acting as lead placement agent for the offering. Brookline Capital Markets, a division of Arcadia Securities, LLC is acting as co-placement agent for the offering."
2023-07-27 17:13:47	ANBK	Inozyme Pharma, Inc. Announces $60M Proposed Offering Of Common Stock	Inozyme Pharma, Inc. (NASDAQ: ANBK ), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced that it is commencing an underwritten public offering of $60,000,000 of shares of its common stock. In addition, Inozyme intends to grant the underwriters an option for a period of 30 days to purchase up to an additional 15% of the shares of its common stock offered in the offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering. All of the shares of common stock are to be offered by Inozyme. BofA Securities, TD Cowen and Piper Sandler are acting as joint book-running managers for the offering.
2023-07-27 18:37:26	GN	Waste Management Announces Pricing Of $2B Senior Notes; $750M Aggregate Principal Amount Of 4.875% Due February 15, 2029; $1.25B Aggregate Principal Amount Of 4.875% Due February 15, 2034	Waste Management, Inc. (NYSE: GN ) (&quot;GN&quot; or the &quot;Company&quot;) today announced that it has priced a public offering of $2,000,000,000 aggregate principal amount of senior notes under an effective shelf registration statement previously filed with the Securities and Exchange Commission (the &quot;SEC&quot;), as follows: $750,000,000 aggregate principal amount of 4.875% senior notes due February 15, 2029; and $1,250,000,000 aggregate principal amount of 4.875% senior notes due February 15, 2034. The notes will be fully and unconditionally guaranteed by the Company's wholly owned subsidiary, Waste Management Holdings, Inc. The notes have been assigned ratings of A- by Standard & Poor's, BBB+ by Fitch and Baa1 by Moody's. The offering is expected to close on August 3, 2023, subject to the satisfaction of closing conditions. The Company intends to use the net proceeds from the offering (i) to repay borrowings under its commercial paper program used for working capital, which is fully supported by the Company's $3.5 billion revolving credit facility, (ii) to repay borrowings under the Company's $1.0 billion, two-year, U.S. term credit agreement and (iii) for general corporate purposes.
2023-07-31 09:30:30	SHXJ	ElectroCore, Inc. Announces $8.145M Registered Direct Offering And Concurrent Private Placements Priced At Market Under Nasdaq Rules	electroCore, Inc. (NASDAQ: SHXJ ) (&quot;electroCore&quot; or the &quot;Company&quot;), a commercial-stage bioelectronic medicine and wellness company, today announced that it has agreed to issue and sell to certain institutional and accredited investors an aggregate of 1,675,914 registered shares of common stock (or common stock equivalents) and unregistered warrants to purchase up to an aggregate of 837,955 shares of common stock. Each share of common stock is being sold together with one-half of one warrant at a combined effective offering price of $4.4125 per share and related warrant. The warrants will be exercisable commencing six months after the date of issuance at a price of $4.35 per share and will expire five years after they first become exercisable. In a separate concurrent private placement, electroCore has also agreed to issue and sell 169,968 of its shares of common stock (or common stock equivalents) and warrants to purchase up to an aggregate of 84,982 shares of common stock, to certain of the Company's officers and directors. Each share of common stock is being sold together with one-half of one warrant at a combined effective offering price of $4.4125 per share and related warrant. The warrants issued and sold to insiders will have the same terms as the warrants sold to the institutional and accredited investors. The aggregate gross proceeds to the Company from the issuance and sale of the securities described above is expected to be approximately $8.145 million, before deducting the placement agent's fees and expenses, and other offering expenses payable by electroCore. The Company currently intends to use the net proceeds from these sales for sales and marketing, working capital and general corporate purposes. Paulson Investment Company, LLC, is acting as the exclusive placement agent in connection with the sale of the securities described above to the institutional and accredited investors. The issuance and sale of the securities described above were priced &quot;at market&quot; under Nasdaq rules. The offerings described above are expected to close on or about August 2, 2023, subject to the satisfaction of customary closing conditions.
2023-07-31 17:13:04	EBS	Mueller Industries, Inc. Announces Special Meeting To Approve Increase In Authorized Common Stock From 100M Shares To 250M Shares	Mueller Industries, Inc. (NYSE: EBS ) today announced that is has filed a preliminary proxy statement with the Securities and Exchange Commission for a special meeting of shareholders to approve an amendment to the Company's Restated Certificate of Incorporation to increase the total number of its authorized shares of Common Stock from 100,000,000 shares to 250,000,000 shares. The primary purpose of the charter amendment is to facilitate a stock split of the Common Stock in the form of a stock dividend. Assuming the charter amendment is approved at the Special Meeting, the decision by the Board of Directors whether to approve a stock split following the Special Meeting, including the size of the stock split, will depend upon factors at the time including, but not limited to, the then-current trading price of the Company's Common Stock. As of July 21, 2023, the Company has 56,778,790 shares of Common Stock outstanding, and the current number of authorized shares of Common Stock is 100,000,000.
2023-08-01 07:52:26	NADC	Vision Marine Technologies Announced That It Has Entered Into A Definitive Agreement With Investors For The Issuance And Sale Of 493,832 Of Its Common Shares At $4.05/Share, For Gross Proceeds Of ~$2M In A Registered Direct Offering	Vision Marine Technologies Inc. (NASDAQ: NADC ) (&ldquo;Vision Marine&rdquo; or the &ldquo;Company&rdquo;), a global leader and innovator within the performance electric recreational boating industry, today announced that it has entered into a definitive agreement with investors for the issuance and sale of 493,832 of its common shares for a price of $4.05 per share, for gross proceeds of approximately $2 million, in a registered direct offering. Additionally, Vision Marine will issue to the investors in a concurrent private placement warrants to purchase up to 493,832 common shares, which represents 100% of the number of common shares issued in the registered direct offering. The warrants will have an exercise price of $4.05 per share, will be exercisable six (6) months following the issuance date and will expire three (3) years following the issuance date. Bancroft Capital served as placement agent for the transaction. The offering is expected to close on August 2, 2023, subject to customary closing conditions.
2023-08-01 08:17:25	VUGK	Comera Life Sciences Announces $4.1M Private Placement	Comera Life Sciences Holdings, Inc. (NASDAQ: VUGK ), a life sciences company developing a new generation of biologic medicines to improve patient access, safety, and convenience, today announced that it has executed a definitive agreement to complete a $4.1 million private placement of shares of its common stock, and accompanying warrants to purchase shares of its common stock, to existing stockholders at a purchase price of $0.51125 per share. The shares are accompanied by five-year warrants to purchase shares of common stock at an exercise price of $0.6135 per share, beginning six months and one day after issuance. On July 31, 2023, Comera sold and issued a total of 4,399,016 shares of its common stock and warrants to purchase an aggregate of 10,997,550 shares of its common stock in a first closing, resulting in gross proceeds of $2.25 million to Comera. Comera expects to sell and issue an additional 3,561,851 shares of its common stock and warrants to purchase an aggregate of 8,904,641 shares of its common stock in a second closing, resulting in additional gross proceeds of $1.82 million, conditioned upon receipt of stockholder approval under the applicable Nasdaq listing standards. Warrants issued in connection with the second closing will be immediately exercisable. Proceeds from the private placement are expected to be used for working capital and general corporate purposes. &quot;We appreciate the continued support and confidence of existing investors. This infusion of capital will support our efforts to leverage our SQore&trade; platform to transform the delivery of biologics from intravenous to subcutaneous form and achieve our mission of improving patient quality of life by offering treatments that support greater independence,&quot; said Jeffrey Hackman, Chairman and Chief Executive Officer of Comera. The securities sold in the private placement, including the shares of common stock underlying the warrants, are being sold in a transaction not involving a public offering, have not been registered under the Securities Act of 1933, as amended, and may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements. Concurrently with the closing, Comera and the investors entered into a registration rights agreement pursuant to which the Company has agreed to file a registration statement with the Securities and Exchange Commission registering the resale of the securities sold in the private placement. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
2023-08-01 08:24:14	RFS	Blue Water Biotech Announces Exercise Of Warrants And Issuance Of New Warrants In A Private Placement For $2.7M Gross Proceeds	Blue Water Biotech, Inc. (&quot;Blue Water&quot; or the &quot;Company&quot;) (NASDAQ: RFS ), today announced it has entered into a definitive agreement for the exercise of certain existing warrants to purchase 2,486,214 shares of its common stock at a reduced exercise price of $1.09 per share, in exchange for new warrants as described below. The aggregate gross proceeds from the exercise of the existing warrants is expected to total approximately $2.7 million, before deducting placement agent fees and other offering expenses payable by the Company. The transaction is expected to close on or about August 2, 2023, subject to satisfaction of customary closing conditions. L.C. Wainwright is acting as the exclusive placement agent for this transaction. The Company expects to use the net proceeds from the transaction for working capital and general corporate purposes, including executing on launch activities for Blue Water's commercial portfolio announced in a letter to shareholders issued earlier this month.
2023-08-02 06:24:37	ZWK	Booz Allen Hamilton Raises $650M Via Debt Offering	Booz Allen Hamilton Holding Corporation (NYSE: ZWK ) said its wholly-owned subsidiary, Booz Allen Hamilton Inc, has priced $650 million aggregate principal amount of its 5.950% Senior Notes due 2033. The offering is expected to close on August 4, 2023, subject to certain closing conditions. The company intends to use a portion of the net proceeds to repay revolving borrowings outstanding under its revolving credit facility and for general corporate purposes. Also Read : Booz Allen Hamilton: AI-Enabled Contracts Key To Medium-Term Success, Predicts Stifel Analyst Price Action : ZWK shares closed higher by 1.86% at $123.33 on Tuesday.
2023-08-02 08:42:04	XSPY	Adamis Pharmaceuticals Announces Pricing Of $8M Public Offering Of 5.93M Units At A Price Of $1.35/Unit	Adamis Pharmaceuticals Corporation (NASDAQ: XSPY ), a commercial-stage biopharmaceutical company, today announced the pricing of its public offering of 5,930,000 units at a public offering price of $1.35 per unit. Each unit consists of one share of common stock (or a prefunded warrant in lieu thereof) and one warrant to purchase one share of common stock. The common warrants will be immediately exercisable at an exercise price of $1.35 per share and will expire five years from the date of issuance. The shares of common stock (or pre-funded warrants in lieu thereof) and accompanying common warrants can only be purchased together in this offering, but will be issued separately and will be immediately separable upon issuance. Gross proceeds, before deducting placement agent fees and other offering expenses, are expected to be approximately $8.0 million. The offering is expected to close on August 4, 2023, subject to the satisfaction of customary closing conditions. Maxim Group LLC is acting as sole placement agent in connection with this offering. The securities described above are being offered pursuant to a
2023-08-02 09:19:08	FVJZ	SuperCom Announces Pricing Of $2.75M Public Offering Of 3,235,295 Units At A Price Of $0.85/Unit	SuperCom (NASDAQ: FVJZ ) (&quot;SuperCom&quot; or the &quot;Company&quot;), a global provider of secured solutions for the e-Government, IoT and Cybersecurity sectors, today announced the pricing of its public offering of 3,235,295 units at a public offering price of $0.85 per unit with a single institutional investor. Each unit consists of one ordinary share (or a prefunded warrant in lieu thereof) and one warrant to purchase one ordinary share. The common warrants will be immediately exercisable at an exercise price of $0.85 per share and will expire five years from the date of issuance. The ordinary shares (or pre-funded warrants in lieu thereof) and accompanying warrants can only be purchased together in this public offering, but will be issued separately and will be immediately separable upon issuance. Gross proceeds to the Company, before deducting placement agent fees and other offering expenses, are expected to be approximately $2.75 million. The offering is expected to close on August 3, 2023, subject to the satisfaction of customary closing conditions. Maxim Group LLC is acting as sole placement agent in connection with this public offering.
2023-08-02 17:19:31	JL	QuantumScape Announces $300M Proposed Public Offering of Class A Common Stock	QuantumScape Corporation (NYSE: JL ), a leader in developing next-generation solid-state lithium-metal batteries, today commenced a proposed underwritten public offering of shares of its Class A common stock. QuantumScape intends to offer $300 million of shares of its Class A common stock for working capital and general corporate purposes. QuantumScape intends to grant the underwriters a 30-day option to purchase up to an additional $45 million of shares of Class A common stock at the public offering price, less underwriting discounts and commissions. The proposed offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Evercore ISI and Morgan Stanley are acting as joint lead book-running managers for the Offering.
2023-08-02 17:37:06	TZH	Kimbell Royalty Partners, LP Announces Public Offering Of 6M Common Units	Kimbell Royalty Partners, LP (NYSE: TZH ) (&quot;Kimbell&quot;) today announced that it has commenced an underwritten public offering of 6,000,000 common units representing limited partner interests, subject to market and other conditions. In connection with the offering, Kimbell intends to grant the underwriters an option to purchase up to 900,000 additional common units at the public offering price less the underwriting discount and commissions. Kimbell intends to use the net proceeds from the offering for the repayment of outstanding borrowings under its revolving credit facility. At the closing of the pending acquisition of oil and natural gas mineral and royalty interests held by a private seller (the &quot;Acquisition&quot;), as described in Kimbell's Current Report on Form 8-K filed with the Securities and Exchange Commission (the &quot;SEC&quot;) on August 2, 2023, Kimbell intends to use amounts borrowed from its revolving credit facility to fund a portion of the purchase price of the Acquisition and to pay related fees and expenses. Kimbell may use future amounts borrowed under its revolving credit facility for general partnership purposes, including a potential redemption of a portion of its 6.0% Series A Cumulative Convertible Preferred Units that are expected to be issued in connection with the Acquisition. Citigroup and BofA Securities are acting as lead book-running managers for the offering. When available, a copy of the preliminary prospectus for the offering may be obtained from:
2023-08-02 19:22:51	TZH	Kimbell Royalty Partners, LP Announces Pricing Of $101.5M Upsized Public Offering Of 7.25M Common Units At A Price Of $14/Unit	Kimbell Royalty Partners, LP (NYSE: TZH ) (&quot;Kimbell&quot;) today announced the pricing of its public offering of 7,250,000 common units representing limited partner interests, at a public offering price of $14.00 per common unit. The total gross proceeds of the offering, before underwriters' discounts and estimated offering expenses, will be approximately $101.5 million. Kimbell has granted the underwriters an option to purchase up to 1,087,500 additional common units at the public offering price less the underwriting discount and commissions. The offering is expected to close on August 7, 2023, subject to customary closing conditions. Kimbell intends to use the net proceeds from the offering for the repayment of outstanding borrowings under its revolving credit facility. At the closing of the pending acquisition of oil and natural gas mineral and royalty interests held by a private seller (the &quot;Acquisition&quot;), as described in Kimbell's Current Report on Form 8-K filed with the Securities and Exchange Commission (the &quot;SEC&quot;) on August 2, 2023, Kimbell intends to use amounts borrowed from its revolving credit facility to fund a portion of the purchase price of the Acquisition and to pay related fees and expenses. Kimbell may use future amounts borrowed under its revolving credit facility for general partnership purposes, including a potential redemption of a portion of its 6.0% Series A Cumulative Convertible Preferred Units that are expected to be issued in connection with the Acquisition.
2023-08-03 08:37:29	CNPK	Bio-Path Holdings, Inc. Announces Pricing Of $2.1M Public Offering Of 3.5M Shares Of Common Stock And Warrant For A Purchase Price Of $0.60/Unit	Bio-Path Holdings, Inc., (NASDAQ: CNPK ) (&quot;Bio-Path&quot; or the &quot;Company&quot;), a biotechnology company leveraging its proprietary DNAbilize&reg; antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced the pricing of a public offering of 3,500,000 shares of common stock, together with accompanying common stock purchase warrants, at a price to the public of $0.60 per share and accompanying common stock purchase warrant, for aggregate gross proceeds to the Company of approximately $2.1 million, before deducting the fees and estimated offering expenses payable by the Company. Each share of common stock is being sold in the offering together with a common stock purchase warrant to purchase one share of common stock at an exercise price of $0.60 per share. The common stock purchase warrants are exercisable immediately and will expire five years from the date of issuance. The offering is expected to close on or about August 7, 2023, subject to customary closing conditions. Roth Capital Partners acted as the sole placement agent for the offering. Bio-Path currently intends to use the net proceeds from the offering for working capital and general corporate purposes.
2023-08-03 08:50:04	RDXW	"Workhorse Group Mails Letter to Stockholders from Chief Executive Officer, Rick Dauch; Urges Stockholders To Vote ""FOR"" The Proposal To Increase Workhorse's Authorized Shares"	Urges Stockholders to Vote &quot;FOR&quot; The Proposal to Increase Workhorse's Authorized Shares Launches Website for Special Meeting with Information for Stockholders &ndash; www.VoteWKHS.com CINCINNATI, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Workhorse Group Inc. (NASDAQ: RDXW ) (&quot;Workhorse&quot; or &quot;the Company&quot;), an American technology company focused on pioneering the transition to zero emission commercial vehicles, today mailed a letter to Workhorse stockholders from its CEO Rick Dauch providing context on why Workhorse stockholders should vote FOR the proposal to increase the number of authorized shares of Workhorse common stock in connection with the upcoming Special Meeting. Workhorse also launched a website in connection with the Special Meeting, which has information for stockholders regarding the proposal and how to vote: www.VoteWKHS.com . The full text of the letter being mailed to stockholders follows: Dear Fellow Workhorse Stockholders, I am reaching out so you can hear directly from me about where Workhorse is today and why we need your help to build a bridge to continued growth and long-term stockholder value creation. We are asking our stockholders to approve an increase in our authorized common stock and I am asking for you to support the future of Workhorse by voting in favor TODAY. When I joined Workhorse as CEO in August 2021, I knew there was incredible potential, but that there were also a number of legacy issues we needed to solve for first. Since then, we have transformed the business, executing a clear strategy to stabilize, fix and ultimately grow Workhorse into a viable commercial EV OEM. We have revamped our management team, bringing in industry veterans and experts to lead the Company and execute our plans. These business leaders, engineers, operational, supply chain, sales professionals, and plant management have the necessary skills and relevant expertise to develop and advance the initiatives underway across the Company. To facilitate our growth, we have revitalized our facilities , bringing manufacturing and jobs back to the Midwest. I grew up in Indiana and Michigan, and I am extremely proud of what we are building here in the heartland of the United States. In addition to our other facilities, we have completely transformed our Union City, Indiana plant into a world-class manufacturing complex that is ramping up production of our electric vehicles. We have also created a world class technology development and manufacturing site here in Ohio for our Aerospace business. We have developed and are advancing a clear product roadmap, targeting the CL4-6 work truck and step-van segment . Production of our flagship W56 vehicles is on track to begin in September, and customer interest for this commercial vehicle is extremely high. We have already ramped up production of our W4 CC vehicle and initial deliveries of the W750 step-van were made in Q2 this year. Longer-term, we are developing WNext , a next-generation vehicle with improved capabilities, safety systems and technology, over the next three years. At the same time, we are building out our commercial footprint. We have announced partnerships with several regional EV dealers and are continuing to expand our dealership network further in the coming years. In addition to our commercial EVs, we have continued to invest in our Aerospace business and pursue key contracts. We recently signed our first commercial drone purchase orders for our industry leading HorseflyTM product and are holding demonstrations for potential last-mile delivery customers, industry partners, government agencies and officials. In addition, we developed our FALCONTM product, designed purposedly for austere work environments, in less than five months. We have also earned multiple grants or contracts from both Federal and State governments to perform &lsquo;drones as a service' tasks across the country. Finally, we have strengthened the Company's financial position . We addressed balance sheet issues and resolved legacy legal liabilities, providing us with the financial flexibility to invest in our turnaround efforts to date. Our focused efforts have put us on the precipice of success, ready to emerge as not only a survivor but as a leader in the transition to an EV powered system, both on the ground and in the air. I have held executive leadership positions at multiple companies across the global automotive industry over my 30-year career. I know what it takes to succeed, and I am confident in our team, plans and opportunities to do so here at Workhorse. That said, as we look ahead, we need to ensure we have the necessary financial resources to &quot;complete the transition&quot; and are evaluating a range of options to fund our next phase of production and profitable growth. We are contemplating transactions involving common stock or the issuance of equity-linked securities, including convertible debt. These options will only be available to us if we have the flexibility to issue more shares of our stock. This is why we need your help to build a bridge to continued growth and long-term stockholder value. To continue on our journey, we need our stockholders to vote FOR the proposal to increase the number of authorized shares of Workhorse common stock. I am incredibly proud of the progress we are making, and I have the utmost confidence in our path forward to deliver growth, profitability, and stockholder value. We appreciate your support and thank you in advance for voting FOR Workhorse's future. Sincerely, Rick Dauch CEO Workhorse Group
2023-08-03 09:38:07	JL	Why QuantumScape Stock Is Falling Thursday	QuantumScape Corp (NYSE: JL ) shares are trading lower Thursday after the company proposed a $300 million public offering . What Happened: QuantumScape said it intends to offer $300 million of shares of its common stock in a public offering. The lithium battery company intends to grant the underwriters an option to purchase up to an additional $45 million worth of stock. QuantumScape said it intends to use the proceeds for working capital and general corporate purposes. QuantumScape reported second-quarter financial results last week. As of June 30, the company said it had $232.84 million in cash and equivalents. Capital expenditures in the second quarter totaled $25 million. Operating expenses were $124 million. The company maintained its full-year outlook for capital expenditures of $100 million to $150 million and cash operating expenses of $225 million to $275 million. QuantumScape aims to transform energy storage with solid-state lithium-metal battery technology. See Also: Wayfair Stock Is Soaring - Here's What's Driving The Move JL Price Action: QuantumScape shares were down 13.1% at $9.66 at the time of publication, according to Benzinga Pro . Photo: Dean Simone from Pixabay.
2023-08-03 17:26:44	OV	Missfresh Announces Entry Of Share Purchase Agreements For Financing And Business Acquisition;  Investors Agree To Subscribe 5.4B Class B Ordinary Shares Of The Company In Aggregate For A Total Purchase Price Of $27	Missfresh Limited (&quot;Missfresh&quot; or the &quot;Company&quot;) (NASDAQ: OV ), today announced that it entered into two share purchase agreements with two investors, respectively (the &quot;Share Purchase Agreements for Financing&quot;), and another share purchase agreement with Mejoy Infinite Limited and its shareholder (the &quot;Share Purchase Agreement for Business Acquisition&quot;). The entry of the Share Purchase Agreements for Financing and the Share Purchase Agreement for Business Acquisition and the transactions contemplated thereunder have been approved by the board of directors of the Company (the &quot;Board&quot;) and the special committee under the Board. Under the Share Purchase Agreements for Financing, the investors agree to subscribe 5,400,000,000 Class B ordinary shares of the Company in aggregate for a total purchase price of US$27.0 million, subject to the satisfaction of certain closing conditions. Upon the completion of transactions under the Share Purchase Agreements for Financing, the new investors will hold 5,400,000,000 Class B ordinary shares of the Company, representing 88.1% of the Company's total issued and outstanding shares. Each of the investors has agreed to irrevocably and fully delegate the voting rights of all shares issued pursuant to the Share Purchase Agreements for Financing to Mr. Zheng Xu, the chairman of the Board and chief executive officer of the Company. Under the Share Purchase Agreement for Business Acquisition, the Company agrees to purchase all ordinary shares of Mejoy Infinite Limited held by its shareholder at an aggregate purchase price of US$12.0 million in cash, subject to the satisfaction of certain closing conditions. Pursuant to the Share Purchase Agreement for Business Acquisition, this acquisition is planned to be closed within 45 business days after the satisfaction or waiver of closing conditions or at such other time agreed in writing by the relevant parties. Upon the closing of the Share Purchase Agreement for Business Acquisition, the Company will start to provide customized digital marketing solutions and services. &quot;We are excited to announce this acquisition and have Mejoy as part of our Company,&quot; said Mr. Zheng Xu, &quot;and we believe this acquisition could take full advantage of our extensive market know-how on the online marketing and ecommerce industry.&quot; Mejoy Infinite Limited is a digital marketing solution provider incorporated in Hong Kong. Mejoy is dedicated to helping its clients deliver their online marketing campaigns to engage their target customers and drive higher growth of the clients' businesses.
2023-08-04 09:01:15	IBOJ	IBOJ Bioscience Announces Pricing Of $4.5M Public Offering Of 1.58M Units At A Price Of $2.85/Unit	IBOJ Bioscience, Inc. (NASDAQ: IBOJ ) (&quot;IBOJ&quot; or the &quot;Company&quot;), a healthcare services fertility company focused on expanding access to advanced treatment worldwide with its INVOcell&reg; medical device and the intravaginal culture (&quot;IVC&quot;) procedure it enables, today announced the pricing of its public offering of 1,580,000 units, with each unit consisting of one share of common stock and two warrants, each to purchase one share of common stock. Each unit is being sold at a public offering price of $2.85. The warrants will be immediately exercisable at a price of $2.85 per share and will expire five years from the date of issuance. The shares of common stock and accompanying warrants can only be purchased together in this offering, but will be issued separately and will be immediately separable upon issuance. Gross proceeds, before deducting placement agent fees and other offering expenses, are expected to be approximately $4.5 million. The offering is expected to close on August 8, 2023, subject to customary closing conditions. Maxim Group LLC is acting as sole placement agent in connection with this offering.
2023-08-04 09:02:10	EEAO	Hayward Holdings Announces Pricing Of Secondary Offering of 22,259,780 Shares Of Common Stock By Selling Stockholders At A Price Of $14.30/Share	Hayward Holdings, Inc. (NYSE: EEAO ) (the &quot;Company&quot; or &quot;Hayward&quot;), a global designer, manufacturer and marketer of a broad portfolio of pool and outdoor living technology, today announced the pricing of the previously announced underwritten public offering (the &quot;Offering&quot;) by funds affiliated with CCMP Capital Advisors, LP and a subsidiary of Alberta Investment Management Corporation (the &quot;Selling Stockholders&quot;), of 22,259,780 shares of its common stock at a public offering price of $14.30 per share pursuant to an automatic shelf registration statement filed with the Securities and Exchange Commission (the &quot;SEC&quot;). The Selling Stockholders will receive all of the net proceeds from this Offering. No shares are being sold by the Company. Goldman Sachs & Co. LLC is serving as the underwriter for the Offering.
2023-08-04 16:02:02	RTCP	Tivic Health Announces Proposed Public Offering Of Common Stock; No Size Or Financial Terms Disclosed	Tivic Health&reg; Systems, Inc. ((&quot;Tivic Health&quot;, NASDAQ: RTCP ), a health tech company that develops and commercializes bioelectronic medicine, today announced that it intends to offer and sell shares of its common stock in a public offering. All of the shares of common stock are being offered by Tivic. Tivic intends to use the net proceeds of the offering, if any, for working capital and general corporate purposes. Consummation of the offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Maxim Group LLC is acting as the sole placement agent, on a reasonable best efforts basis, for the offering.
2023-08-07 07:57:14	HFZT	Gracell Biotechnologies Announced Up to $150M Private Placement Financing Joined by a Syndicate of Premier Healthcare Investors; 27,78M ADS At $3.60/Share Plus Warrants	"Gracell Biotechnologies Inc. (("", Gracell"", or the "", Company"", , NASDAQ:HFZT), a global clinical-stage biopharmaceutical company dedicated to developing innovative and highly efficacious cell therapies for the treatment of cancer and autoimmune diseases, today announced that it has entered into a purchase agreement with a select group of institutional and accredited healthcare specialist investors for the private placement of (i) 138,900,000 ordinary shares of the Company (the ""Ordinary Shares"") (equivalent to 27,780,000 of the Company's American depositary shares (""ADSs"")), at a purchase price equivalent to $3.60 per ADS, and (ii) warrants to purchase up to 44,802,870 Ordinary Shares (equivalent to 8,960,574 ADSs) (the ""Warrants"") at an exercise price equivalent to $5.58 per ADS, representing a 55% premium to the purchase price of Ordinary Shares. Gracell will receive $100 million in proceeds from the private placement of Ordinary Shares, and up to an additional $50 million if the Warrants are fully exercised. The Warrants will remain exercisable at the election of the investors within 24 months after the closing of the private placement. The financing is expected to close on August 10, 2023, subject to customary closing conditions."
2023-08-07 08:33:02	VIZA	IO Biotech, Inc. Announces $75M Private Placement Financing; Shares Spike Higher;  Investors Have Agreed To Purchase 37,065,647 Shares Of The Company's Common Stock And Accompanying Warrants At A Price Of $2.025/Unit	Offering includes participation from both new and existing healthcare-dedicated investors Proceeds extend the company's cash runway into the fourth quarter of 2025 NEW YORK, Aug. 07, 2023 (GLOBE NEWSWIRE) -- IO Biotech, Inc. (NASDAQ: VIZA ), a clinical biopharmaceutical company developing novel, immune-modulating cancer vaccines based on its F-win&reg; technology platform, today announced that it has entered into a definitive securities purchase agreement for a private placement that is expected to result in gross proceeds of approximately $75 million, before deducting offering expenses. The private placement includes participation from new and existing investors, including Lundbeckfonden BioCapital; Kurma Growth Opportunities Fund; Vivo Capital; Armistice Capital; Marshall Wace; Samsara BioCapital; Novo Holdings; Stonepine Capital Management; PFM Health Sciences, LP; HBM Healthcare Investments (Cayman) Limited; Pivotal Life Sciences; Sunstone Life Science Ventures; Logos Capital; Altamont Pharmaceutical Holdings, LLC; and The Red Hook Fund LP; among others. Members of the company's management team also participated in this transaction. &quot;The continued strong support that we have received from our existing investors and the enthusiasm from an impressive group of new healthcare investors are testaments to the potential of IO102-IO103, to the strength of the data generated to date from the Phase 1/2 study in metastatic melanoma and from our ongoing Phase 2 basket study (IOB-022/KND38),&quot; said Mai-Britt Zocca, PhD, President and CEO of IO Biotech. &quot;With the proceeds of this financing, we expect to have sufficient capital to fund our operations into the fourth quarter of 2025, supporting the continued development of IO102-IO103 through critical clinical milestones from our pivotal Phase 3 trial in first-line advanced melanoma, as well as from our Phase 2 studies.&quot; Under the securities purchase agreement, the investors have agreed to purchase 37,065,647 shares of the company's common stock and accompanying warrants to purchase up to an aggregate of 37,065,647 shares of common stock, at a combined purchase price of $2.025 per share and accompanying warrant. Each accompanying warrant will represent the right to purchase one share of the company's common stock at an exercise price of $2.47 per share. The warrants will be exercisable for a period of three years and six months following the date of issuance. Morgan Stanley and Piper Sandler acted as joint placement agents for the financing.
2023-08-07 08:39:07	YRO	Valaris Limited Announces $350M Private Placement Of Additional 8.375% Senior Secured Second Lien Notes Due 2030	Valaris Limited (NYSE: YRO ) (&quot;Valaris&quot;) and its wholly-owned subsidiary, Valaris Finance Company LLC (together with Valaris, the &quot;Issuers&quot;), announced today that, subject to market conditions, they intend to offer (the &quot;Offering&quot;) for sale to eligible purchasers in a private placement under Rule 144A and Regulation S of the Securities Act of 1933, as amended (the &quot;Securities Act&quot;), an additional $350 million in aggregate principal amount of their 8.375% Senior Secured Second Lien Notes due 2030 (the &quot;Additional Notes&quot;). Valaris intends to use the net proceeds of the Offering to finance the aggregate purchase price of approximately $337 million (assuming a December 31, 2023 delivery date) for the drillships VALARIS DS-13 and VALARIS DS-14, which Valaris intends to exercise its right to take delivery of on or prior to December 31, 2023, and for general corporate purposes. If Valaris does not elect to exercise its right for either or both drillships, Valaris intends to use the net proceeds of the Offering (not otherwise used to finance the purchase price of either drillship) for general corporate purposes. The Additional Notes will constitute a further issuance of the Issuers' 8.375% Senior Secured Second Lien Notes due 2030 in the aggregate principal amount of $700 million, which were issued on April 19, 2023 (the &quot;Existing Notes&quot;). The Additional Notes will form a single series with, and have the same terms (other than the initial offering price) as, the Existing Notes. The securities to be offered have not been registered under the Securities Act, or any state securities laws, and unless so registered, the securities may not be offered or sold in the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and applicable state securities laws. Valaris plans to offer and sell the securities only to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act and to persons outside the United States pursuant to Regulation S under the Securities Act. This press release shall not constitute an offer to sell, or the solicitation of an offer to buy, any of these securities, nor shall there be any sale of these securities in any state in which such offer, solicitation, or sale would be unlawful. This press release is being issued pursuant to and in accordance with Rule 135c under the Securities Act.
2023-08-07 08:51:06	SWPS	Meten Holding Group Ltd. Announces Entry Into Share Subscription Agreements In Connection With Private Placement Of Ordinary Shares For The Issue And Sale Of 4M Shares At A Value Of $0.003/Share For A Total Of $1M Or $0.25/Share	Meten Holding Group Ltd. (&quot;Meten Holding Group&quot; or the &quot;Company&quot;) (NASDAQ: SWPS ), a cryptocurrency mining company, today announced that it has entered into subscription agreements (the &quot;Subscription Agreements&quot;) with two foreign investors, including an institutional investor, Future Satoshi Ltd, and an individual investor, for the issue and sale of 4,000,000 ordinary shares of the Company, par value US$0.003 per share (the &quot;Ordinary Shares&quot;), for total gross proceeds of $1,000,000, or US$0.25 per share. The Company expects the transactions contemplated by the Subscription Agreements to close on or about August 16, 2023. The Company plans to use the proceeds to purchase additional mining machines, which is expected to further increase the aggregate computing power of the Company's cryptocurrency mining fleet. &quot;We are excited to announce the entry into the Subscription Agreements. With the capital injection, we are aim to further grow our cryptocurrency mining business,&quot; said Mr. Alan Peng, Chief Executive Officer of Meten Holding Group.
2023-08-07 10:48:53	GFRT	Reported Earlier, GFRT Announces Proposed Private Offering Of $350M Green Exchangeable Senior Unsecured Notes And Intention To Enter Into Capped Call Transactions	Hannon Armstrong Sustainable Infrastructure Capital, Inc. (&quot;GFRT,&quot; &quot;we,&quot; &quot;our,&quot; or the &quot;Company&quot;) (NYSE: GFRT ), a leading investor in climate solutions, today announced, subject to market conditions, a private offering of $350 million in aggregate principal amount of green exchangeable senior unsecured notes due 2028 (the &quot;Notes&quot;) by its indirect subsidiaries, HAT Holdings I LLC (&quot;HAT I&quot;) and HAT Holdings II LLC (&quot;HAT II,&quot; and together with HAT I, the &quot;Issuers&quot;). At issuance, the Notes will be guaranteed by the Company, Hannon Armstrong Sustainable Infrastructure, L.P. and Hannon Armstrong Capital, LLC. The Issuers also expect to grant the initial purchasers of the Notes an option to purchase, during the 13-day period beginning on, and including the first date on which the Notes are issued, up to $52.5 million additional aggregate principal amount of the Notes. The Company may use a portion of the net proceeds from this offering to repurchase certain of the 2023 Convertible Notes as described below. Additionally, the Company intends to use cash on hand to enter into privately negotiated capped call transactions as described below. The Company intends to allocate an amount equal to the net proceeds of the offering to acquire, invest in or refinance, in whole or in part, new and/or existing eligible green projects. Investment opportunities have already been identified and are consistent with the Company's normal course investment profile. In addition, these eligible green projects may include projects with disbursements made during the twelve months preceding the issue date of the Notes and those with disbursements to be made following the issue date. Prior to the full investment of such net proceeds, the Company intends to invest such net proceeds in interest-bearing accounts and short-term, interest-bearing securities which are consistent with the Company's intention to continue to qualify for taxation as a REIT. The Notes will accrue interest payable semi-annually in arrears on February 15 and August 15 of each year, beginning on February 15, 2024 until the maturity date, unless the Notes are earlier repurchased, redeemed or exchanged in accordance with their terms prior to such date. Upon any exchange of the Notes, holders will receive cash, shares of common stock, $0.01 par value per share (the &quot;Common Stock&quot;) or a combination of cash and shares of Common Stock, at the Company's election, based on the exchange rate for the Notes. The exchange rate will be subject to adjustment upon the occurrence of certain events, but will not be adjusted for any accrued and unpaid interest. The Company may redeem the Notes if GFRT's board of directors determines such redemption is reasonably necessary to preserve its qualification as a REIT or, in whole or in part, at the Company's option, on or after August 20, 2026 and prior to the 62nd scheduled trading day immediately preceding the maturity date, under certain circumstances. Any shares of Common Stock issuable upon exchange of the Notes will have certain registration rights. The interest rate, exchange rate and other terms of the Notes are to be determined upon pricing of the offering. Contemporaneously with the pricing of the Notes in the offering, the Company may enter into separate and individually negotiated transactions with certain holders of its 0.00% Convertible Senior Notes due 2023 (the &quot;2023 Convertible Notes&quot;) to repurchase for cash certain of the 2023 Convertible Notes (the &quot;concurrent note repurchases&quot;). The terms of any concurrent note repurchases are anticipated to be individually negotiated with each holder of the 2023 Convertible Notes and will depend on several factors, including the market price of the Common Stock and the trading price of the 2023 Convertible Notes at the time of each such concurrent note repurchase. No assurance can be given as to how much, if any, of the 2023 Convertible Notes will be repurchased or the terms on which they will be repurchased. The Company expects that certain holders of any 2023 Convertible Notes that the Company agrees to repurchase that have hedged their equity price risk with respect to such 2023 Convertible Notes will, concurrently with the pricing of the Notes offered hereby, unwind all or part of their hedge positions by buying the Common Stock and/or entering into or various unwinding derivative transactions with respect to the Common Stock. Any repurchase of the 2023 Convertible Notes, and the potential related market activities by holders of the 2023 Convertible Notes participating in the concurrent note repurchases, could increase (or reduce the size of any decrease in) the market price of the Common Stock, which may affect the trading price of the Notes at that time and the initial exchange price of the Notes. The Company cannot predict the magnitude of such market activity or the overall effect it will have on the price of the Notes or the Common Stock. In connection with the pricing of the Notes, the Company expects the Issuers will enter into privately negotiated capped call transactions with one or more of the initial purchasers or their respective affiliates or other financial institutions (the &quot;option counterparties&quot;). The capped call transactions are expected to cover, subject to customary anti-dilution adjustments substantially similar to those applicable to the Notes, the same number of shares of the Common Stock that will initially underly the Notes. The capped call transactions are expected generally to reduce the potential dilution to the Company's common and/or offset potential cash payments the Issuers are required to make in excess of the principal amount, in each case, upon any exchange of the Notes, with such reduction and/or offset subject to a cap. If the market price per share of Common Stock, as measured under the terms of the capped call transactions, exceeds the cap price of the capped call transactions, there would nevertheless be dilution and/or there would not be an offset of such potential cash payments, in each case, to the extent that such market price exceeds the cap price of the capped call transactions. In connection with establishing their initial hedges of the capped call transactions, the option counterparties (and/or their respective affiliates) have advised the Issuers that they expect to enter into various derivative transactions with respect to the Common Stock and/or purchase shares of Common Stock or other securities of the Company or the Issuers in secondary market transactions concurrently with or shortly after the pricing of the Notes, including with certain investors in the Notes. This activity could increase (or reduce the size of any decrease in) the market price of the Common Stock or the Notes at that time. In addition, the option counterparties (and/or their respective affiliates) may modify their hedge positions by entering into or unwinding various derivatives with respect to the Common Stock and/or purchasing or selling shares of the Common Stock or other securities of the Company or the Issuers in secondary market transactions following the pricing of the Notes and prior to the maturity of the Notes (and are likely to do so during any observation period related to an exchange of Notes or following any early exchange, redemption or repurchase of Notes). The effect, if any, of these activities on the market price of the Common Stock or the Notes will depend in part on market conditions and cannot be ascertained at this time, but this activity could also cause or avoid an increase or decrease in the market price of the Common Stock or the Notes, which could affect the holders' ability to exchange the Notes, and it could affect the amount of cash and/or the number and value of the shares of the Common Stock holders receive upon exchange of the Notes. The Notes and the related guarantees will be offered only to persons reasonably believed to be qualified institutional buyers in reliance on Rule 144A under the Securities Act of 1933, as amended (the &quot;Securities Act&quot;). The Notes and the related guarantees will not be registered under the Securities Act or any state securities laws and may not be offered or sold in the United States absent an effective registration statement or an applicable exemption from the registration requirements of the Securities Act or any state securities laws. This press release shall not constitute an offer to sell, or the solicitation of an offer to buy, these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
2023-08-07 16:57:41	PQPY	Safehold Announces Public Offering Of 6.5M Shares Of Common Stock And Concurrent Private Placement	Safehold Inc. (NYSE: PQPY ) (the &quot;Company&quot;) announced today that it has commenced an underwritten public offering to sell 6,500,000 shares of its common stock. The Company intends to grant the underwriters in the offering a 30-day option to purchase up to an additional 975,000 shares of its common stock. BofA Securities, Goldman Sachs & Co. LLC, J.P. Morgan and Morgan Stanley will act as joint book-running managers for the public offering. Concurrently with the completion of the public offering, Safehold is expected to sell, subject to customary closing conditions, to certain affiliates of MSD Partners, L.P. in a private placement a number of shares of common stock equal to approximately 8.5% of the total number of shares of common stock sold in the offering, subject to a cap of 639,656 shares of common stock due to current limitations under NYSE rules and regulations. The Company intends to use the net proceeds from the public offering and concurrent private placement for general corporate purposes, which may include repaying or repurchasing indebtedness (including amounts outstanding from time to time under the Company's revolving credit facility), making additional investments in ground leases, providing for working capital and funding obligations under existing ground lease commitments.
2023-08-07 17:01:38	PDUM	Hercules Capital, Inc. Announces Public Offering Of 6M Shares Of Common Stock	Hercules Capital, Inc. (NYSE: PDUM ) (&quot;Hercules&quot;) today announced that it plans to make a public offering of 6,000,000 shares of its common stock. Hercules also expects to grant the underwriters for the offering an option to purchase up to an additional 900,000 shares of its common stock. Morgan Stanley, UBS Investment Bank and Wells Fargo Securities are acting as joint lead book-running managers, Goldman Sachs & Co. LLC, Jefferies and Keefe, Bruyette & Woods, A Stifel Company , are acting as joint book-running managers, and Compass Point, JMP Securities, a Citizens Company and MUFG are acting as co-managers in this offering. Hercules expects to use the net proceeds from this offering (i) to fund investments in debt and equity securities in accordance with its investment objectives, (ii) to repay indebtedness under its revolving credit facility and (iii) for other general corporate purposes.
2023-08-07 17:09:35	SYTX	Beacon Roofing Supply, Inc. Announces Secondary Offering Of 5M Shares Of Common Stock	Beacon Roofing Supply, Inc. (NASDAQ: SYTX ) (&quot;Beacon&quot;) announced today the commencement of an underwritten secondary public offering of 5 million shares of Beacon's common stock by CD&R Boulder Holdings, L.P., an entity affiliated with Clayton, Dubilier & Rice, LLC. Morgan Stanley is acting as the sole underwriter in the registered public offering of those shares. The selling stockholder will receive all of the net proceeds from this offering and will continue to hold 10,171,964 shares of Beacon common stock after the completion of the offering. No shares are being sold by Beacon, and the total number of Beacon's shares outstanding will not change as a result of the offering. The offering of these shares is being conducted as a public offering pursuant to Beacon's effective shelf registration statement on Form S-3ASR under the Securities Act of 1933, as amended. The proposed offering will be made only by means of a prospectus and prospectus supplement that will form part of the effective registration statement relating to the offering. Information about the offering is available in the preliminary prospectus supplement being filed today with the U.S. Securities and Exchange Commission (the &quot;SEC&quot;). Copies of the preliminary prospectus supplement and the accompanying prospectus relating to the offering, and the final prospectus supplement, when available, may be obtained by contacting Morgan Stanley & Co. LLC, 180 Varick Street, 2nd Floor, New York, NY 10014, Attention: Prospectus Department, or by visiting the SEC's website located at www.sec.gov . You should read the preliminary prospectus supplement and the accompanying prospectus and other documents Beacon has filed with the SEC for more complete information about Beacon and this offering. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
2023-08-07 17:14:48	YRO	Valaris Limited Announces Pricing Of $400M Upsized Private Placement Of Additional 8.375% Senior Secured Second Lien Notes Due 2030	Valaris Limited (NYSE: YRO ) (&quot;Valaris&quot;) and its wholly-owned subsidiary, Valaris Finance Company LLC (together with Valaris, the &quot;Issuers&quot;), announced today the pricing of their private placement (the &quot;Offering&quot;) under Rule 144A and Regulation S of the Securities Act of 1933, as amended (the &quot;Securities Act&quot;), of $400 million in aggregate principal amount of additional 8.375% Senior Secured Second Lien Notes due 2030 (the &quot;Additional Notes&quot;). The Offering was upsized to $400 million in aggregate principal amount of Additional Notes from the original offering size of $350 million in aggregate principal amount of Additional Notes. The Additional Notes mature on April 30, 2030 and will be issued at 100.75% of par. The Offering is expected to close on August 21, 2023, subject to customary closing conditions. Valaris intends to use the net proceeds of the Offering to finance the aggregate purchase price of approximately $337 million (assuming a December 31, 2023 delivery date) for the drillships VALARIS DS-13 and VALARIS DS-14, which Valaris intends to exercise its right to take delivery of on or prior to December 31, 2023, and for general corporate purposes. If Valaris does not elect to exercise its right for either or both drillships, Valaris intends to use the net proceeds of the Offering (not otherwise used to finance the purchase price of either drillship) for general corporate purposes. The Additional Notes will constitute a further issuance of the Issuers' 8.375% Senior Secured Second Lien Notes due 2030 in the aggregate principal amount of $700 million, which were issued on April 19, 2023 (the &quot;Existing Notes&quot;). The Additional Notes will form a single series with, and have the same terms (other than the initial offering price) as, the Existing Notes. The securities to be offered and sold have not been registered under the Securities Act, or any state securities laws, and unless so registered, the securities may not be offered or sold in the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and applicable state securities laws. Valaris plans to offer and sell the securities only to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act and to persons outside the United States pursuant to Regulation S under the Securities Act. This press release shall not constitute an offer to sell, or the solicitation of an offer to buy, any of these securities, nor shall there be any sale of these securities in any state in which such offer, solicitation, or sale would be unlawful. This press release is being issued pursuant to and in accordance with Rule 135c under the Securities Act.
2023-08-08 06:28:37	KXK	Engineering & Construction Firm Fluor Raises $500M Via Debt	Fluor Corp (NYSE: KXK ) has priced a $500 million aggregate principal amount of 1.125% convertible senior notes due 2029 in a private offering. Fluor has granted the initial purchasers of the notes an option to purchase, within a 13-day period from the first issue date, up to an additional $75 million principal amount of the notes on the same terms and conditions. The notes will bear interest at 1.125% per year, which will accrue from August 10, 2023, and will be payable semiannually in arrears on February 15 and August 15 of each year, beginning on February 15, 2024. The company estimates that the net proceeds from the Offering will be approximately $486.3 million. Fluor intends to use a portion of the net proceeds to pay the cost of the capped call transactions and the remainder to repurchase all or a portion of the company's outstanding 2024 notes. The sale of the notes to the initial purchasers is expected to be completed on August 10, 2023. Fluor may redeem for cash all or any portion of the Notes, at its option, on or after August 20, 2026. Price Action : KXK shares closed lower by 4.7% at $34.24 on Monday.
2023-08-08 08:38:38	FMS	Embraer S.A. Announces Early Results Of Offer To Purchase For Cash Certain Outstanding Securities, Change In Consideration For 2025 Notes And Notice Of Optional Redemption Of 2025 Notes	Embraer S.A. (&quot;Embraer&quot;) (NYSE: FMS ) announces the early results of its previously announced offer to purchase for cash up to US$750.0 million in aggregate principal amount (subject to increase or decrease by Embraer in its sole discretion, the &quot;Maximum Tender Amount&quot;) of the outstanding 6.950% senior unsecured guaranteed notes due 2028 (the &quot;2028 Notes&quot;), 5.050% senior unsecured guaranteed notes due 2025 (the &quot;2025 Notes&quot;) and 5.400% senior unsecured guaranteed notes due 2027 (the &quot;2027 Notes&quot;) (all such notes, collectively, the &quot;Notes&quot; and each a &quot;series&quot; of Notes), issued by Embraer Netherlands Finance B.V. (&quot;Embraer Finance&quot;) and unconditionally and irrevocably guaranteed by Embraer (the &quot;Tender Offer&quot;). Additionally, Embraer informs that it has amended the Tender Offer Consideration and the Total Consideration for the 2025 Notes, including for the 2025 Notes holders who have already tendered their notes, as set forth in the table below and Embraer has, on this date, delivered notice of optional redemption of all outstanding 2025 Notes. The 2025 Notes will be redeemed on September 7, 2023 (the &quot;Redemption Date&quot;) at a redemption price (the &quot;Redemption Price&quot;) equal to 100.00% of the principal amount of the 2025 Notes to be redeemed, plus accrued and unpaid interest to, but excluding, the Redemption Date. 2025 Notes held through The Depository Trust Company (&quot;MAF&quot;) should be surrendered for redemption in accordance with MAF's procedures therefor. The Notice of Redemption of the 2025 Notes will be sent to all registered holders on August 8, 2023. Interest on the 2025 Notes will cease to accrue on and after the Redemption Date, subject to certain exceptions, and the only remaining right of holders of the 2025 Notes is to receive payment of the Redemption Price. Except for the change with respect to the consideration for the 2025 Notes, there are no other modifications being made with respect to the Tender Offer. The complete terms and conditions of the Tender Offer are set forth in the offer to purchase dated July 25, 2023, as amended by the press release dated July 27, 2023 (the &quot;Offer to Purchase&quot;).
2023-08-08 16:57:37	EJIO	Mirati Therapeutics Announces Proposed $250M Public Offering Of Common Stock, And, To Certain Investors, Pre-funded Warrants To Purchase Shares Of Common Stock	Mirati Therapeutics, Inc. (NASDAQ: EJIO ), a commercial stage biotechnology company, today announced that it intends to offer and sell $250.0 million of shares of its common stock, and, to certain investors, pre-funded warrants to purchase shares of common stock, in an underwritten public offering. The purchase price of each pre-funded warrant will equal the price per share at which shares of common stock are being sold to the public in this offering, minus $0.001, which will be the per share exercise price of each pre-funded warrant. In addition, Mirati expects to grant the underwriters of the offering a 30-day option to purchase up to an additional $37.5 million of shares at the public offering price, less the underwriting discounts and commissions. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Goldman Sachs & Co. LLC is acting as the book-running manager for the proposed offering. Leerink Partners LLC is acting as financial advisor for the proposed offering.
2023-08-08 17:48:42	KW	NuStar Energy L.P. Announces Public Offering Of 12M Common Units	NuStar Energy L.P. (NYSE: KW ) (the &quot;Partnership&quot;) announced today that it plans to conduct an offering of 12,000,000 common units pursuant to an effective shelf registration statement previously filed with the Securities and Exchange Commission (&quot;SEC&quot;). The Partnership will grant the underwriters a 30-day option to purchase up to 1,800,000 additional common units. The Partnership intends to use the net proceeds from the offering to redeem outstanding Series D Cumulative Convertible Preferred Units and to pay related fees and expenses. Pending such use, the Partnership intends to repay outstanding borrowings under its revolving credit agreement. Barclays and Citigroup are acting as lead book-running managers for the offering. A copy of the prospectus supplement and accompanying base prospectus relating to this offering may be obtained from any of the underwriters, including Barclays Capital Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue Edgewood, NY 11717, Email: Barclaysprospectus@broadridge.com , Telephone: 888-603-5847; and Citigroup, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, Telephone: 800-831-9146. You may also obtain these documents for free when they are available by visiting the SEC's website at www.sec.gov . This news release does not constitute an offer to sell or a solicitation of an offer to buy the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. The offering may be made only by means of a prospectus and related prospectus supplement meeting the requirements of Section 10 of the Securities Act of 1933, as amended. NuStar Energy L.P., a publicly traded master limited partnership based in San Antonio, Texas, is one of the largest independent liquids terminal and pipeline operators in the nation. The Partnership currently has approximately 9,500 miles of pipeline and 63 terminal and storage facilities that store and distribute crude oil, refined products, renewable fuels, ammonia and specialty liquids. The Partnership's combined system has approximately 49 million barrels of storage capacity, and the Partnership has operations in the United States and Mexico.
2023-08-08 18:13:40	CJSJ	Gates Announces Secondary Offering Of 15M Ordinary Shares	Gates Industrial Corporation plc (NYSE: CJSJ , &quot, , Gates&quot, , or the &quot, , Company&quot, , ))))) announced today that certain selling stockholders affiliated with Blackstone Inc. (the &quot;Selling Stockholders&quot;) have commenced a secondary offering of 15,000,000 of Gates' ordinary shares (the &quot;Offering&quot;). In connection with the Offering, the Selling Stockholders intend to grant to the underwriters a 30-day option to purchase up to 2,250,000 additional ordinary shares. Gates is not offering any ordinary shares in the Offering and will not receive any proceeds from the sale of ordinary shares in the Offering. Citigroup and Goldman Sachs & Co. LLC are serving as the joint lead book-running managers of, and as representatives of the underwriters for, the Offering. The offering of these securities is being made pursuant to an effective shelf registration statement. The offering will be made only by means of a prospectus. A copy of the prospectus relating to these securities may be obtained, when available, from: Citigroup, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 (Tel: 800-831-9146); or Goldman Sachs & Co. LLC, Attn: Prospectus Department, 200 West Street, New York, NY 10282 (Tel: 866-471-2526) or by e-mail at prospectus-ny@ny.email.gs.com . This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
2023-08-09 05:42:00	JEW	JEW REIT Raises $500 Via Debt Offering	Real estate investment trust JEW REIT Inc (NYSE: JEW ) has priced its public offering of $500 million of 5.600% senior unsecured notes due 2033. The notes were offered at 97.676% of the principal amount with a yield to maturity of 5.905%. Interest on the notes will be payable semi-annually on April 15 and October 15 of each year, commencing on April 15, 2024. The notes mature on October 15, 2033. The offering is expected to close on or about August 15, 2023. The company intends to use the net proceeds from the offering to repay all of the outstanding indebtedness under its credit facility, to fund future property acquisitions and for general corporate purposes. Price Action : JEW shares closed lower by 1.43% at $39.00 on Tuesday.
2023-08-09 08:08:41	YSOE	Sunworks Announces $3.3M Registered Direct Offering Of 3.3M Shares Of Common Stock At A Price Of $1/Share	"Sunworks, Inc. (NASDAQ: YSOE ) ""Sunworks"" or the ""Company""), a leading provider of solar power and battery storage solutions for residential, agriculture, commercial, industrial, and public works markets, today announced that it has entered into a definitive agreement with a single ESG-focused institutional investor for the purchase and sale of 3,300,000 shares of the Company's common stock at a purchase price of $1.00 per share of common stock in a registered direct offering. The closing of the offering is expected to occur on or about August 11, 2023, subject to the satisfaction of customary closing conditions. Roth Capital Partners is acting as the exclusive placement agent for the offering. The gross proceeds to the Company from the offering are expected to be $3,300,000, before deducting the placement agent's fees and other offering expenses payable by the Company. The Company intends to use the net proceeds from the offering for working capital and other general corporate purposes."
2023-08-09 08:10:40	TMUB	Tigo Energy, Inc. Announces Redemption Of Warrants	"Tigo Energy, Inc. (NASDAQ: TMUB ) (""TMUB"" or the ""Company"") today announced that it will redeem all of its outstanding public warrants and private warrants (together, the ""Warrants"") to purchase shares of the Company's common stock (the ""Common Stock"") that were issued under the Warrant Agreement, dated as of August 5, 2021 (the ""Warrant Agreement""), by and between the Company and Continental Stock Transfer & Trust Company, as warrant agent, and that remain outstanding following 5:00 p.m. New York City time on September 8, 2023, for a redemption price of $0.01 per warrant. Under the terms of the Warrant Agreement, the Company is entitled to redeem all of its outstanding Warrants for $0.01 per Warrant if the reported closing price of the Company's Common Stock is at least $18.00 per share on each of twenty trading days within a thirty trading day period ending on the third trading day prior to the date on which a notice of redemption is given. This performance threshold was achieved following the market close on August 4, 2023. All outstanding Warrants may be exercised by the holders thereof until 5:00 p.m. New York City time on September 8, 2023 to purchase shares of the Common Stock, at the exercise price of $11.50 per share, payable in cash. At the direction of the Company, Continental Stock Transfer & Trust Company, in its capacity as warrant agent, has mailed a notice of redemption to each of the registered holders of the outstanding Warrants. Holders of Warrants in ""street name"" should immediately contact their broker to determine their broker's procedure for exercising their Warrants since the process to exercise is voluntary. The shares of Common Stock underlying the Warrants have been registered by the Company under the Securities Act of 1933, as amended, and are covered by a registration statement filed on Form S-1 with, and declared effective by, the Securities and Exchange Commission (Registration No. 333-272832). Questions concerning redemption and exercise of the Warrants can be directed to Continental Stock Transfer & Trust Company, 1 State Street, 30th Floor, New York, New York 10004, Attention: Compliance Department, telephone number (212) 509-4000. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any TMUB securities and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offering, solicitation or sale would be unlawful."
2023-08-09 16:44:38	NJKJ	Merus N.V. Announces Proposed Public Offering Of Common Shares; No Size Or Amount Disclosed	"Merus N.V. (NASDAQ: NJKJ ) (""Merus"", the ""Company,"" ""we"" and ""our""), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics&#xAE; and Triclonics&#xAE;), today announced the launch of a proposed underwritten public offering of its common shares (the ""Offer Shares""). All of the common shares are being offered by Merus. In addition, Merus expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the Offer Shares (the ""Option Shares"" and together with the Offer Shares, the ""Shares""). The offering is subject to market conditions and other closing conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Merus currently intends to use the net proceeds from the offering, together with its existing cash, cash equivalents and marketable securities, to advance the clinical development of its product candidates, for preclinical research and technology development, and for working capital and general corporate purposes. Jefferies, BofA Securities, Guggenheim Securities and William Blair are acting as joint book-running managers for the offering. Van Lanschot Kempen is acting as lead manager for the offering."
2023-08-09 17:07:09	WRCE	Innoviz Announces $60M Public Offering Of Ordinary Shares	Innoviz Technologies Ltd. (NASDAQ: WRCE ) (&quot;Innoviz&quot;), a leading Tier-1 direct supplier of high-performance, automotive grade LiDAR sensors and perception software, today announced that it has commenced an underwritten public offering of $60.0 million of its ordinary shares. Innoviz intends to grant the underwriters an option to purchase up to an additional $9.0 million of its ordinary shares at the public offering price less the underwriting discount and commissions. The offering is subject to market and other conditions, and there can be no assurance as to whether, or when, the offering may be completed or as to the actual size or terms of the offering. Innoviz intends to use the net proceeds that it will receive from the offering for general corporate purposes. Goldman Sachs & Co. LLC is acting as lead book-runner and representative of the underwriters for the offering. Cantor and Berenberg are acting as passive book-runners for the offering. Rosenblatt is acting as co-manager for the offering.]
2023-08-10 08:44:16	WRCE	Why Innoviz Stock Is Tumbling Today	Innoviz Technologies Ltd (NASDAQ: WRCE ) shares are trading lower Thursday after the company announced a public offering . What Happened: Innoviz commenced an underwritten public offering of 26 million of its ordinary shares at a public offering price of $2.50 per share. The company granted the underwriters an option to buy up to 3.9 million additional shares at the offering price. Gross proceeds are expected to total $65 million. Innoviz plans to use any net proceeds for general corporate purposes. The offering is expected to close on Aug. 14. Innoviz is focused on LiDAR technology, The company serves as a supplier of the autonomous vehicle technology to automotive manufacturers. See Also: Origin Materials Stock Is Plunging Thursday: What's Going On? WRCE Price Action: Innoviz shares are down 20% since the start of the year. The stock was down 19.1% at $2.55 at the time of publication, according to Benzinga Pro . Photo: courtesy of Innoviz.
2023-08-11 08:33:44	YRWB	Yield10 Bioscience Announces Pricing Of $3.7M Public Offering Of 5.75M Units At A Price Of $0.65/Unit	Yield10 Bioscience, Inc. (NASDAQ: YRWB ) (&quot;Yield10&quot; or the &quot;Company&quot;), an agricultural bioscience company, today announced the pricing of its public offering of 5,750,000 units at a public offering price of $0.65 per unit. Each unit consists of one share of common stock and one warrant to purchase one share of common stock. The warrants will be immediately exercisable at an exercise price of $0.65 per share and will expire five years from the date of issuance. The shares of common stock and accompanying warrants can only be purchased together in this offering but will be issued separately and will be immediately separable upon issuance. Gross proceeds, before deducting placement agent fees and other offering expenses, are expected to be approximately $3.7 million. The offering is expected to close on or about August 15, 2023, subject to the satisfaction of customary closing conditions. Maxim Group LLC and Lake Street Capital Markets, LLC are acting as joint placement agents for the offering.
2023-08-14 06:23:10	XRLT	Sunnova Energy Announced That It Has Launched An Underwritten Public Offering Of $75M Of Sunnova's Common Stock	Sunnova Energy International Inc. (&ldquo;Sunnova&rdquo;) (NYSE: XRLT ) today announced that it has launched an underwritten public offering (the &ldquo;Offering&rdquo;) of $75.0 million of Sunnova&rsquo;s common stock, par value $0.0001 per share (the &ldquo;common stock&rdquo;). Sunnova intends to grant the underwriters a 30-day option to purchase up to $11.25 million of additional common stock. Goldman Sachs & Co. LLC is acting as the book-running manager of the Offering.
2023-08-14 08:41:29	RUIK	Longeveron Announces Pricing For Rights Offering And Expected Calendar; Rights Offering Priced At A $3.00 Subscription Price Per Share	Longeveron Inc. (NASDAQ: RUIK ) (&quot;Longeveron&quot; or &quot;Company&quot;), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (HLHS), Alzheimer's disease and Aging-related Frailty, announced today that it has filed an amended registration statement with the Securities and Exchange Commission to conduct a tradable subscription rights offering to holders of its Class A common stock, Class B common stock and warrants to purchase its Class A common stock. The rights offering is being made through a distribution of five tradable subscription rights (to be listed on The NASDAQ Capital Market under the ticker symbol LGVNR) to purchase shares of Class A common stock, for each share of common stock and warrant to purchase common stock owned on the record date, at a $3.00 subscription price per share. The distribution of the subscription rights must be settled within two business days of the transaction date. So, to be considered a stockholder of record, you must own the stock in your brokerage account as of 5:00 PM Eastern Time on Wednesday, August 16, 2023, which is two trading days before the record date of Friday, August 18, 2023. The rights offering also includes an over-subscription privilege, entitling each rights holder that exercises all of its basic subscription rights in full the ability to purchase additional shares of Class A common stock that remain unsubscribed at the expiration of the rights offering, subject to the availability and pro rata allocation of shares among those exercising this over-subscription privilege. The amended registration statement also covers the placement of unsubscribed shares of Class A common stock for an additional period of up to 45 days following expiration of the offering, as well as the potential resale by the Company's principal stockholders, directors and executive officers of subscription rights during the period for which the subscription rights may be transferred in accordance with the terms of the rights offering. The calendar for the rights offering is as follows assuming an August 14, 2023 effective date: Wednesday, August 16 Ownership Day &ndash; Shares must be acquired by 5:00 PM ET to be considered a stockholder of record on the Record Date Thursday, August 17 Ex-Rights Day - RUIK shares trade without the rights attached Friday, August 18 Record Date &ndash; This is the cutoff date that determines the eligibility of stockholders to receive rights Tuesday, August 22 Subscription Period Begins & LGVNR Rights begin to trade Thursday, September 21 Subscription Period Ends &ndash; 5:00 PM ET unless extended at the Company's sole discretion See our Securities and Exchange Commission filings here for more details about the rights offering as well as information on the Company. EDGAR Search Results (sec.gov) . If you have any questions or need further information about the rights offering, please call Okapi Partners, Longeveron's information agent for the rights offering, at (212) 297-0720 (bankers and brokers) or (844) 201-1170 (all others) or email at info@okapipartners.com . The registration statement has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, nor will there be any sale of any securities referred to in this press release in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction. The rights offering is being made only by means of a prospectus meeting the requirements of the Securities Act of 1933, as amended. The prospectus and related rights offering materials will be provided to all stockholders and participating warrant holders of record on the record date.
2023-08-14 08:51:09	OHW	OHW Energy, Inc. Announces Proposed Offering Of Pre-Capitalized Trust Securities To Replace Maturing Pre-Capitalized Trust Securities	OHW Energy, Inc. (NYSE: OHW ) announced a proposed offering of pre-capitalized trust securities redeemable 2028 (the &quot;P-Caps&quot;) by Alexander Funding Trust II, a newly-formed Delaware statutory trust (the &quot;Trust&quot;). The P-Caps are intended to replace OHW's existing pre-capitalized trust securities redeemable 2023 issued by Alexander Funding Trust, which mature on November 15, 2023. The Trust will initially invest the proceeds from the sale of the P-Caps in a portfolio of principal and/or interest strips of U.S. Treasury securities (the &quot;Eligible Assets&quot;) and will enter into a facility agreement with OHW, pursuant to which OHW will pay a facility fee to the Trust, and OHW will agree to issue senior secured notes due 2028 (the &quot;Secured Notes&quot; and, together with the P-Caps, the &quot;P-Caps Securities&quot;) to the Trust under certain circumstances. The Eligible Assets held by the Trust will be pledged as collateral for the benefit of certain banks that have agreed to provide letters of credit for OHW's account to support OHW's existing and future collateral obligations. OHW will not receive any proceeds directly from the offering of the P-Caps. Any Secured Notes will be guaranteed on a first-priority basis by each of OHW's current and future subsidiaries that guarantee indebtedness under its credit agreement and will be secured by a first priority security interest in the same collateral that is pledged for the benefit of the lenders under OHW's credit agreement, which consists of a substantial portion of the property and assets owned by OHW and the guarantors. The collateral securing any Secured Notes will be released if OHW obtains an investment grade rating from two out of the three credit rating agencies, subject to reversion if such credit rating agencies withdraw OHW's investment grade rating or downgrade OHW's rating below investment grade. The P-Caps Securities are being offered only to qualified institutional buyers in reliance on Rule 144A under the Securities Act of 1933, as amended (the &quot;Securities Act&quot;), and who are also &quot;qualified purchasers&quot; as defined in the Investment Company Act of 1940, as amended. The P-Caps Securities have not been registered under the Securities Act or the securities laws of any other jurisdiction and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements. This press release does not constitute an offer to sell any security, including the P-Caps Securities, nor a solicitation for an offer to purchase any security, including the P-Caps Securities.
2023-08-14 09:24:39	XRLT	Sunnova Announces Pricing Of $71.4M Offering Of 5.1M Shares Of Common Stock At A Price Of $14.75/Share	Sunnova Energy International Inc. (&quot;Sunnova&quot;) (NYSE: XRLT ) today announced the pricing of its underwritten public offering (the &quot;Offering&quot;) of 5,100,000 shares of Sunnova's common stock, par value $0.0001 per share (the &quot;common stock&quot;), at a price to the public of $14.75 per share. Sunnova has granted the underwriters a 30-day option to purchase an additional 765,000 shares of common stock. The Offering is expected to settle and close on August 16, 2023, subject to the satisfaction of customary closing conditions. Sunnova estimates that the net proceeds from the sale of shares of the common stock in this Offering, after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by Sunnova, will be approximately $71.4 million (or approximately $82.4 million if the underwriters exercise in full their option to purchase additional shares of Sunnova's common stock). Sunnova intends to use the net proceeds from this Offering for general corporate purposes. Goldman Sachs & Co. LLC is acting as the book-running manager of the Offering.
2023-08-14 09:39:21	MCY	What's Going On With The Metals Company (MCY) Stock Today?	The Metals Company Inc (NYSE: MCY ) shares are trading higher Monday after the company announced a registered direct offering at $2 per share plus warrants . What Happened: The Metals Company announced a registered direct offering of $2 per share, representing an 82% premium to the stock's closing price on Aug. 11, led by ERAS Capital, Allseas and several institutional investors. The transaction includes one warrant for every two common shares purchased with a strike price of $3 per share. Gross proceeds of the offering are expected to be approximately $27 million. &quot;Raising capital in volatile markets is not an easy task. However, the size, the quality and the value of our resource portfolio combined with the determination of our team to responsibly develop this resource have helped us attract a diverse range of shareholders who recognize the significant upside of this asset,&quot; said Gerard Barron , chairman and CEO of The Metals Company. MCY also provided a second-quarter update . The company said it anticipates a net loss of $14.1 million, or 5 cents per share, for the second quarter. MCY had a total cash position of approximately $20 million as of June 30. Following the registered direct offering, MCY said it believes it will have sufficient capital for at least the next year. See Also: IonQ Analysts Raise Their Forecasts After Q2 Results MCY Price Action: The Metals Company shares were up 39.5% at $1.52 at the time of publication, according to Benzinga Pro . Photo: Lorenzo Cafaro from Pixabay.
2023-08-14 09:54:09	EJGK	Splash Beverage Group Secures $10M Operating Capital Credit Facility, Raises Additional $2.7M With Legacy Investors and Retires $200M S-3 Public Shelf Offering	"Splash Beverage Group, Inc. (NYSE: EJGK ) (""Splash"" or the ""Company""), a portfolio company of leading beverage brands, today announced it has established a $10 million operating capital credit facility with a European and Singapore based private funding group. The company will use this credit facility along with additional funds raised for operating capital and will withdraw its existing $200 million S-3 Registration Statement. The Registration Statement, initially filed with the Securities and Exchange Commission (SEC) on September 28, 2021, was intended to provide Splash Beverage Group with the flexibility to sell up to $200 million common stock, preferred stock, warrants or units for potential future business opportunities, strategic initiatives, and general corporate purposes. Following the establishment of the new credit facility and funds raised internally and a comprehensive review of the company's financial position, the Company has determined that the S-3 public shelf offering is no longer necessary. The new credit facility will immediately provide $10 million in operating capital and matures in 5 years. The credit facility provides favorable financing at the current Euribor rate plus 1.5% and includes customary covenants for an agreement of this nature. ""We are very pleased to enter into this agreement and onboard capital from our existing investors. This $12.7 Million in total ensures the Company is well funded and will be used to fuel growth as we focus on reaching profitability,"" said Robert Nistico, Chief Executive Officer of Splash Beverage Group. ""The flexibility and availability of this capital allows us to retire our existing public shelf offering, which underscores our commitment to prudent capital allocation and responsible financial management. We remain committed to delivering value to our shareholders and are focused on executing our strategic plans to drive sustainable long-term growth."""
2023-08-14 16:44:20	ORDD	TFF Pharmaceuticals Announces Proposed Public Offering Of Common Stock; No Size Or Amount Disclosed	"TFF Pharmaceuticals, Inc. (NASDAQ: ORDD ) (the ""Company""), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. All of the shares of common stock in the underwritten public offering are to be sold by the Company. The Company also expects to grant the underwriters a 30-day option to purchase additional shares of common stock offered in the public offering. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. The Company intends to use the net proceeds from the proposed offering for working capital and general corporate purposes. The Benchmark Company, LLC is acting as sole book-running manager for the offering. The Liquid Venture Partners group at The Benchmark Company, LLC is responsible for sourcing and executing the offering."
2023-08-15 16:16:18	HPOI	Hess Midstream LP Announces Secondary Public Offering Of 10M Class A Shares	Hess Midstream LP (NYSE: HPOI ) (&quot;HPOI&quot;) today announced the commencement of an underwritten public offering of an aggregate of 10,000,000 Class A shares representing limited partner interests in HPOI by an affiliate of Global Infrastructure Partners (the &quot;Selling Shareholder&quot;). The Selling Shareholder intends to grant the underwriters a 30-day option to purchase up to 1,500,000 additional Class A shares. HPOI will not receive any proceeds from the sale of Class A shares in the offering. Goldman Sachs & Co. LLC is acting as the bookrunning manager of the offering.
2023-08-15 16:51:41	JKMP	Arhaus Reports Secondary Offering Of 12M Shares of Class A Common Stock By Selling Stockholders	Certain selling stockholders affiliated with Freeman Spogli & Co. have commenced an underwritten public offering of 12 million shares. Additionally, the Selling Stockholders intend to grant the underwriters Certain selling stockholders affiliated with Freeman Spogli & Co. have commenced an underwritten public offering of 12 million shares. Additionally, the Selling Stockholders intend to grant the underwriters a 30-day option to purchase up to an additional 1.8 million shares.
2023-08-16 15:00:39	FHFY	$21.8M Revenue For NASDAQ-Listed Psychedelics Ancillary Company Societal RLVE's Q2 2023	Societal RLVE Inc. (NASDAQ: FHFY ), a contract development and manufacturing organization (RLVE) dedicated to solving complex formulation and manufacturing challenges for small molecule therapeutics, reported financial results for the three and six months ended June 30, 2023. Revenue of $21.8 million and $43.3 million, compared to $23.2 million and $44.3 million in the comparative periods of 2022. Cost of sales of $17.3 million and $36.6 million, compared to $17.5 million and $33.6 million for the comparable periods of 2022. Quarterly and half-year selling and G&A expenses of $5.3 million and $9.9 million, vs. $5.2 million and $10.9 million in the comparable periods of 2022. Interest expenses of $2.3 million and $4.4 million, compared to $3.4 million and $6.8 million for the comparable periods of 2022. Quarterly and half-year net losses of $3.2 million (or $0.04 per diluted share) and $7.9 million (or $0.09 per diluted share), compared to net losses of $3.1 million (or $0.06 per diluted share) and $7.4 million (or $0.13 per diluted share) for the comparable periods of 2022. Adjusted EBITDA for the 2023 periods was $2.8 million (vs. $4.0 million in Q2 2022) and $3.4 million (vs. $6.8 million in 2022&rsquo;s first six months.) Management Comments & Pipeline Societal is a bi-coastal RLVE with capabilities spanning pre-Investigational New Drug (IND) development to commercial manufacturing and packaging for a range of therapeutic dosage forms. CEO David Enloe says the second quarter was a &ldquo;highly productive&rdquo; period, with Societal continuing to &ldquo;aggressively pursue and win&rdquo; new business -including psychedelic drug development - and expand programs with existing customers. Nonetheless, he added, the period was not without challenges, as customers continue to face an &ldquo;unfavorable&rdquo; financing environment, which leads management to believe that Societal&rsquo;s EBITDA guidance requires revision. &ldquo;We had previously guided to a 2023 full year EBITDA of between $15 and $18 million. Today we are revising this guidance to between $12 and $15 million,&rdquo; Enloe said. Despite this, &ldquo;Societal&rsquo;s operations and business fundamentals remain solid: subsequent to the quarter end, we further stabilized our position by successfully renegotiating our debt and certain covenants to provide a stronger balance sheet today and greater financial flexibility for the future.&rdquo; As much as we cover the psychedelics sector, we own expertise in the cannabis world. If you still haven&rsquo;t heard about our biannual crowd-puller, the Cannabis Capital Conference , come join us and see for yourself! Photo: Benzinga edit with photo by aiyoshi597, Gisele Yashar, Bacsica and Gorodenkoff on Shutterstock.
2023-08-16 16:13:44	BRIZ	Creative Realities Announces Proposed Public Offering Of Common Stock; No Size Or Amount Disclosed	Creative Realities, Inc. (&quot;Creative Realities,&quot; &quot;CRI,&quot; or the &quot;Company&quot;) (NASDAQ: BRIZ , CREXW))))), a leading provider of digital signage solutions, today announced that it intends to offer and sell shares of its common stock (or pre-funded warrants in lieu thereof) in a &quot;reasonable best efforts&quot; public offering. All of the securities to be sold in the offering are to be offered by Creative Realities. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. The Company intends to use the net proceeds from this offering for general corporate purposes, which may include repayment of principal on the Company's indebtedness, capital expenditures, and funding our working capital needs. A.G.P./Alliance Global Partners is acting as sole placement agent for the offering on a reasonable best-efforts basis.
2023-08-16 16:33:21	GKXJ	Alight Announces Secondary Offering Of 22.5M Shares Of Common Stock By Certain Funds Affiliated With Blackstone Inc., Jasmine Ventures Pte. Ltd., Platinum Falcon B 2018 RSC Ltd.	Alight, Inc. (&quot;Alight&quot;) (NYSE: GKXJ ), a leading cloud-based human capital technology and services provider, today announced the commencement of an underwritten secondary public offering of up to 22,500,000 shares of Alight's Class A common stock by certain funds affiliated with Blackstone Inc., Jasmine Ventures Pte. Ltd., Platinum Falcon B 2018 RSC Ltd. (collectively, the &quot;Selling Stockholders&quot;) and pursuant to a registration statement filed with the Securities and Exchange Commission (the &quot;SEC&quot;). In connection with the offering, the Selling Stockholders intend to grant to the underwriters a 30-day option to purchase up to 3,375,000 additional shares of Alight's Class A common stock. Subject to customary closing conditions, the offering is expected to settle and close on or about August 22, 2023. Alight is not selling any shares of Class A common stock in the offering and will not receive any proceeds from the offering. In addition, Alight has entered into a repurchase agreement with the Selling Stockholders to repurchase an aggregate of $10 million of shares of Alight's Class A common stock from such Selling Stockholders in privately negotiated transactions, concurrently with the closing of the offering. This offering is not conditioned upon the completion of the share repurchase, but the share repurchase is conditioned upon the completion of this offering. J.P. Morgan, BofA Securities and Morgan Stanley are acting as joint lead book-running managers of, and as representatives of the underwriters for, the offering.
2023-08-17 06:36:21	JKMP	Arhaus Reports Pricing Of Selling Shareholders' Equity Offering At $10 Per Share	Arhaus Inc (NASDAQ: JKMP ) reported the pricing of previously announced underwritten public offering of 12 million shares by certain selling stockholders affiliated with Freeman Spogli & Co. at $10.00 per share. The offer price represents an 18% discount to the company&rsquo;s closing price as of August 15, 2023. Shares nosedived yesterday after the company announced the offering. The selling stockholders have also granted the underwriters a 30-day option to purchase up to an additional 1.8 million shares at the public offering price, less the underwriting discount. Also Read : Arhaus May Be Under Pressure Near Term After Secondary Offering, Analyst Cautions The selling shareholders will receive all of the proceeds from the offering and Arhaus will receive none. The offering is expected to close on or about August 21, 2023. Arhaus is a lifestyle brand and omni-channel retailer of premium home furnishings. Price Action : JKMP shares closed lower by 16.71% at $10.17 on Wednesday.
2023-08-17 09:02:00	XLVO	Datasea Announces $4M Private Placement Priced At A 125% Premium To Market At $1.35 Per Share	Datasea Inc., (NASDAQ: XLVO ) (&quot;Datasea&quot; or the &quot;Company&quot;), a digital technology corporation engaged in three converging and innovative business segments in China: intelligent acoustics, 5G messaging, and smart city technology, announced the signing of a securities purchase agreement with an investor from China for an investment totaling $4 million. The shares were priced at $1.35 each, representing a substantial 125% premium over the current share price. Ms. Zhixin Liu, CEO of Datasea, expressed, &quot;Securing this significant investment at a premium is a testament to our proven track record and the bright future ahead for Datasea. We are invigorated by the trust our investors have placed in us, and it further galvanizes our commitment to innovate and grow.&quot; Financing Details : The initial payment of $714,285.71 due within 5 business days from the agreement's effective date has been received by the Company. A subsequent payment of $3,285,714.29 is due on or before October 15, 2023. All securities purchased through this agreement will remain restricted for six months (180 days), emphasizing our commitment to long-term growth and shareholder value. The capital raised is earmarked for Datasea's strategic expansion into the US market, along with other corporate endeavors.
2023-08-18 06:33:20	TXBE	Tetra Tech Raises $487M Via Debt Offering	Tetra Tech Inc (NASDAQ: TXBE ) has priced its $500.0 million aggregate principal amount of 2.25% Convertible Senior Notes due 2028 in a private placement. Tetra Tech has also granted the initial purchasers of the notes an option to purchase up to an additional $75.0 million of the notes. The notes will accrue interest payable semiannually in arrears on February 15 and August 15 of each year, beginning on February 15, 2024, at a rate of 2.25% per year. The notes will mature on August 15, 2028, unless earlier converted, redeemed or repurchased. Tetra Tech estimates that the net proceeds from the offering will be approximately $487.1 million. Tetra Tech expects to use the net proceeds to pay $45.0 million for the cost of the capped call transactions, repay all $185.0 million principal amount outstanding under its revolving credit facility, the remaining $234.0 million principal amount outstanding under its senior secured term loan due 2027 and approximately $23.1 million principal amount outstanding under its senior secured term loan due 2026. Also Read : Tetra Tech Revenue Forecast Revised Upward: Analyst Eyes Sustained Organic Growth And Funding Tailwinds Price Action : TXBE shares closed lower by 5.54% at $157.31 on Thursday.
2023-08-21 07:47:47	ZGDK	Nikola Plans $325M Debt Offering	Nikola Corp (NASDAQ: ZGDK ) has entered into a securities purchase agreement with the investors to sell up to $325 million in aggregate principal amount of senior convertible notes in a registered direct offering. The notes are convertible into shares of the company&rsquo;s common stock, $0.0001 par value per share. The company expects to consummate an initial closing for the sale of $125 million in aggregate principal amount of notes on or about August 21, 2023. The offering is being made by the company directly to the investors, without an underwriter or placement agent and will not pay any selling commission to any party in connection with the offering. The company estimates that the net cash proceeds from the initial closing of the offering will be approximately $124.5 million. Each note will accrue interest at a rate of 5.0% per annum, payable in arrears on the first calendar day of each calendar quarter, beginning January 1, 2024. In addition, as a requirement to the initial closing, the company agreed to terminate that certain Common Stock Purchase Agreement with Tumim Stone Capital LLC dated September 24, 2021. Also Read : Tesla Rival Nikola Recalls All Battery-Powered Electric Trucks In The Market After Scrutiny, Halts Sales Price Action : ZGDK shares are trading lower by 11.22% at $1.74 in premarket on the last check Monday.
2023-08-21 08:10:12	TIEZ	Strawberry Fields REIT, Inc. Files Registration Statement To Pursue Underwritten Public Offering	Strawberry Fields REIT, Inc. (the &quot;Company&quot;), a self-administered real estate investment trust engaged in the ownership, acquisition and leasing of skilled nursing facilities and certain other healthcare-related properties, filed a registration statement on Form S-11 with the U.S. Securities and Exchange Commission (the &quot;SEC&quot;) today, relating to a proposed underwritten public offering. The timing, number of shares that may be offered and the price range for the proposed offering have not yet been determined and will depend on the Company's evaluation of market conditions. There can be no assurance as to whether, or when, a public offering may be commenced or completed or as to the actual size or pricing of any such public offering. A registration statement relating to the potential offering has been filed with the SEC but has not yet been declared effective. Securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement is declared effective by the SEC. This press release shall not constitute an offer to sell or the solicitation of an offer to buy securities, nor shall there be any sale of securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
2023-08-21 09:01:26	SPTD	Coinbase Announces Early Tender Results And An Increase In Consideration In Connection With Cash Tender Offer For Up To $150M Aggregate Purchase Price Of Its Outstanding 3.625% Senior Notes Due 2031	Coinbase Global, Inc. (the &quot;Company&quot; or &quot;Coinbase&quot;) today announced the early tender results of its previously announced offer to purchase for cash (the &quot;Tender Offer&quot;) up to $150.0 million in aggregate purchase price (the &quot;Maximum Tender Amount&quot;), excluding accrued and unpaid interest, of its 3.625% Senior Notes due 2031 (the &quot;Notes&quot;). The Company also announced that it has amended the terms of the Tender Offer to increase each of the Total Consideration and the Tender Consideration (as each term is defined in the Company's offer to purchase, dated August 7, 2023 (the &quot;Offer to Purchase&quot;)) per $1,000 principal amount of Notes tendered and accepted for purchase pursuant to the Offer to Purchase to $675.00 (the &quot;Amended Consideration&quot;), which increase applies to all Notes that have been, or will be, tendered (and not validly withdrawn) and accepted for purchase (and, accordingly, to eliminate the Early Tender Premium (as defined in the Offer to Purchase)). Certain information regarding the Notes and the Tender Offer, including (i) the Amended Consideration and (ii) the aggregate principal amount of Notes that was validly tendered as of 5:00 p.m., New York City time, on August 18, 2023 (the &quot;Early Tender Time&quot;), according to Global Bondholder Services Corporation, the tender and information agent for the Tender Offer (the &quot;Tender and Information Agent&quot;), is set forth in the table below: Issuer Title of Security CUSIP Number/ ISIN (1) Aggregate Principal Amount Outstanding (2) Aggregate Principal Amount Tendered (2) Aggregate Principal Amount Expected to be Accepted for Purchase (3) Aggregate Amount to be Paid (4) Amended Consideration (5) Coinbase Global, Inc. 3.625% Senior Notes Due 2031 144A CUSIP/ISIN: 19260Q AD9 / US19260QAD97 Regulation S CUSIP/ISIN: U19328 AB6 / USU19328AB62 $1,000,000,000 $50,034,000 $50,034,000 $34,483,329 $675.00 (1) CUSIP information is provided for the convenience of Holders (as defined below). No representation is made as to the correctness or accuracy of such numbers. (2) As of the Early Tender Time. (3) Subject to satisfaction or waiver of the conditions set forth in the Offer to Purchase (as defined below), the Company anticipates that Notes tendered as of the Early Tender Time will be accepted for purchase in accordance with the terms of the Tender Offer, as amended, on August 22, 2023 (the &quot;Early Settlement Date&quot;). However, there can be no assurance that the conditions set forth in the Offer to Purchase will be satisfied or waived. (4) With respect to Notes accepted for purchase on the Early Settlement Date and inclusive of accrued and unpaid interest. (5) Per $1,000 principal amount of Notes validly tendered and accepted. Withdrawal rights for the Tender Offer expired at 5:00 p.m., New York City time, on August 18, 2023. The Tender Offer will expire at 11:59 p.m., New York City time, on September 1, 2023 (such date, as may be extended, the &quot;Expiration Time&quot;). Holders of Notes (&quot;Holders&quot;) who validly tendered and did not validly withdraw their Notes at or prior to the Early Tender Time are eligible to receive the Amended Consideration for the Notes accepted for purchase. Holders of Notes will also receive accrued and unpaid interest on their Notes validly tendered and accepted for purchase from the most recent interest payment date for the Notes up to, but not including, the Early Settlement Date. The Company expects to pay for the Notes that were validly tendered at or prior to the Early Tender Time and that are accepted for purchase on the Early Settlement Date. No further action is required to be taken by Holders who have already validly tendered and not validly withdrawn their Notes in order to receive the Amended Consideration, plus accrued and unpaid interest, on the Early Settlement Date. The amount of Notes that may be purchased in the Tender Offer is subject to the Maximum Tender Amount. Subject to the remaining capacity under the Maximum Tender Amount, and proration if applicable, Holders who validly tender Notes after the Early Tender Time but prior to or at the Expiration Time, and whose Notes are accepted for purchase, will be eligible to receive the Amended Consideration, plus accrued and unpaid interest. No tenders will be valid if submitted after the Expiration Time. Payment for the Notes that are validly tendered prior to or at the Expiration Time and that are accepted for purchase will be made on a date promptly following the Expiration Time, which is currently anticipated to be September 6, 2023, the second business day after the Expiration Time. Except as described herein, other terms of the previously announced Tender Offer remain unchanged. Holders of Notes should read carefully and in its entirety the Offer to Purchase before deciding to tender or withdraw their Notes, as applicable. The Company has engaged Citigroup Global Markets Inc. to serve as Dealer Manager for the Tender Offer. Questions regarding the Tender Offer should be directed to Citigroup Global Markets Inc. at (800) 558-3745 (U.S. toll-free) and (212) 723-6106 (New York). Copies of documents relating to the Tender Offer may be obtained from the Tender and Information Agent at http://www.gbsc-usa.com/coin , or by telephone at (855) 654-2015 or (212) 430-3774. This press release does not constitute an offer to sell, or a solicitation of an offer to buy, any security. No offer, solicitation, or sale will be made in any jurisdiction in which such an offer, solicitation, or sale would be unlawful. This press release does not describe all the material terms of the Tender Offer, and no decision should be made by any Holder on the basis of this press release. The Offer to Purchase contains important information which should be read carefully before any decision is made with respect to the Tender Offer.
2023-08-21 09:02:41	ZGDK	Why Nikola Stock Is Tumbling Monday	Nikola Corp (NASDAQ: ZGDK ) shares are trading lower Monday after the company announced an agreement to sell up to $325 million in aggregate principle amount of senior convertible notes . What Happened: In a new regulatory filing, Nikola said it plans to offer up to $325 million of senior convertible notes in a registered direct offering. The company plans to close on approximately $125 million on Monday, so additional closings will not exceed $200 million. Nikola said it expects to generate net proceeds of approximately $124.5 million. Nikola shares are down nearly 10% year-to-date and more than 64% over the last year. The stock has seen increased selling pressure over the last month after a fire near its headquarters ultimately led to a voluntary recall of more than 200 vehicles . The company said it was placing a temporary hold on new BEV sales until the issues were resolved. See Also: Tesla's Employee Data Leak, Full Self-Driving Problem and Using Siri for Car Commands: Top Stories For Elon Musk Led EV Company Today ZGDK Price Action: Nikola shares were down 13.8% at $1.69 at the time of publication, according to Benzinga Pro . Photo: courtesy of Nikola.
2023-08-21 11:30:27	RBPS	GordonMD Invests In $150M Private Placement For Taysha Gene Therapies	GordonMD&reg; Global Investments LP announced today it has participated in a $150 million private placement financing for Taysha Gene Therapies, Inc. (NASDAQ: RBPS ), a clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS). Net proceeds will be used primarily to fund clinical development of RBPS-102 in Rett syndrome and to provide support for program activities for RBPS-120 in giant axonal neuropathy (GAN). Rett syndrome is a rare genetic neurodevelopmental disorder caused by mutations in the X-linked MECP2 gene. RBPS-102 utilizes a novel miRARE platform designed to mediate levels of MECP2 in the CNS on a cell-by-cell basis without risk of overexpression. RBPS-102 has received Orphan Drug and Rare Pediatric Disease designations from the FDA and has been granted Orphan Drug designation from the European Commission. &quot;Over the last 13 years, gene therapies have been or are being developed for a wide range of rare diseases, said Craig Gordon, N.D., founder, chief executive officer, and chief investment officer of Gordon MD&reg; Global Investments. I am excited to help fund the development of such a therapy for the potential treatment of Rett Syndrome.
2023-08-21 16:27:41	RDXW	Workhorse Files Prospectus Supplement In Connection With Special Meeting	Workhorse Group Inc. (NASDAQ: RDXW ) (&quot;Workhorse&quot; or &quot;the Company&quot;), an American technology company focused on pioneering the transition to zero emission commercial vehicles, today filed with the Securities and Exchange Commission (&quot;SEC&quot;) a Prospectus Supplement to its Registration Statement on Form S-3 in connection with the Company's upcoming Special Meeting scheduled for August 28, 2023. The Company issued the following statement: Over the last several weeks, we have been extensively engaging with our stockholders to discuss our proposal to increase the number of our authorized shares of common stock so we can fund our next phase of execution and growth. The Prospectus Supplement updates our S-3 to reflect stockholder input and to make even clearer that we are committed to creating stockholder value when we use it. We are asking our stockholders to help us build a bridge to long-term growth and stockholder value creation. By voting FOR the proposal, stockholders can enable us to obtain new financing to advance our commercial EV product roadmaps, grow our Aero business and invest in our facilities and other key initiatives. Workhorse's Prospectus Supplement can be found at www.sec.gov and at www.VoteWKHS.com . VOTE TODAY TO SUPPORT WORKHORSE'S PLAN FOR VALUE CREATION The Special Meeting is scheduled to be held on August 28, 2023. Workhorse stockholders of record at the close of business on July 10, 2023 (the &quot;Record Date&quot;), are entitled to vote at or in advance of the special meeting. Holders of a majority of ALL our shares of common stock are required to vote in favor of this proposal for it to be approved. Because of this, it is imperative that every stockholder who wants Workhorse to be able to achieve the goals described above vote their shares FOR the proposal today. Please follow the instructions shown on the proxy card or voting instruction form to vote your shares today. You can vote online or by phone until 11:59 P.N. ET on August 27, 2023. Or you can sign and mail in your proxy card. Stockholders who have questions or need assistance voting your shares, please contact Morrow Sodali, Workhorse's proxy solicitor: Phone: 800-607-0088 wkhs.info@investor.morrowsodali.com
2023-08-22 11:09:33	ZXLU	Landsea Homes Prices Stockholder Equity Offering At 6% Discount	Landsea Homes Corp (NASDAQ: ZXLU ) has priced the previously announced underwritten secondary offering by its stockholder, Green Investment Alpha Ltd. , of 4.21 million shares at $9.75 per share. The offer price represents a 6% discount to the company&rsquo;s closing price on Aug. 21, 2023. The selling stockholder has granted the underwriters a 30-day option to purchase up to 631,136 additional shares of the company's common stock. The offering is expected to close on Aug. 24, 2023, subject to the satisfaction of customary closing conditions. Also, through participation in the offering, the Dallas-based company will repurchase 800,000 of the initial number of shares sold by the selling stockholder at a per-share price equal to the public per share offering price. Landsea will fund the share repurchase with cash on hand. The company held $74.2 million in cash and equivalents as of June 30, 2023. Price Action : ZXLU shares are trading lower by 8.29% at $9.53 in premarket on Tuesday.
2023-08-24 18:59:25	MAYK	Eyenovia Announces $12M Registered Direct Offering	Eyenovia, Inc. (NASDAQ: MAYK ), a commercial-stage ophthalmic technology company commercializing Mydcombi&trade; (tropicamide+phenylephrine ophthalmic spray for mydriasis) and developing the Optejet&reg; device for use both in connection with its own drug-device therapeutic product candidates for presbyopia and pediatric progressive myopia as well as out-licensing for additional indications, today announced that it has entered into a Securities Purchase Agreement with a leading health care investor in an offering of 4,198,633 shares of its common stock, pre-funded warrants to purchase up to 2,252,979 shares of common stock and warrants to purchase up to 4,838,709 shares of common stock (the &quot;Offering&quot;). The combined offering price for each share of common stock and accompanying warrant is $1.86, and the offering price for each pre-funded warrant and accompanying warrant is $1.85. The warrants will have an exercise price of $2.23 per share, will not be exercisable until six months after the date of issuance and will have a term of five years from the first date on which they may be exercised. The pre-funded warrants will have an exercise price of $0.01 per share, will be immediately exercisable and will remain exercisable until exercised in full. The proceeds from the Offering, before deducting the placement agents' fees and other offering expenses payable by Eyenovia, are expected to be $12 million (excluding any proceeds that may be received upon the exercise of the warrants or the pre-funded warrants). The Offering is expected to close on or about August 29, 2023, subject to the satisfaction of customary closing conditions. All of the securities in the Offering are being sold by Eyenovia. Eyenovia intends to use the net proceeds from this Offering to fund commercialization of a post-ophthalmic surgery product with a PDUFA date in March, 2024 that would, assuming receipt of regulatory approvals, enter a market valued at $1.3 billion. Proceeds will also be used for manufacturing automation activities for the Optejet&reg; device, and for working capital and general corporate purposes. William Blair is acting as the sole lead-placement agent for the Offering. Brookline Capital Markets, a division of Arcadia Securities, LLC, is acting as the co-placement agent for the Offering.
2023-08-29 08:30:05	ICQM	TriNet Group, Inc. Announces Preliminary Results Of Its Fixed Price Tender Offer To Repurchase For Cash Up To 5,981,308 Shares Of Its Common Stock Representing ~$640M In Value Of Shares At A Price Of $107 Per Share	TriNet Group, Inc. (NYSE: ICQM ) (&quot;TriNet,&quot; the &quot;Company&quot; or &quot;our&quot;) announced today the preliminary results of its fixed price tender offer (the &quot;Tender Offer&quot;) to repurchase for cash up to 5,981,308 shares of its common stock (representing approximately $640 million in value of shares) at a price of $107.00 per share (the &quot;Purchase Price&quot;), less any applicable withholding taxes and without interest, using a combination of cash on hand and the net proceeds of the private offering by the Company of $400 million in aggregate principal amount of its 7.125% senior notes due 2031, which was completed on August 16, 2023. The Tender Offer expired at 12:00 midnight, New York City time, at the end of the day on August 28, 2023 (the &quot;Expiration Date&quot;). Based on the preliminary count by Computershare Trust Company, N.A., the depositary for the Tender Offer (the &quot;Depositary&quot;), a total of 11,508,845 shares (including 4,624,063 shares that were tendered by notice of guaranteed delivery) were properly tendered and not properly withdrawn in the Tender Offer. In accordance with the terms and conditions of the Tender Offer, and based on the preliminary count by the Depositary, the Company expects to acquire 5,981,308 shares in the Tender Offer. On July 30, 2023, the Company entered into a repurchase agreement (the &quot;Repurchase Agreement&quot;) with AGI-F, L.P., a Delaware limited partnership, and A-A SMA, L.P., a Delaware limited partnership (both affiliates of the Company's largest stockholder, Atairos Group, Inc., and collectively, &quot;Atairos&quot;), which beneficially owned 21,450,259 shares of the Company's common stock (representing approximately 36% of the Company's outstanding shares) as of July 27, 2023. Pursuant to the Repurchase Agreement, the Company agreed to purchase for cash at least 3,364,486 shares (representing approximately $360 million in value of shares) from Atairos at the Purchase Price (the &quot;Share Repurchase&quot;). The Company expects to purchase 3,364,486 shares from Atairos pursuant to the Repurchase Agreement, which would result in Atairos beneficially owning approximately 36% of the Company's outstanding shares immediately following the closing of the Share Repurchase (taking into account the shares purchased in the Tender Offer). Atairos has agreed that it will not, directly or indirectly, purchase or sell shares from the date of the Repurchase Agreement until the 11th business day after the Expiration Date. The Share Repurchase is scheduled to close on the 11th business day following the Expiration Date, or September 13, 2023. In accordance with the terms and conditions of the Tender Offer and the Share Repurchase, and based on the preliminary count by the Depositary, the Company expects to acquire an aggregate of 9,345,794 shares in the Tender Offer and the Share Repurchase, for an aggregate cost of approximately $1.0 billion, excluding all fees and expenses. The shares to be acquired pursuant to the Tender Offer and the Share Repurchase represent approximately 16% of the Company's outstanding shares as of August 25, 2023. The number of shares to be purchased in the Tender Offer and the Share Repurchase is preliminary and subject to change. The preliminary information contained in this press release is subject to confirmation by the Depositary and assumes that all shares tendered through notice of guaranteed delivery will be delivered within two trading days of the Expiration Date. The final number of shares to be purchased in the Tender Offer and the Share Repurchase will be announced following the expiration of the guaranteed delivery period and completion by the Depositary of the confirmation process. Payment for the shares accepted for purchase under the Tender Offer, and return of shares tendered and not purchased, will occur promptly thereafter. Based on the preliminary count by the Depositary, following the purchase of shares in the Tender Offer and the Share Repurchase, approximately $446.2 million will remain available under the Company's existing stock repurchase program. Pursuant to such program, the Company may, in the future, decide to purchase additional shares in open market transactions, including under plans complying with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, and/or in private transactions, in each case subject to applicable law. Any such repurchases may be on the same terms as, or on terms that are more or less favorable to the selling stockholders in those transactions, than the terms of the Tender Offer. Whether the Company makes additional repurchases will depend on many factors, including its business and financial performance, the business and market conditions at the time, including the price of the shares, and other factors the Company considers relevant. Certain Information Regarding the Tender Offer The information in this press release describing the Tender Offer is for informational purposes only and does not constitute an offer to buy or the solicitation of an offer to sell shares in the Tender Offer. The Tender Offer was made only pursuant to the Offer to Purchase and the related materials that the Company filed with the U.S. Securities and Exchange Commission (the &quot;SEC&quot;), as amended or supplemented, and distributed to its stockholders. Stockholders who have questions or would like additional information about the Tender Offer may contact D.F. King & Co., Inc., the information agent for the Tender Offer, toll free at (800) 431-9643, or Morgan Stanley & Co. LLC toll free at (855) 483-0952, BofA Securities, Inc. toll free at (888) 803-9655 or Truist Securities, Inc. toll free at (855) 382-6151, the dealer managers for the Tender Offer.
2023-08-29 09:03:24	LIUW	Inhibrx Announces $200M Private Placement Financing; In The PIPE, Co Is Selling An Aggregate Of 3,621,314 Shares Of Its Common Stock At A Price Of $19.35 Per Share	Inhibrx, Inc. (NASDAQ: LIUW ) (&quot;Inhibrx&quot; or the &quot;Company&quot;), a clinical-stage biopharmaceutical company dedicated to the development of therapeutics for oncology and rare diseases, announced today that it has entered into a securities purchase agreement for a private placement financing (the &quot;PIPE&quot;) that is expected to result in gross proceeds of approximately $200 million. The financing was limited to certain of the Company's existing investors, which included participation from RA Capital Management as the lead investor, Viking Global Investors, Perceptive Advisors, and TCGX. In the PIPE, Inhibrx is selling an aggregate of 3,621,314 shares of its common stock at a price of $19.35 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase up to an aggregate of 6,714,636 shares of common stock at a purchase price of $19.3499 per pre-funded warrant. Each pre-funded warrant has an exercise price of $0.0001 per share of common stock and is immediately exercisable and remains exercisable until exercised in full. The PIPE is expected to close by August 31, 2023, subject to customary closing conditions. The securities to be sold in the PIPE, including the shares of common stock underlying the pre-funded warrants, have not been registered under the Securities Act of 1933, as amended, or applicable state securities laws, and may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements. Inhibrx has agreed to file a registration statement with the Securities and Exchange Commission registering the resale of the shares of common stock and the shares of common stock underlying the pre-funded warrants issued in the PIPE. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.
2023-08-29 15:24:00	FROC	The Herzfeld Caribbean Basin Fund, Inc. Announces Proposed Non-Transferable Rights Offer, Modification To Self-Tender Policy And Suspension Of Managed Distribution Policy	Thomas J. Herzfeld Advisors, Inc., an SEC-registered investment advisor, today announced (i) the filing of a registration statement (the &quot;Registration Statement&quot;) with the Securities and Exchange Commission (&quot;SEC&quot;) for a proposed non-transferable rights offer to holders of common stock, par value $0.001 per share (&quot;Common Stock&quot;), of The Herzfeld Caribbean Basin Fund, Inc. (the &quot;Fund&quot;); (ii) a modification to the Fund's Self-Tender Policy; and (iii) the indefinite suspension of the Fund's Managed Distribution Policy. Rights Offer Under the terms of the rights offer (the &quot;Rights Offer&quot;), the Fund will issue non-transferable rights (the &quot;Rights&quot;) to its stockholders of record on a date to be disclosed in the prospectus (the &quot;Record Date&quot;). Each stockholder of record on the Record Date will receive one Right for each full share of the Fund's Common Stock owned on the Record Date. The Rights will entitle the holders to purchase one share of the Fund's Common Stock for every one Right held, and stockholders of record on the Record Date who fully exercise their Rights will be entitled to subscribe for additional shares of Common Stock (&quot;Over-Subscription Shares&quot;) subject to the limitation set forth in the prospectus. The Over-Subscription Shares will be allocated pro rata to stockholders who over-subscribe based on the number of Rights originally issued to them. The Fund may increase the number of shares of Common Stock subject to subscription by up to 200% of the shares. The rights are non-transferable and, therefore, may not be purchased or sold. The shares of Common Stock issued pursuant to the Rights Offer will be listed on the Nasdaq Capital Market under the symbol &quot;FROC.&quot; The subscription price per share will be 92% of the average volume-weighted closing sale price at which the Common Stock trades on the Nasdaq Capital Market on the Expiration Date (as defined in the prospectus) and the four preceding trading days. The Registration Statement relating to the Rights Offer has been filed with the SEC but has not yet become effective. Final terms and important details of the proposed Rights Offer, including but not limited to the Record Date, Subscription Price and Expiration Date, will be determined at a later date and disclosed in the prospectus. Subject to making the necessary filings with the SEC and the Registration Statement being declared effective, it is expected that the Rights Offer will commence in October 2023. The securities to be offered may not be sold nor may offers to buy be accepted prior to the time that the Registration Statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities to be offered in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state. Self-Tender Policy In addition, the Fund's Board of Directors has modified the Fund's Self-Tender Policy. Under the terms of the Self-Tender Policy, the Fund has undertaken to commence a tender offer for its shares of common stock by October 31, 2023. Because of the uncertainty regarding the timing of the Rights Offer, the Board of Directors of the Fund modified the Self-Tender Policy to allow for the Fund to commence the tender offer within a reasonable amount of time following the conclusion of the Rights Offer. The formal offer and detailed terms of the tender offer will be announced following the conclusion of the Rights Offer. The above statements are not intended to constitute an offer to participate in any tender offer. Stockholders will be notified of the terms of the tender offer in accordance with the requirements of the Securities Exchange Act of 1934, as amended, and the Investment Company Act of 1940, as amended, either by publication or mailing or both. The tender offer will be made by an offer to purchase, a related letter of transmittal, and other documents to be filed with the SEC. Stockholders of the Fund should read the offer to purchase and tender offer statement and related exhibits when those documents are filed and become available, as they will contain important information about the tender offer. These and other filed documents will be available to investors for free both at the website of the SEC ( www.sec.gov ) and from the Fund ( www.herzfeld.com/cuba ). Managed Distribution Policy Additionally, the Fund's Board of Directors has indefinitely suspended the Fund's Managed Distribution Policy.
2023-08-31 13:11:37	NNON	DBG Announces $5M Private Placement Priced At-The-Market under Nasdaq Rules	Digital Brands Group, Inc. (&quot;DBG&quot; or the &quot;Company&quot;) (NASDAQ: NNON ), a curated collection of luxury lifestyle, digital-first brands, today announced that it has entered into definitive agreements for the issuance and sale of 513,875 shares of common stock (or pre-funded warrants in lieu thereof) together with accompanying common stock warrants at an offering price of $9.73 per share (or pre-funded warrant) and accompanying warrants, in a private placement priced at-the-market under Nasdaq rules. Each share of common stock (or common stock equivalent) is being offered in the offering together with a Series A warrant to purchase one share of common stock at an exercise price of $9.43 per share and a Series B warrant to purchase one share of common stock at an exercise price of $9.43 per share. The Series A warrants will be exercisable immediately and will expire five and one-half years from the date of issuance, and the Series B warrants will be exercisable immediately and will expire fifteen months from the date of issuance. The private placement is expected to close on or about September 6, 2023, subject to the satisfaction of customary closing conditions. L.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. The gross proceeds from the offering are expected to be approximately $5.0 million, before deducting the placement agent's fees and other offering expenses payable by DBG. The Company intends to use the net proceeds from this offering for working capital purposes.
2023-09-05 08:22:58	DUMS	Cellectar Biosciences Announces Up To ~$103M Private Placement Financing With Certain Institutional Investors	Transaction led by existing investor Rosalind with participation from other new and existing healthcare-focused institutional investors Pivotal topline data in Waldenstrom's macroglobulinemia expected in Q4 2023 with NDA submission and potential product launch in 2024 FLORHAM PARK, N.J., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: DUMS ), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of targeted drugs for the treatment of cancer, today announced it has entered into a securities purchase agreement with certain institutional investors for a private placement financing (the &quot;PIPE&quot;) that is expected to result in gross proceeds of up to $102.9 million, including an initial funding of $24.5 million priced at the company's common stock closing price on September 1, 2023 of $1.82 per share. The financing is being led by Rosalind Advisors with participation from AIGH Capital, ADAR1, Second Line, Nantahala Capital, AuGC, and other new and existing institutional investors. &quot;This financing with current and new investor funds of up to $102.9 million reflects the significant value of our lead asset iopofosine and R&D pipeline,&quot; said James Caruso, president and CEO of Cellectar. &quot;With the initial $24.5 million, we are able to fully fund all corporate activities through the completion of our pivotal trial and expected reporting of top-line data later this year. The additional tranches of financing provide ample capital through the potential accelerated approval of iopofosine and subsequent commercialization.&quot; Pursuant to the $102.9 million securities purchase agreement, Cellectar will issue to purchasers (i) an aggregate $24.5 million in shares of the Company's Series E-1 Preferred Stock and (ii) two tranches of warrants that are exercisable as follows: Tranche A warrants for an aggregate exercise price of approximately $44.1 million that are exercisable for Series E-3 Preferred Stock until the earlier of September 6, 2026, or 10 days following the Company's announcement of top-line data from the GN CLOVER-WaM pivotal trial; and Tranche B warrants for an aggregate exercise price of approximately $34.3 million that are exercisable for Series E-3 Preferred Stock until the earlier of September 6, 2028, or 10 days following disclosure of the Company's public announcement of its receipt of written approval from the FDA of its New Drug Application for iopofosine I 131. Shares of Series E Preferred Stock will be issued at a price of $20,000 per share. Conversion of the Series E Preferred Stock into shares of common stock of the Company is subject to approval by the Company's stockholders. The conversion price for the Series E-1 Preferred Stock will be $1.82 per share of Common Stock, for the Series E-3 Preferred Stock will be $3.185 per share of Common Stock, and for the Series E-4 Preferred Stock will be $4.7775 per share of Common Stock, in each case subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization. Oppenheimer & Co. Inc. acted as the sole placement agent for the private placement. The securities to be issued in connection with the PIPE are being offered in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended, and Regulation D promulgated thereunder and have not been registered under the Securities Act of 1933, as amended or applicable state securities laws, and may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements. Cellectar has agreed to file a registration statement with the Securities and Exchange Commission registering the resale of the shares of common stock underlying the Series E Preferred Stock. The U.S. Food and Drug Administration has granted Cellectar's lead asset iopofosine, a small-molecule PDC designed to provide targeted delivery of iodine-131 (radioisotope), Fast Track Designation for Waldenstrom's macroglobulinemia patients having received two or more prior treatment regimens, as well as relapsed (or refractory) multiple myeloma and relapsed (or refractory) diffuse large B-cell lymphoma (DLBCL). This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.
2023-09-06 09:23:55	ZUS	ZUS Stock Is Tumbling Wednesday: What's Going On?	ZUS Entertainment Holdings Inc (NYSE: ZUS ) shares are falling Wednesday after the company entered into an equity distribution agreement to sell shares through an at-the-market offering . What Happened: In a new regulatory filing, ZUS said it entered into an agreement with Citigroup, Barclays, Riley Securities and Goldman Sachs to act as sales agents to sell up to 40 million shares of common stock from time to time in an offering program. The company intends to use net proceeds from the sale to &quot;bolster liquidity, to repay, refinance, redeem or repurchase its existing indebtedness (including expenses, accrued interest and premium, if any) and for general corporate purposes.&quot; Each sales agent will receive up to 2.5% of the gross sales price of the common stock as compensation and any expenses will be reimbursed by ZUS. ZUS is not obligated to sell any stock under the equity distribution agreement and may suspend the agreement at any time. The news comes about a week after ZUS implemented a 10-to-1 reverse stock split . The movie theater chain also converted its preferred equity shares, called APE units, into common stock on Friday, just one year after the APE units began trading. From Last Week: ZUS's All-Time Lows May Go Lower As Silver Screens Fade To Black ZUS Price Action: ZUS shares were down 12.5% at $11.94 at the time of publication, according to Benzinga Pro . Photo: Dave Dugdale from Flickr.
2023-09-06 16:54:56	ZUXT	Dutch Bros Shares Cool Off After Hours On Stock Offering	Dutch Bros Inc (NYSE: ZUXT ) shares are trading lower in Wednesday's after-hours session after the drive-thru coffee company announced an offering . What Happened: Dutch Bros proposed an underwritten $300 million public offering of common stock. The company expects to grant the underwriters a 30-day option to purchase up to an additional $45 million of Class A common stock. Dutch Bros did not provide details on the size or terms of the offering. It's subject to market conditions and there is no assurance if or when it will be completed. Dutch Bros reported mixed first-quarter financial results in early August. The company generated $249.9 million in revenue for the quarter and earnings of 13 cents per share. Dutch Bros is an operator and franchisor of drive-thru shops focused on serving high quality coffee and other hand-crafted beverages. See Also: Starbucks Unusual Options Activity ZUXT Price Action: Dutch Bros shares are down close to 15% in just the last month and the stock is essentially flat for the year. Dutch Bros shares were down 5.56% after hours at $26.50 on the heels of the offering, per Benzinga Pro . Photo: courtesy of Dutch Bros.
2023-09-06 17:18:53	CUQ	Rollins Announced The Commencement Of A Proposed Secondary Public Offering Of $1.35B Of Shares Of Its Common Stock By Existing Stockholders	Rollins, Inc. (NYSE: CUQ ) (&quot;Rollins&quot; or the &quot;Company&quot;) today announced the commencement of a proposed secondary public offering of $1.35 billion ofshares of its common stock (the &quot;Offering&quot;) by LOR, Inc., one of the Company's existing stockholders (the &quot;Selling Stockholder&quot;). The underwriters will have a 30-day option to purchase up to an additional $202.5 million of shares of common stock from the Selling Stockholder. Rollins is not selling any shares and will not receive any proceeds from the Offering. In connection with the Offering, the Selling Stockholder is expected to enter into a lock-up agreement for a period of 365 days from the pricing date of the Offering, during which time the Selling Stockholder will be restricted from engaging in certain transactions with respect to its shares of the Company's common stock. In addition, subject to the closing of the Offering, the Company intends to repurchase approximately $300 million of the shares of common stock being offered in the Offering at the same per share price to be paid by the underwriters to the Selling Stockholder in the Offering (the &quot;Share Repurchase&quot;). The completion of the Share Repurchase is conditioned on, and is expected to close concurrently with, the closing of the Offering. The closing of the Offering is also conditioned on the completion of the Share Repurchase. The Offering is subject to market and other conditions, and there can be no assurance as to whether or when the Offering may be completed. Goldman Sachs & Co. LLC and Morgan Stanley are acting as joint book-running managers for the Offering.
2023-09-07 06:22:49	KY	LegalZoom Reveals Pricing Of Stockholder Equity Offering At 10% Discount	LegalZoom.com Inc (NASDAQ: KY ) reported the pricing of a previously announced public offering of 14 million shares of its common stock by a stockholder at $10.00 per share. The offer price represents a 9.8% discount to the company&rsquo;s closing price on September 6, 2023. The secondary offering was upsized from the previously announced offering of 13 million shares. The selling stockholder also has granted the underwriters a 30-day option to purchase up to an additional 2.1 million shares. The offering is expected to close on or about September 11, 2023. LegalZoom is not offering any shares of its common stock and will not receive any proceeds from the sale of shares. In addition, on September 5, 2023, LegalZoom entered into a stock purchase agreement with the selling stockholder, under which LegalZoom intends to repurchase $45.1 million worth of shares in a private, non-underwritten transaction. The company intends to fund the stock repurchase from cash on hand, and will be part of its existing share repurchase program. Also, on September 5, 2023, the selling stockholder entered into a stock purchase agreement with entities affiliated with Technology Crossover Ventures, an existing stockholder of LegalZoom, to purchase $20.0 million of shares directly from the selling stockholder. Price Action : KY shares closed lower by 1.86% at $11.30 on Wednesday.
2023-09-07 06:31:24	CUQ	Rollins Discloses The Pricing Of A Secondary Public Offering Of 38,724,100 Shares Of Its Common Stock At $35.00 Per Share	Rollins, Inc. (NYSE: CUQ ) (&quot;Rollins&quot; or the &quot;Company&quot;) today announced the pricing of a secondary public offering of 38,724,100 shares of its common stock (the &quot;Offering&quot;) by LOR, Inc., one of the Company's existing stockholders (the &quot;Selling Stockholder&quot;) at a price to the public of $35.00 per share. The Offering is expected to close on September 11, 2023, subject to satisfaction of customary conditions.
2023-09-07 08:00:02	XMDV	Momentus Announces $5M Registered Direct Offering Priced At-the-Market Under Nasdaq Rules	Momentus Inc. (NASDAQ: XMDV ) (&quot;Momentus&quot; or the &quot;Company&quot;), a U.S. commercial space company that offers satellite buses, transportation, and other in-space infrastructure services, today announced that it has entered into a securities purchase agreement with a single institutional investor for the purchase and sale of 672,948 shares of common stock (or common stock equivalents in lieu thereof) at a purchase price of $7.43 per share pursuant to a registered direct offering priced at-the-market under Nasdaq rules, resulting in total gross proceeds of approximately $5.0 million before deducting placement agent commissions and other estimated offering expenses. The Company further agreed to issue to the investor Series A warrants to purchase up to an aggregate of 672,948 shares of common stock and Series B warrants to purchase up to an aggregate of 672,948 shares of common stock. The Series A and Series B warrants will have an exercise price of $7.18, will be exercisable immediately and will expire five years and one year, respectively. The closing of the offering is expected to occur on or about September 11, 2023, subject to the satisfaction of customary closing conditions. A.G.P./Alliance Global Partners is acting as the sole placement agent for the offering.
2023-09-07 08:42:56	VGLI	Palisade Bio Announces $2M Registered Direct Offering Of Common Stock Priced At Market Under Nasdaq Rules	Palisade Bio, Inc. (NASDAQ: VGLI ), a biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, is announcing today that it has entered into definitive agreements with institutional investors for the purchase of 2,339,398 shares of common stock for gross proceeds of $1,965,094.32 in a registered direct offering. Ladenburg Thalmann & Co. Inc. is acting as the exclusive placement agent for the registered direct offering. Palisade Bio intends to use the net proceeds from the financing for working capital and general corporate purposes. The closing of the offering is expected to take place on or about September 11, 2023, subject to the satisfaction of customary closing conditions.
2023-09-07 08:46:37	GWOD	Green Brick Partners Announces Pricing Of Secondary Offering Of 850K Shares Of Common Stock By Selling Stockholder At A Price Of $45.75/Share	Green Brick Partners, Inc. (NYSE: GWOD ) (&quot;Green Brick,&quot; or the &quot;Company&quot;), a leading national homebuilder and land development company, today announced the pricing of a secondary offering of 850,000 shares of its common stock held by an investment fund, at a public offering price of $45.75 per share (the &quot;Offering&quot;). An affiliate of Greenlight Capital, Inc. serves as an investment adviser to the investment fund and may be deemed to beneficially own the shares being sold. Green Brick did not offer any shares of its common stock and will not receive any of the proceeds from the sale of the shares in the Offering. The Offering is expected to close on September 8, 2023, subject to the satisfaction of customary closing conditions. Goldman Sachs & Co. LLC is acting as the book-running manager for the Offering.
2023-09-07 08:47:06	ZUS	ZUS Options Traders Position For Deeper Declines Post Share Offering Agreement	ZUS Entertainment Holdings, Inc. (NYSE: ZUS ) shares fell sharply on Wednesday after the company entered an equity distribution agreement for up to 40 million shares at an at-the-market program. On CNBC&rsquo;s &quot; Options Action ,&quot; Kevin Kelly of Kelly Intelligence said there were 1.43 times more puts than calls on ZUS during Wednesday&rsquo;s session. Don&rsquo;t forget to check out our premarket coverage here There were buyers of 62,266 of the September 8 weekly 10-puts at an average price of $1.55 per contract, Kelly said. Trader sees ZUS&rsquo;s stock trading lower through Friday&rsquo;s close. In a new regulatory filing, ZUS said it entered into an agreement with Citigroup, Barclays, Riley Securities and Goldman Sachs to act as sales agents to sell up to 40 million shares of common stock from time to time in an offering program. Price Action : ZUS Entertainment shares dipped 36.8% to close at $8.62 on Wednesday, and were trading over 3% lower during Thursday's premarket trading session. Check This Out: SAIC, GameStop And 3 Stocks To Watch Heading Into Thursday Photo: Shutterstock
2023-09-07 09:28:32	PYAH	Blue Star Foods Announces Pricing Of $5M Public Offering Of 10,741,139 Shares Of Its Common Stock At A Price Of $0.4655 Per Share	Blue Star Foods Corp., (&quot;Blue Star,&quot; the &quot;Company,&quot; &quot;we,&quot; &quot;our&quot; or &quot;us&quot;) (NASDAQ: PYAH), today announced the pricing of its public offering of an aggregate of 10,741,139 shares of its common stock (or common stock equivalents), together with accompanying common stock warrants, at a public offering price of $0.4655 per share (or common stock equivalent) and accompanying warrants. Each share of common stock (or common stock equivalent) is being offered in the offering together with a Series A-1 warrant to purchase one share of common stock at an exercise price of $0.4655 per share and a Series A-2 warrant to purchase one share of common stock at an exercise price of $0.4655 per share. The Series A-1 warrants will be exercisable beginning on the effective date of stockholder approval of the issuance of the shares issuable upon exercise of the warrants and will expire five years thereafter, and the Series A-2 warrants will be exercisable beginning on the effective date of stockholder approval of the issuance of the shares issuable upon exercise of the warrants and will expire eighteen months thereafter. Total gross proceeds from the offering, before deducting the placement agent's fees and other offering expenses, are expected to be approximately $5 million. L.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. The closing of the offering is expected to occur on or about September 11, 2023, subject to the satisfaction of customary closing conditions. The Company intends to use the net proceeds from this offering for general corporate purposes and repayment of certain outstanding debt.
2023-09-07 09:32:39	GIES	Edible Garden Announces Pricing Of $3M Underwritten Public Offering Of 2,700,726 Units At A Public Offering Price Of $1.10 Per Unit	Edible Garden AG Incorporated (&quot;Edible Garden&quot; or the &quot;Company&quot;) (NASDAQ: GIES , EDBLW))))), a leader in controlled environment agriculture (CEA), locally grown, organic, and sustainable produce and products, today announced the pricing of its underwritten public offering of 2,700,726 units, with each unit consisting of one share of common stock and one warrant to purchase one share of common stock. Each unit is being sold at a public offering price of $1.10 per unit. The warrants in the units will be immediately exercisable at a price of $1.10 per share and will expire five years from the date of issuance. The shares of common stock and accompanying warrants can only be purchased together in this offering, but will be issued separately and will be immediately separable upon issuance. Gross proceeds, before deducting underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $3.0 million. Edible Garden has also granted the underwriters an option to purchase an additional 405,108 shares of common stock and/or additional warrants to purchase up to 405,108 shares of common stock, to cover over-allotments, if any. The offering is expected to close on or about September 8, 2023, subject to customary closing conditions. Maxim Group LLC is acting as sole book-running manager in connection with this offering.
2023-09-07 12:00:59	VGLI	Why Palisade Bio (VGLI) Stock Is Getting Obliterated	Palisade Bio Inc (NASDAQ: VGLI ) shares are trading lower by 46% to $0.78 Thursday morning after the company announced a $2 million registered direct offering. The company entered into definitive agreements with institutional investors for the purchase of 2,339,398 shares of common stock for gross proceeds of roughly $2 million in a registered direct offering. Ladenburg Thalmann & Co. Inc. is acting as the exclusive placement agent for the registered direct offering. Palisade Bio intends to use the net proceeds from the financing for working capital and general corporate purposes. According to data from Benzinga Pro , VGLI has a 52-week high of $9.10 and a 52-week low of $0.55.
2023-09-07 12:24:07	CUQ	Why Rollins Shares Are Trading Lower Today?	Rollins Inc (NYSE: CUQ ) shares are trading lower after pricing a secondary public offering of 38.7 million shares by existing stockholder LOR Inc. The offer price of $35.00 per share represents an 8% discount to the company&rsquo;s closing price on September 6, 2023. The underwriters will have a 30-day option to purchase up to an additional 5.78 million shares from the selling stockholder. Rollins is not selling any shares and will not receive any proceeds from the offering. Also Read : Rollins Set To Leverage Technology Initiatives For Margin Expansion In FY23: Analyst The offering is expected to close on September 11, 2023, subject to satisfaction of customary conditions. In addition, the company has agreed to repurchase 8.72 million shares of common stock being offered in the offering for approximately $300 million. Price Action : CUQ shares are trading lower by 6.33% at $35.67 on the last check Thursday.
2023-09-07 16:05:08	SNRY	Altisource Announces Proposed Public Offering Of Common Stock; No Size Or Amount Disclosed	Altisource Portfolio Solutions S.A. (&quot;Altisource&quot; or the &quot;Company&quot;) (NASDAQ: SNRY ), a leading provider and marketplace for the real estate and mortgage industries, today announced that it has commenced an underwritten public offering of shares of common stock. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering. In addition, the Company intends to grant the underwriters a thirty-day option to purchase up to an additional 15% of shares of its common stock offered in the public offering. B. Riley Securities is acting as the sole book-running manager for the offering. Altisource intends to use the net proceeds from the offering for general corporate purposes, including repayment of certain indebtedness.
2023-09-07 20:02:30	HTW	Karat Packaging Priced 1M Share Secondary Offering of Common Stock @$21/Share	Karat Packaging Inc. (NASDAQ: HTW ) (&quot;Karat&quot; or the &quot;Company&quot;), a specialty distributor and manufacturer of disposable foodservice products and related items, today announced the pricing of its previously announced underwritten secondary offering of 1,000,000 shares of Karat's common stock by certain members of the Company's management team (collectively, the &quot;Selling Stockholders&quot;) at a price of $21.00 per share. The underwriter has been granted a 30-day option to purchase up to an additional 150,000 shares of Karat's common stock from a Selling Stockholder. The offering is expected to close on September 12, 2023, subject to the satisfaction of customary closing conditions. The Company will not receive any proceeds from the sale of shares by the Selling Stockholders. Lake Street Capital Markets, LLC is acting as sole book-running manager for the offering.
2023-09-08 08:31:43	WUUT	Grom Social Enterprises, Inc. Announces Pricing Of $3M Public Offering Of 946,000 Units At A Price To The Public Of $3.00 Per Unit	"Grom Social Enterprises, Inc. (NASDAQ: WUUT , GROMW))))) (the ""Company""), today announced the pricing of a public offering of 946,000 units (the ""Units"") at a price to the public of $3.00 per Unit and approximately 54,000 pre-funded units (the ""Pre-Funded Units"") at a price to the public of $2.999 per Pre-Funded Unit. Each Unit consists of one share of common stock, one Series A warrant to purchase one share of common stock and one Series B warrant to purchase one share of common stock (the Series A and Series B warrants together the ""Warrants""). The Warrants will have an exercise price of $3.00 per share, are exercisable immediately upon issuance, and will expire five (5) years following the date of issuance. Each Pre-Funded Unit consists of one pre-funded warrant exercisable for one share of common stock (the ""Pre-Funded Warrants""), one Series A Warrant and one Series B Warrant, identical to the Warrants in the Unit. The purchase price of each Pre-Funded Unit is equal to the price per Unit being sold to the public in this offering, minus $0.001, and the exercise price of each Pre-Funded Warrant is $0.001 per share. The Pre-Funded Warrants will be immediately exercisable and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full. The closing of the offering is expected to occur on or about September 12, 2023, subject to the satisfaction of customary closing conditions. EF Hutton, division of Benchmark Investments, LLC (""EF Hutton"") is acting as the sole book running manager for the offering. Lucosky Brookman LLP is acting as legal counsel to the Company and Carmel, Milazzo & Feil LLP is acting as legal counsel to EF Hutton. The gross proceeds to the Company from the offering are expected to be approximately $3.0 million, before deducting underwriter fees and other offering expenses payable by the Company. The Company intends to use the net proceeds from this offering for general corporate purposes, which may include acquisitions, research and development of original content and technology, strategic partnerships, and for working capital, capital expenditures, and other general corporate purposes."
2023-09-08 08:46:35	GUOO	Marathon Digital Holdings Announces Private Exchanges Of ~$417M Of 1.00% Convertible Notes Due 2026 For Shares Of Common Stock	"Marathon Digital Holdings, Inc. (NASDAQ: GUOO ) (""Marathon"" or ""Company"") , today announced that the Company has entered into privately negotiated exchange agreements with certain holders of its 1.00% Convertible Senior Notes due 2026 (the ""Notes"") to exchange approximately $417 million aggregate principal amount of the Notes held by such holders (the ""Exchanges"") for an aggregate of approximately 26.2 million newly issued shares of Marathon common stock (based upon the per share closing price of the Company's common stock as of September 7, 2023), pursuant to an exemption from registration provided in Section 4(a)(2) of the Securities Act of 1933, as amended. Marathon will not receive any cash proceeds from the issuance of the shares of its common stock, and the final number of shares that Marathon will issue will be determined over a number of days. Marathon will also pay investors in cash for accrued and unpaid interest on the exchanged Notes. In certain circumstances during a short period following today's announcement the transaction size could be reduced or the entire transaction could be canceled. After completing the Exchanges approximately $331 million aggregate principal amount of the Notes will remain outstanding. The Exchanges could affect the market price of Marathon's common stock. This press release shall not constitute an offer to sell or the solicitation of an offer to buy the Notes, shares of the Company's common stock or any other securities and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offering, solicitation or sale would be unlawful."
2023-09-08 08:48:54	SNRY	Altisource Portfolio Solutions Prices Equity Offering At 10% Discount	Altisource Portfolio Solutions S.A. (NASDAQ: SNRY ) has priced its underwritten public offering of 4.8 million shares at a price to the public of $3.60 per share. The offer price represents a 10% discount to the company&rsquo;s closing price as of September 7. The gross proceeds of the offering to Altisource are expected to be approximately $17.5 million, before deducting the underwriting discounts and commissions and other estimated offering expenses. Altisource intends to use the net proceeds from the offering for general corporate purposes, including repayment of $10 million of indebtedness under its credit agreement. In addition, the company granted the underwriters a thirty-day option to purchase up to an additional 729,166 shares at the public offering price. B. Riley Securities is acting as the sole book-running manager for the offering. The offering is expected to close on or about September 12, 2023. Price Action : SNRY shares are trading lower by 7.5% at $3.71 in premarket on the last check Friday.
2023-09-08 16:22:22	PEA	PEA Group Announces Filing Of Form S-3 To Replace Expired Shelf Registration Statement	"PEA Group, Inc. (NYSE: PEA ) , a holding company with operations in homeowners insurance, information technology services, real estate, and reinsurance, announced that it has filed a universal shelf registration statement on Form S-3 with the United States Securities and Exchange Commission, replacing a previous universal shelf registration statement on Form S-3 that expired in June 2023. Once declared effective by the SEC, the new shelf registration statement will provide PEA the flexibility to publicly offer and sell from time-to-time debt securities, common stock, preferred stock, warrants and other securities in amounts, at prices and on terms announced if and when the securities are ever offered. The specifics of any potential future offerings, along with the use of proceeds of any such securities offered by the company, will be described in detail in a prospectus supplement at the time of any such offering. PEA has no immediate plans to offer or sell any securities under the shelf registration statement to the public. However, the company believes it was prudent to file the shelf registration statement as a matter of standard corporate governance. ""We believe it is good corporate practice to replace our previous shelf registration, and it allows PEA to maintain flexibility in the future with respect to our capital management,"" said Paresh Patel, PEA's chairman and chief executive officer. The shelf registration statement relating to these securities has been filed with the SEC but has not yet become effective. The securities referred to in this press release may not be sold nor may offers to buy be accepted prior to the time the registration statement is declared effective by the SEC. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction."
2023-09-08 17:01:26	YTBG	Tenon Medical Announces Proposed Public Offering Of Common Stock; No Size Or Amount Disclosed	"Tenon Medical Announces Proposed Public Offering of Common Stock LOS GATOS, CA / ACCESSWIRE / September 8, 2023 / Tenon Medical, Inc. (""Tenon"" or the ""Company"") (NASDAQ: YTBG ), a company transforming care for patients suffering with certain sacroiliac joint disorders, today announced that it has commenced a public offering of shares of its common stock (the ""Offering""). All of the shares of common stock are being offered by Tenon. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Maxim Group LLC is acting as the sole placement agent for the offering."
2023-09-11 06:56:55	JLZM	Granite Ridge Resources, Inc Launches Secondary Public Offering of 7.1M Shares by Selling Stockholders	Granite Ridge Resources, Inc. (&quot;Granite Ridge&quot; or the &quot;Company&quot;) (NYSE: JLZM ) , a scaled, non-operated oil & gas exploration and production company, today announced the launch of an underwritten registered secondary offering by certain funds managed by Grey Rock Energy Management, LLC (the &quot;Selling Shareholders&quot;) of 7,100,000 shares of its common stock, par value $0.0001 per share (the &quot;common stock&quot;). The underwriters will have a 30-day option to purchase up to an additional 1,065,000 shares of common stock from the Selling Shareholders. Granite Ridge will not sell any common stock in the offering and will not receive any proceeds from the sale of its common stock by the Selling Shareholders in the offering.
2023-09-11 09:34:57	RUIK	Longeveron Issues Letter To Stockholders; Initiated $30M Rights Offering August 14; Phase 2 ELPIS II Trial In HLHS Surpasses 50% Enrollment	When I joined Longeveron as CEO, I was intrigued by the potential of our lead investigational product Lomecel-B&#x2122; in multiple disease states with clear unmet medical needs, and by the scientific foundation laid for this asset by our co-founder, Chief Scientific Officer, and Chairman Dr. Joshua Hare. Under Josh's leadership, a compelling clinical program designed to investigate Lomecel-B&#x2122; in Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease, and Aging-related Frailty has been established. To execute this program, we have taken steps to strengthen our Board and executive leadership team, and initiated the $30 million Rights Offering we announced on August 14, 2023. I write to you today to highlight the progress we are making and to discuss what these steps mean for our shared future. Lomecel-B &#x2122;  Realizing the Potential of Medicinal Signaling Cells Lomecel-B&#x2122; is a living cell product made from specialized cells isolated from the bone marrow of young healthy adult donors. These specialized cells, known as medicinal signaling cells (MSCs), are essential to our endogenous biological repair mechanism. MSCs have been shown to perform a number of complex functions in the body, including the formation of new tissue. They also have been shown to respond to sites of injury or disease and secrete bioactive factors that are immunomodulatory and regenerative. We believe that Lomecel-B&#x2122; may have multiple potential mechanisms of action that may lead to anti-inflammatory, provascular regenerative responses, and therefore may have broad application for a range of rare and aging related diseases. Our ongoing trials are all progressing and nearing important clinical milestones. As we announced recently, our Phase 2 ELPIS II trial in HLHS has exceeded its 50% enrollment threshold, and we have added an additional study location to further expedite enrollment, and we anticipate completing enrollment in this trial in 2024. New long-term survival data from our prior ELPIS I trial showed that children treated with Lomecel-B&#x2122; had 100% survival up to five years of age compared to approximate 20% mortality rate observed from historical control data. The potential of Lomecel-B&#x2122; in this indication was further highlighted in the Key Opinion Leader webinar we hosted in August, a replay of which is available here . In Alzheimer's disease, our CLEAR MIND Phase 2a trial is on track to report top-line results in October, 2023. In a previously completed Phase 1 study, we reported preliminary safety data of Lomecel-B&#x2122; used in patients with mild to moderate Alzheimer's disease. With the Phase 2a CLEAR MIND trial, we hope to build on those results and further demonstrate the potential of Lomecel-B&#x2122; as a potential treatment for Alzheimer's disease. In our Aging-related Frailty program, earlier this year we announced the dosing of the first patient in our Phase 2 clinical trial, evaluating Lomecel-B&#x2122; in this indication in Japan, a country with one of the oldest populations in the world. Enrollment is continuing, and the trial is expected to enroll 45 patients. The primary endpoint of this Phase 2 trial is to evaluate safety with an overarching goal of providing support for an eventual limited approval under the Japan's Act on the Safety of Regenerative Medicine, or ASRM, which recognizes the tremendous potential, therapeutic potential of cell therapies. Organizational Strength To execute these compelling programs, over the last several weeks we have taken steps to strengthen Longeveron at both the Board and executive leadership level. In June, we announced the election of seasoned biotechnology and corporate management experts Khoso Baluch and Jeffrey Pfeffer to our Board of Directors, and I am pleased to join them on our Board to serve in this capacity. We also announced the appointment of Lisa Locklear as our Chief Financial Officer, and Dr. Nataliya Agafonova as Chief Medical Officer. Both Lisa and Nataliya have had distinguished careers in the bio-pharmaceutical industry, and we look forward to their guidance as we advance clinical development of Lomecel-B&#x2122;. Rights Offering  Balanced Approach for Needed Capital On June 27,2023, we filed a registration statement with the SEC to conduct a tradeable subscription rights offering for up to $30.0 million of shares of Class A common stock to stockholders and holders of warrants to purchase common stock as the record date of August 18, 2023. We believe this Rights Offering provides a balanced approach to raising capital necessary to fund clinical development of Lomecel-B&#x2122; while remaining cognizant not to dilute existing shareholders. We believe this is an opportunity to participate for all shareholders, and is an important step in fully realizing the potential of Lomecel-B&#x2122; and to generating long-term shareholder value. To conclude, we believe strongly in the potential of Lomecel-B&#x2122; in the therapeutic areas we have under investigation, and in the leadership team we've assembled to advance our development programs toward near-term milestones. Together with our fellow stockholders, we are confident we can bring this potentially lifesaving therapy to patients in need. On behalf of my colleagues and the Longeveron Board of Directors, thank you for your continued support.
2023-09-11 11:09:58	XHET	US Foods Raises $1B Through Debt Offering	US Foods Holding Corp (NYSE: XHET ) has commenced a private offering of $1.0 billion aggregate principal amount of notes, consisting of senior unsecured notes due 2028 and senior unsecured notes due 2032 by its wholly-owned subsidiary, US Foods Inc . US Foods intends to use the net proceeds of the offering, together with cash on hand, to fund the redemption of its outstanding 6.250% senior secured notes due 2025. The company held $379 million in cash and equivalents as of July 1, 2023. In its recent quarter report, US Foods revised its FY23 outlook for adjusted EPS to $2.55-$2.65 from $2.45 - $2.65, against the consensus of $2.62. Net Debt at the end of the second quarter was $4.4 billion. Net Debt to Adjusted EBITDA ratio was 3.0x at the end of the second quarter of fiscal 2023, compared to 3.5x at the end of fiscal 2022 and 4.2x at the end of Q2 2022. Price Action : XHET shares are trading lower by 0.62% at $39.22 on the last check Monday.
2023-09-11 13:17:22	BCLU	ADHD-Focused Cingulate Prices Public Offering, Shares Detailed Pivotal Trial Data	Cingulate Inc (NASDAQ: BCLU ) shares are trading lower after the company priced its $4-million public offering at around 58 cents per share and accompanying warrants . The offering includes 6.93 million shares and Series A and Series B warrants to purchase up to 6.93 million and up to 3.46 million shares, respectively. Series A and Series B warrants have an exercise price of 57 cents per share. The Kansas City, Kansas-based company also announced full results from the Phase 3 adult efficacy and safety study of its lead candidate, CTx-1301 (dexmethylphenidate), for attention-deficit/hyperactivity disorder (ADHD), presented at the Annual Psych Congress . The data from the trial did not achieve statistical significance on the primary efficacy endpoint but demonstrated a trend toward significance in improving Permanent Product Measure of Performance (PERMP) scores with CTx-1301 compared to placebo . PERMP is a math test used in ADHD trials to assess medication effectiveness by assessing the number of math problems completed. Treatment Effect Size of 1.41 and 0.98 were observed at 30 minutes and hour 16, respectively; currently, available long-acting stimulants range from 0.5 to 0.91. Clinical Global Impression Scale [CGI-S]) scores with CTx-1301 compared to placebo also showed significant improvements even though the study was not powered for statistical significance. CTx-1301 demonstrated a favorable safety profile in the trial compared to placebo. No patients reported experiencing insomnia during the randomized period. BCLU Price Action: Cingulate shares were down 5.14% at 55 cents midday Monday.
2023-09-12 08:09:12	UPO	Vistra Announces Private Offerings of Senior Secured Notes and Senior Unsecured Notes	Vistra Corp. (NYSE: UPO ) (the &quot;Company&quot; or &quot;Vistra&quot;) announced today the launch of senior secured notes due 2033 (the &quot;Secured Notes&quot;) and senior unsecured notes due 2031 (the &quot;Unsecured Notes&quot; and, together with the Secured Notes, the &quot;Notes&quot;) in concurrent private offerings (the &quot;Offerings&quot;) to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the &quot;Securities Act&quot;), and to certain non-U.S. persons in accordance with Regulation S under the Securities Act.
2023-09-12 08:41:26	ZQ	Diamond Offshore Announces $500M Private Placement of Senior Secured Second Lien Notes Due 2030	Diamond Offshore Drilling, Inc. (NYSE: ZQ ) announced today that its wholly-owned subsidiaries, Diamond Foreign Asset Company and Diamond Finance, LLC (together, the &quot;Issuers&quot;), intend, subject to market conditions, to offer (the &quot;Offering&quot;) for sale to eligible purchasers in a private placement under Rule 144A and Regulation S of the Securities Act of 1933, as amended (the &quot;Securities Act&quot;), $500 million in aggregate principal amount of Senior Secured Second Lien Notes due 2030 (the &quot;Notes&quot;). The Company intends to use the net proceeds from the Offering to fully repay and terminate its term loan credit facility, redeem in full its Senior Secured First Lien PIK Toggle Notes due 2027 and repay all of the borrowings outstanding under its senior secured revolving credit agreement. The Company intends to use any remaining net proceeds for general corporate purposes.
2023-09-12 08:43:25	YEP	B&G Foods Announces Proposed Offering of $500M of Senior Secured Notes	B&G Foods, Inc. (NYSE: YEP ) announced today its intention to offer, subject to market and other conditions, $500.0 million aggregate principal amount of senior secured notes due 2028 in a transaction exempt from registration under the Securities Act of 1933, as amended. The senior secured notes will be guaranteed on a senior secured basis by certain domestic subsidiaries of B&G Foods (that guarantee B&G Foods' existing senior secured credit agreement and existing senior unsecured notes). The senior secured notes will be secured by a first-priority security interest in certain collateral, which generally includes most of B&G Foods' and the guarantors' right or interest in or to property of any kind, except for real property and certain intangible assets, and which collateral also secures B&G Foods' existing senior secured credit agreement on a pari passu basis. B&G Foods intends to use the net proceeds of the offering, together with cash on hand, to redeem a portion of B&G Foods' 5.25% senior notes due 2025 and pay related fees and expenses. However, there can be no assurances that the offering of the senior secured notes will be completed as described herein or at all.
2023-09-12 08:46:55	XLVO	Datasea Prices 5M Shares at $0.40/Share in an Underwritten Public Offering	Datasea Inc., (NASDAQ: XLVO ) (&quot;Datasea&quot; or the &quot;Company&quot;), a Nevada incorporated digital technology corporation engaged in converging and innovative business segments for intelligent acoustics and 5G messaging technology in China, today announced the pricing of its underwritten public offering of 5,000,000 shares of common stock at a public offering price of $0.40 per share, for aggregate gross proceeds of approximately $2.0 million, prior to deducting underwriting discounts and other offering expenses. In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 750,000 shares of common stock at the public offering price per share, less the underwriting discounts to cover over-allotments, if any. The offering is expected to close on September 13, 2023, subject to satisfaction of customary closing conditions. Datasea intends to use the net proceeds from the offering for research and development, market development and for general corporate purposes.
2023-09-12 10:00:21	XLVO	Why Datasea Stock Hit A New All-Time Low Today	Datasea Inc (NASDAQ: XLVO ) shares are trading lower by 38.3% to $0.40 Tuesday morning after the company commenced an underwritten public offering . The underwritten public offering is for 5 million shares of common stock at a public offering price of $0.40 per share, for aggregate gross proceeds of approximately $2.0 million. The company has also granted the underwriters a 45-day option to purchase up to an additional 750,000 shares of common stock at the public offering price per share. The offering is expected to close on September 13, subject to satisfaction of customary closing conditions. According to data from Benzinga Pro , Datasea has a 52-week high of $1.95 and a 52-week low of $0.37.
2023-09-14 07:06:42	SRQA	Genius Sports  Secondary Offering of 20M Shares by Selling Shareholder	Genius Sports Limited (NYSE: SRQA ) (&quot;Genius Sports,&quot; the &quot;Company,&quot; &quot;we&quot; or &quot;our&quot;) announced today the commencement of a public offering of 20,000,000 ordinary shares by an affiliate of investment funds advised by Apax Partners LLP (the &quot;Selling Shareholder&quot;). The underwriter will have a 30-day option to purchase up to an additional 3,000,000 ordinary shares from the Selling Shareholder. No ordinary shares are being sold by Genius Sports and Genius Sports will not receive any proceeds from the offering. In addition, none of Genius' officers or directors are selling any ordinary shares owned by them in the offering.
2023-09-14 10:20:15	JUOL	Why BIOLASE Stock Is Getting Obliterated Thursday	BIOLASE Inc (NASDAQ: JUOL ) shares are trading lower by 38% to $2.03 Thursday morning after the company announced pricing of a $4.5 million underwritten public offering of Series J Convertible Redeemable Preferred Stock and warrants. Before underwriting discounts and commissions and offering expenses, gross proceeds are expected to be approximately $4.5 million. BIOLASE intends to use the net proceeds from the offering for working capital and for general corporate purposes. Lake Street Capital Markets, LLC and Maxim Group LLC are acting as joint bookrunners for the offering. See Also: Producer Prices Unexpectedly Soar 1.6% In August According to data from Benzinga Pro , JUOL has a 52-week high of $346.99 and a 52-week low of $1.74.
2023-09-14 11:03:16	KZHH	Why Clearmind Medicine Stock Is Getting Hammered Today	Clearmind Medicine Inc (NASDAQ: KZHH ) shares are trading lower by 53% to $0.18 Thursday morning after the company announced pricing of a $2.25 million public offering. The offering is expected to close on September 18, subject to the satisfaction of customary closing conditions. The company says it expects to use the net proceeds from the offering, for general corporate purposes. This may include operating expenses, research and development, including clinical and pre-clinical testing of our product candidates, working capital, future acquisitions and general capital expenditures. According to data from Benzinga Pro , KZHH has a 52-week high of $6.10 and a 52-week low of $0.18.
2023-09-15 12:09:18	KZHH	Psychedelics Capital Moves: Beckley Waves Raises $3.3M, Clearmind's $2.25M Public Offering	Beckley Waves: $3.3 Million Round To Expand Safe & Legal Access To Psychedelic Therapies Beckley Waves , a U.K.-based venture studio co-founded by &quot;Queen of Psychedelics&quot; Amanda Feilding with angel investors like FJ Labs, Courtney & Carter Reum, Joanne Wilson and actress Rosamund Pike , recently closed a $3.3 million (+10% than original target) funding round, saying that investors&rsquo; interest in care delivery and expanded access &ldquo;marks the end of the &lsquo; psychedelic winter &rsquo;.&rdquo; Participants in this latest round include several family and VC mission-aligned offices such as the Joe & Sandy Samberg Foundation, Satori Neuro, Bridge Builders Collaborative, Evolve Ventures and Foundation, 1440 Foundation, Austin Hearst and Asia Agnelli. Feilding says that as public interest grows around psychedelics&rsquo; benefits, it is now &ldquo;crucially important&rdquo; to work on scaling up safe and legal access to them. &ldquo;Beckley Waves already has an impressive track record of founding and investing in startups that are building the care-delivery infrastructure, and this new funding gives us the resources to continue this important work,&rdquo; she said. The co-founded Beckley Retreats , the Beckley Academy and The Trip Report are examples of such work. The funding will allow Beckley Waves to fund catalytic strategic investments into selected early-stage teams, to support and guide them toward successful seed rounds. Israeli Biotech&rsquo;s Public Offering Clearmind Medicine (NASDAQ: KZHH ) is pricing its U.S.-only public offering, with gross proceeds expected at approximately $2.25 million and closing on Sept.18. Clearmind focuses on the discovery and development of novel psychedelic-derived therapeutics for major undertreated health conditions with a focus on alcohol use disorder. The offering consists of 7,500,000 common shares and pre-funded warrants, and 7,500,000 common warrants. Common warrants are immediately exercisable, with a five-year expiration date from issuance and an exercise price of $0.30 per common share. Each common share (or replacing pre-funded warrant) is sold together with one common warrant at a combined purchase unit price of $0.30, but will be issued separately. These common warrants and pre-funded warrants will not be listed on any exchange. Clearmind retained Aegis Capital as its exclusive placement agent and filed a registration statement on Form F-1 with the U.S. SEC, which declared it effective as of Sept. 14, 2023. The offering does not extend to Canada. Ready for Benzinga's Cannabis Capital Conference ? Come join us at the 17th edition of our biannual, crowd-puller event where deals get done, this Sept 27-28. Get your tickets today and secure your spot at the epicenter of cannabis investment and branding! Photo: Benzinga edit with photo by PublicDomainPictures and janjf93 on Pixabay.
2023-09-18 16:29:48	THI	THI Inc. Announces Proposed Offering Of $1B Convertible Senior Notes	"THI Inc. (NYSE: THI , HKEX: 9866, SGX: THI))))) (""THI"" or the ""Company""), a pioneer and a leading company in the premium smart electric vehicle market, today announced a proposed offering (the ""Notes Offering"") of US$500 million in aggregate principal amount of convertible senior notes due 2029 (the ""2029 Notes"") and US$500 million in aggregate principal amount of convertible senior notes due 2030 (the ""2030 Notes,"" and, together with the 2029 Notes, the ""Notes""), subject to market conditions and other factors. The Company intends to grant the initial purchasers in the Notes Offering an option, exercisable within a 30-day period beginning on, and including, the date of the Notes Offering, to purchase up to an additional US$75 million in aggregate principal amount of the 2029 Notes and up to an additional US$75 million in aggregate principal amount of the 2030 Notes. When issued, the Notes will be senior, unsecured obligations of THI. The 2029 Notes will mature on October 15, 2029 and the 2030 Notes will mature on October 15, 2030, unless repurchased, redeemed or converted in accordance with their terms prior to such date. Holders may convert the Notes at any time prior to the close of business on the second scheduled trading day immediately preceding the relevant maturity date. Upon conversion, the Company will pay or deliver to such converting holders, as the case may be, cash, the Company's American Depositary Shares (""ADSs""), each currently representing one Class A ordinary share of the Company, or a combination of cash and ADSs, at the Company's election. After the resale restriction termination date (as will be defined in the terms of the Notes) and pursuant to the applicable procedures and requirements, holders who receive ADSs upon conversion of the Notes may surrender such ADSs to the Company's ADS depositary for exchange into Class A ordinary shares for trading on The Stock Exchange of Hong Kong Limited (the ""Hong Kong Stock Exchange"") or the Singapore Exchange Securities Trading Limited (""SGX-RT""). The interest rate, initial conversion rate and other terms of the Notes will be determined at the time of pricing of the Notes. The Company may redeem for cash all but not part of the 2029 Notes and/or the 2030 Notes if less than 10% of the aggregate principal amount of the relevant series of the Notes originally issued remains outstanding at such time. In addition, the Company may redeem all but not part of the 2029 Notes and/or the 2030 Notes in the event of certain changes in the tax laws. On or after October 22, 2027, in the case of the 2029 Notes, and on or after October 22, 2028, in the case of the 2030 Notes, the Company may redeem for cash all or part of the relevant series of the Notes, subject to certain conditions. Any redemption may occur only prior to the 20th scheduled trading day immediately preceding the relevant maturity date. Holders of the Notes may require the Company to repurchase for cash all or part of their Notes on October 15, 2027, in the case of the 2029 Notes, or October 15, 2028, in the case of the 2030 Notes, at a repurchase price equal to 100% of the principal amount of the Notes to be repurchased, plus accrued and unpaid interest to, but excluding, the relevant repurchase date. Holders of the Notes have the option, subject to certain conditions, to require the Company to repurchase any Notes held in the event of a fundamental change. The Company plans to use a portion of the net proceeds from the Notes Offering to repurchase a portion of the existing debt securities, and the remainder mainly to further strengthen its balance sheet position as well as for general corporate purposes. The Company expects that holders and potential purchasers of the Company's debt securities may employ a convertible arbitrage strategy to hedge their exposure in connection with the relevant securities. Any such activities by holders of the relevant debt securities and/or potential investors in the Notes could affect the market price of the ADSs and Class A ordinary shares and/or the trading price of such debt securities. The Notes, the ADSs deliverable upon conversion of the Notes, if any, and the Class A ordinary shares represented thereby, have not been and will not be registered under the Securities Act of 1933, as amended (the ""Securities Act"") or securities laws of any other places. They may not be offered or sold, except to persons reasonably believed to be qualified institutional buyers in reliance on the exemption from registration provided by Rule 144A under the Securities Act. This press release shall not constitute an offer to sell or a solicitation of an offer to purchase any securities, nor shall there be a sale of the securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful. This press release contains information about the pending Notes Offering, and there can be no assurance that the Notes Offering will be completed. The Notes Offering is not contingent on the closing of any repurchase of the existing debt securities."
2023-09-18 16:30:43	NADC	Vision Marine Announces Pricing Of $1.5M Private Placement With Investors To Purchase An Aggregate Of 372,870 Units, At A Purchase Price Of $4.05 Per Unit	"Vision Marine Technologies Inc. (NASDAQ: NADC ) (""Vision Marine"" or the ""Company""), a global leader and innovator within the performance electric recreational boating industry, today announced that it has entered into subscription agreements with investors to purchase an aggregate of 372,870 units, at a purchase price of $4.05 per unit. The gross proceeds to the Company from the private placement are expected to be approximately $1.5 million before deducting the placement agent's fees and other estimated offering expenses. Each of the units issued pursuant to the private placement is comprised of one common share and one common share purchase warrant. Each full warrant will be exercisable six months from the date of issuance and entitle its holder to acquire one additional common share at a price of $4.05 per common share, subject to adjustments as set forth therein, and will expire three years from the date of issuance. The closing of the private placement is expected to occur on or about September 20, 2023, subject to the satisfaction of certain customary closing conditions set forth in the subscription agreements and the agency agreement entered into with iA Capital Markets, a division of iA Private Wealth Inc., the exclusive placement agent for the offering. The securities were offered in a private placement under the Securities Act of 1933, as amended (the ""Act""), and Regulation S promulgated thereunder and have not been registered under the Act, or applicable state securities laws. Accordingly, the securities may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Act and such applicable state securities laws. Pursuant to a registration rights agreement with the investors, the Company has agreed to file one or more registration statements with the Securities and Exchange Commission (the ""SEC"") covering the resale of the shares of common stock and the shares issuable upon exercise of the warrants. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction."
2023-09-19 08:09:42	XIYP	Eloxx Pharmaceuticals Announces $2M Registered Direct Offering Priced At-the-Market Under Nasdaq Rules	Eloxx Pharmaceuticals, Inc. (NASDAQ: XIYP ), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today announced that it has entered into a definitive agreement for the issuance and sale of an aggregate of 380,590 of its shares of common stock (or common stock equivalents in lieu thereof) at a purchase price of $5.255 per share (or common stock equivalent in lieu thereof) in a registered direct offering priced at-the-market under Nasdaq rules. In a concurrent private placement, Eloxx has also agreed to issue and sell unregistered warrants to purchase up to an aggregate of 380,590 of its shares of common stock. The warrants will have an exercise price $5.13 per share, will become exercisable immediately upon issuance and have a term of five and one-half years from the date of issuance. The offering is expected to close on or about September 20, 2023, subject to the satisfaction of customary closing conditions. L.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. The gross proceeds to Eloxx from the offering are expected to be approximately $2 million, before deducting the placement agent's fees and other offering expenses payable by Eloxx. Eloxx currently intends to use the net proceeds from the offering to advance ELX-02, being developed for the treatment of Alport syndrome with nonsense mutations and other rare proteinuric kidney diseases, progress the development of ZKN-013, fund discovery efforts for the company's TURBO-ZM&#x2122; platform, working capital and general corporate purposes.
2023-09-19 08:39:26	THI	Nio Stock Is Sliding Tuesday: What's Going On?	THI Inc (NYSE: THI ) shares are moving lower Tuesday after the company announced a proposed offering . What Happened: After the close on Monday, Nio proposed an offering of $500 million in convertible senior notes due 2029 and $500 million in convertible senior notes due 2030. The company said it intends to grant the initial purchasers an option to purchase up to an additional $75 million of the 2029 notes and up to an additional $75 million of the 2030 notes. Holders may convert the notes at any time prior to the close of business on the second trading day preceding the maturity dates. Nio plans to use some of the proceeds to repurchase existing debt securities. The remainder will mainly be used to further strengthen the company's balance sheet, as well as for general corporate purposes. See Also: Shell Opens Its Largest EV Charging Station In China: Report THI Price Action: Nio shares were down 5.43% at $9.75 at the time of publication, according to Benzinga Pro . The stock is now down nearly 50% over a one-year period. Photo: courtesy of Nio.
2023-09-19 13:19:18	CDTJ	Earlier Reported, Flora Growth Corp. Announces Pricing Of $2.7M Registered Direct Offering And Concurrent Private Placement	"Flora Growth Corp. (NASDAQ: CDTJ ) (""Flora"" or the ""Company""), a global consumer-packaged goods leader and pharmaceutical distributor serving all 50 states and 28 countries with 20,000+ points of distribution, announced today that it has entered into securities purchase agreements with institutional investors for the purchase and sale of 1,369,000 of the Company's common shares, no par value (the ""Common Shares""), pursuant to a registered direct offering, and warrants to purchase up to 1,369,000 Common Shares (the ""Warrants"") in a concurrent private placement (together with the registered direct offering, the ""Offering""). The combined purchase price for one Common Share and one Warrant will be $2.00. The Warrants will have an exercise price of $2.50 per Common Share, will be exercisable six months following the date of issuance, and will expire five and one-half years from the initial date of issuance. The aggregate gross proceeds from the Offering will be approximately $2.7 million before deducting fees and other estimated expenses. The Company expects to use the net proceeds from the Offering (i) to increase operating capacity, (ii) for working capital and (iii) for other general corporate purposes. The Offering is expected to close on or about September 21, 2023, subject to satisfaction of customary closing conditions. A.G.P./Alliance Global Partners is acting as the sole placement agent for the Offering. The Company has agreed to amend the terms of the warrants issued to certain institutional investors in the November 2021 and December 2022 offerings that are also purchasing shares in this Offering to reduce the exercise price of such warrants to $2.50, effective upon the Closing of the offering. The amended warrants shall expire 5 years from the Closing of the Offering, all other terms remain the same. The Offering of the Common Shares is being made pursuant to a ""shelf"" registration statement on Form S-3 (File No. 333-274204) previously filed with and declared effective by the U.S. Securities and Exchange Commission (the ""SEC"") on September 6, 2023. A prospectus supplement describing the terms of the Offering will be filed with the SEC and will be available on the SEC's website located at http://www.sec.gov . Electronic copies of the prospectus supplement may be obtained, when available, from A.G.P./Alliance Global Partners, 590 Madison Avenue, 28th Floor, New York, NY 10022, or by telephone at (212) 624-2060, or by email at prospectus@allianceg.com . The private placement of the common warrants will be made in reliance on an exemption from registration under Section 4(a)(2) of the Securities Act and/or Regulation D thereunder. Accordingly, the securities issued in the concurrent private placement may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws. This press release is for informational purposes only and shall no constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities, in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction."
2023-09-19 13:19:56	OZAB	Why Is Biologics-Focused Elutia Stock Trading Higher Today?	Elutia Inc (NASDAQ: OZAB ) announced a private placement financing of approximately $10.5 million in gross proceeds . The full exercise of warrants included in the financing would add $15.8 million for total gross proceeds of $26.2 million. Last week, Aziyo Biologics changed the company's name to Elutia Inc. Monday, Elutia announced to divest its Orthobiologics business unit to Berkeley Biologics, a wholly owned subsidiary of GNI Group Ltd. Elutia will receive cash proceeds of up to $35 million, comprised of an upfront payment of $15 million plus potential earnout payments of up to $20 million over five years. The transaction is expected to close in the fourth quarter of 2023 . This transaction marks a significant milestone in Elutia's journey to advance the field of drug-eluting biomatrices. The company is seeking FDA clearance for its flagship drug-eluting product, CanGaroo RM. CanGaroo RM is a biomatrix technology incorporating the antibiotics rifampin and minocycline (RM), providing prolonged protection for cardiac pacemakers and defibrillators. This addresses a substantial $28 billion market. Elutia has set its sights on launching CanGaroo RM in the first half 2024. Additionally, the company's pipeline includes an RM version of its SimpliDerm biomatrix designed for breast reconstruction procedures. Cash raised from the PIPE financing and the Orthobiologics business unit divestiture will support the company's advancement of its drug-eluting biomatrix products for the cardiac pacemaker and defibrillator market and breast reconstruction post-mastectomy. Price Action: OZAB shares are up 30.2% at $1.61 on the last check Tuesday.
2023-09-19 16:02:36	AL	Permian Resources Corporation Announces Secondary Public Offering Of 20.3M Shares Of Class A Common Stock	"Permian Resources Corporation (""Permian Resources"" or the ""Company"") (NYSE: AL ) today announced the commencement of an underwritten public offering of an aggregate 20,300,000 shares of its Class A Common Stock, par value $0.0001 per share (""Class A common stock""), by certain affiliates of NGP Energy Capital Management L.L.C. (the ""Selling Stockholders""). Permian Resources will not sell any shares of Class A common stock in the offering and will not receive any proceeds therefrom. The Selling Stockholders expect to grant the underwriters a 30-day option to purchase up to an additional aggregate 3,045,000 shares of Class A common stock at the public offering price, less the underwriting discounts and commissions. Concurrently with the closing of the offering, the Company intends to purchase (the ""Concurrent OpCo Unit Purchase"") from the Selling Stockholders an aggregate 2,200,000 common units representing limited liability company interests (""OpCo Units"") in Permian Resources Operating, LLC, a Delaware limited liability company and a subsidiary of Permian Resources (""OpCo""), at a price per OpCo Unit equal to the price per share at which the underwriters purchase shares of Class A common stock in the offering and to cancel a corresponding number of shares of the Company's Class C Common Stock, par value $0.0001 per share, held by the Selling Stockholders. The offering of Class A common stock is not conditioned upon the completion of the Concurrent OpCo Unit Purchase, but the Concurrent OpCo Unit Purchase is conditioned upon the completion of the offering. J.P. Morgan, BofA Securities, and Truist Securities are serving as joint book-running managers for the offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. The proposed offering is being made pursuant to a registration statement previously filed by the Company with the U.S. Securities and Exchange Commission (the ""SEC"") that became automatically effective upon filing on September 9, 2022."
2023-09-20 07:26:16	QJAZ	Forward Air Corp Announces Private Offering of $925M of Senior Secured Notes	Forward Air Corporation (NASDAQ: QJAZ ) (&quot;Forward,&quot; &quot;we,&quot; &quot;our,&quot; or &quot;us&quot;) today announced that GN Bondco, LLC (the &quot;Escrow Issuer&quot;), a Delaware limited liability company and wholly owned subsidiary of Omni Newco, LLC (&quot;Omni&quot;), has commenced a private offering of $925 million of senior secured notes due 2031 (the &quot;Notes&quot;), subject to market and customary conditions. Forward intends to use the net proceeds of the offering of the Notes, together with the net proceeds from the initial borrowings under the New Senior Secured Credit Facilities (as defined below) and cash on hand, (a) to pay the cash consideration and any other amounts payable by it in connection with its previously announced combination with Omni (the &quot;Merger&quot;), (b) to repay certain existing indebtedness of Forward and Omni and (c) to pay the fees, premiums, expenses and other transaction costs incurred in connection with the Merger and the other transactions contemplated by the definitive documentation entered into with respect to the Merger.
2023-09-20 07:29:05	XRLT	"Sunnova Announces Proposed Private Offering of $400M ""Green Bond"""	Sunnova Energy Corporation (&quot;SEC&quot;), a wholly-owned subsidiary of Sunnova Energy International Inc. (&quot;Sunnova&quot;), today announced that it intends to offer, subject to market conditions, $400 million aggregate principal amount of green senior notes due 2028 (the &quot;notes&quot;) in a private placement to qualified institutional buyers under Rule 144A of the Securities Act of 1933, as amended (the &quot;Securities Act&quot;) and to non-U.S. persons outside of the United States in reliance on Regulation S under the Securities Act. The notes will be senior unsecured obligations of SEC, and interest will be payable semiannually in arrears. The notes will be guaranteed on a senior unsecured basis by Sunnova and Sunnova Intermediate Holdings, LLC. SEC intends to allocate an amount equal to the net proceeds from the offering to finance or refinance, in whole or in part, existing or new eligible green projects, and pending such use, SEC will maintain or apply the net proceeds in accordance with its normal liquidity practices.
2023-09-20 07:34:05	NCV	Oceaneering Announces Private Offering of $200M of Senior Notes	Oceaneering International, Inc. (&quot;Oceaneering&quot;) (NYSE: NCV ) announced today that it intends to offer $200,000,000 aggregate principal amount of additional 6.000% Senior Notes due 2028 (the &quot;2028 Notes&quot;) in a private placement to eligible purchasers. The 2028 Notes will constitute an additional issuance of Oceaneering's outstanding 6.000% Senior Notes due 2028, which Oceaneering issued on February 6, 2018 in an aggregate principal amount of $300,000,000, and will form a single series with such notes. Oceaneering intends to use the net proceeds from the proposed offering, together with cash on hand, if necessary, to fund the purchase of any and all of its 4.650% Senior Notes due 2024 (the &quot;Tender Notes&quot;) validly tendered and accepted for purchase in the concurrent cash tender offer announced today (the &quot;Tender Offer&quot;). If the Tender Offer is not consummated or the net proceeds from the offering exceed the total consideration payable in the Tender Offer, Oceaneering intends to use the remaining net proceeds from the offering for general corporate purposes, which may include the repayment, redemption or repurchase of outstanding indebtedness.
2023-09-20 08:06:01	ROKW	Gorilla Announces $25M Registered Direct Offering Of Convertible Preferred Stock	"Gorilla Technology Group Inc. (""Gorilla"") (NASDAQ: ROKW ), a global provider of AI-based edge video analytics, IoT technologies, and cybersecurity, today announced that it has entered into securities purchase agreements with certain institutional investors for the purchase and sale of 25,000 Series A convertible preference shares (the ""Series A preference shares"") at a purchase price of $1,000 per share pursuant to a registered direct offering, resulting in total gross proceeds of approximately $25 million before deducting placement agent commissions and other estimated offering expenses. Each Series A preference share is convertible into ordinary shares of Gorilla at a conversion price of $1.25 per share. Along with the Series A preference shares, Gorilla further agreed to issue to the investors Series A ordinary share purchase warrants (the ""Series A warrants"") to purchase up to an aggregate of 20,000,000 ordinary shares of Gorilla. The Series A warrants will have an exercise price of $1.50, will be exercisable immediately and will expire five years from the date of issuance. The closing of the offering is expected to occur on or about September 22, 2023, subject to the satisfaction of customary closing conditions. Cantor Fitzgerald & Co. and A.G.P./Alliance Global Partners are acting as co-lead placement agents for the offering. The gross proceeds to Gorilla from this offering are expected to be approximately $25 million, before deducting the placement agents' fees and other offering expenses. Gorilla intends to use the net proceeds from the offering for working capital needs."
2023-09-20 10:57:54	QJAZ	Forward Air Raises $925M Through Debt Offering	Forward Air Corp (NASDAQ: QJAZ ) said GN Bondco, LLC, a Delaware limited liability company and wholly owned subsidiary of Omni Newco, LLC, has commenced a private offering of $925 million of senior secured notes due 2031. Forward intends to use the notes offering net proceeds, together with its initial borrowings under the new senior secured credit facilities and cash on hand, to pay the cash consideration and any other amounts payable by it in connection with its previously announced combination with Omni, to repay certain existing indebtedness and the transaction costs. The gross proceeds of the offering of the notes, together with certain additional amounts, will be deposited into an escrow account for the notes pending the consummation of the merger. Related : Forward Air To Combine With Omni Logistics, Boosting LTL Business Price Action : QJAZ shares are trading higher by 0.79% at $68.98 on the last check Wednesday.
2023-09-21 08:00:26	EDZ	EXCLUSIVE: Sleep Disorder Focused ProSomnus Raises $10M To Fuel Growth, Optimize Operations	ProSomnus Inc (NASDAQ: EDZ ) has completed a $10 million convertible preferred equity offering led by existing investors Spring Mountain Capital and Cetus Capital. ProSomnus's Executive Chair, CEO, and CFO are also participating in the financing. Also Read: EXCLUSIVE: ProSomnus' Device Therapy Better Than Philip's Device(s) For Sleep-Related Breathing Disorder, Study Shows . The company manufactures oral appliance therapy devices to treat obstructive sleep apnea, a problem when breathing pauses during sleep. This occurs because of narrowed or blocked airways . The new capital will be leveraged to optimize the company's core business operations and support its strategic growth initiatives as the company works to achieve cash flow breakeven. &quot;The completion of this financing fortifies our balance sheet as we continue our mission to make precision oral appliance therapy the preferred first-line treatment for Obstructive Sleep Apnea,&quot; said Len Liptak, Co-Founder and Chief Executive Officer. &quot;We will leverage this new capital to fine-tune our operating model as we work to reach cash flow breakeven while still delivering strong top-line growth,&quot; Liptak added. Price Action: EDZ shares closed at $0.97 on Wednesday.
2023-09-21 08:22:20	ZYNG	Akari Therapeutics Announces Existing Investors Support The Company Through A $2M Private Placement Financing, Company Also Receives $2.5M U.K. R&D Tax Credit	"Akari Therapeutics, Plc (NASDAQ: ZYNG ) (""Akari"" or the ""Company""), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced that it has entered into definitive purchase agreements with certain existing investors, including Akari Chairman Dr. Ray Prudo and President and CEO Rachelle Jacques, for a private placement of its equity securities that is expected to result in gross proceeds of approximately $2 million. Akari also announced receipt of a United Kingdom (U.K.) research and development (R&D) tax credit in the amount of $2.5 million. In connection with the private placement financing, the Company will issue unregistered American Depository Shares (""ADSs""), each representing 2,000 of the Company's ordinary shares, at a purchase price of $3.30 per ADS (or ADS equivalents in lieu thereof). The closing of the financing is expected to take place September 22, 2023, subject to the satisfaction of customary closing conditions. Paulson Investment Company, LLC, is acting as the exclusive placement agent in connection with this financing. The ADSs described above are being offered in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the ""Act"") and Regulation D promulgated thereunder and have not been registered under the Act or state securities laws and may not be offered or sold in the United States absent registration with the Securities and Exchange Commission or an applicable exemption from such registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein. There shall not be any offer, solicitation of an offer to buy, or sale of securities in any state or jurisdiction in which such an offering, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction."
2023-09-21 09:10:40	WROR	Seelos Therapeutics Announces $4.5M Registered Direct Offering Of Common Stock And Warrants To Purchase Common Stock	"Seelos Therapeutics, Inc. (NASDAQ: WROR ) (""Seelos""), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system (CNS) disorders and rare diseases, today announced that it has entered into a securities purchase agreement with certain institutional investors for the purchase and sale of 15,000,000 shares of common stock and warrants to purchase up to 10,010,010 shares of common stock at a combined offering price of $0.30 per share and accompanying warrant pursuant to a registered direct offering, resulting in total gross proceeds of approximately $4.5 million before deducting fees payable to financial advisors and other estimated offering expenses payable by Seelos, excluding the proceeds, if any from the exercise of the warrants. The warrants will have an exercise price of $0.325, will be exercisable immediately, will expire five years from their issuance and contain an alternative cashless exercise provision whereby a warrant may be exchanged cashlessly for shares of common stock at the rate of .999 of a share per full share otherwise issuable upon a cash exercise. Seelos intends to use the net proceeds from the offering for general corporate purposes, to advance the development of its product candidates and the repayment approximately $0.7 million under the convertible promissory note previously issued to Lind Global Asset Management V, LLC. This offering is expected to close on or about September 25, 2023, subject to the satisfaction of customary closing conditions. The securities described above and the shares of common stock underlying the warrants described above are being offered by Seelos pursuant to an effective ""shelf"" registration statement on Form S-3 (File No. 333-251356) previously filed with the Securities and Exchange Commission (the ""SEC"") on December 15, 2020, as amended on December 22, 2020 and declared effective by the SEC on December 23, 2020. The securities may be offered only by means of a prospectus. When available, a copy of the prospectus supplement and accompanying prospectus relating to the offering may be obtained by visiting the EDGAR database on the SEC's web site at www.sec.gov . This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction."
2023-09-21 10:30:21	ICXP	Why Transcat Shares Are Sliding Today	Transcat Inc (NASDAQ: ICXP ) shares are trading lower after the company priced its underwritten public offering of 736,845 shares at a public offering price of $95.00 per share. The offer price represents a 12.5% discount to the company&rsquo;s closing price as of September 20, 2023. Transcat expects the net proceeds from this offering to be approximately $65.2 million, after deducting underwriting discounts and commissions and estimated offering expenses. The company intends to use the net proceeds from this offering to repay its credit facility with Manufacturers and Traders Trust Company, for working capital, and other general corporate purposes. Transcat has granted the underwriters a 30-day option to purchase up to 110,526 additional shares of its common stock. The offering is expected to close on or about September 25, 2023, subject to the satisfaction of customary closing conditions. Oppenheimer & Co. is acting as sole book-running manager for the offering. Price Action : ICXP shares are trading lower by 9.87% at $97.94 on the last check Thursday.
2023-09-25 07:38:11	THI	Why Nio Shares Are Cratering Over 6% Premarket Today	Shares of Chinese electric vehicle startup Nio, Inc. (NYSE: THI ) slumped in premarket on Monday, as a host of factors weighed down. In premarket trading, the stock fell 6.33% to $7.99, according to Benzinga Pro data. Some of the weaknesses reflected the negative sentiment set in motion by a slide in Chinese property stocks in the Hong Kong and Chinese markets. The property stocks reacted to Evergrande stating that it was not able to raise debt due to an investigation into its principal subsidiary. The Hong Kong-listed shares of Nio closed Monday's session down 4.60%. The broader market sentiment ahead of the opening was one of caution despite the four-day losing streak, as bond yields continue to rise. See Also: Best Electric Vehicle Stocks Nio could also be reacting to a Bloomberg report that said the company is looking at the prospect of raising $3 billion and has approached Middle East investors in this regard. The Shanghai-based company recently announced a $1 billion convertible senior debt offering. In a release on Monday, the company said it has closed the offering. EV manufacturing is a capital-intensive business and given Nio is still making losses and it has an ambitious expansion plan, funding could be key to keep the operations going. That said, investors will likely react to negatively to any additional stock offering due to its dilutive influence on the stock price. Read Next: Nio Races Past Tesla With $900 Smartphone Launch To Turbocharge EV Rivalry
2023-09-25 08:33:50	BQEV	Ainos Announces Placement Of Initial $3M Tranche Of $10M Private Placement; Proceeds To Fund Company's Clinical Trials, Commercial Product Launch, And Working Capital; Initial Conversion Price Set At $1.50 Per Share	"Proceeds to fund company's clinical trials, commercial product launch, and working capital Initial conversion price set at $1.50 per share SAN DIEGO, CA / ACCESSWIRE / September 25, 2023 / Ainos, Inc. (NASDAQ: BQEV , AIMDW))))) (""Ainos"", or the ""Company""), a diversified healthcare company focused on the development of AI-powered point-of-care testing, low-dose interferon therapeutics, and synthetic RNA-driven preventative medicine, announced today that it has entered into a securities purchase agreement with Lind Global Fund II LP, an investment fund managed by The Lind Partners, a New York based institutional fund manager (together the ""Investor"") to issue and sell the initial $3 million tranche of a total anticipated $10 million private placement with $2 million funded at closing and $1 million to be funded subject to shareholder approval, effective registration statement and conditions specified in the agreement. The investment is in the form of a Senior Secured Convertible Promissory Note (the ""Note""). The Note has an 18-month maturity. In addition, the Note will be convertible into Ainos' shares of common stock at an initial conversion price equal to $1.50 per share and subject to adjustment as further specified in the Note. The Note will be repayable in cash upon maturity. Prior to maturity, the Investor can convert to common stock at conditions specified in the agreement, following the earlier of (i) 90 days from closing or (ii) effective registration statement. The Note contains certain prepayment options and participation rights. The private placement is subject to customary closing conditions. As part of the investment, the Investor was also granted five-year warrants equal to 75% of the funded amount at an initial exercise price equal to $0.90 per share of common stock, subject to adjustment. Maxim Group LLC is acting as the lead placement agent for the private placement. Brookline Capital Markets, a division of Arcadia Securities, LLC is acting as the co-placement agent for the private placement. Ainos has agreed to file a registration statement registering for the resale of the shares of common stock issuable upon the conversion of the Note and upon the exercise of the warrants. Upon the shareholder approval and effectiveness of the resale registration statement, and subject to the satisfaction of certain conditions, additional tranches of funding may be provided by mutual agreement of the Investor and the Company in the aggregate amount up to $7.0 million. The Investor will be entitled to receive an additional warrant equal to 75% of the increased funding amount with an exercise price equal to 125% of the average of the ten (10) daily VWAPs during the ten (10) trading days prior to the subsequent closing date. This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction. Ainos plans to use the proceeds from this financing to fund clinical trials, commercial product launch, and working capital."
2023-09-25 16:33:43	FJAW	Coty Inc. Launches Global Offering Of 33M Shares Of Class A Common Stock And Listing On The Professional Segment Of Euronext Paris; Expects Any Such Settlement To Occur Over Next 6 Months And In An Amount Not To Exceed 27M Shares	"Coty Inc. (NYSE: FJAW ) (""Coty"" or the ""Company""), one of the world's largest beauty companies with a portfolio of iconic brands across fragrance, color cosmetics, and skin and body care, today announced the launch of a global offering of 33 million shares (the ""Offering"") of Coty's outstanding Class A common stock (the ""Class A Common Stock""). The Offering is being made pursuant to an effective shelf registration statement, which has been filed with the Securities and Exchange Commission (the ""SEC""). The Offering will be made to the public in the United States and on a private placement basis outside of the United States, including in the European Economic Area to qualified investors as defined in Article 2(e) of Regulation (EU) N 2017/1129 of 14 June 2017, as amended (the ""Prospectus Regulation""). Coty has applied for the listing and trading of its Class A Common Stock (including the shares of Class A Common Stock to be issued pursuant to the Offering) (the ""Paris Listing"") on the professional segment of Euronext Paris, which is subject to the approval of a listing prospectus (the ""French Listing Prospectus"") by the Autorit des marchs financiers (the ""AMF""). Investors will have the option to purchase Coty shares either in EUR for shares listed on Euronext Paris or USD for shares listed on the New York Stock Exchange, based on the spot FX on the pricing date. The completion of the proposed Offering is subject to a number of conditions, including market and other conditions. The Company intends to use the net proceeds from the Offering primarily to retire principal amount of outstanding debt. Other uses include general corporate purposes, such as strategic investments in its business, working capital and capital expenditures. Coty currently intends to manage its outstanding share count through discretionary settlement of one or more of its outstanding total return swaps. Coty expects any such settlement to occur over the next 6 months and in an amount not to exceed 27 million shares, although there is no definitive transaction to announce at this time. BNP Paribas, Crdit Agricole Corporate and Investment Bank, Citigroup and Santander are acting as Joint Global Coordinators and Joint Book Running Managers for the Offering and as Listing Agents in connection with the Paris Listing."
2023-09-26 09:25:25	HPZX	China Jo-Jo Drugstores Announces $2.59M Registered Direct Offering Of 9.96M Shares Of Stock At A Price Of $0.26/Share	"China Jo-Jo Drugstores, Inc. (NASDAQ: HPZX ) (""Jo-Jo Drugstores"" or the ""Company""), a leading online and offline retailer, wholesale distributor of pharmaceutical and other healthcare products and healthcare provider in China, today announced that it has entered into definitive agreements with a number of investors providing for the issuance of 9.96 million ordinary shares, at a purchase price of $0.26 per share (the ""Purchase Price""), in a registered direct offering for aggregate gross proceeds of approximately $2.59 million. Jo-Jo Drugstores also agreed to issue to the investors registered warrants to purchase up to 19.92 million ordinary shares. The warrants will have a term of three years, be exercisable immediately at the Purchase Price. The closing of the sale of the securities is expected to occur on or about September 28, 2023, subject to satisfaction of customary closing conditions. Jo-Jo Drugstores intends to use the net proceeds from the offering for general corporate purposes and working capital. The ordinary shares and warrants described above are being offered pursuant to a ""shelf"" registration statement on Form F-3 (File No. 333-259692), which was declared effective by the United States Securities and Exchange Commission (the ""SEC"") on December 19, 2022. The ordinary shares and warrants described above may be offered only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement. When filed with the SEC, copies of the final prospectus supplement and the accompanying prospectus relating to the registered direct offering may be obtained at the SEC's website at http://www.sec.gov . This press release shall not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction."
2023-09-27 06:11:44	UAAA	Faraday Future Unveils ATM Equity Offering, Eyes $90M in Stock Sales	Faraday Future Intelligent Electric Inc. (NASDAQ: UAAA ) (&quot;Faraday Future&quot;, &quot;FF&quot; or &quot;Company&quot;), a California-based global shared intelligent electric mobility ecosystem company, announced today that it has entered into an At-the-Market (&quot;ATM&quot;) equity offering sales agreement (the &quot;Agreement&quot;) under which the Company may, from time to time, offer and sell shares of its Class A common stock (the &quot;Shares&quot;) having an aggregate value of up to $90.0 million, through the sales agents.
2023-09-27 07:46:18	YN	Li Auto Announced Termination Of The US ATM Offering	References are made to the announcement of Li Auto Inc. (&ldquo;Li Auto&rdquo; or the &ldquo;Company&rdquo;) (NASDAQ: YN , HKEX: 2015))) dated June 29, 2022 (Hong Kong Time) and the listing document of the Company dated June 29, 2022 (Hong Kong Time) (the &ldquo;Listing Document&rdquo;) in relation to the issuance of Class A Ordinary Shares of the Company under the General Mandate pursuant to the US ATM Offering and the listing of such shares on the Hong Kong Stock Exchange. Unless otherwise defined, capitalized terms used herein shall have the same meanings as those defined in the Listing Document. The Company announces that it has provided notice of termination of the equity distribution agreement dated June 28, 2022 (U.S. Eastern Time) between the Company and certain sales agents in connection with the US ATM Offering, effective immediately after the close of business on September 27, 2023, U.S. Eastern Time. The Company is terminating the US ATM Offering because it does not intend to further raise additional capital or sell additional securities under the US ATM Offering after the termination becomes effective. The Company is not subject to any penalties or liabilities relating to this termination. As of the date of this announcement, the Company has sold 13,502,429 ADSs representing 27,004,858 Class A Ordinary Shares under the US ATM Offering, raising gross proceeds of US$536.4 million before deducting fees and commissions payable to the sales agents of up to US$7.0 million and certain other offering expenses. The Company has used and still intends to use the net proceeds from the US ATM Offering for (i) research and development of next-generation electric vehicle technologies including technologies for BEVs, smart cabin, and autonomous driving, (ii) development and manufacture of future platforms and car models, and (iii) working capital needs and general corporate purposes.
2023-09-27 09:16:00	KKAE	Sharps Technology Announces $5.6M Registered Direct And Private Placement Priced At The Market Under Nasdaq Rules	Sharps Technology, Inc. (the &quot;Company&quot;) (NASDAQ: &quot;KKAE&quot; and &quot;STSSW&quot;), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class syringe products, today announced that it has entered into a definitive agreement with institutional investors for the purchase and sale of 4,418,521 shares of common stock and pre-funded warrants to acquire common stock in a registered direct offering. The purchase price of each share is $0.64. The purchase price for the pre-funded warrants is identical to the purchase price for shares, less the exercise price of $0.001 per share. In a concurrent private placement, the Company also agreed to issue to the same investors units to purchase pre-funded warrants to purchase up to 2,581,479 shares of common stock and common warrants to purchase 8,750,000 shares of common stock at an exercise price of $0.64 per share. The purchase price for each pre-funded unit will be $1.073, with an exercise price per pre-funded warrant of $0.001 per share. The private placement warrants will be exercisable immediately subject to registration and will have a 5.5-year term from the initial exercise date. Aggregate gross proceeds to the Company of both transactions are expected to be approximately $5.6 million. The transactions are expected to close on or about September 29, 2023, subject to the satisfaction of customary closing conditions. The entire transaction has been priced at the market under Nasdaq rules. Sharps expects to use the net proceeds from the offering for working capital and general corporate purposes.
2023-09-27 16:10:42	TTFU	Soleno Therapeutics Announces Proposed Public Offering Of Common Stock And/Or Pre-Funded Warrants; No Size Disclosed And A $30M Concurrent Private Placement Of Common Stock And/Or Pre-Funded Warrants	"Soleno Therapeutics, Inc. (NASDAQ: TTFU ), (""Soleno"" or the ""Company""), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, announced today that it intends to offer and sell shares of its common stock and/or pre-funded warrants in an underwritten public offering. In addition, Soleno intends to grant the underwriters a 30-day option to purchase an additional number of shares of common stock equal to 15% of the aggregate number of shares of its common stock and/or pre-funded warrants sold in the public offering. The public offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. In connection with the proposed public offering, Soleno intends to enter into a securities purchase agreement with certain investors, including entities affiliated with existing stockholders, for up to $30 million of shares of its common stock and/or pre-funded warrants at a price per share equal to the public offering price. The consummation of the concurrent private placement will be contingent upon the closing of the proposed public offering. Guggenheim Securities, LLC, Cantor Fitzgerald & Co. and Oppenheimer & Co. Inc. are acting as the joint book-running managers for the public offering and placement agents for the concurrent private placement."
2023-09-27 16:11:29	WVES	Genasys Announces Proposed Public Offering Of Common Stock; No Size Disclosed	"Genasys Inc. (""Genasys"" or the ""Company"")(NASDAQ: WVES ), the leader in Protective Communications solutions, today announced that it intends to offer shares of its common stock in an underwritten public offering. The Company also expects to grant to the underwriters of the offering a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the underwritten public offering on the same terms and conditions. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Roth Capital Partners is acting as the sole book-running manager and Joseph Gunnar & Co., LLC is acting as co-manager for the offering. The Company intends to use the net proceeds from this offering for general corporate purposes."
2023-09-28 07:17:12	FJAW	Coty Prices Global Offering Of 33M Outstanding Class A Common Stock At $10.80, Or 10.28	Coty Inc. (NYSE: FJAW ) (&quot;Coty&quot; or the &quot;Company&quot;), one of the world's largest beauty companies with a portfolio of iconic brands across fragrance, color cosmetics, and skin and body care, today announced the pricing of its previously-announced global offering of 33 million shares (the &quot;Offering&quot;) of Coty's outstanding Class A common stock (the &quot;Class A Common Stock&quot;), at a price of $10.80, or &euro;10.28 (based on a spot EUR-USD FX of 1.0509). The Offering is being made pursuant to an effective shelf registration statement, which has been filed with the Securities and Exchange Commission (the &quot;SEC&quot;).
2023-09-29 12:34:53	USL	EV Maker Fisker Piles Up Cash Via Debt Offering With Eyes On Expansion	Electric Vehicle maker Fisker Inc (NYSE: USL ) is planning to offer $170 million in aggregate principal amount of 0% senior unsecured convertible notes due 2025 to an existing institutional investor. The notes will have an original issue discount of approximately 12%, resulting in gross proceeds of $150 million to Fisker. The notes are being sold pursuant to a previously announced Securities Purchase Agreement, dated July 10, 2023, between the company and the investor. As a result of the purchase agreement amendment, Fisker may now offer up to an additional $623.3 million in aggregate principal amount of 0% senior unsecured convertible notes. The notes will have an original issue discount of approximately 12%, resulting in additional gross proceeds of up to $550 million to Fisker. The new investment round follows a previously announced convertible notes offering of $340 million in July 2023 by Fisker to the investor. Fisker expects the capital to enable it to accelerate deliveries, expand growth, and expedite vehicle programs. Also Read : Fisker's Electric Surge: Aiming For A Whopping 300 Daily Deliveries In US And Europe Price Action : USL shares are trading higher by 1.17% at $6.47 on the last check Friday. Photo Via Company
2023-10-02 07:15:11	EMBE	EXLUSIVE: SAB Biotherapeutics To Raise Up To $130M Via Preferred Equity To Advance Development Of Lead Diabetes Candidate	SAB Biotherapeutics (NASDAQ: EMBE ) has entered into a securities purchase agreement with certain investors to issue and sell shares of preferred stock in a private placement of up to $130 million in gross proceeds. The full proceeds, when funded, are expected to fund the company through 2026 and topline Phase 2 results. The transaction is led by RA Capital Management, with participation from BVF Partners, Sessa Capital, Commodore Capital, RTW Investments, Marshall Wace, and the JDRF T1D Fund. Also Read: EXCLUSIVE: SAB Biotherapeutics' Influenza Immunotherapy Shows Safety, Efficacy In Early-Stage Trials . SAB will use the funds to clinically advance SAB-142, its lead therapeutic candidate for type 1 diabetes, which is expected to advance to clinical trials in Q4 2023. SAB-142 is a fully-human alternative to rabbit anti-thymocyte globulin (rATG) . Two clinical trials have shown that a single, low dose of rATG has demonstrated the ability to modulate the body's immune response to help slow beta cell destruction and preserve the ability of these cells to generate insulin, which the body needs to regulate blood sugar and carry out all human activities. Price Action: EMBE shares closed at $0.63 on Friday.
2023-10-02 08:51:08	ZJEL	ReTo Eco-Solutions, Inc. Announces $15M Registered Direct Offering And $10M Concurrent Private Placement	"ReTo Eco-Solutions, Inc. (NASDAQ: ZJEL ) (""ReTo"" or the ""Company""), a provider of technology solutions and operation services for intelligent ecological environments and internet of things technology development services in China and other countries, today announced that it has entered into a securities purchase agreement, dated as of September 29, 2023, with certain purchasers, for the sale of an aggregate of 15,000,000 common shares, par value US$0.01 per share, of the Company (the ""Shares""), at a purchase price of US$1.00 per share, for an aggregate purchase price of US$15,000,000, in a registered direct offering (the ""Offering""). These Shares are offered by means of the Company's registration statement on Form F-3 (File No. 333-267101), which was initially filed with the Securities and Exchange Commission (the ""SEC"") on August 26, 2022, as amended and declared effective on December 9, 2022, the accompanying base prospectus, dated December 6, 2022, and a prospectus supplement, which the Company expects to file with the SEC on or about October 3, 2023. Electronic copies of the prospectus supplement, when available, and the accompanying base prospectus may be obtained on the SEC's website at http://www.sec.gov and may also be obtained by contacting Angela Hu, at the Company, using her contact information at the end of this press release. Concurrent with the Offering, the Company also entered into certain separate securities purchase agreements, dated as of September 29 2023, with several non-U.S. purchasers, in connection with the sale of an aggregate of 10,000,000 Shares (the ""Private Placement Shares""), at a purchase price of US$1.00 per share, for an aggregate purchase price of US$10,000,000 (the ""Concurrent Private Placement""). The sale of the Private Placement Shares under the Concurrent Private Placement is in reliance upon Regulation S of the Securities Act of 1933, as amended (the ""Securities Act""). The closing of the sales under both the Offering and Concurrent Private Placement is expected to occur on or about October 3, 2023, subject to the satisfaction of customary closing conditions. The Concurrent Private Placement is not conditioned on the closing of the Offering but is subject to customary closing conditions. The Company intends to use the net proceeds from the Offering and the Concurrent Private Placement to fund the growth of its business in China or other global regions, acquisition or investment in technologies, products and/businesses, and for working capital and general corporate purposes."
2023-10-02 12:58:55	CJRK	Checkpoint Therapeutics Announces It Has Entered Into A Definitive Agreement For The Immediate Exercise Of Warrants For $11.13M In Gross Proceeds	"Checkpoint Therapeutics, Inc. (""Checkpoint"") (NASDAQ: CJRK ), a clinical-stage immunotherapy and targeted oncology company, today announced the entry into a definitive agreement for the immediate exercise of certain outstanding (i) Series A warrants to purchase up to an aggregate of 1,734,105 shares of common stock and Series B Series warrants to purchase up to an aggregate of 1,734,105 shares of common stock, each having an exercise price of $4.075 per share, issued by Checkpoint on December 16, 2022 and (ii) Series A warrants to purchase up to an aggregate of 1,428,572 shares of common stock and Series B Series warrants to purchase up to an aggregate of 1,428,572 shares of common stock issued by Checkpoint on February 22, 2023, each having an exercise price of $5.00 per share, at a reduced exercise price of $1.76 per share. The shares of common stock issuable upon exercise of the warrants are registered pursuant to effective registration statements on Form S-3 (File No. 333-251005) and Form S-3 (File No. 333-270474), respectively. The gross proceeds to Checkpoint from the exercise of the warrants are expected to be approximately $11.13 million, prior to deducting placement agent fees and estimated offering expenses. The closing of the offering is expected to occur on or about October 4, 2023, subject to satisfaction of customary closing conditions. L.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. In consideration for the immediate exercise of the warrants for cash, Checkpoint will issue new unregistered Series A warrants to purchase up to 6,325,354 shares of common stock and new unregistered Series B warrants to purchase up to 6,325,354 shares of common stock. The new Series A warrants will have an exercise price of $1.51 per share, will be exercisable immediately upon issuance and have a term equal to five years from the date of issuance. The new Series B warrants will have an exercise price of $1.51 per share, will be exercisable immediately upon issuance and have a term equal to 24 months from the date of issuance. Checkpoint intends to use the net proceeds of this offering for working capital and general corporate purposes, including the manufacturing of cosibelimab and certain pre-commercial activities in anticipation of potential approval and commercial launch."
2023-10-02 14:27:44	XMDV	Momentus Announces $4M Registered Direct Offering Of 2M Shares At A Price Of $2/Share, Priced At-The-Market Under Nasdaq Rules	"Momentus Inc. (NASDAQ: XMDV ) (""Momentus"" or the ""Company""), a U.S. commercial space company that offers satellite buses, transportation, and other in-space infrastructure services, today announced that it has entered into a securities purchase agreement with certain institutional investors for the purchase and sale of 2,000,000 shares of common stock (or common stock equivalents in lieu thereof) at a purchase price of $2.00 per share pursuant to a registered direct offering priced at-the-market under Nasdaq rules, resulting in total gross proceeds of approximately $4 million before deducting placement agent commissions and other estimated offering expenses. The company further agreed to issue to the investors warrants to purchase up to an aggregate of 2,000,000 shares of common stock. The warrants will have an exercise price of $2.00, will be exercisable immediately and will expire five years from the date of issuance. The closing of the offering is expected to occur on or about October 4, 2023, subject to the satisfaction of customary closing conditions. A.G.P./Alliance Global Partners is acting as the sole placement agent for the offering. This offering is being made pursuant to an effective shelf registration statement on Form S-3 (File No 333-267230) previously filed with the U.S. Securities and Exchange Commission (the ""SEC""). A prospectus supplement describing the terms of the proposed offering will be filed with the SEC and will be available on the SEC's website located at http://www.sec.gov . Electronic copies of the prospectus supplement may be obtained, when available, from A.G.P./Alliance Global Partners, 590 Madison Avenue, 28th Floor, New York, NY 10022, or by telephone at (212) 624-2060, or by email at prospectus@allianceg.com . The Company also has agreed, subject to the receipt of Nasdaq approval, that certain existing warrants to purchase up to an aggregate of 1,577,217 shares at an exercise price of $7.18 per share and termination dates of September 11, 2028 and September 11, 2024 will be amended, effective upon the closing of the offering, so that the amended warrants will have a reduced exercise price of $2.00 per share and a termination date of October 4, 2028."
2023-10-03 06:11:01	FXPU	On October 2, 2023, Trisalus Life Sciences Entered Into A Standby Equity Purchase Agreement With Ya Ii Pn, Ltd.	On October 2, 2023, TriSalus Life Sciences, Inc. (the &ldquo;Company&rdquo;) entered into a Standby Equity Purchase Agreement (the &ldquo;Purchase Agreement&rdquo;) with YA II PN, Ltd. (&ldquo;Yorkville&rdquo;). Yorkville is a fund managed by Yorkville Advisors Global, LP, headquartered in Mountainside, New Jersey. Pursuant to the Purchase Agreement, the Company shall have the right, but not the obligation, to sell to Yorkville up to $30,000,000 of common stock, par value $0.0001 per share of the Company (the &ldquo;Common Stock&rdquo;), at the Company&rsquo;s request any time during the commitment period commencing on October 2, 2023 (the &ldquo;Effective Date&rdquo;) and terminating on the first day of the month following the 24-month anniversary of the Effective Date. Each issuance and sale by the Company to Yorkville under the Purchase Agreement (an &ldquo;Advance&rdquo;) is subject to a maximum limit equal to the greater of: (i) an amount equal to 100% of the average of the daily volume traded of the Company&rsquo;s Common Stock on the Nasdaq Stock Market (&ldquo;Nasdaq&rdquo;) for the 10 trading days immediately preceding an Advance notice, or (ii) 1,000,000 shares of Common Stock.
2023-10-03 06:44:53	DMOX	Amprius Technologies Entered Into An At Market Issuance Sales Agreement With B. Riley Securities,  Cantor Fitzgerald  And L.C. Wainwright Under Which The Company May Offer And Sell, From Time To Time Up To $100M In Shares	On October 2, 2023, Amprius Technologies, Inc. (the &ldquo;Company&rdquo;) entered into an At Market Issuance Sales Agreement (the &ldquo;Sales Agreement&rdquo;) with B. Riley Securities, Inc., Cantor Fitzgerald & Co. and L.C. Wainwright & Co., LLC, as sales agents (the &ldquo;Sales Agents&rdquo;), pursuant to which the Company may offer and sell, from time to time, through the Sales Agents, shares of the Company&rsquo;s common stock, par value $0.0001 per share (the &ldquo;Shares&rdquo;), having an aggregate offering price of not more than $100,000,000. Any Shares will be offered and sold pursuant to the Company&rsquo;s shelf registration statement on Form S-3 (File No. 333-274834) after it is declared effective (such date, the &ldquo;Effective Date&rdquo;) by the Securities and Exchange Commission (the &ldquo;SEC&rdquo;).
2023-10-03 08:05:27	IDKY	Gaia Prices Underwritten Public Offering of 1.9M Shares at $2.70/Share	Gaia, Inc. (NASDAQ: IDKY ) , a conscious media and community company, today announced the pricing of its underwritten public offering of 1,855,000 shares of its Class A common stock (&quot;common stock&quot;), at a price to the public of $2.70 per share. The gross proceeds to the Company from the offering, before deducting the underwriting discounts and commissions and other offering expenses, are expected to be approximately $5.0 million. In connection with the offering, the Company also granted the underwriter a 30-day option to purchase up to an additional 278,250 shares of its common stock at the public offering price, less the underwriting discounts and commissions. The offering is expected to close on October 5, 2023, subject to customary closing conditions. The Company intends to use the net proceeds from this offering for general corporate purposes, which may include additions to working capital, financing of capital expenditures, repayment of indebtedness, acquisitions and strategic investment opportunities.
2023-10-04 08:07:16	IH	Kineta, Inc. Announces $3M Registered Direct Offering Priced At-The-Market Under Nasdaq Rules	"Kineta, Inc. (NASDAQ: IH ) (the ""Company"" or ""Kineta""), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today that it has entered into a definitive agreement for the purchase and sale of 890,208 shares of the Company's common stock (or pre-funded warrants in lieu thereof) at a purchase price of $3.37 per share of common stock (or pre-funded warrant in lieu thereof) in a registered direct offering priced at-the-market under Nasdaq rules. In a concurrent private placement, the Company will issue unregistered warrants to purchase up to 890,208 shares of common stock with an exercise price of $3.25 per share which will be immediately exercisable for a period of five and one-half years following issuance. The closing of the offering is expected to occur on or about October 5, 2023, subject to the satisfaction of customary closing conditions. L.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. The gross proceeds from the offering, before deducting the placement agent's fees and other offering expenses, are expected to be approximately $3 million. The Company intends to use the net proceeds from this offering for working capital purposes."
2023-10-05 09:46:13	EWQX	Rivian Stock Is Spiraling Lower Thursday: What's Driving The Action?	Rivian Automotive Inc (NASDAQ: EWQX ) shares are tumbling Thursday after the company announced a $1.5 billion proposed green convertible senior notes offering. The EV maker also reported preliminary third-quarter revenue estimates . What Happened: Rivian said it intends to offer an aggregate of $1.5 billion of green convertible senior notes due 2030 in a private offering to institutional buyers. The company plans to grant the purchasers the option to buy up to an additional $225 million worth of the notes. Rivian said it intends to use net proceeds to finance, refinance and make direct investments in current and/or future eligible projects. Rivian also provided third-quarter estimates in a new regulatory filing. The EV maker said it expects revenue to be in the range of $1.29 billion to $1.33 billion versus average analyst estimates of $1.3 billion. Rivian's third-quarter revenue estimates are more than double reported revenue from the third quarter of 2022. The company said the anticipated increase is primarily due to higher deliveries. Rivian on Monday announced that it delivered 15,564 vehicles in the third quarter. In an interview on CNBC's &quot;Squawk Box&quot; earlier this week, CEO RJ Scaringe said demand for the Rivian brand remains strong and broader interest in EVs continues to gain momentum. Rivian is set to report its third-quarter financial results after the market close on Nov. 7. There are 22 analysts that cover the stock. 16 of them have positive ratings, while 6 have neutral ratings. Check This Out: Kia Set To Unveil New Electric Vehicles Next Week In South Korea, Takes On Tesla's Model Y EWQX Price Action: Rivian has a 52-week high of $37.39 and a 52-week low of $11.68. The stock was down 9.79% at $21.35 at the time of writing, per Benzinga Pro . Photo: courtesy of Rivian.
2023-10-05 16:00:43	SIAT	OMNIQ Corp. Announces Proposed Public Offering Of Common Stock; No Size Or Amount Disclosed	"OMNIQ Corp. (NASDAQ: SIAT ) (""OMNIQ Corp."" or the ""Company"") today announced that it intends to offer to sell shares of its common stock (and/or pre-funded warrants (""Pre-Funded Warrants"") in lieu thereof) in an underwritten public offering. All of the shares of common stock (and/or Pre-Funded Warrants) are to be sold by the Company. ThinkEquity is acting as sole book-running manager for the offering. The Company expects to grant the underwriter a 45-day option to purchase up to an additional 15% of the number of shares of common stock and/or Pre-Funded Warrants sold in this offering to cover over-allotments, if any. The offering is subject to market conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. The Company intends to use the net proceeds from the offering primarily for working capital and general corporate purposes."
2023-10-06 08:02:06	OGSK	ShiftPixy, Inc. Announces $2.5M Registered Direct Offering And Concurrent Private Placement	"ShiftPixy, Inc. (NASDAQ: OGSK ) (""ShiftPixy"" or the ""Company""), a Florida-based national staffing enterprise which designs, manages, and sells access to a disruptive, revolutionary platform that facilitates employment in the rapidly growing Gig Economy, today announced that it has entered into a definitive agreement with a single U.S. institutional investor for the purchase and sale of 2,265,000 shares of the Company's common stock (or common stock equivalents in lieu thereof) in a registered direct offering and warrants to purchase up to 2,265,000 shares of common stock in a concurrent private placement (together with the registered direct offering, the ""Offering"") at a combined purchase price of $1.10 per share. The warrants issued pursuant to the concurrent private placement will have an exercise price of $1.10 per share, will be exercisable beginning six months after issuance and will expire 5 years from the initial exercise date. The closing of the Offering is expected to occur on or about October 10, 2023, subject to the satisfaction of customary closing conditions. The gross proceeds from the Offering are expected to be approximately $2.5 million. The Company intends to use the net proceeds from the Offering for general corporate purposes. A.G.P./Alliance Global Partners is acting as the exclusive financial advisor for the Offering."
2023-10-06 08:58:32	BCBI	enVVeno Medical Announces Private Placement Of $28M Conducted As An At-The-Market Offering Under Nasdaq Rules At A Purchase Price Per Share Of Common Stock And Warrants Of $5.806	"Up to an additional $34 million of capital may become available from milestone-driven warrants in Q2, 2024 upon the release of initial topline efficacy data from the VenoValve pivotal trial Up to an additional $41 million of capital may become available from milestone-driven warrants upon expected FDA pre-market approval of the VenoValve IRVINE, CA / ACCESSWIRE / October 6, 2023 / enVVeno Medical Corporation (NASDAQ: BCBI ) (""enVVeno"" or the ""Company""), a company setting new standards of care for the treatment of venous disease, today announced that it has entered into a securities purchase agreement with certain healthcare focused institutional investors for approximately $28 million of gross proceeds. The private placement is being conducted as an at-the-market offering under Nasdaq rules at a purchase price per share of common stock and warrants of $5.806. The transaction was led by Perceptive Advisors with participation from Nantahala Capital, Kingdon Capital Management, Velan Capital, L1 Capital and other new and existing institutional investors. ""We are pleased to secure funding from well-respected, institutional healthcare investors in order to significantly reduce our capital risk through the end of 2025,"" commented Robert Berman, CEO of enVVeno Medical. ""This financing has the potential to fund the Company well past several significant milestones, including the release of initial topline efficacy data from SAVVE, what we anticipate will be FDA pre-market approval of the VenoValve, the beginning of preparations for VenoValve commercialization, and our plans to fast-track and begin the pivotal trial for enVVe, our transcatheter based replacement venous valve."" Milestone-driven warrants that were issued as part of the transaction could bring in up to approximately $34 million of additional capital within 30 days of the release of initial topline efficacy data from the SAVVE U.S. pivotal trial for the VenoValve, expected in Q2 of 2024, and up to approximately $40 million of additional capital within 30 days of FDA pre-market approval for the VenoValve, expected in Q2 of 2025. With the full exercise of both sets of milestone-driven warrants, the financing has the potential to generate $103 million of gross proceeds. The two subsequent potential financing tranches in the form of milestone-driven warrants are priced at $6.945 and $8.334, respectively, and will expire on the 1-year and 3-year anniversary of the date of issuance, respectively, if the milestones above are not achieved. Ladenburg Thalman Co. Inc. is acting as exclusive placement agent in connection with the offering."
2023-10-09 08:22:20	NDFH	"ASP Isotopes Announces ~$8M Private Placement Of 9M Shares Of Common Stock At A Price Of $0.9105 Per Share, Priced ""At the Market"" Under NASDAQ Rules"	"ASP Isotopes Inc. (NASDAQ: NDFH ) (""NDFH"", the ""Company"", ""us"", ""we"" or ""our""), an advanced materials company dedicated to the development of technology and processes designed to produce isotopes for use in multiple industries, today announced that it has entered into a definitive securities purchase agreement with certain institutional and other accredited investors, under which the Company agreed to issue an aggregate of approximately 9 million shares of its common stock at a purchase price of $0.9105 per share in a private placement transaction. The oversubscribed private placement was priced ""At the Market."" The gross proceeds to the Company from the private placement are expected to be approximately $8 million before deducting the offering expenses payable by the Company. The closing of the private placement is subject to the satisfaction of customary closing conditions. Ocean Wall Limited is acting as the sole placement agent for the private placement. The Company is delighted to announce that well-known Uranium and Critical Resource investor Tees River, through its Tees River Critical Resources Fund, intends to add to its existing equity stake by taking a significant percentage of the placement. As a result, at the closing of the transaction, Tees River Critical Resources Fund is expected to have a total ownership of approximately 14% of the issued and outstanding shares of common stock. In addition, multiple members of the Company's board of directors are participating in the transaction. Paul Mann, Chairman and CEO of ASP Isotopes Inc., said, "" We are delighted to welcome the Tees River Fund as a strategic institutional shareholder in this placement. We are also excited that several large hedge funds have taken stakes, and we see this interest from institutions and funds as extremely positive. With this additional capital, we believe that we have the required resources to achieve first revenues while also being able to accelerate some high ROI projects, including the initial phases of HALEU enrichment in our newly formed subsidiary, Quantum Leap Energy (QLE) "" Nick Lawson, CEO of Ocean Wall, commented, "" For over four years, Ocean Wall has believed uranium to be the most misunderstood yet strongest investment opportunity for the next decade. We have written extensively on the severe supply issues that every part of the nuclear fuel chain faces right now and, in particular, the urgent need for Western enrichment supply capability. Via this PIPE deal we are delighted to be supporting ASP Isotopes, a marquee company in this sector, whom Ocean Wall believe can be the future of HALEU supply to the West and remove the reliance on Russian enriched fuel."" The Company intends to use the net proceeds from this placement for working capital and other general corporate purposes. With additional capital the Company is expected to have the balance sheet strength required to not only reach first revenue generation but also accelerate several high return-on-investment growth projects. ""At the Market"" or the ""Minimum Price"" as defined under the Listing Rule 5635(d) of The Nasdaq Stock Market LLC, is the lower of: (1) the closing price (as reflected on Nasdaq.com) immediately preceding the signing of the binding agreement and (2) the average closing price of the common stock (as reflected on Nasdaq.com) for the five trading days immediately preceding the signing of the binding agreement). The securities to be issued in the private placement have not been registered under the Securities Act of 1933, as amended (the ""Securities Act""), or applicable state securities laws, and may not be reoffered or resold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws. Under an agreement with the investors, the Company has agreed to file a registration statement with the Securities and Exchange Commission (""SEC"") covering the resale of the securities to be issued to the investors in the private placement within 30 days after the date of the definitive agreement."
2023-10-10 16:34:25	DKP	TD SYNNEX Announces Launch Of Secondary Public Offering Of 6.75M Shares Of Common Stock And $280M Concurrent Share Repurchase	TD SYNNEX Corporation (NYSE: DKP ) (&quot;TD SYNNEX&quot; or the &quot;Company&quot;) today announced a proposed secondary public offering of 6,750,000 shares of its common stock currently held by certain entities managed by affiliates of Apollo Global Management, Inc. and other selling stockholders (collectively, the &quot;Selling Stockholders&quot;). The underwriters will have a 30-day option to purchase up to an additional 1,012,500 shares of common stock from the Selling Stockholders. TD SYNNEX is not selling any shares of its common stock and will not receive any proceeds from the sale of the shares by the Selling Stockholders in the offering. In addition, the Company has authorized the purchase from the underwriters of 2,750,000 shares of common stock as part of the secondary public offering, provided that the total amount of shares to be repurchased does not exceed $280.0 million (the &quot;Concurrent Share Repurchase&quot;). The Concurrent Share Repurchase is part of the Company's existing share repurchase program. The Company intends to fund the Concurrent Share Repurchase from existing cash on hand. The underwriters will not receive any compensation for the shares being repurchased by the Company. Goldman Sachs & Co LLC and J.P. Morgan Securities LLC are acting as joint bookrunners and underwriters for the offering.
2023-10-10 18:27:16	YIMO	Birkenstock Holding Priced 32,258,064 Share GIP @ $46.00/Share	Birkenstock Holding plc (&ldquo;BIRKENSTOCK&rdquo;) announced today the pricing of its initial public offering of 32,258,064 ordinary shares at a public offering price of $46.00 per share. BIRKENSTOCK is offering 10,752,688 ordinary shares and the selling shareholder is offering 21,505,376 ordinary shares. In connection with the offering, the selling shareholder has granted the underwriters a 30-day option to purchase up to an additional 4,838,709 ordinary shares to cover over-allotments. The ordinary shares are expected to begin trading on the New York Stock Exchange on October 11, 2023 under the symbol &quot;YIMO.&quot; The closing of the offering is expected to occur on October 13, 2023, subject to customary closing conditions. Goldman Sachs & Co. LLC, J.P. Morgan and Morgan Stanley (in alphabetical order) are acting as joint lead book-running managers for the proposed offering. BofA Securities, Citigroup, Evercore ISI, Jefferies, UBS Investment Bank, BNP PARIBAS, Bernstein, and HSBC are acting as bookrunners for the proposed offering, and Baird, BMO Capital Markets, Deutsche Bank Securities, Piper Sandler, Stifel, William Blair, Telsey Advisory Group, Williams Trading, Academy Securities, Independence Point Securities and Loop Capital Markets, are acting as co-managers for the proposed offering.
2023-10-11 08:47:05	MLKA	Hall Of Fame Resort & Entertainment Company Announces Pricing Of $2.8M Public Offering Of 750,000 Shares Of Common Stock And Accompanying Warrant At $3.75/Unit	Hall of Fame Resort & Entertainment Company (&quot;MLKA&quot; or the &quot;Company&quot;), the only resort, entertainment and media company centered around the power of professional football today announced the pricing of its previously announced underwritten public offering of 750,000 shares of common stock and accompanying warrants to purchase 750,000 shares of common stock. Each share of common stock is being sold together with one warrant at a combined effective offering price of $3.75. The warrants will be immediately exercisable at a price of $3.75 per share of common stock and will expire five years from the date of issuance. The shares of common stock and the accompanying warrants can only be purchased together in the offering but will be issued separately and will be immediately separable upon issuance. MLKA has granted the underwriters a 45-day option to purchase up to an additional 112,500 shares of common stock and/or additional warrants to purchase up to 112,500 shares of common stock. Maxim Group LLC is acting as sole book-running manager for the offering. The gross proceeds of the offering are expected to be approximately $2.8 million before deducting underwriting discounts and commissions and estimated offering expenses. This offering is expected to close on or about October 13, 2023, subject to customary closing conditions. Hall of Fame Resort & Entertainment Company intends to use the net proceeds from this offering for general corporate purposes, including the potential repayment of indebtedness.
2023-10-11 09:16:03	ETHX	SciSparc Ltd. Announces Pricing Of $5.026M Private Placement	"SciSparc Ltd. (NASDAQ: ETHX ) (""SciSparc"" or the ""Company""), today announced that it has entered into a securities purchase agreement with an institutional investor to raise gross cash proceeds of approximately $5.026 million through a private placement, before deducting fees to the placement agent and other offering expenses payable by the Company. In connection with the private placement, the Company will issue an aggregate of 1,930,108 units, each unit consisting of two Pre-Funded Warrants. The Pre-Funded Warrants have an exercise price of $0.001 and a term of five years from the date of issuance. The closing of the private placement is expected to occur on or about October 13, 2023, subject to the satisfaction of certain customary closing conditions. Aegis Capital Corp. is acting as the exclusive placement agent for the private placement. The securities described above are being sold in a private placement exempt from the registration requirements of the Securities Act of 1933, as amended (the ""Act""), and have not been registered under the Act, or applicable state securities laws. Accordingly, the securities may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Act and such applicable state securities laws. Pursuant to a registration rights agreement with the investor, the Company has agreed to file one or more registration statements with the Securities and Exchange Commission (the ""SEC"") covering the resale of the ordinary shares issuable upon exercise of the Pre-Funded Warrants. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction."
2023-10-11 12:01:52	GPEZ	Fuel Price Surge & Global Events: How They're Shaping Norwegian Cruise Line's Strategy	Norwegian Cruise Line Holdings Ltd (NYSE: GPEZ ) said that in the third quarter and into the fourth quarter of FY23, it experienced operational impacts from higher fuel prices as well as global events, including the wildfires in Maui and the escalating conflict in Israel. The company noted that Pride of America, which offers year-round inter-island Hawaii itineraries, modified certain itineraries in August to avoid stressing local resources in Maui. The wildfires also led to a slowdown in close-in bookings for sailings in Hawaii, primarily concentrated in the fourth quarter of 2023. Pride of America accounts for approximately 3% of the cruiseliner&rsquo;s capacity in the fourth quarter of 2023. In addition, after the escalation of the conflict in Israel , Norwegian Cruise Line is canceling and redirecting all calls to Israel for the remainder of 2023. Prior to the conflict, approximately 6% of the company&rsquo;s capacity in the fourth quarter of 2023 had visits to Israel. As of October 5, 2023, Norwegian had hedged approximately 45%, 35% and 5% of its total projected metric tons of fuel consumption for the remainder of 2023, 2024 and 2025, respectively in order to mitigate the impact of fuel price volatility. GPEZ also said it continues to experience strong consumer demand and remains at its optimal booked position on a 12-month forward basis. NCL Corporation Ltd, a subsidiary of Norwegian Cruise Line, has offered to sell $790 million of its senior secured notes due 2029 in a private offering. Price Action : GPEZ shares are trading lower by 0.89% at $16.46 on the last check Wednesday.
2023-10-11 19:20:25	TFHQ	Astria Therapeutics Priced 8,253,895 Share Offering Of Its Common Stock And Accompanying Common Stock Warrants To Purchase An Aggregate Of 6,190,418 Shares Of Common Stock, @ $6.514	Astria Therapeutics, Inc. (&ldquo;Astria Therapeutics,&rdquo; &ldquo;Astria,&rdquo; the &ldquo;Company,&rdquo; &ldquo;our,&rdquo; or &ldquo;us&rdquo;) (NASDAQ: TFHQ ), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced the pricing of an underwritten offering of (i) 8,253,895 shares of its common stock and accompanying common stock warrants to purchase an aggregate of 6,190,418 shares of common stock, and (ii) to certain investors in lieu of common stock who so choose, pre-funded warrants to purchase up to an aggregate of 1,571,093 shares of common stock and accompanying common stock warrants to purchase up to an aggregate of 1,178,320 shares of common stock. Each share of common stock and accompanying common stock warrant are being sold together at a combined public offering price of $6.514, and each pre-funded warrant and accompanying common stock warrant are being sold together at a combined public offering price of $6.513. The aggregate gross proceeds of the offering are expected to be approximately $64 million, before deducting underwriting discounts and commissions and other estimated offering expenses. Each pre-funded warrant will have an exercise price of $0.001 per share, will be exercisable immediately and will be exercisable until all of the pre-funded warrants are exercised in full. Each common stock warrant will have an exercise price of $8.025 per share, will be exercisable immediately and will expire 5 years from the date of issuance. All of the securities are being offered by Astria. The offering is expected to close on or about October 16, 2023, subject to satisfaction of customary closing conditions. Jefferies and Evercore ISI are acting as joint book-running managers for the offering. LifeSci Capital and Oppenheimer & Co. are acting as co-lead managers.
2023-10-11 19:22:21	PYE	The Real Good Food Company Priced 6,785,715 Share Offering Of Common Stock @ $2.10/Share	The Real Good Food Company, Inc. (NASDAQ: PYE ) (the &ldquo;Company&rdquo;), a leading health and wellness frozen and refrigerated food company, today announced the pricing of an underwritten public offering of 6,785,715 shares of its Class A common stock at a public offering price of $2.10 per share. The aggregate gross proceeds to the Company from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by the Company, are expected to be approximately $14.3 million. The Company intends to use the net proceeds from this offering for general corporate purposes. In addition, the Company has granted the underwriters a 30-day option to purchase additional 1,017,857 shares of its Class A common stock. The offering is expected to close on or about October 16, 2023, subject to satisfaction of customary closing conditions. B. Riley Securities is acting as the sole bookrunning manager in the offering.
2023-10-12 08:02:02	GDIF	Sidus Space Announces $2M Registered Direct Offering And Concurrent Private Placement	"Sidus Space, Inc. (""Sidus"" or the ""Company"") (NASDAQ: GDIF ), a multi-faceted Space and Data-as-a-Service company, today announced that it has entered into a securities purchase agreement with certain institutional investors for the purchase and sale of 2,000 shares of its Series A Convertible Preferred Stock, stated value $1,000 per share in a registered direct offering. The shares of Series A Convertible Preferred Stock are initially convertible into an aggregate of 19,700,552 shares of common stock at a conversion price of $0.10152. In addition, in a concurrent private placement, Sidus will issue to the investors unregistered warrants to purchase up to an aggregate of 19,700,552 shares of common stock. The warrants will have an exercise price of $0.10152 per share, will be exercisable immediately following the date of issuance and will expire in five years. The closing of the registered direct offering and the concurrent private placement is expected to occur on or about October 13, 2023, subject to the satisfaction of customary closing conditions. Dawson James Securities, Inc. acted as the sole placement agent for the offering. The gross proceeds to Sidus from the offering are expected to be approximately $2.0 million, before deducting the placement agent's fees and other offering expenses payable by Sidus. Sidus intends to use the net proceeds from the offering for working capital."
2023-10-12 08:08:10	RUIK	Longeveron Announces $4M Registered Direct Offering Of 2,424,243 Shares Of Common Stock At a Price Of $1.65/Share, Priced At-the-Market Under Nasdaq Rules	"Longeveron Inc. (NASDAQ: RUIK ) (""Longeveron"" or ""Company""), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (HLHS), Alzheimer's disease and Aging-related Frailty, today announced that it has entered into a definitive agreement for the issuance and sale of an aggregate of 2,424,243 of its shares of Class A common stock (""common stock""), or common stock equivalents in lieu thereof, at a purchase price of $1.65 per share, or per common stock equivalent in lieu thereof, in a registered direct offering priced at-the-market under Nasdaq rules. In a concurrent private placement, Longeveron has also agreed to issue and sell unregistered Series A warrants to purchase up to an aggregate of 2,424,243 shares of its common stock and unregistered Series B warrants to purchase up to an aggregate of 2,424,243 shares of its common stock. The offering is expected to close on or about October 13, 2023, subject to the satisfaction of customary closing conditions. L.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. The unregistered Series A warrants will have an exercise price $1.65 per share, will become exercisable commencing on the effective date of stockholder approval of the issuance of the shares issuable upon exercise of the Series A warrants and have a term of five and one-half years from the date of issuance. The unregistered Series B warrants will have an exercise price $1.65 per share, will become exercisable commencing on the effective date of stockholder approval of the issuance of the shares issuable upon exercise of the Series B warrants and have a term of eighteen months from the date of issuance. The gross proceeds to Longeveron from the offering are expected to be approximately $4 million, before deducting the placement agent's fees and other offering expenses payable by the Company. Longeveron currently intends to use the net proceeds from the offering to fund the ongoing clinical and regulatory development of Lomecel-B&#x2122; and for capital expenditures, working capital and general corporate purposes."
2023-10-12 11:46:27	JELP	Earlier Reported, Spectaire Inc, And Merging Co, Perception Capital Corp. II, Secure $3.5M PIPE Commitment from Dr. Jrg Mosolf And Announce Order Of AireCore Units From German Logistics Operator Mosolf MX & Co. KG At A Unit Price Of $2,000 Each	"Spectaire Inc. (""Spectaire"" or ""Company""), a provider of cutting-edge solutions for customers to monitor, track and meet emissions targets via its patented micro-mass-spectrometer (MMS) device, and Perception Capital Corp. II (NASDAQ: JELP ) (""Perception""), today announced that Perception has entered into a private placement subscription agreement (the ""PIPE Subscription Agreement"") with Dr. Jrg Mosolf (the ""PIPE Investor""), the chairman of Mosolf MX & Co. KG (""Mosolf"") and a director of Spectaire, for an aggregate purchase price of $3,500,000 in connection with the proposed business combination between Spectaire and Perception (the ""Transaction""). The Company also announced that it has received a firm order for initial units of its MMS device AireCore&#x2122; from Mosolf at the standard unit price of $2,000. Mosolf has over 1,000 trucks in its fleet. Mosolf was the first company where Spectaire designed the integration of AireCore&#x2122; MMS on vehicles. Based on a sample of 208 Class 8 trucks from Mosolf's fleet, the Company estimates that the use of the Company's AireCore&#x2122; technology on Mosolf's Class 8 fleet alone will result in an aggregate emissions reduction of approximately 60% and generate nearly 50,000 carbon credits annually for Mosolf. The PIPE Investor will close on the purchase of 50,000 shares of Perception substantially concurrently with the closing of the Transaction (""the Closing"") at a price of $10.00 per share for an aggregate purchase price of $500,000. Within two years following the Closing, the PIPE investor will purchase additional shares of post-combination company in one or multiple subsequent closings at a purchase price per share of $10.00 (subject to adjustment as described in the PIPE Subscription Agreement) for an aggregate purchase price of $3,000,000. The purchase and sale of the shares pursuant to the PIPE Subscription Agreement are conditioned upon the Closing as well as other typical conditions for transactions of this type."
2023-10-12 12:40:40	XNHN	OpGen Enters Into Warrant Inducement Transaction For Up To $11.2M In Gross Proceeds	"OpGen, Inc. (NASDAQ: XNHN ) (""OpGen"" or ""the Company""), a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease, announced today that it has entered into an agreement with an institutional investor that is an existing holder of warrants to purchase common shares of the Company for cash (the ""Existing Warrants""), wherein the investor agreed to exercise the Existing Warrants to purchase up to a maximum of 10,892,728 common shares at an exercise price of $0.7785 per share. As part of the agreement, the existing holder has agreed to pay an additional $0.25 consideration per share, resulting in gross proceeds of up to approximately $11.2 million, assuming full exercise of the existing warrants and before deducting offering fees and expenses. A.G.P./Alliance Global Partners acted as the exclusive financial advisor in connection with the transaction. In consideration for the exercise of the Existing Warrants for cash, for each share received upon exercise warrants, the exercising holders will receive new warrants (the ""New Warrants"") to purchase up to an aggregate of 10,892,728 common shares in a private placement pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended (the ""Securities Act""). The offering is expected to close on or about October 16, 2023. The New Warrants are immediately exercisable upon issuance at an exercise price of $0.336 per common share and will expire on October 16, 2028. The New Warrants described above were offered in a private placement pursuant to an applicable exemption from the registration requirements of the Securities Act and, along with the common shares issuable upon their exercise, have not been registered under the Securities Act, and may not be offered or sold in the United States absent registration with the SEC or an applicable exemption from such registration requirements. The securities were offered only to accredited investors. The Company has agreed to file a registration statement with the SEC covering the resale of common shares issuable upon exercise of the New Warrants. This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction."
2023-10-12 14:10:36	CBOU	Why Is Infectious Disease Player Edesa Biotech Stock Soaring Today?	Edesa Biotech Inc (NASDAQ: CBOU ) has secured a commitment of up to C$23 million from the Government of Canada for a pivotal Phase 3 clinical study of the company's first-in-class therapeutic candidate. Edesa's experimental drug, EB05 (paridiprubart), belongs to a class of therapies called Host-Directed Therapeutics (HDTs) designed to modulate the body's immune response when confronted with infectious diseases or even chemical agents. These therapies are agnostic to the causal agent and can be stockpiled preemptively for seasonal outbreaks and unexpected emergencies and threats. Related: Edesa Biotech's COVID-19 Candidate Restraints Inflammation From Influenza, Other Pathogens In Preclinical Studies . Edesa's current project builds on the government-supported Phase 2 study completed during the pandemic, which demonstrated that paridiprubart reduced mortality by 84% among critically ill patients with a severe form of respiratory disease called Acute Respiratory Distress Syndrome (FOBC). A parallel in vitro study at the University of Toronto also demonstrated recently that paridiprubart inhibits inflammation from influenza and other pathogens. Edesa intends to use the SIF funding toward study expenses, including hospital and physician expenditures, and scale-up of commercial drug product should the development program be successful. Price Action: CBOU shares are up 81.50% at $4.90 on the last check Thursday.
2023-10-13 08:33:17	CBWB	Nuwellis Announces Pricing Of $2.25M Public Offering Of Series J Convertible Redeemable Preferred Stock And Warrants	Nuwellis, Inc. (NASDAQ: CBWB ) (&quot;Nuwellis&quot; or the &quot;Company&quot;), a commercial-stage company focused on transforming the lives of people with fluid overload, today announced the pricing of a public offering of 150,000 units (the &quot;Units&quot;), with each Unit consisting of one share of the Company's Series J Convertible Redeemable Preferred Stock, par value $0.0001 per share, with a liquidation preference of $25.00 per share (the &quot;Series J Convertible Preferred Stock&quot;), and one warrant (the &quot;Warrants&quot;) to purchase one-half of one (0.50) share of Series J Convertible Preferred Stock. The offering is expected to close on October 17, 2023, subject to customary closing conditions. The purchase price for one Unit is $15.00, which reflects the issuance of the Series J Convertible Preferred Stock with an original issue discount. The Series J Convertible Preferred Stock has a term of three (3) years and is convertible at the option of the holder at any time into shares of the Company's common stock at a conversion price of $1.01. If any shares of our Series J Convertible Preferred Stock are outstanding at the end of the three-year term, then the Company will promptly redeem all of such outstanding shares of Series J Convertible Preferred Stock on a pro rata basis among all of the holders of Series J Convertible Preferred Stock commencing on the third-year anniversary of the closing date of this offering (the &quot;Mandatory Redemption Date&quot;) in cash, to the extent legally permissible under Delaware law, or, if redemption for cash is not legally permissible in duly authorized, validly issued, fully paid and non-assessable shares of the Company's common stock equal in number to the quotient obtained by dividing such unpaid amount by the closing price of the Company's common stock on the Nasdaq on the Mandatory Redemption Date. Dividends on the Series J Convertible Preferred Stock will be paid, if and when declared by the Board of Directors, in-kind (&quot;PIK dividends&quot;) in additional shares of Series J Convertible Preferred Stock based on the stated value of $25.00 per share at a dividend rate of 5.0%. The PIK dividends will be paid on a quarterly basis for three (3) years following the Closing Date to holders of the Series J Convertible Preferred Stock of record at the close of business on October 31, January 31, April 30, and July 31 of each year. The Warrants have a term of three (3) years. Each Warrant will have an exercise price of $7.50 (50.0% of the public offering price per Unit) per one-half of one (0.5) share of Series J Convertible Preferred Stock and will be immediately exercisable. Lake Street Capital Markets, LLC and Maxim Group LLC are acting as placement agents for the offering. The gross proceeds to Nuwellis from the offering, before underwriting discounts and commissions and offering expenses, are expected to be approximately $2.25 million. Nuwellis intends to use the net proceeds from the offering for working capital and for general corporate purposes.
2023-10-13 09:06:39	QFA	QFA House Inc. Announces Pricing Of $5.4M Public Offering Of 28,421,053 Shares Of Common Stock At A Price Of $0.19/Share	QFA House Inc. (the &quot;Company&quot; or &quot;QFA House&quot;) (NASDAQ: QFA ) , today announced the pricing of a public offering of 28,421,053 shares of common stock, par value $ 0.0001 per share at a public offering price of $0.19 per share, for aggregate gross proceeds of approximately $5.4 million, prior to deducting underwriting discounts and other offering expenses. The offering is expected to close on October 16, 2023, subject to satisfaction of customary closing conditions. EF Hutton, division of Benchmark Investments, LLC (&quot;EF Hutton&quot;) is acting as the sole book running manager for the offering. Nauth LPC is acting as legal counsel to the Company and Sichenzia Ross Ference Carmel LLP is acting as legal counsel to EF Hutton.
2023-10-16 13:31:24	JYZV	WiSA Technologies Announces Pricing Of $4.8M Public Offering Of Series B Convertible Redeemable Preferred Stock And Warrants	"WiSA Technologies, Inc. (NASDAQ: JYZV ), a developer of spatial, wireless sound technology for smart devices and next-generation home entertainment systems, today announced the pricing of a public offering of 87,000 units (the ""Units""), with each Unit consisting of one share of the Company's Series B Convertible Redeemable Preferred Stock, par value $0.0001 per share, with a liquidation preference of $100.00 per share (the ""Series B Convertible Preferred Stock""), and two warrants (the ""Warrants""), each to purchase one (1) share of Series B Convertible Preferred Stock for gross proceeds of approximately $4.8 million. The Company expects to use the proceeds to repay certain outstanding indebtedness, to repurchase certain outstanding common stock purchase warrants and for working capital and general corporate purposes. The purchase price for one Unit is $55.00, which reflects the issuance of the Series B Convertible Preferred Stock with an original issue discount. The Series B Convertible Preferred Stock has a term of two (2) years and is convertible at the option of the holder at any time into shares of the Company's common stock at a conversion price of $0.4147. Dividends on the Series B Convertible Preferred Stock will be paid, if and when declared by the Board of Directors, in-kind (""PIK dividends"") in additional shares of Series B Convertible Preferred Stock based on the stated value of $100.00 per share at a dividend rate of 20.0%. The PIK dividends will be paid in a one-time payment on the one-year anniversary of the Closing Date to holders of the Series B Convertible Preferred Stock of record. The Warrants have a term of two (2) years. Each Warrant will have an exercise price of $55.00 per Warrant, be exercisable for one (1) share of Series B Convertible Preferred Stock and will be immediately exercisable. Maxim Group LLC is acting as the sole placement agent for the offering. The offering is expected to close on October 17, 2023, subject to customary closing conditions."
2023-10-17 07:13:44	XTRJ	Canadian Solar Successfully Issues A JPY18.5B Green Samurai Private Placement In Japan	Canadian Solar Inc. (the &quot;Company&quot;, or &quot;Canadian Solar&quot;) (NASDAQ: XTRJ ) today announced the successful placement of a JPY 18.5 billion green samurai private placement (&quot;private placement&quot;). Goldman Sachs Japan Co., Ltd. (&quot;GS&quot;), was the lead arranger and sole book runner with the domestic bond investors. The private placement has a 3-year tenor with a mix of both semi-annual fixed (1.82% p.a.) and floating (circa 1.49% p.a.) coupons. The Japan Credit Rating Agency, Ltd. (&quot;JCR&quot;) has assigned this structured bond with an investment grade rating of &quot;A-&quot;. Also importantly, JCR certified the issuer with the highest Green 1 rating under the Japanese Green Bond guidelines. Orix Bank Corporation has been appointed as the trustee. Canadian Solar has been a seasoned project bond issuer in Japan and had closed seven transactions for its ground mounted solar projects totaling over forty billion Japanese yen since 2016.
2023-10-17 16:22:48	AYCH	Bridger Aerospace Announces $70M Proposed Public Follow-On Offering To Fund Growth Initiatives	Bridger Aerospace Group Holdings, Inc. (&quot;Bridger&quot; or &quot;Bridger Aerospace&quot;) (NASDAQ: AYCH ) today announced the commencement of a proposed underwritten public offering by Bridger of $70 million of shares of its common stock, par value $0.0001 per share (&quot;Common Stock&quot;). Bridger intends to grant the underwriters a 30-day option to purchase up to an additional $10.5 million of shares of its Common Stock at the public offering price less the underwriting discounts and commissions. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Bridger intends to use the net proceeds of the offering to finance the cash purchase price for four additional Super Scooper aircraft from the Spanish government and for the previously announced acquisition of Bighorn Airways, Inc., and the remainder for general corporate purposes, including funding the upgrade costs for the acquired Super Scoopers and other working capital needs. Stifel, Nicolaus & Company, Incorporated is acting as the lead book-running manager for the offering and BTIG LLC and Canaccord Genuity LLC are also acting as joint book-runners for the offering.
2023-10-18 08:37:29	QBGD	NuZee Prices $1.275M Underwritten Public Offering Of 425,000 Shares Of Its Common Stock At A Public Offering Price Of $3.00 Per Share	NuZee, Inc. (NASDAQ: QBGD ), a leading coffee co-packing and technology company, today announced the pricing of its underwritten public offering of 425,000 shares of its common stock at a public offering price of $3.00 per share, resulting in anticipated gross proceeds to NuZee of approximately $1.275 million, before deducting underwriting discounts and commissions and offering expenses. Maxim Group LLC is acting as the sole book-running manager for the offering. NuZee has granted the underwriter a 45-day option to purchase up to an additional 63,750 shares at the public offering price, less underwriting discounts and commissions. The public offering is expected to close on or about October 20, 2023, subject to customary closing conditions.
2023-10-18 09:08:18	XSZW	Nuvve Holding Corp. Announces Pricing Of $1M Underwritten Public Offering Of 7,142,857 Shares Of Common Stock At A Price To The Public Of $0.14 Per Share	"Nuvve Holding Corp. (NASDAQ: XSZW ) (""Nuvve""), a global technology leader accelerating the electrification of transportation through its proprietary vehicle-to-grid (V2G) platform, announced today the pricing of an underwritten public offering with gross proceeds to the Company expected to be approximately $1,000,000, before deducting underwriting discounts and other estimated expenses payable by the Company. The offering consists of 7,142,857 shares of common stock at a price to the public of $0.14 per share. The Company intends to use the net proceeds from this offering for working capital and other general corporate purposes. In addition, the Company has granted Aegis Capital Corp. a 45-day option to purchase additional shares of common stock and/or pre-funded warrants at the public offering price, less underwriting discounts and commissions solely to cover over-allotments, if any. The offering is expected to close on October 20, 2023, subject to the satisfaction of customary closing conditions."
2023-10-18 09:16:53	UMJI	Celcuity Inc. Announces $50M Private Placement	"Celcuity Inc. (NASDAQ: UMJI ), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, announced today that it has entered into a securities purchase agreement to sell securities in a private placement that is expected to result in gross proceeds of approximately $50 million. In the private placement, an institutional investor has agreed to purchase pre-funded warrants to purchase shares of Celcuity's common stock at a price of $8.699 per warrant, each with an exercise price of $0.001 per share (for aggregate consideration equating to $8.70 per share). Subject to certain limitations, each pre-funded warrant will be exercisable immediately. The closing of the private placement is subject to customary closing conditions and is expected to occur on October 20, 2023. The Company expects to use the net proceeds to advance clinical development of gedatolisib and for general corporate purposes. The securities to be sold in the private placement have not been registered under the Securities Act of 1933, as amended (the ""Securities Act""), or any state or other jurisdiction's securities laws, and accordingly may not be offered or resold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws. The Company has agreed to file a registration statement with the SEC registering the resale of the shares of common stock issuable upon the exercise of the pre-funded warrants purchased in the private placement. This press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities being offered, nor shall there be any sale of the securities being offered in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction. Any offering of the securities under the resale registration statement will only be made by means of a prospectus."
2023-10-23 08:09:10	VYBL	Aligos Therapeutics Announces $92M Private Placement Financing	Proceeds expected to fund the following: - NASH (ALG-055009): top line data from Phase 2a study (Q4 2024) - Hepatitis B/CAM-E (ALG-000184): Phase 2 enabling activities (H2 2024) - Funding expected to extend cash runway through end of 2025 SOUTH SAN FRANCISCO, Calif., Oct. 23, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ: VYBL ), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced that it has entered into a securities purchase agreement for a private placement that is expected to result in gross proceeds of approximately $92 million, before deducting placement agent fees and other expenses, to advance its portfolio of drug candidates. The private placement is being led by a life sciences dedicated investment firm with participation from other new and existing institutional investors including Armistice Capital, Deep Track Capital, EcoR1 Capital and Roche Venture Fund, among others. Also participating in the private placement are certain members of the company's Board of Directors, including Lawrence N. Blatt, Ph.D., N.B.A, the company's Chairman and Chief Executive Officer. Aligos currently expects to use the net proceeds from the private placement, together with its existing cash, cash equivalents and investments, to fund the continued advancement of its Phase 2a NASH, ALG-055009 study evaluating its thyroid hormone receptor beta agonist, its CAM-E candidate, ALG-000184, as well as to fund discovery and research to broaden its pipeline of drug candidates, and for other general corporate purposes. Aligos believes its cash, cash equivalents and investments, including the expected net proceeds from the private placement, will provide sufficient funding of planned operations through the end of 2025. In the private placement, Aligos is selling 31,429,266 shares of common stock, pre-funded warrants to purchase up to 81,054,686 shares of common stock and accompanying warrants to purchase up to 56,241,973 shares of common stock, at a combined price of $0.8193 per share of common stock and accompanying warrant and $0.8192 per pre-funded warrant and accompanying warrant. Each pre-funded warrant will have a nominal exercise price of $0.0001 per share of common stock, will be immediately exercisable and will be exercisable until exercised in full. The accompanying warrants will have an exercise price of $0.7568 per share of common stock, will be immediately exercisable and will expire on October 25, 2030. The private placement is expected to close on October 25, 2023, subject to the satisfaction of customary closing conditions. Piper Sandler is acting as sole placement agent for the private placement. The securities sold in this private placement have not been registered under the Securities Act of 1933, as amended, or applicable state securities laws, and may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements. Aligos has agreed to file a registration statement with the Securities and Exchange Commission registering the resale of the shares of common stock issued in the private placement and the shares of common stock issuable upon exercise of the pre-funded warrants and the common warrants issued in the private placement. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.
2023-10-23 08:18:52	SBXP	Cyclo Therapeutics Announces Early Exercise Of Warrants By Board Members, Management And A Significant Shareholder Resulting In Cash Proceeds Of $2.4M	Issues New Warrants to this Investment Group for Possible Additional Funding of Up to $3.47 Million (if exercised) Cyclo Therapeutics, Inc. (NASDAQ: SBXP ) (&quot;Cyclo Therapeutics&quot; or the &quot;Company&quot;), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced that it had entered into a securities purchase agreement with certain accredited investors (the &quot;Investors&quot;) to raise $2,359,584 in a private offering (the &quot;Offering&quot;). The Investors owned vested warrants to purchase an aggregate of 3,323,358 shares of the Company's common stock at an exercise price of $0.71 per share (the &quot;Original Warrants&quot;), which they purchased in private offerings in April and May 2023. In the Offering, the Investors exercised their Original Warrants in full, in consideration of the receipt of new warrants (&quot;New Warrants&quot;) with an exercise price equal to $0.95 per share, to purchase 110% of the number of shares of the Company's common stock covered under the Original Warrants. The New Warrants will be exercisable for cash only and have a term of four years from the issuance date. The Investors include Rafael Holdings, Inc., a significant shareholder of the Company, several directors of the Company, Company management, and their affiliates. N. Scott Fine, CEO of Cyclo Therapeutics, commented, &quot;We continue to navigate through difficult market conditions with the best interest of our shareholders in the near and long term as a priority. We are incredibly grateful for the continued support and commitment to the future of Cyclo Therapeutics, and importantly the Niemann-Pick Disease Type C (&lsquo;NPC') community, from Rafael Holding and other longtime shareholders as well as members of our management team and Board of Directors. The exercise of these warrants further extends our cash runway and provides us and our shareholders the confidence that we have the necessary resources to continue our mission and our work on continuing to advance our clinical trials of Trappsol&reg; Cyclo&trade;, with the goal of providing much-needed hope for a beloved community in desperate need for a therapeutic solution.&quot; William Conkling, Chief Executive Officer of Rafael, added, &quot;As part of our ongoing support for development of Trappsol&reg; Cyclo&trade;, and the NPC community we have determined to exercise our warrants to support the Phase III study of Trappsol&reg; Cyclo&trade;. We believe the significant clinical progress and demonstrated operational execution by the Cyclo team has the potential to translate into significant value creation.&quot; The Company intends on using the net proceeds from this Offering for general working capital purposes. In the aggregate, the Company issued to the Investors New Warrants to purchase a total of 3,655,694 shares of common stock in exchange for receipt of cash consideration of $2,359,584 from the exercise of the Original Warrants by the Investors. The Offering was conducted pursuant to the exemption from registration provided by Section 4(a)(2) of the Securities Act of 1933, as amended (&quot;Securities Act&quot;). Each Investor represented in writing that he, she, or it is an accredited investor and acquired the securities for his, her or its own account for investment purposes and any subsequent transfer or sales of these securities will be in accordance with the Securities Act or exempt from registration under the Securities Act. The New Warrants and the shares of the Company's common stock issuable upon exercise of the New Warrants will be &quot;restricted securities&quot; under Rule 144 of the Securities Act, and certificates representing the foregoing will bear a Rule 144 restrictive legend.
2023-10-23 12:53:53	YMXZ	Borr Drilling Limited Announces Launch Of Senior Secured Notes Offering; Subsidiary Borr Ihc, And Certain Other Units Intend To Offer $1.5B Worth Of Senior Secured Notes Due 2028 & 2030; Co Is Contemplating Private Placement In Norway Of ~$50M In Shares	"Borr Drilling Limited (the ""Company"") (NYSE and OSE: YMXZ) announced today that its wholly owned subsidiary Borr IHC Limited, and certain other subsidiaries intend to offer, subject to market conditions, $1,500,000,000 in aggregate principal amount of senior secured notes due 2028 and 2030. The notes will be guaranteed by the Company and certain of its subsidiaries and will be secured on a senior basis on substantially all of the assets of the Company and certain subsidiary guarantors. In connection with the notes offering, the Company is contemplating: (i) a private placement in Norway of approximately $50 million in shares and (ii) entering into a $180 million super senior revolving credit facility, to be secured on a super senior basis by the same collateral that will secure the notes. The proceeds from the notes offering are intended to be used, together with the proceeds from the equity offering, to repay all of the Company's outstanding secured borrowings, being borrowing under the DNB Facility, the Hayfin Facility, the shipyard delivery financing arrangements with OPPL and PPL, the $150 million Norwegian law Senior Secured Bonds, and to pay related premiums, fees, accrued interest and expenses, in connection with the foregoing, and the remainder, if any, for general corporate purposes. Pricing of the notes offering is expected on or about October 24, 2023. The settlement of the equity offering is subject to certain conditions, including the pricing and settlement of the notes offering. The Company has conducted a selective pre-sounding of its largest existing shareholders and received indications such that the $50 million private placement will be covered. In case of demand from other existing shareholders during a contemplated bookbuilding for the private placement, these investors may be scaled down to their pro-rata allocation. No shares will be offered or sold in transactions on the NYSE. This information is considered to be inside information pursuant to the EU Market Abuse Regulation and subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act. This stock exchange notice was published by Andreas Lavik Lie, VP Treasury & DB, on the date and time as set out above."
2023-10-24 09:10:37	QGVW	AppTech Payments Corp. Announces Pricing Of $3.5M Registered Direct Offering	"AppTech Payments Corp. (NASDAQ: QGVW ) (the ""Company"" or ""AppTech""), a pioneering Fintech company powering frictionless commerce between business to business and business to consumer, announced today that it has entered into a securities purchase agreement with a single institutional investor to purchase approximately $3.5 million of its common stock and warrants in a registered direct offering. The combined effective purchase price for each share of common stock and associated warrant to purchase one share of common stock will be $2.10. Under the terms of the securities purchase agreement, AppTech has agreed to issue 1,666,667 shares of common stock and warrants to purchase up to 1,666,667 shares of the Company's common stock from the date of issuance until the fifth anniversary of the issuance date for $2.74 per share, subject to adjustment for stock splits, reorganizations and recapitalization. Titan Partners Group, a division of American Capital Partners, is acting as sole placement agent for the offering. The offering is expected to close on or about October 26, 2023, subject to the satisfaction of customary closing conditions. The shares of common stock and warrants are being offered pursuant to a shelf registration statement on Form S-3 (File No. 333-265526) previously filed and declared effective by the Securities and Exchange Commission (SEC) on July 15, 2022. The offering of the shares of common stock and warrants will be made only by means of a prospectus supplement that forms a part of the registration statement. Copies of the prospectus supplement and the accompanying prospectus relating to this offering may be obtained, when available, on the SEC's website at http://www.sec.gov or by contacting Titan Partners Group, a division of American Capital Partners, 4 World Trade Center, 29th Floor, New York, NY 10007, by telephone at (929) 833-1246 or by email at info@titanpartnersgrp.com . This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction."
2023-10-24 16:44:08	USD	InMed Pharmaceuticals Announces $5.2M Private Placement And Preferred Investment Option Exercise Priced At-The-Market under Nasdaq Rules	InMed Pharmaceuticals Inc. (NASDAQ: USD ) (&quot; InMed &quot; or the &quot; Company &quot;), a leader in the pharmaceutical research, development, manufacturing and commercialization of rare cannabinoids and cannabinoid analogs, today announced that it has entered into definitive agreements for the issuance and sale of 3,012,049 of its common shares (or pre-funded warrants in lieu thereof) and preferred investment options to purchase up to an aggregate of 3,012,049 common shares, at a purchase price of $0.83 per share (or pre-funded warrant in lieu thereof) and associated preferred investment option in a private placement priced at-the-market under Nasdaq rules (the &quot;private placement&quot;). The Company has also entered into a definitive agreement with respect to certain of its outstanding preferred investment options issued in November 2022 and exercisable for 3,272,733 common shares, in the aggregate, to exercise such preferred investment options for cash at a reduced exercise price of $0.83 per share, in exchange for unregistered new preferred investment options to purchase up to 6,545,466 common shares (the &quot;preferred investment option exercise&quot; and, collectively with the private placement, the &quot;offerings&quot;). The common shares issuable upon exercise of the preferred investment options are registered pursuant to effective registration statement on Form S-1 (File No. 333-268700) with the U.S. Securities Exchange (&quot;SEC&quot;) on December 7, 2022 and declared effective on December 14, 2022. The preferred investment option to be issued in the offerings will be exercisable immediately upon issuance at an exercise price of $0.83 per share and will expire five and one-half years from the date of issuance. L.C. Wainwright & Co. is acting as the exclusive placement agent for the offerings. The aggregate gross proceeds to the Company from the offerings are expected to be approximately $5.2 million, before deducting placement agent fees and other offering expenses. The offerings are expected to close on or about October 26, 2023, subject to the satisfaction of customary closing conditions. The Company intends to use the net proceeds from the offerings to continue pipeline development of its pharmaceutical drug candidates, support commercial sales of rare cannabinoids through its subsidiary BayMedica LLC, and for general working capital purposes. The securities sold in the private placement and the new preferred investment options sold in the preferred investment option exercise described above were offered in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the &quot;Act&quot;) and Regulation D promulgated thereunder and, along with the common shares underlying the preferred investment options sold in the offerings, have not been registered under the Act or applicable state securities laws. Accordingly, such securities may not be offered or sold in the United States absent registration with the SEC or an applicable exemption from such registration requirements. The securities were offered only to accredited investors. Pursuant to a registration rights agreement, the Company has agreed to file one or more registration statements with the SEC covering the resale of the unregistered securities to be issued in the private placement and the new preferred investment options to be issued in the preferred investment option exercise. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
2023-10-25 08:02:32	WTVG	Sonnet BioTherapeutics Announces Pricing Of $4.55M Underwritten Public Offering	"Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: WTVG ) (""we,"" ""us,"" ""our,"" ""Sonnet"" or the ""Company""), a clinical-stage company developing innovative targeted biologic drugs, today announced the pricing of an underwritten public offering of 2,843,750 shares of common stock (or pre-funded warrants to purchase shares of common stock in lieu of shares of common stock) and investor warrants to purchase up to an aggregate of 5,687,500 shares of common stock. Each share of common stock (or pre-funded warrant in lieu thereof) is being sold together with two investor warrants at a combined offering price of $1.60, for total gross proceeds of approximately $4.55 million, before underwriting discounts and commissions and offering expenses payable by Sonnet. Each investor warrant is exercisable for one share of common stock at an exercise price of $1.60 per share for a period of five years from the date of issuance. The offering is expected to close on or about October 27, 2023, subject to the satisfaction or waiver of customary closing conditions. The offering is being led by existing investors. Chardan and Ladenburg Thalmann & Co. Inc. are acting as joint book-running managers in connection with the offering. Sonnet anticipates using the net proceeds from the offering for research and development, including clinical trials, working capital and general corporate purposes."
2023-10-26 09:10:46	XSZW	Nuvve Holding Corp. Announces Pricing Of $2.066M Registered Direct Offering Priced At-the-Market	"Nuvve Holding Corp. (NASDAQ: XSZW ) (""Nuvve""), a global technology leader accelerating the electrification of transportation through its proprietary vehicle-to-grid (V2G) platform, today announced that it has entered into a definitive agreement with a single institutional investor for the purchase and sale of 13,772,940 shares of common stock and pre-funded warrants to acquire common stock in a registered direct offering. The purchase price of each share is $0.15 priced yesterday at-the-market under Nasdaq rules. The purchase price for the pre-funded warrants is equivalent to the purchase price for the shares, less the exercise price of $0.0001 . The aggregate gross proceeds to the Company are expected to be approximately $2.066 million . The transaction is expected to close on or about October 27, 2023, subject to the satisfaction of customary closing conditions. Aegis Capital Corp. is acting as the Exclusive Placement Agent."
2023-10-26 09:21:08	OQTK	Sonoma Pharmaceuticals, Inc. Announces Pricing Of $1.7M Public Offering Of 8.5M Shares Of Common Stock At A Price Of $0.20 Per Share	Sonoma Pharmaceuticals, Inc. (NASDAQ: OQTK ), a global healthcare leader developing and producing patented Microcyn&#xAE; technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, today announced the pricing of its public offering of 8,500,000 shares of common stock at a price of $0.20 per share. The gross proceeds of the offering to the Company, before deducting placement agent fees and commissions and estimated offering expenses, are expected to be approximately $1.7 million. The offering is expected to close on or about October 30, 2023, subject to customary closing conditions. Maxim Group LLC is acting as the sole placement agent in connection with the offering.
2023-10-26 09:23:31	KXIF	Bit Brother Limited Announces Pricing Of $5.04M Registered Direct Offering	"Bit Brother Limited (""Bit Brother, "" ""We"" or the ""Company"") (NASDAQ: KXIF ), announced today that it has entered into a securities purchase agreement with certain accredited investors to sell $5.04 million of its Class A ordinary shares, Class B warrants and Class C warrants in a registered direct offering. Under the terms of the securities purchase agreement, Bit Brother has agreed to sell 14,000,000 Class A ordinary shares, Class B warrants to purchase 14,000,000 Class A ordinary shares, and Class C warrants to purchase 14,000,000 Class A ordinary shares at a combined purchase price of $0.36 per Class A ordinary share and associated warrants. The Class B warrants will be exercisable immediately upon the date of issuance for a term of five years and have an initial exercise price of $0.36 and the Class C warrants will be exercisable immediately upon the date of issuance for a term of two years and have an initial exercise price of $0.46 subject to certain reset 30 trading days after closing. In addition to the customary cashless exercise rights provided in both the Class B warrants and the Class C warrants, the Class C warrants will also provide an alternate cashless exercise allowing the holder to right to exercise at any time, on a cashless exercise basis for a larger number of Class A ordinary shares under certain conditions. The gross proceeds to Bit Brother are estimated to be $5.04 million before deducting the placement agent fees and other estimated offering expenses. The registered direct offering is expected to close on or about October 30, 2023, subject to the satisfaction of customary closing conditions. Maxim Group LLC acted as sole placement agent for the offering."
2023-10-26 09:28:00	HZI	SunCar Technology Group Inc. Announces $21M Follow-On Offering	"SunCar Technology Group Inc. (the ""Company"" or ""SunCar"") (NASDAQ: HZI ), a leading provider of digitalized enterprise automotive after-sales services and online auto insurance intermediation services in China, today announced that it has entered into certain securities purchase agreements with certain institutional investors for a follow-on offering of $21 million of Class A Ordinary Shares, par value $0.0001 per share (the ""Ordinary Shares"") at a price of $8.18 per share. The Company will issue a total of 2,567,238 Ordinary Shares to the institutional investors. As part of the transaction, the Company will issue to the investors certain common warrants (""Common Warrants"") for the purchase of up to 3,850,856 Ordinary Shares at an exercise price of $9.00 per share, which Common Warrants will have a term of five years from the date of issuance. The net proceeds from this offering will be used for working capital and general corporate purposes. The offering is expected to close on or about October 30, 2023, subject to the satisfaction of customary closing conditions. FT Global Capital, Inc. acted as the exclusive placement agent for the transaction. These securities are being offered through a prospectus contained in the Company's effective registration statement on Form F-1(Filing No. 333-275144) which has been filed with and declared effective by the Securities and Exchange Commission (the ""SEC"") on October 25, 2023. A final prospectus related to the offering will be filed with the SEC and may be obtained via the SEC's website at www.sec.gov .. This press release does not constitute an offer to sell or the solicitation of an offer to buy, and these securities cannot be sold in any state in which this offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state. Any offer will be made only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement. For further details of this transaction, please see the Form 6-K to be filed with the SEC."
2023-10-26 09:30:51	XFJT	ParaZero Technologies Announces Pricing of $5.1M Private Placement	In connection with the offering, the Company will issue an aggregate of 4,636,364 units and pre-funded units. The pre-funded units will be sold at the same purchase price less the pre-funded warrant exercise price of $0.005. Each unit and pre-funded unit will consist of one ordinary share (or pre-funded warrant) and one common warrant exercisable for one ordinary share at an exercise price of $1.10 per ordinary share. The common warrants will be exercisable upon issuance and will have a term of 5.5 years from the issuance date. The number of securities issued under the units is subject to adjustment as described in more detail in the report on Form 6-K to be filed in connection with the offering.
2023-10-26 12:31:37	AAAZ	Mustang Bio Announces $4.4M Registered Direct Offering Of 2,588,236 Of Its Shares Of Common Stock At A Price Of $1.70/Share, Priced At-the-Market Under Nasdaq Rules	"Mustang Bio, Inc. (""Mustang"" or the ""Company"") (NASDAQ: AAAZ ), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapies into potential cures for difficult-to-treat cancers and rare genetic diseases, today announced that it has entered into a definitive agreement for the issuance and sale of an aggregate of 2,588,236 of its shares of common stock (or common stock equivalents in lieu thereof) at a purchase price of $1.70 per share (or common stock equivalent in lieu thereof) in a registered direct offering priced at-the-market under Nasdaq rules. In a concurrent private placement, Mustang has also agreed to issue and sell unregistered warrants to purchase up to an aggregate of 2,588,236 shares of its common stock. The offering is expected to close on or about October 30, 2023, subject to the satisfaction of customary closing conditions. L.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. The unregistered warrants will have an exercise price $1.58 per share, will become exercisable immediately upon issuance and will expire five and one-half years from the date of issuance. The gross proceeds to Mustang from the offering are expected to be approximately $4.4 million, before deducting the placement agent's fees and other offering expenses payable by the Company. Mustang currently intends to use the net proceeds from the offering for working capital and general corporate purposes."
2023-10-26 16:36:45	GQNG	TransCode Therapeutics Announces Public Offering Of Common Stock; No Size Or Amount Disclosed	"TransCode Therapeutics, Inc. (NASDAQ: GQNG ), (the ""Company""), an RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced the commencement of an underwritten public offering of shares of its common stock. In addition, the Company expects to grant the underwriters a 45-day option to purchase additional shares of its common stock in an amount equal to 15% of the shares offered in the public offering. The offering of common stock is subject to market and other conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. All shares to be sold in the proposed offering of common stock will be offered by the Company. ThinkEquity is acting as sole book-running manager for the offering."
2023-10-30 08:38:10	VZNI	Viridian Therapeutics Appoints  Stephen Mahoney As New Chief Executive Officer, Unveils Next Generation FcRn Inhibitor Programs And Announces $185M Private Placement Financing	" Stephen Mahoney appointed President and Chief Executive Officer   Potential best-in-class subcutaneous and intravenous thyroid eye disease (TED) programs targeting insulin-like growth factor 1 receptor (IGF-1R) remain on track; subcutaneous program selection expected by year-end 2023 and VZNI-001 THRIVE Phase 3 topline results in active TED expected in mid-2024   Company discloses novel portfolio of preclinical neonatal Fc receptor (FcRn) inhibitors with broad potential to treat autoimmune diseases; first Investigational New Drug (IND) submission planned by year end 2024   Private placement with participation from new and existing investors to fund portfolio strategy and extend operating runway into 2026  Viridian Therapeutics, Inc. (NASDAQ: VZNI ), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that Stephen Mahoney has been appointed the company's President and Chief Executive Officer, and a member of the Board of Directors, effective immediately. Viridian also disclosed a preclinical portfolio of FcRn inhibitors designed to deliver next generation treatments for patients suffering from antibody-mediated autoimmune diseases. To advance its expanded strategic priorities, the company also announced that it has entered into an agreement to sell shares of its common and Series B preferred stock to certain institutional investors in a private placement transaction and will receive aggregate gross proceeds of $185 million, before deducting estimated offering expenses. New Chief Executive Officer to Drive Expanded Strategic Priorities Stephen Mahoney's appointment as President and Chief Executive Officer combines his leadership and track record of operational execution with the company's strategy of delivering potentially best-in-class next generation molecules in commercially established disease areas. Viridian's pipeline is composed of intravenous and subcutaneous IGF-1R inhibitors for patients with TED and, as of today's announcement, next generation FcRn inhibitors for the treatment of autoimmune diseases. Scott Myers's departure as President and CEO of the company was effective as of October 29, 2023. ""We are grateful for Scott's contributions and the operational progress Viridian was able to achieve during his tenure,"" said Tomas Kiselak, Chairman of Viridian's Board of Directors. ""The Board believes that the transition to Steve's leadership with his strong track record of driving execution and his alignment with our corporate strategy can enable Viridian to build a potentially best-in-class IGF-1R inhibition franchise in TED and advance our efforts to deliver next generation FcRn inhibitors for the treatment of autoimmune diseases."" Mr. Mahoney brings more than two decades of experience in the biopharmaceutical industry where he has held a number of strategic, operational, financial, business development and legal roles with regional and global responsibilities. He most recently served as President, Chief Financial and Operating Officer of Magenta Therapeutics. Prior to Magenta, Mr. Mahoney served as President and Chief Operating Officer of Kiniksa Pharmaceuticals. He also served as Chief Commercial Officer, among other executive titles of increasing responsibility, at Synageva Biopharma Corp. and was a business and transactional attorney at Genzyme Corporation. Mr. Mahoney holds an N.B.A. and J.D. from Boston College and a B.A. from Colorado College. ""I am excited to join the Viridian team at this critical time and help deliver on the promise of the company's broad pipeline,"" said Mr. Mahoney. ""As we seek to optimize our future commercial position with the TED franchise, we have a dual focus of delivering the results from our two THRIVE Phase 3 clinical trials of VZNI-001 in both active and chronic TED while also prioritizing and accelerating the development of a potentially best-in-class subcutaneous delivery option for patients. As announced today, we are also thrilled about the potential of our novel portfolio of FcRn inhibitors, and we look forward to moving these programs to the clinic as quickly as possible."" Viridian also announced that Thomas Beetham will be joining the company as Chief Operating Officer, and Shan Wu, Ph.D., will be joining as Chief Business Officer, each of whom have worked with Mr. Mahoney in prior companies and will strengthen Viridian's management team. TED Clinical Development Remains On Track with Selection of Subcutaneous Program by Year End 2023 and VZNI-001 THRIVE Topline Results in Active TED Expected in Mid-2024 Viridian continues to advance its differentiated and improved product candidates for TED patients and is simultaneously focused on developing both its subcutaneous and intravenous IGF-1R inhibitor programs. The company has designed the subcutaneous program to be a potentially best-in-class, self-administered, infrequent, and low-volume injection for patients. The intravenous VZNI-001 program, which features a shorter infusion time and fewer infusions compared to the currently marketed IGF-1R inhibitor, is on track for its Phase 3 data readouts. The company expects that its intravenous VZNI-001 has the potential to establish a strong foothold in the multi-billion-dollar TED commercial market and will help facilitate the future introduction of its subcutaneous program. Viridian is on track to select its lead subcutaneous IGF-1R program by the end of 2023 and expects such program to enter a pivotal Phase 2/3 trial in mid-2024. The company expects topline results from the first THRIVE Phase 3 clinical trial for intravenous VZNI-001 for active TED to be available in mid-2024. The THRIVE-2 clinical trial in chronic TED patients is recruiting patients, and the company expects topline clinical results by year end 2024. Next Generation FcRn Inhibitor Portfolio Unveiled; First IND Filing Planned by Year End 2024 Consistent with Viridian's vision to develop the next generation of best-in-class products for severe autoimmune and rare diseases, the company disclosed that it is developing a portfolio of engineered FcRn inhibitors, VZNI-006 and VZNI-008. FcRn inhibitors have the potential to treat a broad array of autoimmune diseases, representing a significant commercial market opportunity. Viridian's multi-pronged engineering approach has resulted in a portfolio of FcRn-targeting molecules that leverage the clinically and commercially validated mechanism of FcRn inhibition while potentially addressing the limitations of current agents such as incomplete IgG suppression and needed improvements in safety. VZNI-006 is a FcRn-targeting Fc fragment, and in non-human primate studies, demonstrated specificity for blocking FcRn-IgG interactions while showing no increases in albumin or low-density lipoprotein (LDL) levels. In head-to-head non-human primate studies, VZNI-006 demonstrated comparable potency and IgG lowering to efgartigimod, the current standard of care in FcRn inhibition, as well as a similar safety profile. Viridian plans to file an IND for VZNI-006 by year end 2024 and expects healthy volunteer data for VZNI-006 in the second half of 2025. VZNI-008 is a novel, first-in-class FcRn inhibitor that aims to pair IgG suppression with extended half-life technology, potentially enabling deeper and more durable suppression than existing anti-FcRn therapies. Both molecules are designed to be convenient, self-administered, subcutaneous products. The company plans to share additional details about its FcRn portfolio in 2024. $185 Million Financing to Fund Expanded Pipeline and Extend Cash Runway Viridian announced it has entered into agreements for a private placement financing that is expected to close by November 1, 2023, and result in anticipated gross proceeds of approximately $185 million, before deducting estimated offering expenses. The financing was led by Fairmount Funds with participation from both existing investors, including Braidwell LP, Commodore Capital, Deep Track Capital, Venrock, Paradigm BioCapital and Perceptive Advisors, as well as new investors, including entities managed by RTW Investments, LP and Surveyor Capital (a Citadel company). In the private placement, Viridian is selling an aggregate of 8,789,022 shares of its common stock at a price of $12.38 per share and an aggregate of 92,312 shares of its Series B preferred stock at a price of $825.3746 per share, which are convertible into approximately 6,154,441 shares of common stock, subject to beneficial ownership conversion limits. Proceeds will be used to fund pipeline programs, including the FcRn portfolio, and for general corporate purposes and working capital. The company also expects that the proceeds will extend its cash runway to fund its operating plan into 2026. Jefferies, Evercore ISI, and Stifel are acting as lead placement agents for the private placement financing. LifeSci Capital LLC and Wedbush PacGrow are also acting as co-placement agents for the private placement financing. The securities being sold in the private placement have not been registered under the Securities Act of 1933, as amended (the Securities Act), or any states' securities laws, and may not be offered or sold in the United States, except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act. Viridian has agreed to file a registration statement with the Securities and Exchange Commission registering the resale of the shares issued in the private placement. This press release shall not constitute an offer to sell, or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Notice of Issuance of Inducement Grants Viridian also announced the grant of an inducement award to Mr. Mahoney, as well as to Mr. Beetham and to two other new employees, including Dr. Wu, in each case as an inducement material to such executive officer or employee's employment pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules. Mr. Mahoney was granted an option to purchase 1,259,400 shares of Viridian's common stock, Mr. Beetham was granted an option to purchase 474,400 shares of Viridian's common stock, and the other new employees were granted options to purchase an aggregate of 268,200 shares of Viridian's common stock. In each case, the shares underlying the options vest become exercisable as follows: one quarter of the underlying shares on the first anniversary of October 30, 2023 and then in equal monthly installments thereafter over the following 36 months, subject to the grantee's continued service to the company. The exercise price of the stock options will equal the closing price of the company's common stock on October 30, 2023, the date of the grant. The inducement awards were granted outside of the company's Amended and Restated 2016 Equity Incentive Plan but remain subject to the terms and conditions of such plan."
2023-10-30 14:24:54	EWZP	BIO-key International Announces Pricing Of $3.75M Public Offering	BIO-key &#xAE; International, Inc. (NASDAQ: EWZP ), an innovative provider of workforce and customer Identity and Access Management (IAM) featuring passwordless, phoneless and token-less Identity-Bound Biometric (IBB) authentication solutions, today announced the pricing of its public offering of 21,430,000 units, with each unit consisting of one share of common stock (or a pre-funded warrant in lieu thereof) and one warrant to purchase one share of common stock. Each unit is being sold at a public offering price of $0.175. The warrants in each unit will be immediately exercisable at a price of $0.175 per share and will expire five years from the date of issuance. The shares of common stock (or pre-funded warrants in lieu thereof) and the accompanying warrants can only be purchased together in this offering but will be issued separately and will be immediately separable upon issuance. Gross proceeds, before deducting placement agent fees and estimated offering expenses, are expected to be approximately $3.75 million. The offering is expected to close on October 31, 2023, subject to customary closing conditions. Maxim Group LLC is acting as sole placement agent in connection with this offering.
2023-10-30 16:35:46	GQNG	TransCode Therapeutics Withdraws Public Offering	"TransCode Therapeutics, Inc. (NASDAQ: GQNG ) (the ""Company""), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, announced today that it is withdrawing the underwritten public offering of its common stock. This reflects the Company's belief that current market conditions were not conducive for an offering on terms that would be in the best interests of the Company's stockholders. This press release shall not constitute an offer to sell or the solicitation of an offer to buy the Company's common stock or any securities, and there shall not be any offer, solicitation or sale of securities mentioned in the press release in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such any state or jurisdiction."
2023-10-30 16:57:38	FTF	Western Digital Announces Proposed $1.3B Convertible Notes Offering	"Western Digital Corporation (NASDAQ: FTF ) (""Western Digital"") today announced a proposed offering of $1.3 billion aggregate principal amount of convertible senior notes due 2028 (the ""notes""), subject to market and other conditions. The notes will be senior unsecured obligations of Western Digital and will be guaranteed, jointly and severally, on a senior unsecured basis by each of Western Digital's wholly-owned subsidiaries from time to time guaranteeing Western Digital's 4.75% senior unsecured notes due 2026 (the ""2026 Notes"") (initially, Western Digital Technologies, Inc.) or that is a guarantor or obligor with respect to certain refinancing indebtedness with respect to the 2026 Notes. Upon any conversion of the notes, Western Digital will pay cash up to the aggregate principal amount of the notes to be converted and pay or deliver, as the case may be, cash, shares of Western Digital's common stock or a combination of cash and shares of common stock, at Western Digital's election, in respect of the remainder, if any, of its conversion obligation in excess of the aggregate principal amount of the notes being converted. Interest on the notes will be payable semiannually in arrears on May 15 and November 15 of each year, beginning on May 15, 2024. The notes will mature on November 15, 2028, unless earlier repurchased, redeemed or converted. The interest rate, initial conversion rate, offering price and other terms of the notes will be determined at the time of pricing the offering. Western Digital intends to offer the notes in a private offering only to persons reasonably believed to be qualified institutional investors in accordance with Rule 144A under the Securities Act of 1933, as amended (the ""Securities Act""). In connection with the offering, Western Digital expects to grant the initial purchasers an option to purchase, during the 13-day period beginning on, and including, the first date on which the notes are issued, up to an additional $200 million principal amount of notes. Western Digital will use the net proceeds of the notes offering (1) to pay the cost of entering into capped call transactions in connection with the offering, (2) to pay the purchase price for the refinancing through private repurchases of a portion of Western Digital's existing 1.50% convertible senior notes due 2024 (the ""Existing Convertible Notes""), (3) to repay the remaining principal amount owed on the Existing Convertible Notes on the maturity date of the Existing Convertible Notes or prior to such date through further private repurchases, and (4) after the application of the proceeds in accordance with clauses (1)  (3) (or, with respect to clause (3), if Western Digital holds the requisite amount of funds to be used in accordance with such clause), for general corporate purposes, which may include repayment or repurchase of certain of Western Digital's outstanding non-convertible debt securities through tender offers, open market or privately negotiated repurchases, redemption or otherwise or repayment of any of Western Digital's other indebtedness. Contemporaneously with the pricing of the notes in the offering, Western Digital expects to enter into one or more separate and individually negotiated transactions with one or more holders of the Existing Convertible Notes to repurchase a portion of the outstanding Existing Convertible Notes for cash on terms to be negotiated separately with each holder (each, a ""note repurchase""). The terms of each note repurchase are anticipated to be individually negotiated with each holder of the Existing Convertible Notes and will depend on several factors, including the market price of Western Digital's common stock and the trading price of the Existing Convertible Notes at the time of each such note repurchase. No assurance can be given as to how much, if any, of the Existing Convertible Notes will be repurchased or the terms on which they will be repurchased. Western Digital expects that counterparties that sell their Existing Convertible Notes to it as described above and that have hedged their equity price risk with respect to such Existing Convertible Notes may enter into or unwind various transactions with respect to Western Digital's common stock (including entering into derivatives with one or more of the initial purchasers in this offering or their respective affiliates) and/or purchase shares of Western Digital's common stock concurrently with or shortly after the pricing of the notes. This activity could increase (or reduce the size of any decrease in) the market price of Western Digital's common stock, including concurrently with the pricing of the notes, resulting in a higher effective conversion price of the notes. Western Digital cannot predict the magnitude of such market activity or the overall effect it will have on the price of the notes or Western Digital's common stock. In connection with the pricing of the notes, Western Digital also expects to enter into privately negotiated capped call transactions with one or more of the initial purchasers of the notes or their respective affiliates and/or certain other financial institutions, as option counterparties. The capped call transactions will cover, subject to anti-dilution adjustments, the number of shares of Western Digital's common stock initially underlying the notes. The capped call transactions are expected generally to reduce potential dilution to Western Digital's common stock upon conversion of any notes and to offset any cash payments made in excess of the principal amount of converted notes, as the case may be, with such reduction and/or offset subject to a cap. If the initial purchasers exercise their option to purchase additional notes, Western Digital expects to enter into additional capped call transactions with the option counterparties. In connection with establishing their initial hedges of the capped call transactions, Western Digital expects the option counterparties or their respective affiliates to purchase shares of Western Digital's common stock and/or enter into various transactions with respect to Western Digital's common stock concurrently with or shortly after the pricing of the notes. This activity could increase (or reduce the size of any decrease in) the market price of Western Digital's common stock or the notes at that time. In addition, the option counterparties or their respective affiliates may modify their hedge positions by entering into or unwinding various transactions with respect to Western Digital's common stock and/or purchasing or selling Western Digital's common stock or other Western Digital securities or instruments in secondary market transactions following the pricing of the notes and prior to the maturity of the notes (and (x) are likely to do so during any observation period related to a conversion of notes or following any repurchase of notes by Western Digital in connection with any optional redemption or fundamental change and (y) are likely to do so following any repurchase of notes by Western Digital other than in connection with any optional redemption or fundamental change if Western Digital elects to unwind a corresponding portion of the capped call transactions in connection with such repurchase). This activity could also cause or avoid an increase or a decrease in the market price of Western Digital's common stock or the notes. The notes, the common stock, if any, deliverable upon conversion of the notes and the related guarantee have not been and will not be registered under the Securities Act or the securities laws of any other jurisdiction. They may not be offered or sold in the United States or to, or for the benefit of, U.S. persons absent registration under, or an applicable exemption from, the registration requirements of the Securities Act. This press release does not constitute an offer to sell or buy or a solicitation of an offer to buy or sell the notes or any other security, nor will there be any sale of the notes or any other security in any state or jurisdiction in which such an offer, solicitation or sale is not permitted. Any offer or sale will be made only by means of an offering memorandum, as applicable."
2023-10-30 17:00:47	WRXX	Orgenesis Announces Proposed Underwritten Public Offering; No Size Or Amount Disclosed	"Orgenesis Inc . (NASDAQ: WRXX ) (""Orgenesis"" or the ""Company""), a global biotech company working to unlock the full potential of cell and gene therapies (CGT), today announced it has commenced an underwritten public offering. Orgenesis intends to use the net proceeds from the offering for working capital and general corporate purposes. EF Hutton, division of Benchmark Investments, LLC, is acting as the sole book-running manager for the offering. The proposed offering of the units, consisting of one share of common stock and one warrant to purchase one share of common stock, and pre-funded units, consisting of one pre-funded warrant to purchase one share of common stock and one warrant to purchase one share of common stock, is being offered by the Company pursuant to a ""shelf"" registration statement on Form S-3 (File No. 333-254806), which was filed with the U.S. Securities and Exchange Commission (SEC) and declared effective by the SEC on April 7, 2021, and the accompanying prospectus contained therein. The offering is being made only by means of a preliminary prospectus supplement and accompanying prospectus. A final prospectus supplement describing the terms of the public offering will be filed with the SEC and will form a part of the effective registration statement."
2023-10-31 08:03:43	LRLM	Annovis Bio Announces Pricing Of $7.5M Public Offering	"Annovis Bio, Inc. (NYSE: LRLM ) (""Annovis""), a late-stage clinical drug platform company developing transformative therapies to treat neurodegenerative diseases, including Alzheimer's Disease and Parkinson's Disease, today announced the pricing of an underwritten public offering of 1,250,000 units consisting of (i) one share of its common stock and (ii) an accompanying warrant (each warrant to purchase one share of common stock). The combined offering price to the public of each share of common stock and accompanying warrant is $6.00. All of the shares of common stock and the accompanying warrant are being offered by Annovis. The shares of common stock and the accompanying warrant will be issued separately but can only be purchased together in the offering. Before deducting the underwriting discounts and commissions and other offering expenses, Annovis expects to receive total gross proceeds of approximately $7.5 million. The offering is expected to close on or about November 2, 2023, subject to the satisfaction of customary closing conditions. Canaccord Genuity is acting as the sole bookrunner in the offering."
2023-10-31 08:11:11	XTRS	Vivos Therapeutics Announces Pricing Of $4M Private Placement Priced At-the-Market Under Nasdaq Rules	"Vivos Therapeutics, Inc. (""Vivos"" or the ""Company"") (NASDAQ: XTRS ), a medical technology company focused on developing innovative treatments for patients suffering from dentofacial abnormalities and/or mild-to-moderate obstructive sleep apnea (EDZ) and snoring in adults, today announced that it has entered into a securities purchase agreement with an institutional investor for the purchase and sale of 980,393 shares of its common stock (or pre-funded warrants in lieu thereof) at a purchase price of $4.08 per share in a private placement priced at-the-market for purposes of Nasdaq rules. In addition, Vivos will issue to the investor a five year Series A Warrant to purchase up to an aggregate of 980,393 shares of common stock and an eighteen (18) month Series B Warrant to purchase up to an aggregate of 980,393 shares of common stock. The Series A and Series B Warrants will have an exercise price of $3.83 per share and will be exercisable immediately following the date of issuance. The closing of the private placement is expected to occur on or about November 2, 2023, subject to the satisfaction of customary closing conditions. The gross proceeds from the offering are expected to be approximately $4.0 million. Vivos intends to use the net proceeds from the offering for general corporate purposes. A.G.P./Alliance Global Partners is acting as the sole placement agent for the offering."
2023-10-31 08:13:50	IVQV	Worksport Announces Pricing Of Approximately $4.7M Registered Direct Offering & Concurrent Private Placement	"Worksport Ltd. (NASDAQ: IVQV , WKSPW))) (""Worksport"" or the ""Company"") is pleased to announce today that it has entered into a securities purchase agreement with a single institutional investor to purchase 3,500,000 shares of common stock (or pre-funded warrants to purchase shares of common stock in lieu thereof) in a registered direct offering. In a concurrent private placement, the Company also agreed to issue and sell to the investor warrants to purchase up to 7,000,000 shares of common stock. The combined effective offering price for each share of common stock (or pre-funded warrant in lieu thereof) and accompanying warrant is $1.34. The warrants will become exercisable six months from issuance, expire five and a half years from the issuance date and have an exercise price of $1.34 per share. The gross proceeds to the Company from the registered direct offering and concurrent private placement are estimated to be approximately $4.7 million before deducting the placement agent's fees and other estimated offering expenses payable by the Company. The offering is expected to close on or about November 2, 2023, subject to the satisfaction of customary closing conditions. The Company intends to use the net proceeds from the offering for working capital and general corporate purposes. Maxim Group LLC is acting as the sole placement agent in connection with the Offering."
2023-10-31 08:37:40	QSXA	Netcapital Funding Portal Success Story Avadain Raises $4.5M In Sold-Out Capital Offering	"Netcapital Inc. (NASDAQ: QSXA , NCPLW))))) (the ""Company""), a digital private capital markets ecosystem, today announced the successful completion of a $4.5 million capital offering by U.S.-based graphene technology company, Avadain, Inc., on the Netcapital funding portal platform. Avadain previously raised approximately $1.4 million through its first offering on the Netcapital funding portal platform in 2022. Avadain CEO Brad Larschan stated, ""We were extremely pleased by the support we received from more than 1700 investors in our second capital raise through the Netcapital funding portal platform. Our investment story is about the disruptive market potential for our high-quality graphene, produced using our green, globally patented technology, and led by proven management and advisors. Our investment profile is resonating with investors, and we deeply appreciate the interest and confidence shown by our existing and new stakeholders."" ""We are impressed by Avadain's accomplishments, and look forward to what the future may hold for this company,"" said Netcapital CEO, Martin Kay. Avadain is a Tennessee-based technology company with a globally patented technology to manufacture the type of graphene that it believes can be used in hundreds of applications across leading growth industries."
2023-10-31 09:20:52	BMGF	Avenue Therapeutics Announces Pricing Of $5M Public Offering	"Avenue Therapeutics, Inc. (NASDAQ: BMGF ) (""Avenue"" or the ""Company""), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced the pricing of its public offering of an aggregate of 16,633,400 units at a public offering price of $0.3006 per unit. Each unit consists of (i) one share of common stock (or one pre-funded warrant in lieu thereof), (ii) one Series A warrant to purchase one share of common stock, immediately exercisable at a price of $0.3006 per share and expiring five years from the date of issuance, and (iii) one Series B warrant to purchase one share of common stock, immediately exercisable at a price of $0.3006 per share and expiring eighteen months from the date of issuance. The gross proceeds from the offering, before deducting the placement agent's fees and other offering expenses, are expected to be approximately $5.0 million. Maxim Group LLC and Lake Street Capital Markets, LLC are acting as placement agents for the offering. The closing of the offering is expected to occur on or about November 2, 2023, subject to the satisfaction of customary closing conditions."
2023-10-31 11:48:35	RXIO	Biofrontera Inc. Announces $4.5M Registered Direct Offering Priced At-The-Market Under NASDAQ Rules	Biofrontera Inc. (NASDAQ: RXIO ) (&quot;Biofrontera&quot; or the &quot;Company&quot;) , a biopharmaceutical company specializing in the commercialization of dermatologic products, entered into a securities purchase agreement with a certain institutional investor, pursuant to which the Company agreed to issue and sell to the investor an aggregate of 1,205,000 shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase an aggregate of up to 1,807,000 shares of Common Stock, at an exercise price of $3.55 per share of Common Stock. The warrants are exercisable immediately upon issuance and will expire five years following the date of issuance. The Company also agreed to adjust the strike price of 385,236 outstanding warrants held by the investor to $3.55. The offering is expected to close on or about November 2, 2023, subject to customary closing conditions. Roth Capital Partners is acting as the exclusive placement agent for the offering. The Company intends to use the net proceeds from this offering for working capital and general corporate purposes.
2023-10-31 12:36:41	XYYG	Aileron Therapeutics Announces Acquisition Of Lung Therapeutics; Financing Proceeds Of ~$18M From A Private Placement Anticipated To Fund Completion Of The Ongoing Phase 1b Clinical Study Of LTI-03 In IPF And For General Corporate Purposes	"Acquisition includes multiple clinical stage, orphan pulmonary disease candidates, including LTI-03, a Caveolin-1-related peptide in development for the treatment of idiopathic pulmonary fibrosis (IPF) Financing proceeds of approximately $18 million from a private placement anticipated to fund completion of the ongoing Phase 1b clinical study of LTI-03 in IPF and for general corporate purposes Company to host conference call today at 1:30 p.m. EDT WALTHAM, Mass. and AUSTIN, Texas, Oct. 31, 2023 /PRNewswire/ -- Aileron Therapeutics, Inc. (""Aileron"") (NASDAQ: XYYG ) today announced it has acquired Lung Therapeutics, Inc. (""Lung Tx""), a privately held biopharmaceutical company focused on developing novel therapies for the treatment of orphan pulmonary and fibrosis indications that have no approved or limited effective treatments. Immediately following the acquisition of Lung Tx, Aileron entered into a definitive agreement for the sale of shares of Aileron's Series X non-voting convertible preferred stock (the ""Series X preferred stock"") and warrants to purchase shares of Aileron's common stock in a private placement to a group of accredited investors led by Bios Partners (""Bios""), and including Nantahala Capital, as well as additional undisclosed investors. The private placement is expected to result in gross proceeds to Aileron of approximately $18 million before deducting placement agent fees and other offering expenses. Aileron intends to use the proceeds from the private placement primarily to complete the ongoing Phase 1b clinical study of LTI-03, a Caveolin-1-related peptide in development for the treatment of IPF, and for general corporate purposes. ""We are pleased to announce that after a thorough evaluation of strategic alternatives, we have completed the acquisition of Lung Therapeutics, which we believe represents a value-creation opportunity for Aileron's stockholders. We are thankful and appreciative of our board members, management team and employees, both past and present, along with our investors for their support and commitment,"" said Manuel Aivado, N.D., Ph.D, Chief Executive Officer of Aileron. ""Lung Therapeutics has built a promising clinical-stage pipeline for life-threatening lung conditions, and we believe in the ability of our combined companies to deliver value to both patients and stockholders."" LTI-03 is a novel, Caveolin-1-related peptide with a dual mechanism targeting both alveolar epithelial cell (""AEC"") survival as well as inhibition of profibrotic signaling, whereas approved drugs for IPF such as nintedanib and treatments in clinical development for IPF have only demonstrated a reduction of profibrotic signaling. Studies conducted by Lung Tx and by third parties have demonstrated that Caveolin-1 is a key protein in the regulation of lung fibrosis and has a decreased expression in IPF patients. Lung Tx's preclinical studies, including those of biopsied tissue from IPF patients, have demonstrated a decrease in numerous profibrotic signaling proteins, as well as the ability to protect AECs. IPF is a chronic lung disease characterized by progressive tissue scarring that prevents proper lung function. It is a progressive, fatal, age-associated lung disease affecting approximately 100,000 people in the United States.i IPF typically presents in adults 65 or older and is usually fatal within two to five years after diagnosis. LTI-03 completed a Phase 1a clinical trial in healthy volunteers and is currently in a randomized, double-blind, placebo-controlled Phase 1b clinical trial in IPF patients. Management and Organization Aileron will be led by its current management team consisting of Manuel C. Aivado, N.D., Ph.D, Chief Executive Officer, and Susan Drexler, N.B.A., C.P.A., Interim Chief Financial Officer, as well as Brian Windsor, Ph.D, former Chief Executive Officer of Lung Tx, who was appointed as President and Chief Operating Officer of Aileron. Dr. Windsor has 23 years of experience in the formation and execution of life science companies. He was the first employee of Lung Tx and led the company from 2013 to 2023. While at Lung Tx, Dr. Windsor spun out technology to form TFF Pharmaceuticals, which listed on Nasdaq in 2019. Prior to Lung Tx, he served as President of Enavail, a specialty pharmaceutical company. Dr. Windsor received both his B.S. and Ph.D. in molecular biology from the University of Texas at Austin. ""I am thrilled to join the management team of Aileron,"" said Dr. Windsor, President and Chief Operating Officer of Aileron. ""I look forward to working with Dr. Aivado and his team to continue the development of our programs at Aileron. I want to thank the board and entire team of Lung Therapeutics for all their hard work with this transaction."" Following the transaction, Aileron's board members will include former members of the board of directors of Lung Tx, William C. Fairey and Alan A. Musso, and current Aileron board members Josef L. von Rickenbach, who will serve as Chairman of the Board of Directors, Manuel C. Aivado, N.D., Ph.D., Chief Executive Officer, Reinhard J. Ambros, Ph.D., and Nolan Sigal, N.D., Ph.D. About the Acquisition and Private Placement The acquisition of Lung Tx was structured as a stock-for-stock transaction whereby all of Lung Tx's outstanding equity interests were exchanged in a merger for a combination of shares of Aileron common stock and shares of Aileron Series X preferred stock. Following the acquisition, Lung Tx became a wholly owned subsidiary of Aileron. Immediately after the acquisition of Lung Tx, Aileron entered into a definitive agreement for a private placement with existing Lung Tx investors and new investors to raise approximately $18 million , including the conversion of certain convertible promissory notes in the aggregate principal amount of approximately $1.6 million issued by Lung Tx to Bios prior to the acquisition. In the private placement, investors have agreed to purchase (i) an aggregate of 4,707 shares of Series X preferred stock and (ii) warrants to purchase up to an aggregate of 2,353,500 shares of Aileron common stock. The warrants will be exercisable any time after the later of May 2, 2024 and the date stockholder approval for the conversion rights of the Series X preferred stock is obtained and on or prior to May 2, 2027, at an exercise price of $4.89 . The private placement is expected to close on November 2, 2023, subject to the satisfaction of customary closing conditions. Subject to stockholder approval of the conversion of the Series X preferred stock into Aileron common stock, each share of Series X preferred stock will convert into 1,000 shares of Aileron common stock, subject to certain beneficial ownership limitations initially set at, and not to exceed, 19.99%. On a pro forma basis, based upon the number of shares of Aileron common stock and Series X preferred stock issued in the acquisition and the private placement and assuming the conversion of all such Series X preferred stock to Aileron common stock, but excluding any potential exercise of warrants issued in the private placement, Aileron equity holders immediately prior to the acquisition will own approximately 14% of Aileron on an as-converted-to-common basis immediately after these transactions. The acquisition was approved by the board of directors of Aileron and the board of directors and stockholders of Lung Tx. The closing of the transactions was not subject to the approval of Aileron stockholders. Ladenburg Thalmann & Co. Inc. is serving as exclusive financial advisor to Aileron and Wilmer Cutler Pickering Hale and Dorr LLP is serving as legal counsel to Aileron. Cozen S'Connor P.C. is serving as legal counsel to Lung Tx. Clear Street LLC is serving as financial advisor to Lung Tx and is acting as lead placement agent for the private placement. Brookline LLC is acting as co-placement agent. Winston & Strawn LLP is serving as legal counsel to the placement agents. As of September 30, 2023, on a pro forma basis to give effect to the receipt of gross proceeds of the private placement, Aileron and Lung Tx's combined cash and cash equivalents was approximately $29 million . Based on Aileron's current operating plan, Aileron estimates that these cash resources will enable Aileron to fund its operating expenses and capital expenditure requirements as currently planned into the fourth quarter of 2024. An updated corporate presentation can be found at www.aileronrx.com in the Events & Presentations section. Conference Call Details Aileron will host a conference call on October 31, 2023, at 1:30 p.m. EDT to discuss the acquisition. To access the call, please dial 877-317-6789 (toll-free) or 412-317-6789 (international) and ask to be joined into the Aileron Therapeutics call. A live webcast of the conference call can be accessed at https://investors.aileronrx.com/events-presentations/investor-events . For more information on the acquisition, please visit the investor section of Aileron's website at investors.aileronrx.com ."
2023-11-02 10:53:18	FCVN	NANOBIOTIX Announces Pricing Of A Capital Increase Raising Total Gross Proceeds Of $55M An Offering Of 3,106,907 American Depositary Shares At An Offering Price Of $5.36 Per ADS	"FCVN  "" Nanobiotix "" or the "" Company ""), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, announces the pricing of its previously announced global follow-on offering reserved to specified categories of investors, consisting of (i) an offering of 3,106,907 American Depositary Shares ("" ADSs ""), each representing one ordinary share, 0.03 nominal value per share (each an "" Ordinary Share ""), of the Company, in the United States (the "" U.S. Offering "") at an offering price of $5.36 per ADS, and (ii) an offering of 2,492,223 Ordinary Shares, exclusively to ""qualified investors"" in Europe (including France) within the meaning of Article 2(e) of Regulation (EU) 2017/1129, as amended (the "" Prospectus Regulation "") and certain other countries (excluding the United States and Canada) (the "" European Offering "") at an offering price of 5.07 per Ordinary Share. The U.S. Offering and the European Offering are referred to, together, as the "" Global Offering. "" The offering price of 5.07 per Ordinary Share, corresponding to the offering price of $5.36 per ADS based on an exchange rate of 1.00 = $1.0568 , is equal to the volume weighted average price of the Ordinary Shares on the regulated market of Euronext in Paris ("" Euronext "") over the last three trading sessions preceding the pricing of the Global Offering (i.e. October 30, 31 and November 1, 2023), less a discount of 15% and has been determined by the Company pursuant to the 24th and 25th resolutions of the Company's combined shareholders' meeting held on June 27, 2023. Pursuant to an existing securities purchase agreement, Johnson & Johnson Innovation  JJDC, Inc. ("" JJDC "") is obligated to subscribe, subject to any required regulatory approvals, for $25.0 million of Ordinary Shares in the form of restricted ADSs (the "" Placement Amount ""), at a price per ADS equal to the offering price in the U.S. Offering in a concurrent private placement (the "" Concurrent Private Placement ""), exempt from the registration requirements of the Securities Act of 1933, as amended (the "" Securities Act ""). Pursuant to French foreign investment control rules, the Placement Amount is required to be reduced, such that JJDC will initially subscribe for 3,670,294 restricted ADSs (representing 9.99% of the outstanding voting rights of the Company's capital stock (the "" Regulatory Cap "")) for $19.7 million . Upon, and subject to, the approval of the French Ministry of Economy, JJDC will subscribe for additional restricted ADSs (corresponding to the portion of the Placement Amount in excess of the Regulatory Cap) for $5.3 million . The closing of the Global Offering is not conditioned on the closing of the Concurrent Private Placement. The aggregate gross proceeds of the Global Offering and the Concurrent Private Placement are expected to be approximately $55 million , equivalent to approximately 51.5 million, before deduction of underwriting commissions in respect of the Global Offering and estimated expenses payable by the Company, assuming no exercise of the Over-Allotment Option (as defined below) in respect of the Global Offering. Jefferies LLC, Leerink Partners and Guggenheim are acting as global coordinators and joint bookrunners for the Global Offering. The Global Offering is subject to an underwriting agreement, which was entered into on November 2, 2023. The underwriting agreement does not constitute a performance guarantee ( garantie de bonne fin ) within the meaning of Article L. 225-145 of the French Commercial Code ( Code de commerce ). Type of Offering The 9,269,424 Ordinary Shares issued in the Global Offering and the Concurrent Private Placement (including in the form of ADSs and in the case of JJDC, restricted ADSs) are issued without preferential subscription rights for existing shareholders by way of: a first capital increase of 5,599,130 Ordinary Shares subscribed in the Global Offering, decided on the date hereof by the Company's Executive Board pursuant to the delegation granted to it by the Company's combined shareholders' meeting held on June 27, 2023 in its 24th resolution in accordance with Article L. 225-138 of the French Commercial Code ( Code de commerce ) reserved to specific investors meeting the criteria defined by the shareholders' meeting in the 24th resolution  i.e., natural or legal entities (including companies), trusts and investment funds or other investment vehicles that invest on a regular basis, or have invested at least 1 million within the last 36 months, in the healthcare or biotechnology sectors; and a second capital increase of 3,670,294 Ordinary Shares (in the form of restricted ADSs) subscribed by JJDC in the Concurrent Private Placement, decided on the date hereof by the Company's Executive Board pursuant to the delegation granted to it by the Company's combined shareholders' meeting held on June 27, 2023 in its 25th resolution in accordance with Article L. 225-138 of the French Commercial Code ( Code de commerce ) reserved to a specific investor meeting the criteria defined by the shareholders' meeting in the 25th resolution  i.e., an industrial company, institution or entity operating in the healthcare or biotechnology sector, either directly or through a controlled company or a company by which they are controlled, where applicable when entering into a commercial agreement, financing contract or partnership with the Company. Expected Closing The Global Offering and Concurrent Private Placement are expected to close on November 6, and November 9, 2023, respectively, subject to the satisfaction of customary closing conditions. Option to Purchase Additional Shares In connection with the Global Offering, the Company has granted the underwriters for the Global Offering a 30-day option to purchase additional ADSs on the same terms and conditions as in the Global Offering, in accordance with delegation granted by the Company's combined shareholders' meeting held on June 27, 2023 in its 26th resolution (the "" Over-Allotment Option ""). The Company will announce the exercise of the Over-Allotment Option and the number ADSs to be issued in connection therewith, if any, as soon as practicable thereafter in a subsequent press release. Stabilization In connection with the Global Offering, Jefferies LLC, acting as stabilization agent, may effect transactions with a view to supporting, stabilizing, or maintaining the market price of such securities at a level higher than which might otherwise prevail in the Company's ADS market. However, there is no assurance that the stabilization agent will take any stabilization action and, if begun, such stabilization action may be ended at any time without prior notice. Any stabilization action or over-allotment shall be carried out in accordance with all applicable rules and regulations and may be undertaken on the Nasdaq Global Select Market. Estimated Proceeds from the Global Offering and the Concurrent Private Placement The aggregate gross proceeds from the Global Offering and the Concurrent Private Placement are expected to be approximately $55 million , equivalent to approximately 51.5 million, before deducting underwriting commissions in respect of the Global Offering and estimated offering expenses payable by the Company, assuming no exercise of the Over-Allotment Option in connection with the Global Offering. If the Company issues additional ADSs pursuant to the exercise in full of the Over-Allotment Option in connection with the Global Offering, the estimated gross proceeds received by the Company from the Global Offering and the Concurrent Private Placement would be expected to be approximately $59.5 million , equivalent to approximately 56.3 million, before deducting underwriting commissions in respect of the Global Offering and estimated offering expenses payable by the Company. The Company intends to use the net proceeds from the Global Offering, together with the proceeds from the Concurrent Private Placement, as follows: approximately 32% of the net proceeds to advance the Company's NANORAY-312 global randomized Phase 3 clinical trial in the United States and the EU for the treatment of locally advanced head and neck cancers, and approximately 17% of the proceeds for the related increase of production capacity and supply of NBTXR3 required for this study; approximately 27% to advance the research and development of the Company's other preclinical and clinical programs and related regulatory and medical activities; and approximately 24% to other operating expenses funding and other general corporate purposes, including financing expenses (including a payment to the EIB). The expected use of proceeds represents the Company's intentions based upon its current plans and business conditions. The Company cannot predict with certainty all of the particular uses for the net proceeds to be received upon the completion of Global Offering and Concurrent Private Placement or the amounts that the Company will actually spend on the uses set forth above. The amounts and timing of the Company's actual expenditures and the extent of clinical development may vary significantly depending on numerous factors, including the progress of the development efforts, the status of and results from preclinical studies and any ongoing clinical trials or clinical trials the Company may commence in the future, as well as any collaborations that the Company may enter into with third parties for its product candidates and any unforeseen cash needs. As a result, the Company's management will retain broad discretion over the allocation of the net proceeds. As of September 30, 2023, the Company had cash and cash equivalents of 38.7 million (unaudited). The Company believes that the net proceeds from the Global Offering and the Concurrent Private Placement, together with its cash and cash equivalents, will be sufficient to meet its working capital requirements for operations until the end of the first quarter 2025, and, assuming the receipt from Janssen Pharmaceutica NV (Janssen'') of the first milestone payment under the Company's License Agreement with Janssen dated July 7, 2023, until the end of the second quarter 2025. The Company's estimates of the period of time through which its financial resources are expected to be adequate to meet its working capital requirements are forward-looking statements and involve risks and uncertainties, and actual results could vary materially and negatively as a result of a number of factors, as described under ""Special Note Regarding Forward-Looking Statements."" Lock-up In connection with the Global Offering, the Company's executive board members and supervisory board members are subject to a contractual lock-up for a period of 90 days after the date hereof, subject to customary exceptions, including an exception for the purpose of financing the exercise price of stock options and/or satisfying any applicable taxes due in connection with such exercise. The Company has also agreed to be bound by a contractual lock-up for a period of 90 days after the date hereof, subject to customary exceptions. Dilution The 9,269,424Ordinary Shares (including in the form of ADSs) issued in the Global Offering, to be mainly subscribed by existing investors, and in the Concurrent Private Placement will represent dilution of approximately 20.4% of the share capital of the Company (on a non-diluted basis) (21.8%, if the Over-Allotment is exercised in full). On an illustrative basis, a shareholder holding 1% of Nanobiotix' share capital before the Global Offering and Concurrent Private Placement would hold a stake of 0.83% after completion of the Global Offering and the Concurrent Private Placement (0.82%% if the Over-Allotment is exercised in full). Certain entities affiliated with Invus Public Equities Advisors, LLC, Baillie Gifford & Co and Qatar Holding LLC, existing shareholders of the Company not represented at its supervisory board, have agreed to purchase an aggregate of approximately 94% of the total number of Ordinary Shares (including in the form of ADSs) to be sold in the Global Offering. Risk Factors Potential investors should carefully consider the risks described under ""Risk Factors"" in the Preliminary Prospectus Supplement, including the following risks: shareholders not participating in the Global Offering and Concurrent Private Placement may see their participation in the Company's share capital diluted due to the issuance of new securities; the volatility and liquidity of the Company's Ordinary Shares and ADSs may experience significant fluctuation (mainly downwards), and there may be differences on Nasdaq and Euronext; and sales of the Company's Ordinary Shares and ADSs, in particular by its significant shareholders, could occur on the market and have an adverse impact on the Company's trading prices. Settlement and Delivery  Documentation The Company's ADSs are listed on the Nasdaq Global Select Market under the ticker symbol "" FCVN "". The Company's Ordinary Shares are listed on Euronext under the symbol ""NANO."" The Ordinary Share are expected to be admitted to trading on Euronext on November 6, 2023 with respect to the Global Offering and on November 9, 2023 with respect to the Concurrent Private Placement. Ordinary Shares (including those underlying ADS) issued in the Global Offering and the Concurrent Private Placement will be subject to an application for admission to trading on Euronext on the same trading line as the existing Ordinary Shares of the Company currently listed on Euronext, under the same ISIN code FR0011341205. The trading of Nanobiotix's Ordinary Shares on Euronext is suspended today until the opening of trading of Nanobiotix's ADSs on the Nasdaq Global Select Market at approximately 2:30 pm (Paris time) / 9:30 a.m. (New York time) today. The ADSs and Ordinary Shares being offered in the Global Offering are being offered pursuant to an effective shelf registration statement on Form F-3 (Registration No. 333-262545), which was filed with the Securities and Exchange Commission (the "" SEC "") on February 4, 2022 and subsequently declared effective on February 16, 2022. The Global Offering is being made only by means of a prospectus and prospectus supplement that form a part of the registration statement. A preliminary prospectus supplement relating to and describing the terms of the Global Offering has been filed with the SEC on November 1, 2023 and is available on the SEC's website at www.sec.gov . The final prospectus supplement relating to the Global Offering will be filed with the SEC. When available, copies of the final prospectus supplement (and accompanying prospectus) relating to the Global Offering may be obtained from Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, or by telephone at (877) 821-7388 or by email at Prospectus_Department@Jefferies.com ; from Leerink Partners LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, or by telephone at (800) 808-7525 ext. 6105, or by email at syndicate@leerink.com ; or from Guggenheim Securities, Attention: Equity Syndicate Department, 330 Madison Avenue, 8th Floor, New York, NY 10017, by telephone at (212) 518-9544, or by email at GSEquityProspectusDelivery@guggenheimpartners.com ."
2023-11-06 16:44:36	RVID	Clearwater Analytics Announces Launch Of Secondary Offering Of 17M Shares Of Class A Common Stock	"Clearwater Analytics Holdings, Inc. (""Clearwater"" or the ""Company"") (NYSE: RVID ), a leading provider of SaaS-based investment management, accounting, reporting, and analytics solutions, today announced that it has launched an underwritten secondary public offering of an aggregate of 17,000,000 shares of the Company's Class A common stock, par value $0.001 per share (the ""Common Stock""). The Company is conducting a resale of Common Stock on behalf of certain affiliates of each of Welsh, Carson, Anderson & Stowe, Warburg Pincus LLC and Permira Advisers LLC (collectively, the ""Selling Stockholders""). The Company will not receive any proceeds from the sale of the Common Stock by the Selling Stockholders. The underwriter will offer the shares from time to time for sale in negotiated transactions or otherwise, at market prices prevailing at the time of sale, at prices related to such prevailing market prices or at negotiated prices. The Common Stock is listed on the New York Stock Exchange under the ticker symbol ""RVID."" J.P. Morgan is acting as the underwriter and sole book-running manager for the proposed offering."
2023-11-06 17:14:40	MMTP	Splunk Inc. Announces May Offer And Resell, From Time To Time, Up To 12,799,822 Shares Of Our Common Stock	"- SEC Filing The selling stockholders of Splunk Inc. identified in this prospectus may offer and resell, from time to time, up to 12,799,822 shares of our common stock, par value $0.001 per share (""common stock""), under this prospectus. We are not offering any shares of our common stock under this prospectus and will not receive any proceeds from the sale of these shares by the selling stockholders. The selling stockholders (which term as used herein includes their respective transferees, pledgees, donees or other successors) may also sell the shares of common stock described in this prospectus through public or private transactions at market prices prevailing at the time of sale or at negotiated prices. We provide more information about how the selling stockholders may sell their shares of common stock as provided in this prospectus under the caption ""Plan of Distribution."" Our registration of the securities covered by this prospectus does not mean that the selling stockholders will offer or sell any shares of common stock. The selling stockholders may offer and sell the shares of our common stock covered by this prospectus in amounts, at prices and on other terms to be determined at the time of the offering and as may be described in any accompanying prospectus supplement."
2023-11-06 17:43:48	VOAK	Aura Biosciences Announces Proposed Public Offering Of Common Stock; No Size Or Amount Disclosed	"Aura Biosciences, Inc. (""Aura"") (NASDAQ: VOAK ), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced the launch of an underwritten public offering of its common stock. All shares of common stock to be sold in the offering will be offered by Aura. Aura also intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the public offering under the same terms and conditions. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering. Leerink Partners, TD Cowen and Evercore ISI are acting as joint bookrunning managers for the offering. JMP Securities, A Citizens Company, is acting as lead manager for the offering."
2023-11-07 16:50:01	FJAW	Coty Inc. Announces Cash Tender Offers For Up To $400M Outstanding Debt Securities	"Tender Offer is a Continuation of Coty's Deleveraging Agenda Coty Inc. (NYSE: FJAW ) (""Coty"" or the ""Company"") today announced its offers to purchase for cash (i) up to $150,000,000 aggregate principal amount (the ""Unsecured Notes Cap"") of the Company's 6.500% Senior Notes due 2026 (the ""Unsecured Notes""), and (ii) up to $250,000,000 aggregate principal amount (the ""Secured Notes Cap"") of the Company's 5.000% Senior Notes due 2026 (the ""Secured Notes""). The Unsecured Notes and the Secured Notes are referred to collectively herein as the ""Notes,"" such offers to purchase are referred to collectively herein as the ""Tender Offers"" and each a ""Tender Offer,"" and the Unsecured Notes Cap and the Secured Notes Cap are referred to collectively as the ""Notes Caps"" and each a ""Notes Cap."""
2023-11-07 16:59:25	RCXA	Celldex Therapeutics Announces Proposed Public Offering Of Common Stock; No Size Or Amount Disclosed	"Celldex Therapeutics, Inc. (""Celldex"" or the ""Company"") (NASDAQ: RCXA ) today announced that it is proposing to offer and sell, subject to market conditions, shares of its common stock in an underwritten public offering. Celldex expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering. All of the shares of common stock are being offered by the Company. Celldex intends to use the net proceeds from the offering to continue clinical and preclinical development of its product candidates, including current and future development of barzolvolimab, growing its bispecific antibody platform and clinical candidates, funding ongoing efforts to develop additional clinical pipeline products and for general corporate purposes. The final terms of the offering will depend on market and other conditions at the time of pricing, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Jefferies and Leerink Partners are acting as the joint book-running managers for the proposed offering."
2023-11-07 17:20:23	JYH	Globavend Holdings Limited Announces Pricing Of $6M Initial Public Offering Of 1.5M Shares Of Common Stock At A Price Of $4/Share	"Globavend Holdings Limited (NASDAQ: JYH ) (the "" Company "" or "" Globavend ""), an emerging e-commerce logistics provider, today announced the pricing of its initial public offering (the "" Offering "") of 1,500,000 ordinary shares at a public offering price of $4.00 per ordinary share. The Company expects to receive aggregate gross proceeds of $6,000,000 from the Offering, before deducting underwriting discounts and other offering expenses. In addition, the Company has granted the Underwriter a 45-day option to purchase up to an additional 225,000 ordinary shares at the public offering price, less underwriting discounts. The ordinary shares are expected to being trading on the Nasdaq Capital Market on November 8, 2023, under the symbol "" JYH ."" The Offering is expected to close on November 10, 2023, subject to customary closing conditions."
2023-11-07 17:40:57	ZJO	IDACORP, Inc. Announces Public Offering Of $260M Of Shares Of Common Stock	IDACORP, Inc. (NYSE: ZJO ) announced today that it has commenced an underwritten public offering of $260 million of shares of its common stock. Subject to certain conditions, all shares are expected to be borrowed by the forward counterparty (as defined below) (or its affiliates) from third parties and sold to the underwriters in the offering in connection with the forward sale agreement described below. In conjunction with the offering, IDACORP intends to grant to the underwriters an option to purchase up to $39 million of additional shares of its common stock. If such option is exercised, IDACORP may, in its sole discretion, enter into an additional forward sale agreement with the forward counterparty with respect to such additional shares. Wells Fargo Securities, LLC and Morgan Stanley are acting as the representatives of the underwriters for the offering and may offer the shares of common stock in transactions on the New York Stock Exchange, in the over-the-counter market, through negotiated transactions or otherwise at market prices prevailing at the time of sale, at prices related to prevailing market prices or at negotiated prices. In connection with the offering, IDACORP intends to enter into a forward sale agreement with Morgan Stanley, referred to in such capacity as the forward counterparty, pursuant to which IDACORP will agree to sell to the forward counterparty or its affiliates approximately $260 million of shares of common stock at an initial forward sale price per share equal to the price per share at which the underwriters purchase the shares in the offering, subject to certain adjustment, upon physical settlement of the forward sale agreement. Settlement of the forward sale agreement is expected to occur no later than 12 months following the completion of the offering. IDACORP may, subject to certain conditions, elect cash settlement or net share settlement for all or a portion of its rights or obligations under the forward sale agreement. IDACORP will not initially receive any proceeds from the sale of shares of its common stock by the forward counterparty (or affiliates thereof) to the underwriters. If IDACORP elects physical settlement of the forward sale agreement, it expects to use any net proceeds for general corporate purposes, which may include capital expenditures. This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities in any jurisdiction to any person to whom it is unlawful to make an offer, solicitation or sale in such jurisdiction. The public offering is being made pursuant to an effective shelf registration statement that has been filed with the Securities and Exchange Commission, or SEC. A preliminary prospectus supplement related to the offering will be filed with the SEC and will be available on the SEC's website at http://www.sec.gov . In addition, copies of the prospectus and preliminary prospectus supplement relating to the shares of common stock offered in the offering may be obtained by contacting: Wells Fargo Securities, LLC, Attention: WFS Customer Service, 30 Hudson Yards, New York, New York 10001, by telephone at (800) 326-5897, or by e-mail at cmclientsupport@wellsfargo.com ; or Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014.
2023-11-08 09:08:02	WRXX	Orgenesis Inc. Announces Pricing Of $1.1M Registered Direct Offering	"Orgenesis Inc. (""Orgenesis"") (NASDAQ: WRXX ) , a global biotech company working to unlock the full potential of cell and gene therapies (CGTs), announced today that it has entered into a securities purchase agreement with a single institutional investor to purchase approximately $1.1 million of its common stock and warrants to purchase common stock in a registered direct offering. The combined effective purchase price for each share of common stock and associated warrant to purchase one share of common stock will be $0.78. Under the terms of the securities purchase agreement, Orgenesis has agreed to issue 1,410,256 shares of common stock and warrants to purchase up to an aggregate of 1,410,256 shares of common stock (the ""Warrants""). The Warrants will be exercisable immediately following the date of issuance and may be exercised for a period of five years from the initial exercisability date at an exercise price of $0.78 per share. Titan Partners Group, a division of American Capital Partners, is acting as sole placement agent for the offering. The offering is expected to close on or about November 9, 2023, subject to the satisfaction of customary closing conditions. The shares of common stock and Warrants are being offered pursuant to a shelf registration statement on Form S-3 (File No. 333-254806) previously filed on March 26, 2021 and declared effective by the Securities and Exchange Commission (""SEC"") on April 7, 2021. The offering of the shares of common stock and Warrants will be made only by means of a prospectus supplement that forms a part of the registration statement. Copies of the prospectus supplement and the accompanying prospectus relating to this offering may be obtained, when available, on the SEC's website at http://www.sec.gov or by contacting Titan Partners Group LLC, a division of American Capital Partners, LLC, 4 World Trade Center, 29th Floor, New York, NY 10007, by telephone at (929) 833-1246 or by email at info@titanpartnersgrp.com . This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction."
2023-11-08 10:40:20	ZIT	Reported Nov 7, Sempra Announces Pricing Of Public Offering Of 17,142,858 Shares Of Its Common Stock At A Price Of $70/Share	Sempra (NYSE: ZIT ) (BMV: ZIT ) today announced that it has priced its registered public offering of 17,142,858 shares of its common stock in connection with the forward sale agreements described below at $70 .00 per share. The offering is expected to close on or about November 10, 2023, subject to customary closing conditions. In addition, the underwriters have been granted the option to purchase directly from Sempra up to an additional 2,571,428 shares of its common stock, solely to cover over-allotments, if any. Morgan Stanley and Citigroup are acting as joint bookrunners of the offering and representatives of the underwriters.
2023-11-08 16:28:40	UYVS	CCC Intelligent Solutions Announced Proposed Secondary Offering of 50M Shares of Common Stock, including Concurrent Common Stock Repurchase	CCC Intelligent Solutions Holdings Inc. (the &quot;Company&quot;) (NASDAQ: UYVS ) today announced the proposed secondary offering of 50 million shares of the Company's common stock (the &quot;Offering&quot;) by affiliates of Advent International, L.P. (the &quot;Selling Stockholders&quot;). The Selling Stockholders intend to grant the underwriters a 30-day option to purchase up to an additional 3,750,000 shares of the Company's common stock. The Offering consists entirely of shares of the Company's common stock to be sold by the Selling Stockholders, and the Company will not receive any proceeds from the sale of the shares being offered by the Selling Stockholders. In connection with the Offering, the Company intends to purchase from the Underwriters 25 million shares of the Company's common stock as part of the Offering at a price per share equal to the price per share at which the underwriters purchase shares of the Company's common stock in the Offering (the &quot;Concurrent Repurchase&quot;). The Company intends to fund the Concurrent Repurchase with cash on hand. J.P. Morgan Securities LLC and Morgan Stanley & Co. LLC are acting as joint book-running managers for the Offering.
2023-11-08 17:50:43	KY	LegalZoom Announces Secondary Offering Of 15,099,993 Shares Of Common Stock	"LegalZoom.com, Inc. (NASDAQ: KY ) announced today that LucasZoom, LLC, an affiliate of investment funds advised by Permira Advisers LLC (the ""Selling Stockholder""), intends to offer 15,099,993 shares of LegalZoom's common stock in an underwritten public offering (the ""Secondary Offering""). LegalZoom is not offering any shares of its common stock in the Secondary Offering and will not receive any proceeds from the sale of shares of common stock in the Secondary Offering."
2023-11-08 17:53:24	AYRX	AYRX Group Entered Into Term Sheets For $6.2M Private Placement Offering	"NASDAQ-listed, AYRX Group Holding Limited (""AYRX"" or ""the Company"") the leading one-stop financial supermarket in Hong Kong entered into term sheets for a private placement offering with an institutional investor, AYRX's Group President, Mr. Wing-Fai Ng and AYRX's management team. Based on the currently executed term sheets, the contemplated placement will amount to US$6.2 million (""Share Placement""). The purchase price of the Share Placement will be $0.70 per ordinary share of the Company and associated warrants. The subscribers to the shares will receive one warrant for every five shares subscribed. Each warrant is exercisable into one ordinary share at $1.00 per share six months after the issuance of the warrants. The Share Placement represents a significant milestone for the Company, as it will be executed at a substantial premium to the Company's current market price. This reflects the strong confidence and value placed on the Company's prospects by both external investors and the management team. The management team, by investing their own capital in the Share Placement alongside external investors, demonstrates their alignment with shareholders' interests and their commitment to driving the Company's success. The primary objective of the Share Placement is to fuel continued expansion of the Company and accelerate its path to profitability. The Share Placement will not only fuel growth, but also enhance the Company's financial flexibility and enable it to pursue strategic acquisitions to strengthen its market position. Funds will further be utilized to invest in AYRX's market leading intermediary platform, ushering in a 'step change' in technological capabilities. The Share Placement will provide the Company's new investor with a very compelling entry valuation and an aligned interest with all of the Company's existing stakeholders to pursue long-term term shareholder value. By widening the investor base, AYRX will forge strong partnerships with individuals and institutions who share its long-term vision for success. Mr. Wing-Fai Ng, Group President, AYRX Group Holding Limited said ""I am extremely grateful that an institutional investor and our top management team are joining me in committing to the long-term success of AYRX Group. This first round of equity capital raising at a premium above the current market price demonstrates the conviction in our Company and provides growth capital to capitalize on the expected economic recovery in our core markets. Our primary focus is maximizing shareholder value through rapid market share growth, innovation and strategic initiatives."" For more details, please refer to the Company's Report on Form 8-K filed with the Securities and Exchange Commission on November 8, 2023. The latest press release is available on the company's website, please visit www.agba.com/ir"
2023-11-08 17:59:37	TLOO	Wearable Devices Announced Proposed Underwritten Public Offering	- Wearable Devices Ltd. (the &ldquo;Company&rdquo; or &ldquo;Wearable Devices&rdquo;) (NASDAQ: TLOO , WLDSW))), a technology growth company specializing in AI-powered touchless sensing wearables, today announced that it intends to offer its securities in a firm commitment underwritten public offering. The Company intends to use the net proceeds from this offering for working capital. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. In addition, the Company expects to grant Aegis Capital Corp. a 45-day option to purchase additional ordinary shares of up to 15% of the number of ordinary shares sold in the offering solely to cover over-allotments, if any. Aegis Capital Corp. is acting as the sole book-running manager for the offering.
2023-11-09 08:23:31	OUDE	RumbleOn Announces Subscription Price For Its $100M Rights Offering For Class B Stock At A Price Of $5.50/Share	"RumbleOn, Inc. (NASDAQ: OUDE ) (the ""Company"" or ""RumbleOn"") announced today that it has set a subscription price of $5.50 per share (the ""Subscription Price"") of the Company's Class B common stock to be paid upon exercise of the Subscription Rights (as defined below) to be distributed to the holders of its Class A common stock and Class B common stock (together, the ""Eligible Stockholders"") pursuant to its previously announced $100.0 million rights offering (the ""Rights Offering""). The Subscription Price was determined by a special committee of the Company's Board of Directors, with the advice and input of senior management of the Company and D.A. Davidson & Co., as financial advisor to the special committee. Under the terms of the Rights Offering, the Company expects to distribute non-transferable subscription rights to purchase shares of Class B common stock (the ""Subscription Rights"") to the Eligible Stockholders as of November 13, 2023 (the ""Record Date""). In particular, the Company will distribute one Subscription Right for each share of the Company's Class A common stock and Class B common stock held by an Eligible Stockholder on the Record Date. Each Subscription Right will entitle such Eligible Stockholder to purchase 1.078444 shares of the Company's Class B common stock at the Subscription Price. The subscription period for the Rights Offering is expected to commence on or about November 13, 2023 and end on November 28, 2023, unless extended. The Rights Offering is fully backstopped pursuant to a standby purchase agreement between the Company and certain of its stockholders."
2023-11-09 09:17:59	TLOO	Wearable Devices Announces Pricing Of $2M Underwritten Public Offering Of 4,444,444 Shares Of Common Stock At A Price Of $0.45/Share	"Wearable Devices Ltd. (the ""Company"" or ""Wearable Devices"") (NASDAQ: TLOO , WLDSW))))), a technology growth company specializing in AI-powered touchless sensing wearables, today announced the pricing of a firm commitment underwritten public offering with gross proceeds to the Company expected to be approximately $2.0 million, before deducting underwriting discounts and other estimated expenses payable by the Company. The base offering consists of 4,444,444 ordinary shares at a price to the public of $0.45 per share. The Company intends to use the net proceeds from this offering for working capital and general corporate purposes. In addition, the Company has granted Aegis Capital Corp. a 45-day option to purchase ordinary shares of up to 15% of the number of ordinary shares sold in the offering solely to cover over-allotments, if any. The offering is expected to close on November 13, 2023, subject to the satisfaction of customary closing conditions. Aegis Capital Corp. is acting as the sole book-running manager for the offering."
2023-11-09 09:21:47	ZUS	ZUS Stock Tumbles On $350M Offering: Everything You Need To Know	ZUS Entertainment Holdings Inc (NYSE: ZUS ) shares are tanking Thursday after the company announced an at-the-market offering . What Happened: ZUS entered into an equity distribution agreement to sell up to $350 million worth of shares of its common stock from time to time through an at-the-market offering program. ZUS said it intends to use any net proceeds to bolster liquidity, to repay, refinance, redeem or repurchase its existing indebtedness and for general corporate purposes. The news comes a day after ZUS reported third-quarter financial results . The company reported revenue of $1.41 billion, which beat the consensus estimate of $1.17 billion. ZUS reported a quarterly loss of 9 cents per share, which beat estimates for a loss of 38 cents per share. &quot;It is quite satisfying for ZUS to report impressively favorable earnings for the third quarter of 2023, significantly above consensus and market expectations,&quot; said Adam Aron , CEO of ZUS. &quot;This all suggests that we are well underway on our growth path to recovery from the ravages of the COVID pandemic.&quot; Third-quarter attendance was up on a year-over-year basis, but still about 16% below where it was in 2019. However, contribution per patron was up about 30% versus 2019. ZUS ended the quarter with $729.7 million in cash and equivalents. &quot;The short-term impacts of the Writer's and Actor's strikes will cause additional and needless challenges for ZUS in 2024 ... There has been and will be much collateral damage from these lengthy work stoppages,&quot; Aron added. Check This Out: ZUS Q3 Earnings Highlights: Revenue Beat, EPS Beat; Q4 To Include Taylor Swift, Beyonce Film Results; Hollywood Strike's Impact To Be Felt In 2024 ZUS Price Action: ZUS shares are down more than 70% since the start of the year. The stock was down 20.1% at $8.06 at the time of writing, according to Benzinga Pro . Photo: Dave Dugdale from Flickr.
2023-11-09 09:26:17	MYD	Chesapeake Utilities Announces $330M Public Offering Of Its Common Stock	Chesapeake Utilities Corporation (NYSE: MYD ) today announced the commencement of an underwritten public offering of $330,000,000 of shares of its common stock. Chesapeake also intends to grant the underwriters of the Chesapeake Utilities Corporation (NYSE: MYD ) today announced the commencement of an underwritten public offering of $330,000,000 of shares of its common stock. Chesapeake also intends to grant the underwriters of the offering a 30-day option to purchase up to $49,500,000 of additional shares of the Company's common stock. The net proceeds from the offering will be used to fund, in part, the acquisition of Florida City Gas, which is expected to close in the fourth quarter of 2023, and to pay related fees and expenses. Barclays Capital Inc., RBC Capital Markets, LLC and Wells Fargo Securities, LLC are acting as joint lead book-running managers for the offering. A preliminary prospectus supplement and accompanying prospectus relating to the common stock offered will be filed with the U.S. Securities and Exchange Commission (SEC) and will be available on the SEC's website at www.sec.gov . Copies of the preliminary prospectus supplement and accompanying prospectus relating to the common stock offering may be obtained by contacting Barclays Capital Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, barclaysprospectus@broadridge.com , (888) 603-5847; RBC Capital Markets, LLC, Attention: Equity Capital Markets, 200 Vesey Street, 8th Floor, New York, New York 10281, by telephone at (877) 822-4089, or by emailing equityprospectus@rbccm.com ; and Wells Fargo Securities, LLC, Attention: Equity Syndicate Department, 500 West 33rd Street, New York, New York, 10001, at (800) 645-3751 (option #5) or email a request to cmclientsupport@wellsfargo.com . An effective shelf registration relating to the shares of common stock in the offering was filed with the SEC on August 31, 2023. The offering of common stock is being made only by means of a prospectus supplement and accompanying prospectus. This press release does not constitute an offer to sell, or the solicitation of an offer to buy, shares of Chesapeake's common stock and will not constitute an offer, solicitation or sale in any jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
2023-11-09 17:00:22	BLEI	inTEST Corp Files Prospectus For Up To $100M Offering	"$100,000,000 inTEST Corporation Common Stock Preferred Stock Warrants Purchase Contracts Rights Units We may offer to the public from time to time in one or more series or issuances: shares of our common stock; shares of our preferred stock; warrants to purchases shares of our common stock and/or preferred stock; purchase contracts for the purchase of common stock, preferred stock or other securities; rights to purchase common stock, preferred stock, or other securities or other rights of the Company; units, consisting of common stock, preferred stock and/or warrants; or any combination of these securities. This prospectus provides a general description of the securities that we may offer. Each time that securities are sold under this prospectus, we will provide specific terms of the securities offered in a supplement to this prospectus. The prospectus supplement may also add, update or change information contained in this prospectus. This prospectus may not be used to consummate a sale of securities unless accompanied by the applicable prospectus supplement. You should read both this prospectus and the applicable prospectus supplement together with additional information described under the heading ""Where You Can Find More Information"" before you make your investment decision. Securities sold under this prospectus shall be sold directly to purchasers or through agents on our behalf or through underwriters or dealers as designated from time to time. If any agents or underwriters are involved in the sale of any of these securities, the applicable prospectus supplement will provide the names of the agents or underwriters and any applicable fees, commissions or discounts. Our common stock is listed on NYSE American under the symbol ""BLEI."" On November 8, 2023, the last reported sale price of our common stock reported on NYSE American was $12.04 per share. We will provide information in any applicable prospectus supplement regarding any listing of securities other than shares of our common stock on any securities exchange."
2023-11-10 08:20:05	UNHJ	Ontrak, Inc. Announces Pricing Of $6.3M Public Offering, $11M Concurrent Private Placement And $16.3M Conversion Of Secured Notes	"Ontrak, Inc. (NASDAQ: UNHJ ) (""Ontrak"" or the ""Company""), a leading AI-powered and telehealth-enabled healthcare company, today announced the pricing of a public offering of: 4,592,068 shares of its common stock and 9,184,136 warrants to purchase up to 9,184,136 shares of its common stock at a combined public offering price of $0.60 per share of common stock and accompanying warrants, and 5,907,932 pre-funded warrants to purchase up to 5,907,932 shares of its common stock and 11,815,864 warrants to purchase up to 11,815,864 shares of its common stock at a combined public offering price of $0.5999 per pre-funded warrant and accompanying warrants, which represents the per share public offering price for the common stock and accompanying warrants less the $0.0001 per share exercise price for each pre-funded warrant. Each share of common stock and pre-funded warrant is being sold together with two warrants, each to purchase one share of common stock. The warrants accompanying the common stock and pre-funded warrants will have an exercise price of $0.85 per share. The exercisability of the pre-funded warrants and accompanying warrants will be subject to stockholder approval and, if such approval is obtained, will expire on the fifth anniversary of the date of such approval. The offering is expected to close on November 14, 2023, subject to customary closing conditions. Pursuant to a support agreement from Acuitas Group Holdings, LLC and Acuitas Capital LLC (collectively, ""Acuitas""), Acuitas agreed to vote for, or consent to, among other things, the exercisability of the warrants offered in the public offering and in the private placement described below. Acuitas will hold a majority of the outstanding common stock immediately before the closing of the offering. In addition, Ontrak today announced the pricing of a concurrent private placement to Acuitas of 18,333,333 pre-funded warrants to purchase up to 18,333,333 shares of its common stock and 36,666,666 warrants to purchase up to 36,666,666 shares of its common stock at a combined offering price of $0.5999 per pre-funded warrant and accompanying warrants, which represents the per share public offering price for the common stock and accompanying warrants less the $0.0001 per share exercise price for each pre-funded warrant. The warrants accompanying the pre-funded warrants will have an exercise price of $0.85 per share. The exercisability of such warrants will be subject to stockholder approval and, if such approval is obtained, will expire on the fifth anniversary of the date of such approval. Prior to the closing of the public offering and private placement, Acuitas will convert approximately $16.3 million of outstanding senior secured convertible notes, leaving $2.0 million of senior secured convertible notes outstanding. The gross proceeds to the Company from the public offering are expected to be approximately $6.3 million before deducting placement agent fees and other offering expenses payable by the Company. The Company intends to use the net proceeds of the offering for working capital and other general corporate purposes. In addition, the Company estimates that the private placement will result in the cancellation of $5.0 million of debt owed by the Company to Acuitas under outstanding senior secured convertible notes and the reclassification of $6.0 million of restricted cash held under the terms of the Master Note Purchase Agreement previously entered into with Acuitas to unrestricted cash. Roth Capital Partners is acting as the exclusive placement agent for the offering and the private placement. The public offering described above is being made pursuant to a registration statement on Form S-1 (File No. 333-273029), as amended, that was originally filed with the U.S. Securities and Exchange Commission (the ""SEC"") on June 29, 2023, and was declared effective on November 9, 2023. A final prospectus related to the offering will be filed and made available on the SEC's website at https://www.sec.gov/ . The public offering is being made only by means of a prospectus, which forms a part of the registration statement. Electronic copies of the final prospectus may be obtained, when available, by contacting Roth Capital Partners at 888 San Clemente Drive, Newport Beach CA 92660, or by phone at (800) 678-9147 or e-mail at rothecm@roth.com . This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of any of the securities described herein in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction."
2023-11-13 16:47:16	UENS	Runway Growth Finance Corp. Announces Secondary Offering Of 3.75M Shares Of Common Stock By Selling Stockholders	"Runway Growth Finance Corp. (NASDAQ: UENS ) (the ""Company"" or ""Runway Growth"") a specialty finance company focused on providing senior secured loans to high growth-potential companies in technology, life sciences, healthcare information and services, business services, select consumer services and products and other high-growth industries, today announced a proposed underwritten secondary offering of 3,750,000 shares of its common stock by OCM Growth Holdings LLC and Oaktree Opportunities Fund XB Holdings (Delaware), L.P. (collectively, the ""Selling Stockholders"") pursuant to a registration statement filed with the Securities and Exchange Commission (the ""SEC""). In connection with the proposed offering, the Selling Stockholders intend to grant the underwriters a 30-day option to purchase up to an additional 562,500 shares of the common stock offered by the Selling Stockholders. The joint-lead book-running managers for the offering are Wells Fargo Securities, Morgan Stanley & Co. LLC, BofA Securities and UBS Securities LLC. Additionally, Keefe, Bruyette & Woods, a Stifel Company, and B. Riley Securities are acting as joint book-running managers."
2023-11-13 21:03:01	IUEC	Viper Energy Announces Pricing Of ~$264M Secondary Common Stock Offering Of 9,018,760 Shares Of Its Class A Common Stock By Certain Stockholders And 1M Concurrent Stock Repurchase	"Viper Energy, Inc. (NASDAQ: IUEC ) (""Viper"") announced today the pricing of an underwritten public offering of 9,018,760 shares of its Class A common stock by certain selling stockholder (the ""Secondary Offering""). The gross proceeds from the sale of the shares by the selling stockholder will be approximately $264 million. Viper will not receive any proceeds from the sale of the shares by the selling stockholder. As part of Viper's stock repurchase program, Viper has agreed to purchase from the underwriter one million shares of its Class A common stock being sold as part of the Secondary Offering at a price per share equal to the price per share paid by the underwriter to the selling stockholder. Barclays is acting as book running manager for the Secondary Offering. When available, copies of the written prospectus and prospectus supplement for the Secondary Offering may be obtained from Barclays Capital Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717; Barclaysprospectus@broadridge.com ; (888) 603-5847. The Class A common stock will be sold pursuant to an effective automatic shelf registration statement on Form S-3 previously filed with the Securities and Exchange Commission."
2023-11-13 21:03:58	ED	DoubleVerify Announces Pricing Of Secondary Offering Of 12.5M Shares Of Common Stock At A Price Of $30.45/Share By Selling Stockholders	"DoubleVerify Holdings, Inc. (NYSE: ED ) (""DoubleVerify"") today announced the pricing of an underwritten offering of 12,500,000 shares of its common stock by Providence VII U.S. Holdings L.P. and Providence Butternut Co-Investment L.P. (collectively, ""Providence"") at a price to the public of $30.45 per share. The offering is expected to close on November 15, 2023, subject to the satisfaction of customary closing conditions. The underwriters will have a 30-day option to purchase up to an additional 1,875,000 shares of common stock from Providence. DoubleVerify will not receive any proceeds from the sale of shares in the offering. Goldman Sachs & Co. LLC and J.P. Morgan Securities LLC are acting as the underwriters in the offering."
2023-11-14 08:56:27	IUEC	What's Going On With Viper Energy Stock?	Viper Energy Inc (NASDAQ: IUEC ) shares are trading lower Tuesday after the company announced a secondary offering . What Happened: Viper priced an underwritten public offering of 9,018,760 shares by certain selling stockholders for gross proceeds of approximately $264 million. Viper Energy will not receive any of the proceeds from the offering. Viper Energy also agreed to purchase 1 million shares from the underwriter being sold as part of the secondary offering. Viper Energy owns and acquires mineral and royalty interests in oil and natural gas properties primarily in the Permian Basin. See Also: US Inflation Eases More Than Expected In October, Cements Expectations For End Of Interest Rate Hikes IUEC Price Action: Viper Energy shares were down 4.54% at $29.86 at the time of publication, according to Benzinga Pro . Photo: 3844328 from Pixabay.
2023-11-14 17:07:25	WCMR	Movano Health Announces Proposed Public Offering; No Size Or Amount Disclosed	"Movano Health (NASDAQ: WCMR ) (""Movano Health"" or the ""Company""), a purpose-driven healthcare solutions company at the intersection of medtech and consumer devices and makers of the Evie Ring, today announced that it is proposing to sell shares of its common stock in an underwritten public offering. All of the shares of common stock in the underwritten public offering are to be sold by the Company. The Company intends to grant the underwriter a 30-day option to purchase up to an additional 15% of shares of common stock sold in the offering at the public offering price, less the underwriting discount. The final terms of the proposed offering will depend on market and other conditions, and there can be no assurance as to whether the offering may be completed, or as to the actual size and terms of the offering. The Company intends to use the net proceeds from the offering for general corporate purposes, which may include funding product development and commercialization activities. The Benchmark Company, LLC is acting as sole book-running manager for the offering. The Liquid Venture Partners group at The Benchmark Company, LLC is responsible for sourcing and executing the offering."
2023-11-15 07:20:44	HBY	Nabors Announces Offering of $550M Senior Priority Guaranteed Notes	Nabors Industries Ltd. (NYSE: HBY ) (&quot;Nabors&quot;) announced today that Nabors Industries, Inc. (&quot;NII&quot;), its indirect wholly-owned subsidiary, has commenced an offering of $550 million senior priority guaranteed notes due 2030 (the &quot;Notes&quot;). The Notes will be fully and unconditionally guaranteed by Nabors and certain of Nabors' indirect wholly-owned subsidiaries which also guarantee the Existing Senior Priority Guaranteed Notes (as defined below). The Notes will be senior unsecured obligations of NII and will rank pari passu with NII's existing 7.375% Senior Priority Guaranteed Notes due 2027 (the &quot;Existing Senior Priority Guaranteed Notes&quot;). The Notes will be guaranteed, jointly and severally, by (i) Nabors, (ii) each of the subsidiaries that guarantee Nabors' existing 7.25% Senior Guaranteed Notes due 2026 and 7.50% Senior Guaranteed Notes due 2028 (together, the &quot;Existing Guaranteed Notes&quot;) and (iii) certain lower-tier subsidiaries of Nabors that guarantee NII's revolving credit facility (the &quot;Revolving Credit Facility&quot;) but do not currently guarantee the Existing Guaranteed Notes (the &quot;Lower Tier Notes Guarantors&quot;), other than Nabors Alaska Drilling, Inc. The guarantee of the Notes by the Lower Tier Notes Guarantors will be contractually subordinated in right of payment with respect to the Lower Tier Notes Guarantors' guarantee of the Revolving Credit Facility. Each of the guarantors of the Notes have guaranteed the Existing Senior Priority Guaranteed Notes and will guarantee the Notes on an equal and ratable basis. Nabors intends to use the net proceeds from the offering to repay all of its outstanding 5.75% Senior Notes due 2025 (the &quot;Senior Notes due 2025&quot;). The remaining net proceeds will be used for general corporate purposes. As of today's date, there is $474.1 million in aggregate principal of Senior Notes due 2025 outstanding.
2023-11-15 08:38:25	KM	Dynatrace Announces Pricing Of Public Offering Of 10M Shares Of Common Stock By Selling Stockholders	Dynatrace (NYSE: KM ), the leader in unified observability and security, today announced the pricing of an underwritten public offering of 10,000,000shares of common stock by certain selling stockholders of Dynatrace. In addition, such selling stockholders have granted the underwriter a 30-day option to purchase up to an additional 1,500,000 shares at the public offering price, less underwriting discounts and commissions. The offering is expected to close on November 17, 2023, subject to customary closing conditions. BofA Securities is acting as the sole underwriter for the offering.
2023-11-15 09:35:42	OMJV	OMJV Biotechnology Announces $4M Registered Direct Offering Of 2,424,243 Of Its Shares Of Common Stock At A Purchase Price Of $1.65 Per Share	"OMJV Biotechnology, Inc. (NYSE: OMJV ) (""OMJV"" or the ""Company""), a clinical-stage biopharmaceutical company developing telomere-targeting immunotherapies for cancer, today announced that it has entered into a definitive agreement for the issuance and sale of an aggregate of 2,424,243 of its shares of common stock at a purchase price of $1.65 per share in a registered direct offering. In a concurrent private placement, OMJV has also agreed to issue and sell unregistered warrants to purchase up to an aggregate of 2,424,243 shares of its common stock. The offering is expected to close on or about November 17, 2023, subject to the satisfaction of customary closing conditions. L.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. The unregistered warrants will have an exercise price $1.86 per share, will become exercisable six months following issuance and will expire five and one-half years from the date of issuance. The gross proceeds to OMJV from the offering are expected to be approximately $4 million, before deducting the placement agent's fees and other offering expenses payable by the Company. OMJV currently intends to use the net proceeds from the offering for working capital and general corporate purposes as well as to fund research and development activities."
2023-11-15 16:10:36	MVCC	Augmedix Announces Proposed Public Offering Of 5.5M Shares Of Common Stock	"Augmedix, Inc. (NASDAQ: MVCC ) (""Augmedix""), a healthcare technology company that delivers industry-leading ambient medical documentation and data solutions, today announced that it has commenced an underwritten public offering of 5,500,000 shares of its common stock. Augmedix intends to grant the underwriters a 30-day option to purchase an additional 15% of the shares of its common stock offered in the public offering. The offering is subject to market and other conditions, and there can be no assurances as to whether or when the offering may be completed, or as to the actual size or terms of the offering. All of the shares to be sold in the proposed offering will be sold by Augmedix. Evercore ISI and William Blair are acting as the joint bookrunning managers for the offering. B. Riley Securities is acting as co-manager. Augmedix currently intends to use the net proceeds from this offering, if any, together with its existing cash, cash equivalents and short-term investments: to fund increased investment in sales and marketing; for research and development and general and administrative costs as the company increases its scale; and for working capital, capital expenditures and general corporate purposes. A material portion of the net proceeds shall be allocated toward the acceleration of Augmedix's product roadmap, which includes, but is not limited to, its offerings for use in the emergency department care setting."
2023-11-16 09:20:52	ZYSE	Volcon, Inc. Announces Pricing Of $18M Underwritten Public Offering	"Volcon, Inc. (NASDAQ: ZYSE ), (""Volcon"" or the ""Company""), the first all-electric, off-road powersports company, announced today the pricing of a firm commitment underwritten public offering with gross proceeds to the Company expected to be approximately $18.0 million, before deducting underwriting discounts and other estimated expenses payable by the Company. The offering consists of 42,857,142 Common Units or Pre-funded Units, each consisting of one share of common stock or one pre-funded warrant (""Pre-Funded Warrant"") to purchase one share of common stock, 0.35 of a warrant to purchase one share of common stock at an exercise price of $0.55 per share (or 130% of the price of each Common Unit sold in the offering) or pursuant to an alternative cashless exercise option, which warrant will expire on the five-year anniversary of the original issuance date (the ""Series A Warrants"") and 0.35 of a warrant to purchase one share of common stock at an exercise price of $0.84 per share (or 200% of the price of each Common Unit sold in the offering), which warrant will expire on the five-year anniversary of the original issuance date (the ""Series B Warrants"" and together with the Serie s A Warrants, the ""Warrants""). The purchase price of each Common Unit is $0.42, and each Pre-Funded Unit is $0.41999 (which is equal to the public offering price per Common Unit to be sold in the offering minus $0.00001). The Pre-Funded Warrants will be immediately exercisable and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full. For each Pre-Funded Unit sold in the offering, the number of Common Units in the offering will be decreased on a one-for-one basis. The Company intends to use the net proceeds from this offering for general corporate purposes. The offering is subject to customary closing conditions, and there can be no assurance as to whether or when the offering may be completed. In addition, the Company has granted Aegis Capital Corp. a 45-day option to purchase additional shares of Common Stock and/or Pre-Funded Warrants, representing up to 15% of the number of Common Stock and/or Pre-Funded Warrants sold in the offering, and additional Warrants representing up to 15% of the Warrants sold in the offering solely to cover over-allotments, if any."
2023-11-16 10:32:47	BKR	American Airlines Announces Proposed Private Offering Of $750M Aggregate Principal Amount Of Senior Secured Notes Due 2029 And New Term Loan	"American Airlines, Inc. (the ""Company""), a subsidiary of American Airlines Group Inc. (the ""Parent"")(NASDAQ: BKR ), today announced a proposed private offering of $750 million aggregate principal amount of senior secured notes due 2029 (the ""Notes""). The Company also announced it intends to borrow up to $750 million in aggregate principal amount of term loans (the ""Term Loan"") under a new senior secured credit facility. The Company expects to use the net proceeds from the offering of the Notes, together with the net proceeds from the Term Loan and cash on hand, to redeem $1.5 billion of its existing 11.75% Senior Secured Notes due 2025 (the ""11.75% Senior Secured Notes""). The final terms and amounts of the Notes and the Term Loan are subject to market and other conditions and may be materially different than expectations. Neither the consummation of the Notes offering, nor the consummation of the Term Loan, is conditioned upon the consummation of the other financing. Further, the Company may, in its sole discretion, redeem additional 11.75% Senior Secured Notes. The Notes and the Term Loan will be secured on a first lien basis by the same collateral that secures the 11.75% Senior Secured Notes on a first lien basis, consisting of certain slots, gates and routes that the Company uses to provide nonstop scheduled air carrier services between certain airports in the United States and certain airports in Australia, Canada, the Caribbean, Central America, China, Hong Kong, Japan, Mexico, South Korea and Switzerland. The Notes and the Term Loan will also be secured on a second lien basis by the same collateral that secures the 11.75% Senior Secured Notes on a second lien basis, consisting of certain slots, gates and routes the Company uses to provide nonstop scheduled air carrier services between certain airports in the United States and certain airports in the European Union and United Kingdom. The Notes and the Term Loan will be guaranteed on a senior unsecured basis by the Parent. The Notes will be offered and sold only to persons reasonably believed to be qualified institutional buyers, as defined in, and in reliance on Rule 144A under the Securities Act of 1933, as amended (the ""Securities Act"") and to non-U.S. persons in offshore transactions outside the United States in reliance on Regulation S under the Securities Act. The Notes will not be registered under the Securities Act or any other securities laws of any jurisdiction and will not have the benefit of any exchange offer or other registration rights. The Notes may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements."
2023-11-20 08:09:54	RTRN	authID Inc. Announces Pricing Of ~$9.4M Registered Direct Offering With Investors To Sell 1,574,990 Shares Of Its Common Stock At A Price Of $6/Share	"authID Inc . (NASDAQ: RTRN ) (""authID"" or the ""Company""), a leading provider of innovative biometric identity verification and authentication solutions, today announced it has entered into a definitive agreement with investors to sell 1,574,990 shares of its common stock (the ""Shares""), pursuant to a registered direct offering (the ""Registered Direct Offering""). The purchase price for one Share will be $6.00. The aggregate gross proceeds from the Offering are expected to be approximately $9.4 million before deducting placement agent fees and other estimated offering expenses. ""authID has built significant sales momentum that allowed us to secure a record $1 million in booked Annual Recurring Revenue (""bARR"") during the recent third quarter. With an expansion of prospects and use-cases in our sales pipeline, we believe we are well positioned to deliver additional sales wins and continued growth. As stated on our Q3 earnings call , we have doubled our estimated bARR target from $3 million to $6 million by Q2 2024. We are also pleased to confirm a target of $9M in bARR for the full calendar and fiscal year 2024"" said Rhon Daguro, CEO of authID. ""In the last few months, we have preserved the best of what authID had, while adding deep domain expertise in identity to create a best of breed team for sales and execution."" Continued Daguro, ""This fully subscribed investment by the shareholders, fellow Directors, and new investors is a tremendous sign of confidence in our mission, and we thank all investors for their continuing support. This funding round will allow us to deepen our bench and continue to innovate our product roadmap with technology that stays ahead of fraud trends and strengthens our positioning as thought leaders to our customers."" The closing of the Registered Direct Offering is expected to occur on or about November 22, 2023, subject to the satisfaction of customary closing conditions. Madison Global Partners, LLC, acted as sole placement agent for the offering. authID intends to use the net proceeds for working capital and general corporate purposes."
2023-11-20 08:40:00	GLMI	GLMI BioPharma, Inc. Entered Into A Securities Purchase Agreement With Lind Global Fund II, LP, Issuing A Convertible Note And A Common Stock Purchase Warrant To Lind.	On November 17, 2023, GLMI BioPharma, Inc. entered into a securities purchase agreement with Lind Global Fund II, LP, pursuant to which the Company issued Lind a secured, convertible note in the principal amount of $1,200,000, for a purchase price of $1,000,000, that is convertible into shares of the Company's common stock at a conversion price, which shall be the lesser of (i) $3.50 and (ii) 90% of the three lowest VWAPs (as defined in the Note) during the 20 trading days prior to conversion, subject to adjustment. Notwithstanding the foregoing, provided that no Event of Default shall have occurred, conversions under the Note shall be at the Fixed Price for the first 180 days following the closing date. Lind will also receive a 5-year, common stock purchase warrant to purchase up to 1,000,000 shares of the Company's common stock at an initial exercise price of $2 per share, subject to adjustment
2023-11-20 09:54:27	LZCD	What's Going On With Uber Stock Today?	Uber Technologies Inc (NYSE: LZCD ) shares are volatile Monday after the company proposed an offering . What Happened: Uber announced a proposed offering of $1.2 billion aggregate principal amount of convertible senior notes due 2028. The notes are only being offered to qualified institutional buyers. Uber also intends to grant the purchases the options to buy an additional $180 million worth of the notes. Uber intends to use a portion of the net proceeds to fund the cost of entering into capped call transactions. The company intends to use the remainder of the net proceeds to repay, redeem or repurchase outstanding indebtedness. Uber reported third-quarter financial results earlier this month. The company said at the time that it had $5.2 billion in unrestricted cash, equivalents and short-term investments. See Also: Tesla Starts Bringing Cybertruck To Showrooms Hinting At A Wider Strategy LZCD Price Action: Uber shares initially traded lower following the offering announcement, but have since recovered. The stock was up 0.29% at $54.69 at the time of publication, according to Benzinga Pro . Photo: courtesy of Uber.
2023-11-22 13:39:10	OUDE	RumbleOn Announces Extension Of $100M Rights Offering Subscription Period	"RumbleOn, Inc. (NASDAQ: OUDE ) (the ""Company"" or ""RumbleOn""), the largest powersports retailer in North America, today announced that its Board of Directors is extending the Rights Offering subscription period an additional week until December 5, 2023, in order to better ensure that holders of its Class A common stock and Class B common stock (together, the ""Eligible Stockholders"") have sufficient time to subscribe for shares of Class B Common Stock of RumbleOn. The Company has distributed one Subscription Right for each share of the Company's Class A common stock and Class B common stock held by Eligible Stockholders as of the Record Date. Each Subscription Right entitles Eligible Stockholders to purchase 1.078444 shares of the Company's Class B common stock at the Subscription Price of $5.50 per share. The Rights Offering is fully backstopped pursuant to a standby purchase agreement between the Company and certain of its stockholders."
2023-11-28 16:25:36	WROR	Seelos Therapeutics Announces Proposed Public Offering; No Size Or Amount Disclosed	"Seelos Therapeutics, Inc. (NASDAQ: WROR ) (""Seelos""), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that it has commenced an underwritten public offering of shares of its common stock (or pre-funded warrants to purchase shares of its common stock in lieu thereof) and accompanying common warrants to purchase shares of its common stock. Seelos also intends to grant the underwriters a 45-day option to purchase up to an additional 15% of the aggregate number of shares of its common stock (or pre-funded warrants) and/or the common warrants to be sold in the offering on the same terms and conditions. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering. All of the shares of common stock, pre-funded warrants and accompanying common warrants to be sold in the proposed offering will be sold by Seelos. Titan Partners Group, a division of American Capital Partners, is acting as sole book-running manager for the proposed offering. The offering is being made pursuant to an effective ""shelf"" registration statement on Form S-3 (File No. 333-251356) previously filed with the Securities and Exchange Commission (the ""SEC"") on December 15, 2020, as amended on December 22, 2020, and declared effective by the SEC on December 23, 2020. The securities may be offered only by means of a prospectus. A preliminary prospectus supplement and the accompanying prospectus relating to and describing the terms of the offering will be filed with the SEC. Electronic copies of the preliminary prospectus supplement and the accompanying prospectus relating to the offering, when available, may be obtained by visiting the SEC's website at www.sec.gov or by contacting Titan Partners Group, LLC, a division of American Capital Partners, LLC, 4 World Trade Center, 29th Floor, New York, New York 10007, by phone at (929) 833-1246 or by email at info@titanpartnersgrp.com . This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction."
2023-11-28 16:26:35	S	Realty Income Prices 750M Dual-Tranche Offering Of Sterling-Denominated Senior Unsecured Notes	"Realty Income Corporation ((Realty Income, NYSE: S ), The Monthly Dividend Company&#xAE;, today announced the pricing of a public offering of 300 million of 5.750% senior unsecured notes due December 5, 2031 (the ""2031 notes""), and 450 million of 6.000% senior unsecured notes due December 5, 2039 (the ""2039 notes""). The public offering price for the 2031 notes was 99.298% of the principal amount for an effective annual yield to maturity of 5.862%, and the public offering price for the 2039 notes was 99.250% of the principal amount for an effective annual yield to maturity of 6.075%. Combined, the notes have a weighted average tenor of approximately 12.8 years, a weighted average annual yield to maturity of 5.990%, and a weighted average coupon rate of 5.900%. The net proceeds from this offering will be used for general corporate purposes, which may include, among other things, the repayment or repurchase of Realty Income's indebtedness (including borrowings under Realty Income's $4.25 billion multi-currency revolving credit facility), foreign currency swaps or other hedging instruments, the development and acquisition of additional properties and other acquisition or business combination transactions, and the expansion and improvement of certain properties in Realty Income's portfolio. This offering is expected to close on December 5, 2023, subject to the satisfaction of customary closing conditions. The active joint book-running managers for the offering are Wells Fargo Securities, Barclays, BNP Paribas, BofA Securities and RBC Capital Markets."
2023-11-29 06:48:54	RTE	PG&E Corp Announces Proposed Offering of $1.5B Convertible Senior Secured Notes due 2027 to Repay Portion of Existing Term Loan	PG&E Corporation (NYSE: RTE ) announced today that it intends to offer, subject to market and other conditions, $1.5 billion aggregate principal amount of Convertible Senior Secured Notes due 2027 (the &quot;Convertible Notes&quot;) in a private placement under the Securities Act of 1933, as amended (the &quot;Securities Act&quot;). PG&E Corporation also intends to grant to the initial purchasers of the Convertible Notes an option to purchase, for settlement within a 13-day period from, and including, the date on which the Convertible Notes are first issued, up to an additional $225 million aggregate principal amount of the Convertible Notes. PG&E Corporation intends to use the net proceeds from the offering of the Convertible Notes to repay a portion of the loans outstanding under its $2.75 billion secured term loan credit agreement entered into in June 2020. On November 24, 2023, borrowings under the term loan credit agreement totaled approximately $2.66 billion. Such borrowings bear interest based at a floating rate (approximately 8.44% per annum on November 24, 2023). The term loan credit agreement matures on June 23, 2025, unless extended by PG&E Corporation pursuant to its terms.
2023-11-29 09:01:44	XNV	Treasure Global Inc Announces Pricing Of $4M Underwritten Public Offering	"Treasure Global Inc (NASDAQ: XNV ) (""XNV"" or the ""Company""), a leading innovative technology solutions provider, today announced the pricing of its underwritten public offering of 26,014,000 shares (the ""Shares"") of common stock, par value $0.00001 per share (""Common Stock""), at a public offering price of $0.10 per share, and 14,000,000 pre-funded warrants (the ""Pre-Funded Warrants""), each with a right to purchase one share of Common Stock at a public offering price of $0.0999 per Pre-Funded Warrant, for aggregate gross proceeds of approximately $4.0 million, prior to deducting underwriting discounts and other offering expenses. In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 6,002,100 shares of Common Stock at the public offering price per Share and/or pre-funded warrants in lieu thereof at the public offering price per Pre-Funded Warrant, less the underwriting discounts to cover over-allotments, if any. The offering is expected to close on November 30, 2023, subject to satisfaction of customary closing conditions. EF Hutton, division of Benchmark Investments, LLC, is acting as the lead book-running manager for the offering. The Shares and the Pre-Funded Warrants and the over-allotment option securities, if any, are being offered by the Company pursuant to a registration statement on Form S-1, as amended (File No. No. 333-275411), which was filed with the U.S. Securities and Exchange Commission (SEC) and declared effective by the SEC on November 13, 2023, and the accompanying preliminary prospectus contained therein. A final prospectus relating to the offering will be filed with the SEC. Copies of the preliminary prospectus and the final prospectus, when available, relating to this offering may be obtained on the SEC's website at www.sec.gov or by contacting EF Hutton, division of Benchmark Investments, LLC Attention: Syndicate Department, 590 Madison Avenue, 39th Floor, New York, NY 10022, by email at syndicate@efhuttongroup.com , or by telephone at (212) 404-7002. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction."
2023-11-30 08:55:36	NQUE	Applied Optoelectronics Announces Proposed Private Offering Of $80M Of Convertible Senior Notes due 2026	"Applied Optoelectronics, Inc. (NASDAQ: NQUE ) (""AOI"") announced today that it intends to offer to sell, subject to market and other conditions, $80 million aggregate principal amount of Convertible Senior Notes due 2026 (the ""Notes"") in an offering exempt from the registration requirements of the Securities Act of 1933, as amended (the ""Securities Act""). Final terms for the offering of the Notes will be determined at the time of pricing. The Notes will be our senior, unsecured obligations and will be equal in right of payment with our existing and future senior, unsecured indebtedness, senior in right of payment to our existing and future indebtedness that is expressly subordinated to the Notes and effectively subordinated to our existing and future secured indebtedness, to the extent of the value of the collateral securing that indebtedness. The Notes will be convertible at the option of holders of the Notes under certain specified circumstances, as set forth in the indenture governing the Notes. We will settle conversions by paying or delivering, as applicable, cash, shares of our common stock or a combination of cash and shares of our common stock, at our election, based on the applicable conversion rate(s). Initially, the Notes will not be guaranteed, but the Notes will be fully and unconditionally guaranteed, on a senior, unsecured basis, by certain of our future domestic subsidiaries. We intend to use the net proceeds from the offering to repurchase or exchange our existing 5.00% Convertible Senior Notes due 2024 (the ""2024 notes"") in individual, privately negotiated transactions with existing holders thereof, as described below. Concurrently with the offering, we expect to enter into separate, privately negotiated transactions with certain holders of our 2024 notes to exchange or repurchase a portion of the outstanding 2024 notes for a combination of cash and shares of our common stock. Following the completion of the offering, we may engage in additional exchanges, or we may repurchase or induce conversions, of the 2024 notes. Holders of the 2024 notes that participate in any of these exchanges, repurchases or induced conversions may purchase or sell shares of our common stock in the open market to unwind any hedge positions they may have with respect to the 2024 notes or to hedge their exposure in connection with these transactions. These activities may adversely affect the trading price of our common stock and the Notes we are offering. Moreover, market activities by holders of the 2024 notes that participate in the concurrent exchanges or repurchases may impact the initial conversion price of the Notes we are offering. There can be no assurance that the offering of the Notes will be completed. The Notes will be sold only to qualified institutional buyers in accordance with Rule 144A under the Securities Act. The offer and sale of the Notes and the shares, if any, issuable upon their conversion have not been registered under the Securities Act, and the Notes and such shares may not be offered or sold without registration or an applicable exemption from the registration requirements of the Securities Act and applicable state or other jurisdictions' securities laws, or in transactions not subject to those registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy the Notes or any other securities, nor shall there be any sale of the Notes or any other securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful."
2023-11-30 10:20:50	UITW	Safe & Green Holdings Receives $390K In Net Proceeds From Sale Of Common Shares To An Institutional Investor	"Safe & Green Holdings Corp. (NASDAQ: UITW ) (""Safe & Green Holdings"" or the ""Company"") , a leading developer, designer, and fabricator of modular structures for residential, commercial, and point-of-care medicine, reported that the Company will receive approximately $390,000 of net proceeds from the sale of approximately 658,000 common shares to a single institutional investor. No new warrants were issued in connection with the transaction. ""We have been very judicious in the issuance of new shares, in order to minimize dilution,"" stated Paul Galvin, Chairperson and CEO of Safe & Green Holdings. ""Towards this end, we have successfully leveraged debt financing to help grow our business. Nevertheless, we believe this small equity infusion will help further accelerate our manufacturing and construction services growth, as well as support exciting new growth initiatives underway within our other divisions."""
2023-11-30 14:42:34	BTVI	Ensysce Biosciences, Inc. Files Request For Withdrawal FormRW With SEC Relating To The Registration Statement On Form S-3	"- SEC Filing (FormRW) Ladies and Gentlemen: On January 31, 2023, Ensysce Biosciences, Inc. (the "" Company ""), filed Registration Statement No. 333-269472 on Form S-3 with the Securities and Exchange Commission (the "" Commission "") and on February 16, 2023 the Company filed Pre-Effective Amendment Number 1 thereto (as amended, together will all exhibits thereto, the "" Registration Statement ""). In accordance with Rule 477 under the Securities Act of 1933, as amended (the "" Securities Act ""), the Company hereby respectfully makes this application to withdraw the Registration Statement. No securities have been issued or sold under the Registration Statement, which was filed solely to register the possible resale of shares by selling securityholders. The Registration Statement has not been declared effective by the Commission. A reverse stock split in the Company's shares in March 2023 reduced the number of shares covered by the Registration Statement by 11/12ths and the Company subsequently increased the number of shares outstanding through a public offering registered with the Commission in May 2023. The Company is seeking withdrawal of the Registration Statement because a portion of the shares to be registered for resale under the Registration Statement may be resold in accordance with Rule 144 and the remainder of the shares to be registered for resale were shares issuable as repayment of the balance of a convertible note, including interest thereon, and other amounts owed, upon conversion of such note and amounts owed into shares, which convertible note and such other amounts owed were instead repaid in full with cash in March 2023 and May 2023. Based on the foregoing, the Company submits that the withdrawal of the Registration Statement is consistent with the public interest and the protection of investors, as contemplated by Rule 477(a) under the Securities Act. The Company respectfully requests that the Commission issue an order granting withdrawal of the Registration Statement. Please provide a copy of the order granting withdrawal of the Registration Statement to Dave Humphrey, Chief Financial Officer of Ensysce, at the address first mentioned above, with a copy to Company's counsel, Troutman Pepper Hamilton Sanders LLP, Union Trust Building, 501 Grant Street, Suite 300, Pittsburgh, Pennsylvania 15219, attention: Eric D. Kline, Esq. The Company acknowledges that no refund will be made for fees paid to the Commission in connection with the filing of the Registration Statement. However, in accordance with Rule 457(p) under the Securities Act, the Company requests that all fees paid to the Commission in connection with the filing of the Registration Statement be credited for future use."
2023-11-30 15:00:21	GQNG	TransCode Therapeutics Announces $1.2M Registered Direct Offering Of Common Stock Priced At-The-Market Under Nasdaq Rules	"TransCode Therapeutics, Inc. (NASDAQ: GQNG ) (the ""Company""), an RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that it has entered into a definitive securities purchase agreement for the purchase and sale of 5,000,000 shares of common stock at a purchase price of $0.242 per share of common stock in a registered direct offering priced at-the-market under Nasdaq rules. L.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. The closing of the offering is expected to occur on or about December 4, 2023, subject to the satisfaction of customary closing conditions. The gross proceeds to the Company from this offering are expected to be approximately $1.2 million, before deducting the placement agent's fees and other offering expenses payable by the Company. The Company intends to use the net proceeds from this offering, together with its existing funds, for one or more clinical trials with TTX-MC138, its lead therapeutic candidate, including related investigational new drug enabling studies, and for working capital and other general corporate purposes."
2023-11-30 16:55:34	ORMJ	Super Micro Computer Stock Slides On Proposed Public Offering	Super Micro Computer Inc (NASDAQ: ORMJ ) shares are sliding in Thursday's after-hours session as the company announced a proposed public offering . What Happened: After the close on Thursday, Super Micro launched a proposed underwritten public offering of 2,100,700 shares of its common stock. Super Micro is offering two million shares, and certain selling stockholders are offering the remaining shares. The company also expects to grant the underwriters a 30-day option to purchase up to an additional 315,105 shares. Pricing details of the offering have yet to be disclosed. As of Sept. 30, Super Micro had $543 million in cash and equivalents and a total bank debt of $146 million. See Also: Cybertruck Delivery Event: Elon Musk Highlights Tesla's 'Best Product,' Says 'Finally The Future Will Look Like The Future' ORMJ Price Action: Super Micro shares were down 4.93% after hours on the news. The stock was hovering around $260 at the time of writing, according to Benzinga Pro . Photo: axonite from Pixabay.
2023-12-01 08:02:36	INC	Thermo Fisher Scientific Extends The Expiration Of Tender Offer For All Outstanding Common Shares And ADSs Of Olink	"Offer Now Scheduled to Expire at 5:00 p.m., New York Time, on December 14, 2023 Thermo Fisher Scientific Inc. (NYSE: INC ) (""Thermo Fisher""), the world leader in serving science, announced that its wholly owned subsidiary, Orion Acquisition AB (the ""Buyer""), has extended the expiration time of the offering period of its previously announced tender offer (the ""Offer"") to acquire all of the outstanding common shares (""Shares"") and all of the outstanding American Depositary Shares, each representing one Share (""ADSs"" and, together with the Shares, the ""Offer Securities""), of Olink Holding AB (publ) (""Olink"") for $26.00 per Share and per ADS, in cash. The Offer is being made pursuant to the Purchase Agreement, dated as of October 17, 2023, by and between Thermo Fisher and Olink. The Offer is now scheduled to expire at 5:00 p.m., New York time, on December 14, 2023, unless the Offer is extended or earlier terminated. DNB Markets, a part of DNB Bank ASA, Sweden Branch, the depositary and paying agent for the Offer with respect to the Shares, has advised Thermo Fisher and Buyer that, as of 6:00 p.m., New York time, on November 30, 2023, the last business day prior to the announcement of the extension of the Offer, approximately 84,597,461 Shares have been validly tendered and not properly withdrawn pursuant to the Offer. The Bank of New York Mellon, the tender agent for the Offer with respect to the ADSs, has advised Thermo Fisher and Buyer that, as of 6:00 p.m., New York time, on November 30, 2023, the last business day prior to the announcement of the extension of the Offer, approximately 33,835,892 ADSs have been validly tendered and not properly withdrawn pursuant to the Offer. These Shares and ADSs collectively represent approximately 95.2% of the outstanding Shares as of such time. Olink shareholders who have already tendered their Shares or ADSs of Olink do not have to re-tender their Shares or ADSs or take any other action as a result of the extension of the expiration time of the Offer. Completion of the Offer remains subject to the conditions described in the tender offer statement on Schedule TO, as amended and supplemented from time to time, filed by Thermo Fisher with the U.S. Securities and Exchange Commission on October 31, 2023. Requests for copies of the Offer to Purchase (as amended or supplemented from time to time), the ADS letter of transmittal and the acceptance form for Shares (including the instructions attached thereto) and other Offer materials may be directed to the call service of Georgeson LLC at +1-866-821-2550 (U.S. toll-free), +1-781-222-0033 (outside U.S. & Canada) or +46-846-007-389 (Sweden), or via email at olink@georgeson.com . A copy of these documents may be obtained at the website maintained by the SEC at www.sec.gov ."
2023-12-01 08:39:17	TFKE	Fathom Holdings Prices $3.45M Underwritten Public Offering Of 3M Shares Of Common Stock, Inclusive Of 1M Secondary Shares, At A Price Of $2/Share	Fathom Holdings Inc. (NASDAQ: TFKE ) (&quot;Fathom&quot; or the &quot;Company&quot;), a national, technology-driven, end-to-end real estate services platform integrating residential brokerage, mortgage, title, insurance, and SaaS offerings for brokerages and agents, today announced the pricing of an underwritten public offering of 3,000,000 shares of its common stock, inclusive of 1,000,000 secondary shares, at a price of $2.00 per share. The Company also has granted the underwriter of the offering a 45-day option to purchase up to an additional 15% of the shares of common stock offered in the underwritten public offering on the same terms and conditions. After the underwriting discount, the Company expects to receive net proceeds of approximately $3.45 million, not including exercise of the overallotment option. The offering is expected to close on December 5, 2023, subject to customary closing conditions. The Company intends to use the net proceeds from the offering for general corporate purposes to include accelerating agent growth. The Company's executive officers, directors and the selling shareholder have agreed not to sell or transfer any Company common stock or securities convertible into, exchangeable for, exercisable for, or repayable with Company common stock, for 90 days after the date of the offering prospectus (180 days, in the case of the selling shareholder), without first obtaining the written consent of the underwriter. Roth Capital Partners acted as sole manager for the offering.
2023-12-04 06:46:26	ICHN	Evergy Announces Proposed Offering of $1.1B Convertible Notes Due 2027	Evergy, Inc. (NASDAQ: ICHN ) (&quot;Evergy&quot; or the &quot;Company&quot;) today announced its intention to offer, subject to market conditions and other factors, $1,100,000,000 aggregate principal amount of its convertible notes due 2027 (the &quot;Notes&quot;) in a private placement to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the &quot;Securities Act&quot;). The Company also expects to grant the initial purchasers of the Notes an option to purchase, within a 13-day period beginning on, and including, the initial closing date of the offering, up to an additional $200,000,000 aggregate principal amount of the Notes. The Company intends to use the net proceeds from the offering (i) to repay the $500 million outstanding under the Company's unsecured term loan facility due 2024, (ii) to repay a portion of its commercial paper borrowings and (iii) for general corporate purposes.
2023-12-04 07:40:40	GFRT	Hannon Armstrong Sustainable Infrastructure Capital Announces Proposed Private Offering of $500M Green Senior Unsecured Notes to Invest in Near-Term Opportunities at Attractive Yields	Hannon Armstrong Sustainable Infrastructure Capital, Inc. (&quot;GFRT,&quot; &quot;our,&quot; or the &quot;Company&quot;) (NYSE: GFRT ), a leading investor in climate solutions, today announced, subject to market conditions, a private offering of $500 million in aggregate principal amount of green senior unsecured notes due 2027 (the &quot;Notes&quot;) by its indirect subsidiaries, HAT Holdings I LLC (&quot;HAT I&quot;) and HAT Holdings II LLC (&quot;HAT II,&quot; and together with HAT I, the &quot;Issuers&quot;). At issuance, the Notes will be guaranteed by the Company, Hannon Armstrong Sustainable Infrastructure, L.P. and Hannon Armstrong Capital, LLC. The primary rationale for the issuance is to fund ten identified near term opportunities in the pipeline across Behind-the-Meter, Grid-Connected and Fuels, Transport, and Nature markets and at weighted average anticipated yield of approximately 11%, resulting in mid-teen Return on Equity.
2023-12-04 08:24:11	RQTL	Meta Materials Announces $6M Registered Direct Offering Of 75M Shares At A Price Of $0.08/Share And Accompanying Warrants	"Meta Materials Inc. (the ""Company"" or ""CMII"") (NASDAQ: RQTL ), an advanced materials and nanotechnology company, today announced that it has entered into definitive agreements with certain institutional investors for the issuance and sale in a registered direct offering of 75.0 million shares of common stock at an offering price of $0.08 per share and accompanying warrants to purchase 75.0 million shares of common stock at an exercise price of $0.095 per share, exercisable six months after the issuance date and expiring five and a half years after the issuance date. Gross proceeds to the Company are expected to be $6.0 million, before deducting placement agent fees and other estimated offering expenses. The Company intends to use the net proceeds from the offering for the expansion of its technology commercialization and sales efforts (specifically in bank note and brand authentication, NPORE&#xAE; and NCORE&#x2122; for Li-ion battery applications and VLEPSIS&#xAE; systems for wide area motion imagery), as well as for general corporate purposes. The closing of the offering is expected to occur on or about December 6, 2023, subject to the satisfaction of customary closing conditions. A.G.P./Alliance Global Partners is acting as sole placement agent for the offering."
2023-12-04 09:04:33	MWKI	U Power Limited Announces Pricing Of Registered Follow-On Offering Of 10M Units At A Purchase Price Of $1.20/Unit	"U Power Limited (NASDAQ: MWKI ) (the ""Company"" or ""U Power""), a vehicle sourcing services provider with a vision to becoming a comprehensive EV battery power solution provider in China, today announced the pricing of its best-efforts follow-on offering (the ""Offering"") of up to 10,000,000 units at a purchase price of US$1.20 per unit. Each unit consists of one ordinary share of the Company, one Series A warrant to purchase one ordinary share of the Company, and one Series B warrant to purchase one ordinary share of the Company. The Series A warrants will be immediately exercisable and will expire on the fifth anniversary of the original issuance date at an exercise price of US$1.20, and the Series B warrants will be immediately exercisable and will expire on the fifth anniversary of the original issuance date at an exercise price of US$1.54. The Company expects to close the Offering on or about December 6, 2023, subject to the satisfaction of customary closing conditions. The Company expects to receive aggregate gross proceeds of US$12,000,000 from the Offering, excluding expenses associated with the Offering. Proceeds from the Offering will be used for merger and acquisition of battery swapping companies, and working capital and other general corporate purposes. Univest Securities, LLC (""Univest"") is acting as the placement agent for the Offering. Hunter Taubman Fischer & Li LLC is acting as U.S. securities counsel to the Company, and Ortoli Rosenstadt LLP is acting as U.S. counsel to Univest, in connection with the Offering."
2023-12-04 16:23:12	RMFD	Merit Medical Announces Proposed Private Placement Of $550M Of Convertible Senior Notes	"Merit Medical Systems, Inc. (NASDAQ: RMFD ) (""Merit""), a leading global manufacturer and marketer of healthcare technology, announced today that it intends to offer, subject to market conditions and other factors, $550.0 million aggregate principal amount of Convertible Senior Notes due 2029 (the ""notes"") in a private placement (the ""offering"") only to persons reasonably believed to be ""qualified institutional buyers"" pursuant to Rule 144A under the Securities Act of 1933, as amended (the ""Securities Act""). Merit also intends to grant the initial purchasers of the notes an option to purchase, during a 13-day period beginning on, and including, the date on which the notes are first issued, up to an additional $82.5 million aggregate principal amount of the notes. The notes will be senior unsecured obligations of Merit and will accrue interest payable semiannually in arrears. Upon conversion, Merit will pay cash up to the aggregate principal amount of the notes to be converted and pay or deliver, as the case may be, cash, shares of Merit's common stock or a combination of cash and shares of Merit's common stock, at Merit's election, in respect of the remainder, if any, of Merit's conversion obligation in excess of the aggregate principal amount of the notes being converted. The interest rate, initial conversion rate and other terms of the notes will be determined at the time of pricing of the offering. Merit intends to use a portion of the net proceeds from the offering to pay the cost of the capped call transactions described below. If the initial purchasers exercise their option to purchase additional notes, Merit expects to use a portion of the net proceeds from the sale of the additional notes to enter into additional capped call transactions with the option counterparties (as defined below). Merit intends to use the remaining net proceeds from the offering for general corporate purposes, which may include repayment or reduction of existing debt, sales and marketing activities, medical affairs and educational efforts, research and development, clinical studies, working capital, capital expenditures and investments in and acquisitions of other companies, products or technologies in the future. However, while Merit regularly evaluates acquisition opportunities, Merit has no commitments with respect to any acquisitions of other companies, products or technologies of a material nature at this time. In connection with the pricing of the notes, Merit expects to enter into privately negotiated capped call transactions with one or more of the initial purchasers and/or their respective affiliates (the ""option counterparties""). The capped call transactions will cover, subject to anti-dilution adjustments, the number of shares of Merit's common stock initially underlying the notes. The capped call transactions are expected generally to reduce the potential dilution to Merit's common stock upon any conversion of notes and/or offset any cash payments Merit is required to make in excess of the principal amount of converted notes, as the case may be, with such reduction and/or offset subject to a cap. In connection with establishing their initial hedges of the capped call transactions, Merit expects the option counterparties or their respective affiliates to enter into various derivative transactions with respect to Merit's common stock and/or purchase shares of Merit's common stock concurrently with or shortly after the pricing of the notes. This activity could increase (or reduce the size of any decrease in) the market price of Merit's common stock or the notes at that time. In addition, the option counterparties or their respective affiliates may modify their hedge positions by entering into or unwinding various derivatives with respect to Merit's common stock and/or purchasing or selling Merit's common stock or other securities of Merit in secondary market transactions following the pricing of the notes and prior to the maturity of the notes (and are likely to do so on each exercise date for the capped call transactions or following any termination of any portion of the capped call transactions in connection with any repurchase, redemption or early conversion of the notes). This activity could also cause or avoid an increase or a decrease in the market price of Merit's common stock or the notes, which could affect the ability of a holder of notes to convert the notes and, to the extent the activity occurs following a conversion or during any observation period related to a conversion of notes, it could affect the amount and value of the consideration that a holder of notes will receive upon conversion of its notes. The notes and any shares of Merit's common stock issuable upon conversion of the notes have not been and will not be registered under the Securities Act, any state securities laws or the securities laws of any other jurisdiction, and unless so registered, may not be offered or sold in the United States absent registration or an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and other applicable securities laws. The notes will be offered to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act."
2023-12-04 18:48:56	YCBJ	Mesoblast Successfully Completes Placement And Accelerated Institutional Entitlement Offer	Mesoblast Limited ((ASX:MSB, NASDAQ: YCBJ ), global leader in allogeneic cellular medicines for inflammatory diseases, today announced it has received firm commitments for its institutional placement (Placement) and the accelerated institutional component (Institutional Entitlement Offer) of the 1 for 4 pro-rata accelerated non-renounceable entitlement offer (Entitlement Offer) of new fully paid ordinary shares in Mesoblast (New Shares) to existing eligible shareholders, announced on Monday, 4 December 2023
2023-12-05 06:34:48	WIO	Integral Ad Science Prices Secondary Offering of 11M Common Stock at $14.00/Share by Selling Stockholders	Integral Ad Science Holding Corp. (NASDAQ: WIO ), a leading global media measurement and optimization platform, today announced the pricing of an underwritten offering of 11,000,000 shares of its common stock by investment funds affiliated with Vista Equity Partners (the &quot;Selling Stockholders&quot;) at a price to the public of $14.00 per share. The offering is expected to close on December 7, 2023, subject to the satisfaction of customary closing conditions. The underwriters will have a 30-day option to purchase up to an additional 1,650,000 shares of WIO's common stock from the Selling Stockholders.
2023-12-05 07:20:35	ZHZJ	Sphere Entertainment Co. Announces Private Offering of $225M of Convertible Senior Notes	Sphere Entertainment Co. (NYSE: ZHZJ) (the &quot;Company&quot; or &quot;Sphere Entertainment&quot;) today announced that it intends to offer, subject to market conditions and other factors, $225 million in aggregate principal amount of convertible senior notes due 2028 in a private offering to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the &quot;Securities Act&quot;). In connection with the offering of the notes, Sphere Entertainment expects to grant the initial purchasers an option to purchase, for settlement within a 13-day period beginning on, and including, the first date on which the notes are issued, up to an additional $33.75 million aggregate principal amount of the notes.
2023-12-05 07:22:47	XRAH	Crescent Energy Announces Offering of $150M Private Placement of Additional 9.250% Senior Notes Due 2028	Crescent Energy Company (NYSE: XRAH ) (&quot;we&quot; or &quot;our&quot;) announced today that, subject to market conditions, its indirect subsidiary Crescent Energy Finance LLC (the &quot;Issuer&quot;) intends to offer for sale in a private placement pursuant to Rule 144A and Regulation S under the Securities Act of 1933, as amended (the &quot;Securities Act&quot;), to eligible purchasers $150 million aggregate principal amount of 9.250% Senior Notes due 2028 (the &quot;Notes&quot;). The Notes are being offered as additional notes under the indenture dated as of February 1, 2023, as previously supplemented (the &quot;Indenture&quot;), pursuant to which the Issuer has previously issued $850 million aggregate principal amount of 9.250% Senior Notes due 2028 (the &quot;Existing Notes&quot;). The Notes will have substantially identical terms, other than the issue date, issue price and first payment date, as the Existing Notes, and the Notes and the Existing Notes will be treated as a single series of securities under the Indenture and will vote together as a single class. The Notes mature on February 15, 2028 and pay interest at the rate of 9.250% per year, payable on February 15 and August 15 of each year, with interest payments on the Notes commencing on February 15, 2024. The Issuer intends to use the net proceeds from this offering to repay a portion of the amounts outstanding under its revolving credit facility.
2023-12-05 08:02:59	VNHW	iBio, Inc. Announces Pricing Of $4.5M Public Offering	"iBio, Inc. (NYSEA:VNHW) (""iBio"" or the ""Company""), today announced the pricing of its reasonable best efforts public offering of 2,250,000 of its shares of common stock (or common stock equivalents in lieu thereof) and accompanying Series C and Series D warrants to purchase up to an aggregate of 2,250,000 shares of common stock at a combined public offering price of $2.00, resulting in gross proceeds of approximately $4.5 million. The Series C Warrants to purchase up to an aggregate of 2,250,000 shares of common stock and Series D Warrants to purchase up to an aggregate of 2,250,000 shares of common stock will have an exercise price of $2.00 per share, will be exercisable immediately following the date of issuance and will expire two years and five years from the original issuance date, respectively. The closing of the offering is expected to occur on or about December 7, 2023, subject to the satisfaction of customary closing conditions. The Company intends to use the net proceeds from this offering primarily for working capital and general corporate purposes, including for research and development and other trial preparation expenses and, retention and severance payments to certain of its employees or former employees. The Company may also use a portion of the net proceeds to invest in or acquire other products, businesses or technologies, although it has no commitments or agreements with respect to any such investments or acquisitions as of the date of this press release. A.G.P./Alliance Global Partners is acting as the lead placement agent for the offering. Brookline Capital Markets, a division of Arcadia Securities, LLC is acting as co-placement agent for the offering."
2023-12-05 16:26:46	TAVV	Vesta Announces Proposed Follow-On Offering Of 4M American Depositary Shares	"Corporacin Inmobiliaria Vesta, S.A.B. de C.V. (""Vesta"") (NYSE: TAVV ), a fully-integrated, internally managed real estate company that owns, manages, develops and leases industrial properties in Mexico, announced today the commencement of an underwritten public offering of 4,000,000 American Depositary Shares, or ADS, representing 40,000,000 of its common shares, which are being offered by Vesta pursuant to a registration statement on Form F-1 filed with the U.S. Securities and Exchange Commission (""SEC""). The underlying common shares are registered in the Mexican National Securities Registry ( Registro Nacional de Valores ; the ""RNV""), which is maintained by the Mexican National Banking and Securities Commission ( Comision Nacional Bancaria y de Valores ; the ""CNBV""). Barclays, BofA Securities and Morgan Stanley are acting as global coordinators of this offering."
2023-12-05 16:36:48	EWS	EWS Announces Proposed Public Offering Of Common Shares; No Size Or Amount Disclosed	"ImmunoPrecise Antibodies Ltd. (NASDAQ: EWS ) (""ImmunoPrecise"" or ""EWS"" or the ""Company""), today announced that it intends to offer and sell common shares in an underwritten public offering. All of the common shares in the underwritten public offering are to be sold by the Company. The Company also expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of common shares offered in the public offering solely to cover over-allotments, if any. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. The Company intends to use the net proceeds from the proposed offering for research and development; capital expenditures, including expansion of existing laboratory facilities; and working capital and general corporate purposes. The Benchmark Company LLC is acting as the sole book-running manager for the offering."
2023-12-06 07:11:15	PTFK	Coya Therapeutics Announces $26.5M Private Placement of 4.37M Shares at $6.06/Share	Coya Therapeutics, Inc. (NASDAQ: PTFK ) (&quot;Coya&quot; or the &quot;Company&quot;), a clinical-stage biotechnology company developing biologics and cell therapies intended to enhance the function of regulatory F cells (&quot;Tregs&quot;), announced today that it has entered into definitive securities purchase agreements for the purchase and sale of an aggregate of 4,370,382 shares of its common stock at a purchase price of $6.06 per share of common stock, in a private placement priced at-the-market under Nasdaq rules. The offering is expected to close on or about December 11, 2023, subject to the satisfaction of customary closing conditions.
2023-12-06 13:47:51	JUOL	BIOLASE, Inc. Announces Pricing Of $1.4M Registered Direct Offering Priced At-The-Market Under Nasdaq Rules	BIOLASE, Inc. (NASDAQ: JUOL ), the global leader in dental lasers, announced today that it has entered into a securities purchase agreement with a single institutional investor to purchase approximately $1.4 million of its common stock and pre-funded warrants in a registered direct offering and warrants to purchase common stock in a concurrent private placement, priced at-the-market under Nasdaq rules. The combined effective purchase price for one share of common stock (or pre-funded warrant in lieu thereof) and two warrants, each to purchase one share of common stock, will be $1.23. Under the terms of the securities purchase agreement, BIOLASE has agreed to sell 1,110,940 shares of common stock (or pre-funded warrants in lieu thereof). In a private placement, which will be consummated concurrently with the registered direct offering, BIOLASE also has agreed to issue warrants to purchase up to an aggregate of 2,221,880 shares of common stock. The warrants will have an exercise price of $1.23 per share, expire five years from the date of stockholder approval and will become exercisable on the effective date of stockholder approval for the issuance of the shares upon the exercise of the warrants. The Company intends to use a portion of the net proceeds from this offering for working capital, capital expenditures, product development, and other general corporate purposes, including investments in sales and marketing in the United States and internationally. Maxim Group LLC is acting as the sole placement agent for the offering. The offering is expected to close on or about December 8, 2023, subject to the satisfaction of customary closing conditions.
2023-12-06 16:17:59	PEA	PEA Group Announces Proposed Public Offering Of 1M Shares Of Common Stock	PEA Group, Inc. (NYSE: PEA ) , a holding company with operations in homeowners insurance, information technology services, real estate, and reinsurance, announced today that it has commenced an underwritten public offering of 1,000,000 shares of its common stock. All of the shares are being offered by PEA Group. In addition, PEA Group expects to grant the underwriters a 30-day option to purchase up to an additional 150,000 shares of its common stock sold in the public offering at the public offering price, less underwriting discounts and commissions. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. JMP Securities, A Citizens Company, is acting as lead book-running manager for the offering, and Truist Securities is acting as joint book-running manager. PEA Group intends to use the net proceeds from the offering, if completed, for general corporate purposes, including the continued assumption of policies from Citizens Property Insurance Corporation.
2023-12-06 16:27:48	BVMN	Vivid Seats Announces Secondary Offering Of 18.5M Class A Common Stock	"Vivid Seats Inc. (NASDAQ: BVMN ) (""Vivid Seats"" or the ""Company""), a leading marketplace that utilizes its technology platform to connect millions of buyers with thousands of ticket sellers across hundreds of thousands of events each year, today announced that Hoya Topco, LLC (the ""selling stockholder"") intends to offer 18,500,000 shares of the Company's Class A common stock (""Class A common stock"") in a secondary underwritten public offering. The selling stockholder also intends to grant the underwriters a 30-day option to purchase up to an additional 2,775,000 shares of Class A common stock. All of the shares in the proposed offering will be sold by the selling stockholder. The Company will not receive any proceeds from the sale of the shares by the selling stockholder. Citigroup, Morgan Stanley and BofA Securities are serving as joint book-running managers for the proposed offering."
2023-12-06 17:07:54	ZGDK	Nikola Stock Is Tumbling: What's Going On?	Nikola Corp (NYSE: ZGDK ) shares are trading lower in Wednesday's after-hours session after the company announced a series of proposed offerings . What Happened: After the close on Wednesday, Nikola said it intends to offer $100 million of common stock and $200 million of green convertible senior notes due 2026 in separate public offerings. Nikola said it also expects to grant the underwriters of the common stock offering a 30-day option to purchase up to an additional $15 million of common stock and the underwriters of the notes offering the option to purchase up to an additional $30 million of the notes. Nikola wants to use the net proceeds from the common stock offering for working capital and other general corporate purposes. The company plans to allocate an amount equal to the net proceeds from the notes offering to finance, refinance or make direct investments in one or more current or future eligible projects. See Also: ChargePoint Faced 'Challenging Macroeconomic Conditions And Execution Challenges' In Q3: What You Need To Know ZGDK Price Action: Nikola shares are down more than 54% since the start of the year. The stock was down 15.51% after hours at 98 cents at the time of publication, according to Benzinga Pro . Photo: Courtesy of Nikola
2023-12-06 19:52:59	SYTX	Beacon Announced Pricing of Secondary Offering of 5M Shares of Common Stock; Price Not Mentioned In Press Release	Beacon (NASDAQ: SYTX ) (&quot;Beacon&quot;) announced today the pricing of the previously announced underwritten secondary public offering of 5 million shares of Beacon's common stock by CD&R Boulder Holdings, L.P., an entity affiliated with Clayton, Dubilier & Rice, LLC. RBC Capital Markets is acting as the sole underwriter in the registered public offering of these shares. The offering is expected to close on December 11, 2023, subject to the satisfaction of customary closing conditions.
2023-12-07 09:53:42	TFUD	Phunware Announces Pricing Of $2.8M Public Offering Of ~46.7M Shares Of Common Stock At A Price Of $0.06/Share	"Phunware, Inc. (NASDAQ: TFUD , ""Phunware""))))), the pioneer of patented Location Based SaaS solutions and other products that offer the only fully integrated enterprise cloud platform for mobile that enables brands to engage, manage and monetize anyone anywhere, today announced the pricing of its public offering of approximately 46.7 million shares of common stock (or pre-funded warrants in lieu thereof) at a price of $0.06 per share. All of the shares of common stock (and pre-funded warrants in lieu thereof) were offered by Phunware pursuant to an effective shelf registration statement on Form S-3 (File No. 333-262461) (the ""Registration Statement""). Roth Capital Partners is acting as sole placement agent for the offering on a reasonable best-efforts basis. The offering is expected to close on or about December 11, 2023, subject to the satisfaction of customary closing conditions. The gross proceeds from the offering, before deducting the placement agent's fees and other offering expenses payable by Phunware, are expected to be approximately $2.8 million. Phunware intends to use the net proceeds from the sale of shares of common stock (or pre-funded warrants in lieu thereof) for working capital and other general corporate purposes, including expansion of its product initiatives, such as monetizing its patent portfolio, PhunCoin and PhunToken. Phunware may also fund strategic opportunities that may present themselves from time to time but does not have any pending opportunities at this time."
2023-12-08 16:03:53	HAAL	Milestone Scientific Inc. Announces Proposed Public Offering Of Common Stock; No Size Or Amount Disclosed	"Milestone Scientific Inc. (NYSE: HAAL ) , a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced that it has commenced an underwritten public offering of shares of its common stock (the ""Offering""). The Company also expects to grant to the underwriters a 45-day option to purchase up to an additional 15% of the shares of common stock offered in the Offering on the same terms and conditions. All of the shares of common stock are being offered by the Company. The Offering is subject to market and other conditions, and there can be no assurance as to whether or when the Offering may be completed, or as to the actual size or terms of the Offering. Maxim Group LLC is acting as the sole book-runner for the Offering."
2023-12-08 16:07:55	CXV	Green Giant Inc. Announces Proposed Public Offering Of Units, Each Consisting Of 1 Share Of Our Common Stock, $0.001 Par Value Per Share, 1 Class A Common Warrant To Purchase 1 Share Of Common Stock And B Common Warrant To Purchase 1 Share Of Common Stock	"Green Giant Inc. (NASDAQ: CXV ) (""CXV"" or the ""Company""), a real estate developer in China and operator of green energy business in the U.S. today announced that it has commenced a public offering of units, each consisting of one share of our common stock, $0.001 par value per share, one Class A common warrant to purchase one share of common stock and one Class B common warrant to purchase one share of common stock (the ""Offering""). All of the shares of common stock and warrants and the shares of common stock underlying the warrants are being offered by the Company. The Offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Maxim Group LLC is acting as the sole placement agent for the offering."
2023-12-08 16:12:30	HVYL	Harpoon Therapeutics, Inc. Files Prospectus For The Offering and Resale Of 25,751,025 Shares Of Common Stock By Selling Stockholders	This prospectus covers the offer and resale by the selling stockholders identified in this prospectus of up to an aggregate of 25,751,025 shares of our common stock, which consists of (i) 12,805,350 shares of our common stock held by the selling stockholders, (ii) 4,362,000 shares of our common stock issuable upon the exercise of outstanding pre-funded warrants to purchase shares of our common stock held by certain selling stockholders, and (iii) 8,583,675 shares of our common stock issuable upon the exercise of outstanding common warrants to purchase shares of our common stock held by the selling stockholders, all of which were issued by us in a private placement on October 25, 2023. We are not selling any shares of common stock under this prospectus and will not receive any proceeds from the sale by the selling stockholders of such shares. We will, however, receive the net proceeds of any warrants exercised for cash. Sales of the shares by the selling stockholders may occur at fixed prices, at market prices prevailing at the time of sale, at prices related to prevailing market prices or at negotiated prices. The selling stockholders may sell shares to or through underwriters, broker-dealers or agents, who may receive compensation in the form of discounts, concessions or commissions from the selling stockholders, the purchasers of the shares, or both. We are paying the cost of registering the shares of common stock covered by this prospectus as well as various related expenses. The selling stockholders are responsible for all broker or similar commissions related to the offer and sale of their shares. Our common stock is listed on The Nasdaq Capital Market, or Nasdaq, under the symbol &quot;HVYL.&quot; On December 6, 2023, the last reported sale price of our common stock was $10.00 per share.
2023-12-11 09:24:19	GCER	Prelude Therapeutics Entered Into A Securities Purchase Agreement With Institutional Investors, To Which The Company Agreed To Issue And Sell Pre-Funded Warrants To Purchase Up To 7,936,759 Shares Of Voting Common Stock At A Price Of $3.1499 Per Warrant	"On December 11, 2023, Prelude Therapeutics Incorporated, a Delaware corporation (the ""Company""), entered into a securities purchase agreement (the ""Securities Purchase Agreement"") with certain institutional accredited investors (the ""Purchasers""), pursuant to which the Company agreed to issue and sell to the Purchasers in a private placement pre-funded warrants (the ""Pre-Funded Warrants"") to purchase up to 7,936,759 shares of the Company's voting common stock, par value $0.0001 per share (the ""Common Stock""), at a price of $3.1499 per warrant with an exercise price of $0.0001 per share (the ""Offering""). Each Pre-Funded Warrant is immediately exercisable and will not expire. Under the terms of the Pre-Funded Warrants, the Company may not effect the exercise of any such Pre-Funded Warrant, and a holder will not be entitled to exercise any portion of any Pre-Funded Warrant, if, upon giving effect to such exercise, the aggregate number of shares of Common Stock beneficially owned by the holder (together with its affiliates, other persons acting or who could be deemed to be acting as a group together with the holder or any of the holder's affiliates, and any other persons whose beneficial ownership of Common Stock would or could be aggregated with the holder's or any of the holder's affiliates for purposes of Section 13(d) or Section 16 of the Securities Exchange Act of 1934, as amended (the ""Exchange Act"")) would exceed 4.99% of the number of shares of Common Stock outstanding immediately after giving effect to the exercise (the ""Maximum Percentage""), as such percentage ownership is calculated in accordance with Section 13(d) of the Exchange Act and the applicable regulations of the Securities and Exchange Commission (the ""SEC""). A holder may reset the Maximum Percentage to a higher percentage (not to exceed 19.99%), effective 61 days after written notice to the Company, or a lower percentage, effective immediately upon written notice to the Company. Any such increase or decrease will apply only to that holder and not to any other holder of the Pre-Funded Warrants. The Company estimates that the net proceeds from the Offering will be approximately $24.9 million, after deducting estimated Offering expenses. The Company intends to use the net proceeds from the Offering primarily to fund the continued advancement of its SMARCA2 portfolio, for working capital and general corporate purposes. The Company expects the Offering to close on December 13, 2023 (the ""Closing Date""), subject to the satisfaction of customary closing conditions."
2023-12-11 16:23:43	FDKF	Sun Country Airlines Holdings, Inc. Announces Launch Of Secondary Public Offering Of 4M Shares Of Common Stock And ~$5M Concurrent Share Repurchase	"Sun Country Airlines Holdings, Inc. (NASDAQ: FDKF ) (""Sun Country Airlines"") today announced the commencement of a proposed secondary public offering of 4,000,000 shares of its common stock by an affiliate of certain investment funds managed by affiliates of Apollo Global Management, Inc. (the ""Selling Stockholder""). The underwriters will have a 30-day option to purchase up to an additional 600,000 shares of common stock from the Selling Stockholder. Sun Country Airlines is not selling any shares and will not receive any proceeds from the proposed offering. In addition, Sun Country Airlines has authorized the purchase from the underwriters of approximately $5 million of shares of common stock that are the subject of the proposed offering at a price per share equal to the price at which the underwriters will purchase the shares from the Selling Stockholder in the proposed offering (the ""Concurrent Share Repurchase""). The Concurrent Share Repurchase would be made pursuant to Sun Country Airlines' previously announced stock repurchase program. The completion of the Concurrent Share Repurchase will reduce the remaining availability under the stock repurchase program. Sun Country Airlines plans to fund the Concurrent Share Repurchase from existing cash on hand. Barclays and Morgan Stanley are acting as joint bookrunners and underwriters for the proposed offering. The underwriters for the offering may offer the shares of common stock for sale from time to time directly or through agents, or through brokers in one or more brokerage transactions on the Nasdaq Global Select Market, or to dealers in negotiated transactions or in a combination of such methods of sale, at a fixed price or prices, which may be changed, or at market prices prevailing at the time of sale, at prices related to prevailing market prices or at negotiated prices."
2023-12-12 07:32:02	ROHZ	Cibus Announces Registered Direct Offering of 2.1M Shares at $9.00/Share	Cibus, Inc. (NASDAQ: ROHZ ) , a leading agricultural technology company that develops and licenses plant traits to seed companies, today announced that it has priced an underwritten offering of 2,106,723 shares of its Class A Common Stock and Pre-Funded Warrants to purchase up to 50,000 shares of its Class A Common Stock. The shares of Class A Common Stock are being sold at an offering price of $9.00 per share, before underwriting discounts and commissions, except for shares of Class A Common Stock purchased by an executive officer, which will have an offering price of $10.58 per share, which is the closing bid price for shares of our Class A Common Stock on December 11, 2023. The Pre-Funded Warrants are being sold to one of Cibus' executive officers at an offering price of $10.57, before underwriting discounts and commissions, which is the closing bid price for shares of Class A Common Stock on December 11, 2023, minus $0.01 per share. The Pre-Funded Warrants will have an exercise price of $0.01 per share, will be immediately exercisable and will remain exercisable until exercised in full. Cibus estimates the gross proceeds from this offering to be approximately $20.3 million before deducting underwriting discounts and commissions and other offering expenses, and excluding the exercise of the Pre-Funded Warrants. The offering is expected to close on or about December 14, 2023, subject to the satisfaction of customary closing conditions. Cibus intends to use the net proceeds from this offering to fund further development of new and existing seed traits, including Canola and Rice, Trait Machine maintenance, research and development and working capital and general corporate purposes.
2023-12-12 08:48:22	FPAG	Greenidge Generation Entered Into Partnership And Share Exchange With Infinite Reality; Announces Launch Of Its New Service Offering, GreenidgeAI; iR Obtaining Shares Valued At $8.33/Share In Exchange For Equivalent Amount Of iR Stock Of $2.5B Valuation	Provides for iR obtaining shares of Greenidge valued at $8.33 per share in exchange for an equivalent amount of iR stock reflecting a $2.5 billion valuation. Greenidge granting iR a one-year warrant to purchase shares of Greenidge stock at $7.00 per share, the proceeds of which will be used by Greenidge in connection with the development of a new datacenter. iR granting Greenidge a one-year warrant to purchase an equivalent value of iR shares, reflecting a $2.5 billion valuation of iR, the proceeds of which will be used for general working capital purposes.
2023-12-12 09:02:32	CXV	Green Giant Announces Pricing Of Public Offering; To Sell $5.95M Of Its Units; Agreed To Sell 35M Units At Per Unit Purchase Price Of $0.17	Under the terms of the securities purchase agreement, CXV has agreed to sell 35,000,000 units at a per unit purchase price of $0.17. The Class A common warrants will be exercisable immediately upon the increase of the Company's authorized shares for a term of five years and have an initial exercise price of $0.17 subject to certain reset 30 trading days after the increase of the Company's authorized shares. The Class B common warrants will be exercisable immediately upon the date of issuance for a term of five years and have an initial exercise price of $0.27. In addition to the customary cashless exercise rights provided in both the Class A common warrants and the Class B common warrants, the Class B common warrants will also provide an alternate cashless exercise allowing the holder to right to exercise at any time, on a cashless exercise basis for a larger number of shares of common stock under certain conditions. The Company agreed to hold a shareholders' meeting within 120 days of closing of the Offering to increase the authorized share of common stock of the Company. The holders of the warrants agreed not to exercise cashlessly below $1.50 during the first 20 trading days after effectuation of a reverse split of the common stock.
2023-12-12 16:11:59	XMD	Bread Financial Announces Pricing And Upsize Of Private Offering Of $600M Of Senior Notes	"Bread Financial Holdings, Inc. (NYSE: XMD ) (""Bread Financial"" or the ""Company"") announced today the pricing and upsize of its previously announced offering of $600 million in aggregate principal amount of its 9.750% senior notes due 2029 (the ""Notes""), in a private offering that is exempt from the registration requirements of the Securities Act of 1933, as amended (the ""Securities Act""). The size of the offering reflects an increase of $100 million in aggregate principal amount of Notes from the previously announced offering size of $500 million. The Notes will be sold at a price of 100% of the principal amount thereof. The closing of the issuance of the Notes is expected to occur on December 22, 2023, subject to customary closing conditions, and is expected to result in approximately $592.5 million in net proceeds to the Company, after deducting the initial purchasers' discount but before the Company's estimated offering expenses. The Company intends to use the net proceeds from the Offering to (i) fund the redemption in full of the Company's outstanding 4.750% Senior Notes due 2024, (ii) fund the repayment in full of the Company's existing term loans under the Company's existing credit agreement and (iii) pay related fees, premiums and expenses, with any remaining proceeds to be used for general corporate purposes. The Notes will be guaranteed, on a full, joint and several basis, by each of the Company's domestic subsidiaries that guarantees the Company's obligations under its existing senior notes and its senior credit facilities."
2023-12-14 08:37:23	NADC	Vision Marine Technologies Inc. Announces $3M Private Placement Of Convertible Preferred Shares and Warrants; Will Not Complete Public Offering, Withdraws Effectiveness Of Previously Filed Registration Statement	"Will not complete public offering, withdraws effectiveness of previously filed registration statement MONTREAL, QC / ACCESSWIRE / December 14, 2023 / Vision Marine Technologies Inc. (NASDAQ: NADC ) (""Vision Marine"" or the ""Company""), a global leader and innovator within the performance electric recreational boating industry, announced today that it has entered into definitive securities purchase agreements with several institutional and accredited investors (the ""Investors"") for the sale of its preferred shares and warrants. Vision Marine sold an aggregate of 3,000 shares of its non-dividend bearing Series A Preferred Shares, with a stated value of US$1,000 per share, and Warrants to purchase up to 2,857,142 of its common shares for aggregate gross proceeds of US$3.0 million, before deducting placement agent fees and other offering expenses. Investors were also granted an option to purchase up to an additional 3,000 shares of Series A Preferred Shares and up to an additional 2,857,142 Warrants for a period of six (6) months from the execution of the definitive securities purchase agreements. The shares of Series A Preferred Shares are initially convertible into an aggregate of 2,857,142 common shares of the Company at a conversion price of $1.05 per share, as may be adjusted, for a period of twelve (12) months, at which time the Series A Preferred Shares becomes mandatorily convertible, subject to a potential price adjustment at maturity. The Warrants have an exercise price of $1.05 per share and will expire five (5) years from the date of issuance. Simultaneously with the execution of the definitive securities purchase agreement, the Company has agreed to reduce the exercise price of 2,922,935 of its previously issued warrants from US$4.05 and US$4.25 to US$1.05, which includes certain participating Investors, who have entered into warrant amendment agreements with the Company. Joseph Gunnar & Co., LLC is acting as the exclusive placement agent for the offering. The offering is expected to close on or about December 15, 2023, subject to satisfaction of customary closing conditions."
2023-12-14 09:05:06	OFLE	Veru Announced Today The Pricing Of An ~$33M Underwritten Public Offering Of 45,833,333 Shares Of Its Common Stock At A Price To The Public Of $0.72/Share	Veru intends to use the net proceeds from the offering to fund its clinical stage drug development with a primary near-term focus on funding a Phase 2b clinical trial designed to evaluate the safety and efficacy of enobosarm, an oral selective androgen receptor modulator, initially as a treatment to augment fat loss and to prevent muscle loss in sarcopenic obese or overweight elderly patients receiving a glucagon-like peptide-1 receptor agonist who are at-risk for developing muscle atrophy and muscle weakness. Some of the proceeds will also be used for working capital purposes, including existing vendor obligations, and for other general corporate purposes.
2023-12-14 16:27:57	JUCA	Eos Energy Announces Launch Of Proposed $40M Public Offering	"Eos Energy Enterprises, Inc. (NASDAQ: JUCA ) (""Eos"" or the ""Company""), a leading provider of safe, scalable, efficient, and sustainable zinc-based long duration energy storage systems, today announced a proposed underwritten public offering in which it intends to offer and sell (i) shares of its common stock and (ii) accompanying common warrants to purchase shares of common stock. All of the shares of common stock and accompanying common warrants are being offered by Eos. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. TD Cowen and Stifel are acting as joint bookrunning managers in the proposed offering."
2023-12-14 19:32:06	JUCA	Eos Energy Prices 34,482,759 Shares Plus Accompanying Warrants At $1.45/Unit	- Eos Energy Enterprises, Inc. (NASDAQ: JUCA ) (&quot;Eos&quot; or the &ldquo;Company&rdquo;), a leading provider of safe, scalable, efficient, and sustainable zinc-based long duration energy storage systems, today announced the pricing of an underwritten public offering of (i) 34,482,759 shares of its common stock and (ii) accompanying common warrants to purchase one share of common stock for each share of common stock sold. The combined offering price to the public of each share of common stock and accompanying one common warrant is $1.45. The accompanying common warrants have an exercise price of $1.60 per share, are exercisable immediately, and will expire five years following the date of issuance. All of the shares of common stock and accompanying common warrants are being offered by Eos. Before deducting the underwriting discounts and commissions and other offering expenses, Eos expects to receive total gross proceeds of approximately $50 million. The offering is expected to close on or about December 19, 2023, subject to the satisfaction of customary closing conditions TD Cowen and Stifel are acting as joint bookrunning managers in the offering.
2023-12-15 09:48:42	PAPU	TAT Technologies Announces $9.8M Proposed Private Placement Of 1,158,600 Ordinary Shares, For A Purchase Price Of $8.60 Per Share To Israeli Institutional And Accredited Investors	"TAT Technologies Ltd. (NASDAQ: PAPU ) ("" TAT "" or the "" Company ""), a leading provider of products and services to the commercial and military aerospace and ground defense industries, announced today that, following the approval of its Board of Directors, it has received and accepted commitments from Israeli institutional and accredited investors (as defined under Israel's Securities Law, 5728-1968 (the "" Investors ""), to participate in a in a private placement (the "" Private Placement "") of Ordinary Shares, par value NIS 0.90 per share, of the Company ("" Ordinary Shares ""). The Company is expected to issue and sell to the Investors an aggregate of 1,158,600 Ordinary Shares (the "" Shares ""), for a purchase price of NIS 31.70 per Share (approximately $8.60 per Share&#x2A;). The newly issued Shares are expected to represent approximately 11.5% of the Company's issued and outstanding Ordinary Shares after the consummation of such sale. The closing of the transaction is subject to customary closing conditions and is expected to be completed by December 31, 2023. The Company expects to receive net proceeds from the sale of the Shares, after deducting offering expenses, of approximately NIS 36.2 million (or approximately $9.8 million&#x2A;). The Company intends to use such proceeds for general corporate purposes."
2023-12-15 10:40:48	JENT	Mangoceuticals, Inc. Announces Pricing Of $1.2M Public Offering Of 4M Shares Of Common Stock At A Price Of $0.30 Per Share	"Mangoceuticals, Inc. (NASDAQ: JENT ) (""MangoRx"" or the ""Company""), a company focused on developing, marketing, and selling a variety of men's health and wellness products via a secure telemedicine platform, including its uniquely formulated hair growth product (""GROW"") and erectile dysfunction (""ED"") drug (""Mango""), today priced its previously announced underwritten public offering of 4,000,000 shares of its common stock, par value $0.0001 per share, at a public offering price of $0.30 per share, for aggregate gross proceeds of $1,200,000 to the Company, prior to deducting underwriting discounts and commissions and other offering expenses payable by the Company. In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 600,000 shares of its common stock at the public offering price of $0.30 per share, less the underwriting discounts and commissions, to cover over-allotments, if any. The offering is expected to close on or about December 19, 2023, subject to customary closing conditions. The Company intends to use the net proceeds from the offering to finance the marketing and operational expenses associated with the planned marketing of its Mango ED and GROW hair growth products, to hire additional personnel to build organizational talent, to develop and maintain software, and for working capital and other general corporate purposes. Boustead Securities, LLC is acting as the sole underwriter for the offering."
2023-12-18 11:43:24	QHZ	LG Display Has Announced That January 26, 2024, Will Be The Record Date For Determining Shareholders Eligible To Participate In The Company's Proposed Offering Of Common Stock And American Depositary Shares	" SEC Filing Notice of Record Date for Rights Offering LG Display Co., Ltd. (the ""Company"") announced that January 26, 2024 will be the record date for the determination of (i) the shareholders who are eligible to participate in the Company's proposed offering of shares of its common stock, par value Won 5,000 per share (the ""Shares""), pursuant to an offering of rights to purchase Shares (the ""Rights Offering"") and (ii) the holders of American depositary shares (the ""ADSs"") who are eligible to receive ADS rights and participate in the Rights Offering. The Company will close its shareholder registry book from January 29, 2024 to February 2, 2024. For more details regarding the Rights Offering, please refer to the Report of a Material Event (Resolution Regarding Paid-in Capital Increase) dated December 18, 2023, which was furnished to the United States Securities and Exchange Commission under Form 6-K on the same date."
2023-12-19 09:19:00	ZLRZ	Why Bluebird Bio Stock Is Tumbling Tuesday	Bluebird Bio Inc (NASDAQ: ZLRZ ) shares are trading lower Tuesday after the company announced a proposed offering . What Happened: Bluebird Bio said it commenced an underwritten public offering of $150 million worth of shares of its common stock. The company also intends to grant the underwriters the option to purchase up to an additional $22.5 million worth of its common stock. Bluebird said it intends to use the net proceeds to support commercialization and manufacturing for three approved gene therapies including ZYNTEGLO, SKYSONA and LYFGENIA, as well as to fund working capital and for other general corporate purposes. Bluebird did not provide pricing details for the offering and noted that there can be no assurance as to whether or when the offering may be completed. All shares in the offering are being sold by the company. See Also: What's Going On With Boeing Stock Tuesday? ZLRZ Price Action: Bluebird Bio shares were down 12.8% at $2.66 at the time of publication, according to Benzinga Pro . Photo: 3844328 from Pixabay.
2023-12-19 09:28:52	BYCV	Evaxion Biotech Announces $5.3M Private Placement Financing	"MSD Global Health Innovation Fund (MSD GHI), a corporate venture capital arm of Merck & Co., Inc., Rahway, NJ, USA, is contributing with some 25% of the total offering amount Company's management and board of directors with significant participation in the total offering COPENHAGEN, Denmark, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: BYCV ) (""Evaxion"" or the ""Company""), a clinical-stage TechBio company specializing in developing AI-Immunology&#x2122; powered vaccines, is pleased to announce a private placement (the ""Private Placement"") financing to raise gross proceeds of approximately $5.3 million. The Private Placement includes participation from existing and new shareholders, with the largest new shareholder being MSD Global Health Innovation Fund (MSD GHI), a corporate venture capital arm of Merck & Co., Inc., Rahway, NJ, USA, accounting for some 25% of the total offering amount. Further, the Private Placement includes significant participation by all members of the Company's management and the Company's board of directors. Christian Kanstrup, CEO of Evaxion Biotech, says, ""This Private Placement is an important step in our long-term financing strategy, and I am very pleased to see the mix of existing as well as new shareholders joining us. Further, I am excited to welcome MSD GHI as a shareholder of the Company. We believe that the broad participation in our Private Placement clearly shows the belief in our refined strategy with a strong focus on value realization."" Pursuant to the Private Placement, the Company has entered into definitive agreements for the issuance and sale of 9,726,898 of the Company's ordinary shares, DKK 1 nominal value (""Ordinary Shares""), represented by American Depositary Shares (""ADSs""), and accompanying warrants (the ""Warrants"") to purchase up to 9,726,898 Ordinary Shares represented by ADSs at a purchase price of $0.544 per Ordinary Share for an aggregate purchase price of $5.3 million. The Warrants are exercisable immediately upon issuance, have a term of three years, and an exercise price equal to $0.707 per Ordinary Share. Each Ordinary Share is represented by one (1) ADS. The Private Placement is expected to close on or about December 21, 2023, subject to the satisfaction of customary closing conditions. No brokerage, finder's fees, or commissions were payable by the Company in connection with the Private Placement. The gross proceeds from the Private Placement are expected to be approximately $5.3 million before deducting offering expenses payable by the Company. The Company intends to use the proceeds from the Private Placement for working capital and general corporate purposes."
2023-12-19 09:31:15	AL	Permian Resources Corporation Announces Pricing Of $512.4M Secondary Public Offering Of 39,414,415 Shares Of Class A Common Stock	"Permian Resources Corporation (""Permian Resources"" or the ""Company"") (NYSE: AL ) today announced the pricing of an underwritten public offering of an aggregate 39,414,415 shares of its Class A Common Stock, par value $0.0001 per share (""Class A common stock""), by certain affiliates of NGP Energy Capital Management L.L.C., Riverstone Investment Group LLC and EnCap Investments L.P. (the ""Selling Stockholders""), resulting in total gross proceeds of approximately $512.4 million. Permian Resources will not sell any shares of Class A common stock in the offering and will not receive any proceeds therefrom. Concurrently with the closing of the offering, the Company has agreed to purchase (the ""Concurrent OpCo Unit Purchase"") from certain of the Selling Stockholders an aggregate 2,252,252 common units representing limited liability company interests (""OpCo Units"") in Permian Resources Operating, LLC, a Delaware limited liability company and a subsidiary of Permian Resources (""OpCo""), at a price per OpCo Unit equal to the price per share at which the underwriter purchases shares of Class A common stock in the offering and to cancel a corresponding number of shares of the Company's Class C Common Stock, par value $0.0001 per share, held by such Selling Stockholders. The offering of Class A common stock is not conditioned upon the completion of the Concurrent OpCo Unit Purchase, but the Concurrent OpCo Unit Purchase is conditioned upon the completion of the offering. J.P. Morgan Securities LLC is serving as the underwriter for the offering. The offering is expected to close on December 21, 2023, subject to customary closing conditions. The offering is being made pursuant to a registration statement previously filed by the Company with the U.S. Securities and Exchange Commission (the ""SEC"") which became automatically effective upon filing on November 8, 2023."
2023-12-19 11:44:20	ZKTW	ZKTW Digital Announces $25M Bought Deal Private Placement Of 5M Special Warrants At A Price Of $5/Warrant Financing To HODL Bitcoin Production And Expand Green Mining Footprint By 100MW	This news release constitutes a &quot;designated news release&quot; for the purposes of the Company's prospectus supplement dated May 10, 2023 to its short form base shelf prospectus dated May 1, 2023. VANCOUVER, BC, Dec. 19, 2023 /CNW/ - ZKTW Digital Technologies Ltd. (TSX.V:ZKTW) (NASDAQ: ZKTW ) (FSE:YO0.F) (the &quot;Company&quot; or &quot;ZKTW&quot;) a leading digital asset miner and &quot;green&quot; focused data center builder and operator is pleased to announce that it has entered into an agreement with Stifel Canada and Canaccord Genuity as co-lead underwriters and joint bookrunners (the &quot;Underwriters&quot;), whereby the Underwriters will purchase, on a bought-deal basis, 5,000,000 special warrants of the Company (the &quot;Special Warrants&quot;) at a price of $5.00 per Special Warrant for aggregate gross proceeds to the Company of $25,000,000 (the &quot;Offering&quot;). The completion of the Offering will be subject to receipt of all necessary regulatory and corporate approvals or consents. The Company will grant the Underwriters an option to increase the size of the Offering by up to an additional 15% of the Special Warrants sold under the Offering, exercisable in whole or in part, at any time and from time to time up to 48 hours prior to the Closing Date (as hereinafter defined).
2023-12-20 08:01:59	IHMY	Aspen Aerogels, Inc. Announces $75M Registered Direct Offering Of 6,060,607 Shares Of Common Stock At An Offering Price Of $12.375 Per Share	"Aspen Aerogels, Inc. (NYSE: IHMY ) (""Aspen"" or the ""Company""), a technology leader in sustainability and electrification solutions, today announced that it has entered into a securities purchase agreement with Hood River Capital Management and certain other institutional investors for the purchase and sale in a registered direct offering of 6,060,607 shares of common stock at an offering price of $12.375 per share. The offering is expected to close on December 22, 2023, subject to customary closing conditions. All of the shares in the offering are being sold by Aspen. The gross proceeds to Aspen from this offering are expected to be approximately $75 million. Aspen intends to use the proceeds from the offering to fund capital expenditures, working capital and other general purposes as it prepares for additional anticipated growth in its energy industrial and EV thermal barrier business segments. The offering is being made pursuant to an effective shelf registration statement on Form S-3 (File No. 333-263622) previously filed with the Securities and Exchange Commission (the ""SEC""), which was declared effective on April 21, 2023. The securities may be offered only by means of a prospectus. A prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and will be available on the SEC's website located at www.sec.gov . This press release does not constitute an offer to sell, or the solicitation of an offer to buy, any securities referred to in this press release, nor will there be any sale of any such securities, in any state or other jurisdiction in which such offer, sale or solicitation would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction."
2023-12-20 08:05:55	OIDI	OIDI Announces Pricing Of $900,000 Public Offering Of 4.5M Shares Of Common Stock At A Price Of $0.20/Share	"OIDI Technology Group, Inc. (NYSE: OIDI ) (the ""Company"" or ""OIDI""), a global leader in sustainable energy management, today announced it has priced its underwritten public offering (the ""Offering"") of 4,500,000 shares of its common stock at a public offering price of $0.20 per share. All shares of common stock in the underwritten public offering are to be sold by the Company. The Company expects to receive aggregate gross proceeds of $900,000 from the Offering, before deducting underwriting discounts and other offering expenses. In addition, the Company has granted the Underwriter a 30-day option to purchase up to an additional 675,000 shares of its common stock at the public offering price, less underwriting discounts. The Company expects to close the offering on December 22, 2023, subject to customary conditions. OIDI will use a portion of the net proceeds from this offering to repay certain amount owed to Yorkville and for general corporate and working capital purposes. R.F. Lafferty & Co., Inc. is acting as the sole book-running manager for the offering."
2023-12-20 08:54:33	QFA	QFA House Cancels Representative Warrants To Bolster Shareholder Confidence; Committing To A Hiatus On Offerings And Capital Raises, Redirecting Efforts On Expanding E-Commerce Presence And Cultivating Marketing Partnerships	"With approximately $8 million in cash reserves, QFA House believes that the Company can preserve cash flow, sustain business growth, and prioritize profitability. On December 16, 2023, QFA House and designees of EF Hutton LLC (""EF Hutton"") entered into several agreements to cancel EF Hutton's representative warrants to purchase a total of 9,335,696 shares of the Company's common stock. These warrants had been issued to EF Hutton designees in three public offerings of the Company's common stock completed since August 11, 2023, with exercise prices ranging from $5.00 per share to $0.07 per share, encompassing all outstanding warrants of the Company. In consideration for the cancellation, QFA House agreed to compensate EF Hutton designees a total of $60,000. Given the current business environment, QFA House has also opted to delay further offerings and capital raises at this time, choosing instead to explore ventures that may enhance Company's value. This strategic decision aligns with the Company's dedication to prudent financial management and long-term value creation for its shareholders."
2023-12-20 09:26:44	ZLRZ	Why Bluebird Bio Shares Are Getting Crushed Wednesday	Bluebird Bio Inc (NASDAQ: ZLRZ ) shares are tanking Wednesday after the company announced the pricing of a $125 million public offering of common stock . What Happened: Late Tuesday, Bluebird Bio announced the pricing of the proposed offering it announced earlier this week. The company plans to offer 83.33 million shares at a public offering price of $1.50 per share. Bluebird also granted the underwriters a 30-day option to purchase up to an additional 12.5 million shares. The offering is expected to close on or about Dec. 22. Gross proceeds are expected to total $125 million. Bluebird said it intends to use the proceeds to support commercialization and manufacturing for three approved gene therapies including ZYNTEGLO, SKYSONA and LYFGENIA, as well as to fund working capital and for other general corporate purposes. Bluebird is a biotechnology company engaged in researching, developing and commercializing potentially curative gene therapies. Check This Out: Why Is Cheerios Maker General Mills Stock Falling Today? ZLRZ Price Action: Bluebird Bio shares closed Tuesday down 20.3%. The stock was down 49% at $1.24 Wednesday morning, according to Benzinga Pro . Photo: Pexels from Pixabay.
2023-12-20 10:36:06	TKXJ	Tonix Pharmaceuticals Announces Registered Direct Offering Of Up To $144M; $30M Financing Upfront With Up To An Additional $114M Tied To The Exercise Of Warrants	Led by healthcare-focused institutional investors. $30 million financing upfront with up to an additional $114 million tied to the exercise of warrants. CHATHAM, N.J., Dec. 20, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ: TKXJ ), a biopharmaceutical company with marketed products and a pipeline of development candidates, today announced that the Company has signed securities purchase agreements with certain healthcare-focused institutional investors that have agreed to provide up to $144 million in gross proceeds to Tonix through a registered direct offering that includes initial upfront funding of $30 million. About the Registered Direct Offering Pursuant to the securities purchase agreements, the Company has agreed to issue an aggregate of 54,054,054 shares of common stock (or prepaid warrants) and two series of registered warrants to purchase an aggregate of 162,162,162 shares of common stock for a purchase price of $0.555 per share and associated warrants (less $0.0001 in the case of prepaid warrants). The Series C warrants are exercisable at $0.555 per share and the Series D warrants are exercisable at $0.85 per share as follows: Series C warrants for an aggregate cash exercise price of approximately $45 million, exercisable until the earlier of two years from the initial exercisable date and 10 trading days following notice by the Company to the warrant holder of the Company's public announcement of the U.S. Food and Drug Administration's acknowledgement and acceptance of the Company's new drug application relating to TNX-102 SL in patients with Fibromyalgia; Series D warrants for an aggregate cash exercise price of approximately $69 million exercisable for five years from the initial exercisable date. Neither the Series C nor the Series D warrants shall be exercisable until the Company receives shareholder approval authorizing the exercise of such warrants. A.G.P./Alliance Global Partners is acting as the sole placement agent for the offering. The closing of the offering is expected to occur on December 22, 2023, subject to customary closing conditions. Tonix currently intends to use the net proceeds from the offering for the preparation of their new drug application relating to TNX-102 SL in patients with fibromyalgia, as well as working capital and general corporate purposes. For further information, please see the Company's current report on Form 8-K to be filed with the SEC.
2023-12-21 08:03:45	TOMH	Shattuck Labs Announces $50M Public Offering Of Common Stock And Concurrent Private Placement Of Pre-Funded Warrants	"Shattuck Labs, Inc. (""Shattuck"" or the ""company"") (NASDAQ: TOMH ), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced the pricing of a registered offering of 4,651,163 shares of common stock, par value $0.0001 (the ""common stock""), at a price of $6.45 per share, which is priced at the closing price on Nasdaq for the common stock on December 20, 2023. In addition to the shares sold in the registered offering, Shattuck announced the concurrent pricing of a private placement of pre-funded warrants to purchase 3,100,823 shares of common stock at a purchase price of $6.4499 per pre-funded warrant, which represents the per share offering price for the common stock less the $0.0001 per share exercise price for each pre-funded warrant. The gross proceeds to Shattuck from the registered offering and private placement, before deducting the underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $50 million. The offering is expected to close on or about December 26, 2023, subject to customary closing conditions. Evercore ISI is acting as sole book-running manager for the offering. Shattuck intends to use the net proceeds from the registered offering and the private placement for the development of its pipeline candidates, including SL-172154, and working capital and general corporate purposes."
2023-12-21 08:05:53	RUIK	Longeveron Announces $2.36M Registered Direct Offering of 1.36M Shares at $1.745/Share	Longeveron Inc. (NASDAQ: RUIK ) (&quot;Longeveron&quot; or &quot;Company&quot;), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (HLHS), Alzheimer's disease and Aging-related Frailty, today announced that it has entered into a definitive agreement for the issuance and sale of an aggregate of 1,355,301 of its shares of common stock at a purchase price of $1.62 per share in a registered direct offering priced at-the-market under Nasdaq rules. In a concurrent private placement, Longeveron has also agreed to issue and sell unregistered warrants to purchase up to an aggregate of 1,355,301 shares of its common stock. The warrants will have an exercise price $1.62 per share, will become exercisable immediately upon issuance and have a term of five and one-half (5.5) years from the date of issuance. The offering is expected to close on or about December 26, 2023, subject to the satisfaction of customary closing conditions. L.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. The gross proceeds to Longeveron from the offering are expected to be approximately $2.36 million, before deducting the placement agent's fees and other offering expenses payable by the Company. Longeveron currently intends to use the net proceeds from the offering for working capital and general corporate purposes.
2023-12-21 09:07:03	QH	Guardant Health Announces $90.7M Registered Direct Offering With Baillie Gifford Of 3,387,446 Shares Of Its Common Stock At An Offering Price Of $26.77 Per Share	"Guardant Health, Inc. (NASDAQ: QH ), a leading precision oncology company, today announced that it has entered into a common stock purchase agreement with Baillie Gifford on behalf of accounts that it manages for the sale of 3,387,446 shares of its common stock in a registered direct offering at an offering price of $26.77 per share. Gross proceeds are approximately $90.7 million, before deducting expenses payable by Guardant Health. Guardant Health intends to use the net proceeds from the offering primarily for general corporate purposes, including working capital, operating expenses and capital expenditures. ""We are proud to be supported by Baillie Gifford,"" said Helmy Eltoukhy, co-founder and co-CEO of Guardant Health. ""At Guardant, we are driven by the impact our products have on patient outcomes each and every day, and look forward to Baillie Gifford's continued support as we work to serve many more patients with our growing product portfolio."" ""We have deep conviction in Guardant's ability to execute on the opportunity ahead,"" said Brogan Harris at Baillie Gifford. ""We look forward to a long-term partnership with Guardant's team, as they work to continue to improve outcomes and transform patient lives across the continuum of care."" The shares of common stock are being offered by Guardant Health pursuant to an automatic shelf registration statement on Form S-3 that was previously filed with the U.S. Securities and Exchange Commission, or the SEC, and automatically became effective upon filing. A final prospectus supplement and accompanying prospectus relating to and describing the terms of the offering will be filed with the SEC and is available on the SEC's website at www.sec.gov . Electronic copies of the final prospectus supplement and accompanying prospectus may be obtained when available, on the SEC's website at http://www.sec.gov or by contacting Guardant Investor Relations, 3100 Hanover Street, Palo Alto, California 94304, by email: investors@guardanthealth.com or by telephone: (657) 254-5417. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction."
2023-12-21 10:37:36	RUIK	UPDATE: Longeveron Announces $2.36M Registered Direct Offering of 1.36M Shares at $1.745/Share	"Longeveron Inc. (NASDAQ: RUIK ) (""Longeveron"" or ""Company""), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (HLHS), Alzheimer's disease and Aging-related Frailty, today announced that it has entered into a definitive agreement for the issuance and sale of an aggregate of 1,355,301 of its shares of common stock at a purchase price of $1.745 per share in a registered direct offering priced at-the-market under Nasdaq rules. In a concurrent private placement, Longeveron has also agreed to issue and sell unregistered warrants to purchase up to an aggregate of 1,355,301 shares of its common stock. The warrants will have an exercise price $1.62 per share, will become exercisable immediately upon issuance and have a term of five and one-half (5.5) years from the date of issuance. The offering is expected to close on or about December 22, 2023, subject to the satisfaction of customary closing conditions. L.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. The gross proceeds to Longeveron from the offering are expected to be approximately $2.36 million, before deducting the placement agent's fees and other offering expenses payable by the Company. Longeveron currently intends to use the net proceeds from the offering for working capital and general corporate purposes."
2023-12-22 08:36:56	GRFR	Stronghold Enters Into $15.4M Private Placement To Sell 2.3M Shares Of Class A Common Stock And Share Equivalents, In Each Case At A Price Of At A Price Of $6.71/Share Equivalent	Stronghold Digital Mining, Inc. (NASDAQ: GRFR ) (&quot;Stronghold&quot;, or the &quot;Company&quot;) today announced that it entered into a securities purchase agreement with an existing institutional investor (the &quot;Purchaser&quot;) to sell 2,300,000 shares of Class A Common Stock and share equivalents, in each case at a price of $6.71 per share equivalent (the &quot;Private Placement&quot;). The Company also issued to the Purchaser warrants to purchase an aggregate of 2,300,000 shares of Class A Common Stock, with an initial exercise price of $7.00 per share (subject to adjustments), and such warrants are not exercisable until six months after issuance. The non-brokered Private Placement was executed on December 21, 2023, and is expected to close on December 22, 2023. Gross proceeds from the Private Placement will be $15.4 million, before deducting offering expenses. Proceeds will be used to enhance growth and efficiency of the Company's miner fleet, accelerate its carbon capture initiative, and improve its working capital position and for general corporate purposes. Additionally, the exercise price for 1,400,000 warrants previously issued on April 21, 2023, and September 19, 2022, will be adjusted from $10.10 per share and $11.00 per share, respectively, to $7.00 per share.
2023-12-26 08:34:59	AUHA	BTC Digital Ltd. Announces Entry Into $1.014M Share Subscription Agreements In Connection With Private Placement Of Ordinary Shares For The Issue And Sale Of 303,497 Ordinary Shares Of The Company, Par Value $0.06 Per Share	BTC Digital Ltd. (&quot;BTC Digital&quot; or the &quot;Company&quot;) (NASDAQ: AUHA ), a cryptocurrency mining company, today announced that it has entered into subscription agreements (the &quot;Subscription Agreements&quot;) with three individual investors (the &quot;Investors&quot;), for the issue and sale of 303,497 ordinary shares of the Company, par value US$0.06 per share (the &quot;Ordinary Shares&quot;), for total gross proceeds of $1,014,286, or US$3.342 per share. Each of the Investors represented that he or she was not a resident of the United States and was not &quot;U.S. persons&quot; as defined in Rule 902(k) of Regulation S and was not acquiring the ordinary shares of the Company for the account or benefit of any U.S. person. The Subscription Agreements and the transactions contemplated thereby have been approved by the Company's board of directors. The Company expects the transactions contemplated by the Subscription Agreements to close on or about January 3, 2024. The Company plans to use the proceeds to purchase additional mining machines, which is expected to further increase the aggregate computing power of the Company's cryptocurrency mining fleet. &quot;We are excited to announce the entry into the Subscription Agreements. With the capital injection, we are aim to further grow our cryptocurrency mining business,&quot; said Mr. Alan Peng, Chief Executive Officer of BTC Digital.
2023-12-27 09:12:25	WFBE	Trevena Inc. Announces $4M Concurrent Private Placement Of 2,779,906 Shares Of Common Stock At A Price Of $0.70/Share And Warrant Exercise	"Trevena Inc. ("" Trevena "" or the "" Company "") (NASDAQ: WFBE ), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that it has entered into definitive agreements for the issuance and sale of 2,779,906 shares of common stock (or pre-funded warrants in lieu thereof) of Trevena and warrants to purchase up to an aggregate of 2,779,906 shares of common stock of Trevena, at a purchase price of $0.70 per share (or pre-funded warrant in lieu thereof) and associated warrant in a private placement, for expected gross proceeds to the Company of approximately $1.946 million (the ""private placement""). The Company has also entered into a definitive agreement for the immediate exercise for cash of certain existing warrants to purchase up to an aggregate of 2,934,380 shares of common stock issued in July 2022 and November 2022 at a reduced exercise price of $0.70 per share, in exchange for the issuance of unregistered new warrants to purchase up to 5,868,760 shares of common stock, for expected gross proceeds to the Company of approximately $2.054 million (the ""induced warrant exercise"" and, collectively with the private placement, the ""offerings""). The shares of common stock issuable upon exercise of the existing warrants are registered pursuant to an effective registration statement on Form S-3 (File No. 333-251006), filed with the U.S. Securities Exchange (""SEC"") on November 27, 2020 and declared effective on December 4, 2020. The warrants to be issued in the offerings will have an exercise price of $0.70 per share, will be exercisable commencing on the effective date of stockholder approval of the issuance of the shares issuable upon exercise of such warrants and will expire five years thereafter. L.C. Wainwright & Co. is acting as the exclusive placement agent for the offerings."
2023-12-27 11:57:28	ODSN	First Wave BioPharma Announces Exercise Of Warrants And Issuance Of New Warrants In A Private Placement For $4.8M Gross Proceeds Priced	"First Wave BioPharma, Inc. (""First Wave BioPharma"" or the ""Company"") (NASDAQ: ODSN ), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced it has entered into agreements with certain holders of its existing warrants exercisable for 881,337 shares of its common stock, in the aggregate, to exercise their warrants at a reduced exercise price of $5.50 per share, in exchange for new warrants as described below. The aggregate gross proceeds from the exercise of the existing warrants is expected to total approximately $4.8 million, before deducting financial advisory fees. The reduction in the exercise price of the existing warrants and the issuance of the new warrants was structured as an at-market transaction under Nasdaq rules. Roth Capital Partners is acting as the Company's financial advisor for this transaction."
2023-12-27 16:18:25	BJPU	Profound Medical Announces Proposed Public Offering Of Common Shares; Terms Not Disclosed	The Company intends that the Offering will be priced in the context of the market, with such price and the total size of the Offering to be determined at the time of entering into an underwriting agreement with respect thereto. The Company expects to grant the underwriter for the Offering an over-allotment option to purchase up to an additional 15% of the Common Shares to be sold pursuant to the Offering on the same terms and conditions, and that the over-allotment option will be exercisable for a period of 30 days after closing. All of the securities in the offering will be sold by the Company.
2023-12-28 11:14:58	DCHS	Why BlueJay Diagnostics Stock Is Falling	Bluejay Diagnostics, Inc. (NASDAQ: DCHS ) shares are trading lower Thursday after the company announced the pricing of a $3.5 million public offering . The Details: BlueJay Diagnostics announced the public offering of 2,692,308 shares at $1.30 per share. The gross proceeds from the offering are expected to be approximately $3.5 million, and BlueJay Diagnostics intends to use the proceeds to fund matters related to obtaining FDA approval, other research and development activities and for general working capital needs. On Wednesday, the company announced the initiation of a multicenter clinical study to evaluate the Symphony IL-6 test in sepsis patients. BlueJay Diagnostics shares are falling on heavy trading volume following the announcement of a public offering. According to data from Benzinga Pro , more than 447,000 shares have been traded in the session, compared to the stock's 100-day average of less than 26,000 shares. BlueJay Diagnostics shares are trading below the stock's 50-day moving average of $3.29 and well-below its 52-week high of $17.60. Related News: Why Coherus BioSciences Stock Is Climbing Today DCHS Price Action: According to Benzinga Pro , BlueJay Diagnostics shares are down 29% at $1.24 at the time of publication. Image: Mohamed Hassan from Pixabay
2023-12-29 10:40:35	QFLH	Why Fortress Biotech Shares Are Tumbling Today	Fortress Biotech Inc (NASDAQ: QFLH ) shares are trading lower by over 18% after it announced the pricing of a $11 million registered direct offering. The company entered a deal for the issuance and sale of 3.30 million common shares and warrants to purchase up to 3.30 million shares of common stock at a combined offering price of $3.33 per share and accompanying warrant priced at-the-market under Nasdaq rules. The warrants have an exercise price of $3.21 per share, are immediately exercisable, and will expire five years following the date of issuance. Roth Capital Partners is acting as the exclusive placement agent for the offering, which is expected to close on or about January 3, 2024, subject to the satisfaction of customary closing conditions. Fortress expects to use the net proceeds for its operations, including, but not limited to, general corporate purposes, which may include research and development expenditures, clinical trial expenditures, license or acquisition of new products, and working capital. In November, the company closed a $10 million public offering. Price Action : QFLH shares are down by over 18.64% at $3.1650 on the last check Friday. Photo via Company
